Clustering O 0 2.046906047326047e-05
of O 0 2.5602799880175553e-08
missense O 0 4.737083145300858e-05
mutations O 0 3.3806416013248963e-06
in O 0 1.881710431916872e-07
the O 0 1.9116227122140117e-05
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
gene O 0 4.342455213190988e-05
in O 0 9.550588941920068e-08
a O 0 6.581618805512335e-08
sporadic B-Disease 0 0.062031425535678864
T I-Disease 1 0.9999504089355469
- I-Disease 0 0.2254336029291153
cell I-Disease 1 0.8956984281539917
leukaemia I-Disease 1 0.9996135830879211
. O 0 7.862634561206505e-07

Ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 0 0.13245581090450287
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 3.775440404751862e-09
is O 0 4.0033720782872706e-10
a O 0 1.520585968250998e-08
recessive B-Disease 1 0.9080883860588074
multi I-Disease 1 0.9966276288032532
- I-Disease 1 0.9999994039535522
system I-Disease 1 0.9329225420951843
disorder I-Disease 1 0.9649105668067932
caused O 0 2.1504280312001356e-07
by O 0 1.2633267765238543e-09
mutations O 0 3.44220509873594e-08
in O 0 2.6524256124815793e-09
the O 0 1.4788759106210136e-09
ATM O 0 8.216931064453092e-07
gene O 0 8.022976061283771e-08
at O 0 5.731247654239269e-08
11q22 O 0 6.605160365324991e-07
- O 0 4.088830337423133e-06
q23 O 0 2.1882069631828927e-06
( O 0 1.2318896125407264e-08
ref O 0 3.020022631972097e-06
. O 0 7.924039757689627e-10
3 O 0 6.298756627387547e-09
) O 0 3.3794775866624605e-09
. O 0 1.6007252412464368e-08

The O 0 2.3900952328403946e-07
risk O 0 8.77076672622934e-07
of O 0 5.138415026806342e-09
cancer B-Disease 0 1.0529776091061649e-06
, O 0 3.880010979173676e-09
especially O 0 1.945040750683802e-08
lymphoid B-Disease 0 3.6792978335142834e-06
neoplasias I-Disease 0 1.9648048692033626e-05
, O 0 1.6168616445710882e-09
is O 0 3.2746633182867413e-10
substantially O 0 5.847196504760177e-08
elevated O 0 3.026475425826902e-08
in O 0 2.7243652311881306e-07
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 0.07273685187101364
and O 0 4.9448491523662597e-08
has O 0 3.832606232379021e-09
long O 0 3.0396754002737225e-09
been O 0 6.291972276528668e-09
associated O 0 9.0494030047239e-09
with O 0 3.3892458617401644e-08
chromosomal O 1 1.0
instability O 1 0.9999979734420776
. O 0 7.800568937454955e-07

By O 0 2.2364882568126632e-07
analysing O 0 3.4185326512670144e-05
tumour B-Disease 1 0.9999992847442627
DNA O 0 1.7082217027564184e-06
from O 0 1.116648995491687e-08
patients O 0 4.9957279202317295e-08
with O 0 8.478728275029823e-10
sporadic B-Disease 0 0.00018755208293441683
T I-Disease 1 0.9998446702957153
- I-Disease 0 0.11241821199655533
cell I-Disease 1 0.9715629816055298
prolymphocytic I-Disease 1 0.9258241057395935
leukaemia I-Disease 1 0.9999299049377441
( O 0 3.157890091642912e-07
T B-Disease 0 0.008295967243611813
- I-Disease 0 5.87140311836265e-05
PLL I-Disease 0 8.337423059856519e-05
) O 0 5.828665106122344e-09
, O 0 6.857776568836016e-10
a O 0 2.4421402677887727e-09
rare O 0 1.543561864991716e-07
clonal B-Disease 0 3.791213657677872e-06
malignancy I-Disease 0 2.304735426150728e-05
with O 0 1.5408028186669753e-09
similarities O 0 6.1705357268238e-08
to O 0 2.9304791926421103e-09
a O 0 2.8903130555590906e-08
mature B-Disease 0 8.196761314138712e-07
T I-Disease 0 0.02878134697675705
- I-Disease 0 8.6644031398464e-05
cell I-Disease 0 0.008284499868750572
leukaemia I-Disease 1 0.931216299533844
seen O 0 7.963878942973679e-07
in O 0 7.189225215142869e-08
A B-Disease 1 1.0
- I-Disease 1 0.9999823570251465
T I-Disease 1 1.0
, O 0 4.033619216414763e-09
we O 0 8.015427210850135e-10
demonstrate O 0 3.15131004624547e-10
a O 0 3.9387504369159387e-10
high O 0 8.965717945841334e-09
frequency O 0 2.5605338294099056e-08
of O 0 4.3885245437635945e-10
ATM O 0 3.5229791137680877e-06
mutations O 0 1.227340078457928e-07
in O 0 1.0965165841980706e-07
T B-Disease 0 0.036593955010175705
- I-Disease 0 4.008853284176439e-05
PLL I-Disease 0 0.0003306860162410885
. O 0 4.555056420940673e-07

In O 0 3.26196897049158e-07
marked O 0 4.741159642662751e-08
contrast O 0 1.2835549512146827e-08
to O 0 6.09307215793109e-10
the O 0 5.646596523689595e-10
ATM O 0 1.8480410290067084e-05
mutation O 0 7.957109460221545e-08
pattern O 0 1.5942086406539602e-07
in O 0 4.469361556402873e-07
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
, O 0 3.463283881899315e-09
the O 0 1.1928899534829895e-10
most O 0 9.141425116876434e-11
frequent O 0 6.223839221775052e-10
nucleotide O 0 2.9479421126410443e-09
changes O 0 1.5509752371301033e-09
in O 0 4.8509622985193346e-09
this O 0 6.50273035418536e-09
leukaemia B-Disease 0 0.0006040714215487242
were O 0 7.435133397848404e-07
missense O 0 1.9920107661164366e-05
mutations O 0 5.8117552725889254e-06
. O 0 2.8120521733399073e-07

These O 0 8.195770817565062e-08
clustered O 0 8.973557186209291e-08
in O 0 2.662248199669648e-09
the O 0 2.0851703697033486e-10
region O 0 2.3430610229802085e-10
corresponding O 0 2.4661567232797665e-10
to O 0 1.8571728876981553e-10
the O 0 1.7972960619783152e-10
kinase O 0 2.6372626749093797e-08
domain O 0 1.5342104253690536e-09
, O 0 1.088770740231837e-10
which O 0 1.5049142487733036e-10
is O 0 4.4300171170297276e-11
highly O 0 1.5435787370510212e-10
conserved O 0 3.901202694223116e-10
in O 0 2.454108027905022e-09
ATM O 0 3.944607215089491e-06
- O 0 5.1170182757687144e-08
related O 0 6.621355019831299e-09
proteins O 0 1.8750594410477106e-09
in O 0 4.939888054167341e-09
mouse O 0 4.3160645191164804e-07
, O 0 3.1777969144997087e-09
yeast O 0 1.506405311602066e-07
and O 0 7.651587807799842e-09
Drosophila O 0 1.7633142590511852e-07
. O 0 2.4070605064707706e-08

The O 0 1.258604385157014e-07
resulting O 0 1.1402033095464503e-07
amino O 0 1.662433959381815e-07
- O 0 8.897339398572512e-07
acid O 0 2.506644669608704e-08
substitutions O 0 2.6780478279420095e-08
are O 0 5.760832921808401e-10
predicted O 0 8.997838918389789e-09
to O 0 2.8742630497902155e-10
interfere O 0 6.975027222466679e-09
with O 0 3.7199415769961774e-10
ATP O 0 1.6562481164328346e-07
binding O 0 2.33647643455015e-08
or O 0 8.191375577837334e-09
substrate O 0 3.723735986227439e-08
recognition O 0 1.874942334723073e-08
. O 0 4.054044921986133e-08

Two O 0 1.5067631409237947e-07
of O 0 3.691543737360803e-09
seventeen O 0 2.9727661399192584e-07
mutated O 0 5.792841420770856e-06
T B-Disease 0 0.0012659552739933133
- I-Disease 0 1.8859494957723655e-05
PLL I-Disease 0 1.976806925085839e-05
samples O 0 5.829679849966851e-08
had O 0 2.1908592273689464e-08
a O 0 7.921531208765487e-10
previously O 0 1.1432102375863451e-08
reported O 0 2.1367130102589726e-05
A B-Disease 1 1.0
- I-Disease 1 0.9999986886978149
T I-Disease 1 1.0
allele O 0 0.0002519252884667367
. O 0 5.209838036535075e-07

In O 0 1.5277147724646056e-07
contrast O 0 3.903915768432853e-08
, O 0 1.2450035447031382e-09
no O 0 1.479019795525005e-09
mutations O 0 1.0735758948499097e-08
were O 0 1.572794339210759e-08
detected O 0 1.7573352550925847e-08
in O 0 6.341970837375754e-10
the O 0 1.6250972789677576e-10
p53 O 0 6.163922705582081e-09
gene O 0 1.055469045496693e-08
, O 0 1.7769431759351306e-10
suggesting O 0 9.078066298684462e-09
that O 0 1.0769614089412016e-09
this O 0 1.351459744114436e-08
tumour B-Disease 1 1.0
suppressor O 0 2.103304723277688e-06
is O 0 4.004199194440616e-09
not O 0 1.0505377678882155e-09
frequently O 0 4.0200625051056704e-09
altered O 0 3.997562103563723e-08
in O 0 2.6079302273274152e-08
this O 0 4.027985767152131e-08
leukaemia B-Disease 0 0.001007912214845419
. O 0 9.93172335483905e-08

Occasional O 0 4.109905057703145e-05
missense O 0 9.376806701766327e-05
mutations O 0 2.8168403787276475e-06
in O 0 1.7375144878428728e-08
ATM O 0 1.1632513405857026e-06
were O 0 4.459594293848568e-08
also O 0 5.068370168004321e-09
found O 0 8.549927876799757e-09
in O 0 3.2795614401948114e-07
tumour B-Disease 1 0.9999995231628418
DNA O 0 1.4016396221450123e-07
from O 0 2.0836408154423225e-09
patients O 0 5.816836790017987e-09
with O 0 1.94710622625216e-10
B B-Disease 0 1.2696543308265973e-05
- I-Disease 0 2.9871448532503564e-06
cell I-Disease 0 0.017947355285286903
non I-Disease 1 0.9859395027160645
- I-Disease 1 0.9999984502792358
Hodgkins I-Disease 1 0.9999998807907104
lymphomas I-Disease 1 0.9423388242721558
( O 0 4.6495014061065376e-08
B B-Disease 0 1.8172228010371327e-05
- I-Disease 0 1.2305343943808111e-06
NHL I-Disease 0 1.0780043879776713e-07
) O 0 3.1361996333245656e-10
and O 0 2.8292970744026036e-10
a O 0 3.904703227419759e-09
B B-Disease 0 4.723450547317043e-05
- I-Disease 0 2.2199312752491096e-06
NHL I-Disease 0 7.175552241278638e-07
cell O 0 5.227029760135338e-06
line O 0 1.7690099411993288e-05
. O 0 3.637805718881282e-07

The O 0 1.2943031535428418e-08
evidence O 0 4.404047793116206e-09
of O 0 5.333641167615255e-11
a O 0 4.782133578018488e-10
significant O 0 7.132918145025258e-10
proportion O 0 2.246661967575392e-09
of O 0 1.4296097639032723e-10
loss O 0 5.617373233235412e-08
- O 0 7.660484158122927e-08
of O 0 1.251942549629348e-09
- O 0 7.099912977537315e-07
function O 0 3.037079254752939e-09
mutations O 0 1.2222120204796738e-08
and O 0 2.3617003908071865e-09
a O 0 1.8274326496481308e-09
complete O 0 5.961097837570151e-09
absence O 0 5.725322882454975e-09
of O 0 3.911243898202521e-11
the O 0 2.176246960416961e-10
normal O 0 3.567649731195388e-09
copy O 0 2.6921725293505006e-08
of O 0 1.247700970319343e-10
ATM O 0 2.3563860906961054e-07
in O 0 1.78015657770203e-09
the O 0 5.539346759064756e-10
majority O 0 1.4331597020245113e-09
of O 0 3.131873205219904e-09
mutated O 0 0.0003931125102099031
tumours B-Disease 1 0.9999994039535522
establishes O 0 9.39956805723341e-07
somatic O 0 2.335154704269371e-06
inactivation O 0 1.3377681398196728e-06
of O 0 2.1416780848770856e-10
this O 0 2.3569021734282103e-10
gene O 0 8.84006112755742e-09
in O 0 3.022101457972326e-09
the O 0 2.3229356216347696e-09
pathogenesis O 0 9.036694592623462e-08
of O 0 1.6609222885932695e-09
sporadic B-Disease 0 0.000107909319922328
T I-Disease 1 0.9987687468528748
- I-Disease 0 0.006165876053273678
PLL I-Disease 0 5.4114603699417785e-05
and O 0 1.191067777739363e-08
suggests O 0 6.905083171915294e-09
that O 0 3.705064310910444e-10
ATM O 0 2.3156007955549285e-07
acts O 0 1.752050593495369e-08
as O 0 1.1100595997959317e-08
a O 0 2.782898036457482e-07
tumour B-Disease 1 0.9999998807907104
suppressor O 0 8.315769082400948e-05
. O 0 4.176082200046949e-07

As O 0 9.009898604972477e-08
constitutional O 0 2.4375950147259573e-08
DNA O 0 4.1369538905655645e-08
was O 0 1.8820795588680994e-08
not O 0 1.1471297522991364e-10
available O 0 2.162922202453288e-10
, O 0 5.6220163940912116e-11
a O 0 2.738606896812712e-09
putative O 0 1.4289454384197597e-06
hereditary O 0 0.0003766007430385798
predisposition O 0 2.8208241928950883e-06
to O 0 1.0201181765978617e-07
T B-Disease 1 0.8729058504104614
- I-Disease 0 0.00016181464889086783
PLL I-Disease 0 4.9170481361215934e-05
will O 0 8.621112712603463e-09
require O 0 1.2252270309431879e-09
further O 0 1.203301791541378e-09
investigation O 0 7.2720935939685205e-09
. O 0 1.66178748539636e-09
. O 0 7.290426040640341e-09

Myotonic B-Disease 1 0.9999998807907104
dystrophy I-Disease 1 1.0
protein O 0 7.345483754761517e-05
kinase O 0 1.178390175482491e-05
is O 0 1.1325841597908948e-08
involved O 0 2.663106402067683e-09
in O 0 6.174838973471708e-10
the O 0 3.5088548733241964e-10
modulation O 0 6.354009318698672e-09
of O 0 1.2606567179052064e-10
the O 0 1.1557856893773533e-09
Ca2 O 0 2.506762371012883e-07
+ O 0 4.041453394165728e-07
homeostasis O 0 2.1053035652585095e-06
in O 0 1.5730545044334576e-07
skeletal O 0 0.00012474373215809464
muscle O 0 6.840832611487713e-06
cells O 0 1.0875472753468785e-06
. O 0 2.5229536504411954e-07

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9910791516304016
DM B-Disease 1 1.0
) O 0 7.491397724379567e-08
, O 0 1.5112489037960586e-09
the O 0 3.015656613314377e-10
most O 0 4.150276566861066e-09
prevalent O 0 0.0002440372627461329
muscular B-Disease 1 0.9948194622993469
disorder I-Disease 0 0.02208148129284382
in O 0 5.159326121884078e-08
adults O 0 7.212840955617139e-07
, O 0 4.2503409125593805e-10
is O 0 2.19498128006812e-10
caused O 0 7.140190216858855e-09
by O 0 6.100037142076076e-10
( O 0 2.845300661746819e-09
CTG O 0 2.8251375283616653e-07
) O 0 8.946802743103888e-10
n O 0 4.227650052257559e-08
- O 0 3.2380719972024963e-07
repeat O 0 6.222894910479226e-08
expansion O 0 5.836207073173227e-09
in O 0 1.0156753216250536e-09
a O 0 2.7551930181779483e-10
gene O 0 4.705140721483758e-09
encoding O 0 3.1843374603823804e-09
a O 0 2.366692175570506e-09
protein O 0 3.241087256355968e-07
kinase O 0 2.3041640815790743e-05
( O 0 2.1192765586874884e-07
DM B-Disease 1 0.9999995231628418
protein O 0 4.527308874457958e-07
kinase O 0 2.4320465854543727e-06
; O 0 7.608728758157213e-09
DMPK O 0 2.6791215077537345e-06
) O 0 8.605599011168863e-10
and O 0 2.5068236375602737e-10
involves O 0 7.11650238738315e-10
changes O 0 3.3874476557116395e-09
in O 0 4.374995477007815e-09
cytoarchitecture O 0 6.644647783105029e-07
and O 0 8.142851726233857e-09
ion O 0 5.86781993661134e-07
homeostasis O 0 6.160614702821476e-06
. O 0 1.761908947628399e-07

To O 0 4.2290370316777626e-08
obtain O 0 2.452878788972157e-08
clues O 0 1.1282681100510672e-07
to O 0 1.496859303173892e-09
the O 0 5.422919890918365e-10
normal O 0 4.447682222519234e-09
biological O 0 1.7934206342218317e-09
role O 0 1.1913398045848567e-09
of O 0 1.8215123853693171e-10
DMPK O 0 1.9798793005065818e-07
in O 0 2.828548284483645e-09
cellular O 0 1.0946630624175668e-07
ion O 0 4.194358282916255e-08
homeostasis O 0 5.476706519402796e-07
, O 0 1.3306361568155012e-09
we O 0 1.3439377388735352e-09
have O 0 1.6303129679595685e-10
compared O 0 1.1931340360149534e-09
the O 0 2.359195894197086e-10
resting O 0 8.69172822604014e-09
[ O 0 1.9785884042278212e-09
Ca2 O 0 2.0392484145759227e-08
+ O 0 6.193221935291149e-08
] O 0 1.6844333572407777e-07
i O 0 4.318711717132828e-07
, O 0 9.335317935343923e-11
the O 0 3.338337939418068e-11
amplitude O 0 3.999190145709264e-10
and O 0 1.043617747775727e-09
shape O 0 1.3426445732989123e-08
of O 0 2.777114649354928e-10
depolarization O 0 9.770829478839005e-08
- O 0 2.07743300961738e-06
induced O 0 1.3670978660229594e-06
Ca2 O 0 5.341173618944595e-07
+ O 0 2.783460786304204e-07
transients O 0 1.7094031363740214e-06
, O 0 3.4785616054300306e-10
and O 0 5.831406191258992e-11
the O 0 1.1948568003072868e-11
content O 0 6.005212993542841e-10
of O 0 6.901586940832871e-11
ATP O 0 8.013616081825603e-08
- O 0 1.337106603216398e-08
driven O 0 1.3250775587891894e-08
ion O 0 1.0734264144218741e-08
pumps O 0 1.5288952681657975e-07
in O 0 3.8481008601820577e-08
cultured O 0 1.3481352652888745e-05
skeletal O 0 1.673333827056922e-05
muscle O 0 3.6562778404913843e-07
cells O 0 8.199363854544117e-09
of O 0 4.415863508189233e-10
wild O 0 1.2801174342769173e-08
- O 0 9.884248584057787e-07
type O 0 3.1387335184263065e-06
and O 0 7.92064724919328e-08
DMPK O 0 1.7291526091867127e-05
[ O 0 3.051175951895857e-07
- O 0 2.2822969185654074e-05
/ O 0 0.00017127829778473824
- O 0 7.122340321075171e-05
] O 0 1.5376467672467697e-06
knockout O 0 0.00024778625811450183
mice O 0 5.6715365644777194e-05
. O 0 1.9009577556516888e-07

In O 0 4.422417418936675e-07
vitro O 0 2.5466644729021937e-05
- O 0 1.961053021659609e-05
differentiated O 0 1.7589737808521022e-06
DMPK O 0 4.1109124140348285e-05
[ O 0 7.545755238425045e-07
- O 0 4.559857916319743e-05
/ O 0 6.718866643495858e-05
- O 0 8.820256880426314e-06
] O 0 9.307629511567939e-08
myotubes O 0 1.4614805365908978e-07
exhibit O 0 5.006151049258278e-09
a O 0 4.715292600820931e-09
higher O 0 8.977733756410089e-08
resting O 0 4.278398080259649e-08
[ O 0 5.53883161558133e-09
Ca2 O 0 8.858158651037229e-08
+ O 0 1.8213376051789965e-07
] O 0 1.3604255855170777e-07
i O 0 2.5465780595368415e-07
than O 0 2.9688804192851137e-10
do O 0 1.0562116736778648e-09
wild O 0 2.108933916389333e-09
- O 0 1.803744282824482e-07
type O 0 3.5718531421480293e-07
myotubes O 0 5.395779112404853e-07
because O 0 1.6841265049194476e-09
of O 0 2.2203286084709895e-11
an O 0 7.332184165376177e-11
altered O 0 5.8200440022915245e-09
open O 0 5.042172901426056e-09
probability O 0 4.210440884833133e-10
of O 0 9.503094838825277e-11
voltage O 0 2.045238005621286e-07
- O 0 4.324403448663361e-07
dependent O 0 2.370111360505689e-07
l O 0 2.6832558432943188e-06
- O 0 2.360256701194885e-07
type O 0 2.672945242920832e-07
Ca2 O 0 1.441187151840495e-07
+ O 0 5.2429427910283266e-08
and O 0 5.575484074427095e-09
Na O 0 1.7122668793945195e-07
+ O 0 2.9689459779547178e-08
channels O 0 3.821324128239212e-07
. O 0 1.1209407801970883e-07

The O 0 1.773810112126739e-07
mutant O 0 1.6316902247126563e-06
myotubes O 0 1.7457314243074507e-06
exhibit O 0 5.5202090010197935e-08
smaller O 0 3.2613215239507554e-08
and O 0 1.5834530131542124e-08
slower O 0 8.804171329757082e-07
Ca2 O 0 1.3967080292331957e-07
+ O 0 3.79330025168656e-08
responses O 0 4.174284029545561e-09
upon O 0 3.636029255460471e-10
triggering O 0 3.892582700615321e-09
by O 0 7.419862502189289e-10
acetylcholine O 0 2.0219945895405544e-07
or O 0 1.3678599586341988e-08
high O 0 5.132070768354424e-08
external O 0 1.8259882494930935e-07
K O 0 7.024769388408458e-07
+ O 0 2.9527052447519964e-07
. O 0 4.383325702406182e-08

In O 0 9.408099543861681e-08
addition O 0 6.067040647650401e-09
, O 0 6.679192199321449e-10
we O 0 4.578033230284717e-10
observed O 0 1.1519710185758925e-10
that O 0 2.4858438224528712e-11
these O 0 1.0810852907328083e-10
Ca2 O 0 1.6077752462706485e-08
+ O 0 5.1639037934592125e-08
transients O 0 3.617743118411454e-07
partially O 0 5.031780503372829e-08
result O 0 3.109445367854846e-09
from O 0 1.3263252995887598e-10
an O 0 4.666259045826848e-11
influx O 0 3.564138428835406e-10
of O 0 4.822846635943456e-11
extracellular O 0 1.4952015181535216e-09
Ca2 O 0 1.0611453049591546e-08
+ O 0 5.157483329298884e-09
through O 0 9.41714040081365e-10
the O 0 1.2372105562263869e-09
l O 0 5.07146808104153e-07
- O 0 1.0417095097636775e-07
type O 0 2.0707345527171128e-07
Ca2 O 0 2.468246975695365e-07
+ O 0 1.6476998609959992e-07
channel O 0 2.529707217036048e-06
. O 0 8.704390808134121e-08

Neither O 0 9.70755650087085e-07
the O 0 5.9472311519925825e-09
content O 0 8.554397190607688e-09
nor O 0 1.210867850431896e-08
the O 0 5.039218486935226e-10
activity O 0 8.210083279891478e-09
of O 0 3.802322068313657e-10
Na O 0 1.8337365759180102e-07
+ O 0 5.9545556041484815e-08
/ O 0 1.3745950866450585e-07
K O 0 5.564353244835729e-08
+ O 0 7.82874209903639e-08
ATPase O 0 1.2948273706570035e-06
and O 0 2.717462166401674e-08
sarcoplasmic O 0 3.2425391509605106e-06
reticulum O 0 3.83322640118422e-06
Ca2 O 0 1.2724561884169816e-06
+ O 0 8.375120614800835e-07
- O 0 4.2388657561787113e-07
ATPase O 0 1.117332772082591e-06
are O 0 2.314629821142944e-09
affected O 0 4.5908365997604506e-09
by O 0 2.493035111683639e-09
DMPK O 0 8.667280781082809e-06
absence O 0 3.269025796726055e-07
. O 0 5.1472163420385186e-08

In O 0 2.3170721874521405e-07
conclusion O 0 2.9676607837814117e-08
, O 0 3.4253108682769096e-10
our O 0 1.48779849551417e-10
data O 0 8.193668521450093e-10
suggest O 0 1.1565156610160443e-09
that O 0 3.9038003385449827e-10
DMPK O 0 2.440596347241808e-07
is O 0 5.3520868292800117e-11
involved O 0 2.1520912829586791e-10
in O 0 3.0775232362501015e-10
modulating O 0 2.077582017534496e-08
the O 0 1.1793077625554815e-09
initial O 0 2.646896701818946e-09
events O 0 1.356779577577072e-09
of O 0 2.1727424026618536e-10
excitation O 0 4.0665372580406256e-07
- O 0 0.0002518899564165622
contraction O 0 2.240992762381211e-05
coupling O 0 5.564639309341146e-07
in O 0 6.953563769229731e-08
skeletal O 0 4.258894477970898e-05
muscle O 0 2.9623163300129818e-06
. O 0 1.314617747993907e-08
. O 0 2.416223310319765e-08

Constitutional O 0 3.3777243515942246e-05
RB1 O 0 0.008296736516058445
- O 0 0.00036887696478515863
gene O 0 5.808203241031151e-06
mutations O 0 3.1792767458682647e-06
in O 0 6.708934563448565e-08
patients O 0 2.7349497599971073e-07
with O 0 1.9174650756070832e-09
isolated O 0 1.2385922900648438e-06
unilateral B-Disease 0 5.167752897250466e-05
retinoblastoma I-Disease 0 0.001838219235651195
. O 0 1.969036247828626e-06

In O 0 2.7223029519518605e-07
most O 0 3.2699666974167485e-08
patients O 0 9.649171062164896e-08
with O 0 1.275785255216988e-09
isolated O 0 1.5466768843452883e-07
unilateral B-Disease 0 6.097284767747624e-06
retinoblastoma I-Disease 0 0.00022739671112503856
, O 0 1.2988088826659805e-08
tumor B-Disease 0 7.331691165290977e-08
development O 0 2.5100879152972766e-09
is O 0 3.29008320587576e-10
initiated O 0 2.839862789372205e-09
by O 0 6.529647378350489e-10
somatic O 0 2.0764178998433636e-07
inactivation O 0 3.6900186728416884e-07
of O 0 1.5832851696373496e-10
both O 0 8.057734479649525e-10
alleles O 0 2.228257045544524e-08
of O 0 5.16552356444322e-10
the O 0 1.169399066469623e-08
RB1 O 0 1.7281205145991407e-05
gene O 0 1.6750730083003873e-06
. O 0 1.9120085426038713e-07

However O 0 3.7739602021247265e-07
, O 0 1.3256203912348496e-09
some O 0 1.9374299387031613e-10
of O 0 1.5592551555476675e-11
these O 0 3.203464438161774e-10
patients O 0 8.310204968609014e-09
can O 0 2.445193381106492e-09
transmit O 0 1.4234477703212178e-06
retinoblastoma B-Disease 0 0.0002291787095600739
predisposition O 0 7.608863597852178e-06
to O 0 1.5114570928176363e-08
their O 0 2.0671309997055687e-08
offspring O 0 1.4110092649843864e-07
. O 0 7.002943647194115e-08

To O 0 5.5801894660589824e-08
determine O 0 3.836770190446259e-08
the O 0 2.9694087189113816e-09
frequency O 0 8.629868375464866e-08
and O 0 5.2231374780831175e-09
nature O 0 7.438197835440974e-10
of O 0 3.1425767543780125e-10
constitutional O 0 5.8355315246672035e-08
RB1 O 0 7.238372199935839e-05
- O 0 1.313577172368241e-06
gene O 0 5.278508865558251e-07
mutations O 0 3.574228344405128e-07
in O 0 2.386024533507225e-08
patients O 0 4.6997076452726105e-08
with O 0 2.819556810251811e-10
isolated O 0 1.2185626019345364e-07
unilateral B-Disease 0 1.8703152591115213e-06
retinoblastoma I-Disease 0 1.9185406927135773e-05
, O 0 3.3906344398815236e-09
we O 0 6.717045808457556e-10
analyzed O 0 1.0465041055951474e-09
DNA O 0 3.5349876359447308e-09
from O 0 5.587532658779537e-10
peripheral O 0 4.05668316716401e-07
blood O 0 1.674951874974795e-07
and O 0 2.354357064859869e-08
from O 0 3.700894168900959e-08
tumor B-Disease 0 1.920813701872248e-06
tissue O 0 2.1158666640985757e-06
. O 0 8.647811711171016e-08

The O 0 4.166458822396635e-08
analysis O 0 2.752574701503363e-08
of O 0 3.079650312542981e-09
tumors B-Disease 1 0.9999990463256836
from O 0 5.6539062320837274e-09
54 O 0 2.766190299041682e-08
( O 0 8.117060912304908e-10
71 O 0 3.503321011066873e-08
% O 0 1.4046351581864513e-10
) O 0 4.4682806066287384e-11
of O 0 5.410983466846986e-11
76 O 0 5.830213467561407e-08
informative O 0 5.267571054901055e-07
patients O 0 8.321656423504464e-06
showed O 0 2.336762918275781e-06
loss O 0 2.9512627008898562e-08
of O 0 4.985014623315465e-10
constitutional O 0 6.145834419157836e-08
heterozygosity O 0 2.322540785826277e-05
( O 0 3.787697551160818e-07
LOH O 1 0.9994840621948242
) O 0 2.0799291178263957e-08
at O 0 1.080894946881017e-07
intragenic O 0 3.005662165378453e-06
loci O 0 1.7136682117779856e-06
. O 0 2.3613553423729172e-07

Three O 0 2.713014168875816e-07
of O 0 8.113782534735492e-09
13 O 0 2.1586325260614103e-07
uninformative O 0 8.644373883726075e-05
patients O 0 3.758149978239089e-05
had O 0 1.2297718967602123e-06
constitutional O 0 1.4721285879204515e-07
deletions O 0 8.48160925670527e-06
. O 0 2.0948340306858881e-07

For O 0 5.4912359104264397e-08
39 O 0 7.621513731237428e-08
randomly O 0 1.7789218986763444e-08
selected O 0 3.895793554420379e-08
tumors B-Disease 1 0.9999998807907104
, O 0 9.533004607931161e-09
SSCP O 0 8.478843483317178e-06
, O 0 6.042718769805333e-09
hetero O 0 8.54696463647997e-06
- O 0 3.466048497102747e-07
duplex O 0 2.875993459383608e-06
analysis O 0 1.515645919880626e-08
, O 0 3.061937092763145e-10
sequencing O 0 2.0124701904933318e-09
, O 0 1.7636968274725717e-10
and O 0 1.4329402941992697e-10
Southern O 0 1.5337481285015997e-09
blot O 0 1.8494088180887047e-06
analysis O 0 4.747346515898698e-09
were O 0 4.365143357887291e-09
used O 0 1.5554426635588925e-09
to O 0 2.6498567784472016e-09
identify O 0 2.246682981876802e-07
mutations O 0 1.0383378139522392e-06
. O 0 1.1281582601441187e-07

Mutations O 0 1.3236070117272902e-05
were O 0 1.1230400787098915e-07
detected O 0 2.1011403816828533e-07
in O 0 3.998894548828957e-09
21 O 0 1.887569212044582e-08
( O 0 4.4897430218071577e-10
91 O 0 5.62472468601527e-09
% O 0 2.0453701232714394e-10
) O 0 1.5227408223239536e-10
of O 0 2.0596209182599523e-09
23 O 0 0.00792638398706913
tumors B-Disease 1 1.0
with O 0 1.3997578207636252e-06
LOH O 1 0.999993085861206
. O 0 1.080355445992609e-06

In O 0 2.34072786042816e-07
6 O 0 1.1901735774699773e-07
( O 0 7.801654433592375e-09
38 O 0 9.985397397827e-09
% O 0 3.670045101156205e-10
) O 0 1.5068674086293754e-10
of O 0 4.203973003047423e-10
16 O 0 1.6649593817419372e-05
tumors B-Disease 1 1.0
without O 0 2.3507841433456633e-06
LOH O 1 0.9995738863945007
, O 0 5.755155241260468e-10
one O 0 4.2865130889246927e-10
mutation O 0 4.86614126771201e-09
was O 0 1.2556114370454452e-08
detected O 0 6.286552434175974e-08
, O 0 2.0140897283305037e-10
and O 0 6.434339172578518e-10
in O 0 2.027882972654993e-09
9 O 0 2.071045734908239e-08
( O 0 7.310096417079137e-10
56 O 0 6.857897361101095e-09
% O 0 8.726253747370905e-11
) O 0 3.280544585981815e-11
of O 0 7.905210513969863e-11
the O 0 4.219843958708225e-07
tumors B-Disease 1 1.0
without O 0 5.912617780268192e-06
LOH O 1 0.9998998641967773
, O 0 1.8653247835231923e-09
both O 0 1.1579148750939794e-09
mutations O 0 1.8387478206705055e-08
were O 0 9.86763737387264e-08
found O 0 2.5071802411957833e-08
. O 0 1.2783655023440588e-08

Thus O 0 1.8367695986398758e-07
, O 0 2.111276264926687e-09
a O 0 2.59892968257347e-10
total O 0 1.228036283773548e-10
of O 0 6.089641985118632e-11
45 O 0 2.302138923937491e-09
mutations O 0 1.3265645470994514e-08
were O 0 2.9038401905268074e-08
identified O 0 8.572172305321146e-08
in O 0 2.847031908004283e-07
tumors B-Disease 1 0.9999998807907104
of O 0 4.414947962771976e-09
36 O 0 6.346151053548965e-07
patients O 0 4.6574365342166857e-07
. O 0 6.346550662783557e-08

Thirty O 0 3.1863328331382945e-05
- O 0 1.3295263670443092e-05
nine O 0 6.952672659821246e-09
of O 0 7.622476261293087e-11
the O 0 4.0973405224242754e-10
mutations O 0 3.9127645123926413e-08
- O 0 3.7886870529746375e-08
including O 0 6.632588367416759e-10
34 O 0 8.222808212110522e-09
small O 0 2.6530582175610107e-09
mutations O 0 5.092880428492208e-08
, O 0 4.77564321421653e-10
2 O 0 7.598123241692178e-10
large O 0 2.0071342365923783e-09
structural O 0 0.0015908622881397605
alterations O 0 0.0032442344818264246
, O 0 4.054584223922575e-09
and O 0 5.5858726533131176e-09
hypermethylation O 0 1.9346236967976438e-06
in O 0 2.2802944954491977e-07
3 O 0 2.785861170195858e-06
tumors O 1 1.0
- O 0 2.769465027085971e-05
were O 0 9.353364589514968e-07
not O 0 3.799221381939333e-09
detected O 0 1.981157460306804e-08
in O 0 3.3319655368124756e-10
the O 0 2.0959042834611807e-10
corresponding O 0 2.3255601888649835e-09
peripheral O 0 1.0810883850354003e-06
blood O 0 1.8778705168642773e-07
DNA O 0 5.307913397700759e-07
. O 0 5.066246799856344e-08

In O 0 3.470421177098615e-07
6 O 0 8.24833747969933e-08
( O 0 3.405327131389413e-09
17 O 0 2.343160554474366e-09
% O 0 5.588361370878481e-11
) O 0 1.533503879436182e-11
of O 0 1.4463945666176592e-11
the O 0 7.440212890230669e-10
36 O 0 1.6518471568360837e-07
patients O 0 3.012055671547387e-08
, O 0 1.2906876956098046e-10
a O 0 2.463234061167441e-09
mutation O 0 3.207980014963141e-08
was O 0 1.1176146585967217e-07
detected O 0 3.5721861024740065e-08
in O 0 1.0421536966731537e-09
constitutional O 0 1.0418437224046784e-09
DNA O 0 7.170925631072578e-09
, O 0 1.904713470279873e-10
and O 0 9.976059561767059e-11
1 O 0 1.1053743337319233e-10
of O 0 1.031224064473868e-11
these O 0 3.280489768719974e-10
mutations O 0 1.317817965862389e-09
is O 0 3.1238997499905e-11
known O 0 2.1648785542005555e-10
to O 0 2.2566287727343592e-10
be O 0 5.052134266492203e-10
associated O 0 1.0424440199940932e-09
with O 0 4.547148213518426e-10
reduced O 0 9.29212760070186e-08
expressivity O 0 6.7070036493532825e-06
. O 0 1.583394606541333e-07

The O 0 2.1012780848650436e-08
presence O 0 5.8476392617023976e-09
of O 0 8.734896833617611e-11
a O 0 1.1139807964966053e-09
constitutional O 0 1.0748626877443712e-08
mutation O 0 3.340992904554696e-08
was O 0 1.984720796599504e-07
not O 0 3.6159727989648616e-10
associated O 0 1.9659178451814086e-10
with O 0 6.437564370465054e-11
an O 0 7.054968276243301e-10
early O 0 1.3527731425710954e-05
age O 0 8.902535597599126e-08
at O 0 1.7721962564110072e-08
treatment O 0 5.921687318277691e-08
. O 0 2.3245590341502975e-08

In O 0 2.7193087248633674e-07
1 O 0 1.4833732109309494e-07
patient O 0 4.336293102369382e-07
, O 0 2.9901705556056868e-09
somatic O 0 4.0137675227924774e-07
mosaicism O 0 2.8984039090573788e-05
was O 0 4.5144435034671915e-07
demonstrated O 0 3.077718524480133e-09
by O 0 1.9873773460243882e-10
molecular O 0 1.4592981267824712e-09
analysis O 0 9.583682736291621e-10
of O 0 2.0086037000321966e-10
DNA O 0 2.9530870193639203e-08
and O 0 2.4095718753613937e-09
RNA O 0 3.775846124653981e-08
from O 0 5.6095110778642265e-09
peripheral O 0 6.272518476180267e-06
blood O 0 1.7456948171457043e-06
. O 0 2.5795588953769766e-07

In O 0 6.000541930006875e-07
2 O 0 1.6903746313801093e-07
patients O 0 6.618149939185969e-08
without O 0 1.739509869480571e-09
a O 0 3.17375059566416e-09
detectable O 0 1.987278665183112e-06
mutation O 0 1.3206486926264915e-07
in O 0 1.030358642850615e-08
peripheral O 0 1.028168662742246e-05
blood O 0 1.1734407507901778e-06
, O 0 1.4239915024916172e-08
mosaicism O 0 2.2527642613567878e-06
was O 0 4.728182432245376e-07
suggested O 0 8.080131230769894e-09
because O 0 9.949346901905187e-10
1 O 0 3.7009889597428014e-10
of O 0 7.486330999562085e-11
the O 0 6.243269456973621e-09
patients O 0 2.1812584236613475e-06
showed O 0 0.01736121065914631
multifocal O 1 0.9999796152114868
tumors B-Disease 1 1.0
and O 0 1.065172980929674e-07
the O 0 8.162767684005701e-10
other O 0 9.994309824179481e-10
later O 0 2.4724469582793063e-08
developed O 0 5.4756625900154177e-08
bilateral B-Disease 0 2.0172421955066966e-06
retinoblastoma I-Disease 0 0.00011754065053537488
. O 0 6.715808922308497e-07

In O 0 2.9648495569745137e-07
conclusion O 0 5.421767212965278e-08
, O 0 8.352693536828326e-10
our O 0 2.5243607204572527e-10
results O 0 3.6926686708405043e-10
emphasize O 0 3.944810311740099e-10
that O 0 6.597773022365416e-11
the O 0 1.3974467416577596e-10
manifestation O 0 5.514597223310602e-09
and O 0 2.438472757049226e-09
transmissibility O 0 6.25794811526248e-08
of O 0 1.4084070021347372e-10
retinoblastoma B-Disease 0 6.054373358210796e-08
depend O 0 4.427318511801559e-09
on O 0 5.750582232622037e-09
the O 0 1.6790932533261582e-10
nature O 0 1.03335701107099e-10
of O 0 1.163474958737476e-11
the O 0 5.254928783782198e-11
first O 0 4.85901652247378e-10
mutation O 0 2.920528541228151e-10
, O 0 1.2147382925931094e-11
its O 0 2.375427111955819e-11
time O 0 8.579818522314042e-10
in O 0 4.256319741102743e-10
development O 0 2.3649401881264964e-10
, O 0 2.1407345340840322e-10
and O 0 1.3716598690205473e-10
the O 0 4.4410915917003635e-11
number O 0 9.602706130262817e-11
and O 0 1.1171761432615668e-10
types O 0 2.322965569900859e-10
of O 0 1.3300029480523001e-11
cells O 0 4.452577750946318e-10
that O 0 7.805505131130985e-10
are O 0 4.5856973773794607e-10
affected O 0 3.923606328726237e-09
. O 0 1.1835847857355475e-09
. O 0 1.464613674784232e-08

Hereditary B-Disease 1 0.9999988079071045
deficiency I-Disease 1 0.9997764229774475
of I-Disease 0 3.387996994064224e-09
the I-Disease 0 1.4390406644082532e-09
fifth I-Disease 0 1.922512282703792e-08
component I-Disease 0 2.8805045015900532e-09
of I-Disease 0 7.02172625599573e-11
complement I-Disease 0 3.758441557977221e-09
in O 0 7.165200344161349e-08
man O 0 1.2726632121484727e-05
. O 0 9.161511371758024e-08

I O 0 0.021649276837706566
. O 0 9.58129362516047e-07

Clinical O 0 5.703846545657143e-05
, O 0 1.3341825422230613e-07
immunochemical O 0 1.809287459764164e-05
, O 0 1.207917588175178e-08
and O 0 4.574901790732611e-09
family O 0 9.823053481738953e-09
studies O 0 2.9725610417585813e-08
. O 0 3.523001268490589e-08

The O 0 7.488726794235845e-08
first O 0 1.4841749162997075e-08
recognized O 0 2.5450586083053395e-09
human O 0 3.1007865164411896e-09
kindred O 0 6.693631439702585e-05
with O 0 1.8349835499975597e-06
hereditary B-Disease 1 0.9999995231628418
deficiency I-Disease 1 0.9196365475654602
of I-Disease 0 5.690948823300346e-10
the I-Disease 0 1.6780729028553765e-09
fifth I-Disease 0 7.498917398152116e-08
component I-Disease 0 1.300489671507421e-08
of I-Disease 0 4.1931302874331777e-10
complement I-Disease 0 3.2579389852571694e-08
( O 0 2.859556502698979e-08
C5 O 0 2.413323045402649e-06
) O 0 1.0150341678283326e-09
is O 0 7.772805732386701e-10
described O 0 3.336872467230023e-08
. O 0 3.878133725265798e-08

The O 0 2.471935829362337e-07
proband O 0 5.029361545894062e-06
, O 0 2.83121481814419e-09
a O 0 1.3828485023736903e-09
20 O 0 2.5685755744575545e-08
- O 0 2.674072447916842e-06
year O 0 1.3896650443712133e-06
- O 0 7.763856046949513e-06
old O 0 0.00014263544289860874
black O 0 7.591800255113412e-08
female O 0 2.952901390074203e-08
with O 0 1.266198808025365e-07
systemic B-Disease 1 1.0
lupus I-Disease 1 0.9999998807907104
erythematosus I-Disease 1 1.0
since O 0 1.1213016477995552e-05
age O 0 4.3761332335634506e-07
11 O 0 4.59877691483257e-09
, O 0 5.178219519841321e-10
lacked O 0 2.100677392036232e-07
serum O 0 5.950433319412696e-07
hemolytic O 0 1.7734220818965696e-05
complement O 0 7.083154685005866e-08
activity O 0 3.522457916460553e-07
, O 0 2.570166968141052e-09
even O 0 6.233607852124123e-09
during O 0 9.64343058740269e-08
remission O 0 7.318236043829529e-07
. O 0 2.9812596835654404e-08

C5 O 0 0.0006286503630690277
was O 0 9.692690809970372e-07
undetectable O 0 1.1969979141213116e-06
in O 0 7.458460515863408e-09
her O 0 5.202774211454653e-09
serum O 0 1.4064810649472292e-08
by O 0 5.65884450409726e-10
both O 0 6.119151851891047e-09
immunodiffusion O 0 4.643618012778461e-06
and O 0 1.4809633341883455e-07
hemolytic O 0 0.00023078602680470794
assays O 0 3.585890226531774e-05
. O 0 2.932122526999592e-07

Other O 0 4.3560469009662484e-08
complement O 0 1.91141182881438e-08
components O 0 2.5642776790846256e-08
were O 0 1.5178590828668348e-08
normal O 0 2.2637442143036424e-08
during O 0 3.757461186637556e-08
remission O 0 7.698083237528408e-08
of O 0 8.719486244146424e-10
lupus O 0 2.358209940211964e-06
, O 0 4.32211877399169e-10
but O 0 1.301437446699083e-08
C1 O 0 5.474620138556929e-06
, O 0 8.668082362994767e-10
C4 O 0 2.593174485809868e-06
, O 0 3.522173441794507e-09
C2 O 0 4.6196282710297965e-07
, O 0 7.292966786032196e-10
and O 0 3.1023306146238383e-09
C3 O 0 3.83868473363691e-06
levels O 0 1.49056148757154e-07
fell O 0 0.0002890547621063888
during O 0 3.790689788729651e-07
exacerbations O 0 2.3838401830289513e-05
. O 0 9.821408752941352e-08

A O 0 7.300534889509436e-06
younger O 0 1.6807248357508797e-06
half O 0 1.3710445045944653e-07
- O 0 4.647241439670324e-06
sister O 0 6.681528930130298e-07
, O 0 1.1075677042171606e-09
who O 0 6.4949832179195255e-09
had O 0 6.994107337732203e-08
no O 0 9.40266087212649e-09
underlying O 0 2.768344529613387e-06
disease O 0 9.590215768184862e-07
, O 0 1.6615243625395237e-09
was O 0 3.4809784210665384e-07
also O 0 1.534810389891561e-09
found O 0 1.870005705839617e-09
to O 0 1.5327831226485955e-09
lack O 0 6.150161624418615e-08
immunochemically O 0 1.767836329236161e-05
detectable O 0 3.801201091846451e-05
C5 O 0 3.6970730434404686e-05
. O 0 2.1451965892538283e-07

By O 0 4.716176817964879e-07
hemolytic O 0 0.013801938854157925
assay O 0 2.2193207769305445e-05
, O 0 1.598254151247147e-08
she O 0 1.3635671258782622e-08
exhibited O 0 1.105506264309497e-08
1 O 0 9.822261892722395e-10
- O 0 1.322996556751832e-08
2 O 0 3.1509853060107673e-10
% O 0 3.8918958333855613e-11
of O 0 1.0133811324808395e-11
the O 0 3.1150237944643777e-10
normal O 0 1.593776133290703e-08
serum O 0 1.205690978167695e-07
C5 O 0 6.247506689760485e-07
level O 0 1.259252169205638e-08
and O 0 5.240817779750273e-10
normal O 0 3.239287060807783e-09
concentrations O 0 2.5061845931872995e-09
of O 0 6.131248980745241e-11
other O 0 2.2551659151215375e-10
complement O 0 5.702327943168939e-09
components O 0 1.1969883928486524e-07
. O 0 3.774779955278973e-08

C5 O 0 0.0003247353888582438
levels O 0 2.3910411073302384e-07
of O 0 2.451262526292908e-10
other O 0 2.402352206054559e-10
family O 0 1.7219144166080724e-10
members O 0 1.698577216380226e-11
were O 0 7.521744338490066e-10
either O 0 7.314560068749643e-10
normal O 0 4.536997000315068e-09
or O 0 6.796171958534103e-10
approximately O 0 2.412914035243574e-10
half O 0 1.5036132339218966e-08
- O 0 3.842255580366327e-07
normal O 0 4.413888987642167e-08
, O 0 1.0114685755624464e-09
consistent O 0 2.3884515698568975e-08
with O 0 8.312772692420367e-09
autosomal O 0 6.174644659040496e-05
codominant O 0 1.4936115803720895e-05
inheritance O 0 1.6661590507283108e-07
of O 0 8.109029003833257e-10
the O 0 5.447699624738789e-09
gene O 0 4.48670925834449e-06
determining O 0 7.62930721975863e-05
C5 B-Disease 1 1.0
deficiency I-Disease 1 1.0
. O 0 1.5302620113288867e-06

Normal O 0 0.0007324153557419777
hemolytic O 1 0.9881844520568848
titers O 0 0.011525682173669338
were O 0 8.643893352200394e-07
restored O 0 1.8873356566473376e-07
to O 0 2.1355075485729458e-09
both O 0 1.1790474374606674e-08
homozygous O 1 0.8204542994499207
C5 B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
deficient I-Disease 1 1.0
( O 0 6.07321862844401e-06
C5D B-Disease 1 1.0
) O 0 6.8506933459389074e-09
sera O 0 3.512500867941526e-08
by O 0 8.758786751439374e-11
addition O 0 1.5142256892808348e-10
of O 0 8.316983213241258e-11
highly O 0 4.522853203070554e-09
purified O 0 2.5952619608915484e-08
human O 0 1.8441568272464792e-08
C5 O 0 7.937969712656923e-06
. O 0 1.1255350784722395e-07

In O 0 5.592665957010468e-07
specific O 0 1.8636281140516076e-07
C5 O 0 1.210926529893186e-05
titrations O 0 6.848437351436587e-06
, O 0 4.280126475464385e-09
however O 0 1.5676542286513495e-09
, O 0 1.6251437695569138e-10
it O 0 6.300543420323379e-10
was O 0 4.4655777742264036e-08
noted O 0 4.171051004586701e-10
that O 0 4.511037030030529e-11
when O 0 6.529644186459294e-11
limited O 0 8.511422122658985e-11
amounts O 0 1.4029589989750235e-10
of O 0 1.0452806675775861e-10
C5 O 0 8.85447661858052e-08
were O 0 3.6825913429794355e-09
assayed O 0 1.4000681503034684e-08
in O 0 4.5271489335085846e-10
the O 0 2.3056004327948187e-10
presence O 0 8.408912455237783e-10
of O 0 1.9341364621006107e-10
low O 0 1.0265221561667204e-07
dilutions O 0 1.5798621006979374e-06
of O 0 5.055797447361954e-10
either O 0 1.9905135673070617e-07
C5D B-Disease 1 0.9999998807907104
serum O 0 2.024684562229595e-07
, O 0 7.022117887167667e-10
curving O 0 1.1508807240545593e-08
rather O 0 1.4133593184695314e-09
than O 0 3.40620254224433e-10
linear O 0 3.269129411620497e-09
dose O 0 9.500042779109208e-07
- O 0 5.913785798838944e-07
response O 0 9.800035449814004e-09
plots O 0 1.1946079681024457e-08
were O 0 4.3354738465950504e-08
consistently O 0 2.1058188526268395e-09
obtained O 0 4.456137681074779e-10
, O 0 8.328968764681477e-11
suggesting O 0 1.1524067256019066e-09
some O 0 1.5807262443434666e-10
inhibitory O 0 3.2072705380414845e-08
effect O 0 4.374581052957183e-08
. O 0 2.0590169569345562e-08

Further O 0 1.5001847941675805e-07
studies O 0 3.685474325720861e-08
suggested O 0 2.8631749415808372e-08
that O 0 1.7192667289833707e-09
low O 0 1.4975375961512327e-07
dilutions O 0 2.5262877898057923e-05
of O 0 7.230449572404041e-09
C5D B-Disease 1 0.9999997615814209
serum O 0 7.176826244403856e-08
contain O 0 3.759509592526911e-09
a O 0 4.398037489750095e-09
factor O 0 8.433024945020406e-09
( O 0 3.510367552195248e-10
or O 0 8.685360208815496e-10
factors O 0 8.10321587607632e-10
) O 0 1.1919733255982834e-10
interfering O 0 5.0015507291334416e-09
at O 0 1.1935784804961713e-08
some O 0 5.784461243329986e-10
step O 0 2.613465888146038e-09
in O 0 1.6404075875442459e-09
the O 0 4.167243439212598e-09
hemolytic O 0 9.111355211643968e-06
assay O 0 2.510358001472923e-07
of O 0 3.6274694359406112e-09
C5 O 0 1.4676089449494611e-05
, O 0 7.340765773022895e-10
rather O 0 9.505637388329546e-10
than O 0 1.366873281227754e-09
a O 0 4.570130940351191e-09
true O 0 7.161305859426648e-08
C5 O 0 5.08934454046539e-06
inhibitor O 0 1.1281255183348549e-06
or O 0 5.6612687870938316e-08
inactivator O 0 4.765739049616968e-06
. O 0 1.3509783514109586e-07

Of O 0 3.9059042222788776e-08
clinical O 0 2.898279944929527e-07
interest O 0 2.0944517231669124e-08
are O 0 1.1721272841214159e-09
( O 0 7.101071952675397e-10
a O 0 8.988229049933238e-10
) O 0 2.385030228868601e-10
the O 0 8.276444529720095e-10
documentation O 0 5.6126179259763376e-08
of O 0 3.8897622900435636e-09
membranous O 0 0.092083640396595
glomerulonephritis B-Disease 1 1.0
, O 0 2.077272438327782e-05
vasculitis B-Disease 1 1.0
, O 0 4.617025126663066e-07
and O 0 0.00021052363445051014
arthritis B-Disease 1 1.0
in O 0 5.496118404835215e-08
an O 0 1.3121720376929602e-09
individual O 0 2.887430072817665e-09
lacking O 0 1.6674418930051615e-06
C5 O 0 1.0145885426027235e-05
( O 0 1.3146095323435247e-09
and O 0 3.610025611777701e-10
its O 0 1.2365235224631732e-10
biologic O 0 6.27160616772926e-08
functions O 0 2.7178015393758415e-10
) O 0 1.3776667306952817e-10
, O 0 1.503425162141525e-10
and O 0 9.002795731127833e-10
( O 0 8.235973014691922e-10
b O 0 2.983739832984611e-08
) O 0 6.688469222915217e-11
a O 0 3.4327146680723786e-10
remarkable O 0 8.216804125993349e-09
propensity O 0 3.378661403985461e-07
to O 0 2.2418952028147032e-07
bacterial B-Disease 1 1.0
infections I-Disease 1 1.0
in O 0 2.5075036091948277e-07
the O 0 1.2869796783832044e-08
proband O 0 8.73822273206315e-07
, O 0 4.1518344318092204e-10
even O 0 9.900846809074437e-10
during O 0 9.423068991765149e-10
periods O 0 1.456384013387435e-09
of O 0 1.262733667628524e-10
low O 0 2.506128851109679e-07
- O 0 9.997616956525235e-08
dose O 0 1.0610809653144315e-07
or O 0 1.1387771614579378e-08
alternate O 0 6.243688943641246e-08
- O 0 1.7031010202117614e-06
day O 0 3.2219065815297654e-07
corticosteroid O 0 1.2241189324413426e-05
therapy O 0 1.0532726264500525e-05
. O 0 7.747118502265948e-08

Other O 0 7.510855937198357e-08
observations O 0 6.74052529348046e-08
indicate O 0 4.554982524496154e-08
that O 0 8.630979264623306e-10
the O 0 1.6300341076913583e-09
C5D B-Disease 1 0.9999994039535522
state O 0 5.020970306190975e-10
is O 0 1.4125203784409734e-10
compatible O 0 3.808333648436246e-09
with O 0 2.464431159143743e-10
normal O 0 9.534095291030553e-09
coagulation O 0 2.0116807775139023e-08
function O 0 1.4666592385026433e-09
and O 0 1.3109788810083955e-09
the O 0 2.0661591881854235e-10
capacity O 0 8.788494931799562e-10
to O 0 4.522169583243141e-10
mount O 0 9.78967023002042e-08
a O 0 2.2377403752216196e-07
neutrophilic O 0 0.00045166461495682597
leukocytosis O 0 0.00032808029209263623
during O 0 3.140955413982738e-06
pyogenic B-Disease 0 0.003095238469541073
infection I-Disease 0 0.002334738150238991
. O 0 3.8973983151890934e-08
. O 0 7.392648626591836e-08

Susceptibility O 0 0.0024221634957939386
to O 0 0.0006305279093794525
ankylosing B-Disease 1 1.0
spondylitis I-Disease 1 1.0
in O 0 9.214445890393108e-05
twins O 0 3.2769339668448083e-06
: O 0 3.656225044945671e-10
the O 0 4.008611845240928e-11
role O 0 3.1586272486450184e-10
of O 0 2.901305584668279e-11
genes O 0 5.366945554641234e-09
, O 0 1.11484799170114e-09
HLA O 0 3.4501198342695716e-07
, O 0 3.860196606808586e-10
and O 0 6.68419986027402e-10
the O 0 1.1574600167207905e-09
environment O 0 2.5058939812083736e-08
. O 0 2.3419062245011446e-08

OBJECTIVE O 0 9.452145945942902e-07
To O 0 4.1797494354511855e-09
determine O 0 3.4906995072248037e-09
the O 0 2.1378213088674158e-10
relative O 0 4.567621392226329e-09
effects O 0 1.3887222927166931e-08
of O 0 2.7197355478847385e-10
genetic O 0 8.774078352757897e-09
and O 0 2.207034999202051e-09
environmental O 0 6.530232465884467e-10
factors O 0 1.1625177487317728e-09
in O 0 6.032423893742589e-09
susceptibility O 0 2.0375746316858567e-06
to O 0 0.0056623611599206924
ankylosing B-Disease 1 1.0
spondylitis I-Disease 1 1.0
( O 0 1.8684984752326272e-05
AS B-Disease 1 0.9998741149902344
) O 0 1.2433003071521398e-08
. O 0 3.99478743418058e-08

METHODS O 0 7.2265056587639265e-06
Twins O 0 7.073015240166569e-06
with O 0 3.799605075016643e-09
AS B-Disease 1 0.9999967813491821
were O 0 2.5804295589182402e-08
identified O 0 7.665607593132506e-10
from O 0 1.9422842501004567e-10
the O 0 5.566194727357754e-10
Royal O 0 4.606697956432981e-08
National O 0 1.925469117480816e-09
Hospital O 0 2.9477575935743516e-06
for O 0 1.9470789425213297e-07
Rheumatic B-Disease 1 0.9997113347053528
Diseases I-Disease 0 0.0011085855076089501
database O 0 1.1664673138511716e-06
. O 0 3.9297992771025747e-07

Clinical O 0 3.102264599874616e-05
and O 0 1.3787912678253633e-07
radiographic O 0 3.1052182748680934e-05
examinations O 0 5.728474206989631e-05
were O 0 6.677911557062544e-08
performed O 0 3.662313119434657e-09
to O 0 1.169001007106374e-10
establish O 0 8.513735494375396e-09
diagnoses O 0 0.00012444031017366797
, O 0 5.572624139915661e-09
and O 0 3.4578542340568674e-07
disease O 0 1.915257416840177e-05
severity O 0 1.2518529729277361e-05
was O 0 5.100025077808823e-07
assessed O 0 3.689579752830241e-09
using O 0 9.029864633802731e-10
a O 0 5.007698700154606e-09
combination O 0 8.314980703971742e-08
of O 0 1.7652963535397248e-09
validated O 0 1.4840185258435667e-07
scoring O 0 1.4351756760788703e-07
systems O 0 7.081067110448203e-07
. O 0 1.4306783668871503e-07

HLA O 0 0.003980838693678379
typing O 0 0.00016185939603019506
for O 0 1.4586970564778312e-07
HLA O 0 3.370821286807768e-05
- O 0 1.7956313058675732e-06
B27 O 0 2.529309085730347e-06
, O 0 2.3632201973100564e-08
HLA O 0 2.5629292395024095e-06
- O 0 3.3022649859049125e-07
B60 O 0 3.109951762780838e-07
, O 0 8.736317225199741e-10
and O 0 3.662103287283003e-09
HLA O 0 5.368261099647498e-06
- O 0 4.430811259226175e-06
DR1 O 1 0.8973499536514282
was O 0 8.606212418271753e-07
performed O 0 2.3533903714678672e-09
by O 0 8.799375811330279e-11
polymerase O 0 2.758803141489352e-08
chain O 0 1.3472774895717521e-08
reaction O 0 9.264776723583168e-10
with O 0 5.426828084131863e-11
sequence O 0 1.1950197498222792e-09
- O 0 8.750713931249265e-09
specific O 0 1.60072133326139e-09
primers O 0 1.029215468406619e-06
, O 0 1.8415020619499956e-09
and O 0 4.2846188819112285e-09
zygosity O 0 9.117441095440881e-07
was O 0 1.457441385355196e-07
assessed O 0 1.0266549388404655e-08
using O 0 6.768634097653603e-09
microsatellite O 0 1.6230162600550102e-06
markers O 0 3.806168251685449e-06
. O 0 2.908147678226669e-07

Genetic O 0 9.781299013411626e-06
and O 0 3.020846506274211e-08
environmental O 0 1.7790567907738364e-09
variance O 0 1.321936560216841e-09
components O 0 4.971441924794817e-08
were O 0 3.530758192482608e-07
assessed O 0 1.2814854066789394e-08
with O 0 5.490829318999246e-11
the O 0 2.794889597534933e-10
program O 0 3.2683253881060637e-09
Mx O 0 3.110396207262056e-08
, O 0 3.2859298615406374e-11
using O 0 1.3597011017107974e-10
data O 0 1.8870751627986238e-09
from O 0 1.9787384231140237e-10
this O 0 1.347936762208235e-10
and O 0 2.730885517721049e-10
previous O 0 1.2892860112856397e-09
studies O 0 7.149576486398246e-10
of O 0 6.038495398152932e-11
twins O 0 4.8619689607676264e-08
with O 0 5.4974473862046125e-09
AS B-Disease 1 0.9999985694885254
. O 0 1.71440248664112e-07

RESULTS O 0 3.240894147893414e-05
Six O 0 5.349451726033294e-08
of O 0 1.7967177745603635e-09
8 O 0 1.5298273581265676e-07
monozygotic O 0 7.603073754580691e-05
( O 0 8.310666430588753e-07
MZ O 1 0.9999226331710815
) O 0 5.029755811847281e-08
twin O 0 6.3698498706799e-06
pairs O 0 2.363353814871516e-07
were O 0 1.723992136248853e-05
disease O 0 3.7082679682498565e-06
concordant O 0 1.1161952215843485e-06
, O 0 2.5973352357766544e-09
compared O 0 1.3957247801954509e-08
with O 0 4.849942114582007e-10
4 O 0 4.0256336042432395e-09
of O 0 6.901366700340361e-10
15 O 0 6.690302711831464e-08
B27 O 0 2.147408622477087e-06
- O 0 9.43941358855227e-06
positive O 0 7.127347885216295e-07
dizygotic O 0 1.1428238394728396e-05
( O 0 3.5341468418437216e-08
DZ O 0 0.00010589930752757937
) O 0 2.2978616787128203e-09
twin O 0 4.7823750293218836e-08
pairs O 0 1.286201722905389e-08
( O 0 5.115278423062364e-09
27 O 0 4.22410373346338e-08
% O 0 1.5608210557349622e-10
) O 0 5.297901353729095e-11
and O 0 3.7658734464152133e-10
4 O 0 5.511776035582727e-10
of O 0 3.3772204477422463e-10
32 O 0 1.1344411632308038e-06
DZ O 1 0.9205710291862488
twin O 0 2.7928251711273333e-06
pairs O 0 4.7871207442540253e-08
overall O 0 9.340875521957059e-07
( O 0 7.265120061106245e-09
12 O 0 1.3070296844830409e-08
. O 0 4.797993669036771e-10
5 O 0 2.0974810777119046e-09
% O 0 7.384228228879408e-10
) O 0 2.3306312435522614e-09
. O 0 2.7654834866552847e-08

Nonsignificant O 0 7.912136061349884e-05
increases O 0 5.668010203407903e-07
in O 0 6.019183373950909e-09
similarity O 0 6.645900718638131e-09
with O 0 8.613788848865767e-11
regard O 0 1.0796886718011933e-09
to O 0 1.4466415843017444e-09
age O 0 8.198146872473444e-08
at O 0 5.524632342712721e-07
disease O 0 7.172870937210973e-07
onset O 0 1.6112571188386937e-07
and O 0 1.399829807624542e-09
all O 0 7.766414594767568e-11
of O 0 5.051620580176497e-11
the O 0 1.4521132740696885e-08
disease O 0 5.426191819424275e-06
severity O 0 1.5849144574531238e-06
scores O 0 1.1521945708636849e-07
assessed O 0 2.383604780220594e-08
were O 0 3.4078759370004263e-08
noted O 0 1.7867566981522032e-08
in O 0 1.3631333217745123e-07
disease O 0 9.501278691459447e-05
- O 0 0.0059364126063883305
concordant O 0 0.007746185176074505
MZ O 1 0.9999774694442749
twins O 0 8.676524157635868e-05
compared O 0 1.2374470088616363e-06
with O 0 4.5497468903477056e-08
concordant O 0 0.00042380025843158364
DZ O 1 0.9951385259628296
twins O 0 0.00013930784189142287
. O 0 8.408324561059999e-07

HLA O 0 0.25479188561439514
- O 0 0.0010105246910825372
B27 O 0 1.8550012100604363e-05
and O 0 2.309766600205876e-08
B60 O 0 1.6756420961883123e-07
were O 0 5.795175894718341e-09
associated O 0 5.478049125429152e-10
with O 0 9.268660838834819e-11
the O 0 3.72624953115519e-09
disease O 0 1.1175442438116079e-07
in O 0 1.2762654044706778e-08
probands O 0 1.9192389117961284e-06
, O 0 3.153594885230149e-10
and O 0 2.103786450602385e-10
the O 0 7.074628660674875e-10
rate O 0 2.3200128396183572e-07
of O 0 5.70058500404258e-10
disease O 0 9.473698980855261e-08
concordance O 0 1.208733806379314e-07
was O 0 1.6126161028751085e-07
significantly O 0 1.7350572534269304e-08
increased O 0 4.876306025636268e-09
among O 0 8.835207232493758e-09
DZ O 0 0.031038733199238777
twin O 0 2.899114690535498e-07
pairs O 0 4.41777814330635e-09
in O 0 2.5522921553999822e-09
which O 0 1.1123459930928448e-09
the O 0 2.1864456911657726e-09
co O 0 3.682449914776953e-06
- O 0 0.0001150934913312085
twin O 0 1.5935343981254846e-05
was O 0 1.545634631838766e-06
positive O 0 3.198502573908968e-09
for O 0 1.3554882216659792e-10
both O 0 1.2632063173256824e-09
B27 O 0 2.2934541732411162e-07
and O 0 3.768406742210573e-08
DR1 O 0 0.06779980659484863
. O 0 1.1892726803353071e-07

Additive O 0 3.1809629490453517e-06
genetic O 0 1.3822552773490315e-06
effects O 0 3.7434480759657163e-07
were O 0 2.2538609201205873e-08
estimated O 0 2.627619788420077e-10
to O 0 4.821789148512501e-11
contribute O 0 1.8777177035467219e-10
97 O 0 5.927627722002171e-09
% O 0 8.403119866606801e-11
of O 0 2.8615599473313935e-11
the O 0 2.7319274620296596e-10
population O 0 1.3732959214252105e-10
variance O 0 6.615017866806738e-09
. O 0 3.072810628168554e-08

CONCLUSION O 0 3.765906285480014e-06
Susceptibility O 0 2.2247886590776034e-06
to O 0 5.023609972454324e-08
AS B-Disease 1 0.9999566078186035
is O 0 3.245921309513733e-10
largely O 0 4.153973276466161e-10
genetically O 0 4.739376002760309e-09
determined O 0 4.0854985172700253e-08
, O 0 6.777363670273928e-10
and O 0 8.451410127285897e-10
the O 0 5.248060319651415e-10
environmental O 0 3.3978140301371695e-09
trigger O 0 1.4279302718023246e-07
for O 0 1.3917604846369613e-09
the O 0 1.722224851619103e-08
disease O 0 8.928380452744022e-07
is O 0 3.252510927254093e-09
probably O 0 3.563864083844237e-07
ubiquitous O 0 7.686506364734669e-07
. O 0 7.317915873272796e-08

HLA O 0 0.004110309761017561
- O 0 2.7867810786119662e-05
B27 O 0 4.423033317380032e-07
accounts O 0 3.5008214105403113e-09
for O 0 1.7776516370027196e-10
a O 0 4.09359102171436e-10
minority O 0 7.667889101448111e-10
of O 0 8.387444211388484e-11
the O 0 1.0590217591754936e-09
overall O 0 1.8347790842199174e-07
genetic O 0 1.1510315545137928e-07
susceptibility O 0 1.506697060449369e-07
to O 0 7.747709673822101e-08
AS B-Disease 1 0.999997615814209
. O 0 3.280712519426743e-07

Cell O 0 0.00024411664344370365
cycle O 0 3.503778498270549e-05
- O 0 1.0679781553335488e-05
dependent O 0 6.452239063037268e-07
colocalization O 0 1.9437152332102414e-06
of O 0 3.316521945961881e-09
BARD1 O 0 4.54239943792345e-06
and O 0 4.811320675202069e-09
BRCA1 O 0 7.104438282112824e-08
proteins O 0 1.3193621750673401e-09
in O 0 1.4593036778975943e-09
discrete O 0 4.030237121810387e-08
nuclear O 0 1.2360870869088103e-06
domains O 0 8.860014872880129e-07
. O 0 1.1644684150269313e-07

Germ O 0 0.4935743510723114
- O 0 0.3135289251804352
line O 0 1.2458051969588269e-05
mutations O 0 4.890307536697946e-07
of O 0 5.993221474653865e-10
the O 0 2.648250063685964e-09
BRCA1 O 0 3.312078206363367e-06
gene O 0 2.607010856081615e-07
predispose O 0 2.1244123615815624e-07
women O 0 6.944998798275037e-09
to O 0 1.8065903217845403e-09
early O 0 0.0032292611431330442
- O 1 0.9999821186065674
onset O 1 0.9999570846557617
breast B-Disease 1 0.9999996423721313
and I-Disease 1 0.9999982118606567
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.999992847442627
by O 0 3.844474516512264e-09
compromising O 0 1.58407885919587e-07
the O 0 1.0165183139676515e-09
genes O 0 2.7700869154045904e-08
presumptive O 0 3.355762316914479e-07
function O 0 1.2244637304092976e-08
as O 0 1.5915768258878416e-08
a O 0 1.8019218828158046e-07
tumor B-Disease 0 1.3383792975218967e-05
suppressor O 0 7.230258779600263e-05
. O 0 1.4722284049639711e-06

Although O 0 2.570891979303269e-07
the O 0 4.324446134518212e-09
biochemical O 0 4.365936945305293e-08
properties O 0 1.606496802253332e-08
of O 0 5.431677330136608e-10
BRCA1 O 0 1.1847913583551417e-06
polypeptides O 0 7.702445969925975e-08
are O 0 1.206270638931528e-09
not O 0 1.4934143921507825e-09
understood O 0 3.917474789005837e-09
, O 0 9.781444404444173e-11
their O 0 7.740991875282432e-11
expression O 0 1.6175897288306373e-09
pattern O 0 4.0468368212032146e-08
and O 0 1.8096527609756663e-09
subcellular O 0 1.7321596601505007e-07
localization O 0 1.4946938620141736e-07
suggest O 0 1.0554791707306777e-08
a O 0 9.976178771964328e-10
role O 0 3.0247888638257336e-09
in O 0 4.036928569206566e-09
cell O 0 6.453373771364568e-06
- O 0 0.00012204662198200822
cycle O 0 2.1668861336365808e-06
regulation O 0 3.4430572668497916e-06
. O 0 6.286060738602828e-08

When O 0 7.741068657196593e-07
resting O 0 2.7932676971431647e-07
cells O 0 3.017753869016815e-08
are O 0 7.54536766400804e-10
induced O 0 1.2589640441262873e-08
to O 0 8.120962791124953e-10
proliferate O 0 1.5690871180140675e-07
, O 0 4.2919615084180407e-10
the O 0 3.463704878470253e-10
steady O 0 2.68445631945724e-07
- O 0 4.732556124764642e-09
state O 0 1.5476796233482304e-10
levels O 0 3.783519886280118e-10
of O 0 3.1884730966602604e-11
BRCA1 O 0 1.6532395008539424e-08
increase O 0 8.35200797411062e-10
in O 0 2.5075854725997715e-09
late O 0 5.632725788018433e-07
G1 O 0 5.959304303360113e-07
and O 0 1.1107091912876399e-09
reach O 0 1.679142158650393e-09
a O 0 1.1379819309098593e-09
maximum O 0 5.002505076845409e-09
during O 0 4.2425131852041886e-08
S O 0 1.1046062127206824e-06
phase O 0 3.1464065841646516e-07
. O 0 6.277063135939898e-08

Moreover O 0 2.0993247744627297e-06
, O 0 1.7526120998923034e-08
in O 0 1.3670097054330199e-08
S O 0 1.2566102896016673e-06
phase O 0 4.0447996951797904e-08
cells O 0 3.312414165179689e-08
, O 0 2.9336444384853166e-09
BRCA1 O 0 4.5833718331778073e-07
polypeptides O 0 1.1222821427736562e-07
are O 0 3.0991547106395956e-09
hyperphosphorylated O 0 2.3827848849578004e-07
and O 0 5.810316672238969e-09
accumulate O 0 2.4748011639985634e-08
into O 0 3.6736047537289096e-09
discrete O 0 2.071384415103239e-07
subnuclear O 0 1.704411261016503e-05
foci O 0 9.979353308153804e-06
termed O 0 2.852279067155905e-06
" O 0 5.122408879287832e-07
BRCA1 O 0 5.1422498472675215e-06
nuclear O 0 2.104673285430181e-06
dots O 0 2.979424607474357e-05
. O 0 3.5245076901446737e-07

" O 0 6.776012924092356e-06
BRCA1 O 0 8.535121742170304e-05
associates O 0 1.4484337498288369e-06
in O 0 9.244094378857426e-09
vivo O 0 2.5590603058844863e-07
with O 0 1.1279420730758716e-09
a O 0 1.3653497887844424e-08
structurally O 0 3.053118780371733e-05
related O 0 1.1406535804781015e-07
protein O 0 3.344321442000364e-07
termed O 0 3.3512703794258414e-06
BARD1 O 0 0.00025282378192059696
. O 0 5.829924134559406e-07

Here O 0 3.618791879489436e-07
we O 0 3.509847301685909e-09
show O 0 1.850981590223455e-09
that O 0 5.0013739677501334e-11
the O 0 1.2177593655682273e-10
steady O 0 9.316013205307172e-08
- O 0 3.5730294278835117e-09
state O 0 1.2118162029395307e-10
levels O 0 7.904144561088344e-10
of O 0 6.60285923159698e-11
BARD1 O 0 3.548345262061048e-07
, O 0 7.039238636430412e-11
unlike O 0 1.4256641700516326e-10
those O 0 1.1810021016689376e-10
of O 0 9.099847958493612e-11
BRCA1 O 0 3.582230192478164e-07
, O 0 3.9546568797454995e-10
remain O 0 1.3199712434186495e-09
relatively O 0 2.341043137121801e-09
constant O 0 9.388466892801262e-09
during O 0 3.2201306510160066e-08
cell O 0 6.757040864613373e-06
cycle O 0 9.690999149825075e-07
progression O 0 9.174282808999124e-07
. O 0 5.848300688171548e-08

However O 0 3.0572275591111975e-06
, O 0 9.001704626143692e-08
immunostaining O 0 3.769956265387009e-06
revealed O 0 3.2582815379100794e-07
that O 0 4.313687629320384e-09
BARD1 O 0 2.0900436084048124e-06
resides O 0 1.0377151582474653e-08
within O 0 2.5296107430961e-09
BRCA1 O 0 1.6194293266380555e-06
nuclear O 0 5.996451477585651e-07
dots O 0 1.2933970765516278e-06
during O 0 9.191826677579229e-08
S O 0 2.4309747459483333e-07
phase O 0 4.225712668670667e-09
of O 0 4.880953627384166e-11
the O 0 1.888860179377616e-10
cell O 0 1.5792218732713081e-07
cycle O 0 6.670082797199939e-08
, O 0 3.5347832993970485e-10
but O 0 1.1239970065801685e-09
not O 0 2.2785959230553487e-10
during O 0 1.6027804639051624e-09
the O 0 2.8316304856446095e-09
G1 O 0 3.8146642964420607e-06
phase O 0 2.5370346179443004e-07
. O 0 7.047268724136302e-08

Nevertheless O 0 2.141666118404828e-05
, O 0 4.600972758339594e-08
BARD1 O 0 1.5916472193566733e-06
polypeptides O 0 7.421341052804564e-08
are O 0 5.634203104065705e-10
found O 0 1.924722742296936e-10
exclusively O 0 2.154415812416488e-10
in O 0 2.7565755233993627e-10
the O 0 1.1805899313710455e-10
nuclear O 0 9.596802463818221e-09
fractions O 0 4.913632611902585e-09
of O 0 4.2952679607521915e-11
both O 0 8.821831598559982e-10
G1 O 0 1.2831261528845062e-06
- O 0 6.297221233353412e-08
and O 0 1.2936367532745408e-08
S O 0 1.933028443090734e-06
- O 0 3.645241406502464e-07
phase O 0 9.115564836292833e-08
cells O 0 6.029929977557913e-08
. O 0 3.0886170065969054e-08

Therefore O 0 2.9833304893145396e-07
, O 0 9.180329385571895e-09
progression O 0 7.485713382493486e-08
to O 0 2.164689760775218e-09
S O 0 2.5011198090396647e-07
phase O 0 1.1075006689509337e-08
is O 0 2.0142433554415362e-10
accompanied O 0 3.6517924795198553e-10
by O 0 1.3351454664078943e-10
the O 0 3.010266480529822e-10
aggregation O 0 2.781775920723817e-09
of O 0 2.1370141767285133e-10
nuclear O 0 2.7986033046545344e-07
BARD1 O 0 2.025724597842782e-06
polypeptides O 0 1.6481382658639632e-07
into O 0 4.304607514882264e-08
BRCA1 O 0 6.782517175452085e-06
nuclear O 0 2.8212116376380436e-06
dots O 0 2.0982375644962303e-05
. O 0 4.254563350514218e-07

This O 0 2.5313406126770133e-07
cell O 0 6.230000963114435e-06
cycle O 0 2.6758300464280182e-06
- O 0 8.594385008109384e-07
dependent O 0 1.6054958962286037e-07
colocalization O 0 1.3234631524028373e-06
of O 0 1.7856792711157254e-09
BARD1 O 0 1.0850384569494054e-05
and O 0 1.581922504101385e-08
BRCA1 O 0 9.076431410903751e-07
indicates O 0 1.5198349245792997e-08
a O 0 8.512335836208251e-10
role O 0 2.2790795917160267e-09
for O 0 4.917352636191197e-10
BARD1 O 0 1.0272405006617191e-06
in O 0 8.861809419613564e-08
BRCA1 O 0 0.0004299463762436062
- O 0 0.00010807964281411842
mediated O 0 0.0002016076323343441
tumor B-Disease 0 0.0001792040275176987
suppression O 0 4.355675173428608e-06
. O 0 3.9233171378327825e-07

Ethnic O 0 2.609289367683232e-06
differences O 0 2.8128724807174876e-06
in O 0 8.037113019554454e-08
the O 0 4.251423746381988e-08
HFE O 0 0.00016527820844203234
codon O 0 1.3557499187299982e-05
282 O 0 3.1678246159572154e-06
( O 0 1.9509005255713419e-07
Cys O 0 0.01894472911953926
/ O 0 2.188910002587363e-05
Tyr O 0 1.902380245155655e-05
) O 0 4.745918857906872e-08
polymorphism O 0 5.279910965327872e-06
. O 0 1.2746311028877244e-07

Recent O 0 9.5889265594451e-07
studies O 0 8.524887107341783e-08
have O 0 6.591490908647302e-09
shown O 0 3.6117029367233044e-08
that O 0 7.376966550509678e-06
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
( O 0 1.2778392374457326e-05
HH B-Disease 1 0.864378035068512
) O 0 1.1374002850672582e-09
is O 0 6.113047290590146e-10
likely O 0 6.2171507941855e-09
to O 0 2.1145275808098773e-10
be O 0 3.884898625017286e-09
caused O 0 2.6178663681264425e-09
by O 0 1.9687321217709552e-10
homozygosity O 0 9.108995868700731e-08
for O 0 1.8240504939814883e-10
a O 0 6.874542712864695e-09
Cys282Tyr O 0 9.167172834168014e-07
mutation O 0 3.738695397714764e-08
in O 0 4.1291317032232655e-09
the O 0 5.397475355550796e-09
HFE O 0 3.180674866598565e-06
gene O 0 2.158476206659543e-07
located O 0 9.877655315904121e-08
4 O 0 1.5623811577825109e-07
. O 0 1.1952499789913418e-07

5 O 0 1.5173869542195462e-05
Mb O 0 0.00017788939294405282
telomeric O 0 5.960168709862046e-05
to O 0 3.7550080378423445e-07
HLA O 0 7.999045919859782e-05
- O 0 3.802438413913478e-06
A O 0 3.3652901265668334e-07
. O 0 8.980439503147863e-08

Population O 0 2.377112195972586e-08
studies O 0 6.00123151173193e-09
of O 0 7.647480565475817e-11
this O 0 1.306342950480044e-10
polymorphism O 0 3.386196212318282e-08
are O 0 1.635648561038039e-10
facilitated O 0 5.196483798819429e-10
by O 0 9.216039736914539e-11
the O 0 1.7171521149439428e-10
fact O 0 6.664048757265562e-10
that O 0 1.6890636111988044e-10
the O 0 9.150431523607949e-10
Cys282Tyr O 0 8.760751484260254e-07
mutation O 0 3.910712820243134e-08
creates O 0 1.1008981282145669e-08
a O 0 9.767266107019168e-09
Rsal O 0 1.5156625750023522e-06
restriction O 0 2.632629616527993e-07
site O 0 1.952791706116841e-07
. O 0 8.022593078749196e-08

We O 0 3.9199809975798416e-07
have O 0 5.757254673000034e-09
studied O 0 7.478717201081508e-09
the O 0 1.8204193708015737e-09
codon O 0 1.5311906054193969e-06
282 O 0 6.571427206836233e-07
( O 0 7.046287464618217e-08
Cys O 0 0.0637659877538681
/ O 0 1.0287198165315203e-05
Tyr O 0 2.8935237423866056e-06
) O 0 4.68280259013909e-09
polymorphism O 0 2.0861416771822405e-07
in O 0 2.554824796163757e-09
different O 0 1.169505603471066e-09
ethnic O 0 3.547956595184587e-09
groups O 0 4.753091253917319e-09
. O 0 3.1915995180042955e-08

In O 0 2.63485020468579e-07
agreement O 0 3.5599295955535126e-08
with O 0 3.9541664387243713e-10
previous O 0 2.902183160458094e-09
observations O 0 5.995854035489856e-09
the O 0 4.9283968017732604e-09
Tyr O 0 1.5331222584791249e-06
allele O 0 4.0261582512357563e-07
appeared O 0 7.322243504859216e-07
to O 0 1.6733808783087056e-09
be O 0 7.816663982751493e-10
rare O 0 1.8605315066366757e-09
or O 0 1.114427661264017e-08
absent O 0 4.0293919312262005e-08
in O 0 1.2292796114365956e-08
Asiatic O 0 1.9051283572935063e-07
( O 0 9.29947729932934e-10
Indian O 0 9.344728324478524e-10
, O 0 2.0316991145019614e-10
Chinese O 0 1.8071133478514412e-10
) O 0 2.5270827097578774e-10
populations O 0 2.469565885121483e-09
. O 0 1.050694642401595e-08

The O 0 7.118829614682909e-08
highest O 0 4.9004757585180414e-08
allele O 0 6.021316494297935e-07
frequency O 0 2.2545042099864077e-07
( O 0 5.085190490916602e-09
7 O 0 1.7563727139346952e-09
. O 0 8.539293577802809e-11
5 O 0 2.7010371717040016e-10
% O 0 5.2795424282381376e-11
) O 0 7.007797814262418e-11
was O 0 2.502030227446994e-08
found O 0 9.0014777853753e-09
in O 0 4.8809329911136956e-08
Swedes O 0 2.763212614809163e-05
. O 0 4.05494198219003e-08

Saamis O 0 9.451379446545616e-05
( O 0 1.3048320113284717e-07
2 O 0 6.136438024384461e-09
% O 0 5.296449390179703e-10
) O 0 2.1215164347498927e-10
and O 0 1.2363330359477231e-09
Mordvinians O 0 1.417387096580569e-07
( O 0 4.1634440339777257e-10
1 O 0 5.634052668845868e-10
. O 0 1.21120391494145e-10
8 O 0 6.545632924570555e-10
% O 0 5.3615785422511664e-11
) O 0 3.1884061363340876e-11
had O 0 2.8468221557886864e-08
significantly O 0 1.3269161769358107e-08
lower O 0 5.3198323968217665e-08
frequencies O 0 9.70849978187971e-09
of O 0 2.2316190562143845e-10
the O 0 8.624253311495522e-09
Tyr O 0 2.8791055228793994e-06
allele O 0 2.1157495666557224e-06
. O 0 1.419655717427304e-07

Comparisons O 0 1.5440668903465848e-06
with O 0 1.8517136268769718e-08
allele O 0 1.1269114565948257e-06
frequencies O 0 1.1363020036014859e-07
based O 0 2.4661499509193163e-08
on O 0 1.7912340410930483e-07
prevalence O 0 6.27882343451347e-07
estimates O 0 4.2764973784414906e-08
of O 0 2.2546506883713846e-09
HH B-Disease 1 0.9997768998146057
showed O 0 2.1683745217160322e-05
some O 0 2.497694939762596e-09
disagreements O 0 8.040455412583469e-08
with O 0 3.7855049650481476e-10
the O 0 1.0000125172382468e-09
RFLP O 0 5.920975354456459e-07
data O 0 1.4967687533840035e-08
, O 0 3.744600740596127e-10
particularly O 0 5.5672697563124984e-09
in O 0 2.4611594540147053e-08
Finns O 0 1.0168124617848662e-06
. O 0 2.0659289390323465e-08

The O 0 1.860387470742353e-07
newly O 0 2.2262396726091538e-07
described O 0 2.4466928039146296e-07
HFE O 0 4.69024325866485e-06
marker O 0 7.136625868042756e-08
provides O 0 1.5759256122294119e-09
a O 0 1.1306842129243933e-09
new O 0 2.4650810281912072e-09
approach O 0 1.619306821964983e-08
to O 0 3.848390495164722e-10
the O 0 2.8712437982747474e-10
screening O 0 8.266367146347875e-09
of O 0 3.1403357692028067e-10
HH B-Disease 0 9.04655025806278e-05
as O 0 2.4885884464254104e-09
well O 0 9.062509076507297e-10
as O 0 1.7382685568723133e-10
studies O 0 9.580588405944113e-11
of O 0 4.813828589217417e-12
the O 0 1.0874839223573574e-10
relationship O 0 1.6534690283620535e-09
between O 0 1.886891309865746e-09
the O 0 7.74912578549447e-09
HFE O 0 4.3901560275116935e-05
Tyr O 0 6.574694907612866e-06
allele O 0 1.6177745010281797e-06
and O 0 3.875944898368289e-08
different O 0 1.487047427417565e-07
disorders O 0 0.00037292303750291467
including O 0 2.7451093842500995e-07
cancer B-Disease 0 0.0002596724370960146

Autosomal B-Disease 1 0.9999933242797852
dominant I-Disease 1 0.9999439716339111
neurohypophyseal I-Disease 1 0.9999959468841553
diabetes I-Disease 1 0.9999998807907104
insipidus I-Disease 1 0.9943746328353882
associated O 0 9.821893627304235e-07
with O 0 1.3927436093297274e-08
a O 0 8.061446266083294e-08
missense O 0 8.019804954528809e-05
mutation O 0 2.8369895517244004e-06
encoding O 0 9.73303144746751e-07
Gly23 O 0 9.673072781879455e-05
- O 0 0.0007174603524617851
- O 0 0.00037091237027198076
> O 0 1.5539570767941768e-06
Val O 0 1.1709563295880798e-05
in O 0 1.6856643014762085e-07
neurophysin O 0 3.342479976709001e-05
II O 0 1.5349027307820506e-05
. O 0 7.695074089042464e-08

Autosomal B-Disease 1 0.9999932050704956
dominant I-Disease 1 0.9999771118164062
neurohypophyseal I-Disease 1 0.9999988079071045
diabetes I-Disease 1 1.0
insipidus I-Disease 1 0.9998682737350464
( O 0 3.384838691999903e-06
ADNDI B-Disease 0 0.0001628122990950942
) O 0 1.1997501658811416e-08
is O 0 4.08537159657385e-09
an O 0 1.9707803744495322e-07
inherited B-Disease 1 1.0
disease I-Disease 1 1.0
caused O 0 5.073859210824594e-05
by O 0 1.1029687385644138e-07
progressive O 0 0.00011263324995525181
degeneration O 0 0.003961137030273676
of O 0 9.119383026501282e-10
the O 0 4.732050307154623e-09
magnocellular O 0 9.313957889389712e-07
neurons O 0 2.6103338157668077e-08
of O 0 3.348785970747059e-10
the O 0 5.59491231122422e-10
hypothalamus O 0 1.6278415060355655e-08
leading O 0 2.8170493493462345e-08
to O 0 1.3551451072402187e-09
decreased O 0 4.496826377931029e-08
ability O 0 1.885847922267203e-09
to O 0 3.3210398320271395e-10
produce O 0 2.087208628154258e-09
the O 0 5.907887068445916e-09
hormone O 0 1.3552354971579916e-07
arginine O 0 2.4462588044116274e-07
vasopressin O 0 1.5278051535005943e-07
( O 0 2.1822263107651452e-08
AVP O 0 3.023671069968259e-06
) O 0 1.1089380080875344e-08
. O 0 2.1367636549030067e-08

Affected O 0 3.3942615118576214e-06
individuals O 0 4.851073320821797e-09
are O 0 4.234408657044497e-10
not O 0 2.3478041732971633e-09
symptomatic O 0 1.0466627031746611e-07
at O 0 3.640932533244268e-08
birth O 0 1.5826406851715547e-08
, O 0 3.1494232222151197e-10
but O 0 6.081104952926353e-09
usually O 0 1.4377876667026612e-08
develop O 0 1.2226618082422647e-06
diabetes B-Disease 1 0.5098827481269836
insipidus I-Disease 0 0.00016221878468059003
at O 0 2.8189342060613853e-07
1 O 0 1.3850248592461867e-07
- O 0 0.00033471224014647305
6 O 0 1.9962596979894442e-06
yr O 0 5.037074879510328e-05
of O 0 3.36290750801993e-09
age O 0 1.2701995899533358e-07
. O 0 3.909549306513327e-08

The O 0 9.29342149902368e-08
genetic O 0 6.452743832596752e-07
locus O 0 1.7124301621151972e-07
of O 0 2.160770895542896e-09
the O 0 3.1708722758594377e-08
disease O 0 3.72283102478832e-06
is O 0 2.7724744722235073e-09
the O 0 1.2970239993137511e-08
AVP O 0 0.003275893861427903
- O 0 2.8485703296610154e-05
neurophysin O 0 4.2267394746886566e-05
II O 0 5.270241672405973e-06
( O 0 4.988859991783556e-09
NPII O 0 2.2007816369296052e-07
) O 0 2.524370434908718e-10
gene O 0 6.897290738550055e-09
, O 0 2.860628400824794e-10
and O 0 4.3648501479864876e-10
mutations O 0 6.510040062579492e-09
that O 0 1.1575660430196422e-09
cause O 0 8.322831313023471e-09
ADNDI B-Disease 0 4.699255896412069e-06
have O 0 4.305935608073241e-09
been O 0 4.135847220254618e-09
found O 0 5.13450337802368e-10
in O 0 3.001465742613618e-10
both O 0 1.0675552108985187e-10
the O 0 1.1733838900518379e-10
signal O 0 1.584298736645451e-08
peptide O 0 5.043507833590866e-10
of O 0 4.0075720519894276e-11
the O 0 9.735197092908265e-10
prepro O 0 4.203570824756753e-06
- O 0 1.4928369637345895e-05
AVP O 0 0.00012605918163899332
- O 0 1.2463153780117864e-06
NPII O 0 1.7285816511503072e-06
precursor O 0 9.217547614071009e-08
and O 0 5.111241208055617e-09
within O 0 6.062182311694642e-09
NPII O 0 2.550187446104246e-06
itself O 0 1.1473392191874154e-07
. O 0 8.055975087017941e-08

An O 0 1.1461624893627231e-07
affected O 0 6.563128067682555e-07
girl O 0 8.227278885897249e-05
who O 0 1.1803233945784086e-08
presented O 0 1.8228029086131414e-09
at O 0 2.5011619442238953e-08
9 O 0 1.4020027805372592e-08
months O 0 4.6145047782886195e-09
of O 0 7.258907364082745e-11
age O 0 8.20282064495359e-09
and O 0 7.265448798143836e-10
her O 0 1.4022802918844945e-09
similarly O 0 3.5426148681239056e-09
affected O 0 1.2407891603061216e-08
younger O 0 1.2313837771671388e-07
brother O 0 2.5036630546537708e-08
and O 0 5.119104695694432e-09
father O 0 2.0163978931009297e-08
were O 0 4.0076319152149154e-08
all O 0 7.984569949659459e-11
found O 0 6.526161278053166e-10
to O 0 1.2662476622793406e-10
have O 0 9.310462956158005e-10
a O 0 2.305320156992252e-09
novel O 0 1.52951873388929e-08
missense O 0 8.204408914025407e-06
mutation O 0 3.3579874525457853e-07
( O 0 1.0298556674115389e-08
G1758 O 0 8.854339057506877e-07
- O 0 4.826111762668006e-06
- O 0 1.884477023850195e-05
> O 0 1.9085234725935152e-07
T O 0 6.758805852769001e-07
) O 0 7.609145535880657e-10
encoding O 0 3.2418088213859164e-09
the O 0 5.638987055078815e-10
amino O 0 4.370150019639141e-09
acid O 0 3.355129507554011e-09
substitution O 0 1.4463580555457156e-08
Gly23 O 0 3.4733388929453213e-06
- O 0 2.3566051822854206e-05
- O 0 3.66545318684075e-05
> O 0 3.6107599044044036e-07
Val O 0 2.3702409635006916e-06
within O 0 5.630867860872968e-08
NPII O 0 3.8527465221704915e-05
. O 0 2.0989952531635936e-07

The O 0 1.8508860932797688e-07
mutation O 0 1.4702962971568923e-06
was O 0 2.844673474555748e-07
confirmed O 0 3.356936417731049e-08
by O 0 1.7477308489333154e-09
restriction O 0 2.1486937384906923e-07
endonuclease O 0 1.0035624654847197e-05
analysis O 0 2.3211171651382756e-07
. O 0 1.0912525283401919e-07

A O 0 2.2525435269926675e-05
T1 O 0 0.11204159259796143
- O 0 5.6659737310837954e-06
weighted O 0 7.056158892737585e-07
magnetic O 0 3.0252667215791007e-07
resonance O 0 1.3461135495163035e-06
imaging O 0 1.2375565347610973e-05
of O 0 5.114185963606133e-09
the O 0 3.008266347137578e-08
fathers O 0 8.431853188994864e-07
pituitary O 0 4.068306225235574e-07
gland O 0 3.2392827620242315e-07
demonstrates O 0 1.0150080242965487e-07
an O 0 6.265733265564677e-09
attenuated O 0 2.453995648465934e-06
posterior O 0 1.4081651897868142e-05
pituitary O 0 2.925055378000252e-05
bright O 0 4.040193744003773e-05
spot O 0 2.4462020519422367e-05
. O 0 8.444293939646741e-07

This O 0 1.3590678804575873e-07
mutation O 0 7.131862389542221e-07
may O 0 7.103326993274095e-08
be O 0 1.6646732603486925e-10
valuable O 0 3.862671293930475e-10
for O 0 4.313592538718325e-11
developing O 0 9.341485363023594e-10
models O 0 1.6649067902108072e-08
of O 0 1.1703847890842667e-09
dominantly B-Disease 0 4.655628072214313e-05
inherited I-Disease 1 0.9244934916496277
neurodegeneration I-Disease 1 1.0
, O 0 6.852471479135147e-09
as O 0 6.444029754248959e-10
the O 0 2.0334826877910217e-10
early O 0 3.1707367043054546e-07
age O 0 6.052893297692208e-09
of O 0 9.087845753708024e-11
onset O 0 8.843741738928657e-08
of O 0 7.21242954249135e-10
symptoms O 0 4.7681260184617713e-07
suggests O 0 2.9339970453179376e-09
that O 0 1.4362072642271073e-10
this O 0 1.8964700643220311e-10
mutation O 0 1.609284616677087e-08
may O 0 6.750998693405563e-08
be O 0 9.001971945643561e-10
particularly O 0 5.777385236882537e-09
deleterious O 0 7.539433255487893e-08
to O 0 5.02812280700482e-09
the O 0 4.509725037848966e-09
magnocellular O 0 8.493755672134284e-07
neuron O 0 4.6169370193638315e-07
. O 0 1.597940268993625e-08
. O 0 3.12002157443203e-08

Frequent O 0 9.02821120689623e-05
inactivation O 0 0.00012507342034950852
of O 0 7.102622845422957e-08
PTEN O 0 0.008688594214618206
/ O 0 0.0012834790395572782
MMAC1 O 0 0.0010619221720844507
in O 0 4.70035411126446e-06
primary O 1 0.9890967607498169
prostate B-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
. O 0 1.153548396359838e-06

Sporadic B-Disease 1 0.9999970197677612
prostate I-Disease 1 1.0
carcinoma I-Disease 1 1.0
is O 0 6.339727320892052e-08
the O 0 8.825500885656368e-10
most O 0 1.489525613962428e-09
common O 0 1.3371933782480028e-08
male B-Disease 0 5.4668131355128935e-08
cancer I-Disease 0 2.3486295575025906e-08
in O 0 1.1735052929395806e-09
the O 0 3.2728839083340233e-10
Western O 0 7.52692930205967e-09
world O 0 1.170484082990697e-07
, O 0 2.6402194319707917e-10
yet O 0 6.715457634420829e-10
many O 0 2.728494340187293e-11
of O 0 6.034187038927996e-12
the O 0 5.7572929063054445e-11
major O 0 6.975077182502787e-10
genetic O 0 1.6831311899778711e-09
events O 0 2.439355384353803e-10
involved O 0 1.0586137522139438e-09
in O 0 1.3290660794140763e-09
the O 0 1.0346453693799162e-09
progression O 0 9.783731158563569e-09
of O 0 5.0973336662707425e-11
this O 0 5.175899153719854e-10
often O 0 9.303832371188037e-08
fatal O 0 0.00044030899880453944
cancer B-Disease 0 1.4285488759924192e-05
remain O 0 6.297017307588249e-08
to O 0 2.1813637562928534e-09
be O 0 1.8243481392232752e-08
elucidated O 0 1.4182634231474367e-06
. O 0 3.977179829917077e-08

Numerous O 0 2.7070875603385502e-06
cytogenetic O 0 0.0002089000045089051
and O 0 3.504237611196004e-07
allelotype O 0 6.026749360898975e-06
studies O 0 4.159614164223058e-08
have O 0 1.1144339673307968e-08
reported O 0 6.856618739448095e-08
frequent O 0 2.305110236022756e-08
loss O 0 6.434148502876269e-08
of O 0 1.0501310931942953e-09
heterozygosity O 0 2.0043173662998015e-06
on O 0 7.284193657142168e-07
chromosomal O 0 0.004256822168827057
arm O 1 0.788725733757019
10q O 0 3.351429768372327e-05
in O 0 3.382250724826008e-06
sporadic B-Disease 1 0.9999954700469971
prostate I-Disease 1 1.0
cancer I-Disease 1 0.9999996423721313
. O 0 1.565183424645511e-06

Deletion O 0 3.5784742067335173e-05
mapping O 0 1.6415309573858394e-06
studies O 0 1.6639964428577514e-07
have O 0 1.8258379697044802e-08
unambiguously O 0 1.0211188339326327e-07
identified O 0 9.692477043188319e-09
a O 0 9.697557201704399e-10
region O 0 2.922714292807882e-09
of O 0 3.311905472092036e-10
chromosome O 0 2.414107029835577e-07
10q23 O 0 1.3550997834954615e-07
to O 0 1.0576973741294182e-09
be O 0 1.5608130343736093e-09
the O 0 2.466768456166335e-10
minimal O 0 7.94508014934081e-09
area O 0 2.790171871325242e-09
of O 0 1.3914311924878575e-09
loss O 0 8.17759257643047e-07
. O 0 6.844427957730659e-08

A O 0 3.0820312986179488e-06
new O 0 6.609307092730887e-07
tumor B-Disease 0 8.250591235992033e-06
suppressor O 0 1.0110282346431632e-05
gene O 0 2.2001827346684877e-06
, O 0 4.8624695381249694e-08
PTEN O 0 0.0007610640022903681
/ O 0 0.0002224460622528568
MMAC1 O 0 0.0003968446690123528
, O 0 9.701169645381924e-09
was O 0 8.172465015832131e-08
isolated O 0 1.6639162936371577e-08
recently O 0 1.1283670886541586e-07
at O 0 4.1651300186629214e-09
this O 0 5.167827277219317e-11
region O 0 2.4849633462054044e-10
of O 0 9.999586575437647e-11
chromosome O 0 1.6010358194762375e-07
10q23 O 0 7.899223675167377e-08
and O 0 7.823047765143087e-10
found O 0 2.0566257585841186e-09
to O 0 4.088596683438084e-10
be O 0 9.038255699422848e-10
inactivated O 0 6.300030275241397e-09
by O 0 3.245320956413167e-10
mutation O 0 2.1375218040020627e-08
in O 0 1.2507192082011898e-07
three O 0 0.003121404442936182
prostate B-Disease 1 1.0
cancer I-Disease 1 0.9999992847442627
cell O 0 4.0416813135379925e-05
lines O 0 1.6796011550468393e-05
. O 0 6.404775376722682e-07

We O 0 3.069837021030253e-06
screened O 0 5.627467544400133e-05
80 O 0 2.7177758965990506e-05
prostate B-Disease 1 0.9685577750205994
tumors I-Disease 1 0.9999982118606567
by O 0 2.7604967201000363e-09
microsatellite O 0 1.7838256383129192e-07
analysis O 0 1.2265744864237149e-08
and O 0 2.39323383333101e-09
found O 0 1.1775911801237271e-08
chromosome O 0 3.026337367373344e-07
10q23 O 0 9.766636566155285e-08
to O 0 1.2679883809596504e-09
be O 0 2.1130810434755176e-09
deleted O 0 5.608583464322692e-08
in O 0 5.985547613107656e-09
23 O 0 4.137529785452898e-08
cases O 0 1.9980291199317435e-08
. O 0 2.7416918513267774e-08

We O 0 1.1155843822052702e-06
then O 0 1.964458107295286e-08
proceeded O 0 1.5398105901454073e-08
with O 0 6.476890551665448e-11
sequence O 0 5.363525179546969e-10
analysis O 0 4.390768582052118e-10
of O 0 9.58228843495057e-11
the O 0 1.6071580732912594e-09
entire O 0 9.077931650836035e-08
PTEN O 0 0.0007506543188355863
/ O 0 2.595059595478233e-05
MMAC1 O 0 6.6956085902347695e-06
coding O 0 9.044487114806543e-07
region O 0 2.8785452244051157e-08
and O 0 6.457124168690598e-09
tested O 0 1.6019134463363116e-08
for O 0 3.5288957866974613e-10
homozygous O 0 5.34915578498385e-08
deletion O 0 2.3513905489380704e-08
with O 0 2.8927699124992046e-10
new O 0 9.521720301108871e-09
intragenic O 0 1.2250872032382176e-06
markers O 0 2.149136406615071e-07
in O 0 3.6296634586818755e-09
these O 0 4.872714454151605e-10
23 O 0 9.572506343147325e-09
cases O 0 7.171824800700222e-10
with O 0 6.372916083741131e-10
10q23 O 0 6.220758450581343e-07
loss O 0 1.8142266355880565e-07
of O 0 3.5286822352986746e-09
heterozygosity O 0 6.720487363054417e-06
. O 0 1.6090244514543883e-07

The O 0 3.432442952089332e-08
identification O 0 2.5135387105024165e-08
of O 0 2.1200158295542337e-10
the O 0 8.15050860136779e-10
second O 0 4.783050044920856e-08
mutational O 0 7.727917363808956e-07
event O 0 1.3727263770135778e-08
in O 0 6.37907282552419e-09
10 O 0 3.4696707729153786e-09
( O 0 1.0422929186404417e-09
43 O 0 3.459007658079827e-08
% O 0 7.389529432799691e-09
) O 0 9.219411367666908e-08
tumors B-Disease 1 1.0
establishes O 0 6.9541279117402155e-06
PTEN O 0 0.02907950058579445
/ O 0 0.0003310986503493041
MMAC1 O 0 3.434871541685425e-05
as O 0 1.193132348475956e-08
a O 0 3.787196778404223e-09
main O 0 2.2006677369290628e-08
inactivation O 0 2.1295382168773358e-07
target O 0 2.9704072090908085e-08
of O 0 8.668214479534697e-10
10q O 0 4.1016886598299607e-07
loss O 0 3.743873264738795e-07
in O 0 5.489067689268268e-07
sporadic B-Disease 1 0.9999990463256836
prostate I-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
. O 0 2.9546084689968666e-08
. O 0 5.280296022647235e-08

Risk O 0 4.516313492786139e-05
reversals O 0 1.4439773622143548e-05
in O 0 6.571170274582983e-08
predictive O 0 3.2716816349420696e-06
testing O 0 1.702589429442014e-06
for O 0 3.339725651585468e-07
Huntington B-Disease 1 1.0
disease I-Disease 1 0.9999998807907104
. O 0 8.125446129270131e-07

The O 0 7.057168716073647e-08
first O 0 1.480166211820233e-08
predictive O 0 2.713728406433802e-07
testing O 0 1.6169617822470173e-07
for O 0 1.2103441804356407e-07
Huntington B-Disease 1 1.0
disease I-Disease 1 1.0
( O 0 1.0972629915784182e-08
HD B-Disease 0 1.1563093721633777e-05
) O 0 1.1014855694213566e-09
was O 0 6.399033747328531e-09
based O 0 2.875792937118149e-10
on O 0 2.756229688927192e-09
analysis O 0 4.4701239931832504e-10
of O 0 1.1147836820324386e-10
linked O 0 9.502437592345814e-08
polymorphic O 0 8.805113793641794e-08
DNA O 0 3.76121107592553e-08
markers O 0 1.4138723969381317e-08
to O 0 5.392719049090999e-10
estimate O 0 5.3617275064254954e-09
the O 0 2.1976244435339964e-10
likelihood O 0 3.034508422317117e-09
of O 0 1.7676672625643874e-10
inheriting O 0 3.263150460952602e-08
the O 0 2.026846690483808e-09
mutation O 0 3.096651113310145e-08
for O 0 4.556918398179732e-09
HD B-Disease 0 7.983097020769492e-05
. O 0 3.3622427508817054e-07

Limits O 0 2.3639555024601577e-07
to O 0 3.368428203032181e-09
accuracy O 0 1.3581525237782444e-08
included O 0 3.476770538135554e-10
recombination O 0 3.6220004773213077e-09
between O 0 5.645832135137141e-10
the O 0 5.726914498183078e-10
DNA O 0 8.18505085931065e-09
markers O 0 1.250802217356295e-08
and O 0 9.517049370799668e-10
the O 0 1.1065647287367142e-09
mutation O 0 2.2826306178558298e-08
, O 0 1.3210543770014738e-09
pedigree O 0 7.550038816361848e-08
structure O 0 6.193195289938558e-09
, O 0 2.1087881441061995e-10
and O 0 2.4465449111055193e-10
whether O 0 3.0475458268064415e-10
DNA O 0 1.6999078811252843e-09
samples O 0 3.938976089745694e-10
were O 0 1.8946633151273318e-09
available O 0 8.462055500757515e-10
from O 0 1.1181808812210647e-09
family O 0 2.7278155290133554e-09
members O 0 1.177954511710766e-09
. O 0 1.0263260463716506e-08

With O 0 1.2802834348235592e-08
direct O 0 1.627298118478393e-08
tests O 0 5.520293200333981e-08
for O 0 1.1474055039428777e-10
the O 0 2.812735322432758e-10
HD B-Disease 0 1.3047456377535127e-05
mutation O 0 1.2924973091799075e-08
, O 0 3.146145288734914e-10
we O 0 4.988648383275063e-10
have O 0 2.385175668084827e-10
assessed O 0 5.569402161675896e-10
the O 0 4.518210111603693e-11
accuracy O 0 7.934146672994302e-09
of O 0 3.305378887263899e-11
results O 0 8.333724821341093e-10
obtained O 0 7.131554374817384e-11
by O 0 1.1641658470562533e-10
linkage O 0 1.3725222736127307e-08
approaches O 0 5.150415205434911e-09
when O 0 5.896232391222611e-10
requested O 0 2.4656771069331285e-10
to O 0 1.2128174853298646e-10
do O 0 2.624155337471734e-09
so O 0 1.0427318730688029e-10
by O 0 9.989783306130207e-12
the O 0 2.213868116607287e-10
test O 0 6.39853325878903e-09
individuals O 0 4.0245642929370717e-10
. O 0 3.7074909808865186e-09

For O 0 3.979744889193171e-08
six O 0 4.4162784540446864e-09
such O 0 6.946250519224151e-11
individuals O 0 5.1701143366500446e-11
, O 0 1.558533441192722e-10
there O 0 1.9155932395875652e-09
was O 0 3.4302964024846005e-08
significant O 0 1.0121227189685555e-09
disparity O 0 6.8139192066496435e-09
between O 0 1.2229249835016276e-09
the O 0 2.5684074866916262e-09
tests O 0 1.0971672281812062e-07
. O 0 1.4718247065559353e-08

Three O 0 1.5066883918279927e-07
went O 0 9.9767014205554e-08
from O 0 8.140875751294629e-10
a O 0 8.089780512143818e-10
decreased O 0 9.293776059848824e-08
risk O 0 3.3733016380210756e-09
to O 0 6.879625341627005e-11
an O 0 4.926051927478525e-11
increased O 0 2.7313140638085542e-09
risk O 0 7.965214265936993e-09
, O 0 1.1874644323395245e-10
while O 0 3.2782318526436427e-10
in O 0 6.795070617293675e-10
another O 0 1.682527672741685e-09
three O 0 5.252847046222087e-10
the O 0 1.4235589373967628e-09
risk O 0 1.4473853582330776e-07
was O 0 1.6408847614002298e-07
decreased O 0 2.8477759883571707e-07
. O 0 2.5982830109683164e-08

Knowledge O 0 1.3966572964818624e-07
of O 0 1.0995712118599954e-09
the O 0 3.6221300958594327e-10
potential O 0 8.516460869856246e-10
reasons O 0 5.58354862345567e-10
for O 0 1.7914494540582915e-11
these O 0 1.5152535476348206e-11
changes O 0 2.8025337606152334e-10
in O 0 5.810560921304386e-09
results O 0 1.356663847928985e-08
and O 0 4.6457385161069453e-10
impact O 0 1.1687452117215003e-09
of O 0 2.7355291642994217e-11
these O 0 4.849072809953725e-10
risk O 0 1.2708072816280946e-08
reversals O 0 4.639102257897321e-08
on O 0 2.7452224937718483e-09
both O 0 1.1203048488894751e-09
patients O 0 4.664786334984683e-09
and O 0 5.084498932994563e-10
the O 0 2.508837582126944e-10
counseling O 0 2.5430062500220174e-09
team O 0 2.362302575775743e-10
can O 0 4.16625414723093e-11
assist O 0 2.888110063603566e-11
in O 0 2.438336477172953e-10
the O 0 1.5716922208142137e-10
development O 0 5.2013702372954995e-11
of O 0 1.444519850957171e-11
strategies O 0 8.435643295001682e-10
for O 0 5.312857792594272e-11
the O 0 2.759437123245334e-10
prevention O 0 4.791293140016251e-09
and O 0 9.954567170566975e-10
, O 0 4.898375455253401e-11
where O 0 8.599113782148393e-11
necessary O 0 2.0936958833317476e-09
, O 0 1.1075487194034395e-09
management O 0 1.5393047947398486e-09
of O 0 1.756685769072064e-11
a O 0 2.3579149743824246e-09
risk O 0 5.441804162842345e-08
reversal O 0 5.675897085666293e-08
in O 0 6.730165313939551e-10
any O 0 1.0423844010176708e-09
predictive O 0 2.221776540523024e-08
testing O 0 4.062753333755609e-08
program O 0 2.683907851519507e-08
. O 0 4.654840957130091e-09
. O 0 2.004671273425629e-08

A O 0 2.0761178802786162e-06
novel O 0 9.737673281051684e-07
common O 0 7.661637368983065e-07
missense O 0 0.00011546019231900573
mutation O 0 2.159275936719496e-06
G301C O 0 1.3308800816957955e-06
in O 0 1.35153701563695e-08
the O 0 2.7196798146889023e-09
N O 0 2.262901489302749e-06
- O 0 2.2446815819421317e-06
acetylgalactosamine O 0 0.00029405023087747395
- O 0 1.2156393495388329e-05
6 O 0 4.442330805431993e-07
- O 0 1.8973981923409156e-06
sulfate O 0 6.905585792083002e-07
sulfatase O 0 3.967250904679531e-06
gene O 0 7.235307748487685e-07
in O 0 9.238650733323084e-08
mucopolysaccharidosis B-Disease 0 2.1589285097434185e-05
IVA I-Disease 0 8.415839693043381e-05
. O 0 5.942414418314002e-07

Mucopolysaccharidosis B-Disease 0 0.45772770047187805
IVA I-Disease 1 0.997585654258728
( O 0 0.0004965761909261346
MPS B-Disease 1 0.9999995231628418
IVA I-Disease 1 0.9999984502792358
) O 0 8.07800759616839e-08
is O 0 1.99587706362081e-08
an O 0 5.1552046187453016e-08
autosomal B-Disease 1 0.999617338180542
recessive I-Disease 1 0.9999988079071045
lysosomal I-Disease 1 0.9999488592147827
storage I-Disease 1 0.9998852014541626
disorder I-Disease 1 0.99998939037323
caused O 0 2.5847969027381623e-06
by O 0 7.223185605198523e-09
a O 0 7.409181307593826e-06
genetic B-Disease 1 1.0
defect I-Disease 1 1.0
in O 0 7.820204928066232e-08
N O 0 2.8479240427259356e-05
- O 0 2.2312600776785985e-05
acetylgalactosamine O 0 0.010929948650300503
- O 0 0.0001298347197007388
6 O 0 5.8512632676865906e-06
- O 0 0.00013390433741733432
sulfate O 0 9.054531801666599e-06
sulfatase O 0 6.499941082438454e-05
( O 0 1.0916252080050981e-07
GALNS O 0 1.0415847100375686e-05
) O 0 3.362306344456556e-08
. O 0 3.451764740702856e-08

In O 0 1.504475903857383e-07
previous O 0 4.500799377638032e-08
studies O 0 8.616130919847365e-09
, O 0 5.331945440723018e-10
we O 0 6.173402344877843e-10
have O 0 1.2039325092416675e-10
found O 0 1.893491752280596e-10
two O 0 5.363296959326469e-11
common O 0 7.419466152569498e-10
mutations O 0 6.350665326948501e-09
in O 0 3.3923293063509163e-09
Caucasians O 0 8.804592965816482e-08
and O 0 2.7571025462691523e-09
Japanese O 0 3.372975143633994e-08
, O 0 6.566941990193698e-10
respectively O 0 1.6442049499687528e-08
. O 0 1.3946044319368411e-08

To O 0 1.3150810218576225e-07
characterize O 0 1.054929612109845e-06
the O 0 1.8132263690517902e-08
mutational O 0 2.300087317053112e-06
spectrum O 0 1.0062892386031308e-07
in O 0 2.192522163824151e-09
various O 0 1.8453723271694145e-10
ethnic O 0 2.849475655430922e-10
groups O 0 1.9518991978273448e-10
, O 0 1.3247375418856677e-10
mutations O 0 2.32290453539008e-09
in O 0 1.0519675130993278e-09
the O 0 1.1236305219597398e-09
GALNS O 0 3.0289186270238133e-07
gene O 0 3.2305148778277726e-08
in O 0 5.190265550680806e-09
Colombian O 0 5.352457606022654e-07
MPS B-Disease 1 0.9999997615814209
IVA I-Disease 1 0.9999995231628418
patients O 0 3.6171536521578673e-06
were O 0 1.5542870102080997e-08
investigated O 0 9.583138727009555e-09
, O 0 6.848636241452155e-11
and O 0 3.5868547021422614e-10
genetic O 0 3.155582017910774e-09
backgrounds O 0 1.0702148500740805e-08
were O 0 6.239484040548859e-09
extensively O 0 3.1569427072497547e-09
analyzed O 0 1.601570320808321e-09
to O 0 2.0232071573644816e-10
identify O 0 1.959031603604444e-09
racial O 0 1.100374791285219e-09
origin O 0 4.033171019379722e-10
, O 0 1.1552847567486424e-10
based O 0 2.8862720546918297e-10
on O 0 6.6261804931855295e-09
mitochondrial O 0 2.372483010049109e-08
DNA O 0 1.2500775881107984e-07
( O 0 6.225884252586411e-09
mtDNA O 0 2.1640207137352263e-07
) O 0 7.238866839287539e-09
lineages O 0 4.840765086555621e-07
. O 0 7.651576794387438e-08

Three O 0 2.8592737066901464e-07
novel O 0 2.668554373030929e-07
missense O 0 3.38406243827194e-05
mutations O 0 1.71461306308629e-06
never O 0 2.395711078406748e-07
identified O 0 1.2397765480898215e-08
previously O 0 2.4424664513134076e-09
in O 0 4.3998812926382413e-10
other O 0 9.717419924282211e-11
populations O 0 1.0851902015884818e-10
and O 0 4.4311518343498335e-10
found O 0 2.4966897438361e-09
in O 0 4.377967322000131e-09
16 O 0 6.994851808883595e-09
out O 0 9.621778929158609e-10
of O 0 1.7246819250527068e-10
19 O 0 5.46101865950277e-08
Colombian O 0 9.629688975110184e-07
MPS B-Disease 1 0.9999983310699463
IVA I-Disease 1 0.9999457597732544
unrelated O 0 1.2933033985973452e-06
alleles O 0 2.504055203189637e-07
account O 0 3.619668476062543e-08
for O 0 5.423522519976132e-09
84 O 0 2.280077069372055e-07
. O 0 7.643933486178867e-08

2 O 0 2.3436317064806644e-07
% O 0 4.342150194958094e-09
of O 0 5.218083951041841e-11
the O 0 2.1836149555198858e-10
alleles O 0 4.1422261176649045e-09
in O 0 4.931593799994971e-09
this O 0 1.8267044543662792e-09
study O 0 8.331566547781222e-09
. O 0 2.3695841733228917e-08

The O 0 6.41365033970942e-07
G301C O 0 1.089299712475622e-05
and O 0 4.9390706635676906e-08
S162F O 0 2.796311662223161e-07
mutations O 0 4.6723577895591006e-08
account O 0 3.2467901700528046e-09
for O 0 1.3543207666444346e-09
68 O 0 2.715374876061105e-07
. O 0 2.93526358774443e-08

4 O 0 1.4413110420719022e-06
% O 0 4.568129341464555e-08
and O 0 1.3178185653828223e-08
10 O 0 2.339932692052571e-08
. O 0 2.578682689602374e-08

5 O 0 1.6166011107543454e-07
% O 0 2.365514228941379e-09
of O 0 2.5079810450634454e-10
mutations O 0 3.5126884512237666e-08
, O 0 7.722975037260937e-10
respectively O 0 2.5051329899383745e-09
, O 0 2.6113072815192595e-10
whereas O 0 1.3022437572729473e-09
the O 0 2.6373808692525813e-10
remaining O 0 9.531059497192018e-09
F69V O 0 2.025363528446178e-06
is O 0 2.567044909973504e-10
limited O 0 6.313126132972968e-10
to O 0 3.158054928675824e-10
a O 0 6.201529068050604e-09
single O 0 1.1357428775227163e-07
allele O 0 3.88412536267424e-06
. O 0 2.007926411806693e-07

The O 0 2.451483283039124e-07
skewed O 0 2.8175468287372496e-06
prevalence O 0 1.7232292748303735e-06
of O 0 1.8283671243679578e-09
G301C O 0 1.9751757918129442e-07
in O 0 2.3082329381196587e-09
only O 0 9.737352035799063e-10
Colombian O 0 8.799552198013316e-09
patients O 0 2.4471868087516668e-08
and O 0 2.4861974701195777e-09
haplotype O 0 8.07800759616839e-08
analysis O 0 2.3688915273822886e-09
by O 0 5.086769339079922e-10
restriction O 0 4.262303576751947e-08
fragment O 0 1.1868433347217433e-07
length O 0 2.2682995037826004e-08
polymorphisms O 0 2.0637122588595957e-07
in O 0 5.360949906219048e-09
the O 0 2.798272724646722e-09
GALNS O 0 8.289444508591259e-07
gene O 0 3.3546065481004916e-08
suggest O 0 1.1518578979519134e-08
that O 0 9.137420819982367e-10
G301C O 0 3.213234123222719e-08
originated O 0 1.6966533067375167e-08
from O 0 1.977803698594016e-09
a O 0 2.6131270480789226e-09
common O 0 1.6985119088985812e-08
ancestor O 0 2.1066661304303125e-07
. O 0 1.2149631345437228e-07

Investigation O 0 3.471381262443174e-07
of O 0 1.1631343665996496e-09
the O 0 6.935728658064022e-10
genetic O 0 1.2217156175609034e-08
background O 0 6.029950316843724e-09
by O 0 1.3965567591256445e-10
means O 0 1.7967144438912896e-09
of O 0 1.3961785894078815e-10
mtDNA O 0 3.485844501938118e-08
lineages O 0 1.382511616299098e-08
indicate O 0 1.7364676807574142e-08
that O 0 7.785863065379317e-10
all O 0 1.3491044392743845e-10
our O 0 6.739529490040752e-10
patients O 0 3.900520351152181e-09
are O 0 1.6801474100880398e-10
probably O 0 9.694307578911321e-09
of O 0 3.365239684138821e-11
native O 0 1.5910175399369564e-09
American O 0 4.578587819992208e-08
descent O 0 2.724798832787201e-06

Low O 0 2.1549603843595833e-05
frequency O 0 3.0407145459321328e-06
of O 0 2.1576544995127733e-08
BRCA1 O 0 5.0559981900732964e-05
germline O 0 5.982690709060989e-06
mutations O 0 3.3821109468590294e-07
in O 0 3.2736487298734573e-08
45 O 0 5.739993298448098e-07
German O 1 0.9999995231628418
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 2.3253542167367414e-06
. O 0 1.8626332121129963e-07

In O 0 1.7737423263497476e-07
this O 0 2.597057902065103e-09
study O 0 1.0694347629680578e-09
we O 0 8.361284442592876e-10
investigated O 0 8.670004270072695e-09
45 O 0 3.34655432254749e-08
German O 1 0.9999992847442627
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
families O 0 1.3738265636220603e-08
for O 0 1.7895832593595173e-09
germline O 0 3.008613248312031e-06
mutations O 0 3.2764384627625986e-07
in O 0 1.688714235115185e-08
the O 0 1.4342433019010059e-08
BRCA1 O 0 1.0752311027317774e-05
gene O 0 2.590203621366527e-06
. O 0 3.4847019492190157e-07

We O 0 7.420916290357127e-07
identified O 0 1.870404844339646e-07
four O 0 8.976189569409598e-09
germline O 0 1.447583031222166e-06
mutations O 0 6.551229034812422e-07
in O 0 1.3321825065304438e-07
three O 0 3.5687448871613014e-06
breast B-Disease 0 0.09171098470687866
cancer I-Disease 0 5.880474873265484e-06
families O 0 3.500273848544566e-09
and O 0 2.5357458355301787e-09
in O 0 2.9024279868394842e-08
one O 0 0.3378019630908966
breast B-Disease 1 1.0
- I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
family O 0 5.936637492709451e-08
. O 0 3.611657917179656e-10
among O 0 1.7834726750987073e-10
these O 0 8.286359792775144e-11
were O 0 2.2855669357113584e-08
one O 0 9.368719133817649e-09
frameshift O 0 4.304231879359577e-06
mutation O 0 3.563584272114895e-08
, O 0 8.92170226585165e-10
one O 0 3.6723575291830457e-09
nonsense O 0 1.2990318282390945e-05
mutation O 0 4.364346750662662e-08
, O 0 7.743476970745178e-10
one O 0 3.913118995502174e-10
novel O 0 4.460825486773956e-09
splice O 0 4.17326191382017e-06
site O 0 2.0519880195024598e-07
mutation O 0 1.2957734440988133e-07
, O 0 2.4936057663182964e-09
and O 0 3.429391659537373e-09
one O 0 1.4207739873484115e-08
missense O 0 2.8831977033405565e-05
mutation O 0 2.1272740013955627e-06
. O 0 2.557503364641889e-07

The O 0 3.145992764075345e-07
missense O 0 3.592609937186353e-05
mutation O 0 2.1497055513464147e-06
was O 0 1.2147399957029847e-06
also O 0 6.937293850484139e-09
found O 0 3.1938569566847264e-09
in O 0 6.465023183466201e-09
2 O 0 3.524991143422085e-08
. O 0 3.767342704463772e-08

8 O 0 4.4738985138792486e-07
% O 0 2.7342330621848987e-09
of O 0 4.7241099920825036e-11
the O 0 7.163768883655663e-11
general O 0 4.850402371414653e-11
population O 0 1.9544164897578042e-11
, O 0 3.7839651551019315e-11
suggesting O 0 4.356011551465144e-09
that O 0 2.481217453720319e-10
it O 0 3.9165315435241155e-10
is O 0 3.1131233702019756e-10
not O 0 1.9011004326330294e-08
disease O 0 5.678691294974669e-08
associated O 0 2.8241993632605045e-08
. O 0 7.18900565743752e-08

The O 0 5.451798301692179e-08
average O 0 5.54391249352193e-07
age O 0 3.616659682847967e-08
of O 0 1.7472443492039247e-09
disease O 0 2.250155375804752e-06
onset O 0 1.7071957927328185e-06
in O 0 1.4642003165477036e-08
those O 0 3.3725939818651796e-09
families O 0 5.179377815522912e-09
harbouring O 0 7.111596005415777e-07
causative O 0 1.8516836917115143e-06
mutations O 0 6.912101753187017e-07
was O 0 1.8602170825943176e-07
between O 0 1.6102609023960213e-08
32 O 0 3.1064007544046035e-07
. O 0 6.485169024017523e-08

3 O 0 1.4922242144166376e-06
and O 0 8.460062872472918e-08
37 O 0 3.489144546620082e-07
. O 0 9.672646683611674e-08

4 O 0 1.0980031674989732e-06
years O 0 3.1141777157017714e-08
, O 0 3.1683419776662447e-10
whereas O 0 6.910205185839402e-10
the O 0 2.093395318203406e-10
family O 0 2.028300638556857e-09
harbouring O 0 4.332051517508262e-08
the O 0 1.7186013723247129e-09
missense O 0 9.713965027913218e-07
mutation O 0 4.7769965760835476e-08
had O 0 3.219626876216353e-08
an O 0 2.693998635283634e-10
average O 0 5.8666007163310496e-08
age O 0 9.628190689170424e-09
of O 0 3.7781186512653164e-10
onset O 0 3.0522616611960984e-07
of O 0 2.1211412626342963e-09
51 O 0 3.2133880267792847e-07
. O 0 5.543854797451786e-08

2 O 0 5.397099357651314e-06
years O 0 4.6882118454050214e-07
. O 0 1.415775443547318e-07

These O 0 3.4593639952618105e-08
findings O 0 2.5582297169535195e-08
show O 0 1.912374436585651e-08
that O 0 2.517005937008321e-09
BRCA1 O 0 1.3362800928007346e-06
is O 0 1.828548423787879e-09
implicated O 0 9.361752262293521e-09
in O 0 6.823110410003608e-10
a O 0 2.3094294532288728e-10
small O 0 6.155801424156948e-10
fraction O 0 2.25063025993677e-08
of O 0 3.446489245106932e-07
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999997615814209
families O 0 4.9320576067657385e-08
suggesting O 0 4.581881540843824e-08
the O 0 2.912940166854838e-10
involvement O 0 4.061658565035486e-09
of O 0 1.7124718310057574e-10
another O 0 3.7604279690128806e-09
susceptibility O 0 9.68549613844516e-08
gene O 0 1.124683649322833e-06
( O 0 8.601389822615602e-08
s O 0 8.850271115079522e-06
) O 0 2.8821719411098456e-07

Paternal O 0 0.0046843271702528
transmission O 1 0.6187198162078857
of O 0 0.00010556175402598456
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 0 3.044892946491018e-05

We O 0 2.6528373382461723e-06
report O 0 5.293061633437901e-08
a O 0 3.5496556805014734e-09
rare O 0 1.7019850417909765e-08
case O 0 6.498405014099262e-08
of O 0 1.369823188213104e-08
paternally O 0 0.17514237761497498
transmitted O 1 0.9999996423721313
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 0.038729339838027954
DM B-Disease 1 1.0
) O 0 7.274524023159756e-07
. O 0 1.3857778924375452e-07

The O 0 1.3935041920376534e-07
proband O 0 3.721503844644758e-06
is O 0 2.9207081198023843e-09
a O 0 5.693415960905668e-09
23 O 0 1.2160562334884162e-07
year O 0 3.4734203069319847e-08
old O 0 0.008496949449181557
, O 0 3.0466010230156826e-06
mentally B-Disease 1 1.0
retarded I-Disease 1 1.0
male O 0 3.505692120597814e-06
who O 0 1.6660510482324753e-06
suffers O 0 0.0006594904698431492
severe O 1 0.7400878071784973
muscular B-Disease 1 0.997554361820221
weakness I-Disease 1 0.9948034882545471
. O 0 1.785666881914949e-06

He O 0 1.8325002884012065e-06
presented O 0 1.520167529633909e-07
with O 0 2.396012916960899e-07
respiratory O 1 0.9853485226631165
and O 0 3.5188250535611587e-07
feeding O 0 1.6980688144485612e-07
difficulties O 0 1.312475319537043e-06
at O 0 1.2667881321704044e-07
birth O 0 3.7035354694126e-07
. O 0 1.0026950292285619e-07

His O 0 3.449081077633309e-06
two O 0 1.002566591523646e-06
sibs O 0 0.08739715814590454
suffer O 0 0.00026832494768314064
from O 0 1.3127115039424098e-07
childhood O 0 3.586256207199767e-05
onset O 1 0.8236202597618103
DM B-Disease 1 1.0
. O 0 1.8866531945604947e-06

Their O 0 1.787971228850438e-07
late O 0 1.2079485713911708e-05
father O 0 2.8392690865075565e-07
had O 0 1.7029332610718484e-08
the O 0 1.4289337768591537e-10
adult O 0 3.5583189728072284e-09
type O 0 1.956560993221501e-07
of O 0 3.13764481063572e-08
DM B-Disease 1 1.0
, O 0 1.673257266077144e-08
with O 0 4.534479458584428e-09
onset O 0 1.6316823803208536e-06
around O 0 9.610489115630116e-08
30 O 0 3.767184963976433e-08
years O 0 1.2780192903960597e-08
. O 0 1.0293883079270927e-08

Only O 0 6.828571486039436e-08
six O 0 1.216261047431999e-08
other O 0 3.054494157606058e-10
cases O 0 5.715664053163039e-10
of O 0 1.6457030183048005e-10
paternal O 0 2.570585820649285e-06
transmission O 0 0.030670547857880592
of O 0 2.3040191081236117e-05
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
have O 0 7.403728432109347e-06
been O 0 1.5589311885833013e-07
reported O 0 5.130798399477499e-07
recently O 0 2.3387866576740635e-07
. O 0 3.961386951800705e-08

We O 0 5.969827725493815e-07
review O 0 2.963288459056912e-08
the O 0 7.607273699861139e-10
sex O 0 1.30053425806409e-08
related O 0 8.017373431812302e-09
effects O 0 3.455236097238412e-08
on O 0 2.2958438705700246e-07
transmission O 0 0.0001445797533961013
of O 0 3.836817995761521e-06
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
. O 0 3.5907305573346093e-06

Decreased O 0 4.955223630531691e-05
fertility O 0 1.1377846931281965e-06
of O 0 1.267654647918448e-09
males O 0 6.3264611327440434e-09
with O 0 1.6326914265007986e-09
adult O 0 1.7307030475421925e-06
onset O 1 0.7519813776016235
DM B-Disease 1 1.0
and O 0 6.228084430404124e-07
contraction O 0 1.3638526752401958e-06
of O 0 7.309117200371418e-11
the O 0 1.5153756027785903e-10
repeat O 0 5.383492762689457e-09
upon O 0 2.4819887811666774e-10
male O 0 2.073080151987483e-09
transmission O 0 1.6360869992126936e-08
contribute O 0 4.705847378438932e-10
to O 0 3.552098892800615e-10
the O 0 6.415761255595953e-10
almost O 0 6.82873801949313e-09
absent O 0 1.2399563154019688e-08
occurrence O 0 7.172047400416659e-09
of O 0 3.5362399120053567e-10
paternal O 0 8.322626854351256e-07
transmission O 0 0.00030551108648069203
of O 0 7.720521352894139e-06
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
. O 0 6.066295554774115e-06

Also O 0 1.4664256298146938e-07
the O 0 1.2990832853887468e-09
fathers O 0 5.475095932183649e-09
of O 0 4.1160429231634765e-11
the O 0 8.25845225538302e-10
reported O 0 4.3092841224279255e-06
congenitally O 0 3.340045441291295e-05
affected O 0 6.668364704864871e-08
children O 0 1.879622146816473e-08
showed O 0 1.4146633020573063e-07
, O 0 4.0995290495615677e-10
on O 0 2.1509485748083534e-08
average O 0 7.66935883689257e-08
, O 0 1.0828006269392176e-09
shorter O 0 1.6434012195531977e-06
CTG O 0 5.098710971651599e-06
repeat O 0 1.2199759567010915e-06
lengths O 0 1.5400447637148318e-06
and O 0 3.320218100455463e-09
hence O 0 7.429198589647967e-09
less O 0 5.4652286252121485e-08
severe O 0 4.574230115395039e-05
clinical O 0 1.280833294003969e-05
symptoms O 0 1.0101280167873483e-05
than O 0 1.457773568525056e-09
the O 0 7.742236296515159e-10
mothers O 0 5.077194664693252e-09
of O 0 1.0678729428503786e-10
children O 0 4.43579857289933e-08
with O 0 1.5239212416418013e-06
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
. O 0 8.160335710272193e-06

We O 0 2.3498847667724476e-07
conclude O 0 3.125686873772793e-07
that O 0 1.856040654502067e-09
paternal O 0 7.346220058934705e-07
transmission O 0 0.00017133432265836746
of O 0 7.848439054214396e-06
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
is O 0 2.7897294785361737e-07
rare O 0 6.333997504270883e-08
and O 0 5.003039316164859e-09
preferentially O 0 9.19361120566009e-09
occurs O 0 1.1932842491901852e-09
with O 0 4.928704666617989e-10
onset O 0 3.959099217354378e-07
of O 0 3.5043485890895454e-09
DM B-Disease 1 1.0
past O 0 1.594579543962027e-07
30 O 0 9.01199204150771e-09
years O 0 1.989888254172456e-10
in O 0 1.8084099495663253e-10
the O 0 3.25241611420779e-10
father O 0 6.736846636101745e-09
. O 0 5.98842198051841e-10
. O 0 7.01687330462164e-09

The O 0 1.2377397524687694e-06
RB1 O 0 8.45033791847527e-05
gene O 0 2.1562593701673904e-06
mutation O 0 5.996628829052497e-07
in O 0 3.36898224873039e-08
a O 0 1.5053599611292157e-07
child O 0 2.7881420464836992e-05
with O 0 5.344205078472442e-07
ectopic B-Disease 1 0.9999984502792358
intracranial I-Disease 1 0.9999830722808838
retinoblastoma I-Disease 1 0.9667758941650391
. O 0 6.714247319905553e-06

The O 0 9.736855872688466e-07
RB1 O 0 0.00012984499335289001
gene O 0 4.5700821829086635e-06
mutation O 0 1.7127762248492218e-06
was O 0 2.182031266784179e-07
investigated O 0 4.9828148718233933e-08
in O 0 6.317128597999044e-09
a O 0 9.876318074475421e-08
child O 0 5.2078089538554195e-06
with O 0 1.5037902301173744e-07
ectopic B-Disease 1 0.9999772310256958
intracranial I-Disease 0 0.4898868501186371
retinoblastoma I-Disease 0 2.3477191462006886e-06
using O 0 1.4696619032861236e-08
DNA O 0 2.7140226066535433e-08
obtained O 0 1.6201865404852356e-09
from O 0 1.5742341874513954e-09
both O 0 1.0619890522534092e-09
the O 0 3.1319031812415687e-09
pineal B-Disease 0 5.287267867970513e-06
and I-Disease 0 8.094793884083629e-06
retinal I-Disease 1 0.9883497953414917
tumours I-Disease 1 1.0
of O 0 5.162689831195166e-09
the O 0 2.614354777108474e-08
patient O 0 1.9656631593534257e-06
. O 0 6.646486383488082e-08

A O 0 6.560414476552978e-06
nonsense O 0 8.206280472222716e-05
mutation O 0 5.437497065940988e-07
in O 0 1.3844378976557437e-08
exon O 0 5.428140070762311e-07
17 O 0 1.121336339338086e-07
( O 0 4.647353613052019e-09
codon O 0 9.897513564283145e-08
556 O 0 2.3612152233454253e-08
) O 0 1.3666953679880578e-10
of O 0 2.8134260546264223e-11
the O 0 1.188015574804524e-09
RB1 O 0 4.67843989326866e-07
gene O 0 2.1426650675948622e-08
was O 0 3.607833320984355e-08
found O 0 5.487136300885709e-10
to O 0 4.1847868920141806e-11
be O 0 1.350492079277288e-10
present O 0 7.361007636763617e-11
homozygously O 0 4.762694771898168e-08
in O 0 1.7038940258728985e-09
both O 0 2.1567070351835582e-09
the O 0 4.9583142036624395e-09
retinal B-Disease 0 7.682112482143566e-06
and I-Disease 0 1.5262584440733917e-07
the I-Disease 0 7.227666998232962e-08
pineal I-Disease 0 0.0008442734251730144
tumours I-Disease 1 0.9999997615814209
. O 0 6.618465135943552e-07

The O 0 6.729400325866663e-08
same O 0 1.376570146760514e-08
mutation O 0 1.710149533096228e-08
was O 0 7.232159759951173e-09
present O 0 1.2752081335332122e-10
heterozygously O 0 4.035883449660105e-08
in O 0 6.710655919839326e-10
the O 0 2.632827011961325e-10
DNA O 0 2.1566413099805004e-09
from O 0 4.1835417075031245e-11
the O 0 4.036909001525757e-11
constitutional O 0 1.018794631990616e-10
cells O 0 1.2452022746245461e-10
of O 0 1.84000453762323e-11
the O 0 2.502275886495653e-10
patient O 0 8.787442773439125e-09
, O 0 9.525433913859516e-11
proving O 0 1.0323887522645236e-08
it O 0 2.114551728160663e-10
to O 0 1.5925712137931924e-10
be O 0 3.99187405353274e-10
of O 0 1.460330467661919e-10
germline O 0 1.9652118510293803e-07
origin O 0 5.092530841466214e-08
. O 0 5.793963353539766e-08

The O 0 1.2699283047368226e-07
initial O 0 1.269147276161675e-07
mutation O 0 8.60805329239156e-08
was O 0 2.9604636964108977e-08
shown O 0 8.691757313883386e-10
to O 0 3.5597971792533656e-10
have O 0 3.2914844183551395e-09
occurred O 0 9.449856008814095e-09
in O 0 1.2792867876143532e-09
the O 0 2.43477327188657e-09
paternally O 0 8.065058523243351e-07
derived O 0 3.4944758908750373e-07
RB1 O 0 4.108655048185028e-05
allele O 0 1.1130659004265908e-05
. O 0 6.285461608968035e-07

The O 0 8.74923173910247e-08
mutation O 0 1.647828611339719e-07
is O 0 1.2823135886463888e-09
in O 0 6.624736870186609e-10
an O 0 4.0120844146951384e-11
area O 0 1.8204530938259467e-10
of O 0 1.2911155651551542e-11
the O 0 1.3101907059276385e-10
gene O 0 3.0644453641315295e-09
that O 0 1.826449130826191e-10
encodes O 0 7.86814946529546e-10
the O 0 1.8371999754851487e-10
protein O 0 1.2863710097121839e-08
- O 0 8.613143620550545e-08
binding O 0 1.1031808355710382e-08
region O 0 8.092932546333031e-09
known O 0 1.485897183073348e-08
as O 0 4.1301002617899485e-09
the O 0 5.53941004177716e-10
pocket O 0 6.281348305492429e-06
region O 0 1.385618730864735e-08
and O 0 3.198656628455865e-08
has O 0 1.3038916613083984e-09
been O 0 2.0627031194209167e-09
detected O 0 1.082297451659997e-08
in O 0 7.000707791249283e-10
other O 0 2.3513346825154713e-10
cases O 0 7.976187488267783e-10
of O 0 2.1100717007005443e-10
retinoblastoma B-Disease 0 5.452556592899782e-07
. O 0 2.699685275331376e-08
. O 0 8.663495520977449e-08

Low O 0 2.233691338915378e-05
levels O 0 5.856337637055731e-08
of O 0 4.846575918371343e-10
beta O 0 1.4894383504326925e-08
hexosaminidase O 0 2.3835917772885296e-07
A O 0 1.3450411451287891e-08
in O 0 7.637896537460165e-09
healthy O 0 2.1047437570587135e-08
individuals O 0 6.338678193440472e-11
with O 0 3.74365816124822e-10
apparent O 0 1.372712358715944e-05
deficiency O 0 7.55388755351305e-05
of O 0 4.307075252008019e-10
this O 0 5.633206789923406e-09
enzyme O 0 3.0914168291928945e-07
. O 0 7.241190047579948e-08

Appreciable O 0 0.00020996674720663577
beta O 0 7.163578629842959e-06
hexosaminidase O 0 1.6923997463891283e-05
A O 0 2.333219413230836e-07
( O 0 1.1381713349578604e-08
hex O 0 1.9331064038397017e-07
A O 0 1.027074070236722e-08
) O 0 3.520787827948624e-10
activity O 0 9.350475060898589e-09
has O 0 4.1971148778685574e-10
been O 0 1.840982255529866e-09
detected O 0 7.413871117023518e-08
in O 0 2.827988687670313e-08
cultured O 0 0.0008441752870567143
skin O 0 0.214279904961586
fibroblasts O 0 3.6962987906008493e-06
and O 0 3.3304236239928287e-06
melanoma B-Disease 0 0.026411831378936768
tissue O 0 1.204539785248926e-06
from O 0 9.82146097783243e-09
healthy O 0 1.2748542665974583e-08
individuals O 0 6.642459499106579e-11
previously O 0 5.48096512620333e-10
reported O 0 8.178749055787193e-08
as O 0 9.948327495123976e-09
having O 0 9.656016572989756e-07
deficiency B-Disease 0 1.563385694680619e-06
of I-Disease 0 3.157288666622016e-11
hex I-Disease 0 4.565768563224992e-08
A I-Disease 0 5.344655829020439e-09
activity O 0 9.544629975266616e-09
indistinguishable O 0 3.6839473693817126e-09
from O 0 2.3603211052325435e-10
that O 0 1.4052835284328324e-10
of O 0 1.0254288390632027e-10
patients O 0 5.4249117198423846e-08
with O 0 3.183849230481428e-06
Tay B-Disease 1 1.0
- I-Disease 1 1.0
Sachs I-Disease 1 1.0
disease I-Disease 1 0.926743745803833
( O 0 1.6896719046144426e-07
TSD B-Disease 0 7.308403291972354e-05
) O 0 6.38562411836574e-08
. O 0 9.953493673720004e-08

Identification O 0 2.5551732960593654e-06
and O 0 2.3536566473580933e-08
quantitation O 0 1.5123848697840003e-06
of O 0 1.7579412370238856e-09
hex O 0 1.0158490795220132e-06
A O 0 3.762890443681499e-08
, O 0 5.146965631475098e-10
amounting O 0 1.033981078535362e-08
to O 0 2.5725945818066975e-09
3 O 0 4.162312450262107e-08
. O 0 3.638905354819144e-08

5 O 0 3.837169515463756e-06
% O 0 3.054285002690449e-07
- O 0 3.4282702472410165e-06
6 O 0 3.2379702474827354e-07
. O 0 7.672782231793462e-08

9 O 0 7.745470043118985e-07
% O 0 2.3341768518037043e-09
of O 0 5.3238639191599546e-11
total O 0 8.031292991761418e-11
beta O 0 3.1793490062881347e-09
hexosaminidase O 0 4.314405543937028e-08
activity O 0 1.2568910356947072e-08
, O 0 8.338203738578187e-11
has O 0 1.0049854698435112e-10
been O 0 1.1644502029284354e-10
obtained O 0 2.389173581196502e-10
by O 0 1.3623601136103503e-09
cellulose O 0 6.184467110870173e-06
acetate O 0 7.116195774869993e-07
gel O 0 1.494293314863171e-06
electrophoresis O 0 3.7869537550250243e-07
, O 0 5.02510255628863e-09
DEAE O 0 1.4888412351865554e-06
- O 0 3.131325740923785e-07
cellulose O 0 1.5597386209265096e-06
ion O 0 1.272783549666201e-07
- O 0 4.4413991417968646e-07
exchange O 0 3.784678881402215e-07
chromatography O 0 2.438325736875413e-07
, O 0 4.3910137748071065e-09
radial O 0 5.335929245120496e-07
immunodiffusion O 0 4.931243893224746e-06
, O 0 7.2289605412834135e-09
and O 0 1.7648764227828906e-08
radioimmunoassay O 0 6.277820830291603e-06
. O 0 6.584004808019017e-08

Previous O 0 1.4405484307644656e-06
family O 0 5.779427425522954e-08
studies O 0 1.36144127083071e-08
suggested O 0 4.424718369477887e-09
that O 0 6.015206388543248e-11
these O 0 2.214281015489039e-11
individuals O 0 1.6819870149453742e-11
may O 0 3.8883083419705144e-09
be O 0 2.382743169437873e-10
compound O 0 1.8705050841560933e-09
heterozygotes O 0 8.949879060082822e-09
for O 0 8.794023842462195e-11
the O 0 2.773076213102854e-10
common O 0 4.6831512001688225e-09
mutant O 0 2.6099959882230905e-07
TSD B-Disease 0 8.129778507282026e-06
gene O 0 2.41364432440605e-07
and O 0 1.2929707970954496e-08
a O 0 1.5862550384326823e-08
rare O 0 2.7016278636438074e-07
( O 0 2.608129179293428e-08
allelic O 0 3.2729590770941286e-07
) O 0 7.79073960899268e-09
mutant O 0 5.33765955879062e-07
gene O 0 1.922210003613145e-06
. O 0 1.8515710564770416e-07

Thus O 0 2.575952748884447e-07
, O 0 9.921532928558463e-09
the O 0 1.5021790478186858e-09
postulated O 0 8.426083297763398e-08
rate O 0 8.785134752997692e-08
mutant O 0 2.9694216863163092e-08
gene O 0 3.908773749117245e-08
appears O 0 1.3172155810536879e-08
to O 0 2.375351304539919e-10
code O 0 9.863301286827664e-10
for O 0 4.477707787886587e-11
the O 0 1.8689992609122186e-10
expression O 0 9.602675321573884e-10
of O 0 1.7020806986067782e-10
low O 0 2.3825046824299534e-08
amounts O 0 2.1751109802181645e-09
of O 0 1.636601076882016e-09
hex O 0 1.4032837043487234e-06
A O 0 2.098186939747393e-07
. O 0 1.8434644744047546e-07

Heterozygotes O 0 4.846122465096414e-05
for O 0 3.187632913181915e-08
the O 0 2.6157700450113452e-09
rare O 0 1.2444793640042917e-08
mutant O 0 3.3303174973298155e-07
may O 0 1.3409150767529354e-07
be O 0 5.423716475938534e-10
indistinguishable O 0 5.757046395160614e-09
from O 0 3.7587426504614996e-09
heterozygotes O 0 1.1290312329492735e-07
for O 0 7.733189644199001e-10
the O 0 5.230315291981924e-09
common O 0 7.712397831483031e-08
TSD B-Disease 0 6.411800131900236e-05
mutant O 0 4.012487806903664e-06
. O 0 6.335991429295973e-07

However O 0 2.80104103467238e-07
, O 0 2.334640036849578e-09
direct O 0 2.583954383794662e-09
visualization O 0 1.5143304210596398e-07
and O 0 1.0468759192860944e-08
quantitation O 0 4.5537967707787175e-07
of O 0 8.093855030644193e-10
hex O 0 3.1750002449371095e-07
A O 0 7.50581197195288e-09
by O 0 2.599113146928289e-10
the O 0 4.673708087210571e-10
methods O 0 8.501662485116412e-09
described O 0 1.364287705030165e-08
may O 0 2.0772491282627925e-08
prevent O 0 4.247984630723067e-09
false O 0 1.367806987673248e-07
- O 0 9.973787200578954e-07
positive O 0 1.2556563433463452e-07
prenatal O 0 1.5595629520248622e-05
diagnosis O 0 7.182397894212045e-06
of O 0 1.6981189787657058e-09
TSD B-Disease 0 8.444136256002821e-06
in O 0 2.188950531945011e-08
fetuses O 0 2.355276080834301e-07
having O 0 4.306428547096175e-09
the O 0 2.499853879456282e-09
incomplete O 0 2.0630196218007768e-07
hex B-Disease 0 6.42038457954186e-06
A I-Disease 0 1.6250596672762185e-05
deficiency I-Disease 0 5.4828953579999506e-05
of O 0 1.826268025695299e-10
the O 0 7.680960312228535e-10
type O 0 4.371113391243853e-06
described O 0 1.7284452269450412e-07
in O 0 1.377846903238833e-08
the O 0 7.233400989292704e-09
four O 0 3.075748367109554e-08
healthy O 0 1.3016452271585877e-07
individuals O 0 9.559679270410015e-09

The O 0 1.404199451826571e-06
tumor B-Disease 0 4.242299110046588e-05
suppressor O 0 6.891175144119188e-05
gene O 0 3.715657294378616e-05
Smad4 O 0 0.0007807802758179605
/ O 0 0.00022028559760656208
Dpc4 O 0 3.1437602956430055e-06
is O 0 1.1743090944094092e-09
required O 0 9.149104807093522e-10
for O 0 2.87834478474025e-10
gastrulation O 0 3.149270000335491e-08
and O 0 2.070563054346053e-09
later O 0 1.0163578423316721e-08
for O 0 2.140702060060562e-10
anterior O 0 6.972752597533827e-09
development O 0 3.851724494907671e-10
of O 0 2.4333607351323394e-10
the O 0 6.005903330219553e-09
mouse O 0 1.7056496517398045e-06
embryo O 0 1.3549953337133047e-06
. O 0 6.341976472867827e-07

Mutations O 0 3.284503327449784e-05
in O 0 2.310247566583712e-07
the O 0 6.976467403774222e-08
SMAD4 O 0 0.09109017252922058
/ O 0 0.003637951100245118
DPC4 O 0 0.0003413959057070315
tumor B-Disease 0 1.0228990504401736e-05
suppressor O 0 2.586047003205749e-06
gene O 0 2.0467854255912243e-07
, O 0 1.1993560589118601e-09
a O 0 2.6537565478435e-09
key O 0 2.620930956709344e-07
signal O 0 2.6216312107862905e-06
transducer O 0 1.4329287978398497e-06
in O 0 4.066513525913251e-08
most O 0 1.1434915236918641e-08
TGFbeta O 0 1.3798155123367906e-05
- O 0 2.817925633280538e-06
related O 0 6.496162541225203e-08
pathways O 0 4.995620805914314e-09
, O 0 8.587083127897799e-11
are O 0 1.1967976956683835e-11
involved O 0 8.215980673575984e-11
in O 0 2.84809009709619e-10
50 O 0 1.021864148853524e-09
% O 0 3.8077216379939216e-10
of O 0 4.887992233193472e-09
pancreatic B-Disease 0 0.008282680064439774
cancers I-Disease 0 0.0001986117276828736
. O 0 1.7769423266145168e-07

Homozygous O 0 0.0011836867779493332
Smad4 O 0 0.0009586972882971168
mutant O 0 0.0001350733800791204
mice O 0 0.00369031704030931
die O 0 0.0008090894552879035
before O 0 1.3904137574627384e-07
day O 0 1.1784060660602336e-07
7 O 0 1.072377102673272e-07
. O 0 4.917460572073651e-08

5 O 0 1.7749857761373278e-06
of O 0 2.9049534333580596e-08
embryogenesis O 0 6.9656634877901524e-06
. O 0 3.906691290467279e-07

Mutant O 0 1.0238769391435198e-05
embryos O 0 8.980403549685434e-07
have O 0 4.32350830692485e-08
reduced O 0 9.931000022334047e-09
size O 0 1.3694576139755554e-08
, O 0 3.889265354217741e-09
fail O 0 5.487308953888714e-07
to O 0 1.6606371833205458e-09
gastrulate O 0 2.1280732198647456e-06
or O 0 1.0161000929542752e-08
express O 0 8.523062255960667e-09
a O 0 5.6460720543327625e-09
mesodermal O 0 4.198556666779041e-07
marker O 0 3.7240633332658035e-07
, O 0 3.4635347923028803e-09
and O 0 3.900951561774946e-09
show O 0 2.261977272155491e-07
abnormal O 0 3.2415930490969913e-06
visceral O 0 1.069331233338744e-06
endoderm O 0 7.741541594441514e-06
development O 0 2.9347717145356e-07
. O 0 1.3251766972643964e-07

Growth B-Disease 1 1.0
retardation I-Disease 1 0.9999997615814209
of O 0 3.5390959052250537e-09
the O 0 8.550743224589041e-09
Smad4 O 0 0.0001124521077144891
- O 0 0.0036915268283337355
deficient O 0 3.303606354165822e-05
embryos O 0 7.102568133632303e-08
results O 0 2.558415168607553e-08
from O 0 1.0551223228461026e-09
reduced O 0 3.7181346890236e-09
cell O 0 5.224216081956001e-08
proliferation O 0 3.8820708425646444e-08
rather O 0 1.667321170017999e-09
than O 0 3.329627684678371e-10
increased O 0 2.3737309895466296e-09
apoptosis O 0 7.779843258504116e-08
. O 0 3.3479459204954765e-08

Aggregation O 0 4.71659541290137e-06
of O 0 1.710244212915768e-08
mutant O 0 5.852010644957772e-07
Smad4 O 0 2.587924427643884e-06
ES O 0 6.076655836295686e-07
cells O 0 6.575683642040531e-08
with O 0 3.605286513774786e-09
wild O 0 2.5539864623169706e-07
- O 0 8.130024798447266e-05
type O 0 3.219522113795392e-05
tetraploid O 0 4.461805656319484e-05
morulae O 0 0.0006563620991073549
rescues O 0 0.0001435864542145282
the O 0 3.0035249665161246e-07
gastrulation B-Disease 0 5.3515410399995744e-05
defect I-Disease 0 3.6140794691164047e-05
. O 0 3.0181519150573877e-07

These O 0 7.769462939677396e-08
results O 0 3.9777411586783273e-08
indicate O 0 8.984616606255713e-09
that O 0 3.5423630695419206e-10
Smad4 O 0 4.313673329647827e-08
is O 0 1.3932098530400339e-10
initially O 0 9.2750845892553e-10
required O 0 1.0100394826073611e-10
for O 0 1.271132591545987e-11
the O 0 5.7979343548453244e-11
differentiation O 0 8.180067734286922e-10
of O 0 8.010914154255033e-11
the O 0 5.670048319750265e-10
visceral O 0 1.726632170573339e-08
endoderm O 0 1.4471562792550685e-07
and O 0 1.5361664162938382e-09
that O 0 2.381634611747785e-10
the O 0 6.481354342113832e-10
gastrulation B-Disease 0 1.7924473638686322e-07
defect I-Disease 0 1.3465124482081592e-07
in O 0 1.1657641518780792e-09
the O 0 8.135117024465899e-10
epiblast O 0 4.712822772034997e-07
is O 0 6.967657006917705e-10
secondary O 0 9.005599821421129e-09
and O 0 4.153143606799858e-09
non O 0 2.969960632981383e-07
- O 0 8.594241080572829e-06
cell O 0 1.244707982550608e-05
autonomous O 0 7.817668574716663e-07
. O 0 3.574422464680538e-07

Rescued O 0 0.00022583668760489672
embryos O 0 1.2002274161204696e-05
show O 0 2.3700153178651817e-05
severe O 0 0.038275327533483505
anterior O 0 0.00013752396625932306
truncations O 0 1.630953192943707e-05
, O 0 2.2289031065270137e-08
indicating O 0 1.8720555772233638e-07
a O 0 5.511515688283453e-09
second O 0 8.053743449920603e-09
important O 0 1.368934521295273e-09
role O 0 5.5238817964209375e-09
for O 0 1.9623149771774706e-09
Smad4 O 0 1.3883325209462782e-06
in O 0 1.6076776887530286e-07
anterior O 0 6.526473953272216e-06
patterning O 0 1.549059379613027e-05
during O 0 9.318570164396078e-07
embryogenesis O 0 1.4760502381250262e-05
. O 0 3.1784111342858523e-07

Prevalence O 0 0.0003044416953343898
of O 0 5.57336079509696e-08
p16 O 0 1.3301770195539575e-05
and O 0 1.508321645360411e-07
CDK4 O 0 9.915593545883894e-05
germline O 0 1.5593604985042475e-05
mutations O 0 2.14360875361308e-06
in O 0 6.270732910707011e-08
48 O 0 1.1990101484116167e-05
melanoma B-Disease 1 0.9997127652168274
- O 1 0.9252836108207703
prone O 0 0.00035767763620242476
families O 0 6.148929543314807e-08
in O 0 6.49586482381892e-08
France O 0 5.754004087066278e-05
. O 0 2.6276430276084284e-07

The O 0 1.0017034810516634e-06
French O 0 0.0001721639564493671
Familial B-Disease 0 0.1260431855916977
Melanoma I-Disease 1 0.8910143375396729
Study O 0 2.964383156722761e-07
Group O 0 2.603437962989119e-07
. O 0 6.916079087204707e-08

Germline O 0 0.0004314576799515635
mutations O 0 1.2989190508960746e-05
in O 0 6.318071399391556e-08
the O 0 2.9175679649995345e-09
p16 O 0 2.0672420930623048e-07
and O 0 3.282268679072331e-09
CDK4 O 0 8.755305884733389e-07
genes O 0 7.206685470606544e-09
have O 0 1.4411968285443777e-09
been O 0 2.1255677218334768e-09
reported O 0 1.1052911474962457e-08
in O 0 2.2316742898098596e-10
a O 0 3.5684169508165553e-10
subset O 0 8.318831845599561e-09
of O 0 6.244436523417107e-09
melanoma B-Disease 0 0.00015019887359812856
pedigrees O 0 1.744386850077717e-06
, O 0 8.431300102529349e-10
but O 0 1.6062386976045673e-09
their O 0 5.197118291278002e-10
prevalence O 0 3.9171627719269964e-08
is O 0 3.5331726433440735e-10
not O 0 1.004054839270907e-09
well O 0 3.0232545356057017e-09
known O 0 4.2140683831348724e-08
. O 0 7.391449940996608e-08

We O 0 3.16753897777744e-07
searched O 0 1.8561803472039173e-07
for O 0 5.153104609689763e-10
such O 0 1.033347629686432e-09
germline O 0 1.36803691930254e-06
mutations O 0 1.9257112171544577e-07
in O 0 8.873103141127103e-09
48 O 0 2.1372062519731116e-07
French O 0 0.04022134095430374
melanoma B-Disease 1 0.9999969005584717
- O 1 0.884681761264801
prone O 0 7.654419459868222e-05
families O 0 4.671107944886899e-09
selected O 0 3.0719402022150177e-10
according O 0 1.2142362115774574e-10
to O 0 7.022891296282197e-11
two O 0 1.9362957071056286e-10
major O 0 3.7186311807602124e-09
criteria O 0 3.167799578207564e-09
families O 0 1.1159154156281659e-10
with O 0 4.77020575817555e-11
at O 0 1.170485841583968e-08
least O 0 1.414980466130089e-09
three O 0 7.326427797771373e-10
affected O 0 1.7354104819844451e-09
members O 0 1.752640393926086e-10
( O 0 2.3047694308608868e-10
n O 0 7.298592397120274e-09
= O 0 1.017999196051278e-08
20 O 0 3.789017544164608e-09
) O 0 1.362452928255209e-10
or O 0 7.908955712565557e-10
families O 0 1.4124854064156978e-10
with O 0 2.0478126139256148e-11
two O 0 2.3907689716828884e-10
affected O 0 1.2808298865962797e-09
members O 0 1.156387000045278e-10
, O 0 4.538714890034434e-11
one O 0 5.279844617067653e-11
of O 0 4.219135023991738e-12
them O 0 7.035882987338482e-11
affected O 0 3.1431943159354603e-10
before O 0 4.4561124235009686e-10
the O 0 1.8521285893857709e-10
age O 0 2.7101246247163147e-10
of O 0 3.141554724694906e-12
50 O 0 1.0559069590909687e-10
( O 0 1.2357925793793356e-10
n O 0 1.0606313161076741e-08
= O 0 2.0933855537919044e-08
28 O 0 4.8631005000743244e-08
) O 0 1.829084661508773e-10
, O 0 2.108977159576142e-10
and O 0 4.299532396778716e-10
one O 0 1.0734280131430296e-09
additional O 0 2.0806700806730305e-09
minor O 0 1.0058938926249539e-07
criterion O 0 2.809077273013827e-07
. O 0 5.8325046126128655e-08

Sixteen O 0 4.612087650457397e-06
different O 0 1.550160533270173e-07
p16 O 0 5.943371888861293e-06
germline O 0 4.554337010631571e-06
mutations O 0 3.780988322432677e-07
were O 0 1.2512603397851763e-08
found O 0 2.2368917829140855e-09
in O 0 9.266084566306176e-10
21 O 0 6.057351065180683e-09
families O 0 2.409942800873921e-10
, O 0 5.1018463759211485e-11
while O 0 8.93960461212373e-10
one O 0 2.701213475120312e-09
germline O 0 3.3367169294251653e-07
mutation O 0 6.297786114828341e-08
, O 0 9.348936069741853e-10
Arg24His O 0 1.8143337854326091e-07
, O 0 1.1387375487004192e-09
was O 0 5.762926846841765e-08
detected O 0 5.434999295061971e-08
in O 0 3.1336178096808e-09
the O 0 6.316887457558096e-09
CDK4 O 0 6.5802714743767865e-06
gene O 0 8.2671181189653e-07
. O 0 6.388158624304197e-08

The O 0 9.799796174547737e-08
frequency O 0 3.5674887044478965e-07
of O 0 2.281158373307335e-09
p16 O 0 5.488769261319248e-07
gene O 0 7.142481450728155e-08
mutation O 0 9.701688341579029e-09
in O 0 7.040128480184649e-10
our O 0 2.578350588589018e-10
sample O 0 5.180887385769495e-10
( O 0 3.73786473994997e-10
44 O 0 1.233614765894231e-09
% O 0 1.1418078288416567e-10
) O 0 3.3417272421454314e-11
is O 0 7.09251338215644e-11
among O 0 7.6098530255031e-11
the O 0 2.8587626710319114e-10
highest O 0 5.99366174469651e-08
rates O 0 3.947542609239463e-06
yet O 0 2.0345241935615377e-08
reported O 0 3.532064241085209e-08
and O 0 4.743651027538931e-10
the O 0 6.371226879409164e-10
CDK4 O 0 1.2494357406467316e-06
mutation O 0 5.873383113197406e-09
is O 0 1.4654728819341045e-10
the O 0 2.2362164897593573e-10
second O 0 3.032080186926578e-08
mutation O 0 5.0089138170505976e-08
detected O 0 1.5888750226622506e-07
in O 0 5.247161816157586e-09
this O 0 1.3209232596622655e-09
gene O 0 6.969138865997593e-08
worldwide O 0 6.054050061266025e-08
. O 0 8.061692824412603e-08

In O 0 3.692306620450836e-07
summary O 0 7.343292622863373e-07
, O 0 1.419318662598812e-09
our O 0 4.0714998039703687e-10
results O 0 2.589638281591533e-09
show O 0 4.468404313229257e-09
frequent O 0 3.7193832458370935e-09
involvement O 0 5.6775619761140206e-09
of O 0 7.520320477460984e-11
the O 0 3.5156208499920183e-10
p16 O 0 9.643853360330468e-08
gene O 0 6.725756662717686e-08
in O 0 3.0891236235675024e-08
familial B-Disease 0 7.357211143244058e-05
melanoma I-Disease 0 0.013728316873311996
and O 0 2.019873868164268e-08
confirm O 0 4.58544846537734e-08
the O 0 5.022139371035905e-10
role O 0 1.3758870709423832e-09
of O 0 1.0416702916904441e-10
the O 0 2.0825559055026588e-09
CDK4 O 0 6.055666972315521e-07
gene O 0 4.453601221143799e-08
as O 0 1.119367798452231e-08
a O 0 7.929322975996911e-08
melanoma B-Disease 0 0.10820501297712326
- O 0 2.4816945369821042e-05
predisposing O 0 4.739712949231034e-06
gene O 0 1.3457091654345277e-06
. O 0 2.6277026776710954e-08
. O 0 8.550388486128213e-08

Progression O 0 9.779697575140744e-05
of O 0 1.4163749995077524e-07
somatic O 0 2.7072113880421966e-05
CTG O 0 9.701303497422487e-05
repeat O 0 3.6932754028384807e-06
length O 0 1.6117290613237856e-07
heterogeneity O 0 8.926441807943775e-08
in O 0 3.867635101073574e-09
the O 0 3.0110545168327008e-09
blood O 0 1.9534437001311744e-07
cells O 0 5.619772878162621e-07
of O 0 4.239326187871484e-07
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 0 0.17184004187583923
. O 0 4.6179764012777014e-07

The O 0 1.9353420555034972e-07
genetic O 0 4.633720891433768e-07
basis O 0 1.2522804127002019e-07
of O 0 5.345881959328835e-07
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 0.012619832530617714
DM B-Disease 1 1.0
) O 0 5.926995338967345e-09
is O 0 7.593019962781611e-11
the O 0 4.9379705185925715e-11
expansion O 0 1.1181296999396295e-09
of O 0 7.405381169389713e-11
an O 0 2.0956454349629894e-09
unstable O 0 1.1604264727793634e-05
CTG O 0 3.6678068227047333e-06
repeat O 0 1.8463164508375485e-07
in O 0 3.489241784393471e-09
the O 0 9.853654558966696e-10
34 O 0 6.5690746176017e-09
UTR O 0 9.751894225473734e-08
of O 0 6.89027890299343e-10
the O 0 3.486955080234111e-08
DM B-Disease 1 0.9999998807907104
protein O 0 2.1977908204462437e-07
kinase O 0 6.829716880929482e-07
gene O 0 2.276035928616693e-07
on O 0 2.487185781774315e-07
chromosome O 0 1.3809608390147332e-05
19 O 0 1.1738146667994442e-06
. O 0 1.498117399023613e-07

One O 0 2.5948411419562945e-08
of O 0 1.4587965557755211e-10
the O 0 1.4630988087738217e-10
principal O 0 9.530436440030599e-10
features O 0 1.2410157346209871e-09
of O 0 3.10787839907789e-10
the O 0 1.941654772963375e-06
DM B-Disease 1 1.0
mutation O 0 1.7684422459751659e-07
is O 0 6.616970305017844e-10
an O 0 3.675256765589552e-10
extraordinarily O 0 2.4156526023944025e-07
high O 0 5.327681762423708e-08
level O 0 1.1917721920440272e-08
of O 0 4.492741179085158e-10
somatic O 0 1.9103735837688873e-07
mosaicism O 0 2.170296511394554e-06
, O 0 1.7775779737050357e-09
due O 0 2.451838954087293e-09
to O 0 7.662421253051832e-10
an O 0 7.831691961612819e-10
extremely O 0 5.082119400867668e-07
high O 0 2.493607951237209e-07
degree O 0 3.468719711463564e-08
of O 0 5.336035502345737e-10
somatic O 0 5.181401547815767e-07
instability O 0 1.4960829730625846e-07
both O 0 6.828955734228259e-10
within O 0 2.0253113075519025e-10
and O 0 2.920184538623971e-09
between O 0 2.127725773348743e-09
different O 0 6.607300484517964e-09
tissues O 0 2.0045895610110165e-07
. O 0 7.10145755533631e-08

This O 0 1.923972803297147e-07
instability O 0 3.709799614171061e-07
appears O 0 2.602821602692984e-08
to O 0 2.1676387074176517e-10
be O 0 1.8100318466274246e-10
biased O 0 3.926039493507005e-09
towards O 0 1.625444501218709e-10
further O 0 1.3766790485369995e-10
expansion O 0 4.356408012107238e-10
and O 0 9.22124460123186e-11
continuous O 0 1.514890157761073e-10
throughout O 0 2.2079728323465275e-10
the O 0 8.062834427891019e-11
life O 0 3.757842648166587e-11
of O 0 1.4819654834893892e-12
an O 0 4.613969796507522e-12
individual O 0 5.425708059919598e-12
, O 0 1.1829878222846535e-11
features O 0 4.579500390011759e-10
that O 0 6.001620533879759e-09
could O 0 1.6422154658357613e-07
be O 0 3.434548478953303e-10
associated O 0 4.919894491806076e-10
with O 0 6.104829836095504e-11
the O 0 1.9707206977415126e-09
progressive O 0 6.101914085121507e-09
nature O 0 1.0160492447397473e-09
of O 0 5.234983557755868e-10
the O 0 4.617095328285359e-08
disease O 0 2.6583736598695396e-06
. O 0 5.434315397678802e-08

Although O 0 1.8898499831720983e-07
increasing O 0 1.5057196378620574e-08
measured O 0 3.0283228369398785e-08
allele O 0 9.576729098625947e-08
size O 0 1.362943002902739e-08
between O 0 2.0027526304033927e-08
patients O 0 2.3975715635060624e-07
clearly O 0 1.4172905515863476e-08
correlates O 0 2.095841500349138e-09
with O 0 9.15074127583182e-11
an O 0 2.1609140865574972e-10
increased O 0 1.2411772054576886e-08
severity O 0 8.321039217662474e-07
of O 0 2.7721891449061786e-09
symptoms O 0 8.859372542247002e-07
and O 0 1.365013213572297e-09
an O 0 1.9624674107987516e-10
earlier O 0 3.4202099641333916e-07
age O 0 8.044454880007379e-09
of O 0 1.127679200019216e-10
onset O 0 8.417184460540739e-08
, O 0 2.840798429826208e-10
this O 0 4.87050087760732e-11
correlation O 0 8.590396172181158e-10
is O 0 1.3662027065208804e-10
not O 0 1.0305507558427962e-09
precise O 0 3.068792508997831e-08
and O 0 7.504351806630893e-09
measured O 0 2.9299048520670112e-08
allele O 0 1.4657846492127646e-08
length O 0 2.615510474868188e-09
cannot O 0 3.822903771322217e-09
be O 0 2.625270278944214e-10
used O 0 6.304486377395335e-10
as O 0 4.954586740879563e-10
an O 0 7.404406254796214e-11
accurate O 0 2.6719760626292555e-08
predictor O 0 1.1654583431663923e-07
of O 0 4.5180742480610547e-10
age O 0 2.3424600925636696e-08
of O 0 1.191510334841439e-09
onset O 0 1.9708472791535314e-06
. O 0 1.287576765207632e-07

In O 0 4.1768583258772196e-08
order O 0 1.6681928061146323e-09
to O 0 1.8665445578047724e-10
further O 0 6.444434985652947e-10
characterize O 0 2.5954252080850893e-08
the O 0 2.5599269370957245e-09
dynamics O 0 1.3048928337866528e-07
of O 0 1.4494096589601213e-08
DM B-Disease 1 1.0
CTG O 0 1.6467729437863454e-05
repeat O 0 7.570095021947054e-07
somatic O 0 9.454039400225156e-07
instability O 0 6.023607852512214e-07
, O 0 1.8502614995696831e-09
we O 0 7.452655159667643e-10
have O 0 3.061972342344177e-10
studied O 0 3.863660502645416e-09
repeat O 0 1.8779056532025606e-08
length O 0 3.7226051130545557e-09
changes O 0 1.0688474549880311e-09
over O 0 6.816827657907254e-10
time O 0 4.661673269623634e-09
in O 0 1.6482365694514556e-08
111 O 0 0.0006199748022481799
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 0 4.159622039878741e-05
with O 0 9.053197080888253e-10
varying O 0 1.8951881841644536e-08
clinical O 0 1.433933675798471e-06
severity O 0 2.358718847972341e-05
and O 0 1.1214304862505742e-07
CTG O 0 6.994185696385102e-06
repeat O 0 2.571733261902409e-07
size O 0 1.2689591599723826e-08
over O 0 2.717035707533455e-09
time O 0 4.244760987148766e-09
intervals O 0 1.1546955391850133e-08
of O 0 1.4745178689157257e-10
1 O 0 2.2232814700373638e-08
- O 0 2.14944930121419e-06
7 O 0 1.2070542254605243e-07
years O 0 1.820007078379149e-08
. O 0 1.7575665367530746e-08

We O 0 3.5529330943973036e-07
have O 0 4.378927886961037e-09
found O 0 8.114104388390331e-10
a O 0 2.3426099948764545e-10
direct O 0 1.6251726631111296e-09
progression O 0 2.5194328401312305e-08
of O 0 3.3964307061262744e-11
the O 0 3.5606867454518465e-10
size O 0 5.025610594344698e-09
heterogeneity O 0 1.680110628399234e-08
over O 0 2.127234610682649e-09
time O 0 1.8932688750084026e-09
related O 0 1.0413012674348465e-09
to O 0 2.9194369144391885e-10
initial O 0 6.607829394766895e-09
CTG O 0 2.2938174026876368e-07
repeat O 0 5.1302308179401734e-08
size O 0 4.5101296031191396e-09
and O 0 5.035212247150866e-10
the O 0 2.66203864507375e-10
time O 0 2.023439638065838e-09
interval O 0 6.357937287759796e-09
and O 0 5.167721806031977e-10
always O 0 9.020981739382705e-10
biased O 0 8.809158735800793e-09
towards O 0 1.1388895382324904e-09
further O 0 1.9431078968068505e-09
expansion O 0 2.9415462066140208e-08
. O 0 2.6182922496786887e-08

Attempts O 0 1.1125373475806555e-06
to O 0 1.2929509907166903e-08
mathematically O 0 1.5428628330482752e-07
model O 0 3.64197454416626e-08
the O 0 2.2286341661015285e-09
dynamics O 0 7.314162075999775e-08
have O 0 1.645196334720822e-08
proved O 0 9.305215797894562e-08
only O 0 5.402014946476186e-10
partially O 0 1.327323850830453e-08
successful O 0 1.0522208881980077e-08
suggesting O 0 1.7761792037163104e-08
that O 0 1.0685859835879441e-10
individual O 0 2.1604803016050944e-11
specific O 0 1.8275921054300426e-10
genetic O 0 1.8370474919038315e-08
and O 0 1.0667628913552107e-07
/ O 0 1.290189175051637e-06
or O 0 6.116421591428889e-09
environmental O 0 6.997570300981693e-10
factors O 0 4.1933859162845977e-10
also O 0 1.0615152090664992e-09
play O 0 1.8154652892121703e-08
a O 0 1.95012894721458e-09
role O 0 5.777572642529094e-09
in O 0 7.782912092579863e-09
somatic O 0 3.0890444691067387e-07
mosaicism O 0 9.044814760272857e-06
. O 0 4.5656378233616124e-08
. O 0 1.5468273772967223e-07

Aspartylglucosaminuria B-Disease 1 0.999996542930603
among O 0 1.7407274981451337e-06
Palestinian O 0 4.902822183794342e-06
Arabs O 0 2.452879698466859e-06
. O 0 1.9161795705713303e-07

Aspartylglucosaminuria B-Disease 1 1.0
( O 0 0.05319083482027054
AGU B-Disease 1 1.0
) O 0 3.0903610337418286e-08
is O 0 1.1162502033812416e-09
a O 0 2.3159369977321376e-09
rare O 0 6.79836205108586e-07
disorder B-Disease 0 7.23507982911542e-05
of I-Disease 0 7.66354646408729e-10
glycoprotein I-Disease 0 1.811938886930875e-06
metabolism I-Disease 0 3.7783243897138163e-05
caused O 0 1.071784012651733e-07
by O 0 2.2830997092881944e-09
the O 0 1.0260993121846695e-07
deficiency B-Disease 0 1.9266884919488803e-05
of I-Disease 0 2.408472310477805e-10
the I-Disease 0 4.617982884980165e-09
lysosomal I-Disease 0 5.569286258833017e-06
enzyme I-Disease 0 2.205413238698384e-06
aspartylglucosaminidase I-Disease 0 5.106369826535229e-06
( O 0 2.6250075890743574e-08
AGA O 0 2.8863632905995473e-06
) O 0 4.651790419529789e-08
. O 0 5.904498934228286e-08

AGU B-Disease 1 0.9999996423721313
is O 0 2.1138639567652717e-06
inherited O 0 3.2445095712319016e-05
as O 0 8.879574409093038e-08
an O 0 5.671287439668049e-08
autosomal O 1 0.9931300282478333
recessive O 1 0.9999614953994751
trait O 0 8.207828068407252e-05
and O 0 1.0102874625772529e-07
occurs O 0 1.7312150601966891e-09
with O 0 1.0580762654921472e-10
a O 0 8.005576646041845e-09
high O 0 1.7007605492835864e-06
frequency O 0 3.280892087786924e-06
in O 0 2.3526433778897626e-06
Finland O 0 2.322743512195302e-06
because O 0 4.916576479274681e-09
of O 0 3.521363409197953e-11
a O 0 1.8187742423236841e-09
founder O 0 5.758125709576234e-08
effect O 0 7.663743417651858e-08
. O 0 5.255618162891551e-08

While O 0 7.752637429803144e-07
very O 0 2.1584369847005291e-07
few O 0 3.401070713948684e-08
patients O 0 1.4822461480434868e-07
with O 0 1.3852144320480875e-08
AGU B-Disease 1 1.0
have O 0 2.100320450892923e-08
been O 0 5.463370644775978e-09
reported O 0 1.5820219800843915e-08
from O 0 7.328958551156006e-10
non O 0 3.344716503761447e-08
- O 0 2.2918231934454525e-07
Finnish O 0 4.873388803616763e-08
origin O 0 4.53249082710272e-09
, O 0 2.7742412811448958e-09
we O 0 2.1301353569924686e-07
diagnosed O 0 7.310790351766627e-06
the O 0 2.628177453445346e-09
disorder O 0 8.792516723588051e-07
in O 0 2.0539834277855107e-09
8 O 0 1.0421482343758726e-08
patients O 0 4.628714300736192e-09
originating O 0 4.501277572899198e-09
from O 0 2.58308729961243e-09
3 O 0 9.722950222723625e-10
unrelated O 0 1.1848231729061354e-08
families O 0 1.1822806067485203e-09
, O 0 1.3497994388877999e-10
all O 0 3.841026108286627e-11
Palestinian O 0 3.497552469866605e-08
Arabs O 0 2.020039602257384e-08
from O 0 6.422397058614138e-10
the O 0 1.7571391563997452e-10
region O 0 1.1539595945464498e-09
of O 0 4.1969711039868685e-10
Jerusalem O 0 3.207997679055552e-06
. O 0 3.410288229588332e-08

The O 0 3.573802018763672e-07
clinical O 0 1.9067538232775405e-05
diagnosis O 0 0.08351755142211914
of O 0 1.2260660753327102e-07
AGU B-Disease 1 1.0
is O 0 2.7515930867139105e-08
often O 0 1.2170477070583274e-08
difficult O 0 9.213152907250333e-08
, O 0 1.0015677176511417e-10
in O 0 1.2089995671260567e-10
particular O 0 2.505131657670745e-10
early O 0 2.1522254201045143e-07
in O 0 3.486561039878211e-09
the O 0 3.317595920204752e-10
course O 0 1.2645087643647912e-08
of O 0 1.872009318393264e-11
the O 0 2.033545554169791e-09
disease O 0 5.817272707986376e-08
, O 0 4.130689401637966e-10
and O 0 1.5853822421529884e-10
most O 0 1.079305117501761e-10
of O 0 1.472237956545719e-11
the O 0 2.292450895780007e-09
patients O 0 6.93869921519763e-08
are O 0 9.630340080946098e-09
diagnosed O 0 8.572300203013583e-07
after O 0 3.6831042660168123e-09
the O 0 8.510079307910701e-10
age O 0 3.977458362669495e-09
of O 0 1.0638558090025896e-10
5 O 0 1.0620321511112252e-08
years O 0 1.8881992858155172e-08
. O 0 2.311309010849527e-08

However O 0 2.2886779049713368e-07
, O 0 6.195546742304714e-09
since O 0 2.7312725414674333e-09
these O 0 7.06338376676996e-10
patients O 0 1.0191551602645177e-08
excrete O 0 1.0739732658748835e-08
early O 0 5.1952575574887305e-09
large O 0 2.2829156620662872e-10
amounts O 0 9.118565902355158e-10
of O 0 3.394197978234814e-10
aspartylglucosamine O 0 2.2593556536776305e-07
in O 0 6.365460158974656e-09
urine O 0 1.2167157947828855e-08
, O 0 2.545746669024851e-10
biochemical O 0 2.220357409044027e-08
screening O 0 9.221978558571209e-08
is O 0 1.517971304210164e-09
easy O 0 3.4694341621843705e-08
by O 0 2.390177389344217e-09
urine O 0 6.313481293318546e-08
chromatography O 0 1.2957708861449646e-07
. O 0 5.56069057466857e-09
. O 0 1.6578340478190512e-08

Detection O 0 1.6125005686262739e-06
of O 0 1.070862065688516e-08
heterozygous O 0 2.3299618590044702e-07
carriers O 0 1.3490290484696743e-07
of O 0 9.84604620057894e-10
the O 0 9.505348316452e-06
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 0 6.502038445432845e-07
ATM O 0 8.065527254075278e-06
) O 0 3.876874377084505e-09
gene O 0 4.0704165371607814e-08
by O 0 1.0035172692823835e-08
G2 O 0 7.323856698349118e-05
phase O 0 1.3275791843625484e-06
chromosomal O 0 3.340121838846244e-05
radiosensitivity O 0 5.443362624646397e-06
of O 0 1.3440564217148676e-08
peripheral O 0 3.41396480507683e-05
blood O 0 6.767230388504686e-06
lymphocytes O 0 2.45368319156114e-05
. O 0 5.444169914881059e-07

In O 0 0.0034997332841157913
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 0 0.005179471801966429
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 3.593740771634657e-08
patients O 0 2.4368006279473775e-07
, O 0 5.019055726585009e-10
mutations O 0 1.0237979353178162e-08
in O 0 7.577124483404418e-10
a O 0 1.2779259872530702e-09
single O 0 2.763051343279699e-09
gene O 0 5.86096104981948e-09
, O 0 1.4295034600486645e-10
ATM O 0 1.2129024185014714e-07
, O 0 1.8023699199787302e-10
result O 0 3.2288807183533663e-09
in O 0 2.8777333227480995e-07
an O 0 0.003264800878241658
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
syndrome I-Disease 1 1.0
that O 0 2.5214478682755725e-07
embraces O 0 5.2630714009183066e-08
a O 0 3.594410546980953e-09
variety O 0 3.680800553240715e-09
of O 0 5.328895658074373e-10
clinical O 0 3.358979583367727e-08
features O 0 7.595913587010727e-08
and O 0 2.56261586173423e-07
manifests O 0 1.7946966579529544e-07
extreme O 0 2.790940527575003e-07
radiosensitivity O 0 3.0010711270733736e-05
and O 0 3.7061760327361526e-09
a O 0 1.6737637942298988e-09
strong O 0 1.6880322561974026e-07
pre O 0 0.0011708812089636922
- O 0 0.0002734787994995713
disposition O 0 2.2121264464658452e-06
to O 0 6.936529928225355e-08
malignancy B-Disease 0 1.3717753063247073e-05
. O 0 1.1893542506413723e-07

Heterozygotes O 0 1.8412330973660573e-05
for O 0 1.5701386857358557e-08
the O 0 1.0601575173296851e-09
ATM O 0 1.5421538535065338e-07
gene O 0 2.2544757172227037e-08
have O 0 1.8058806672271999e-09
no O 0 5.110536438479585e-10
clinical O 0 1.2057462805969976e-09
expression O 0 1.210756273017921e-09
of O 0 7.335796969876185e-10
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
but O 0 0.0001656952517805621
may O 0 1.7067144653992727e-05
be O 0 1.4602741771341243e-07
cancer B-Disease 0 6.660978897343739e-07
prone O 0 9.620778484986658e-08
with O 0 1.7125925677596854e-10
a O 0 4.764218797248532e-09
moderate O 0 6.007057322676701e-07
increase O 0 2.2826306178558298e-08
in O 0 1.4892962418855404e-08
in O 0 1.4755322297332896e-08
vitro O 0 1.7078405107895378e-06
radiosensitivity O 0 6.6245224843441974e-06
. O 0 1.0148569629109261e-07

We O 0 9.270509053749265e-07
performed O 0 1.1876608851935089e-07
a O 0 1.2089616419075355e-08
blind O 0 8.310650514431472e-07
chromosomal O 0 1.4573289490726893e-06
analysis O 0 1.6898452415148313e-08
on O 0 5.5846606983323e-07
G2 O 0 0.0007107147248461843
- O 0 1.4627091786678648e-06
phase O 0 6.994507373292436e-08
lymphocytes O 0 1.3540997656491527e-07
from O 0 5.0952486674304964e-09
7 O 0 1.822094652936812e-08
unrelated O 0 2.9388777988970105e-07
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 0.0028576916083693504
, O 0 1.3077596783261924e-09
13 O 0 4.9725010775603096e-09
obligate O 0 2.1808040173709742e-07
A B-Disease 1 1.0
- I-Disease 1 0.9999988079071045
T I-Disease 1 1.0
heterozygotes O 0 3.823698716587387e-05
( O 0 5.969585714638015e-09
parents O 0 1.2659487902411115e-09
of O 0 3.102694490220159e-11
the O 0 9.180518012463779e-10
patients O 0 1.563384977032456e-08
) O 0 1.037670643855293e-10
, O 0 3.0272226392291657e-10
and O 0 4.229632200036804e-09
14 O 0 8.451961797106833e-09
normal O 0 1.513540048847517e-08
controls O 0 2.9042396931799885e-07
following O 0 7.687119385479946e-09
X O 0 6.910420893291302e-07
- O 0 5.38161692986705e-08
irradiation O 0 6.63242971654654e-08
with O 0 1.0197457323002368e-09
1 O 0 5.2271240669199415e-09
Gy O 0 1.591483425045226e-07
in O 0 2.6809532371885325e-10
order O 0 9.976287851376497e-11
to O 0 1.2815329353266236e-10
evaluate O 0 1.9992785205147356e-09
this O 0 1.511622771399601e-10
cytogenetic O 0 5.668281133353048e-08
method O 0 2.437045232284163e-09
as O 0 8.547004770598221e-10
a O 0 6.939513408354969e-10
tool O 0 1.4331330788763808e-08
for O 0 1.8219538377994837e-10
detection O 0 8.747893076588298e-09
of O 0 8.256719752353092e-10
ATM O 0 3.971801106672501e-06
carriers O 0 1.7005755807986134e-06
. O 0 9.893172858710386e-08

Both O 0 3.3869698654598324e-06
A B-Disease 1 0.9999997615814209
- I-Disease 1 0.9999997615814209
T I-Disease 1 1.0
homozygotes O 0 0.00045133489766158164
and O 0 2.606547866434994e-08
heterozygotes O 0 5.756587597716134e-07
showed O 0 1.4699526218464598e-07
significantly O 0 1.1758247708826275e-08
increased O 0 1.184497055994882e-09
levels O 0 1.8080520414187617e-09
of O 0 2.521045594505722e-10
radiation O 0 1.3066231986158527e-05
- O 0 0.012929853983223438
induced O 0 1.0103573913511354e-05
chromatid O 0 0.00010138242214452475
damage O 0 3.5132924836034363e-07
relative O 0 3.221787725493641e-09
to O 0 2.426075451644749e-10
that O 0 1.6046211581688397e-10
of O 0 1.2975101548740042e-10
normal O 0 9.613825824317246e-08
controls O 0 1.3772939382761251e-05
. O 0 2.2495582641113288e-07

These O 0 5.462060315153394e-08
results O 0 5.142418046943931e-08
show O 0 1.085294876190801e-08
that O 0 7.880014973871141e-10
the O 0 4.177796331106265e-09
G2 O 0 0.00010754320828709751
- O 0 2.8072126951883547e-06
phase O 0 4.200174146262725e-07
chromosomal O 0 7.112679668352939e-06
radiosensitivity O 0 8.034052143557346e-07
assay O 0 1.0616234646931844e-07
can O 0 4.556350852169544e-10
be O 0 7.339068242018243e-11
used O 0 1.8207796381730645e-10
for O 0 3.1311293835489806e-11
the O 0 1.305055369327235e-10
detection O 0 3.6578309270396403e-09
of O 0 2.0833506031436855e-09
A B-Disease 1 1.0
- I-Disease 1 0.9999997615814209
T I-Disease 1 1.0
heterozygotes O 0 0.0003655230684671551
. O 0 5.162486331755645e-07

In O 0 2.3868466314524994e-07
combination O 0 1.575656511931811e-07
with O 0 1.6786010359481907e-09
molecular O 0 2.515068686648192e-08
genetic O 0 5.243623135697817e-08
analyses O 0 5.340877606840877e-08
, O 0 7.467838014640904e-10
this O 0 3.624079092379162e-10
test O 0 5.368750422007906e-08
may O 0 2.2671232002835495e-08
be O 0 5.6425350503097604e-11
of O 0 3.3698625487299516e-12
value O 0 9.714492404944153e-11
in O 0 4.3742093280840777e-10
studies O 0 1.2325517273481523e-09
of O 0 2.35072461496344e-10
familial B-Disease 0 1.0879107747996386e-07
and I-Disease 0 6.101124938595603e-08
sporadic I-Disease 0 0.00016963882080744952
cancers I-Disease 0 8.330635318998247e-05
aimed O 0 7.326630679926893e-08
at O 0 1.652533399010281e-08
determination O 0 1.7080590275497798e-09
of O 0 2.7202582200680503e-11
the O 0 7.250190031671266e-11
potential O 0 5.590186646919904e-10
involvement O 0 1.4291715588754528e-09
of O 0 1.2871477494957873e-10
ATM O 0 5.434508693724638e-06
mutations O 0 9.790735333581324e-08
in O 0 5.510730360924754e-08
tumor B-Disease 0 1.485700977355009e-06
risk O 0 5.878283104721049e-08
or O 0 4.179733448239631e-09
development O 0 4.022003174952715e-09
. O 0 8.572626164493613e-09
. O 0 4.2171961922576884e-08

Ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
: O 0 1.3914988983287913e-07
identification O 0 2.845096069847841e-08
and O 0 7.461615769699392e-10
detection O 0 3.420820737787267e-09
of O 0 1.9468500422892276e-10
founder O 0 8.945223584078121e-08
- O 0 3.542438435033546e-06
effect O 0 2.2456526949099498e-07
mutations O 0 3.253790836765802e-08
in O 0 1.014619943617845e-09
the O 0 6.414182518454936e-10
ATM O 0 4.978069796379714e-07
gene O 0 1.7282532738249756e-08
in O 0 5.015182935608209e-09
ethnic O 0 3.015226734959242e-09
populations O 0 1.3336427073795676e-08
. O 0 4.2526401955456095e-08

To O 0 4.7613053055783894e-08
facilitate O 0 3.1190342753006917e-08
the O 0 3.0732603129024483e-09
evaluation O 0 3.4858693709338695e-09
of O 0 1.1698263191473046e-10
ATM O 0 1.2661324717555544e-06
heterozygotes O 0 1.6056459628543962e-07
for O 0 3.398726300396504e-10
susceptibility O 0 6.679118591534916e-09
to O 0 1.1465571825297616e-09
other O 0 2.0352850071958528e-08
diseases O 0 2.2155404622026253e-06
, O 0 1.9977795806536136e-10
such O 0 9.095029174233105e-10
as O 0 0.0004757107817567885
breast B-Disease 0 0.09584730118513107
cancer I-Disease 0 7.459924290742492e-06
, O 0 3.5155891531246652e-09
we O 0 3.8392427015310204e-09
have O 0 3.892818289941147e-10
attempted O 0 4.165360500962834e-09
to O 0 3.8698982907092727e-10
define O 0 1.3972982770837916e-09
the O 0 4.1705736086861123e-10
most O 0 7.439475147030805e-10
common O 0 3.72376263158003e-09
mutations O 0 1.0997269761503503e-08
and O 0 4.147109600172172e-10
their O 0 2.2595272874958994e-10
frequencies O 0 1.0020429641599549e-07
in O 0 9.744731505634263e-05
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 0 0.0004967125132679939
A B-Disease 1 1.0
- I-Disease 1 0.9999997615814209
T I-Disease 1 1.0
) O 0 1.7960744003175932e-08
homozygotes O 0 5.886456619919045e-07
from O 0 3.3924649756045255e-09
10 O 0 2.2297479418398325e-09
ethnic O 0 1.6310666151042597e-09
populations O 0 1.1456855908420494e-08
. O 0 3.183331287459623e-08

Both O 0 2.9600951734209957e-07
genomic O 0 1.2455370779207442e-06
mutations O 0 1.4264645642469986e-06
and O 0 6.688578135793932e-09
their O 0 1.8901800125092905e-09
effects O 0 4.362224359510947e-08
on O 0 3.2463642440916374e-08
cDNA O 0 1.8196449502738687e-07
were O 0 3.3379231467733916e-07
characterized O 0 1.183962936579519e-07
. O 0 6.108868433329917e-08

Protein O 0 2.9043389076832682e-05
- O 0 2.03476520255208e-05
truncation O 0 1.7127647424786119e-06
testing O 0 9.231147402033457e-08
of O 0 1.8525313227879536e-10
the O 0 2.1248208748048114e-10
entire O 0 6.878998481951726e-10
ATM O 0 9.374514320370508e-08
cDNA O 0 5.5921336894471096e-08
detected O 0 1.9197096889911336e-07
92 O 0 3.958637861956049e-08
( O 0 1.6674579494946329e-09
66 O 0 2.5805769965359104e-08
% O 0 1.1145099287901417e-09
) O 0 1.1880902928140813e-09
truncating O 0 2.6079533199663274e-07
mutations O 0 3.6722829577229277e-07
in O 0 1.3973469492611912e-08
140 O 0 8.366141912574676e-08
mutant O 0 1.3378307812672574e-06
alleles O 0 3.2011489565775264e-06
screened O 0 1.1299686775601003e-05
. O 0 5.764168236055411e-07

The O 0 1.641952422914983e-07
haplotyping O 0 5.3431772357726e-06
of O 0 2.244969987685863e-09
patients O 0 5.7518690255164984e-08
with O 0 1.6622969667423604e-10
identical O 0 6.975575672640844e-08
mutations O 0 3.25135317780223e-07
indicates O 0 1.3891613548366877e-07
that O 0 9.59196611027835e-10
almost O 0 1.374722335967249e-09
all O 0 6.274755715018898e-11
of O 0 4.7850022555362415e-12
these O 0 9.65762192439712e-12
represent O 0 9.360546365799749e-11
common O 0 5.4416346983998665e-09
ancestry O 0 1.4175716600561827e-08
and O 0 7.850704974998735e-09
that O 0 2.076590455146743e-09
very O 0 3.658830749486697e-08
few O 0 2.478178551257315e-08
spontaneously O 0 2.6640833539204323e-08
recurring O 0 1.817329717823668e-07
ATM O 0 1.3316366676008329e-05
mutations O 0 4.971408884557604e-07
exist O 0 7.452562300613863e-08
. O 0 8.816154917212771e-08

Assays O 0 1.2986045476282015e-05
requiring O 0 2.416735469523701e-07
minimal O 0 5.11091222676896e-08
amounts O 0 2.3374959745581236e-09
of O 0 1.2800233095688895e-10
genomic O 0 3.837617335022969e-09
DNA O 0 2.3052773912013436e-08
were O 0 3.3566276425034403e-09
designed O 0 4.61933069573206e-09
to O 0 2.946568822270734e-10
allow O 0 4.917024010175908e-10
rapid O 0 1.1690311829681832e-08
screening O 0 2.2236758212557106e-08
for O 0 2.3756913103412103e-10
common O 0 4.080979110199223e-09
ethnic O 0 8.986622113127396e-09
mutations O 0 1.3813618124913773e-06
. O 0 2.0016534563183086e-07

These O 0 1.583625532930455e-07
rapid O 0 5.159577085578348e-07
assays O 0 3.4248619158461224e-06
detected O 0 8.032650384848239e-07
mutations O 0 9.345414042627453e-08
in O 0 2.947531552166538e-09
76 O 0 1.2847599428766898e-08
% O 0 9.46982006699848e-11
of O 0 5.263987509773749e-11
Costa O 0 1.0056518284784488e-08
Rican O 0 1.0825534246805546e-08
patients O 0 6.161197774190441e-08
( O 0 3.2954403095253326e-10
3 O 0 3.2887467749098676e-10
) O 0 4.221165431084195e-11
, O 0 3.4681722771434664e-11
50 O 0 1.1373997577113215e-10
% O 0 2.8506648430681736e-11
of O 0 1.2713927133312097e-10
Norwegian O 0 0.0019457547459751368
patients O 0 1.404866196708099e-07
( O 0 3.247178359533365e-10
1 O 0 3.899982559119053e-10
) O 0 5.021236204605373e-11
, O 0 6.669716862139907e-11
25 O 0 4.381708051948152e-10
% O 0 8.75945496692232e-11
of O 0 9.811696594086428e-11
Polish O 0 4.539476321951952e-06
patients O 0 1.2784379066488327e-07
( O 0 3.584030294767615e-10
4 O 0 1.3585559344164722e-09
) O 0 1.4288682737007008e-10
, O 0 1.9046952903778447e-10
and O 0 9.177488213829577e-10
14 O 0 2.403104826242952e-09
% O 0 4.419813126599337e-11
of O 0 5.416941895042271e-11
Italian O 0 3.0290104859886924e-06
patients O 0 7.522669420723105e-08
( O 0 2.8581467748090006e-10
1 O 0 3.3421304612701874e-10
) O 0 7.649858524416686e-11
, O 0 6.030415750091223e-11
as O 0 2.0219262375498204e-10
well O 0 5.068783726080994e-10
as O 0 4.490025573566925e-10
in O 0 1.3077745553147224e-09
patients O 0 2.566018064698028e-09
of O 0 2.5127405711700135e-10
Amish O 0 0.0007116157794371247
/ O 0 4.8462519771419466e-05
Mennonite O 0 9.319598575530108e-06
and O 0 7.897958198554988e-08
Irish O 0 3.571645379452093e-07
English O 0 8.907170467864489e-07
backgrounds O 0 2.072409870379488e-07
. O 0 4.9488686926224545e-08

Additional O 0 5.340307325241156e-07
mutations O 0 1.1875946483996813e-06
were O 0 2.664921971984313e-08
observed O 0 1.4095661304835971e-09
in O 0 3.729817010800218e-10
Japanese O 0 5.700870442382211e-09
, O 0 3.343040427816746e-11
Utah O 0 5.44514155986775e-10
Mormon O 0 3.4953768768275495e-09
, O 0 3.084586752688523e-10
and O 0 2.4115154317883025e-10
African O 0 1.8665349266200337e-09
American O 0 3.105280654835951e-08
patients O 0 1.5453750279448286e-07
. O 0 3.043076546305201e-08

These O 0 1.6735197050365969e-07
assays O 0 6.175646376505028e-07
should O 0 4.920967189292469e-09
facilitate O 0 5.952371928685807e-09
screening O 0 3.663873116011018e-08
for O 0 2.405379451175804e-09
A B-Disease 1 0.9999998807907104
- I-Disease 1 0.9999977350234985
T I-Disease 1 1.0
heterozygotes O 0 3.319591542094713e-06
in O 0 1.0721067589258837e-08
the O 0 1.2149989903065261e-09
populations O 0 2.116465447343785e-09
studied O 0 1.4326575481504733e-08
. O 0 2.993074899038106e-09
. O 0 1.1774833552635755e-08

The O 0 5.718586635339307e-06
von B-Disease 1 0.9969909191131592
Hippel I-Disease 1 0.9998000264167786
- I-Disease 1 0.999991774559021
Lindau I-Disease 1 0.9997878670692444
tumor I-Disease 0 0.011295367032289505
suppressor O 0 1.5552765034954064e-05
gene O 0 8.289927109217388e-07
is O 0 2.7142801339863354e-09
required O 0 1.915673841779153e-09
for O 0 3.6788616597505097e-10
cell O 0 4.782193059327255e-07
cycle O 0 1.52689622723301e-07
exit O 0 9.092851627201526e-08
upon O 0 5.447679196635136e-09
serum O 0 1.7254248518838722e-07
withdrawal O 0 5.652787535836978e-07
. O 0 4.9416808423075054e-08

The O 0 1.409174927857748e-07
inactivation O 0 4.7613778519917105e-07
of O 0 1.0638765424175745e-09
the O 0 1.9114628102556708e-08
von B-Disease 1 0.9982128143310547
Hippel I-Disease 1 0.9998618364334106
- I-Disease 1 0.9999856948852539
Lindau I-Disease 1 0.9999489784240723
( I-Disease 0 3.957191893277923e-06
VHL I-Disease 0 0.0009920193115249276
) I-Disease 0 6.581091582802401e-08
tumor I-Disease 0 8.130414244078565e-06
suppressor O 0 1.3031202797719743e-05
gene O 0 2.053246134892106e-06
predisposes O 0 1.6535225313418778e-06
affected O 0 4.34941362925656e-08
individuals O 0 3.86660786722004e-10
to O 0 7.677913860248964e-10
the O 0 1.411611627588627e-08
human O 0 2.80417334579397e-05
VHL B-Disease 1 1.0
cancer I-Disease 1 1.0
syndrome I-Disease 1 0.9999994039535522
and O 0 1.5959969346113212e-08
is O 0 8.569629450505545e-10
associated O 0 9.293080083239147e-09
with O 0 1.7777924909978537e-08
sporadic B-Disease 1 0.9999860525131226
renal I-Disease 1 1.0
cell I-Disease 1 1.0
carcinomas I-Disease 1 1.0
( O 0 1.4578277841792442e-05
RCC B-Disease 0 0.060566723346710205
) O 0 4.873648862258051e-08
and O 0 1.8742456120435236e-07
brain B-Disease 0 0.00015957880532369018
hemangioblastomas I-Disease 0 0.00011103662836831063
. O 0 3.045381902211375e-07

VHL O 0 0.30618712306022644
- O 0 0.0003164504887536168
negative O 0 2.338161903026048e-05
786 O 0 0.0002673107082955539
- O 0 0.0002556030231062323
0 O 0 3.4101589108104235e-07
RCC B-Disease 0 1.4039922461961396e-05
cells O 0 1.1168452829224407e-07
are O 0 3.5958918065404077e-09
tumorigenic O 0 6.049583021194849e-07
in O 0 3.418995930815072e-08
nude O 0 1.4189226021699142e-05
mice O 0 6.93433264586929e-07
which O 0 9.060158734364165e-10
is O 0 1.2990007680624416e-10
suppressed O 0 8.888462188494373e-10
by O 0 1.544365052508212e-10
the O 0 1.4938702497246936e-09
reintroduction O 0 4.2670375677289485e-08
of O 0 6.5934524506872094e-09
VHL B-Disease 0 1.9922692445106804e-05
. O 0 1.480995734937096e-07

Remarkably O 0 0.0025990509893745184
, O 0 2.2639772723209717e-08
this O 0 6.480390113416945e-10
occurs O 0 5.176482020807782e-10
without O 0 2.4159074740737196e-10
affecting O 0 6.501759131083418e-10
the O 0 3.423051286866041e-10
growth O 0 3.21209441267456e-08
rate O 0 6.33687378126524e-08
and O 0 5.556933801997843e-10
cell O 0 1.8096284293278586e-07
cycle O 0 2.3158984063798016e-08
profile O 0 3.972553397346701e-09
of O 0 2.785925483361762e-11
these O 0 8.176070237508881e-11
cells O 0 1.1601144489503668e-09
in O 0 4.05696720662263e-09
culture O 0 6.201957347684584e-08
. O 0 4.404856568385185e-08

The O 0 3.961259551488183e-07
786 O 0 9.814264558372088e-06
- O 0 2.3990544377738843e-06
0 O 0 4.833933431314108e-08
cell O 0 6.48572552108817e-07
line O 0 5.778986633231398e-06
, O 0 1.0088789803575082e-09
like O 0 5.4556439366137965e-09
many O 0 2.1861827903535413e-09
cancer B-Disease 0 3.1266701228105376e-08
cells O 0 4.9939155033484894e-09
, O 0 6.402021135443192e-10
fails O 0 1.7473951174906688e-08
to O 0 3.9051409328472175e-10
exit O 0 6.846216393796567e-08
the O 0 3.275370863420335e-09
cell O 0 5.71881002997543e-07
cycle O 0 4.508901696453904e-08
upon O 0 3.5482545790443965e-09
serum O 0 1.4666690617559652e-07
withdrawal O 0 3.676634889870911e-07
. O 0 6.791060513933189e-08

Here O 0 9.956178246284253e-07
, O 0 9.06021035973481e-10
it O 0 1.3053143288477287e-10
is O 0 1.29413823407587e-11
shown O 0 1.905356566966887e-10
that O 0 1.1547295758473908e-10
reintroduction O 0 1.2744063582204035e-09
of O 0 6.467618801631048e-11
the O 0 5.582994067054869e-10
wild O 0 1.1302944358249079e-08
- O 0 3.3280996376561234e-06
type O 0 6.976252734602895e-06
VHL B-Disease 0 7.037549039523583e-06
gene O 0 2.138494750170139e-07
restores O 0 4.379047595648444e-07
the O 0 2.2360469031923458e-09
ability O 0 1.5390940077963933e-08
of O 0 3.073500565164977e-09
VHL O 0 0.0014332543360069394
- O 0 0.01187684666365385
negative O 0 0.000297456921543926
RCC B-Disease 1 0.8719764351844788
cancer I-Disease 0 5.572293503064429e-06
cells O 0 3.600986175911203e-08
to O 0 4.851147483719842e-09
exit O 0 9.456115890316141e-08
the O 0 5.160809113391451e-09
cell O 0 8.398868089898315e-07
cycle O 0 9.6518952830138e-08
and O 0 5.346654230464765e-09
enter O 0 1.3439543522508757e-07
G0 O 0 7.313080277526751e-05
/ O 0 1.3542435226554517e-06
quiescence O 0 1.0945404937956482e-06
in O 0 5.651203238699054e-08
low O 0 2.122906607837649e-06
serum O 0 1.0625751656334614e-06
. O 0 1.645551606088702e-07

Both O 0 6.792019576096209e-06
VHL O 0 0.025607101619243622
- O 0 0.0002946471213363111
positive O 0 6.330869268822426e-07
and O 0 1.1672001676288346e-07
VHL O 0 0.0005090657505206764
- O 0 3.269447188358754e-05
negative O 0 2.910141802203725e-06
RCC B-Disease 0 1.7073298295144923e-05
cells O 0 6.717321099358742e-08
exit O 0 1.5812562992323365e-07
the O 0 3.411893434446256e-09
cell O 0 2.7913239364352194e-07
cycle O 0 2.0055049176903594e-08
by O 0 9.731094818832275e-10
contact O 0 9.59766666142059e-08
inhibition O 0 2.3676331295519049e-07
. O 0 3.97196409096523e-08

The O 0 5.522983315131569e-07
cyclin O 0 5.0972052122233436e-05
- O 0 7.142506547097582e-06
dependent O 0 2.3422089725499973e-06
kinase O 0 1.3205457435105927e-05
inhibitor O 0 4.331046056904597e-06
, O 0 5.06236119690584e-09
p27 O 0 4.936998720950214e-07
, O 0 9.077837370696784e-10
accumulates O 0 2.9385109900914586e-09
upon O 0 2.311051072734216e-10
serum O 0 6.356578818866865e-09
withdrawal O 0 6.293112697619563e-09
, O 0 9.23701670707544e-11
only O 0 3.079982449638585e-11
in O 0 8.198573070439252e-11
the O 0 4.6733134723142555e-11
presence O 0 3.5680494669954044e-10
of O 0 1.9594902089803412e-10
VHL B-Disease 0 3.702137121308624e-07
, O 0 4.060688729712325e-10
as O 0 2.5904867140269516e-10
a O 0 5.420365822850215e-10
result O 0 8.228530634646347e-10
of O 0 4.982635831707327e-11
the O 0 8.375410365246694e-10
stabilization O 0 4.503621919837997e-09
of O 0 8.646628552044788e-11
the O 0 7.298588955428897e-10
protein O 0 2.796700115936801e-08
. O 0 2.1757388779519715e-08

We O 0 1.6378689338125696e-07
propose O 0 4.7608693876100006e-08
that O 0 1.1473426653196839e-09
the O 0 2.8988289546560964e-10
loss O 0 5.010832193619308e-09
of O 0 6.60489996029412e-11
wild O 0 2.4020474498342992e-08
- O 0 0.00017556535021867603
type O 0 0.00015367606829386204
VHL B-Disease 0 2.618856706249062e-05
gene O 0 4.6585074642280233e-07
results O 0 8.114761840261053e-08
in O 0 1.0745403455914015e-09
a O 0 8.120653038901082e-10
specific O 0 1.1372051078595291e-09
cellular O 0 4.3605959945125505e-06
defect O 0 2.3661728221213707e-07
in O 0 4.011162957340275e-09
serum O 0 6.550197184651552e-08
- O 0 4.263035577878327e-07
dependent O 0 1.124244590755552e-07
growth O 0 7.347762931431134e-08
control O 0 1.9031430653626558e-08
, O 0 2.6425370225346967e-10
which O 0 6.554853881901579e-10
may O 0 3.831789996411317e-08
initiate O 0 9.200930151109787e-08
tumor B-Disease 0 1.1251513569732197e-06
formation O 0 3.618101374058824e-08
. O 0 4.942633324844792e-08

This O 0 7.247933098142312e-08
is O 0 7.521289369094575e-09
corrected O 0 8.934430439921925e-08
by O 0 2.50542808721832e-10
the O 0 3.0463254141466223e-10
reintroduction O 0 3.89054166660685e-09
of O 0 2.4713034396661726e-10
wild O 0 3.084731403646401e-08
- O 0 0.00011546173482201993
type O 0 0.006064530927687883
VHL B-Disease 0 0.0006567219388671219
, O 0 4.0159953584861796e-08
implicating O 0 1.056715859704127e-06
VHL B-Disease 0 8.63992318045348e-06
as O 0 6.1685332397587445e-09
the O 0 7.581027472447488e-10
first O 0 6.140137287502512e-09
tumor B-Disease 0 6.169500466057798e-08
suppressor O 0 6.327562118713104e-08
involved O 0 5.8770917021888636e-09
in O 0 2.8791256045934688e-09
the O 0 8.459748457312344e-10
regulation O 0 2.2378998210115242e-08
of O 0 8.255818251257097e-11
cell O 0 2.3766142476233654e-07
cycle O 0 4.155046795517592e-08
exit O 0 8.641644910767354e-08
, O 0 3.0906879833203504e-10
which O 0 2.3278268201920582e-10
is O 0 1.082279821318366e-10
consistent O 0 2.2773891661387324e-09
with O 0 4.805483094783014e-11
its O 0 4.3562420337650565e-10
gatekeeper O 0 5.5597492831793716e-08
function O 0 1.3399806819691662e-09
in O 0 7.506785415500872e-09
the O 0 3.378828239419818e-08
kidney O 0 1.151411765931698e-06
. O 0 1.1296263480176094e-08
. O 0 5.81999195503613e-08

Piebaldism B-Disease 1 1.0
with O 0 0.01516661886125803
deafness B-Disease 1 1.0
: O 0 1.3396210363225691e-08
molecular O 0 1.0177584108816973e-08
evidence O 0 2.5600979114415168e-09
for O 0 5.612547648858879e-10
an O 0 4.127761243921668e-09
expanded O 0 1.7243422917090356e-05
syndrome O 1 0.9982346296310425
. O 0 1.676024083963057e-07

In O 0 9.339141371356163e-08
a O 0 1.4287688365755002e-08
South O 0 1.2174865560155013e-08
African O 0 1.1078133077546681e-08
girl O 0 7.284715479727311e-07
of O 0 5.482428955261298e-10
Xhosa O 0 7.612587069161236e-06
stock O 0 1.3639034932566574e-06
with O 0 6.300571175898995e-09
severe O 0 0.00011400708899600431
piebaldism B-Disease 0 0.0007145731942728162
and O 0 1.8726747157415957e-06
profound O 0 0.054800618439912796
congenital O 1 1.0
sensorineural B-Disease 1 1.0
deafness I-Disease 1 1.0
we O 0 4.3067448132205755e-06
identified O 0 1.6370639954743638e-08
a O 0 1.0876400891035587e-09
novel O 0 2.39890551867461e-09
missense O 0 1.5702248390425666e-07
substitution O 0 3.0024537522876926e-08
at O 0 1.0539642936180371e-08
a O 0 8.112153726536064e-10
highly O 0 3.276845461641642e-09
conserved O 0 7.380936750678302e-09
residue O 0 6.701426968902524e-08
in O 0 7.699001436378694e-10
the O 0 3.9956218889081185e-10
intracellular O 0 8.172508003667645e-09
kinase O 0 7.665308032756002e-08
domain O 0 5.454312113073456e-09
of O 0 2.9390923028671523e-10
the O 0 7.133901469558168e-09
KIT O 0 0.00010711242794059217
proto O 0 0.23620307445526123
- O 0 8.080711995717138e-05
oncogene O 0 1.6323876479873434e-05
, O 0 4.153826438368924e-08
R796G O 0 2.300034793734085e-06
. O 0 1.260942354974759e-07

Though O 0 2.508644911358715e-06
auditory B-Disease 0 1.9846194845740683e-05
anomalies I-Disease 0 0.00022702365822624415
have O 0 1.5957471788397015e-08
been O 0 4.571648393181249e-09
observed O 0 1.3461209924514606e-09
in O 0 6.146359865510931e-09
mice O 0 6.333079340947734e-07
with O 0 1.6537402558469694e-09
dominant O 0 8.16016472526826e-06
white O 0 2.6452030397194903e-06
spotting O 0 0.00022985269606579095
( O 0 9.619475349609274e-08
W O 0 0.00044699295540340245
) O 0 3.660580949471637e-09
due O 0 1.6060987206856225e-08
to O 0 1.2135428661963488e-08
KIT O 0 0.03904050216078758
mutations O 0 0.00018639452173374593
, O 0 4.972861643182114e-05
deafness B-Disease 1 1.0
is O 0 1.040553332387617e-08
not O 0 6.216628545274716e-09
typical O 0 1.2699373996838403e-08
in O 0 1.4159260430801623e-08
human O 0 2.1666942018327973e-08
piebaldism B-Disease 0 6.588792984985048e-06
. O 0 8.835361597903102e-08

Thus O 0 1.9053246091971232e-07
, O 0 2.101573581825278e-09
the O 0 8.217896918516487e-10
occurrence O 0 3.445180851713303e-08
of O 0 1.1170561720064143e-07
sensorineural B-Disease 1 1.0
deafness I-Disease 1 1.0
in O 0 3.5943755847256398e-06
this O 0 1.9247945459710536e-08
patient O 0 1.4007804338689311e-07
extends O 0 1.4570627371313094e-08
considerably O 0 1.3840437418366491e-07
the O 0 1.2792599202171573e-09
phenotypic O 0 4.7547800363645365e-08
range O 0 9.781286891552554e-09
of O 0 4.130043251837634e-10
piebaldism B-Disease 0 5.775426643594983e-07
due O 0 8.243756788317569e-09
to O 0 3.2856699583305726e-09
KIT O 0 6.641379286520532e-07
gene O 0 6.354036230504789e-08
mutation O 0 2.991444247868458e-08
in O 0 2.223704331782983e-09
humans O 0 8.48132053477002e-09
and O 0 2.3758158107511917e-08
tightens O 0 7.055256446619751e-06
the O 0 1.9964585540321877e-09
clinical O 0 1.8793389955362727e-08
similarity O 0 9.563089875541664e-09
between O 0 7.241518051870344e-09
piebaldism B-Disease 0 3.930098046112107e-06
and O 0 2.1114616721717994e-09
the O 0 2.0618405593975098e-10
various O 0 5.249742307533722e-10
forms O 0 2.289589851045548e-08
of O 0 5.709273409593152e-07
Waardenburg B-Disease 1 0.9999817609786987
syndrome I-Disease 1 0.9992855191230774
. O 0 2.6406048903027113e-08
. O 0 5.2640253045410645e-08

Cycloheximide O 0 5.190651063458063e-05
facilitates O 0 6.493319801847974e-07
the O 0 5.437930994389717e-09
identification O 0 6.768118065991757e-09
of O 0 1.865352455832081e-10
aberrant O 0 1.15163096836568e-07
transcripts O 0 6.755674064606865e-08
resulting O 0 1.802914040283099e-09
from O 0 5.460992213990323e-10
a O 0 2.0352064478146303e-09
novel O 0 3.325600417269925e-08
splice O 0 9.554883581586182e-05
- O 0 2.9260570499900496e-06
site O 0 9.541412993030463e-08
mutation O 0 8.000252904594163e-08
in O 0 1.1981631686808214e-08
COL17A1 O 0 5.172369583306136e-06
in O 0 8.794636130460276e-09
a O 0 3.037312623632715e-08
patient O 0 8.87283363226743e-07
with O 0 1.2139179439429881e-08
generalized O 0 1.546977728139609e-05
atrophic B-Disease 1 0.9995083808898926
benign I-Disease 1 0.9980944991111755
epidermolysis I-Disease 1 0.9522780776023865
bullosa I-Disease 0 0.4964663088321686
. O 0 3.747906885109842e-05

Patients O 0 0.0014296179870143533
with O 0 5.910673621656315e-07
generalized O 0 0.0002558048872742802
atrophic B-Disease 1 0.9999439716339111
benign I-Disease 1 0.9997236132621765
epidermolysis I-Disease 1 0.9945005178451538
bullosa I-Disease 0 0.2575739920139313
often O 0 4.99577481605229e-06
show O 0 6.193287163114292e-07
decreased O 0 2.745051688179956e-07
expression O 0 6.226929194497188e-09
of O 0 4.08204386959099e-10
type O 0 3.671883860079106e-06
XVII O 0 1.3417248737823684e-05
collagen O 0 1.8993517869603238e-06
, O 0 2.0936958833317476e-09
a O 0 4.0855896443758866e-09
transmembrane O 0 8.095962300558313e-08
hemidesmosomal O 0 2.2182626935318694e-07
protein O 0 1.926715498257181e-08
encoded O 0 2.119690378776795e-08
by O 0 1.125718185335245e-08
COL17A1 O 0 1.848361898737494e-05
. O 0 1.715571897875634e-07

This O 0 1.611386295508055e-07
report O 0 6.079391567936909e-08
documents O 0 7.749804353807122e-09
a O 0 1.461013643400122e-09
novel O 0 2.5463030794981023e-08
splice O 0 0.00010709722118917853
- O 0 2.401038955213153e-06
site O 0 7.350860187216313e-08
mutation O 0 6.27685992071747e-08
in O 0 9.305284542904246e-09
COL17A1 O 0 2.967886985061341e-06
in O 0 5.849011941450044e-09
a O 0 2.5105586942686386e-08
patient O 0 8.271786668956338e-07
with O 0 1.14558282859889e-08
generalized O 0 1.825689287215937e-05
atrophic B-Disease 1 0.9997263550758362
benign I-Disease 1 0.9967806339263916
epidermolysis I-Disease 1 0.5171102285385132
bullosa I-Disease 0 0.02337740547955036
, O 0 1.6927396018218133e-07
and O 0 5.261613367224527e-09
applies O 0 2.6888253845669396e-09
a O 0 1.0757850166243088e-09
new O 0 3.93411259125287e-09
methodology O 0 1.3701002110622085e-08
to O 0 2.8872412793923274e-10
define O 0 7.506957722114294e-09
and O 0 4.136683440236766e-09
characterize O 0 2.212173555449226e-08
the O 0 1.2133269944314407e-09
resulting O 0 3.974698348230277e-09
mRNA O 0 1.1437995084406793e-07
splice O 0 9.421471986570396e-06
variants O 0 2.691423787837266e-06
. O 0 1.851742439384907e-07

Mutational O 0 0.00015326192078646272
analysis O 0 2.070142102184036e-07
of O 0 4.483977189551069e-09
COL17A1 O 0 1.0513418601476587e-05
identified O 0 6.459824675175696e-08
a O 0 1.4468492182118098e-08
maternally O 0 1.0654634934326168e-05
inherited O 0 1.7620999642531388e-05
G O 0 1.8235123206977732e-05
- O 0 1.5109592368389713e-06
to O 0 4.312611778800601e-08
- O 0 2.212089930253569e-05
T O 0 3.0456249078270048e-05
transversion O 0 7.43587804663548e-07
at O 0 1.7444079958295333e-08
the O 0 5.463982599707151e-10
- O 0 2.3736463461432322e-08
1 O 0 1.5931491681442367e-09
position O 0 5.949602588373182e-09
of O 0 5.196136854124234e-10
exon O 0 1.8025527026566124e-07
32 O 0 1.6734716723476595e-07
. O 0 6.410947150925494e-08

This O 0 1.8398007739506284e-07
acceptor O 0 9.363457706967893e-07
splice O 0 3.152589488308877e-05
- O 0 8.324775990331545e-06
site O 0 8.581397992202255e-08
mutation O 0 3.6792091151482964e-08
led O 0 1.5599349589834333e-09
to O 0 2.272861898688916e-10
the O 0 2.642930041485414e-10
formation O 0 2.2344430472553967e-10
of O 0 1.1084103773706389e-10
aberrant O 0 3.471559040235661e-08
transcripts O 0 1.744175115447888e-08
present O 0 2.7693933812855676e-09
at O 0 1.0625026192201403e-07
extremely O 0 2.5000369419103663e-07
low O 0 8.222277187996951e-07
levels O 0 7.919362587927026e-08
. O 0 2.3523416103898853e-08

Based O 0 2.165723742564296e-07
on O 0 3.3868548854343317e-08
our O 0 2.0679187251460007e-09
recent O 0 2.2558594992005965e-09
finding O 0 2.2575468161534218e-09
that O 0 8.381514926547595e-10
cycloheximide O 0 4.458969158349646e-07
stabilized O 0 1.350017646473134e-05
mutant O 0 3.7034189404039353e-07
COL17A1 O 0 2.212938852608204e-06
transcripts O 0 1.738440005283337e-07
in O 0 1.0339080702692627e-08
keratinocytes O 0 3.226568026093446e-07
homozygous O 0 1.2013387618026172e-07
for O 0 1.3544679822174999e-09
a O 0 8.926744676784892e-09
frameshift O 0 2.94704623229336e-05
mutation O 0 1.845960895252574e-07
, O 0 1.9695518549411872e-09
the O 0 2.156594763880193e-10
effects O 0 1.4579133456038562e-08
of O 0 1.3369726159506712e-10
the O 0 4.536382824937846e-09
splice O 0 4.038313636556268e-05
- O 0 9.688079671832384e-07
site O 0 3.589205732623668e-08
mutation O 0 2.9731280548617178e-08
on O 0 9.366218023387773e-09
splicing O 0 6.164065524671969e-08
of O 0 1.0829287466762594e-09
COL17A1 O 0 4.213924000850966e-07
transcripts O 0 7.928778700261319e-08
were O 0 4.890239768684523e-09
determined O 0 2.2111095177024254e-09
using O 0 2.7956585935129397e-09
reverse O 0 1.604557695600306e-07
transcriptase O 0 1.0461492365720915e-06
polymerase O 0 2.291510554641718e-07
chain O 0 7.567267346075823e-08
reaction O 0 2.299470613920107e-09
of O 0 4.142948831220572e-11
total O 0 8.902251852349607e-11
RNA O 0 1.4032601747260287e-08
from O 0 7.320226647067329e-10
keratinocytes O 0 1.831809726127176e-08
incubated O 0 1.6300752747611114e-08
for O 0 5.917040746261648e-10
2 O 0 1.1723113146899777e-08
. O 0 3.8146239944580884e-08

5 O 0 9.708612651593285e-07
h O 0 1.1065251328545855e-06
in O 0 5.386656454220429e-09
the O 0 8.201079260139466e-10
presence O 0 5.344777953553148e-09
or O 0 9.702206149597714e-09
absence O 0 1.6743012309916594e-08
of O 0 3.7934699825825646e-10
10 O 0 1.0776544989710146e-08
microg O 0 1.2053799309796887e-06
cycloheximide O 0 3.1555409805150703e-06
per O 0 5.954339030722622e-07
ml O 0 1.1396285117371008e-05
. O 0 1.279307468848856e-07

Using O 0 5.921517498563844e-08
this O 0 1.212776434833529e-09
approach O 0 3.237293455526924e-08
, O 0 1.0349729961944831e-09
an O 0 8.130059958588731e-10
abnormally O 0 2.0679243561971816e-07
spliced O 0 2.3481156858906616e-06
transcript O 0 7.192260909505421e-06
was O 0 2.442072570829623e-07
identified O 0 7.619820330262428e-10
that O 0 9.619274127237176e-12
contains O 0 4.993726786250985e-12
an O 0 8.047159293089745e-12
extra O 0 5.733658547946163e-10
264 O 0 2.201581805749697e-09
bases O 0 5.068203634550628e-10
upstream O 0 2.807344801070144e-09
from O 0 4.605445746985737e-10
exon O 0 1.1936057475736561e-08
32 O 0 5.389801049915377e-09
, O 0 1.3420747846382142e-10
resulting O 0 5.457743146308758e-10
in O 0 7.929879863866063e-09
a O 0 1.3426387113213423e-07
premature O 0 2.497801915524178e-06
termination O 0 2.3911073299132113e-07
codon O 0 2.818528059833625e-07
27 O 0 4.2898790297840605e-08
bp O 0 4.5298787654246553e-07
downstream O 0 3.7795494733927626e-08
from O 0 2.330084569734936e-09
the O 0 2.3588011544006804e-09
cryptic O 0 7.189141797425691e-07
splice O 0 1.2469747161958367e-05
site O 0 1.280915626011847e-06
. O 0 1.5180552281890414e-07

Three O 0 6.183507395007837e-08
other O 0 4.61346605362678e-09
splice O 0 2.2229226033232408e-06
variants O 0 3.0929444960747787e-07
, O 0 5.007084746821988e-10
including O 0 6.690995674185629e-11
one O 0 1.0969605779287406e-10
derived O 0 2.4781901530879225e-10
from O 0 4.538059372727332e-10
the O 0 2.0480714346682305e-10
skipping O 0 9.27402776795816e-09
of O 0 5.895712390513452e-11
exon O 0 2.2193200166498173e-08
32 O 0 2.576038049539875e-08
, O 0 1.1543999089980161e-09
were O 0 1.6251176404580292e-08
also O 0 5.124966229175243e-09
identified O 0 6.785945316778452e-08
. O 0 2.2203913374596596e-08

These O 0 2.837888644080522e-07
results O 0 1.2485335787459917e-07
indicate O 0 3.290004713107919e-08
the O 0 7.862674400449521e-10
usefulness O 0 1.3179090707637897e-08
of O 0 1.8864083906056095e-10
cycloheximide O 0 1.92417473954265e-07
treatment O 0 1.4643790180457472e-08
in O 0 6.460852963741104e-10
evaluating O 0 2.124100673128737e-09
the O 0 6.004434727202579e-10
abnormal O 0 2.6740256231505555e-08
processing O 0 1.867973775659948e-09
of O 0 5.1338253093113906e-11
mRNA O 0 3.95508115147436e-09
due O 0 2.656658448785265e-09
to O 0 1.1274216005219273e-09
splice O 0 1.4737351193616632e-05
- O 0 9.120231538872758e-07
site O 0 5.205387765272462e-08
mutations O 0 2.1204348854553245e-07
, O 0 1.5851533419208863e-09
because O 0 3.0896052383155848e-09
( O 0 2.4463175929412273e-09
i O 0 5.634004196508613e-07
) O 0 1.742876398758142e-10
aberrant O 0 1.408193650576095e-08
splicing O 0 3.47023529911894e-08
often O 0 7.560713832788224e-09
generates O 0 1.1288466161829547e-08
a O 0 6.207709191130562e-08
premature O 0 3.6288668070483254e-06
termination O 0 1.5511837148096674e-07
codon O 0 9.807481404777718e-08
, O 0 6.52275122803303e-10
( O 0 3.75010439368495e-10
ii O 0 1.6202584163238498e-08
) O 0 6.205951308402291e-10
transcripts O 0 6.768804894363711e-08
with O 0 7.353521791486628e-09
premature O 0 2.7672147098201094e-06
termination O 0 1.9290547470518504e-07
codons O 0 1.1501141727876529e-07
can O 0 3.4903335777158873e-09
occur O 0 1.6931157587052326e-09
at O 0 5.805243397105642e-09
low O 0 9.74267280184904e-08
or O 0 7.94588306263222e-09
undetectable O 0 3.27657261323111e-07
levels O 0 5.822475390715454e-09
due O 0 1.1972899338630327e-09
to O 0 6.574486510757538e-10
nonsense O 0 5.437217396320193e-07
- O 0 1.5605845504751414e-08
mediated O 0 3.710591300887245e-08
mRNA O 0 5.136886471746038e-09
decay O 0 4.512272333556666e-09
, O 0 7.76648884093234e-11
and O 0 5.254848639557608e-11
( O 0 3.4718717484283346e-11
iii O 0 2.062569226524147e-09
) O 0 2.577818167259771e-11
the O 0 5.1810822992992556e-11
levels O 0 4.294942179683403e-10
of O 0 5.117495836814978e-12
these O 0 1.813832244124125e-11
transcripts O 0 2.3725947873032283e-09
can O 0 1.1595984589218844e-10
be O 0 2.7229005508666582e-11
increased O 0 2.8160040965730104e-10
by O 0 6.290097331884681e-10
cycloheximide O 0 1.9562342004064703e-06
. O 0 3.960669303637587e-08

A O 0 2.644473852342344e-06
deletion O 0 6.002498594170902e-06
mutation O 0 4.868186351814074e-07
in O 0 3.6363939415196e-08
COL17A1 O 0 5.06841424794402e-05
in O 0 6.047402223430254e-08
five O 0 4.069710257681436e-08
Austrian O 0 4.61328454548493e-06
families O 0 6.949663511335302e-09
with O 0 5.7041447121264355e-09
generalized O 0 2.8786207622033544e-05
atrophic B-Disease 1 0.9995538592338562
benign I-Disease 1 0.9969714879989624
epidermolysis I-Disease 1 0.7979210019111633
bullosa I-Disease 0 0.0202085729688406
represents O 0 1.5131538475543493e-06
propagation O 0 4.0435045889353205e-07
of O 0 3.223926903217489e-09
an O 0 4.0653636013132655e-09
ancestral O 0 7.477849521819735e-07
allele O 0 3.3998028811765835e-05
. O 0 5.784030463473755e-07

Patients O 0 0.002186407567933202
with O 0 3.769513909901434e-07
generalized O 0 9.500254964223132e-05
atrophic B-Disease 1 0.9999330043792725
benign I-Disease 1 0.9999569654464722
epidermolysis I-Disease 1 0.9987993240356445
bullosa I-Disease 1 0.9881409406661987
, O 0 6.492211355180189e-07
a O 0 4.9779508515257476e-08
usually O 0 1.8082943142871954e-08
nonlethal O 0 6.932401674930588e-07
form O 0 8.630807002418805e-08
of O 0 3.964463601846546e-08
junctional B-Disease 0 0.002294211182743311
epidermolysis I-Disease 1 0.5563220381736755
bullosa I-Disease 0 0.09827424585819244
, O 0 1.1708301173030122e-07
have O 0 1.4133950898553849e-08
generalized O 0 3.8182790262908384e-07
blistering B-Disease 0 0.0004426505183801055
, O 0 3.0850014809402637e-06
nail B-Disease 1 1.0
dystrophy I-Disease 1 0.9999781847000122
, O 0 4.0096011844070745e-07
patchy B-Disease 1 0.9980893731117249
alopecia I-Disease 1 0.9999309778213501
, O 0 2.0497819264164718e-07
and O 0 1.2175119081803132e-06
dental B-Disease 1 0.9993563294410706
abnormalities I-Disease 1 0.9999009370803833
. O 0 8.25260826786689e-07

Skin B-Disease 1 0.9999994039535522
fragility I-Disease 0 0.17518368363380432
in O 0 6.857207068833304e-08
most O 0 1.851963360444131e-09
cases O 0 1.0251026694163556e-09
is O 0 7.141259111831388e-11
due O 0 6.605432312234427e-10
to O 0 9.67372626448082e-10
mutations O 0 1.1341319883229062e-08
in O 0 1.6406077607555858e-09
the O 0 5.67328295453251e-10
gene O 0 3.347275523424287e-08
encoding O 0 1.0054834831407788e-07
type O 0 3.440615182626061e-05
XVII O 0 7.373076368821785e-05
collagen O 0 2.1978628865326755e-05
( O 0 9.915444820762787e-08
COL17A1 O 0 8.322663234139327e-06
) O 0 3.214889332525672e-08
. O 0 3.082137567389509e-08

Recently O 0 1.300248914049007e-05
, O 0 2.1856253695773376e-08
we O 0 4.570863243458234e-09
reported O 0 2.2860115578282603e-08
five O 0 7.590330586282334e-10
Austrian O 0 7.308011618079036e-07
families O 0 2.801231246962743e-09
with O 0 2.3969617402030963e-09
generalized O 0 5.984642029943643e-06
atrophic B-Disease 1 0.9997879862785339
benign I-Disease 1 0.9986135959625244
epidermolysis I-Disease 1 0.9600065350532532
bullosa I-Disease 0 0.3916468322277069
who O 0 3.228234618291026e-06
share O 0 1.2384512615426502e-07
the O 0 7.414207470191059e-09
same O 0 6.943094632561042e-08
COL17A1 O 0 5.4430107411462814e-05
mutation O 0 1.4481173593594576e-06
. O 0 1.409260903528775e-07

Affected O 0 4.438398718775716e-06
individuals O 0 2.296298617920911e-08
in O 0 1.1159718482645076e-08
three O 0 1.0956250351412677e-09
families O 0 3.9475051005766204e-10
are O 0 8.581697158449586e-11
homozygous O 0 4.539126408076299e-09
for O 0 2.798853093732845e-10
4003delTC O 0 4.9481890584957e-08
, O 0 1.606795529962568e-10
whereas O 0 6.094292293035153e-10
those O 0 2.1692184160038153e-10
in O 0 2.0056531990775284e-09
two O 0 1.320822562433932e-09
others O 0 2.730944137496749e-09
are O 0 3.949116589296864e-10
compound O 0 4.5280518889967425e-08
heterozygotes O 0 1.9301123757031746e-06
. O 0 5.130896241212213e-08

To O 0 4.75189700921419e-08
determine O 0 1.44601335350103e-08
if O 0 1.5745764692098874e-09
the O 0 2.74356704021983e-10
occurrence O 0 3.652748770122116e-09
of O 0 1.0404213601766799e-10
4003delTC O 0 4.168780165514363e-08
in O 0 6.530419538464116e-10
these O 0 7.968944948366641e-11
unrelated O 0 3.7541285635711574e-09
families O 0 5.898043164975775e-10
signifies O 0 2.859369629959474e-09
propagation O 0 2.1972275110471173e-09
of O 0 6.78975556334116e-11
an O 0 2.5769344991211085e-10
ancestral O 0 2.256230757780031e-08
allele O 0 4.888340185971174e-07
or O 0 7.160049619869824e-08
a O 0 1.268085156880261e-07
mutational O 0 9.588949615135789e-05
hot O 0 5.6611352192703635e-05
spot O 0 4.530674414127134e-05
, O 0 1.0792465587883271e-08
haplotypes O 0 4.416179706367984e-07
were O 0 1.8341964391765941e-07
determined O 0 1.710919406150424e-08
for O 0 4.699451938705579e-10
polymorphisms O 0 6.54868586025259e-08
both O 0 1.5227066274547951e-09
within O 0 2.9888533870092715e-09
and O 0 6.534412477776641e-08
flanking O 0 2.1276078769005835e-05
COL17A1 O 0 0.0007603560807183385
. O 0 3.368019463323435e-07

Five O 0 1.9153808352712076e-06
intragenic O 0 1.2804399375454523e-05
polymorphisms O 0 1.3140182772986009e-06
were O 0 1.1608566552467892e-08
chosen O 0 5.472253206129096e-10
based O 0 1.3529188880312404e-09
on O 0 6.899990978581627e-08
their O 0 9.61620649775341e-09
informativeness O 0 9.372177487421141e-07
. O 0 2.733181148073527e-08

One O 0 6.414788344955014e-08
of O 0 1.7203123647835383e-10
these O 0 1.5297448030526795e-10
, O 0 5.186540086299374e-11
not O 0 1.2980101715687198e-10
previously O 0 1.6250919498972394e-09
reported O 0 1.4498057510081708e-07
, O 0 1.823907691544946e-10
was O 0 3.384110414117458e-08
2988 O 0 9.706612402737846e-09
A O 0 5.53015455651007e-09
or O 0 8.87340778632506e-09
C O 0 2.0379166016937234e-06
that O 0 3.876916843115197e-10
introduces O 0 1.3747748495163137e-09
a O 0 2.7605175922928993e-09
new O 0 4.499509209665575e-09
restriction O 0 5.1924438082551205e-09
site O 0 6.1775402571129234e-09
for O 0 1.7886243597331486e-09
Eco0109 O 0 8.514810474480328e-07
I O 0 1.9264074580860324e-05
. O 0 1.6228440813392808e-08

All O 0 5.8210240183598216e-08
the O 0 7.002193491700837e-09
4003delTC O 0 2.4727916070332867e-07
alleles O 0 1.0834276054083603e-07
showed O 0 2.0714654169751157e-07
the O 0 7.325254847145857e-10
same O 0 7.143568847567394e-09
haplotype O 0 1.4477208765129035e-07
for O 0 9.167306358470739e-10
these O 0 7.467965690288736e-10
five O 0 7.814029423514057e-09
polymorphic O 0 9.881307505565928e-07
markers O 0 2.29412012231478e-06
. O 0 1.1811513189741163e-07

Fourteen O 0 1.2793651649189997e-06
microsatellite O 0 6.544293228216702e-06
polymorphisms O 0 2.6804630124388495e-06
were O 0 2.4245053964477847e-08
selected O 0 3.353131938776954e-10
based O 0 2.5949176141182306e-10
on O 0 6.2412937040789984e-09
their O 0 4.994036850725081e-10
high O 0 1.4828965788638016e-07
heterozygosity O 0 8.348782642997321e-08
and O 0 6.742499891743137e-10
their O 0 7.995253070713915e-11
location O 0 2.7681312797511737e-09
within O 0 3.604516463084906e-09
10q23 O 0 1.6298565697070444e-06
- O 0 2.833371809174423e-06
q25 O 0 2.9358484425756615e-06
near O 0 2.972226411657175e-06
COL17A1 O 0 0.00010940816719084978
. O 0 1.9849458965381928e-07

Three O 0 2.531321570131695e-07
families O 0 2.5853163165834303e-08
shared O 0 1.163126128744807e-08
microsatellite O 0 2.2257140699366573e-06
polymorphisms O 0 5.929478902544361e-06
covering O 0 3.947306481677515e-07
at O 0 4.250418612627982e-07
most O 0 4.862930946814004e-09
19 O 0 2.80110441508441e-08
cM O 0 1.8728442796600575e-08
, O 0 2.183315056525359e-10
whereas O 0 2.707341240082428e-09
the O 0 4.785198903789478e-10
others O 0 1.8322841022211378e-09
shared O 0 2.3774998636483247e-10
smaller O 0 1.1274216005219273e-09
regions O 0 1.3278801391791717e-09
consistent O 0 1.1542335442982221e-07
with O 0 7.228225795685717e-10
cross O 0 2.1007677730722207e-07
- O 0 4.746634203911526e-06
over O 0 2.480645910907242e-09
events O 0 9.466176731365294e-10
during O 0 2.882774241541597e-09
passage O 0 1.3310397228849524e-09
of O 0 4.127001518305917e-11
this O 0 7.425493553370188e-11
mutation O 0 9.661077493561265e-10
through O 0 3.653345959087062e-10
several O 0 1.214901734769569e-09
generations O 0 1.9882817170469025e-08
. O 0 1.859549669802618e-08

These O 0 1.0873465328131715e-07
results O 0 1.3247722563392017e-07
indicate O 0 2.7783359612953973e-08
that O 0 7.555520098456725e-10
4003delTC O 0 1.121969646078469e-07
occurs O 0 1.147125949785277e-09
on O 0 1.9136323636814723e-09
a O 0 1.89324711463712e-09
single O 0 1.1923020792892203e-08
ancestral O 0 9.039470683092077e-08
allele O 0 1.3992558933750843e-06
. O 0 2.9294243475419535e-08
. O 0 3.9370423365880924e-08

The O 0 8.841589078656398e-07
haptoglobin O 0 0.00012643296213354915
- O 0 3.4770695492625237e-05
gene O 0 1.597933191987977e-06
deletion O 0 9.00571251349902e-07
responsible O 0 1.471642274708529e-08
for O 0 5.361021848671044e-09
anhaptoglobinemia B-Disease 0 5.775741556135472e-06
. O 0 1.278679349070444e-07

We O 0 2.58503604300131e-07
have O 0 4.437201273077562e-09
found O 0 1.6228680621566127e-09
an O 0 2.1069587741173734e-10
allelic O 0 7.207128049913081e-08
deletion O 0 6.770160609903542e-08
of O 0 1.9483099855666097e-10
the O 0 2.2841102342852082e-09
haptoglobin O 0 6.338832463370636e-07
( O 0 2.9788993494150873e-09
Hp O 0 3.352585054017254e-08
) O 0 1.75952030723181e-10
gene O 0 3.822838046119159e-09
from O 0 2.1164734409495622e-09
an O 0 2.1743301603649456e-10
individual O 0 5.13275089097931e-10
with O 0 5.643832068358279e-09
anhaptoglobinemia B-Disease 0 2.309610863449052e-05
. O 0 3.6927082192050875e-07

The O 0 4.2329514826633385e-07
Hp O 0 9.412189001523075e-07
gene O 0 1.0069054923178555e-07
cluster O 0 1.4117516045075718e-08
consists O 0 7.160671500194837e-10
of O 0 2.225315626214197e-10
coding O 0 1.6832545668421517e-07
regions O 0 2.5450586083053395e-09
of O 0 1.4022313865602598e-10
the O 0 4.4858394776525756e-10
alpha O 0 2.809299903816509e-09
chain O 0 9.487746588376922e-09
and O 0 6.559931486904702e-10
beta O 0 1.8611667762513662e-09
chain O 0 4.398574393604804e-09
of O 0 4.280056864480741e-11
the O 0 3.053911568073886e-10
haptoglobin O 0 7.14011108016166e-08
gene O 0 2.1147071649352256e-08
( O 0 1.3562517775511651e-09
Hp O 0 2.3410620997310616e-08
) O 0 1.1688694456779558e-10
and O 0 1.496339024908977e-10
of O 0 2.0055018409848024e-11
the O 0 3.966471318062048e-10
alpha O 0 3.028084671896636e-09
chain O 0 1.7849581368523104e-08
and O 0 5.852010542817254e-10
beta O 0 1.2185127351571623e-09
chain O 0 2.5351074572910193e-09
of O 0 5.1252935923118415e-11
the O 0 7.001762503122677e-10
haptoglobin O 0 2.1225544060143875e-06
- O 0 2.6287938226232654e-07
related O 0 2.855534120271841e-08
gene O 0 1.5042606094084476e-07
( O 0 4.911880679969727e-09
Hpr O 0 4.347713513652707e-07
) O 0 9.267215328456757e-10
, O 0 1.9155704800155604e-10
in O 0 1.9495265402014184e-09
tandem O 0 3.7410001141324756e-07
from O 0 9.056949856756091e-09
the O 0 6.26800433778385e-09
5 O 0 1.891688761190835e-08
side O 0 1.0322912658011774e-06
. O 0 6.109520711561345e-08

Southern O 0 4.083623935002834e-06
blot O 0 8.891101606423035e-05
and O 0 2.10467145933535e-08
PCR O 0 5.46045555438468e-07
analyses O 0 1.8061847129047237e-08
have O 0 1.0316067999838197e-09
indicated O 0 1.130548898942152e-08
that O 0 6.739423602519778e-11
the O 0 3.263046083334942e-11
individual O 0 4.32453274579192e-11
with O 0 1.5687960652766009e-10
anhaptoglobinemia B-Disease 0 2.5894155442074407e-07
was O 0 2.0601602201963942e-08
homozygous O 0 4.367758599244098e-09
for O 0 3.4856329628185634e-11
the O 0 1.258345788679449e-10
gene O 0 4.681713239307328e-09
deletion O 0 1.0637776881594618e-08
and O 0 4.4648068575625643e-10
that O 0 5.050397600125933e-11
the O 0 1.0933948885183398e-10
gene O 0 1.2028479545733717e-08
deletion O 0 2.8741178326185945e-08
was O 0 1.3346300065109062e-08
included O 0 1.171979180369931e-10
at O 0 1.3801502163346413e-09
least O 0 2.1041957065648376e-10
from O 0 1.4850880247774256e-10
the O 0 2.6224228344418066e-10
promoter O 0 2.4212518212607392e-08
region O 0 1.6640933075962039e-09
of O 0 6.163049515173213e-10
Hp O 0 5.9456581880112935e-08
to O 0 1.6112094991527215e-09
Hpr O 0 2.2367738949924387e-07
alpha O 0 9.136694067990447e-09
but O 0 1.2830940754327003e-09
not O 0 3.233143475167566e-10
to O 0 5.934978619670517e-10
Hpr O 0 2.217687296024451e-07
beta O 0 3.094873690656641e-08
( O 0 3.769511813800364e-09
Hpdel O 0 2.1003170047606545e-07
) O 0 4.874306736013523e-09
. O 0 1.8719585881399325e-08

In O 0 9.186744165390337e-08
addition O 0 7.158408088514534e-09
, O 0 9.315614946103778e-10
we O 0 7.478371255587035e-10
found O 0 5.556383131377629e-10
seven O 0 8.156397779401914e-11
individuals O 0 5.6484331101280816e-12
with O 0 2.6523368570896544e-11
hypohaptoglobinemia B-Disease 0 1.3762191031219118e-07
in O 0 1.0295905461532584e-08
three O 0 8.767583326019235e-10
families O 0 1.4735759834572093e-10
, O 0 3.8899584942075904e-11
and O 0 1.9568570375216865e-10
the O 0 3.2321692544634573e-10
genotypes O 0 5.3094186824864664e-09
of O 0 1.03274611085169e-10
six O 0 1.6459361651399718e-09
of O 0 2.7969467020216854e-11
the O 0 3.1955005308503814e-10
seven O 0 9.967714431624586e-10
individuals O 0 1.3640488044641685e-11
were O 0 3.919933710960777e-09
found O 0 9.798665212557012e-10
to O 0 3.939697457155944e-10
be O 0 2.2549228262391807e-08
Hp2 O 0 9.461432455282193e-06
/ O 0 6.507486432383303e-06
Hpdel O 0 5.532585419132374e-06
. O 0 1.9376228976852872e-07

The O 0 2.276357378150351e-07
phenotypes O 0 1.8172480622524745e-06
and O 0 2.6108118333922903e-08
genotypes O 0 2.906714371420094e-07
in O 0 1.0491827850955815e-08
one O 0 4.4654199782279136e-10
of O 0 1.929522340515799e-11
these O 0 3.5526189628987126e-11
three O 0 8.06407995934677e-11
families O 0 1.2436902896428847e-10
showed O 0 5.54938779373515e-08
the O 0 2.1875917743940931e-10
father O 0 4.955742483048198e-09
to O 0 6.014853615177174e-10
be O 0 5.756398469003443e-09
hypohaptoglobinemic B-Disease 0 2.749584666617011e-07
( O 0 1.931140580779811e-09
Hp2 O 0 4.887202464942675e-08
) O 0 1.9252552330151218e-10
and O 0 2.9413989022231135e-09
Hp2 O 0 1.4180388916429365e-06
/ O 0 6.320541956483794e-07
Hpdel O 0 2.6137894337807666e-07
, O 0 2.5863891583988163e-10
the O 0 2.2834033275298538e-10
mother O 0 6.7384662294500686e-09
to O 0 1.0096119079650023e-10
be O 0 3.8220562825763693e-10
Hp2 O 0 9.485307828072109e-08
- O 0 2.2802502996910334e-08
1 O 0 2.316201896945813e-09
and O 0 3.914427448847846e-09
Hp1 O 0 8.192447467081365e-07
/ O 0 2.205050719794599e-07
Hp2 O 0 1.3428191891762253e-07
, O 0 2.9964777881197335e-10
one O 0 4.9819329217548614e-11
of O 0 9.144089131718491e-12
the O 0 8.793202277423973e-11
two O 0 3.701695061586463e-10
children O 0 5.082055887228876e-10
to O 0 2.714579117046867e-10
be O 0 6.760505932845717e-09
hypohaptoglobinemic B-Disease 0 3.7779500416945666e-07
( O 0 1.7395629381411482e-09
Hp2 O 0 4.990356572420751e-08
) O 0 2.796798626025776e-10
and O 0 2.228638384949022e-09
Hp2 O 0 1.5074703014761326e-06
/ O 0 2.7092673917650245e-06
Hpdel O 0 9.437634957976115e-07
, O 0 3.6842759398858504e-10
and O 0 1.648115532937311e-10
the O 0 2.731373807685067e-11
other O 0 2.1570803476755884e-10
child O 0 3.0253255456358374e-09
to O 0 1.532235727186304e-10
be O 0 1.9679597951238748e-09
Hp1 O 0 1.0170020203759123e-07
and O 0 5.049265450196572e-09
Hp1 O 0 2.021390400841483e-06
/ O 0 9.573913075655582e-07
Hpdel O 0 1.847406849719846e-07
, O 0 8.499194681377276e-10
showing O 0 1.0754901857978894e-08
an O 0 3.128778902627971e-10
anomalous O 0 6.400451724175582e-08
inheritance O 0 1.2229610035774385e-07
of O 0 2.078171412733809e-09
Hp O 0 2.920588144661451e-07
phenotypes O 0 6.01946155143196e-08
in O 0 1.4998381203668032e-08
the O 0 1.0298871089275963e-08
child O 0 1.8096490350671957e-07
with O 0 5.90627546870337e-09
Hp1 O 0 7.750022632535547e-06
. O 0 1.1152658885293931e-07

The O 0 7.098938112903852e-07
Hp2 O 0 0.00010425466462038457
/ O 0 3.809852569247596e-05
Hpdel O 0 2.101219479300198e-06
individuals O 0 1.6455374840518289e-09
had O 0 1.0787983484306096e-07
an O 0 2.0879602213863535e-10
extremely O 0 9.98703981736071e-08
low O 0 6.684753657282272e-07
level O 0 7.301461213415905e-09
of O 0 9.296440006689721e-11
Hp O 0 4.28530739782218e-08
( O 0 1.1687318890452048e-09
mean O 0 1.8411027369324984e-08
+ O 0 5.900997734897828e-08
/ O 0 3.496236047340062e-07
- O 0 2.4911881268963043e-07
SD O 0 4.568975327856606e-06
= O 0 5.4523180637033875e-08
0 O 0 8.87388207360118e-09
. O 0 2.365135198800772e-09
049 O 0 1.9062256342294859e-06
+ O 0 2.9341421736717166e-07
/ O 0 7.102100312295079e-07
- O 0 2.2563776269635127e-07
0 O 0 1.7023486620360018e-08
. O 0 5.9913269900846444e-09
043 O 0 2.7719347599486355e-06
mg O 0 0.00046345210284925997
/ O 0 5.204005447012605e-06
ml O 0 7.521219913542154e-07
; O 0 1.7076257075032686e-09
n O 0 2.435368884334821e-08
= O 0 2.1542577499644722e-08
6 O 0 4.246777596250695e-09
) O 0 1.3220088912468952e-10
, O 0 7.938437407428722e-11
compared O 0 2.3865331932881872e-09
with O 0 1.1811079891899112e-10
the O 0 1.7033936483557e-09
level O 0 3.831037176382779e-08
( O 0 1.8227845621776595e-10
1 O 0 3.6397204694615937e-10
. O 0 1.2474463129130697e-10
64 O 0 4.264684161370269e-09
+ O 0 2.541882437867571e-08
/ O 0 2.1082598777866224e-07
- O 0 9.819366653118777e-08
1 O 0 4.800971176166513e-09
. O 0 2.2004147393062112e-09
07 O 0 2.607851286029472e-07
mg O 0 2.7160398531123064e-05
/ O 0 5.170477948013286e-07
ml O 0 6.033691590801027e-08
) O 0 1.5850286361196453e-10
obtained O 0 5.721171869588204e-10
from O 0 1.5692785959586786e-09
52 O 0 3.478936605461058e-08
healthy O 0 1.868231258583819e-08
volunteers O 0 4.111378792970299e-09
having O 0 2.6846759482168636e-08
phenotype O 0 7.416925882353098e-07
Hp2 O 0 5.483501013259229e-07
, O 0 5.979633455055477e-10
whereas O 0 9.775723563976157e-10
the O 0 2.6945123909882795e-10
serum O 0 2.0663190269942788e-08
Hp O 0 7.738493934539292e-08
level O 0 1.0558476759570112e-08
of O 0 4.8538170011047654e-11
an O 0 7.25442275695265e-11
individual O 0 1.3495549122666262e-10
with O 0 1.8414985092363167e-09
Hp1 O 0 0.00010072476288769394
/ O 0 0.0001384645001962781
Hpdel O 0 1.0521542208152823e-05
was O 0 1.0409046353743179e-06
0 O 0 5.632049493442537e-08
. O 0 4.5711971097261994e-08

50 O 0 3.6468234156927792e-06
mg O 0 0.0014135129749774933
/ O 0 2.805371696013026e-05
ml O 0 2.559734184615081e-06
, O 0 8.100665693788756e-10
which O 0 1.8515811106567526e-10
was O 0 4.0137266843487396e-09
approximately O 0 3.183180455335055e-11
half O 0 4.72121175487672e-10
the O 0 6.217997644553108e-11
level O 0 6.064896918012153e-10
of O 0 1.9055373598475533e-11
Hp O 0 4.419286714352211e-09
in O 0 8.181238464466389e-10
control O 0 3.383206959028939e-08
sera O 0 6.074558314139722e-07
from O 0 8.761247838329211e-10
the O 0 3.85343090769652e-09
Hp1 O 0 3.270230990892742e-06
phenotype O 0 2.871140907245717e-07
( O 0 1.0426786101191965e-09
1 O 0 1.3044065827472195e-09
. O 0 5.988787799005024e-10
26 O 0 2.197521986602169e-08
+ O 0 7.733948592658635e-08
/ O 0 4.743991155464755e-07
- O 0 2.2645156150247203e-07
0 O 0 8.563801223715473e-09
. O 0 1.4458306774045582e-09
33 O 0 1.825829798463019e-07
mg O 0 0.0006595859886147082
/ O 0 5.565750143432524e-06
ml O 0 1.000184852273378e-06
; O 0 1.6729596596931628e-09
n O 0 3.316726093771649e-08
= O 0 3.7909998695795366e-08
9 O 0 1.7188316547844806e-08
) O 0 3.609330334608529e-10
, O 0 1.7933170226580586e-10
showing O 0 1.509618918760225e-08
a O 0 7.492124254326882e-09
gene O 0 1.5703834606028977e-06
- O 0 1.2641619832720608e-05
dosage O 0 1.165663888968993e-05
effect O 0 7.093726708262693e-07
. O 0 6.990199352685522e-08

The O 0 5.697862093256845e-08
other O 0 7.958213643632917e-09
allele O 0 5.750184186581464e-07
( O 0 9.20255960323857e-09
Hp2 O 0 1.3963563105789945e-07
) O 0 1.4674587933694028e-10
of O 0 1.7470226654214827e-11
individuals O 0 2.0068181491583736e-11
with O 0 1.4393308767068902e-10
Hp2 O 0 8.312930731335655e-06
/ O 0 5.997703283355804e-06
Hpdel O 0 8.765858297010709e-07
was O 0 2.0886079710180638e-07
found O 0 1.2821692596531875e-09
to O 0 1.1238892455578409e-10
have O 0 6.966527354990149e-10
, O 0 3.3437481949949444e-11
in O 0 1.6906526179027992e-10
all O 0 2.520079145362786e-10
exons O 0 3.4662708259247665e-09
, O 0 3.9275277474715153e-10
no O 0 2.2582058445408393e-09
mutation O 0 2.4181352475949325e-09
, O 0 7.610898022925028e-11
by O 0 1.9548426766213822e-10
DNA O 0 2.1332125399453616e-08
sequencing O 0 9.983268256519295e-08
. O 0 4.7404363101577474e-08

On O 0 7.982739447243148e-08
the O 0 7.905003873709404e-10
basis O 0 6.793606233124194e-10
of O 0 1.8292024145383223e-11
the O 0 7.04410071938888e-11
present O 0 1.4921920643562459e-10
study O 0 2.0807922052057393e-10
, O 0 4.1826483249129964e-11
the O 0 4.000225498068666e-11
mechanism O 0 1.7496921689286182e-09
of O 0 1.477795108506541e-10
anhaptoglobinemia B-Disease 0 4.5756243594041734e-07
and O 0 2.8913318406154076e-09
the O 0 1.8491705389145352e-10
mechanism O 0 4.8588235657121e-09
of O 0 3.9239261839796313e-10
anomalous O 0 1.8983978122832923e-07
inheritance O 0 1.1672737088019858e-07
of O 0 1.3447479796369066e-09
Hp O 0 4.865555069955008e-07
phenotypes O 0 1.0992094701123278e-07
were O 0 3.877734968682489e-07
well O 0 2.6940528030650057e-08
explained O 0 1.3299623446982878e-07
. O 0 2.5580051854490193e-08

However O 0 5.029281169299793e-07
, O 0 2.4706070522739765e-09
the O 0 6.901853533136659e-10
mechanism O 0 1.4109116541760613e-08
of O 0 9.914604692795592e-10
hypohaptoglobinemia B-Disease 0 7.676611858187243e-06
remains O 0 1.0317548913008068e-06
unknown O 0 2.173672555727535e-06

ATM O 0 0.00038834699080325663
mutations O 0 2.1077075871289708e-05
and O 0 6.665249685511299e-08
phenotypes O 0 4.131688911002129e-06
in O 0 0.0001331060193479061
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
families O 0 8.109614100249019e-06
in O 0 3.421279259896437e-08
the O 0 7.3746324602552704e-09
British O 0 2.701830908335978e-06
Isles O 0 1.6349365239420877e-07
: O 0 1.512574648865339e-10
expression O 0 4.108687834403213e-10
of O 0 4.9359370757340315e-11
mutant O 0 1.5559866284320378e-08
ATM O 0 4.3063980115221057e-07
and O 0 2.7660940205009865e-09
the O 0 1.1067546878962276e-09
risk O 0 3.2728305399132296e-08
of O 0 4.499329353535586e-09
leukemia B-Disease 1 0.9933260679244995
, O 0 0.0006681372760795057
lymphoma B-Disease 1 1.0
, O 0 8.443532351520844e-06
and O 0 0.0007590797613374889
breast B-Disease 1 0.9615105986595154
cancer I-Disease 0 0.0003292553301434964
. O 0 6.224806270438421e-07

We O 0 7.342760568462836e-07
report O 0 2.6200254410468915e-08
the O 0 4.221860083752915e-10
spectrum O 0 7.0421872777615135e-09
of O 0 3.5357544669878394e-10
59 O 0 4.5292871675428614e-08
ATM O 0 9.395595043315552e-06
mutations O 0 5.301225201037596e-07
observed O 0 5.3364274776868115e-08
in O 0 1.699632775853388e-05
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 0 0.008512090891599655
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 3.3863251758248225e-08
patients O 0 7.135074042707856e-08
in O 0 3.1766211883166307e-09
the O 0 2.929366971216041e-09
British O 0 3.420200755499536e-06
Isles O 0 3.06179958897701e-06
. O 0 4.937008313277147e-08

Of O 0 7.572247540110766e-08
51 O 0 5.200768669055833e-07
ATM O 0 5.061416231910698e-06
mutations O 0 8.950531338314249e-08
identified O 0 1.4670656689474981e-08
in O 0 6.20838991327588e-10
families O 0 1.6807402691831896e-10
native O 0 1.0148691609312976e-10
to O 0 7.849289967998274e-11
the O 0 4.5053211161771856e-10
British O 0 2.64071923083975e-06
Isles O 0 2.9516070298996055e-07
, O 0 5.037796291240682e-10
11 O 0 5.001796754555698e-10
were O 0 2.3869111132057697e-09
founder O 0 3.2278524297879585e-09
mutations O 0 5.934686964081948e-09
, O 0 3.207976939645363e-10
and O 0 6.297611876426856e-10
2 O 0 1.8288544290090414e-10
of O 0 1.0519564386246572e-11
these O 0 2.8467433965673195e-10
11 O 0 2.5571600392737537e-09
conferred O 0 3.018955974098958e-09
a O 0 1.2938563997977326e-08
milder O 0 0.0005307336105033755
clinical O 0 1.599856659595389e-05
phenotype O 0 8.511075293426984e-07
with O 0 6.966168752953195e-10
respect O 0 1.4306906770400474e-09
to O 0 2.541876265027554e-09
both O 0 7.309002114652685e-08
cerebellar B-Disease 0 0.0002775290631689131
degeneration I-Disease 0 0.14054152369499207
and O 0 3.072013754490399e-08
cellular O 0 1.58905368152773e-06
features O 0 4.222122242936166e-07
. O 0 2.9677352131329826e-07

We O 0 2.0598504590907396e-07
report O 0 2.4933694220408142e-08
, O 0 9.508697301763291e-11
in O 0 2.1042279030325517e-10
two O 0 7.308232241598489e-09
A B-Disease 1 1.0
- I-Disease 1 0.9999997615814209
T I-Disease 1 1.0
families O 0 2.1200865063519814e-08
, O 0 1.844109032145269e-10
an O 0 1.0527377580782371e-10
ATM O 0 2.7681305709847948e-06
mutation O 0 3.852808205806468e-08
( O 0 1.9612074186881046e-09
7271T O 0 6.022298180141661e-07
- O 0 1.5143217524382635e-06
- O 0 3.2360703698941506e-06
> O 0 4.24571879875657e-08
G O 0 7.940159463259988e-08
) O 0 1.0662751931400649e-10
that O 0 1.3718821911812284e-10
may O 0 1.3398663512020903e-08
be O 0 1.0030647146219707e-10
associated O 0 8.900791215182835e-11
with O 0 1.3855849627375516e-11
an O 0 1.0003421008208946e-10
increased O 0 3.378003654574968e-08
risk O 0 2.3653988989735808e-07
of O 0 9.668843503618518e-09
breast B-Disease 0 0.0019318562699481845
cancer I-Disease 0 1.4990279169069254e-06
in O 0 1.42391813895415e-08
both O 0 2.4522051944586565e-08
homozygotes O 0 1.686987616267288e-06
and O 0 5.269708225341674e-09
heterozygotes O 0 2.4063402292995306e-07
( O 0 1.6622471177285547e-09
relative O 0 1.1585672865521701e-08
risk O 0 1.1871377125771687e-07
12 O 0 6.047884859583519e-09
. O 0 2.2580494418722452e-10
7 O 0 2.5018571658819155e-09
; O 0 1.1971551527878432e-09
P O 0 4.6298693632707e-05
= O 0 7.507819788088455e-08
. O 0 2.9141142832145306e-09
0025 O 0 8.507894335707533e-07
) O 0 3.291125150184371e-10
, O 0 6.98405916432776e-11
although O 0 5.867075714149905e-10
there O 0 9.572538317570434e-10
is O 0 8.315016730708891e-11
a O 0 9.327082439725132e-10
less O 0 2.751121712663007e-07
severe O 1 0.8189823031425476
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
phenotype O 0 3.3102276120189345e-06
in O 0 2.5544983905945173e-09
terms O 0 7.658724765491343e-10
of O 0 3.093411291010817e-11
the O 0 1.690272227738987e-10
degree O 0 3.2513963077462904e-08
of O 0 1.0211554268835243e-08
cerebellar B-Disease 0 0.00031826458871364594
degeneration I-Disease 1 0.57673579454422
. O 0 7.060843927320093e-07

This O 0 2.162213377232547e-07
mutation O 0 1.794193508430908e-06
( O 0 3.120343095019962e-08
7271T O 0 9.19498120310891e-07
- O 0 2.041105108219199e-05
- O 0 3.394984742044471e-05
> O 0 8.316804667174438e-08
G O 0 8.88148790068044e-08
) O 0 7.389958783798889e-11
also O 0 4.499479261399486e-11
allows O 0 4.3628749918367404e-11
expression O 0 3.204436160864077e-10
of O 0 4.963352298603674e-11
full O 0 1.651697445481659e-09
- O 0 2.0629872921062997e-08
length O 0 2.0689563395848154e-09
ATM O 0 1.138386735988206e-07
protein O 0 2.6682063225536012e-09
at O 0 2.0332042716120213e-09
a O 0 3.861257147352859e-10
level O 0 1.4882391985437948e-09
comparable O 0 3.6935581260166828e-09
with O 0 1.7007469044205692e-10
that O 0 5.825494531208619e-10
in O 0 7.522809930549101e-09
unaffected O 0 2.500804896499176e-07
individuals O 0 1.8251964384319308e-09
. O 0 2.4097523976251978e-08

In O 0 5.390636914626157e-08
addition O 0 2.1846655595680886e-09
, O 0 3.868053377598102e-10
we O 0 5.26141019641102e-10
have O 0 2.4617063942855566e-10
studied O 0 2.5163160444208188e-08
18 O 0 1.6069435559984413e-07
A B-Disease 1 1.0
- I-Disease 1 0.9999996423721313
T I-Disease 1 1.0
patients O 0 4.0396236727247015e-05
, O 0 7.402419233137891e-10
in O 0 4.81552353548409e-10
15 O 0 6.833256183114145e-10
families O 0 1.5153525656508293e-10
, O 0 3.3506386554194023e-10
who O 0 1.5893682814294152e-08
developed O 0 4.1502556996420026e-05
leukemia B-Disease 1 0.9999933242797852
, O 0 0.00015912190428934991
lymphoma B-Disease 1 1.0
, O 0 5.182196716191356e-08
preleukemic O 0 4.673354487749748e-05
T O 0 0.0015888301422819495
- O 0 2.31924627769331e-06
cell O 0 4.138503754802514e-06
proliferation O 0 1.9963659724453464e-05
, O 0 8.393521966354456e-08
or O 1 0.8222375512123108
Hodgkin B-Disease 1 1.0
lymphoma I-Disease 1 1.0
, O 0 2.1195852184519026e-08
mostly O 0 5.190226470830339e-09
in O 0 2.625648498622013e-08
childhood O 0 8.017451023079047e-07
. O 0 1.3960180922367726e-07

A O 0 8.866135203788872e-07
wide O 0 7.379306765642468e-08
variety O 0 1.1346555695013194e-08
of O 0 8.827689135237904e-10
ATM O 0 8.045182039495558e-05
mutation O 0 9.427499492176139e-08
types O 0 2.311463376258871e-08
, O 0 1.1030624191832317e-09
including O 0 1.1426755097687646e-09
missense O 0 6.6736151893564966e-06
mutations O 0 3.2416656381428766e-07
and O 0 3.091387057452266e-08
in O 0 3.023354508968623e-07
- O 0 0.0002015513164224103
frame O 0 0.00010069920244859532
deletions O 0 1.8497669316275278e-06
, O 0 2.403609089540737e-09
were O 0 1.5132513908611145e-08
seen O 0 6.322338208519795e-08
in O 0 1.9592407696222836e-09
these O 0 1.1348130213306717e-09
patients O 0 4.647941409530176e-08
. O 0 1.606601074399805e-08

We O 0 1.0703499242481485e-07
also O 0 1.8154747705168006e-09
show O 0 3.006549231798772e-09
that O 0 8.79115599761171e-11
25 O 0 9.939630368771546e-11
% O 0 1.5124642857577975e-11
of O 0 7.744178562307802e-12
all O 0 5.530798041775142e-09
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 3.671802915050648e-05
carried O 0 2.3492664524837892e-07
in O 0 3.622783708578936e-07
- O 0 5.974115993012674e-05
frame O 0 5.6514745665481314e-05
deletions O 0 1.8489662352294545e-06
or O 0 1.6485076059780113e-07
missense O 0 5.280223376757931e-06
mutations O 0 2.2930299792278674e-07
, O 0 1.965662910219379e-10
many O 0 2.777817906252089e-11
of O 0 8.737790872792583e-12
which O 0 2.831407608372416e-10
were O 0 5.965991078937805e-08
also O 0 6.768966498427176e-10
associated O 0 1.9547904961392248e-10
with O 0 3.3344434852145e-11
expression O 0 5.762876842396736e-10
of O 0 1.379665270917485e-10
mutant O 0 3.739765119803451e-08
ATM O 0 3.359856009410578e-06
protein O 0 4.223120697588456e-07
. O 0 9.328246619588754e-08

The O 0 7.610871648466855e-07
DMPK O 0 2.3148548280005343e-05
gene O 0 1.9857898223563097e-06
of O 0 4.865995606451179e-08
severely O 0 0.2424495816230774
affected O 0 0.01722831092774868
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 1 0.8433858752250671
is O 0 4.211569404333204e-08
hypermethylated O 0 4.542966962617356e-06
proximal O 0 3.931095307052601e-06
to O 0 7.229111975703972e-09
the O 0 2.3653790037769795e-09
largely O 0 1.177496855575555e-08
expanded O 0 9.43870901437549e-08
CTG O 0 2.6288178560207598e-05
repeat O 0 5.1936581257905345e-06
. O 0 3.3327225423818163e-07

Using O 0 1.3274639059090987e-06
methylation O 0 2.103751467075199e-05
- O 0 4.651346171158366e-05
sensitive O 0 1.4092476021687617e-06
restriction O 0 1.6113385470362118e-07
enzymes O 0 4.033128320202195e-08
, O 0 1.283071426882998e-10
we O 0 1.5004286701980618e-10
characterized O 0 2.462213488652054e-10
the O 0 1.7244713990116622e-10
methylation O 0 4.066629699650548e-08
pattern O 0 1.3112800445469475e-07
on O 0 1.223639998215731e-07
the O 0 2.2594337512060747e-09
5 O 0 1.227268842107776e-09
side O 0 3.0578881649034884e-09
of O 0 5.473607678219139e-11
the O 0 1.3036628443430232e-09
CTG O 0 6.007544470776338e-07
repeat O 0 4.855991164731677e-08
in O 0 1.442068464641011e-09
the O 0 4.451737312116677e-10
DMPK O 0 5.213386344848914e-08
gene O 0 1.9317962784981546e-09
of O 0 4.87547328897886e-11
normal O 0 3.873474430093893e-09
individuals O 0 1.977387698026689e-10
and O 0 5.433076211147636e-10
of O 0 2.4059654268882014e-10
patients O 0 6.581317535392373e-08
affected O 0 6.120251327956794e-08
with O 0 7.37979917175835e-07
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
, O 0 1.9362460079719312e-08
showing O 0 6.671965735449703e-08
expansions O 0 3.76686877245902e-08
of O 0 5.958343818335265e-10
the O 0 3.1909221931414322e-09
repetitive O 0 1.2847915513702901e-06
sequence O 0 6.946591923906453e-08
. O 0 9.164919845261466e-08

The O 0 7.110701005785813e-08
gene O 0 3.012949321146152e-07
segment O 0 9.99858968953049e-08
analyzed O 0 4.365961814301045e-08
corresponds O 0 1.1691136947433733e-08
to O 0 1.121144954652209e-09
the O 0 1.1075065309285037e-09
genomic O 0 1.0104667325094852e-07
SacI O 0 2.3185355530586094e-05
- O 0 2.5863826067507034e-06
HindIII O 0 7.732421636319486e-07
fragment O 0 2.303583528373565e-07
carrying O 0 3.740549914255098e-08
exons O 0 1.5368551942174236e-07
11 O 0 1.2783976899299887e-07
- O 0 2.6730322133516893e-06
15 O 0 1.6117196821596735e-07
. O 0 3.63809320447217e-08

There O 0 1.3354987515867833e-07
is O 0 3.452019781136073e-09
constitutive O 0 6.960384268950293e-08
methylation O 0 1.893194507829321e-07
in O 0 1.2559421058710996e-08
intron O 0 1.040735924107139e-06
12 O 0 2.15288977756245e-08
at O 0 1.3461132208902882e-09
restriction O 0 8.020902275696074e-10
sites O 0 3.3433419921458096e-10
of O 0 1.3325046621659453e-10
SacII O 0 2.5998204478128173e-07
and O 0 8.966949849309458e-09
HhaI O 0 2.2311367331440124e-07
, O 0 1.7468167190504147e-10
localized O 0 3.3951450539859707e-09
1 O 0 2.4712103474655578e-09
, O 0 5.370854316844031e-10
159 O 0 5.672563574421474e-08
- O 0 8.337229218113862e-08
1 O 0 4.703301303976559e-09
, O 0 8.169979692773666e-10
232 O 0 8.71506866673144e-09
bp O 0 6.172795963266253e-08
upstream O 0 3.4700480266991462e-09
of O 0 5.940865160924957e-11
the O 0 5.296832972234711e-10
CTG O 0 3.5555399335862603e-07
repeat O 0 5.743416409131896e-08
, O 0 2.898530304662472e-10
whereas O 0 4.294524458270388e-10
most O 0 1.2770043356091776e-10
, O 0 2.8217128286711635e-11
if O 0 4.3884552242134944e-11
not O 0 1.2887985123555268e-10
all O 0 2.072813275189045e-11
, O 0 3.2646756392001874e-12
of O 0 1.0753978003236186e-12
the O 0 1.4470071842132004e-11
other O 0 1.3416415547973237e-11
sites O 0 1.228556284482707e-10
of O 0 2.1743043129851536e-11
SacII O 0 3.301716233750085e-08
, O 0 2.207139193632912e-10
HhaI O 0 3.020552696852974e-08
, O 0 1.9126170092143013e-10
and O 0 8.56074211519342e-10
HpaII O 0 3.8418960457420326e-08
in O 0 7.13298586862976e-10
this O 0 1.7891454984209076e-10
region O 0 6.64655663840108e-10
are O 0 3.880926968680143e-10
unmethylated O 0 1.9796841499442053e-08
, O 0 2.0427111391274622e-10
in O 0 2.8268640206441376e-10
normal O 0 2.0221202490233736e-09
individuals O 0 4.8412239495032594e-11
and O 0 9.962254632345235e-11
most O 0 9.804026340765049e-11
of O 0 6.67918845231874e-11
the O 0 5.322701834842292e-09
patients O 0 7.715943439734474e-08
. O 0 1.4009121862557095e-08

In O 0 1.2065110865933093e-07
a O 0 6.349647918568735e-09
number O 0 4.0471803686159546e-10
of O 0 2.4353805083698887e-10
young O 0 3.926093583572765e-08
and O 0 1.0140768225141983e-08
severely O 0 2.358761412324384e-05
affected O 0 2.022622602737556e-08
patients O 0 4.643165496531765e-08
, O 0 2.853810798786327e-10
however O 0 1.0255643001499948e-09
, O 0 1.1286173384750242e-10
complete O 0 4.205168158133432e-10
methylation O 0 3.516159141625508e-09
of O 0 1.6475489375555874e-11
these O 0 3.753952704244057e-11
restriction O 0 4.688404109387534e-10
sites O 0 8.01590127608165e-10
was O 0 2.4892306882406956e-08
found O 0 1.2119993897385939e-09
in O 0 8.689485797575003e-10
the O 0 3.1594726834782705e-09
mutated O 0 1.0715322105170344e-06
allele O 0 6.700438007101184e-06
. O 0 1.6153389026385412e-07

In O 0 1.2664655457683693e-07
most O 0 1.0743271827706735e-09
of O 0 4.510864945461712e-11
these O 0 1.1148729855969819e-10
patients O 0 2.5584039331505437e-09
, O 0 2.821427640131713e-11
the O 0 1.9412804697083175e-10
onset O 0 1.0574159858833809e-07
of O 0 2.8621016667784716e-10
the O 0 6.525768014853384e-08
disease O 0 0.005509764887392521
was O 0 0.3384421765804291
congenital O 1 0.9999849796295166
. O 0 6.746802228008164e-07

Preliminary O 0 9.912351742968895e-06
in O 0 2.4491183125974203e-07
vivo O 0 6.098941867094254e-06
footprinting O 0 8.13177121017361e-06
data O 0 2.521913700093137e-08
gave O 0 3.0727385080808745e-09
evidence O 0 3.2969052488063255e-10
for O 0 9.413041179850978e-11
protein O 0 2.330608817047164e-09
- O 0 2.542071442235283e-08
DNA O 0 2.096458295852699e-08
contact O 0 1.0207756417912606e-08
in O 0 2.1028447871884737e-09
normal O 0 5.7056461777449385e-09
genes O 0 3.9211225377755454e-09
at O 0 7.357155329401621e-09
an O 0 1.8272156010468166e-10
Sp1 O 0 1.2948636829435145e-08
consensus O 0 1.5197645364395385e-09
binding O 0 2.009332700225741e-09
site O 0 2.5452917551405108e-09
upstream O 0 4.191548885756902e-09
of O 0 4.70604250013551e-11
the O 0 7.174519867092499e-10
CTG O 0 4.1776476678023755e-07
repeat O 0 3.344205978805803e-08
and O 0 1.1536860355931822e-10
for O 0 1.1726695135771958e-11
a O 0 6.686887155105126e-11
significant O 0 3.013362614989745e-10
reduction O 0 6.012456643667008e-10
of O 0 1.1811322753185749e-11
this O 0 4.0394815964406305e-11
interaction O 0 5.4817154288011594e-11
in O 0 4.873941805705329e-10
cells O 0 1.1138235889163184e-09
with O 0 2.96206476013694e-10
a O 0 2.3127510573317522e-08
hypermethylated O 0 3.750788437173469e-06
DMPK O 0 3.596940587158315e-06
gene O 0 2.2509144059768005e-07
. O 0 9.842652026748056e-09
. O 0 1.782522218718441e-08

The O 0 4.991136847820599e-06
hemochromatosis B-Disease 1 0.9999971389770508
gene O 0 9.732177659316221e-07
product O 0 4.248667551109975e-08
complexes O 0 2.0405558132097212e-08
with O 0 5.196681973629325e-10
the O 0 5.378030243363696e-10
transferrin O 0 5.934350966185775e-08
receptor O 0 1.3716219271486807e-08
and O 0 4.287692867421811e-09
lowers O 0 2.710970115060718e-08
its O 0 4.5647449709029786e-10
affinity O 0 5.9686864339880685e-09
for O 0 4.677007670039757e-10
ligand O 0 2.472965654476411e-08
binding O 0 2.0923481258705579e-07
. O 0 1.2106718827453733e-07

We O 0 1.1373052757335245e-06
recently O 0 1.8619155639498786e-07
reported O 0 3.8336395391525e-08
the O 0 7.570349347396643e-10
positional O 0 2.0365398256672052e-07
cloning O 0 3.486416133569037e-08
of O 0 1.541822086670308e-10
a O 0 3.07669134613775e-09
candidate O 0 4.791277063986854e-08
gene O 0 7.059644758555805e-06
for O 0 1.880066338344477e-05
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
called O 0 0.00011272113624727353
HFE O 0 0.004851941484957933
. O 0 9.23938841879135e-07

The O 0 2.3256101044921706e-08
gene O 0 4.813085396904171e-08
product O 0 2.3966887141568805e-08
, O 0 6.054298173907569e-10
a O 0 9.448679616497202e-10
member O 0 1.0908104419726783e-09
of O 0 2.3428542092474025e-11
the O 0 2.1579033004925918e-10
major O 0 4.234273376368947e-09
histocompatibility O 0 9.199369088719322e-08
complex O 0 2.5741471176843334e-08
class O 0 1.149969762082037e-06
I O 0 0.0029833889566361904
- O 0 2.7365194554818117e-08
like O 0 3.3415392675095745e-09
family O 0 1.2156898820947504e-09
, O 0 1.219623568804451e-10
was O 0 4.5996362274536295e-09
found O 0 3.08746528343562e-10
to O 0 6.294895160685599e-11
have O 0 1.0522684945613037e-09
a O 0 1.2986818287430424e-09
mutation O 0 3.017350991285639e-08
, O 0 5.10744024850851e-09
Cys O 0 0.00033451002673245966
- O 0 3.3126593734778e-06
282 O 0 3.4215058803965803e-06
- O 0 1.2229322237544693e-05
- O 0 9.160442459688056e-06
> O 0 1.3240800456060242e-07
Tyr O 0 8.028844149521319e-07
( O 0 2.3665160941988006e-09
C282Y O 0 1.5171847778105985e-08
) O 0 6.029426957709916e-11
, O 0 3.3790876347028487e-11
in O 0 1.7086772274854667e-10
85 O 0 2.0782704446276057e-09
% O 0 1.9726675848374953e-10
of O 0 3.7271502550950686e-10
patient O 0 3.783694069170451e-07
chromosomes O 0 5.996577669975522e-07
. O 0 1.1169050395665181e-07

This O 0 1.0939137240484342e-07
mutation O 0 5.715440352105361e-07
eliminates O 0 3.0629803404735867e-07
the O 0 2.4518482799607e-09
ability O 0 1.1951298617418615e-08
of O 0 8.119243610771321e-10
HFE O 0 2.3229472390084993e-06
to O 0 2.0543009515705535e-09
associate O 0 1.869685561928236e-08
with O 0 2.066700144354172e-09
beta2 O 0 0.0030477535910904408
- O 0 0.027214640751481056
microglobulin O 0 0.00011323912622174248
( O 0 7.000350521479959e-09
beta2m O 0 2.7143002512275416e-07
) O 0 2.916926700180511e-10
and O 0 3.4108119106868173e-10
prevents O 0 2.920140129702986e-09
cell O 0 2.6169050215685274e-06
- O 0 3.2358850603486644e-06
surface O 0 9.507368758931989e-08
expression O 0 2.4594191927462816e-07
. O 0 8.670835427437851e-08

A O 0 2.014535311900545e-06
second O 0 2.402437644377642e-07
mutation O 0 7.19900867807155e-08
that O 0 1.0769017899647793e-09
has O 0 2.843313640088496e-10
no O 0 7.998154916144529e-10
effect O 0 8.994287092889408e-09
on O 0 1.4328520592243876e-07
beta2m O 0 1.3697183476324426e-06
association O 0 4.518610818848856e-09
, O 0 2.5019608607124155e-10
H63D O 0 1.8532122680881002e-07
, O 0 2.8849292399435456e-10
was O 0 1.3471490589722634e-08
found O 0 6.950534592320423e-10
in O 0 8.243454252543359e-10
eight O 0 2.090196682402734e-09
out O 0 1.9599097900169227e-09
of O 0 7.35710589672145e-11
nine O 0 4.2141245160109975e-08
patients O 0 1.026200635578789e-08
heterozygous O 0 2.7307475392035485e-08
for O 0 5.564665950252845e-10
the O 0 3.1149185453216433e-09
C282Y O 0 8.727437830202689e-07
mutant O 0 1.8504319996281993e-06
. O 0 3.1749880236020545e-07

In O 0 1.0559144669741727e-07
this O 0 8.879904589420562e-10
report O 0 4.075269899317391e-09
, O 0 1.202452165616208e-10
we O 0 3.350057176110255e-10
demonstrate O 0 5.884873699457671e-10
in O 0 2.1794672733221887e-09
cultured O 0 4.4469172166827775e-07
293 O 0 7.083871622626248e-08
cells O 0 4.0968600956148293e-08
overexpressing O 0 1.3200420880821184e-06
wild O 0 8.141333296407538e-08
- O 0 1.2626935586013133e-06
type O 0 6.778597025913768e-07
or O 0 1.6797484292396803e-08
mutant O 0 9.465174599654347e-08
HFE O 0 1.2219601330798469e-06
proteins O 0 2.775511598329672e-09
that O 0 7.206626961853146e-10
both O 0 3.7737038494078945e-10
the O 0 2.815392086130686e-10
wild O 0 7.692869452569084e-09
- O 0 3.3238050036743516e-06
type O 0 1.3297078112373129e-05
and O 0 1.5322963520247868e-07
H63D O 0 1.921624061651528e-05
HFE O 0 2.9318671295186505e-06
proteins O 0 9.900436026555326e-09
form O 0 6.52956355651213e-09
stable O 0 5.992038154545298e-08
complexes O 0 5.470972563870191e-09
with O 0 2.3183799324755228e-10
the O 0 1.0363083724485023e-09
transferrin O 0 4.1894250557561463e-07
receptor O 0 1.0156566787600241e-07
( O 0 2.9503398835117878e-08
TfR O 0 6.328669769573025e-06
) O 0 2.9176362659200095e-08
. O 0 3.764448308629653e-08

The O 0 5.612596396531444e-07
C282Y O 0 6.372779353114311e-06
mutation O 0 6.410446076188236e-07
nearly O 0 1.6899354804422728e-08
completely O 0 6.194757418143126e-08
prevents O 0 5.939760683304485e-09
the O 0 6.249771811184246e-10
association O 0 6.188020651443082e-10
of O 0 5.457210378034816e-11
the O 0 8.396875417204797e-10
mutant O 0 1.1400685195894766e-07
HFE O 0 1.8853941128327278e-06
protein O 0 3.4069334020614406e-08
with O 0 1.7863673873463881e-09
the O 0 3.5760308492172044e-08
TfR O 0 0.00018305038975086063
. O 0 2.345916954027416e-07

Studies O 0 1.0310565130566829e-06
on O 0 8.373725535193444e-08
cell O 0 7.885424793130369e-07
- O 0 1.1203811709492584e-06
associated O 0 2.684194555513386e-08
transferrin O 0 4.2049157400469994e-07
at O 0 8.684953911597404e-08
37 O 0 1.5808998554689424e-08
degrees O 0 1.353900955791687e-07
C O 0 1.5419496776303276e-05
suggest O 0 5.3506351349597026e-08
that O 0 9.854124183306112e-10
the O 0 2.567643431206079e-09
overexpressed O 0 6.145694442238891e-07
wild O 0 7.359459885947217e-08
- O 0 1.2899282637590659e-06
type O 0 1.1075512702518608e-06
HFE O 0 3.4462402709323214e-06
protein O 0 2.2224588391850375e-08
decreases O 0 1.3323257164188362e-08
the O 0 6.233247806797237e-10
affinity O 0 3.212748511671748e-09
of O 0 1.817365424816586e-10
the O 0 2.9625635278307527e-09
TfR O 0 1.5746755934742396e-06
for O 0 3.728261255275811e-09
transferrin O 0 1.0086746442539152e-06
. O 0 1.6971362981621496e-07

The O 0 3.481061412458075e-07
overexpressed O 0 1.6141242667799816e-05
H63D O 0 5.78781646254356e-06
protein O 0 7.721803996219023e-08
does O 0 5.5744844296157225e-09
not O 0 7.80301934177885e-10
have O 0 1.3381003249879342e-10
this O 0 1.7428855234036256e-11
effect O 0 3.2950320250080267e-10
, O 0 2.4447572438690557e-11
providing O 0 5.039033426634809e-11
the O 0 5.559380386599422e-11
first O 0 1.6369811062233453e-10
direct O 0 1.5074307080364946e-10
evidence O 0 3.771710721522936e-10
for O 0 4.4684936306715883e-11
a O 0 2.0838980541171281e-10
functional O 0 1.4976361262242222e-09
consequence O 0 4.968481626121957e-09
of O 0 1.527689225122586e-10
the O 0 4.59948745756833e-09
H63D O 0 1.0619171007419936e-05
mutation O 0 1.4092986475588987e-06
. O 0 1.8153775727114407e-07

Addition O 0 8.702979670260902e-08
of O 0 3.9382266336929206e-09
soluble O 0 4.845619514526334e-07
wild O 0 1.9733701606128307e-07
- O 0 0.0011479344684630632
type O 0 0.005767514929175377
HFE O 1 0.5210613012313843
/ O 0 0.0001076306143659167
beta2m O 0 5.699356734112371e-06
heterodimers O 0 7.396074579446577e-07
to O 0 4.911880679969727e-09
cultured O 0 1.7333098867311492e-07
cells O 0 1.51410599613655e-08
also O 0 3.916906798906439e-09
decreased O 0 1.3728416625724549e-08
the O 0 1.4991900776362144e-10
apparent O 0 2.9475542007162403e-09
affinity O 0 4.689327592899417e-09
of O 0 1.1002504463064611e-10
the O 0 8.179350530213014e-10
TfR O 0 4.8918000317144106e-08
for O 0 1.8708241553144767e-11
its O 0 2.1678029163418877e-11
ligand O 0 1.0459533239526309e-09
under O 0 8.635194781447808e-10
steady O 0 2.390982444921974e-06
- O 0 2.8860769774041728e-08
state O 0 4.1018285990013226e-10
conditions O 0 9.188286043126936e-08
, O 0 2.4610572260663766e-11
both O 0 3.9569104937076105e-11
in O 0 6.03559702216927e-10
293 O 0 1.7589474321511034e-09
cells O 0 1.137597793743339e-09
and O 0 1.5447901846599166e-09
in O 0 2.8439279819991725e-09
HeLa O 0 5.685599262506003e-07
cells O 0 1.2047117081692704e-07
. O 0 3.162356065899985e-08

Furthermore O 0 7.93223307482549e-07
, O 0 6.792689966061971e-09
at O 0 2.9501356912930987e-09
4 O 0 1.4489971444930916e-09
degrees O 0 5.283529844746226e-07
C O 0 0.0014321942580863833
, O 0 1.1156605639328632e-09
the O 0 1.2668232018953063e-09
added O 0 3.8826561876703636e-07
soluble O 0 2.4123918862528626e-08
complex O 0 1.2656573566971474e-08
of O 0 5.00054930796523e-09
HFE O 0 0.0004998832009732723
/ O 0 9.799114195629954e-06
beta2m O 0 3.4879576560342684e-06
inhibited O 0 4.3209695377299795e-07
binding O 0 3.3790602316230434e-08
of O 0 7.123319156754349e-10
transferrin O 0 1.613360609553638e-07
to O 0 4.075207726828012e-09
HeLa O 0 6.263871341616323e-07
cell O 0 2.3222341951623093e-06
TfR O 0 5.211142251937417e-06
in O 0 7.092709974898526e-09
a O 0 6.131827934297007e-09
concentration O 0 4.169886551608215e-07
- O 0 3.995672273049422e-07
dependent O 0 1.648237315521328e-07
manner O 0 8.383615295315394e-07
. O 0 5.621424747914716e-08

Scatchard O 0 6.047865463187918e-05
plots O 0 6.294297349995759e-07
of O 0 3.288227690134704e-09
these O 0 3.348057664442905e-10
data O 0 2.0178281268101728e-09
indicate O 0 1.669077542842956e-09
that O 0 9.840540188266189e-11
the O 0 1.4664235103989398e-10
added O 0 1.9915990634444825e-08
heterodimer O 0 8.526119366081275e-09
substantially O 0 6.401172214509643e-08
reduced O 0 2.6930648822087733e-09
the O 0 2.4811652732381617e-10
affinity O 0 4.493497574031835e-09
of O 0 7.970590854000648e-10
TfR O 0 6.266022296586016e-07
for O 0 2.567036361256214e-09
transferrin O 0 1.0167601658395142e-06
. O 0 1.499940225357932e-07

These O 0 1.1719394166220809e-07
results O 0 5.399619951163004e-08
establish O 0 5.305532013721859e-09
a O 0 2.1835493413391305e-09
molecular O 0 1.0083888390965967e-08
link O 0 2.0061578709373862e-07
between O 0 1.178277955204976e-07
HFE O 0 0.00011809698480647057
and O 0 8.813326068946026e-09
a O 0 5.406035064048353e-10
key O 0 4.122929997407709e-09
protein O 0 1.2498047041731297e-09
involved O 0 7.918690703156983e-10
in O 0 1.2659319148511372e-09
iron O 0 3.5650742802317836e-07
transport O 0 5.793120649855155e-09
, O 0 1.3288523059706847e-10
the O 0 4.741082526571461e-10
TfR O 0 9.607737183614518e-07
, O 0 3.2997110599453094e-10
and O 0 1.5647050322087352e-10
raise O 0 5.178130701999351e-10
the O 0 1.0602015099170359e-10
possibility O 0 9.858279748087284e-10
that O 0 1.0419887175316944e-09
alterations O 0 5.0858623978911055e-08
in O 0 7.082891495535648e-10
this O 0 1.7492640669303228e-10
regulatory O 0 4.556138222255868e-08
mechanism O 0 3.617038757397495e-08
may O 0 1.1955303591548727e-07
play O 0 1.2112790770402171e-08
a O 0 2.988760627875564e-10
role O 0 5.684992476773232e-10
in O 0 4.1935380168389713e-10
the O 0 2.1702419861213684e-09
pathogenesis O 0 8.444229706583428e-07
of O 0 7.466241527254169e-07
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
. O 0 1.474423129366187e-06
. O 0 2.7404848879086785e-07

Genomic O 0 4.163665380474413e-06
organization O 0 1.8676081481316942e-07
of O 0 6.229661675405396e-09
the O 0 3.0003011630697074e-08
UBE3A O 0 0.00017093095812015235
/ O 0 1.1359177733538672e-05
E6 O 0 1.1096161870227661e-05
- O 0 2.41248490056023e-05
AP O 0 1.5518186046392657e-05
gene O 0 3.1094236874196213e-07
and O 0 1.437853480723561e-08
related O 0 4.193662306306578e-08
pseudogenes O 0 2.357074208703125e-06
. O 0 3.9800298168302106e-07

The O 0 4.217779974169389e-07
UBE3A O 0 1.6453222997370176e-05
gene O 0 6.058208441572788e-07
encodes O 0 1.0215960344339692e-07
the O 0 5.44603784291553e-09
E6 O 0 6.662478426733287e-07
- O 0 1.9475151020742487e-06
AP O 0 5.761757165601011e-06
ubiquitin O 0 4.5295115569388145e-07
- O 0 9.978356985129722e-08
protein O 0 9.518251964379942e-09
ligase O 0 1.0938737027288425e-08
and O 0 8.236758497481844e-10
has O 0 4.852319657189241e-10
recently O 0 4.1411438722605e-09
been O 0 4.4153244949107773e-10
shown O 0 3.2190830556722005e-10
to O 0 2.0374035791803635e-10
be O 0 3.789234259699015e-09
mutated O 0 1.77553065441316e-05
in O 1 0.9756467938423157
Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
patients O 0 0.00016080381465144455
who O 0 4.6750677995532897e-08
lack O 0 1.32171209088483e-07
15q11 O 0 2.412006324448157e-05
- O 0 0.00010753274546004832
q13 O 0 7.957342859299388e-06
deletions O 0 4.765675384987844e-06
or O 0 2.44937979232418e-07
chromosome O 0 2.690092151169665e-05
15 O 0 3.6570313000083843e-07
paternal O 0 2.283322100993246e-05
uniparental B-Disease 0 0.004928119480609894
disomy I-Disease 0 0.000713582441676408
. O 0 1.7160101606350509e-06

Previous O 0 2.028732978942571e-06
UBE3A O 0 2.912174204539042e-05
cDNA O 0 6.082604500079469e-07
analysis O 0 4.315796431342278e-08
has O 0 2.4721673597127847e-09
shown O 0 9.130939893076118e-10
a O 0 1.7660943818498254e-09
coding O 0 7.361214926504545e-08
region O 0 3.532419468044168e-09
of O 0 2.349281325031427e-10
approximately O 0 2.1263950600314274e-09
2 O 0 1.1127178289882522e-08
. O 0 1.3068751414380131e-08

6 O 0 4.35216225014301e-06
kb O 0 2.9115769848431228e-06
and O 0 6.5592340448006325e-09
a O 0 1.2148467121164686e-08
3 O 0 3.0942661055632925e-07
- O 0 6.34360549156554e-05
untranslated O 0 2.7725698600988835e-05
region O 0 1.9074335000368592e-07
( O 0 1.372755242812218e-08
UTR O 0 2.1392638416273257e-07
) O 0 3.756210620320388e-10
of O 0 2.0126379729479282e-10
< O 0 3.6820523519054404e-08
50 O 0 4.040248580139405e-09
bp O 0 4.581636687817081e-07
, O 0 3.34835770221531e-10
whereas O 0 7.750022845698368e-10
Northern O 0 5.96350580028826e-10
analysis O 0 1.22029664151313e-09
has O 0 6.527107188070147e-10
indicated O 0 1.2817317207591827e-09
mRNA O 0 8.167315712626078e-10
sizes O 0 1.5968394384557882e-09
of O 0 8.801390172230583e-11
5 O 0 3.2271767480551716e-08
- O 0 4.2721908357634675e-06
8 O 0 1.406647953672291e-07
kb O 0 4.971763246430783e-06
. O 0 9.613055595991682e-08

We O 0 1.864671759221892e-07
have O 0 2.1243924397396086e-09
analyzed O 0 1.31357191790471e-09
additional O 0 1.6954611326003288e-10
cDNA O 0 1.334932964169866e-08
clones O 0 1.5670153175051382e-08
and O 0 4.880537085583114e-10
provide O 0 7.469927454373249e-11
evidence O 0 2.1774926306505904e-10
for O 0 5.5866773013280024e-11
an O 0 9.286834495858542e-11
additional O 0 1.665785842597245e-09
0 O 0 2.4069043647045874e-08
. O 0 3.7261656871123705e-08

5 O 0 1.9729948235180927e-06
kb O 0 2.346347173443064e-06
of O 0 3.5206821902278307e-09
5 O 0 6.344541958469563e-08
- O 0 2.756926051006303e-06
UTR O 0 4.262370566721074e-06
and O 0 2.3656417269535268e-08
> O 0 2.208311933316054e-08
2 O 0 3.4964171558016233e-09
kb O 0 2.396979539298627e-07
of O 0 2.0691575119968775e-09
3 O 0 2.21614598672204e-07
- O 0 3.076477150898427e-05
UTR O 0 0.00012873788364231586
. O 0 5.268033760330582e-07

We O 0 1.5154920163240604e-07
have O 0 1.823240891596356e-09
established O 0 3.1457911275900585e-10
the O 0 7.621764330778547e-11
genomic O 0 1.0124586724558071e-09
organization O 0 2.6151453225153887e-10
of O 0 9.534104061792448e-11
UBE3A O 0 5.129790565661096e-07
and O 0 8.186810673826983e-10
the O 0 3.4309866059345495e-10
sequence O 0 9.109821230701698e-10
of O 0 5.554909865423951e-10
intron O 0 2.8512836252048146e-06
- O 0 1.7239722183148842e-06
exon O 0 1.705415456854098e-06
borders O 0 7.136692943277012e-07
. O 0 3.457946320395422e-07

We O 0 6.971557695578667e-07
have O 0 1.0875535139120984e-08
also O 0 1.2657483949851667e-09
mapped O 0 7.675428292941433e-09
two O 0 5.848294626353834e-10
highly O 0 2.108592189742353e-09
homologous O 0 2.2215647987877674e-08
processed O 0 1.9385371530233897e-08
pseudogenes O 0 8.202886192520964e-08
, O 0 3.1090896523977563e-09
UBE3AP1 O 0 3.7787967244184983e-07
and O 0 1.6334856800526154e-09
UBE3AP2 O 0 2.167713830658613e-07
, O 0 9.293993352699204e-11
to O 0 5.985735518354574e-11
chromosomes O 0 1.147725581240877e-09
2 O 0 9.693379432462734e-10
and O 0 1.760985024468198e-09
21 O 0 6.607350666598677e-09
, O 0 1.457061277188032e-10
respectively O 0 2.1890160795123847e-09
, O 0 1.3279427557577606e-10
and O 0 4.553067090018459e-10
determined O 0 4.504343564804003e-09
their O 0 6.404439201190826e-10
genomic O 0 8.85791795468549e-09
organization O 0 8.945237439661469e-09
. O 0 2.9511840082818708e-08

These O 0 5.424963234190727e-08
results O 0 3.976868612198814e-08
will O 0 2.6677773878880373e-10
form O 0 1.3802864406997628e-10
the O 0 7.589429085186339e-11
basis O 0 1.6524245860516373e-10
for O 0 4.883821819179346e-11
studies O 0 4.266040576350605e-10
of O 0 1.1667378174706755e-10
mutation O 0 1.1666677401933612e-08
and O 0 7.189866479961893e-09
imprinting O 0 5.362282422538556e-07
of O 0 1.1484904582914623e-08
UBE3A O 0 4.269499549991451e-05
. O 0 3.320929806704953e-07

Mutation O 0 0.00012743493425659835
spectrum O 0 1.6636451618978754e-05
and O 0 5.709077299798082e-07
genotype O 0 0.041567735373973846
- O 1 0.5608797073364258
phenotype O 0 2.924564432760235e-05
analyses O 0 6.189726491356851e-07
in O 0 2.736288138294185e-07
Cowden B-Disease 1 0.7278638482093811
disease I-Disease 0 0.00038152895285747945
and O 0 1.1790630196628626e-06
Bannayan B-Disease 1 0.9999264478683472
- I-Disease 1 1.0
Zonana I-Disease 1 0.9999996423721313
syndrome I-Disease 1 1.0
, O 0 3.8936835977665396e-08
two O 0 1.7270991747864173e-07
hamartoma B-Disease 1 0.8467128872871399
syndromes I-Disease 1 0.9141796827316284
with O 0 6.092694775361451e-07
germline O 0 0.0026474278420209885
PTEN O 0 0.0030815601348876953
mutation O 0 8.870998135535046e-05
. O 0 1.9903779957530787e-06

The O 0 1.2972936929145362e-05
tumour B-Disease 1 0.9999998807907104
suppressor O 0 0.00019330493523739278
gene O 0 1.0665859008440748e-05
PTEN O 0 6.877146370243281e-05
, O 0 1.3190155634390521e-08
which O 0 2.301857815467656e-09
maps O 0 3.788759173062317e-08
to O 0 2.8479789193625038e-08
10q23 O 0 9.85942460829392e-06
. O 0 1.7827372289502819e-07

3 O 0 4.435138976077724e-07
and O 0 5.693784999039053e-09
encodes O 0 1.707063290723454e-08
a O 0 4.478464266099991e-09
403 O 0 3.401784098855387e-08
amino O 0 4.997662728101204e-08
acid O 0 5.056949703430291e-08
dual O 0 1.5832557664907654e-07
specificity O 0 3.027985542303213e-07
phosphatase O 0 8.197503484552726e-05
( O 0 1.9986963195606222e-08
protein O 0 1.210168676379908e-07
tyrosine O 0 2.258628455820144e-06
phosphatase O 0 1.5002439795352984e-05
; O 0 3.2003819594450533e-09
PTPase O 0 9.681358648094829e-08
) O 0 3.454599939445302e-10
, O 0 1.4512091528473547e-10
was O 0 1.2914106228834044e-08
shown O 0 1.7209697000808433e-09
recently O 0 2.08773531795714e-08
to O 0 4.267008968383834e-10
play O 0 1.6154938720092105e-08
a O 0 5.447582385187388e-10
broad O 0 7.965229364970128e-09
role O 0 7.509563637597694e-09
in O 0 7.66625518622277e-09
human O 0 3.4435121420983705e-08
malignancy B-Disease 0 2.1998819647706114e-05
. O 0 1.5155772814523516e-07

Somatic O 0 0.0017529713222756982
PTEN O 0 0.005438568536192179
deletions O 0 8.436070493189618e-05
and O 0 1.7994679524235835e-07
mutations O 0 1.274527789973945e-07
were O 0 5.93879789789753e-09
observed O 0 2.8289743880804963e-09
in O 0 5.2433901664983296e-09
sporadic B-Disease 0 0.013888460583984852
breast I-Disease 1 0.7886496186256409
, I-Disease 0 1.1157035260112025e-06
brain I-Disease 1 0.6347095370292664
, I-Disease 0 1.0590282499833847e-06
prostate I-Disease 0 0.3098941743373871
and I-Disease 0 6.957549339858815e-05
kidney I-Disease 0 0.004645659122616053
cancer I-Disease 0 6.834643954789499e-06
cell O 0 8.865137715474702e-06
lines O 0 2.2070202248869464e-05
and O 0 2.255809619100546e-07
in O 0 2.0685982704549133e-08
several O 0 1.6095702548568624e-08
primary O 0 7.559709501947509e-06
tumours B-Disease 1 0.9999998807907104
such O 0 3.753528687866492e-08
as O 0 8.886498835636303e-05
endometrial B-Disease 1 0.9998834133148193
carcinomas I-Disease 1 1.0
, O 1 0.9328199028968811
malignant B-Disease 1 1.0
melanoma I-Disease 1 1.0
and O 1 0.9645406603813171
thyroid B-Disease 1 0.9999971389770508
tumours I-Disease 1 0.9999998807907104
. O 0 1.2242228422110202e-06

In O 0 1.3776384832908661e-07
addition O 0 1.6520512957640676e-08
, O 0 3.886944099917855e-09
PTEN O 0 3.171518528688466e-06
was O 0 1.232021560326757e-07
identified O 0 3.955096250507495e-09
as O 0 1.4778683832261663e-10
the O 0 3.8384498357579844e-10
susceptibility O 0 1.6539555502959047e-08
gene O 0 4.3112219572094546e-08
for O 0 8.32553048724094e-09
two O 0 1.3314335092218244e-06
hamartoma B-Disease 1 0.99988853931427
syndromes I-Disease 1 0.9999994039535522
Cowden B-Disease 1 0.9999929666519165
disease I-Disease 1 0.9919942617416382
( O 0 2.1131816652086854e-07
CD B-Disease 0 4.344905391917564e-06
; O 0 4.757646365760593e-08
MIM O 0 0.0006263082032091916
158350 O 0 7.962769927871705e-07
) O 0 3.184374097742193e-09
and O 0 1.7200253665805576e-08
Bannayan B-Disease 0 0.00013691905769519508
- I-Disease 0 0.0011662483448162675
Zonana I-Disease 0 0.00012804468860849738
( I-Disease 0 3.150363525605826e-08
BZS I-Disease 0 3.27918428411067e-06
) I-Disease 0 5.900454347340656e-09
or I-Disease 0 2.308018309804538e-08
Ruvalcaba I-Disease 0 2.279623549839016e-05
- I-Disease 0 0.0028566806577146053
Riley I-Disease 1 0.728206217288971
- I-Disease 1 0.9999980926513672
Smith I-Disease 1 0.9998908042907715
syndrome I-Disease 1 0.9999465942382812
( O 0 7.539404123235727e-08
MIM O 0 0.00024926720652729273
153480 O 0 3.2861371437320486e-06
) O 0 3.138033477512181e-08
. O 0 5.871996577866412e-08

Constitutive O 0 2.0001923985546455e-05
DNA O 0 2.1447315248224186e-06
from O 0 4.65526923676407e-08
37 O 0 3.4234073353900385e-08
CD B-Disease 0 1.3804094578517834e-07
families O 0 1.461704979277556e-09
and O 0 1.5556207433320424e-09
seven O 0 4.828236033205258e-09
BZS B-Disease 0 2.623221689646016e-06
families O 0 3.4093174949845206e-09
was O 0 2.3008933425217037e-08
screened O 0 1.0680312811928161e-07
for O 0 1.5156661703485952e-08
germline O 0 2.275409860885702e-05
PTEN O 0 0.00028261388069950044
mutations O 0 1.620356852072291e-05
. O 0 4.5035000084681087e-07

PTEN O 0 0.0016359712462872267
mutations O 0 9.470712939219084e-06
were O 0 6.602868296567976e-08
identified O 0 6.489522252905999e-09
in O 0 5.786623957781956e-10
30 O 0 7.774273447225255e-10
of O 0 4.947879606032046e-11
37 O 0 8.715999477715286e-09
( O 0 1.209913724764533e-09
81 O 0 3.3010866928862015e-08
% O 0 5.255993973385387e-10
) O 0 2.1572778285960936e-10
CD B-Disease 0 1.9780920013090508e-07
families O 0 1.4728039898770362e-09
, O 0 1.301629776184754e-10
including O 0 4.0393449696196626e-10
missense O 0 1.6204489838855807e-06
and O 0 7.02401337093761e-08
nonsense O 0 2.29352244787151e-05
point O 0 8.684573060691037e-08
mutations O 0 1.8000630319647826e-08
, O 0 4.2556705381890936e-10
deletions O 0 3.722486141555237e-08
, O 0 1.0319020082860675e-09
insertions O 0 1.1725308723953276e-07
, O 0 1.133095617333879e-09
a O 0 1.0651358905988673e-08
deletion O 0 5.107938250148436e-06
/ O 0 1.9693479771376587e-06
insertion O 0 1.6779655709342478e-07
and O 0 1.925235082467225e-08
splice O 0 1.7179576389025897e-05
site O 0 6.893583872624731e-07
mutations O 0 2.837644387909677e-06
. O 0 1.6873805464001634e-07

These O 0 1.2309318719871953e-07
mutations O 0 5.3478197514778e-07
were O 0 2.6999735780464107e-08
scattered O 0 1.4106391610368973e-09
over O 0 9.812580747947663e-10
the O 0 1.7499582338764696e-10
entire O 0 5.804199898484796e-10
length O 0 1.0878412615156208e-09
of O 0 1.4059002573230117e-10
PTEN O 0 6.075566147956124e-07
, O 0 1.1328660926013256e-10
with O 0 1.1115155670871069e-11
the O 0 9.402489897780697e-11
exception O 0 5.762173516110636e-10
of O 0 1.810932133416987e-11
the O 0 5.230332833505713e-10
first O 0 3.9248040373252024e-09
, O 0 1.289711448748676e-09
fourth O 0 1.3817690387440962e-06
and O 0 4.981293955097499e-08
last O 0 2.944788946024346e-07
exons O 0 3.98267644641237e-07
. O 0 5.7266039021897086e-08

A O 0 1.2648432857531589e-05
hot O 0 1.0719987585616764e-05
spot O 0 1.5125608570087934e-06
for O 0 1.0423550023119788e-08
PTEN O 0 2.2200636522029527e-05
mutation O 0 1.5887947313331097e-07
in O 0 7.067726848219991e-09
CD B-Disease 0 2.214250969245768e-07
was O 0 1.0089183177797167e-07
identified O 0 2.137023225046164e-09
in O 0 5.152545057285352e-10
exon O 0 6.083308967674839e-09
5 O 0 1.09236775180932e-09
that O 0 7.97645630101762e-11
contains O 0 9.217236002223572e-11
the O 0 1.1271937827572742e-09
PTPase O 0 2.268114229764251e-07
core O 0 2.8296613052702924e-08
motif O 0 1.375693603478112e-08
, O 0 1.390539211554298e-10
with O 0 4.1244754139802e-11
13 O 0 6.397029017612965e-10
of O 0 3.391568970112502e-11
30 O 0 3.474067922226709e-09
( O 0 5.656610735371714e-10
43 O 0 8.947029783712424e-09
% O 0 3.136726156593994e-10
) O 0 4.6386994245750657e-10
CD B-Disease 0 2.0957651258868282e-07
mutations O 0 3.269517634407748e-08
identified O 0 1.670253446661718e-08
in O 0 2.0905155384554064e-09
this O 0 2.8769409077256114e-09
exon O 0 8.369004831365601e-07
. O 0 1.4166614903388108e-07

Seven O 0 1.052556513059244e-07
of O 0 7.556485992488149e-10
30 O 0 4.827554356268138e-09
( O 0 6.813850594866722e-10
23 O 0 4.554398191913833e-09
% O 0 6.122834877997363e-11
) O 0 4.560652203111637e-11
were O 0 7.102318178020539e-10
within O 0 2.1556889953644465e-11
the O 0 1.0347495082996261e-10
core O 0 1.2536492732806437e-08
motif O 0 7.488509368158702e-09
, O 0 4.2302267244664904e-10
the O 0 2.1909156433519428e-10
majority O 0 1.1493115348315541e-09
( O 0 5.23115051276335e-10
five O 0 3.7404748742808636e-10
of O 0 2.988337355347426e-11
seven O 0 1.0077730872026791e-09
) O 0 2.9114224919801757e-11
of O 0 2.3065712534409144e-11
which O 0 8.117385097428098e-10
were O 0 7.521851443925698e-07
missense O 0 1.1121661600554944e-06
mutations O 0 3.8864790496973e-08
, O 0 2.794750819656855e-10
possibly O 0 1.2727836562476114e-09
pointing O 0 2.431136358893582e-08
to O 0 3.094746681142624e-10
the O 0 2.0390443500328814e-10
functional O 0 7.929043532861613e-10
significance O 0 1.2836374185809518e-09
of O 0 1.5084317128710722e-10
this O 0 1.3323452341396091e-09
region O 0 3.2297631236133384e-08
. O 0 1.430701530580336e-07

Germline O 0 0.0034083332866430283
PTEN O 0 0.0009256608900614083
mutations O 0 6.9777233875356615e-06
were O 0 7.396936041459412e-08
identified O 0 9.328386063600647e-09
in O 0 8.964482489659531e-10
four O 0 4.439586198667911e-10
of O 0 6.193189711067859e-11
seven O 0 4.515138929406248e-09
( O 0 1.931169890667661e-09
57 O 0 6.111758921178989e-08
% O 0 1.2630763102094988e-09
) O 0 8.054430455928241e-10
BZS B-Disease 0 1.588667373653152e-06
families O 0 5.529036339879667e-09
studied O 0 8.78434747164647e-08
. O 0 3.856624175568868e-08

Interestingly O 0 2.7285845135338604e-05
, O 0 2.2608055871842225e-08
none O 0 6.1230394088340745e-09
of O 0 4.151761226478534e-11
these O 0 1.7063095381075755e-10
mutations O 0 1.0408471418088538e-08
was O 0 8.32899615943461e-08
observed O 0 8.917210858605529e-10
in O 0 1.423417828050333e-09
the O 0 3.211063859254182e-09
PTPase O 0 8.024106250559271e-07
core O 0 3.8613904962403467e-07
motif O 0 1.6985916317935335e-06
. O 0 2.727102526023373e-07

It O 0 8.670538420574303e-08
is O 0 1.2762598755600152e-09
also O 0 8.037794874127258e-10
worthy O 0 1.5248632356801295e-09
of O 0 1.1816893297211806e-10
note O 0 6.501666405256401e-08
that O 0 2.813582977712059e-10
a O 0 6.635827443091102e-10
single O 0 1.2590312792326586e-08
nonsense O 0 1.1779167152781156e-06
point O 0 2.183725200666231e-08
mutation O 0 2.464714210503871e-09
, O 0 2.716982472339424e-10
R233X O 0 1.4393570779702713e-08
, O 0 1.3999278125620407e-10
was O 0 1.2807939597792029e-08
observed O 0 4.976484224705757e-10
in O 0 2.6140081765824164e-10
the O 0 3.842830498257399e-10
germline O 0 7.551449954235068e-08
DNA O 0 1.9372841109088768e-08
from O 0 1.157239304383495e-09
two O 0 1.2041742047941284e-09
unrelated O 0 2.392057751876564e-08
CD B-Disease 0 6.474799647548934e-07
families O 0 3.542391713295956e-09
and O 0 1.7777000982377444e-09
one O 0 6.56874910021088e-09
BZS B-Disease 0 5.99053464611643e-06
family O 0 4.027371147685699e-08
. O 0 4.821934140863959e-08

Genotype O 1 0.9952529668807983
- O 1 0.9983175992965698
phenotype O 0 4.5544693421106786e-05
studies O 0 1.403408020905772e-07
were O 0 5.75148497716782e-08
not O 0 1.7959468356920638e-09
performed O 0 4.353070792717517e-09
on O 0 6.01251670673264e-09
this O 0 2.351702166336622e-10
small O 0 2.0513486465034703e-09
group O 0 2.72550648716674e-09
of O 0 6.569623178798167e-10
BZS B-Disease 0 5.020170647185296e-06
families O 0 5.657641821699144e-08
. O 0 4.398475894618059e-08

However O 0 4.555969042030483e-07
, O 0 3.711964424724101e-08
genotype O 0 0.00027701203362084925
- O 0 0.007537642493844032
phenotype O 0 3.644056278062635e-06
analysis O 0 2.59432155758077e-08
inthe O 0 1.4731384680999327e-06
group O 0 8.341775270537255e-09
of O 0 2.4111013186001173e-10
CD B-Disease 0 1.0251403637084877e-06
families O 0 2.8333808632652335e-09
revealed O 0 1.892879808451653e-08
two O 0 1.5670076347618078e-10
possible O 0 2.1134913263942678e-10
associations O 0 2.8762042747487726e-10
worthy O 0 7.299228999002594e-10
of O 0 2.623967536308225e-11
follow O 0 1.7019784692706708e-08
- O 0 1.9639655874925666e-06
up O 0 2.7774618160947284e-08
in O 0 4.6538644049576305e-09
independent O 0 1.1575357561355304e-08
analyses O 0 8.416991903459348e-08
. O 0 1.9657624861224576e-08

The O 0 1.73015965998502e-08
first O 0 2.0758033514312046e-08
was O 0 9.696734082353942e-08
an O 0 9.632460801212162e-11
association O 0 4.3455117282320543e-10
noted O 0 1.0035818842624167e-09
in O 0 9.850159576885176e-10
the O 0 2.222541595209293e-10
group O 0 7.939924828725964e-10
of O 0 3.878364296383552e-11
CD B-Disease 0 9.56500684878847e-07
families O 0 8.523842964791584e-09
with O 0 5.066440422751839e-08
breast B-Disease 0 0.44757771492004395
disease I-Disease 0 0.0001461283245589584
. O 0 2.460502912526863e-07

A O 0 1.0081947721118922e-06
correlation O 0 6.018657927597815e-07
was O 0 1.239327929170031e-07
observed O 0 4.040379586456311e-09
between O 0 5.717397666415991e-10
the O 0 8.654766903148925e-10
presence O 0 1.0156273155814688e-08
/ O 0 9.361377806271776e-07
absence O 0 1.1175822045572659e-08
of O 0 2.095380674527192e-10
a O 0 1.1449363235271903e-08
PTEN O 0 3.6436747905099764e-05
mutation O 0 7.102053700691613e-08
and O 0 1.125470716623056e-09
the O 0 5.186146512237144e-10
type O 0 1.4993710237831692e-06
of O 0 5.8672022795747125e-09
breast O 0 6.38397250440903e-05
involvement O 0 1.488154111939366e-06
( O 0 3.8224900578143206e-08
unaffected O 0 9.423133633390535e-06
versus O 0 0.00014434241165872663
benign O 0 0.02673119492828846
versus O 0 0.0002019801177084446
malignant O 0 0.005836378782987595
) O 0 1.1056838644663003e-07
. O 0 9.401749423432193e-08

Specifically O 0 1.421712454430235e-07
and O 0 5.965123950346651e-09
more O 0 1.2748530009432102e-10
directly O 0 1.4664067182756924e-10
, O 0 6.907170668757345e-11
an O 0 6.680615088905384e-11
association O 0 6.5815162209048594e-09
was O 0 1.5667230002236465e-07
also O 0 5.923352919268154e-10
observed O 0 1.3700936218885573e-10
between O 0 1.2774233060230955e-10
the O 0 1.1901218899268429e-10
presence O 0 4.665220432187311e-10
of O 0 1.4322790176102274e-10
a O 0 2.8917579442122587e-08
PTEN O 0 0.001616662833839655
mutation O 0 1.2315286767261568e-05
and O 0 6.570285768248141e-05
malignant B-Disease 1 0.9999923706054688
breast I-Disease 1 0.9998326301574707
disease I-Disease 0 0.005184400361031294
. O 0 1.3494219501808402e-06

Secondly O 0 6.760913674952462e-05
, O 0 9.056016381236986e-09
there O 0 8.866770651039246e-10
appeared O 0 7.512303312751101e-08
to O 0 3.025496797537386e-10
be O 0 4.3577708108699653e-10
an O 0 1.9119568428482836e-10
interdependent O 0 1.764425405781367e-08
association O 0 1.4583020346847775e-09
between O 0 1.1207151873193766e-09
mutations O 0 1.6632055732657136e-08
upstream O 0 4.703615275047923e-09
and O 0 2.2955694289894524e-10
within O 0 5.808992523115286e-11
the O 0 4.931168251509632e-10
PTPase O 0 1.455474603062612e-07
core O 0 4.769303529883473e-08
motif O 0 1.4152159444336121e-08
, O 0 1.7358961490465674e-10
the O 0 1.0197685751389685e-10
core O 0 6.5186007702777715e-09
motif O 0 2.1691783924637775e-09
containing O 0 3.5526953601205946e-10
the O 0 4.0816311441815856e-10
majority O 0 3.761186084805246e-10
of O 0 1.542431043999315e-10
missense O 0 9.931692375175771e-07
mutations O 0 1.2157768480847153e-07
, O 0 7.065499296743383e-10
and O 0 3.9232603277206124e-10
the O 0 8.858044853177205e-11
involvement O 0 1.0746653567039743e-09
of O 0 4.803888536963896e-11
all O 0 2.5191998487272826e-10
major O 0 1.8755637043454954e-09
organ O 0 6.30268914392218e-07
systems O 0 1.0686236464607646e-06
( O 0 8.766450676489512e-09
central O 0 2.0086369545424532e-07
nervous O 1 0.9705008864402771
system O 0 8.791585628387111e-07
, O 0 1.1824688783690362e-07
thyroid O 0 0.00030307655106298625
, O 0 1.0630053282056906e-07
breast O 0 0.042277928441762924
, O 0 4.997013547836104e-06
skin O 1 0.9999918937683105
and O 0 0.02254706434905529
gastrointestinal O 1 0.97383713722229
tract O 0 0.0018929832149297
) O 0 7.20976771617643e-08
. O 0 1.6558911397623888e-07

However O 0 2.8895698278574855e-07
, O 0 5.407725933714858e-10
these O 0 2.973112381288168e-11
observations O 0 6.435750821154329e-10
would O 0 8.367554427124446e-10
need O 0 1.112099232147834e-10
to O 0 2.5998902683510572e-11
be O 0 1.6447426753884997e-10
confirmed O 0 5.941151459687433e-10
by O 0 2.219414235726802e-11
studying O 0 2.862723946783774e-10
a O 0 7.806126578469019e-11
larger O 0 2.444142943591743e-10
number O 0 5.010389880766297e-10
of O 0 1.728957116364782e-10
CD B-Disease 0 2.092698196065612e-06
families O 0 1.1855871839827614e-08
. O 0 1.506150582031296e-08

Molecular O 0 0.001378941466100514
defects O 0 0.1608591377735138
leading O 0 5.603055797109846e-08
to O 0 2.1658459470330627e-09
human O 0 2.799057430280527e-09
complement B-Disease 0 3.4797046737367054e-06
component I-Disease 1 0.9975687861442566
C6 I-Disease 1 1.0
deficiency I-Disease 1 1.0
in O 0 1.8452720240702547e-08
an O 0 6.802046703668907e-10
African O 0 5.41550138066782e-09
- O 0 4.878968979937781e-07
American O 0 4.5290970973610456e-08
family O 0 1.0498917646373229e-07
. O 0 7.507117771865524e-08

Complement B-Disease 0 0.00034768320620059967
component I-Disease 1 0.9999258518218994
C6 I-Disease 1 1.0
deficiency I-Disease 1 1.0
( O 0 5.753107643613475e-07
C6D B-Disease 0 0.00011591392831178382
) O 0 1.3427086109629727e-08
was O 0 9.627653525967617e-06
diagnosed O 0 1.2441477338143159e-05
in O 0 2.3071677901498333e-09
a O 0 1.305024355247042e-08
16 O 0 7.192996349658642e-07
- O 0 1.111629671868286e-06
year O 0 9.482412366423887e-08
- O 0 1.2919088021590142e-07
old O 0 1.353055836261774e-06
African O 0 5.5037632229471e-09
- O 0 6.609294445070191e-08
American O 0 7.026703663370881e-09
male O 0 6.205424796235093e-08
with O 0 4.82920547995036e-08
meningococcal B-Disease 1 1.0
meningitis I-Disease 1 1.0
. O 0 8.376406412935467e-07

The O 0 3.282064540144347e-07
patients O 0 4.42245709564304e-06
father O 0 1.40521592584264e-07
and O 0 2.2220509876547112e-09
two O 0 1.1398065824508308e-09
brothers O 0 3.936786896474587e-08
also O 0 2.391180586869268e-09
had O 0 3.780912720685592e-07
C6D B-Disease 0 3.510657279548468e-06
, O 0 3.522634961505844e-10
but O 0 1.7050838518883893e-09
gave O 0 1.878313282688282e-09
no O 0 1.7153297671157475e-09
history O 0 2.0170316528123067e-09
of O 0 5.6247468904757625e-09
meningitis B-Disease 1 0.9999998807907104
or O 0 6.91721311341098e-08
other O 0 4.745131221284282e-08
neisserial B-Disease 0 0.00015086171333678067
infection I-Disease 0 0.0005429982556961477
. O 0 3.4319202768529067e-07

By O 0 3.747705790146938e-08
using O 0 8.977973919854776e-08
exon O 0 1.4717791145812953e-06
- O 0 5.130035560796387e-07
specific O 0 1.824414219697701e-08
polymerase O 0 6.361457280945615e-07
chain O 0 2.7163952154296567e-07
reaction O 0 1.3749327898437969e-08
( O 0 2.2267943045051197e-09
PCR O 0 2.2929577880859142e-07
) O 0 1.1313464609585822e-09
/ O 0 1.8060882567283443e-08
single O 0 1.9865911582428453e-08
- O 0 9.47058936162648e-07
strand O 0 1.5046307453303598e-06
conformation O 0 1.0723483967467473e-07
polymorphism O 0 1.5057634072945802e-07
as O 0 1.203210087119544e-09
a O 0 1.1600238547515573e-09
screening O 0 1.3239432661293904e-08
step O 0 2.1078923051476295e-09
and O 0 1.3475356941405892e-10
nucleotide O 0 7.171004345885024e-10
sequencing O 0 3.60653645836706e-10
of O 0 4.920924778772928e-11
target O 0 6.073165526032653e-09
exons O 0 3.6506659917279194e-09
, O 0 2.5930474434332496e-10
we O 0 5.898088684119784e-10
determined O 0 3.1912431031067e-10
that O 0 5.3793199061846764e-11
the O 0 5.884323583948969e-10
proband O 0 4.3294500073898234e-07
was O 0 1.2099827984002332e-07
a O 0 1.193213639005819e-09
compound O 0 1.152356698952417e-08
heterozygote O 0 1.3626484474116296e-07
for O 0 2.8771329763088715e-09
two O 0 3.3957231693193535e-08
C6 O 0 1.533139766252134e-05
gene O 0 1.3654769190907246e-06
mutations O 0 2.876539383578347e-06
. O 0 1.0115793713794119e-07

The O 0 1.4595411101936406e-08
first O 0 3.924145453026995e-09
, O 0 1.57874671669056e-10
1195delC O 0 3.0980673582092777e-09
located O 0 6.809861563539243e-10
in O 0 1.1102220254244344e-09
exon O 0 2.9702940551601387e-08
7 O 0 2.6224252991369212e-08
, O 0 2.4415244825881643e-10
is O 0 5.0917270399963854e-11
a O 0 4.469339898172109e-10
novel O 0 3.3536389221211493e-09
mutation O 0 3.922319802285301e-09
, O 0 1.799858595497028e-10
while O 0 2.5800034331169286e-10
the O 0 1.1493900275993951e-10
second O 0 3.6825562599318573e-09
, O 0 2.9375901711148344e-10
1936delG O 0 6.951041964242677e-09
in O 0 8.203520085459104e-10
exon O 0 1.7282928865824942e-08
12 O 0 1.580119146638026e-08
, O 0 4.1052330979063356e-10
has O 0 1.6246881617831832e-10
been O 0 4.10050660093475e-10
described O 0 1.2090463075153934e-09
before O 0 1.2263001725187905e-09
to O 0 3.895239408802098e-10
cause O 0 8.464287049037011e-09
C6D B-Disease 0 8.416572541136702e-07
in O 0 9.064445305462243e-10
an O 0 1.8041068639007563e-10
unrelated O 0 1.485432399306319e-08
African O 0 1.0847815978820563e-08
- O 0 2.0591905069977656e-07
American O 0 6.212586889375871e-09
individual O 0 6.829519616502466e-09
. O 0 4.289330490792054e-08

Both O 0 5.760948056376947e-07
mutations O 0 2.588753886811901e-06
result O 0 1.5996515401184297e-07
in O 0 1.5466460467905563e-07
premature O 0 9.898238204186782e-06
termination O 0 1.7018995777107193e-06
codons O 0 1.7448594462621259e-06
and O 0 1.1460478077651715e-07
C6 O 0 7.00113014318049e-05
null O 0 2.2160849766805768e-05
alleles O 0 1.1196377272426616e-05
. O 0 8.494193366459513e-07

Allele O 0 0.0001574341586092487
- O 0 6.912062417541165e-06
specific O 0 4.227972638659594e-08
PCR O 0 2.616043957459624e-06
indicated O 0 9.86771269140263e-08
that O 0 2.744210692018356e-10
the O 0 3.4281608107811223e-10
probands O 0 2.2664751497813995e-07
two O 0 3.3093940920991827e-09
brothers O 0 4.801578157298536e-08
also O 0 1.7602026503027446e-09
inherited O 0 2.3658584424879336e-08
the O 0 2.2841144531327018e-09
1195delC O 0 2.1829471563705738e-07
mutation O 0 3.4138349036538784e-08
from O 0 2.1238009129120883e-09
their O 0 1.0515341930528166e-09
heterozygous O 0 5.120103452327385e-08
mother O 0 1.4322313113268592e-08
and O 0 3.6945568826496356e-10
the O 0 7.537398483137281e-10
1936delG O 0 1.1991261317234603e-07
mutation O 0 1.4488099608911398e-08
from O 0 1.0989569254604703e-09
their O 0 8.760595582302244e-10
homozygous O 0 1.3922422681389435e-07
father O 0 8.416863295224175e-08
. O 0 4.429658417848259e-09
. O 0 1.1546029909936806e-08

PAX6 O 0 0.021743521094322205
mutations O 0 0.0008445880375802517
reviewed O 0 4.930279101245105e-05
. O 0 2.336709485462052e-06

Mutations O 0 7.882811041781679e-05
in O 0 3.5323009228704905e-07
PAX6 O 0 8.770250133238733e-06
are O 0 2.118917263871367e-09
responsible O 0 1.6965714388916808e-09
for O 0 1.3381819263802441e-10
human O 0 2.1028929708677424e-09
aniridia B-Disease 1 1.0
and O 0 1.0487109136647632e-07
have O 0 1.2434757223900306e-08
also O 0 6.483678594015885e-10
been O 0 1.5531304020655057e-09
found O 0 7.611583585642734e-10
in O 0 2.219352923660267e-09
patients O 0 1.5520118523681958e-08
with O 0 1.404834915064157e-08
Peters B-Disease 1 1.0
anomaly I-Disease 1 1.0
, O 0 9.772364819582435e-07
with O 0 0.00012486512423492968
congenital B-Disease 1 1.0
cataracts I-Disease 1 0.9999998807907104
, O 0 2.96472251193336e-07
with O 0 1.0339932998704171e-07
autosomal B-Disease 1 0.9984090924263
dominant I-Disease 1 0.9913418889045715
keratitis I-Disease 1 0.9999892711639404
, O 0 1.79112817022542e-07
and O 0 2.76030842627506e-08
with O 0 1.0949007034355418e-08
isolated B-Disease 0 0.0006650314317084849
foveal I-Disease 1 1.0
hypoplasia I-Disease 1 1.0
. O 0 3.840600129478844e-06

No O 0 3.3720172609719157e-07
locus O 0 1.5984666390522762e-07
other O 0 4.012188359325819e-09
than O 0 4.02972055724149e-09
chromosome O 0 1.050977289196453e-06
11p13 O 0 5.513694532055524e-07
has O 0 3.914397694870786e-09
been O 0 4.776766093783635e-09
implicated O 0 1.9845497689630065e-08
in O 0 7.747887309506041e-08
aniridia B-Disease 1 1.0
, O 0 2.7042035277702325e-09
and O 0 9.029157976847557e-10
PAX6 O 0 3.162395785238914e-07
is O 0 6.980426792146943e-10
clearly O 0 1.5993145696668876e-09
the O 0 6.808169999983349e-11
major O 0 1.8678418811646225e-09
, O 0 3.2743135980339844e-10
if O 0 3.8129105428552634e-10
not O 0 2.5617916121767337e-10
only O 0 1.3489448447145946e-10
, O 0 1.3929919717714512e-10
gene O 0 2.736331694563887e-08
responsible O 0 2.2404282873367265e-08
. O 0 3.080321420156906e-08

Twenty O 0 1.4610955986427143e-05
- O 0 2.5703142455313355e-05
eight O 0 6.586566314581432e-08
percent O 0 1.8916670896373944e-08
of O 0 9.804662637336037e-11
identified O 0 1.8330995388282645e-08
PAX6 O 0 2.3814179712644545e-06
mutations O 0 6.834708443648196e-08
are O 0 3.6018361626588558e-09
C O 0 4.638288010028191e-05
- O 0 1.6964104361250065e-05
T O 0 3.447571725700982e-05
changes O 0 1.8728908202092498e-08
at O 0 1.691812379078783e-08
CpG O 0 3.9381430383400584e-07
dinucleotides O 0 3.504521828290308e-07
, O 0 6.925721662831563e-10
20 O 0 6.158502041664349e-10
% O 0 5.937376285070073e-11
are O 0 6.22199583522054e-11
splicing O 0 3.468084486257794e-08
errors O 0 4.431394700077362e-06
, O 0 3.454777852684998e-10
and O 0 2.2374282981907356e-10
more O 0 4.356480454159595e-11
than O 0 3.1829150426432307e-10
30 O 0 1.1923718679085482e-09
% O 0 4.5506425017105556e-11
are O 0 2.393899245500819e-10
deletion O 0 2.371727347849628e-08
or O 0 2.2731709847789716e-09
insertion O 0 3.05531884237098e-08
events O 0 2.263701048832445e-08
. O 0 5.643491007845114e-08

There O 0 2.759093433724047e-07
is O 0 4.630816174966412e-09
a O 0 5.6114806135099116e-09
noticeably O 0 4.107829226995818e-06
elevated O 0 4.472942904953925e-08
level O 0 6.504541349983128e-09
of O 0 5.460989993544274e-11
mutation O 0 2.0040202830529097e-09
in O 0 9.231984066104815e-10
the O 0 4.575440304410705e-10
paired O 0 9.109530907380758e-09
domain O 0 1.9299253306570563e-09
compared O 0 5.0838129261876475e-09
with O 0 1.315331177309531e-10
the O 0 5.070650010985389e-10
rest O 0 1.8003779578279477e-09
of O 0 4.047486651392873e-11
the O 0 8.319843702864205e-10
gene O 0 9.333585637705255e-08
. O 0 4.6826979627212495e-08

Increased O 0 8.014615104912082e-07
mutation O 0 4.81152540032781e-07
in O 0 1.0770543568128232e-08
the O 0 2.0837558345476737e-09
homeodomain O 0 1.5919250984097744e-07
is O 0 5.369993893999947e-10
accounted O 0 1.2353908118711843e-08
for O 0 1.2218402678509932e-10
by O 0 3.6687991533668196e-10
the O 0 5.542202696773302e-09
hypermutable O 0 4.288056970835896e-06
CpG O 0 3.5733562526729656e-06
dinucleotide O 0 1.5598739082633983e-06
in O 0 3.625977029741989e-08
codon O 0 2.915202912845416e-06
240 O 0 4.66658661935071e-07
. O 0 9.906258213732144e-08

Very O 0 4.830209491046844e-06
nearly O 0 7.09068359583398e-08
all O 0 1.395561666228673e-09
mutations O 0 1.4364828437862798e-08
appear O 0 1.8394844758518047e-08
to O 0 5.48263823230144e-10
cause O 0 9.156215341477036e-09
loss O 0 1.1033701952101183e-08
of O 0 1.39795796466613e-11
function O 0 9.013752938491493e-11
of O 0 1.679460737147309e-11
the O 0 2.0345766738039117e-10
mutant O 0 2.2351654749286354e-08
allele O 0 6.069404179243065e-08
, O 0 5.530563229605434e-10
and O 0 3.0734756406580743e-10
more O 0 4.949465143289089e-11
than O 0 7.744137275889074e-11
80 O 0 3.499510681237439e-10
% O 0 1.0291673069318108e-10
of O 0 1.297841695224733e-10
exonic O 0 2.8719048827952065e-07
substitutions O 0 1.2780832037151413e-07
result O 0 1.7228787285716862e-08
in O 0 5.4467882648623345e-08
nonsense O 0 8.882934707798995e-06
codons O 0 2.873844096029643e-06
. O 0 9.697399860897349e-08

In O 0 4.707028011807779e-08
a O 0 5.0856847622071655e-09
gene O 0 1.8095295928333144e-08
with O 0 3.8419803449762924e-10
such O 0 2.5283664051301002e-09
extraordinarily O 0 2.857190338545479e-06
high O 0 5.677109626844867e-08
sequence O 0 1.132775873102787e-09
conservation O 0 2.77259992742529e-10
throughout O 0 7.936488133353237e-10
evolution O 0 2.9496123321592904e-09
, O 0 2.5573440587400853e-10
there O 0 5.727231466856608e-10
are O 0 4.5947237681254194e-10
presumed O 0 1.3633101048071694e-07
undiscovered O 0 5.205010893405415e-07
missense O 0 1.8783267705657636e-06
mutations O 0 1.0004980310895917e-07
, O 0 5.265847757840447e-10
these O 0 6.074676872636076e-11
are O 0 7.380437233583947e-11
hypothesized O 0 1.5371336425928916e-09
to O 0 1.776448294021904e-10
exist O 0 7.387045974915907e-10
in O 0 3.162402784084861e-09
as O 0 2.995343706402309e-08
- O 0 3.631078300259105e-07
yet O 0 3.303013684785583e-08
unidentified O 0 8.700603757461067e-07
phenotypes O 0 8.550453856059903e-08
. O 0 2.992835090864787e-09
. O 0 1.8575857296809772e-08

Genetic O 0 4.75529559480492e-05
heterogeneity O 0 7.140592970245052e-06
and O 0 1.2147486927460704e-07
penetrance O 0 1.6743319974921178e-06
analysis O 0 1.1387597531609117e-08
of O 0 4.5018938577001677e-10
the O 0 4.005192177913841e-09
BRCA1 O 0 1.4415885743801482e-05
and O 0 3.2652486936513014e-08
BRCA2 O 0 3.866453698719852e-05
genes O 0 1.8147610489904764e-06
in O 0 5.342699296306819e-05
breast B-Disease 1 0.9522114992141724
cancer I-Disease 0 0.00015095928392838687
families O 0 2.046955245305071e-07
. O 0 1.8327067152767995e-07

The O 0 0.00042174491682089865
Breast B-Disease 1 1.0
Cancer I-Disease 1 0.9999995231628418
Linkage O 0 0.0003128110838588327
Consortium O 0 2.9210579668870196e-05
. O 0 6.29868679880019e-07

The O 0 4.0696015446428646e-08
contribution O 0 3.887131327928728e-08
of O 0 1.8451832284327452e-09
BRCA1 O 0 8.4984512795927e-06
and O 0 5.225072996495328e-08
BRCA2 O 0 0.0003059649607166648
to O 0 2.28078497457318e-05
inherited B-Disease 1 1.0
breast I-Disease 1 1.0
cancer I-Disease 1 1.0
was O 0 2.0269177184673026e-05
assessed O 0 9.080183360765659e-08
by O 0 7.344309049805986e-10
linkage O 0 6.278895625655423e-07
and O 0 1.7417647768525057e-08
mutation O 0 1.1072197381167825e-08
analysis O 0 1.6855533635506958e-09
in O 0 2.778165253403131e-09
237 O 0 4.0386861854813105e-08
families O 0 8.83965178832824e-10
, O 0 3.215755439711643e-11
each O 0 6.676586367104775e-12
with O 0 2.0425124092060543e-10
at O 0 4.747204229715862e-08
least O 0 2.0695600788656066e-09
four O 0 9.722116445232132e-10
cases O 0 9.222397956420991e-09
of O 0 4.7099735667188725e-08
breast B-Disease 1 0.7795047163963318
cancer I-Disease 0 7.877924872445874e-06
, O 0 8.100217718798319e-10
collected O 0 4.4172535074160635e-10
by O 0 3.3619262929107663e-09
the O 0 0.0003406710457056761
Breast B-Disease 1 1.0
Cancer I-Disease 1 0.9999995231628418
Linkage O 0 7.024107617326081e-05
Consortium O 0 1.1263205124123488e-05
. O 0 4.802741955245438e-07

Families O 0 1.5480627268971148e-07
were O 0 1.0210424505885385e-08
included O 0 2.2359776530311848e-10
without O 0 1.921524328540869e-10
regard O 0 3.7801009544757846e-10
to O 0 1.1952949741100838e-10
the O 0 3.721488950336749e-10
occurrence O 0 2.4678016075085907e-08
of O 0 6.065015600853485e-09
ovarian B-Disease 0 3.2003918022383004e-06
or I-Disease 0 3.205228082947542e-08
other I-Disease 0 6.014916920094038e-08
cancers I-Disease 0 4.1488387068966404e-05
. O 0 1.227775641154949e-07

Overall O 0 0.00015164139040280133
, O 0 2.4759773964433407e-07
disease O 0 3.14800240630575e-06
was O 0 6.244474803906996e-08
linked O 0 5.653682677575489e-08
to O 0 1.3495632389393108e-09
BRCA1 O 0 1.942022009870925e-07
in O 0 7.411390390288375e-10
an O 0 3.1998109023545496e-11
estimated O 0 1.3123341302545555e-10
52 O 0 1.0892095003711688e-09
% O 0 3.213057944706499e-11
of O 0 5.11433430328001e-12
families O 0 1.2157889972552738e-10
, O 0 3.964329212124973e-11
to O 0 2.1509503900229987e-10
BRCA2 O 0 1.845974821890195e-07
in O 0 3.224406519564127e-09
32 O 0 3.8123162404701816e-09
% O 0 6.96651139553417e-11
of O 0 2.769110635236771e-11
families O 0 4.4201020621414955e-10
, O 0 1.2420878214847164e-10
and O 0 1.8881110563917503e-10
to O 0 1.0545765649627725e-10
neither O 0 2.2469532900970535e-09
gene O 0 3.829194294979743e-09
in O 0 1.492201362474077e-09
16 O 0 1.8930736978006735e-09
% O 0 8.690725222804119e-11
( O 0 5.527080182421429e-11
95 O 0 5.9474469793485696e-09
% O 0 2.424966449865451e-09
confidence O 0 6.643304573117348e-07
interval O 0 2.3793804260208162e-08
[ O 0 2.005156929385521e-08
CI O 0 6.345933343254728e-07
] O 0 1.3646676677581127e-08
6 O 0 1.2210649158461706e-09
% O 0 9.101137621314592e-10
- O 0 2.3257305770130188e-07
28 O 0 2.6263046848384874e-08
% O 0 3.943982918030997e-10
) O 0 1.200344129648201e-10
, O 0 2.3571941620836867e-10
suggesting O 0 1.7885094294456394e-08
other O 0 3.1452525028896616e-09
predisposition O 0 4.675950719956745e-07
genes O 0 4.840423457608267e-07
. O 0 1.260762019228423e-07

The O 0 3.968155581901556e-08
majority O 0 1.03013073626812e-08
( O 0 4.707591205743711e-09
81 O 0 1.1295143487188852e-08
% O 0 1.8412517344135182e-10
) O 0 4.622251886798878e-11
of O 0 9.519186133788438e-11
the O 0 1.7075481082429178e-05
breast B-Disease 1 1.0
- I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 1.533529569996972e-08
were O 0 8.762471637169256e-09
due O 0 2.8486131231630907e-09
to O 0 8.179428245824738e-10
BRCA1 O 0 2.615747121126333e-07
, O 0 1.3066793480565053e-10
with O 0 4.9781328365083866e-11
most O 0 7.23643367450677e-10
others O 0 7.436783633352206e-09
( O 0 6.899971149998407e-10
14 O 0 3.842480555960037e-09
% O 0 1.7004776753370976e-10
) O 0 2.154950107247089e-10
due O 0 5.100226907472916e-09
to O 0 3.163224704394452e-08
BRCA2 O 0 2.446603321004659e-05
. O 0 1.383860279702276e-07

Conversely O 0 4.680484380514827e-06
, O 0 7.778118593648742e-09
the O 0 5.758482024553757e-10
majority O 0 2.994460790439746e-10
of O 0 4.079387175282001e-11
families O 0 3.434679207714453e-10
with O 0 2.834606438462117e-10
male B-Disease 0 7.4750694523118e-08
and I-Disease 0 1.5166515368036926e-06
female I-Disease 0 3.043992728635203e-05
breast I-Disease 0 0.16154158115386963
cancer I-Disease 0 5.207545200391905e-06
were O 0 1.8929490863683895e-07
due O 0 1.8536642443223172e-08
to O 0 1.63682667420062e-08
BRCA2 O 0 1.1245828318351414e-05
( O 0 1.4040312912300124e-08
76 O 0 1.5918492124455952e-07
% O 0 4.565086975105714e-09
) O 0 8.129909190301987e-09
. O 0 4.4431654799836906e-08

The O 0 1.946770389338326e-08
largest O 0 1.7867225921008867e-08
proportion O 0 8.144374064045223e-09
( O 0 2.025042133979582e-09
67 O 0 1.4435800999024195e-08
% O 0 1.2595632870038287e-10
) O 0 1.7960272158390467e-11
of O 0 2.086116002164573e-11
families O 0 2.1164846264465353e-10
due O 0 5.178268924765916e-10
to O 0 8.596555411966023e-11
other O 0 4.3360814938608883e-10
genes O 0 2.0556492064116583e-09
was O 0 3.1742794703859545e-07
found O 0 4.2822820844889975e-09
in O 0 1.1584539993947374e-09
families O 0 1.981401015482831e-10
with O 0 2.920153702179462e-11
four O 0 9.819133284239001e-10
or O 0 4.53228343744172e-09
five O 0 1.912643377011136e-09
cases O 0 2.532241527575252e-09
of O 0 4.178179136005156e-09
female O 0 9.137529559666291e-06
breast B-Disease 0 0.0004602322296705097
cancer I-Disease 0 3.1238382689480204e-06
only O 0 5.5707886303935084e-08
. O 0 9.894645103258881e-08

These O 0 3.6891808719019537e-08
estimates O 0 3.2590083520744884e-08
were O 0 1.0195596367168491e-08
not O 0 1.0028623487201571e-09
substantially O 0 1.8173604843241264e-08
affected O 0 5.489271814873575e-10
either O 0 1.6799134305856e-10
by O 0 7.360769632702713e-11
changing O 0 8.944674334543379e-09
the O 0 2.0529142830127967e-09
assumed O 0 1.9721692723351225e-08
penetrance O 0 9.365274422634684e-08
model O 0 1.225208912103426e-08
for O 0 1.2275334082545442e-09
BRCA1 O 0 2.937048009243881e-07
or O 0 2.2342181438261832e-09
by O 0 1.153518877639037e-10
including O 0 4.341295101184528e-10
or O 0 1.1990455739407935e-08
excluding O 0 1.2519261645138613e-06
BRCA1 O 0 1.9869014067808166e-05
mutation O 0 1.151945525634801e-06
data O 0 4.933699528919533e-07
. O 0 8.248368743579704e-08

Among O 0 1.2432521145910869e-07
those O 0 3.6216138976641332e-09
families O 0 1.5392136454295269e-09
with O 0 1.1230776308934765e-09
disease O 0 1.0488624866411556e-06
due O 0 3.120652536381385e-08
to O 0 6.401365215680244e-09
BRCA1 O 0 7.271846698131412e-07
that O 0 1.1470187022410983e-09
were O 0 1.1733358284971018e-08
tested O 0 1.310033970192137e-09
by O 0 3.1037481612594675e-11
one O 0 1.0876623213196268e-10
of O 0 6.030665983952632e-12
the O 0 1.1327666582516827e-10
standard O 0 6.094542470691522e-08
screening O 0 4.062867819953908e-09
methods O 0 6.88501389234375e-09
, O 0 8.057534639505093e-10
mutations O 0 7.511225419420953e-09
were O 0 1.0273954131889695e-08
detected O 0 2.9750625074598247e-08
in O 0 6.321428380751115e-10
the O 0 3.258719127874343e-10
coding O 0 1.7635235494140034e-08
sequence O 0 1.5379313378360848e-09
or O 0 1.1545892020237147e-09
splice O 0 8.951760577247114e-08
sites O 0 2.1998860511018847e-09
in O 0 7.049050787522049e-10
an O 0 8.077533780737056e-11
estimated O 0 2.574429280866042e-10
63 O 0 2.7755486797786943e-09
% O 0 1.857399650750935e-10
( O 0 1.7453515022136656e-10
95 O 0 6.598598112361742e-09
% O 0 3.4876384003013072e-09
CI O 0 3.0870087357470766e-06
51 O 0 5.469378905331723e-08
% O 0 4.827434896270688e-09
- O 0 1.1777593726947089e-06
77 O 0 1.8751664754290687e-07
% O 0 3.0671936102066866e-09
) O 0 3.3526217357859878e-09
. O 0 1.5967032140906667e-08

The O 0 3.4426911099672e-08
estimated O 0 1.2795974058121828e-08
sensitivity O 0 8.536146367532638e-08
was O 0 6.748938830014595e-08
identical O 0 2.9439861659597e-09
for O 0 1.0365509839349585e-10
direct O 0 1.2778430535931307e-09
sequencing O 0 2.0309379067384725e-08
and O 0 3.3684413036638716e-09
other O 0 1.0004684858344604e-09
techniques O 0 3.8366536614375946e-07
. O 0 5.663212832018871e-08

The O 0 4.906910930913e-07
penetrance O 0 1.0459503755555488e-05
of O 0 5.15998266337192e-09
BRCA2 O 0 1.0682613719836809e-05
was O 0 8.064922241146633e-08
estimated O 0 6.299942789667057e-10
by O 0 6.98950966548928e-11
maximizing O 0 3.765875611350111e-09
the O 0 1.9721158039942566e-09
LOD O 0 1.9307757611386478e-05
score O 0 3.5187369462619245e-08
in O 0 1.9084609448327683e-08
BRCA2 O 0 0.00014188300701789558
- O 0 5.508774847839959e-05
mutation O 0 1.386224539601244e-07
families O 0 5.978519457272569e-09
, O 0 3.0866231792714416e-10
over O 0 4.3034048546886083e-10
all O 0 8.018470332160632e-10
possible O 0 1.725710419009374e-08
penetrance O 0 7.26826215213805e-07
functions O 0 2.0604824513270614e-08
. O 0 9.042609150355929e-08

The O 0 6.550384767933792e-08
estimated O 0 2.165682033705707e-08
cumulative O 0 1.0574321152034827e-07
risk O 0 1.856102329611531e-07
of O 0 5.728217455924778e-09
breast B-Disease 0 0.07964583486318588
cancer I-Disease 0 1.549700573377777e-05
reached O 0 3.9426637954420585e-07
28 O 0 1.9695303166145095e-08
% O 0 4.703648581738662e-10
( O 0 3.5985656121617637e-10
95 O 0 2.34735768600558e-08
% O 0 2.7434270410964245e-09
CI O 0 1.3289193248056108e-06
9 O 0 2.5498605893403692e-08
% O 0 1.198057431039956e-09
- O 0 3.697719108686215e-08
44 O 0 5.70570035662854e-09
% O 0 1.1849032865995923e-10
) O 0 2.3088336797982834e-11
by O 0 4.232016473371125e-11
age O 0 4.2580761139277e-09
50 O 0 3.392942315993963e-10
years O 0 1.016159170696973e-10
and O 0 1.4900108924464917e-10
84 O 0 1.92433091683597e-09
% O 0 1.0397945005014009e-10
( O 0 1.6297128924147586e-10
95 O 0 8.778664906117228e-09
% O 0 1.038577890355441e-09
CI O 0 9.272533816329087e-07
43 O 0 2.3428979645245818e-08
% O 0 1.5429085786777819e-09
- O 0 6.827816179111323e-08
95 O 0 4.007746312595373e-08
% O 0 6.288022325051656e-10
) O 0 8.37294608646566e-11
by O 0 8.095846215638858e-10
age O 0 7.010761748915684e-08
70 O 0 9.192033800786703e-09
years O 0 1.0014083784426475e-08
. O 0 1.970642671267342e-08

The O 0 3.829678462352604e-06
corresponding O 1 0.9029461145401001
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
risks O 0 1.258006705029402e-05
were O 0 1.9529332462298044e-07
0 O 0 1.1176359748787945e-07
. O 0 5.8625847287885335e-08

4 O 0 5.462215995066799e-07
% O 0 1.6259020796383084e-08
( O 0 1.3549796840095496e-09
95 O 0 6.880471747905403e-09
% O 0 1.5020558130629524e-09
CI O 0 3.2410596872978203e-07
0 O 0 3.652295577083464e-09
% O 0 9.537873824072562e-10
- O 0 1.5049788970600275e-08
1 O 0 1.2335159560450393e-09
% O 0 1.7282317243960676e-10
) O 0 1.5458349877928157e-11
by O 0 3.949408161618706e-11
age O 0 2.8471682789188435e-09
50 O 0 1.1624596424342215e-10
years O 0 1.8532203549526116e-10
and O 0 1.8820274505504386e-10
27 O 0 2.3469266530184996e-09
% O 0 3.784550103858031e-11
( O 0 3.139202092716786e-11
95 O 0 3.3711406999259452e-09
% O 0 7.853815930936037e-10
CI O 0 1.7792076789646671e-07
0 O 0 1.670746541115875e-09
% O 0 1.5484628024253766e-09
- O 0 7.194245199571014e-08
47 O 0 2.37821424775575e-08
% O 0 4.798286767915272e-10
) O 0 9.244067317171201e-11
by O 0 5.871677033475464e-10
age O 0 7.388884171177779e-08
70 O 0 1.172432018137215e-08
years O 0 1.2313586594814296e-08
. O 0 2.7211756403744403e-08

The O 0 1.444900163960483e-07
lifetime O 0 5.106863341097778e-07
risk O 0 1.186747795145493e-06
of O 0 1.2053329889738507e-08
breast B-Disease 0 0.3874737322330475
cancer I-Disease 0 6.2411213548330124e-06
appears O 0 2.057968728763626e-08
similar O 0 1.3479065641419652e-09
to O 0 4.2172162983966643e-10
the O 0 8.720650868099256e-10
risk O 0 1.4032441875144741e-08
in O 0 1.5153504007159313e-09
BRCA1 O 0 1.384895256251184e-07
carriers O 0 5.374385025902484e-08
, O 0 1.2174556918154167e-09
but O 0 3.91382259934403e-09
there O 0 4.271780706943673e-10
was O 0 9.690111824056657e-09
some O 0 5.94166937872842e-11
suggestion O 0 1.0544604078788211e-09
of O 0 8.565948644845278e-11
a O 0 6.0244902400086175e-09
lower O 0 0.00020715930440928787
risk O 0 5.589819451756739e-08
in O 0 5.414757531241321e-09
BRCA2 O 0 1.1654088893919834e-06
carriers O 0 2.407162185136258e-07
< O 0 3.9121747619219605e-08
50 O 0 1.7530962237444214e-09
years O 0 7.887022146491063e-10
of O 0 2.6513113926540655e-10
age O 0 2.772623908242622e-08
. O 0 2.2015074208070473e-08

Eye B-Disease 1 0.9997449517250061
movement I-Disease 0 0.00016701244749128819
abnormalities I-Disease 1 0.7468734979629517
correlate O 0 1.6758575611675042e-06
with O 0 4.385600504974718e-08
genotype O 0 0.0010068293195217848
in O 0 7.537019428127678e-06
autosomal O 1 0.9840534329414368
dominant O 0 0.39939042925834656
cerebellar B-Disease 1 0.9508909583091736
ataxia I-Disease 1 0.9999799728393555
type I-Disease 1 0.9999871253967285
I I-Disease 1 0.9997619986534119
. O 0 4.2269809341632936e-07

We O 0 1.2251549605934997e-06
compared O 0 3.5758748140324315e-07
horizontal O 0 8.214679837692529e-06
eye O 1 0.8042891025543213
movements O 0 2.01036218641093e-05
( O 0 1.760985846033236e-08
visually O 0 5.611879672073883e-08
guided O 0 2.3006745664133632e-07
saccades O 0 1.3053739166934974e-05
, O 0 4.509785433981506e-09
antisaccades O 0 5.839439154442516e-07
, O 0 6.094303950376911e-10
and O 0 1.1964133017627887e-09
smooth O 0 1.3949981614302942e-08
pursuit O 0 1.509008740185891e-08
) O 0 2.656707631665256e-10
in O 0 6.773228089507199e-10
control O 0 2.5165416417394226e-08
subjects O 0 5.0953580910118035e-08
( O 0 1.2532110904572846e-09
n O 0 2.660716624802717e-08
= O 0 3.563421202557038e-08
14 O 0 8.620537172987497e-09
) O 0 1.6656293011507728e-10
and O 0 2.7308035832618316e-09
patients O 0 8.280901298007848e-09
with O 0 4.154010468937486e-11
three O 0 4.5604112153263543e-10
forms O 0 5.507480693722755e-09
of O 0 1.443717767557473e-08
autosomal O 0 0.002326817251741886
dominant O 0 0.00017386628314852715
cerebellar B-Disease 0 0.00030907269683666527
ataxias I-Disease 0 0.07865166664123535
type I-Disease 1 0.9441877603530884
I I-Disease 1 0.9697335362434387
spinocerebellar B-Disease 0 0.0020429184660315514
ataxias I-Disease 0 1.383328162773978e-05
1 I-Disease 0 3.565087070001027e-08
and I-Disease 0 2.7022957205247167e-09
2 I-Disease 0 2.737551962894713e-09
( O 0 1.3632230899673914e-09
SCA1 B-Disease 0 8.684819476911798e-07
, O 0 4.1186448695995637e-10
n O 0 9.669359535280364e-09
= O 0 1.6795338453334807e-08
11 O 0 9.02520280732233e-09
; O 0 7.160671500194837e-10
SCA2 B-Disease 0 2.969829210996977e-06
, O 0 1.2885436051490728e-09
n O 0 4.546242138303569e-08
= O 0 3.143017224260802e-08
10 O 0 4.259554486907291e-09
) O 0 4.74590478027892e-10
and O 0 5.6449227514576705e-08
SCA3 B-Disease 1 1.0
/ O 0 5.8911169617203996e-05
Machado B-Disease 0 2.4085450149868848e-06
- I-Disease 0 2.552835940150544e-05
Joseph I-Disease 0 8.157749107340351e-05
disease I-Disease 0 0.030052179470658302
( O 0 1.4139821757908067e-07
MJD B-Disease 1 0.9999997615814209
) O 0 1.67336799972162e-09
( O 0 1.0684805262783925e-09
n O 0 5.699623173427426e-08
= O 0 1.0903912084359035e-07
16 O 0 6.91961474785785e-08
) O 0 4.709261869351167e-09
. O 0 2.0714685078360162e-08

In O 0 7.7970588563403e-07
SCA1 B-Disease 0 2.8671765903709456e-05
, O 0 6.340812763738768e-09
saccade O 0 6.712415370202507e-07
amplitude O 0 2.2383694897598616e-08
was O 0 1.928741433232517e-08
significantly O 0 1.014705652835346e-08
increased O 0 2.1137986916386353e-09
, O 0 2.0523494015378674e-10
resulting O 0 1.0384629822723923e-09
in O 0 1.5273265319137863e-08
hypermetria B-Disease 0 8.742817954043858e-06
. O 0 5.225072996495328e-08

The O 0 1.274366212555833e-07
smooth O 0 2.913855610131577e-07
pursuit O 0 1.7658031481460057e-07
gain O 0 1.4190887895892956e-06
was O 0 7.175442533480236e-07
decreased O 0 8.114201932585274e-07
. O 0 4.3074575017953975e-08

In O 0 6.925120032974519e-07
SCA2 B-Disease 0 1.4719865248480346e-05
, O 0 5.894976062847945e-09
saccade O 0 1.1784762818933814e-06
velocity O 0 4.329078251430474e-07
was O 0 8.469982049064129e-07
markedly O 0 5.093597792438231e-06
decreased O 0 1.3101554259264958e-06
. O 0 1.1006149946979349e-07

The O 0 8.643277737974131e-08
percentage O 0 1.5748648252156272e-07
of O 0 6.939937513550376e-10
errors O 0 1.7116285278007126e-07
in O 0 7.043933436534644e-09
antisaccades O 0 1.8875098248827271e-06
was O 0 2.41016593349741e-08
greatly O 0 1.5649863627231753e-09
increased O 0 1.4589139896159509e-09
and O 0 1.0542774431243629e-09
was O 0 5.884035036984869e-09
significantly O 0 1.4713832374724234e-09
correlated O 0 5.132456681877784e-10
with O 0 3.9113279282076974e-10
age O 0 1.0395500282811554e-07
at O 0 3.452825296790252e-07
disease O 0 4.720641300082207e-06
onset O 0 5.684906227543252e-06
. O 0 1.206490338745425e-07

In O 0 6.730248003350425e-08
addition O 0 2.879696925361941e-09
, O 0 2.734648896218772e-10
a O 0 3.0103178283447107e-10
correlation O 0 7.489209252753426e-09
between O 0 3.208480148231274e-09
smooth O 0 4.825347588166551e-08
pursuit O 0 5.97681122371796e-08
gain O 0 4.855991164731677e-07
and O 0 1.1950630485202396e-09
the O 0 6.754518472318338e-11
number O 0 9.252393295966499e-11
of O 0 2.3966495454885717e-10
trinucleotide O 0 8.921333574107848e-07
repeats O 0 3.8547858594029094e-07
was O 0 4.4827351075582555e-07
found O 0 3.991672414827008e-08
. O 0 1.9481520396880114e-08

In O 0 1.684246126387734e-05
SCA3 B-Disease 1 0.9999998807907104
, O 0 1.762730761356579e-07
gaze B-Disease 0 4.0026108763413504e-05
- I-Disease 0 1.3152746760169975e-05
evoked I-Disease 0 8.454430258098e-07
nystagmus I-Disease 0 6.914416189829353e-06
was O 0 9.699028424847711e-08
often O 0 7.462014339765233e-10
present O 0 1.1039837100046412e-10
as O 0 7.174588700920026e-10
was O 0 2.4409169796513197e-08
saccade O 0 3.9471106560995395e-07
hypometria O 0 7.539878197349026e-07
and O 0 3.824099703564343e-09
smooth O 0 2.1445947240295027e-08
pursuit O 0 3.2433131735842835e-08
gain O 0 5.723741764995793e-07
was O 0 9.199647479363193e-07
markedly O 0 1.1759581184378476e-06
decreased O 0 4.740110739476222e-07
. O 0 3.719853225447878e-08

Three O 0 1.3413460919764475e-07
major O 0 3.9667252593744706e-08
criteria O 0 3.2792105031376195e-08
, O 0 4.5744891208343574e-10
saccade O 0 2.0002184442091675e-07
amplitude O 0 1.4019065908144057e-08
, O 0 8.169231957566581e-10
saccade O 0 1.9917098370569875e-07
velocity O 0 2.5839655748427504e-08
, O 0 5.095469601812397e-10
and O 0 3.38663208587775e-10
presence O 0 8.496909287281085e-10
of O 0 6.272222741188216e-10
gaze B-Disease 0 4.193276254227385e-05
- I-Disease 0 8.47860883368412e-06
evoked I-Disease 0 3.21692652960337e-07
nystagmus I-Disease 0 8.492978054164269e-07
, O 0 4.871831826847028e-10
permitted O 0 9.468632544695765e-10
the O 0 5.628199017948532e-10
correct O 0 4.4251848407839134e-08
assignment O 0 3.7143426112606903e-09
of O 0 1.5198675651362237e-11
90 O 0 3.376937340870967e-10
% O 0 2.6816932355289147e-11
of O 0 9.199105019397358e-12
the O 0 5.186265306100779e-10
SCA1 B-Disease 0 3.742491401226289e-07
, O 0 1.2803749727119396e-10
90 O 0 1.6378307043929397e-10
% O 0 1.720153880446773e-11
of O 0 6.248097091793303e-12
the O 0 3.4464456288851864e-10
SCA2 B-Disease 0 1.9092258298769593e-06
, O 0 1.8434655191246208e-10
and O 0 2.396174370034032e-10
93 O 0 2.3619886047043792e-09
% O 0 4.3161439700067916e-11
of O 0 1.144384413620525e-11
the O 0 1.2836668394911044e-09
patients O 0 4.004292719628211e-08
with O 0 2.7983422246080636e-09
SCA3 B-Disease 1 1.0
to O 0 1.999103105276845e-09
their O 0 6.270153285470315e-10
genetically O 0 5.070546205132587e-09
confirmed O 0 7.353735043125198e-08
patient O 0 6.414690290057479e-08
group O 0 2.477761107400056e-09
and O 0 6.454620726792371e-10
, O 0 1.1273565414526843e-10
therefore O 0 6.305989619370678e-10
, O 0 6.896549997748025e-10
may O 0 4.431502631518924e-08
help O 0 1.1163742819064737e-08
orient O 0 1.87366058526095e-05
diagnoses O 0 1.6742691514082253e-05
of O 0 1.1254879250799377e-09
SCA1 B-Disease 0 2.9897269087086897e-06
, O 0 2.184928238335715e-09
SCA2 B-Disease 0 6.020862883815425e-07
, O 0 7.128483914264905e-10
and O 0 1.5986534762646443e-08
SCA3 B-Disease 1 1.0
at O 0 9.453410854121103e-08
early O 0 6.787990969314706e-08
clinical O 0 6.405810992760053e-09
stages O 0 4.2757366536250174e-09
of O 0 1.445317199255669e-10
the O 0 1.3284534361446276e-08
diseases O 0 3.533322114890325e-06
. O 0 1.0293647711989706e-08
. O 0 4.264376940454895e-08

Genetic O 0 1.7820224456954747e-05
basis O 0 3.335759402034455e-07
and O 0 4.5008508919863743e-08
molecular O 0 2.836116550497536e-07
mechanism O 0 8.19786964711966e-06
for O 0 2.3644031898584217e-05
idiopathic B-Disease 1 1.0
ventricular I-Disease 1 1.0
fibrillation I-Disease 1 1.0
. O 0 3.7601646909024566e-05

Ventricular B-Disease 1 0.9999858140945435
fibrillation I-Disease 1 0.9999899864196777
causes O 0 8.040137799980585e-06
more O 0 7.519367350994344e-09
than O 0 1.9894452751856306e-09
300 O 0 1.6888099807488288e-09
, O 0 3.2893240908826726e-10
000 O 0 2.398704124217943e-09
sudden O 0 3.579020102506547e-08
deaths O 0 7.653529365825307e-09
each O 0 1.2412210148582403e-10
year O 0 6.9036478755890585e-09
in O 0 1.9158346020731187e-09
the O 0 9.117817612036561e-10
USA O 0 2.6999640567737515e-07
alone O 0 2.2297838597751252e-07
. O 0 2.2513818365155203e-08

In O 0 6.55508429758811e-08
approximately O 0 8.333219447820284e-09
5 O 0 1.4837080009044712e-08
- O 0 7.903471441750298e-07
12 O 0 5.903910693660919e-09
% O 0 6.708041760949968e-11
of O 0 7.5772608673641e-12
these O 0 9.820552010486594e-11
cases O 0 6.51253273531438e-10
, O 0 2.339671512086028e-10
there O 0 1.070475597053644e-09
are O 0 4.2470266192751183e-10
no O 0 1.293612150732315e-08
demonstrable O 0 5.223931293585338e-05
cardiac O 0 8.622425957582891e-05
or O 0 1.9765306547014916e-07
non O 0 0.001336781308054924
- O 1 0.9923816323280334
cardiac O 0 0.006758612114936113
causes O 0 8.302172282981246e-09
to O 0 4.900013172992601e-10
account O 0 7.792206879742025e-10
for O 0 6.081343068009559e-11
the O 0 1.7530783769093006e-10
episode O 0 8.879299073782931e-09
, O 0 9.596499289665772e-11
which O 0 1.5344789328075592e-10
is O 0 1.2947956595787957e-10
therefore O 0 1.4545240567542805e-09
classified O 0 1.2893019629700575e-07
as O 0 6.488471262855455e-05
idiopathic B-Disease 1 1.0
ventricular I-Disease 1 1.0
fibrillation I-Disease 1 1.0
( O 0 4.209760300000198e-05
IVF B-Disease 1 0.9999998807907104
) O 0 1.7014373554502527e-07
. O 0 1.0456949439685559e-07

A O 0 4.584460384648992e-07
distinct O 0 6.683364972559502e-08
group O 0 4.9250825640001494e-08
of O 0 5.186693297076772e-09
IVF B-Disease 1 1.0
patients O 0 6.452978414017707e-05
has O 0 2.0510746434609928e-09
been O 0 1.2688762263124431e-09
found O 0 2.2632236362785108e-10
to O 0 5.322107685112876e-11
present O 0 5.725448240512243e-11
with O 0 1.5162199273888177e-10
a O 0 1.5013148058073966e-08
characteristic O 0 3.981939755703934e-07
electrocardiographic O 0 6.759998359484598e-05
pattern O 0 1.0076189028040972e-05
. O 0 4.4109478380960354e-07

Because O 0 1.4182836594045511e-07
of O 0 4.807612641322123e-10
the O 0 1.8718460115252356e-10
small O 0 3.3243735542143327e-10
size O 0 6.998571167038392e-10
of O 0 2.9818123664648866e-11
most O 0 9.706829784406068e-10
pedigrees O 0 1.6685633852375759e-07
and O 0 5.96762472770962e-10
the O 0 1.1740807215332438e-09
high O 0 7.063497378112515e-07
incidence O 0 8.767656254349276e-07
of O 0 2.9582722937959716e-09
sudden B-Disease 0 3.4153833894379204e-06
death I-Disease 0 9.021884039839279e-08
, O 0 4.587560609170538e-10
however O 0 8.128416273400774e-10
, O 0 6.839224325760895e-11
molecular O 0 1.2337935118011956e-09
genetic O 0 1.361903478880322e-08
studies O 0 1.1145552036850859e-08
of O 0 2.6914832584878923e-09
IVF B-Disease 1 1.0
have O 0 2.356451176410701e-07
not O 0 1.2566489182574969e-08
yet O 0 9.440181969466721e-09
been O 0 1.544369609973728e-08
done O 0 3.529155279125007e-08
. O 0 1.246945657840115e-08

Because O 0 0.0001963334798347205
IVF B-Disease 1 1.0
causes O 0 0.0003728363080881536
cardiac O 1 0.9826483726501465
rhythm O 0 0.1260639876127243
disturbance O 0 4.404417268233374e-06
, O 0 2.6846234124633384e-09
we O 0 1.6687782267155171e-09
investigated O 0 7.29196969473378e-09
whether O 0 5.873360464647703e-09
malfunction O 0 2.2198803435458103e-06
of O 0 1.5505781381097705e-10
ion O 0 1.278699546247708e-08
channels O 0 4.628637384485046e-07
could O 0 4.3475911297718994e-06
cause O 0 5.4138823202265485e-08
the O 0 2.1023245366791343e-08
disorder O 0 1.5780219086991565e-07
by O 0 1.580922337485191e-10
studying O 0 5.5710192015112625e-09
mutations O 0 1.8379799016088327e-08
in O 0 2.2206527727774983e-09
the O 0 4.531030217691523e-09
cardiac O 0 1.4909383025951684e-06
sodium O 0 2.132263290377523e-07
channel O 0 2.6281645659764763e-06
gene O 0 3.5349532936379546e-06
SCN5A O 0 3.292356268502772e-05
. O 0 2.086163561898502e-07

We O 0 3.978011022809369e-07
have O 0 5.90307758230324e-09
now O 0 2.50502774079564e-09
identified O 0 4.645075879494698e-09
a O 0 4.588105451119873e-09
missense O 0 4.6243580982263666e-06
mutation O 0 1.6306574934787932e-07
, O 0 1.6118888446214896e-09
a O 0 7.476663732575162e-09
splice O 0 0.0002615202683955431
- O 0 1.9986668121418916e-05
donor O 0 3.367261456332926e-07
mutation O 0 6.575764928129502e-07
, O 0 5.431016969481561e-09
and O 0 3.0727151933973573e-09
a O 0 2.579784741385538e-08
frameshift O 0 0.00015085050836205482
mutation O 0 1.0294161967294713e-07
in O 0 5.514880996315696e-09
the O 0 8.044558907904786e-10
coding O 0 5.7735107361622795e-08
region O 0 3.897129285945766e-09
of O 0 7.692483872112632e-10
SCN5A O 0 3.779257895075716e-06
in O 0 2.576170743395778e-08
three O 0 1.4801317149704118e-07
IVF B-Disease 1 0.9999997615814209
families O 0 5.1323546301773604e-08
. O 0 3.8480273190089065e-08

We O 0 1.325541916230577e-07
show O 0 1.798456850110597e-08
that O 0 1.0349350543226166e-10
sodium O 0 5.524174451210229e-10
channels O 0 3.888649846572889e-09
with O 0 9.258731281658328e-11
the O 0 8.112308602648e-10
missense O 0 1.235814806932467e-06
mutation O 0 1.106002329720468e-07
recover O 0 8.706762741894636e-07
from O 0 2.565499368500923e-09
inactivation O 0 1.8942884594252973e-08
more O 0 7.563633747098564e-11
rapidly O 0 8.015136887529195e-10
than O 0 9.725931171544744e-11
normal O 0 7.226695908357783e-10
and O 0 3.7012712339468123e-10
that O 0 1.3473147597586888e-10
the O 0 1.7154245801620505e-09
frameshift O 0 5.686906661139801e-05
mutation O 0 4.996089941755599e-08
causes O 0 1.000882710044948e-09
the O 0 2.8619598357870757e-10
sodium O 0 2.030522416873737e-09
channel O 0 3.079511046166772e-08
to O 0 6.842267863405027e-10
be O 0 3.3219031969622392e-09
non O 0 8.910945581419583e-08
- O 0 4.015796832845808e-07
functional O 0 1.1820156942121685e-07
. O 0 6.718922662685145e-08

Our O 0 1.9902610404187726e-07
results O 0 5.7985179324759883e-08
indicate O 0 2.494672912689566e-08
that O 0 1.0667029481936652e-09
mutations O 0 3.754130162292313e-08
in O 0 1.0541292283505754e-08
cardiac O 0 1.436778120478266e-06
ion O 0 1.6000284119854769e-07
- O 0 1.0552716958045494e-06
channel O 0 1.5891870930317964e-07
genes O 0 1.7151180031760305e-08
contribute O 0 1.1939057520393703e-09
to O 0 6.327701140840247e-10
the O 0 8.479666413485631e-10
risk O 0 4.2439114444903225e-09
of O 0 3.447004626178085e-10
developing O 0 8.742826906882328e-08
IVF B-Disease 1 0.9999997615814209
. O 0 2.7565782545480033e-08
. O 0 2.7756930975897376e-08

Molecular O 0 7.015141818556003e-06
heterogeneity O 0 5.799131940875668e-06
in O 0 3.304082554222987e-07
mucopolysaccharidosis B-Disease 0 4.650490154745057e-05
IVA I-Disease 0 7.256755634443834e-05
in O 0 6.089103976592014e-08
Australia O 0 3.566066197890905e-08
and O 0 6.965810150916241e-10
Northern O 0 3.3082074857304633e-09
Ireland O 0 1.5545380449566437e-07
: O 0 2.0843989034791122e-10
nine O 0 5.325258012334189e-10
novel O 0 1.0694898300300792e-09
mutations O 0 6.0225828768523115e-09
including O 0 6.008031849802364e-10
T312S O 0 1.805610025940041e-07
, O 0 3.384797997441069e-10
a O 0 1.236986402197715e-09
common O 0 2.8106200034017093e-08
allele O 0 3.626088300734409e-07
that O 0 1.0516671089533247e-08
confers O 0 1.3160808975953842e-07
a O 0 2.2233359686651966e-06
mild O 1 0.9026052951812744
phenotype O 0 0.0003053058171644807
. O 0 4.2955571188940667e-07

Mucopolysaccharidosis B-Disease 0 0.2499469816684723
IVA I-Disease 1 0.9982190728187561
( O 0 0.00027132683317177
MPS B-Disease 1 0.9999997615814209
IVA I-Disease 1 0.999998927116394
) O 0 3.9785458483265757e-08
is O 0 5.42962919070078e-09
an O 0 2.027918633018544e-08
autosomal B-Disease 1 0.9994702935218811
recessive I-Disease 1 0.9999988079071045
lysosomal I-Disease 1 0.9999784231185913
storage I-Disease 1 0.999972939491272
disorder I-Disease 1 0.9999915361404419
caused O 0 2.7797307211585576e-06
by O 0 1.2005879845844447e-08
a O 0 2.168759237974882e-05
genetic B-Disease 1 1.0
defect I-Disease 1 0.9999998807907104
in O 0 1.0543869422008356e-07
N O 0 2.6848741981666535e-05
- O 0 3.437355917412788e-05
acetylgalactosamine O 0 0.0259223785251379
- O 0 4.759451621794142e-05
6 O 0 2.1907565042056376e-06
- O 0 3.7555128074018285e-05
sulfate O 0 3.5588072933023795e-06
sulfatase O 0 1.8135577192879282e-05
( O 0 3.20771711415091e-08
GALNS O 0 2.901210564232315e-06
) O 0 1.578365882437538e-08
. O 0 4.125898200868505e-08

Previous O 0 1.463226908526849e-06
studies O 0 6.128919238790331e-08
of O 0 6.488120041225898e-10
patients O 0 1.6805143943088297e-08
from O 0 6.596593826735386e-10
a O 0 1.3706563661841642e-09
British O 0 3.420899884076789e-05
- O 0 5.212777523411205e-06
Irish O 0 2.694289058524646e-08
population O 0 1.1615110262486184e-10
showed O 0 1.54689896447735e-08
that O 0 1.344019062710089e-10
the O 0 3.7311262413020074e-10
I113F O 0 1.359338739348459e-07
mutation O 0 7.120578793262666e-09
is O 0 2.8636143456495233e-10
the O 0 1.0444436288059578e-10
most O 0 6.603404489879949e-10
common O 0 3.3661673448648344e-09
single O 0 4.250158980312335e-08
mutation O 0 3.6519011814561964e-07
among O 0 3.226272724532464e-07
MPS B-Disease 1 1.0
IVA I-Disease 1 1.0
patients O 0 0.00017428207502234727
and O 0 1.2478569288987273e-08
produces O 0 3.432377582157642e-08
a O 0 3.2535433547309367e-07
severe O 0 0.2641715109348297
clinical O 0 8.581215661251917e-05
phenotype O 0 0.00013404306082520634
. O 0 7.415872005367419e-07

We O 0 6.265813112804608e-07
studied O 0 1.2234602309035836e-07
mutations O 0 4.6072781145767294e-08
in O 0 2.7870497021353913e-09
the O 0 1.0214705747912944e-09
GALNS O 0 3.7926784557384963e-07
gene O 0 2.8323556833242947e-08
from O 0 5.536085367907617e-09
23 O 0 4.4278440469724956e-08
additional O 0 7.534344348414379e-08
MPS B-Disease 1 1.0
IVA I-Disease 1 1.0
patients O 0 2.8780827051377855e-05
( O 0 1.138833027880537e-09
15 O 0 5.204160991034712e-10
from O 0 1.9616179514070353e-10
Australia O 0 1.2942457106035476e-09
, O 0 5.6425780714519647e-11
8 O 0 1.4809102555357612e-10
from O 0 7.57936075013177e-11
Northern O 0 2.7209354769297533e-09
Ireland O 0 3.8400946777983336e-07
) O 0 1.0581852755153776e-10
, O 0 2.3184230577011355e-11
with O 0 6.832179787197301e-12
various O 0 3.9072492463709807e-10
clinical O 0 2.6064888061227975e-06
phenotypes O 0 1.9111112123937346e-06
( O 0 9.625293273529678e-08
severe O 0 0.0014470841269940138
, O 0 7.483911268479915e-09
16 O 0 2.2521247089457574e-08
cases O 0 8.08858136025492e-09
; O 0 7.072915031436366e-10
intermediate O 0 2.425509038062046e-08
, O 0 1.0236197445223638e-09
4 O 0 7.43973460615166e-09
cases O 0 4.324563818158822e-08
; O 0 6.892953763326659e-08
mild O 0 0.17624208331108093
, O 0 1.4002551118608153e-08
3 O 0 1.1041870529027165e-08
cases O 0 1.448326436559455e-08
) O 0 4.574919110211795e-09
. O 0 3.9506044657855455e-08

We O 0 4.3566041085796314e-07
found O 0 8.317181610095759e-09
two O 0 3.545837790053241e-10
common O 0 9.574254722366504e-10
mutations O 0 3.410696391981105e-09
that O 0 1.360892093460464e-10
together O 0 7.874931956530773e-11
accounted O 0 7.060154683102837e-09
for O 0 7.317026151643091e-11
32 O 0 1.1826054580055256e-09
% O 0 3.5488466332278534e-11
of O 0 2.2943294833432937e-11
the O 0 1.1665337584787494e-09
44 O 0 8.12676237416099e-09
unrelated O 0 2.180212810287685e-08
alleles O 0 2.4017499100636996e-08
in O 0 3.6812025427934714e-08
these O 0 2.0807702227898517e-08
patients O 0 6.324171408778057e-07
. O 0 3.8471686281127404e-08

One O 0 2.93931492478805e-07
is O 0 4.033911427114845e-09
the O 0 3.0657019145508002e-09
T312S O 0 6.106620844548161e-07
mutation O 0 5.57595498662522e-08
, O 0 6.52792875310837e-10
a O 0 1.1808856115180788e-09
novel O 0 2.6115488438449574e-08
mutation O 0 7.468485563322247e-08
found O 0 5.769258848431491e-09
exclusively O 0 1.1545413514113534e-08
in O 0 2.2137655264486966e-07
milder O 0 0.00042386737186461687
patients O 0 2.0824651073780842e-05
. O 0 1.6897428167794715e-07

The O 0 3.4846877383643005e-08
other O 0 1.3567538204029006e-09
is O 0 2.5303042994195835e-10
the O 0 2.372616270118755e-10
previously O 0 5.329741981086045e-09
described O 0 3.280142379935569e-08
I113F O 0 9.573076198421404e-08
that O 0 7.834919379945404e-10
produces O 0 7.371342203299491e-09
a O 0 1.5269732500655664e-07
severe O 0 0.021395986899733543
phenotype O 0 0.0001292574597755447
. O 0 2.5683900162221107e-07

The O 0 2.1250930615224206e-07
I113F O 0 1.135125103246537e-06
and O 0 6.626496684702943e-09
T312S O 0 2.1032955999089609e-07
mutations O 0 4.4872820126329316e-08
accounted O 0 1.9640122417285966e-08
for O 0 1.7274341679307526e-10
8 O 0 1.7827661569214115e-09
( O 0 6.615506475959876e-10
18 O 0 1.0543075301683302e-09
% O 0 3.570982051726013e-11
) O 0 3.137047566159623e-11
and O 0 1.0637426495208047e-09
6 O 0 6.199719404520465e-09
( O 0 1.154206175080219e-09
14 O 0 4.3559280626936925e-09
% O 0 1.0242598436072115e-10
) O 0 3.046725025046548e-11
of O 0 9.087255947726192e-11
44 O 0 8.094908743316864e-09
unrelated O 0 4.844030243589259e-08
alleles O 0 9.24667205026708e-08
, O 0 9.532241662668639e-09
respectively O 0 1.8676935553685325e-07
. O 0 1.0478372303168726e-07

The O 0 1.2191368625735777e-07
relatively O 0 1.4125656377927953e-07
high O 0 1.8304464788343466e-07
residual O 0 7.900321179477032e-07
GALNS O 0 1.0281803952238988e-05
activity O 0 3.323882822314772e-07
seen O 0 3.7743841829751545e-08
when O 0 1.5745224013485881e-09
the O 0 7.262013212994134e-10
T312S O 0 3.643885193582719e-08
mutant O 0 2.0641051534653343e-08
cDNA O 0 6.824170384334138e-08
is O 0 1.8149346470153205e-09
overexpressed O 0 1.5304620148981485e-07
in O 0 3.492244937675082e-09
mutant O 0 5.522135992919175e-08
cells O 0 1.4270285397799398e-08
provides O 0 1.983194275467781e-09
an O 0 4.3929462845149203e-10
explanation O 0 3.4525728942469414e-09
for O 0 7.78212161378633e-10
the O 0 1.3517640340410253e-08
mild O 0 0.011546481400728226
phenotype O 0 2.485453114786651e-05
in O 0 1.0050251830762136e-07
patients O 0 1.271586143047898e-07
with O 0 4.5303275020280864e-10
this O 0 1.0466563615807445e-08
mutation O 0 5.753217351411877e-07
. O 0 6.149997489046655e-08

The O 0 1.6502749389246674e-08
distribution O 0 2.529543241536203e-09
and O 0 6.190334356226401e-10
relative O 0 1.0558550700423552e-09
frequencies O 0 6.184979639556332e-09
of O 0 1.0616139217711762e-10
the O 0 1.4151396721118203e-09
I113F O 0 4.6598177760870385e-08
and O 0 2.475243565669416e-09
T312S O 0 2.2200355331847277e-08
mutations O 0 4.6905528350293935e-09
in O 0 3.720608543478221e-10
Australia O 0 6.625116011349519e-10
corresponded O 0 1.3723637504181596e-10
to O 0 3.333566062080351e-11
those O 0 3.7525281493255846e-11
observed O 0 4.9952347813686515e-11
in O 0 2.2448833070232155e-10
Northern O 0 1.6541062963781883e-09
Ireland O 0 2.2306133473648515e-07
and O 0 3.7944106190401783e-10
are O 0 6.7044056938081464e-12
unique O 0 5.929202007842749e-12
to O 0 5.010196077459561e-11
these O 0 1.563886693756178e-11
two O 0 4.595265140627802e-11
populations O 0 3.051150304633765e-11
, O 0 7.358031545168231e-11
suggesting O 0 2.0902124475696837e-09
that O 0 1.4576227724827362e-10
both O 0 1.2765367929379323e-10
mutations O 0 1.8106610655266309e-09
were O 0 1.3983520119609238e-08
probably O 0 8.353780778236342e-09
introduced O 0 4.686812604681734e-10
to O 0 1.296154711338815e-10
Australia O 0 3.8359174170388144e-10
by O 0 3.8039158628544456e-11
Irish O 0 1.5719657797674813e-09
migrants O 0 1.705604435464636e-09
during O 0 5.559934734833405e-10
the O 0 1.4430170947044019e-10
19th O 0 2.9274524138145352e-08
century O 0 2.1645675474246673e-07
. O 0 4.4354770523113984e-08

Haplotype O 0 0.00016243393474724144
analysis O 0 4.936509299113823e-07
using O 0 9.842224102385444e-08
6 O 0 1.1058398996510732e-07
RFLPs O 0 9.480242368908876e-08
provides O 0 7.431448234562765e-10
additional O 0 6.263161100861225e-10
data O 0 5.7569691236381004e-09
that O 0 4.429309696796224e-10
the O 0 9.63277790866357e-10
I113F O 0 2.0744485595969309e-07
mutation O 0 1.8105687615843635e-08
originated O 0 5.3994963167269816e-08
from O 0 2.7156159543295644e-09
a O 0 3.171463314188827e-09
common O 0 1.2462490595055442e-08
ancestor O 0 1.2561508810904343e-07
. O 0 1.7105840299791453e-07

The O 0 5.3673574029744486e-08
other O 0 5.1200124140393655e-09
9 O 0 1.0878128620106509e-08
novel O 0 4.3101264779465964e-09
mutations O 0 1.985439546103862e-08
identified O 0 5.45447864652715e-09
in O 0 8.636018011820568e-10
these O 0 5.466870289794201e-10
23 O 0 2.453178105099596e-08
patients O 0 3.1086861973506075e-09
were O 0 1.329466647881361e-09
each O 0 1.111517648755278e-11
limited O 0 1.4339436582577747e-10
to O 0 3.651290936268481e-10
a O 0 6.553819265064931e-09
single O 0 5.425118843049859e-08
family O 0 2.983842506409928e-08
. O 0 4.110189166794953e-08

These O 0 3.843200957476256e-08
data O 0 7.109545840933151e-09
provide O 0 4.076262938301767e-10
further O 0 4.117505503220542e-10
evidence O 0 3.7079700421216444e-10
for O 0 6.235123528597342e-11
extensive O 0 1.9549404317587005e-09
allelic O 0 1.9076391311045882e-07
heterogeneity O 0 1.9186190058917418e-07
in O 0 1.5729705182820908e-06
MPS B-Disease 1 0.9999998807907104
IVA I-Disease 1 0.9999878406524658
in O 0 4.348658677599815e-08
British O 0 4.9990081606665626e-05
- O 0 0.0002214157284470275
Irish O 0 2.3240077950958948e-07
patients O 0 9.185829874525098e-09
and O 0 1.0693403801331769e-10
provide O 0 3.484204244563749e-11
evidence O 0 2.7789798240362984e-10
for O 0 6.99588512120819e-11
their O 0 1.8796633693973774e-10
transmission O 0 1.9536406270503903e-08
to O 0 8.350431457415652e-10
Australia O 0 8.352597502536696e-10
by O 0 1.5668344399699663e-10
British O 0 2.223531055278727e-06
- O 0 3.0065172040849575e-07
Irish O 0 3.341336807238804e-08
migrants O 0 8.699556630631378e-09
. O 0 6.990872880585641e-10
. O 0 5.498391519864754e-09

Identification O 0 1.1727180435627815e-06
of O 0 8.548656005302746e-09
constitutional O 0 1.8545560465099697e-07
WT1 O 0 5.7335899327881634e-05
mutations O 0 2.172810354750254e-06
, O 0 5.742274211684162e-09
in O 0 8.210725432888921e-09
patients O 0 9.684922730457401e-08
with O 0 4.7744435072161195e-09
isolated O 0 0.00029116845689713955
diffuse B-Disease 1 0.9997270703315735
mesangial I-Disease 1 1.0
sclerosis I-Disease 1 1.0
, O 0 3.6863529118136285e-08
and O 0 2.086305128656818e-09
analysis O 0 4.899931571600291e-09
of O 0 3.4755061051328084e-09
genotype O 0 0.020237524062395096
/ O 0 0.02719031274318695
phenotype O 0 4.8393758333986625e-06
correlations O 0 6.274896691138565e-07
by O 0 1.3887295757797347e-09
use O 0 3.5677518717136536e-09
of O 0 3.756833732992959e-10
a O 0 1.3812780252919765e-08
computerized O 0 3.8757925722165965e-06
mutation O 0 8.303948106913595e-07
database O 0 2.7177944161849155e-07
. O 0 1.0072128731053454e-07

Constitutional O 0 5.4475794968311675e-06
mutations O 0 2.4645428311487194e-06
of O 0 3.402782056127762e-09
the O 0 3.5513825213939754e-09
WT1 O 0 2.7470132408780046e-06
gene O 0 1.397414166603994e-07
, O 0 9.814022927656652e-10
encoding O 0 6.971436317115831e-09
a O 0 2.167074519832113e-08
zinc O 0 0.0018792320042848587
- O 0 0.00011447715223766863
finger O 0 8.055414946284145e-05
transcription O 0 3.9595295220351545e-07
factor O 0 1.8906428422837962e-08
involved O 0 1.2125596526857407e-08
in O 0 5.7445230794428426e-08
renal O 0 5.27052725374233e-05
and O 0 1.0221589796799435e-08
gonadal O 0 4.852426513934915e-07
development O 0 2.7710578276440856e-09
, O 0 2.0078644302756743e-10
are O 0 7.406087548789131e-11
found O 0 6.132947483195039e-10
in O 0 7.214328578974971e-10
most O 0 2.614502836451038e-09
patients O 0 1.0421025820051e-08
with O 0 6.531220009264871e-09
Denys B-Disease 1 0.9999901056289673
- I-Disease 1 1.0
Drash I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 3.1222089091897942e-06
DDS B-Disease 1 1.0
) O 0 1.9245485205487967e-08
, O 0 4.2393564214648904e-09
or O 0 3.2485313568031415e-06
diffuse B-Disease 1 0.9980079531669617
mesangial I-Disease 1 1.0
sclerosis I-Disease 1 1.0
( O 0 1.0853779713215772e-05
DMS B-Disease 0 0.402002215385437
) O 0 3.2699525309709543e-09
associated O 0 8.46829184553144e-09
with O 0 7.188701189875246e-09
pseudohermaphroditism B-Disease 1 1.0
and O 0 0.0004723699239548296
/ O 0 0.23045623302459717
or O 0 3.366362943779677e-05
Wilms B-Disease 1 0.9548993110656738
tumor I-Disease 0 0.0009593689464963973
( O 0 3.145848950225627e-07
WT B-Disease 1 0.9950475692749023
) O 0 2.627111328479259e-08
. O 0 2.9557469360952382e-08

Most O 0 6.945954851289571e-07
mutations O 0 1.19386659207521e-05
in O 0 1.021227399178315e-05
DDS B-Disease 1 1.0
patients O 0 0.0006211992586031556
lie O 0 4.4219282813173777e-07
in O 0 1.2053720688243175e-08
exon O 0 2.0953314106009202e-07
8 O 0 1.924218295812352e-08
or O 0 8.9066416464334e-09
exon O 0 1.3572778811976605e-07
9 O 0 3.347920696228357e-08
, O 0 8.350717339844493e-10
encoding O 0 6.900807392185015e-08
zinc O 0 5.70535303268116e-05
finger O 0 0.026935189962387085
2 O 0 5.367071054251937e-08
or O 0 2.6070654257637216e-07
zinc O 0 9.309655433753505e-05
finger O 0 0.0024152693804353476
3 O 0 1.22305854333149e-08
, O 0 5.957651039167899e-10
respectively O 0 2.620488936955212e-09
, O 0 9.656927341117338e-11
with O 0 1.0971426545047791e-10
a O 0 4.422940236281647e-08
hot O 0 0.00014692275726702064
spot O 0 0.00016664975555613637
( O 0 7.028419624077742e-09
R394W O 0 6.83165950476905e-08
) O 0 8.261272221865568e-10
in O 0 3.1530551503067272e-09
exon O 0 2.5543201331856835e-07
9 O 0 2.4951921773208596e-07
. O 0 4.7941842495902165e-08

We O 0 2.4625947503409407e-07
analyzed O 0 2.403940335682364e-08
a O 0 8.41383740457502e-10
series O 0 3.836080342267678e-09
of O 0 2.9808586154977945e-10
24 O 0 2.142119939207987e-07
patients O 0 4.2689507040449826e-08
, O 0 3.920776758814526e-10
10 O 0 1.1321408255327015e-09
with O 0 1.0825487173349302e-09
isolated B-Disease 0 0.00015257181075867265
DMS I-Disease 1 0.9999592304229736
( O 0 2.00423535545724e-08
IDMS B-Disease 0 2.905934707086999e-06
) O 0 1.5781123074987136e-09
, O 0 4.1637063241672934e-10
10 O 0 4.02263999887964e-09
with O 0 2.6064284952553862e-08
DDS B-Disease 1 1.0
, O 0 3.357096289846595e-08
and O 0 2.019835321220853e-08
4 O 0 1.6189085627615896e-08
with O 0 7.379560429399135e-08
urogenital B-Disease 1 0.9822613000869751
abnormalities I-Disease 1 0.9999995231628418
and O 0 6.0750726333935745e-06
/ O 0 0.009202550165355206
or O 0 3.7243491533445194e-05
WT B-Disease 1 0.9999781847000122
. O 0 3.878763266129681e-07

We O 0 3.233926236134721e-06
report O 0 4.427996600497863e-07
WT1 O 0 2.5557494154782034e-05
heterozygous O 0 4.313403678679606e-06
mutations O 0 5.575698764914705e-07
in O 0 2.0801671496428753e-08
16 O 0 7.624363718150562e-08
patients O 0 7.209217756098951e-08
, O 0 8.637731641059077e-10
4 O 0 2.0670274381018316e-09
of O 0 3.18351012218443e-10
whom O 0 3.214301003140463e-08
presented O 0 1.2031050822258749e-08
with O 0 2.0172750581082255e-08
IDMS B-Disease 0 0.00023472703469451517
. O 0 2.6390196694592305e-07

One O 0 3.9652354644204024e-07
male O 0 2.2096651264291722e-07
and O 0 5.7925020335858335e-09
two O 0 9.08778563513124e-09
female O 0 1.5451570334334974e-07
IDMS B-Disease 0 0.00027660717023536563
patients O 0 3.4669517390284454e-06
with O 0 4.5295717399085333e-08
WT1 O 0 0.0021813875064253807
mutations O 0 0.0003608376136980951
underwent O 0 0.0002993310918100178
normal O 0 1.9375671399757266e-05
puberty O 0 0.00024820331600494683
. O 0 3.810995679032203e-07

Two O 0 8.011871273083671e-07
mutations O 0 1.7387530988344224e-06
associated O 0 2.8463389867283695e-08
with O 0 1.6783161527200718e-09
IDMS B-Disease 0 6.121843853179598e-06
are O 0 7.613631392011655e-10
different O 0 2.627870421267886e-10
from O 0 1.8988164374178496e-09
those O 0 1.973865515481066e-09
described O 0 1.2423596729149722e-07
in O 0 4.835067102249013e-06
DDS B-Disease 1 1.0
patients O 0 4.792489926330745e-05
. O 0 7.084356923314772e-08

No O 0 6.170504548208555e-06
WT1 O 0 0.00010877174645429477
mutations O 0 2.018179202423198e-06
were O 0 7.389702005866639e-08
detected O 0 8.543704410612918e-08
in O 0 2.383248931536741e-09
the O 0 5.564411154068694e-10
six O 0 4.749429738382105e-09
other O 0 8.441956467208911e-09
IDMS B-Disease 0 6.458050484070554e-05
patients O 0 5.911936113989213e-07
, O 0 6.643007810502866e-10
suggesting O 0 4.986912216509154e-08
genetic O 0 1.5628877747531078e-07
heterogeneity O 0 8.062937695285655e-08
of O 0 3.149208671615611e-09
this O 0 1.0440447795190266e-07
disease O 0 5.888842679269146e-06
. O 0 1.2377994096368639e-07

We O 0 2.162290911655873e-06
analyzed O 0 4.292123321647523e-06
genotype O 0 0.0011609658831730485
/ O 0 0.00018452064250595868
phenotype O 0 5.420233719632961e-06
correlations O 0 1.9282394987385487e-06
, O 0 4.205851666938543e-09
on O 0 1.7328800616667195e-09
the O 0 1.421019135694479e-10
basis O 0 4.1300354802764616e-10
of O 0 3.1776969944274924e-11
the O 0 6.845857769555153e-10
constitution O 0 6.05180461299426e-10
of O 0 1.273822436420602e-10
a O 0 9.254096156041669e-09
WT1 O 0 2.7580408641370013e-06
mutation O 0 3.031235706885127e-08
database O 0 6.5234018187254605e-09
of O 0 2.5840221629103155e-10
84 O 0 5.071187203498084e-08
germ O 0 0.0036354290787130594
- O 0 0.013365820981562138
line O 0 2.331933137611486e-05
mutations O 0 9.335187201031658e-08
, O 0 1.7914539296448595e-10
to O 0 3.169947984660304e-11
compare O 0 6.433014121398628e-10
the O 0 2.6139918354872727e-11
distribution O 0 1.4119332092388248e-10
and O 0 1.3309737756372897e-09
type O 0 2.9231395970441554e-08
of O 0 1.2452806841256603e-10
mutations O 0 1.061250554101889e-08
, O 0 1.521933690185051e-10
according O 0 2.0391065225222604e-10
to O 0 3.613435661797837e-10
the O 0 3.171070073193505e-09
different O 0 8.611058177621089e-08
symptoms O 0 1.8753788026515394e-05
. O 0 1.214043550135102e-07

This O 0 2.3423305961500773e-08
demonstrated O 0 4.635988304357852e-08
( O 0 1.8296997250644154e-09
1 O 0 5.945628989145746e-10
) O 0 4.936718048242916e-11
the O 0 5.3937139476989415e-11
association O 0 7.223374676179617e-10
between O 0 4.2924852561299076e-10
mutations O 0 1.4406479564854635e-08
in O 0 3.842656415287138e-09
exons O 0 1.4335267195519918e-08
8 O 0 1.0752419399295832e-08
and O 0 5.148009130095943e-09
9 O 0 6.702411070591552e-08
and O 0 1.1124402732320959e-07
DMS B-Disease 1 0.6204929351806641
; O 0 7.602747875701255e-10
( O 0 6.345576841759737e-10
2 O 0 1.600239052379493e-09
) O 0 1.7350455794318265e-10
among O 0 4.1556530439024186e-10
patients O 0 1.231804969137329e-08
with O 0 1.0900658153900622e-09
DMS B-Disease 0 0.13785840570926666
, O 0 2.77389611280654e-10
a O 0 2.3230985191080578e-10
higher O 0 3.950301419308744e-09
frequency O 0 7.139073332496082e-09
of O 0 2.0938425993044518e-10
exon O 0 3.820019500722083e-08
8 O 0 1.7921015782462746e-08
mutations O 0 1.771094559899211e-08
among O 0 1.7060988177775016e-09
46 O 0 1.3326713066419416e-08
, O 0 1.8506886023672564e-09
XY O 0 1.3296418728714343e-05
patients O 0 7.988936090441712e-07
with O 0 3.2554900997183722e-09
female O 0 1.0357165081131825e-07
phenotype O 0 2.5802626169024734e-07
than O 0 3.572838691567881e-09
among O 0 1.8201694595987306e-09
46 O 0 3.116346292131311e-08
, O 0 4.9955826142422666e-09
XY O 0 1.695058381301351e-05
patients O 0 1.5221534965803585e-07
with O 0 5.438903216692381e-10
sexual O 0 1.7573922761471295e-08
ambiguity O 0 5.800343316764156e-08
or O 0 4.471859327281891e-08
male O 0 8.22431758251696e-08
phenotype O 0 1.820285433495883e-07
; O 0 1.2680730909764293e-09
and O 0 6.237199645653391e-09
( O 0 1.023697793200995e-09
3 O 0 5.36471145284878e-10
) O 0 3.953568722403489e-11
statistically O 0 2.0107973064398266e-09
significant O 0 5.492927224182154e-10
evidence O 0 4.1977097353651516e-09
that O 0 6.869925739394489e-10
mutations O 0 3.536349879595946e-09
in O 0 1.8794958922541127e-09
exons O 0 8.536224171962203e-09
8 O 0 2.8417752595544243e-09
and O 0 1.8191178563498056e-09
9 O 0 8.791550598630238e-09
preferentially O 0 8.75348504791873e-09
affect O 0 1.4684038873724603e-08
amino O 0 2.8541606855725377e-09
acids O 0 3.038120588438886e-10
with O 0 6.073066355360979e-11
different O 0 7.720878797412567e-11
functions O 0 5.542263314950446e-10
. O 0 1.9570223219744776e-09
. O 0 1.1985242132084295e-08

The O 0 3.577477798444306e-07
185delAG O 0 1.1566854482225608e-05
BRCA1 O 0 1.2104786037525628e-05
mutation O 0 9.072824980194127e-08
originated O 0 7.262809731400921e-08
before O 0 4.480352089331063e-09
the O 0 2.1988909304493376e-10
dispersion O 0 4.005245468619023e-09
of O 0 3.08078146327162e-11
Jews O 0 5.830618765578777e-10
in O 0 2.426144840583788e-10
the O 0 9.567075603955644e-11
diaspora O 0 6.75173972286558e-10
and O 0 4.1560099806048356e-10
is O 0 6.631029059178672e-11
not O 0 4.1181813514867827e-10
limited O 0 2.1185615484142772e-09
to O 0 1.4141393833710936e-08
Ashkenazim O 0 5.777790647698566e-06
. O 0 4.4107249408398275e-08

The O 0 3.149027349991229e-07
185delAG O 0 5.242681254458148e-06
mutation O 0 5.600693384621991e-07
in O 0 1.9019054775526456e-08
BRCA1 O 0 3.996093710156856e-06
is O 0 2.4935202791454003e-09
detected O 0 2.0411442847034778e-07
in O 0 1.8439315851992433e-08
Ashkenazi O 0 3.987050547493709e-07
Jews O 0 3.014157368141923e-09
both O 0 1.2910528202070282e-09
in O 0 1.6895713272901958e-08
familial B-Disease 0 0.03330995887517929
breast I-Disease 1 0.9999978542327881
and I-Disease 1 0.9999997615814209
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 2.7706786198677946e-08
in O 0 1.1586218651160607e-09
the O 0 3.0821994956298226e-10
general O 0 6.046900757894491e-10
population O 0 4.3334769106451176e-10
. O 0 1.4297612871416732e-08

All O 0 2.771842275706149e-07
tested O 0 1.7728777947922936e-06
Ashkenazi O 0 2.74094986707496e-06
mutation O 0 5.4697132156888983e-08
carriers O 0 5.681919645894595e-08
share O 0 2.218198602577104e-08
the O 0 1.238254054847232e-09
same O 0 8.14237033353038e-09
allelic O 0 3.045385028599412e-07
pattern O 0 5.7886722970579285e-06
at O 0 2.0676522183293855e-07
the O 0 2.2575308733507882e-08
BRCA1 O 0 1.3222685993241612e-05
locus O 0 1.942977405633428e-06
. O 0 1.7857593093140167e-07

Our O 0 2.785808419503155e-07
previous O 0 4.7811347769766144e-08
study O 0 1.7527417295326586e-09
showed O 0 8.29671087387851e-09
that O 0 9.504164122375869e-11
this O 0 2.5769150702181776e-10
Ashkenazi O 0 1.826148547934281e-07
mutation O 0 4.791813612570195e-09
also O 0 1.0205025713361238e-09
occurs O 0 1.7568609067541985e-10
in O 0 7.188478146069599e-10
Iraqi O 0 5.146114201437513e-09
Jews O 0 2.030154488963376e-09
with O 0 1.1150452783326159e-10
a O 0 2.031285584180864e-09
similar O 0 1.561448037534774e-08
allelic O 0 2.5829019705270184e-06
pattern O 0 1.0807350008690264e-05
. O 0 5.302772478898987e-07

We O 0 1.3610458893253963e-07
extended O 0 1.1281708012234049e-08
our O 0 4.2405023936709085e-10
analysis O 0 1.7309632893702798e-10
to O 0 7.906085508491145e-11
other O 0 1.2888230760399466e-10
non O 0 6.815117359337819e-08
- O 0 4.997591531719081e-07
Ashkenazi O 0 9.943095591324891e-08
subsets O 0 8.322481370726109e-09
354 O 0 2.7754389009260194e-08
of O 0 7.548789371369935e-11
Moroccan O 0 4.70475711722429e-08
origin O 0 3.6357816757259798e-09
, O 0 5.507131417559208e-10
200 O 0 1.96792981910221e-09
Yemenites O 0 6.327006474293739e-08
and O 0 9.674629986022865e-10
150 O 0 1.4183931806854844e-09
Iranian O 0 1.8769531706652742e-08
Jews O 0 5.998373353577335e-08
. O 0 3.130871562007087e-08

Heteroduplex O 0 3.09661882056389e-05
analysis O 0 1.1424651802371955e-07
complemented O 0 6.069739555414344e-08
by O 0 1.1644195607729557e-09
direct O 0 8.68950689181247e-09
DNA O 0 3.5520006491651657e-08
sequencing O 0 1.939528182504091e-08
of O 0 9.88801485135582e-10
abnormally O 0 1.9116420446607663e-07
migrating O 0 1.4939708137262642e-08
bands O 0 3.683106086782573e-08
were O 0 2.588355663135644e-08
employed O 0 1.0152054841228164e-07
. O 0 4.9678394731245135e-08

Four O 0 3.421409644488449e-08
of O 0 9.158305780410103e-10
Moroccan O 0 4.034359690763267e-08
origin O 0 3.80781806086361e-09
( O 0 2.9272262391799586e-10
1 O 0 1.427517132279732e-10
. O 0 2.407777796586963e-11
1 O 0 2.0471224715379321e-10
% O 0 7.384365341422949e-11
) O 0 4.482057086585556e-11
and O 0 1.8152244984914745e-10
none O 0 2.7592963469658116e-09
of O 0 3.825722724726255e-11
the O 0 6.76287525980257e-10
Yemenites O 0 1.0479510592631414e-07
or O 0 2.156456124779993e-09
Iranians O 0 2.645848162785569e-08
was O 0 8.950852503630813e-09
a O 0 2.905127804986307e-10
carrier O 0 9.674985257390745e-09
of O 0 1.0591585247743396e-10
the O 0 1.8383611299910285e-09
185delAG O 0 5.968518053123262e-07
mutation O 0 3.362364680015162e-07
. O 0 7.542266189375368e-08

BRCA1 O 0 0.004142546094954014
allelic O 0 5.5726228310959414e-05
patterns O 0 1.2488551874412224e-05
were O 0 1.151089676909578e-07
determined O 0 1.6528328927734037e-08
for O 0 1.248105646611819e-10
four O 0 1.2154759143623295e-10
of O 0 8.442298943256432e-12
these O 0 4.87129954429566e-11
individuals O 0 1.5546819040479498e-11
and O 0 1.9150664387623806e-10
for O 0 4.032968750622423e-11
12 O 0 4.925068131100829e-10
additional O 0 8.712836563340431e-10
non O 0 8.239868520831806e-07
- O 0 0.00011446417192928493
Ashkenazi O 0 2.9211553282948444e-06
185delAG O 0 2.3562310502711625e-07
mutation O 0 7.587225780980589e-08
carriers O 0 8.265123483397474e-07
who O 0 4.1250885374211066e-07
had O 1 0.7268441915512085
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
. O 0 1.1685673371175653e-06

Six O 0 2.047876023425488e-06
non O 0 2.7867172320839018e-05
- O 0 0.007784712128341198
Ashkenazi O 0 3.261839992774185e-06
individuals O 0 3.575727491877956e-10
shared O 0 2.3523258341207054e-10
the O 0 2.982138147533675e-10
common O 0 2.680306465663307e-08
Ashkenazi O 0 2.2385574993677437e-05
haplotype O 0 2.1185601326578762e-06
, O 0 2.999784420865126e-09
four O 0 2.1389645610270236e-09
had O 0 6.569127464217672e-08
a O 0 1.7045896916201286e-09
closely O 0 2.32122285837022e-08
related O 0 1.2251533121343527e-07
pattern O 0 4.620342679118039e-06
, O 0 5.843369788038899e-09
and O 0 4.007660425742188e-09
the O 0 4.0402081680213087e-10
rest O 0 5.594445351420063e-09
( O 0 9.062215422517284e-10
n O 0 4.818605958689659e-08
= O 0 6.209378966559598e-08
6 O 0 9.333279038514775e-09
) O 0 4.0774916776342707e-10
displayed O 0 1.0874146028072573e-08
a O 0 4.685190901909664e-08
distinct O 0 2.488334018835303e-07
BRCA1 O 0 4.877547689829953e-05
allelic O 0 1.9093560695182532e-05
pattern O 0 2.8224007110111415e-05
. O 0 9.87691691989312e-07

We O 0 6.502745009129285e-07
conclude O 0 2.423983289645548e-07
that O 0 8.482546332011509e-10
the O 0 1.273074978769273e-09
185delAG O 0 2.6029913442471297e-06
BRCA1 O 0 5.4906358855078e-06
mutation O 0 8.120692029933707e-08
occurs O 0 1.9325516742441096e-09
in O 0 6.043810452105447e-10
some O 0 5.252085988338706e-10
non O 0 9.028529035504107e-08
- O 0 9.400686394656077e-06
Ashkenazi O 0 6.178674425427744e-07
populations O 0 1.3552381439296823e-09
at O 0 4.566889533208496e-09
rates O 0 2.6648201867374155e-08
comparable O 0 3.026497052971422e-09
with O 0 1.8106083299329612e-10
that O 0 3.6800265612590977e-10
of O 0 7.886600261741705e-10
Ashkenazim O 0 9.268518624594435e-06
. O 0 5.931996582830834e-08

The O 0 4.236820316805279e-08
majority O 0 9.02869778940385e-09
of O 0 2.1825988238965977e-10
Jewish O 0 2.975351875988963e-08
185delAG O 0 4.7520512680421234e-07
mutation O 0 4.490432559123292e-08
carriers O 0 6.936754459729855e-08
have O 0 2.1058430554887764e-09
a O 0 1.3070289295313842e-09
common O 0 7.664529455553293e-09
allelic O 0 2.075093590292454e-07
pattern O 0 9.673491376815946e-07
, O 0 8.25361778922229e-10
supporting O 0 3.19348381072615e-10
the O 0 4.834389000230033e-10
founder O 0 4.8671253694010375e-09
effect O 0 4.932704023019596e-09
notion O 0 5.978975092801875e-09
, O 0 5.674722358683937e-10
but O 0 1.1635427066281068e-09
dating O 0 6.508897421042548e-09
the O 0 3.465857809081818e-11
mutations O 0 4.944844533838477e-10
origin O 0 1.213081163298213e-10
to O 0 1.1278167982853304e-10
an O 0 1.7045498346135446e-10
earlier O 0 1.694703044563539e-08
date O 0 1.7249666584007173e-08
than O 0 4.165501554798112e-10
currently O 0 4.4737064053279596e-10
estimated O 0 1.4232005574044138e-09
. O 0 1.4178096918726624e-08

However O 0 3.096834575444518e-07
, O 0 1.5941888920067981e-09
the O 0 4.1482012269611346e-10
different O 0 9.666755174109198e-10
allelic O 0 1.6015552262160782e-07
pattern O 0 2.08885217034549e-06
at O 0 1.0645290871025281e-07
the O 0 3.0888982482935035e-09
BRCA1 O 0 3.664953283077921e-07
locus O 0 1.2071390997903109e-08
even O 0 3.935155756806807e-09
in O 0 9.059000771749481e-10
some O 0 1.0280921947103394e-10
Jewish O 0 2.571005186524644e-09
mutation O 0 3.795266767525618e-09
carriers O 0 1.3410705435035197e-08
, O 0 2.8260555007264543e-10
might O 0 3.2470748312363185e-09
suggest O 0 1.0377542158934716e-09
that O 0 3.14194725792305e-10
the O 0 6.698558374651498e-10
mutation O 0 7.418578640283613e-09
arose O 0 1.5956192811472647e-08
independently O 0 1.8585886607525026e-08
. O 0 5.78176173604561e-09
. O 0 1.624472822925327e-08

Crystal O 0 9.376287198392674e-05
structure O 0 4.925115604237362e-07
of O 0 6.338854330323329e-09
the O 0 1.0740043876467098e-07
hemochromatosis B-Disease 1 1.0
protein O 0 1.1256149718974484e-06
HFE O 0 3.251661473768763e-05
and O 0 9.017218083329226e-09
characterization O 0 1.3349864325107319e-08
of O 0 6.701979943235514e-11
its O 0 3.708917617473162e-10
interaction O 0 2.0271906375768367e-09
with O 0 5.928552093692474e-10
transferrin O 0 3.2639167102388456e-07
receptor O 0 2.3460424358745513e-07
. O 0 5.525370738723723e-08

HFE O 0 0.006167419254779816
is O 0 1.1165493418729966e-07
an O 0 6.025984156110553e-09
MHC O 0 1.4852164440526394e-06
- O 0 2.188032652838956e-07
related O 0 1.1645734154797083e-08
protein O 0 9.929938649122505e-09
that O 0 4.4595810377856537e-10
is O 0 6.659979512324554e-11
mutated O 0 1.3236983065212371e-08
in O 0 7.018666980940225e-09
the O 0 1.1243002973060356e-07
iron B-Disease 1 0.9999990463256836
- I-Disease 1 0.9999998807907104
overload I-Disease 1 0.9999798536300659
disease I-Disease 1 0.9999995231628418
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
. O 0 1.3668443898495752e-05

HFE O 0 0.001717377221211791
binds O 0 6.1607906900462694e-06
to O 0 8.81716388789755e-08
transferrin O 0 1.4596296296076616e-06
receptor O 0 1.8894445474870736e-07
( O 0 1.51340717735593e-08
TfR O 0 1.4216244608178386e-06
) O 0 5.081648990490351e-10
and O 0 2.336866256058556e-10
reduces O 0 1.162065554893843e-09
its O 0 7.49829157098425e-11
affinity O 0 3.238131762728358e-09
for O 0 6.237517169438433e-10
iron O 0 1.928718302224297e-05
- O 0 1.9009070229003555e-07
loaded O 0 7.334236329370469e-08
transferrin O 0 2.2275712296959682e-07
, O 0 5.305592409854398e-09
implicating O 0 2.623636987664213e-07
HFE O 0 2.0767813111888245e-05
in O 0 2.871444735319528e-07
iron O 0 0.0013888312969356775
metabolism O 0 2.4438657419523224e-05
. O 0 1.2693470807789708e-07

The O 0 9.135579261965177e-07
2 O 0 7.175087262112356e-07
. O 0 1.685272223994616e-07

6 O 0 5.331347892933991e-06
A O 0 2.264124674411505e-07
crystal O 0 8.51845288707409e-06
structure O 0 5.128802271769928e-08
of O 0 1.5544313614057614e-09
HFE O 0 4.9271489842794836e-05
reveals O 0 1.0611821466000038e-07
the O 0 5.769696387325496e-10
locations O 0 1.4186048780118199e-08
of O 0 8.898155812175901e-08
hemochromatosis B-Disease 1 1.0
mutations O 0 3.7491897728614276e-06
and O 0 1.5262024533058138e-08
a O 0 2.2244945441229902e-08
patch O 0 2.7020296329283156e-05
of O 0 7.537384605349473e-10
histidines O 0 9.969678558263695e-07
that O 0 7.995242246039425e-10
could O 0 6.456077450422981e-09
be O 0 1.7432753851576166e-10
involved O 0 4.116885443661289e-10
in O 0 4.351485838327562e-09
pH O 0 5.6309755080974355e-08
- O 0 5.370900879597684e-08
dependent O 0 5.060375229959391e-08
interactions O 0 4.798639352543432e-08
. O 0 7.002316237958439e-08

We O 0 3.246646826937649e-07
also O 0 5.836641392420461e-09
demonstrate O 0 6.892214798881469e-09
that O 0 9.506326836827839e-10
soluble O 0 2.883279819343443e-07
TfR O 0 5.441001121653244e-06
and O 0 4.280975574033619e-09
HFE O 0 1.9126737242913805e-06
bind O 0 4.47745840403968e-08
tightly O 0 1.5918500295697413e-08
at O 0 7.563987658443239e-09
the O 0 2.624213901736283e-10
basic O 0 5.246761691779511e-09
pH O 0 3.0822007168751497e-09
of O 0 1.5427627925168608e-11
the O 0 1.7160683984940306e-10
cell O 0 4.371228001787131e-08
surface O 0 4.2894021667905236e-09
, O 0 5.384496737370625e-10
but O 0 2.7769730959192884e-09
not O 0 1.2240590763212822e-09
at O 0 3.1549620693738234e-09
the O 0 1.5278152076803053e-09
acidic O 0 1.5396343755469388e-08
pH O 0 9.229911945851654e-09
of O 0 3.561277661656703e-10
intracellular O 0 1.5588716451020446e-07
vesicles O 0 1.058696966538264e-06
. O 0 2.288686573592713e-07

TfR O 1 0.7350014448165894
HFE O 0 0.0033552704844623804
stoichiometry O 0 1.228921701112995e-05
( O 0 2.3230172985222453e-07
2 O 0 1.4382922408628929e-08
1 O 0 3.34306293758857e-09
) O 0 4.790367547080621e-10
differs O 0 1.2213567934793446e-08
from O 0 1.1799969890091688e-08
TfR O 0 3.746108859559172e-06
transferrin O 0 1.7681522024304286e-07
stoichiometry O 0 4.846802781344195e-08
( O 0 1.69238301150898e-09
2 O 0 1.2475754873619849e-09
2 O 0 1.0983659537444623e-09
) O 0 2.392977205278868e-10
, O 0 1.1895046059251513e-10
implying O 0 5.4953295247628375e-09
a O 0 2.7304375427306127e-10
different O 0 9.92758028561802e-11
mode O 0 8.655679728519772e-09
of O 0 5.660644869509568e-11
binding O 0 3.3276423838657365e-09
for O 0 2.110446928327292e-09
HFE O 0 1.1240446156079997e-06
and O 0 2.268973453567469e-09
transferrin O 0 5.3332527727434353e-08
to O 0 5.295987204334551e-09
TfR O 0 5.093257641419768e-06
, O 0 4.810639664398764e-10
consistent O 0 4.1094265768037985e-09
with O 0 7.131010365535317e-11
our O 0 5.240158307273646e-10
demonstration O 0 2.9306859161692955e-09
that O 0 1.2883764055615643e-09
HFE O 0 6.627838615713699e-07
, O 0 5.095051602843625e-10
transferrin O 0 3.0726699407068736e-08
, O 0 1.5627135141471626e-09
and O 0 7.078438724050784e-09
TfR O 0 2.0470561139518395e-06
form O 0 6.708688715661992e-09
a O 0 1.2759295842101892e-08
ternary O 0 1.3701452417080873e-07
complex O 0 3.190440622802271e-07
. O 0 1.169691756786051e-07

Identification O 0 1.3018430990996421e-06
of O 0 3.5248142182808806e-09
three O 0 1.5997996261063463e-09
novel O 0 3.4635809775807047e-09
mutations O 0 2.9473699925119945e-08
and O 0 3.6914591383663264e-09
a O 0 2.2354587070338994e-09
high O 0 3.6901028011016024e-08
frequency O 0 2.992094749743046e-08
of O 0 4.076511628259283e-10
the O 0 5.953802784119944e-09
Arg778Leu O 0 9.187214686789957e-07
mutation O 0 1.5585737145329404e-08
in O 0 5.996529051088828e-09
Korean O 0 2.012855588873208e-07
patients O 0 5.689804183361957e-08
with O 0 4.64521754395264e-09
Wilson B-Disease 0 7.969259058882017e-06
disease I-Disease 0 1.5240027096297126e-05
. O 0 1.8268418955358356e-07

Four O 0 7.586963874928188e-07
mutations O 0 1.4455122254730668e-05
- O 0 5.2151215641060844e-05
- O 0 3.740501415450126e-05
R778L O 0 2.0911163574055536e-06
, O 0 1.939534755024397e-09
A874V O 0 6.393082685463014e-08
, O 0 5.388729462652009e-10
L1083F O 0 1.9947657747820813e-08
, O 0 2.105769725258e-10
and O 0 4.079560855796416e-10
2304delC O 0 1.0731320543300171e-07
- O 0 9.67360591630495e-08
- O 0 3.6219265808767886e-08
in O 0 9.649180343629382e-10
the O 0 4.2638767516756104e-10
copper O 0 1.0812043171881669e-07
- O 0 7.567046544920686e-09
transporting O 0 2.4999109449197476e-09
enzyme O 0 1.168551833075071e-08
, O 0 4.3934744731188857e-10
P O 0 2.187956397392554e-06
- O 0 4.687478849518811e-08
type O 0 5.117692012390762e-07
ATPase O 0 4.1298535506939515e-06
( O 0 9.442955750671445e-09
ATP7B O 0 7.691785413044272e-07
) O 0 2.9290750380717157e-10
, O 0 3.946734952742226e-11
were O 0 1.0960702345741424e-09
identified O 0 1.3244224605912791e-09
in O 0 1.004414884597793e-09
Korean O 0 3.818810156985819e-08
Patients O 0 1.6197763130776366e-08
with O 0 1.5458010427238378e-09
Wilson B-Disease 0 4.365972472442081e-06
disease I-Disease 0 1.3114819921611343e-05
. O 0 2.2815909517248656e-07

Arg778Leu O 0 0.00010737412958405912
, O 0 1.2211470945544534e-08
the O 0 2.537021703830078e-10
most O 0 2.1965769481102626e-10
frequently O 0 8.418428731893357e-10
reported O 0 2.0031500014283665e-08
mutation O 0 1.0135078332140779e-09
of O 0 1.2983438109348544e-11
this O 0 3.694667488618464e-11
enzyme O 0 9.154481617201782e-10
, O 0 7.39962049967069e-11
was O 0 1.8314116445594664e-08
found O 0 1.5619298077140797e-09
in O 0 1.2561210960271296e-09
six O 0 8.992619426884119e-10
of O 0 3.116020635962613e-11
eight O 0 2.5927173741280285e-09
unrelated O 0 2.154907008389273e-08
patients O 0 1.5219329441151785e-07
studied O 0 1.7646744510102508e-08
, O 0 3.3205901917021663e-10
an O 0 1.511446939828076e-10
allele O 0 4.864065061838119e-08
frequency O 0 1.7291607434799516e-07
of O 0 7.064357543384858e-09
37 O 0 1.1869673244291334e-06
. O 0 7.970781013000305e-08

5 O 0 3.544888329543028e-07
% O 0 5.7018492150007205e-09
, O 0 2.1553199502921672e-10
which O 0 9.764090924679891e-11
is O 0 6.200647634235779e-11
considerably O 0 2.241753271903235e-08
higher O 0 4.220928051523742e-09
than O 0 1.368531815648666e-10
those O 0 7.463291096243552e-11
in O 0 2.634826523628675e-10
other O 0 5.127984703534594e-10
Asian O 0 4.530468000751853e-09
populations O 0 2.7924664802725374e-09
. O 0 1.293624407594507e-08

The O 0 4.318538415759576e-08
novel O 0 4.625098526389593e-08
single O 0 3.995465647221863e-08
nucleotide O 0 2.0538794842650532e-07
deletion O 0 2.5971516492973024e-07
, O 0 2.67496313988147e-09
2304delC O 0 8.32759852187337e-08
, O 0 6.016058762270404e-10
was O 0 2.4252083008491354e-08
found O 0 1.6306186401138234e-09
in O 0 1.5985216483827003e-09
one O 0 5.566027638792548e-09
patient O 0 1.4103122225606057e-07
. O 0 3.6320059848549135e-08

Since O 0 5.177361117603141e-07
a O 0 4.1728693389586624e-08
mutation O 0 1.7922353379162814e-07
at O 0 1.592020026919272e-08
cDNA O 0 2.4176483748306055e-07
nucleotide O 0 6.530512450808601e-07
2302 O 0 2.2565835024579428e-05
( O 0 8.131243234288377e-09
2302insC O 0 8.170626131231984e-08
) O 0 7.583659256127362e-10
had O 0 1.3237084317552217e-08
been O 0 2.785338404365234e-09
previously O 0 1.7521634143591314e-09
described O 0 4.401746966919973e-09
, O 0 8.570132103979944e-11
this O 0 1.508255326188035e-11
region O 0 1.2026127316211443e-10
of O 0 5.7133391767605346e-11
the O 0 1.634729240862498e-09
ATP7B O 0 3.837630174530204e-06
gene O 0 1.6515792822247022e-07
may O 0 1.948362609027754e-07
be O 0 4.894028293733754e-09
susceptible O 0 5.912241007877128e-08
to O 0 3.950022531284958e-09
gene O 0 2.0791892438865034e-06
rearrangements O 0 3.197272235411219e-05
causing O 0 5.88648981647566e-06
Wilson B-Disease 0 6.729895540047437e-05
disease I-Disease 0 0.00010188658779952675
. O 0 2.970583921069192e-07

Disruption O 0 2.580839100119192e-05
of O 0 1.3695881762032514e-08
splicing O 0 5.744884106206882e-07
regulated O 0 7.486541164780647e-08
by O 0 2.127137355145692e-09
a O 0 1.519713066500117e-08
CUG O 0 1.7138812836492434e-05
- O 0 5.333212698133138e-07
binding O 0 2.1149979545498354e-07
protein O 0 4.562051572065684e-07
in O 0 1.2992238225706387e-05
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 0 2.48128458224528e-06

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9983856678009033
DM B-Disease 1 1.0
) O 0 2.50612430363617e-07
is O 0 2.6544499931446808e-09
caused O 0 7.482041652906446e-09
by O 0 3.5315084190301604e-10
a O 0 2.455808001400328e-09
CTG O 0 3.314142986710067e-07
expansion O 0 1.6942763636507152e-08
in O 0 5.379561240914654e-09
the O 0 2.3009973926235716e-09
3 O 0 6.558257936717382e-09
untranslated O 0 2.6458135948814743e-07
region O 0 1.4428616523787241e-08
of O 0 1.7710160005179887e-09
the O 0 4.071022772222932e-07
DM B-Disease 1 1.0
gene O 0 5.485569090524223e-06
. O 0 3.076417556258093e-07

One O 0 1.367061059909247e-07
model O 0 2.727037156091683e-07
of O 0 4.0221742381163494e-08
DM B-Disease 1 1.0
pathogenesis O 0 3.605402980610961e-06
suggests O 0 3.757740785204078e-08
that O 0 5.403942293646935e-10
RNAs O 0 5.22331973229484e-08
from O 0 3.863452613384055e-10
the O 0 7.175597616093654e-11
expanded O 0 1.2826438799962148e-09
allele O 0 1.6753265441593612e-08
create O 0 5.082171905534949e-10
a O 0 2.7587805373485708e-09
gain O 0 1.918360567287891e-06
- O 0 1.8253928146805265e-07
of O 0 8.961029140941434e-10
- O 0 1.2952989436598727e-07
function O 0 1.2698205820171893e-09
mutation O 0 1.2382517233788803e-09
by O 0 1.4434961559395276e-10
the O 0 2.0083891494326878e-10
inappropriate O 0 4.568562417262001e-09
binding O 0 6.085685289036746e-10
of O 0 3.569783357804113e-11
proteins O 0 1.5965827271369193e-10
to O 0 3.938134540693028e-10
the O 0 3.4307525709209585e-09
CUG O 0 6.307333933364134e-06
repeats O 0 8.250868859249749e-07
. O 0 6.084031412001423e-08

Data O 0 7.806374355823209e-07
presented O 0 7.179865235684701e-08
here O 0 1.3459623637857021e-08
indicate O 0 4.338251091695611e-09
that O 0 8.549919106037862e-11
the O 0 1.373652164238237e-10
conserved O 0 5.009857417803687e-09
heterogeneous O 0 1.2336695220938054e-08
nuclear O 0 2.8205178637108475e-07
ribonucleoprotein O 0 1.4289372529674438e-06
, O 0 4.4317034486596185e-09
CUG O 0 2.196042487412342e-06
- O 0 1.6504772304415383e-07
binding O 0 5.555307680538135e-08
protein O 0 5.585364348803523e-08
( O 0 4.328398972575087e-09
CUG O 0 2.674896859389264e-05
- O 0 2.5882945919875056e-06
BP O 0 1.9317923943162896e-05
) O 0 5.046721374135643e-10
, O 0 1.78457512656216e-10
may O 0 6.755272341507634e-09
mediate O 0 3.5849637924911804e-08
the O 0 2.305421409332098e-09
trans O 0 2.439384161334601e-07
- O 0 3.0297218245323165e-07
dominant O 0 5.681659587253307e-08
effect O 0 1.2961659301424788e-08
of O 0 1.4855526531132313e-10
the O 0 1.3780564467325007e-09
RNA O 0 2.593941133000044e-07
. O 0 1.903270074876673e-08

CUG O 0 0.19824771583080292
- O 0 0.03641470894217491
BP O 0 0.0011096536181867123
was O 0 1.4455299890414608e-07
found O 0 8.223980940691433e-10
to O 0 7.355071413028824e-11
bind O 0 1.4239609491539795e-09
to O 0 1.9388050886970376e-10
the O 0 1.4715685336952333e-09
human O 0 3.052878128073644e-08
cardiac O 0 0.0014680890599265695
troponin O 0 0.0007614397909492254
T O 0 5.205889101489447e-05
( O 0 6.185439715977736e-09
cTNT O 0 8.746479807086871e-08
) O 0 1.062530063933309e-09
pre O 0 3.173474283357791e-07
- O 0 2.7000669433618896e-07
messenger O 0 6.702935451130543e-08
RNA O 0 1.8326099748833258e-08
and O 0 3.604060661022146e-10
regulate O 0 3.709796914108665e-09
its O 0 1.3192513748094825e-09
alternative O 0 1.8257299672086447e-08
splicing O 0 1.1273585869275848e-06
. O 0 1.3792120512334805e-07

Splicing O 0 1.7777567336452194e-05
of O 0 7.685701319815053e-08
cTNT O 0 5.16713407705538e-06
was O 0 5.721515208279015e-07
disrupted O 0 3.313440902275033e-05
in O 0 2.716267954383511e-05
DM B-Disease 1 1.0
striated O 0 5.201512612984516e-05
muscle O 0 7.430050754919648e-05
and O 0 1.387001624664208e-08
in O 0 2.0886821161525404e-09
normal O 0 1.0214086465509808e-08
cells O 0 4.094654837416556e-09
expressing O 0 1.4096924738637995e-09
transcripts O 0 2.9262189116252557e-08
that O 0 1.0764582558664415e-09
contain O 0 2.6630011973338696e-08
CUG O 0 1.1342896868882235e-05
repeats O 0 2.3281234007299645e-06
. O 0 1.5892871374489914e-07

Altered O 0 1.4296952031145338e-05
expression O 0 3.957891294703586e-07
of O 0 4.477447745898644e-09
genes O 0 8.107551963121296e-08
regulated O 0 1.7722747713833087e-07
posttranscriptionally O 0 7.889705102570588e-07
by O 0 6.426481125032524e-09
CUG O 0 0.00033013540087267756
- O 0 4.313436147640459e-05
BP O 0 1.1207306670257822e-05
therefore O 0 3.805429305003827e-09
may O 0 5.7494635719024245e-09
contribute O 0 8.636034665165937e-10
to O 0 3.780421664600908e-08
DM B-Disease 1 1.0
pathogenesis O 0 2.5142255708487937e-06
. O 0 1.2040002772550906e-08
. O 0 1.92832949608146e-08

Identification O 0 8.813244107841456e-07
of O 0 3.365717926584466e-09
a O 0 1.1555239431970676e-08
novel O 0 8.408359519762598e-08
nonsense O 0 9.690919978311285e-05
mutation O 0 9.882592877374918e-08
and O 0 1.522317494284664e-09
a O 0 2.255549746976726e-09
missense O 0 2.5312249363196315e-07
substitution O 0 3.784628077596608e-08
in O 0 8.085804914514938e-09
the O 0 2.6252466867049407e-09
vasopressin O 0 1.8711665461523808e-07
- O 0 1.2002581115666544e-06
neurophysin O 0 1.756137635311461e-06
II O 0 2.6621336246535066e-07
gene O 0 1.7767483484476543e-08
in O 0 2.971833668041768e-09
two O 0 1.2376826230564575e-09
Spanish O 0 9.054569005684243e-08
kindreds O 0 1.290686213906156e-06
with O 0 2.8630710247057323e-08
familial B-Disease 0 0.004302504006773233
neurohypophyseal I-Disease 1 0.9976390600204468
diabetes I-Disease 1 0.9999648332595825
insipidus I-Disease 1 0.7820417881011963
. O 0 5.076721663499484e-06

Familial B-Disease 1 0.9999511241912842
neurohypophyseal I-Disease 1 0.999994158744812
diabetes I-Disease 1 1.0
insipidus I-Disease 1 0.9999842643737793
( O 0 0.0004256021056789905
FNDI B-Disease 1 1.0
) O 0 4.1368590331103405e-08
is O 0 3.473179965851614e-09
an O 0 9.208704909724474e-09
autosomal B-Disease 1 0.9989940524101257
dominant I-Disease 1 0.999967098236084
disease I-Disease 1 0.9998587369918823
caused O 0 5.894483911106363e-05
by O 0 7.38398114208394e-07
deficiency O 0 0.3319423794746399
in O 0 2.3128658099835775e-08
the O 0 4.1314418552929055e-08
antidiuretic O 0 1.596482252352871e-05
hormone O 0 9.409999393028556e-07
arginine O 0 6.796981324441731e-07
vasopressin O 0 2.6763302685139934e-07
( O 0 5.698946203835931e-09
AVP O 0 2.3546247973627032e-07
) O 0 1.6056436735745194e-10
encoded O 0 5.034626604505377e-10
by O 0 1.8813742230783248e-10
the O 0 7.334793217239621e-09
AVP O 0 7.841396291041747e-05
- O 0 1.728555162117118e-06
neurophysin O 0 9.818982107390184e-06
II O 0 4.327635451772949e-06
( O 0 1.670339599968429e-08
AVP O 0 1.631920713407453e-05
- O 0 6.019863576511852e-07
NPII O 0 1.622230229259003e-06
) O 0 1.8654957578689846e-09
gene O 0 6.750329362148477e-08
on O 0 1.3546578259138187e-07
chromosome O 0 1.4097238818067126e-05
20p13 O 0 8.412564966420177e-06
. O 0 3.4347917221566604e-07

In O 0 1.1278291367489146e-07
this O 0 6.095373650261138e-10
study O 0 4.770335793047309e-10
, O 0 1.178765141052196e-10
we O 0 2.4028379286278323e-10
analyzed O 0 7.640806320985405e-10
two O 0 2.454804415297218e-10
families O 0 3.2422337037374405e-10
with O 0 1.521425624373407e-10
FNDI B-Disease 1 0.9989470839500427
using O 0 2.2193993309826965e-09
direct O 0 8.933966455515474e-09
automated O 0 2.9056971584395797e-07
fluorescent O 0 1.0890921942063869e-07
, O 0 3.8333305418802865e-09
solid O 0 1.8008567792549002e-07
phase O 0 2.1202485100957347e-08
, O 0 5.72739522475274e-10
single O 0 8.754218683293402e-09
- O 0 1.1034590841063618e-07
stranded O 0 6.323001855434995e-08
DNA O 0 1.7050586720301908e-08
sequencing O 0 1.122774051509623e-08
of O 0 1.2384572256607385e-09
PCR O 0 5.933812190050958e-06
- O 0 2.541170943004545e-06
amplified O 0 9.69234315562062e-06
AVP O 0 0.0001449885603506118
- O 0 3.308955683678505e-06
NPII O 0 6.505562851089053e-06
DNA O 0 1.102099759009434e-06
. O 0 1.0437401698482063e-07

In O 0 1.6607432939963473e-07
one O 0 2.2058608273312075e-09
of O 0 2.8240118576938755e-11
the O 0 1.545375771794255e-10
families O 0 3.4421426819974954e-10
, O 0 9.124111188807404e-11
affected O 0 5.647824430354831e-10
individuals O 0 4.9168995264192716e-11
presented O 0 6.842554856056893e-10
a O 0 1.8123333944686237e-09
novel O 0 1.461956689041699e-08
nonsense O 0 1.9814876850432483e-06
mutation O 0 1.2558389883565724e-08
in O 0 1.2370406921036192e-09
exon O 0 1.4100589140753073e-08
3 O 0 8.429161812983921e-10
of O 0 5.136293126928315e-11
the O 0 1.690343143234685e-10
gene O 0 3.3864206994138613e-09
, O 0 7.803789559002183e-11
consisting O 0 3.8093177917586374e-11
in O 0 1.4267121928313031e-09
a O 0 1.0359511470880989e-08
G O 0 6.218152975634439e-06
to O 0 1.4348835897237677e-08
T O 0 1.4848856153548695e-05
transition O 0 1.5892107185777604e-08
at O 0 7.915207156372617e-09
nucleotide O 0 2.3586315123225177e-08
2101 O 0 1.9868834044700634e-07
, O 0 1.969085172692786e-10
which O 0 1.2662161597010169e-10
produces O 0 2.372552987406351e-10
a O 0 1.852154207782064e-09
stop O 0 7.475155427982827e-08
signal O 0 3.2900352380238473e-06
in O 0 4.7287510795968046e-08
codon O 0 5.670091240972397e-07
82 O 0 5.7334784031581876e-08
( O 0 7.346049990530901e-09
Glu O 0 1.0020733043347718e-06
) O 0 3.0637847814318775e-09
of O 0 2.673330889990666e-09
NPII O 0 2.3541771952295676e-05
. O 0 1.6158212190475751e-07

The O 0 5.414026418293361e-07
premature O 0 4.7840544539212715e-06
termination O 0 3.0362036795850145e-07
eliminates O 0 8.122612626948467e-08
part O 0 2.4878812343587242e-09
of O 0 1.6241366584957007e-10
the O 0 7.684491931669868e-10
C O 0 1.3552444215747528e-05
- O 0 1.6261415680673963e-07
terminal O 0 7.169916926841324e-08
domain O 0 7.810244895267715e-09
of O 0 2.444921487487761e-10
NPII O 0 4.313574777370377e-07
, O 0 6.582764194851265e-11
including O 0 2.3804389015502636e-11
a O 0 3.694866912429262e-10
cysteine O 0 1.3682903698963855e-08
residue O 0 3.5196634939893556e-08
in O 0 8.797165773621884e-10
position O 0 3.4243587965221423e-09
85 O 0 9.719983706801827e-10
, O 0 6.535674779151179e-11
which O 0 1.043181444004837e-10
could O 0 7.37125738226041e-09
be O 0 3.2016256312772384e-10
involved O 0 2.617865091369964e-10
in O 0 1.3933540987665083e-09
the O 0 1.485414680146846e-09
correct O 0 3.062513087570551e-07
folding O 0 3.8674301094943075e-08
of O 0 1.0481181478283474e-09
the O 0 1.777409330827595e-08
prohormone O 0 3.159966945531778e-05
. O 0 2.1290244944793812e-07

In O 0 1.3586013380972872e-07
the O 0 6.333222390964011e-09
second O 0 1.9463248790430043e-08
family O 0 1.3224938921752027e-09
, O 0 9.585286037117058e-11
a O 0 2.770739193636018e-10
G279A O 0 1.2887851674747708e-08
substitution O 0 8.212463598056274e-09
at O 0 1.3091154826838647e-08
position O 0 1.4828167138603021e-08
- O 0 5.972239147666869e-09
1 O 0 1.6713863626449665e-10
of O 0 1.496683679769184e-11
the O 0 2.441710722500545e-10
signal O 0 4.1382481441587515e-08
peptide O 0 2.0660027022501026e-09
was O 0 9.355451524584169e-09
observed O 0 6.970794497185295e-10
in O 0 6.537809738027534e-10
all O 0 2.622192740719953e-10
affected O 0 2.354315409291985e-09
individuals O 0 3.145437244000959e-10
. O 0 8.207029722484549e-09

This O 0 2.813237927057344e-07
missense O 0 3.323957571410574e-05
mutation O 0 9.402876344211109e-07
, O 0 7.267559443135951e-09
which O 0 1.4394339054035754e-08
replaces O 0 6.4514601945120376e-06
Ala O 0 6.730255699949339e-05
with O 0 8.78171313445364e-09
Thr O 0 0.0009868418565019965
, O 0 5.0867714485036686e-09
is O 0 5.164430549875476e-10
frequent O 0 1.925888959419808e-08
among O 0 3.6999875874244026e-07
FNDI B-Disease 1 1.0
patients O 0 7.095430646586465e-06
and O 0 2.158620837633407e-09
is O 0 1.6142723269219061e-10
thought O 0 2.5061557273886592e-09
to O 0 1.5064018088484232e-10
reduce O 0 6.145828845838253e-10
the O 0 2.4907334528201375e-10
efficiency O 0 1.708863939242633e-09
of O 0 7.448842931356836e-11
cleavage O 0 1.2672661142687502e-08
by O 0 5.307391193198896e-10
signal O 0 1.3338483313418692e-06
peptidases O 0 4.849336164625129e-06
. O 0 1.1340302918938505e-08
. O 0 2.658545383837918e-08

Genetic O 0 1.712289849820081e-05
heterogeneity O 0 4.550538051262265e-06
of O 0 4.948962839534943e-08
Saethre B-Disease 1 0.992343008518219
- I-Disease 1 0.9999998807907104
Chotzen I-Disease 1 0.9999995231628418
syndrome I-Disease 1 1.0
, O 0 5.189889407120063e-09
due O 0 1.1768052310401345e-08
to O 0 2.898709050569437e-09
TWIST O 0 2.966705505969003e-05
and O 0 6.738905540260021e-07
FGFR O 0 7.797105354256928e-05
mutations O 0 2.4027635845413897e-06
. O 0 8.550159691367298e-08

Thirty O 0 5.72405151615385e-05
- O 0 0.00019379620789550245
two O 0 1.5864063840353992e-08
unrelated O 0 1.4710590789945854e-07
patients O 0 6.967677279590134e-08
with O 0 7.118303863018483e-11
features O 0 5.841285677377073e-09
of O 0 7.462017670434307e-09
Saethre B-Disease 1 0.9993578791618347
- I-Disease 1 0.9999997615814209
Chotzen I-Disease 1 0.999997615814209
syndrome I-Disease 1 0.9999986886978149
, O 0 2.4923030306212013e-09
a O 0 1.4114283963806429e-08
common O 0 1.2187200582047808e-06
autosomal B-Disease 1 0.8434990048408508
dominant I-Disease 1 0.6296160817146301
condition I-Disease 0 0.4461909234523773
of O 0 1.1021633383734297e-07
craniosynostosis B-Disease 0 0.3263546824455261
and O 0 3.2228952477453277e-05
limb B-Disease 1 0.8680473566055298
anomalies I-Disease 0 0.0020691307727247477
, O 0 5.352949639103599e-09
were O 0 1.4805953796326321e-08
screened O 0 2.4393855824200728e-08
for O 0 7.129666856897643e-10
mutations O 0 1.662514037548135e-08
in O 0 8.300778731040737e-09
TWIST O 0 1.258237080037361e-05
, O 0 5.341170172812326e-09
FGFR2 O 0 4.871567398367915e-06
, O 0 1.9980586074552775e-09
and O 0 1.2112928438057224e-08
FGFR3 O 0 1.573636291141156e-05
. O 0 6.239795879992016e-08

Nine O 0 1.3781603911411366e-06
novel O 0 6.672092922599404e-08
and O 0 7.906877819152669e-09
three O 0 3.599803344300767e-09
recurrent O 0 1.2848184951508301e-06
TWIST O 0 0.0003885792102664709
mutations O 0 4.519276899372926e-07
were O 0 6.958141085533498e-08
found O 0 4.370125150643389e-09
in O 0 3.6255050073208395e-09
12 O 0 6.6781251639724815e-09
families O 0 2.3882362754079622e-09
. O 0 1.1508126007697683e-08

Seven O 0 3.815453908373456e-07
families O 0 1.5324213009648702e-08
were O 0 4.5417678506964876e-09
found O 0 4.449114132665244e-10
to O 0 1.2194142917643092e-10
have O 0 7.703907511924513e-10
the O 0 6.867147961386877e-10
FGFR3 O 0 2.4780708827165654e-06
P250R O 0 8.067014789503446e-08
mutation O 0 9.848661441935747e-09
, O 0 1.7406738550551637e-10
and O 0 8.743780699482784e-11
one O 0 4.027787478544376e-11
individual O 0 2.6122970106512433e-11
was O 0 3.0179330678947736e-07
found O 0 3.2129447991025017e-09
to O 0 2.63181282322833e-10
have O 0 1.200875954232572e-09
an O 0 3.6735817166011486e-10
FGFR2 O 0 1.1009821719198953e-05
VV269 O 0 3.5592213407653617e-06
- O 0 2.259752818645211e-06
270 O 0 2.7704152216756484e-07
deletion O 0 5.287005024001701e-06
. O 0 1.786868182307444e-07

To O 0 5.081372833615205e-08
date O 0 5.3196696825352774e-08
, O 0 2.72141142954041e-10
our O 0 1.8753444630537075e-10
detection O 0 3.396492198604051e-09
rate O 0 2.5126759339855198e-08
for O 0 5.988684548263734e-10
TWIST O 0 2.4028461211855756e-06
or O 0 5.5823186073666875e-08
FGFR O 0 1.114467977458844e-05
mutations O 0 6.869538538012421e-08
is O 0 4.151501920013345e-10
68 O 0 9.591514249507327e-09
% O 0 1.351453254860857e-10
in O 0 7.413666347488856e-10
our O 0 2.3698870421640095e-08
Saethre B-Disease 1 0.7440553307533264
- I-Disease 1 0.999998927116394
Chotzen I-Disease 1 0.9999980926513672
syndrome I-Disease 1 0.9999997615814209
patients O 0 1.7615420802030712e-06
, O 0 3.451030294865376e-10
including O 0 1.0692629420772093e-10
our O 0 2.421232103699822e-09
five O 0 1.2820624561982186e-08
patients O 0 1.765361190564363e-08
elsewhere O 0 3.4359210587808775e-08
reported O 0 3.050480472666095e-07
with O 0 2.0073676054721545e-09
TWIST O 0 0.00015040754806250334
mutations O 0 4.829849785892293e-06
. O 0 2.1550124529312598e-07

More O 0 1.886373155457477e-07
than O 0 1.2253375203385986e-08
35 O 0 3.859808472839177e-09
different O 0 4.947853793346724e-10
TWIST O 0 3.300128582850448e-06
mutations O 0 4.027501532277711e-08
are O 0 6.089412307730413e-10
now O 0 4.0619591024082524e-10
known O 0 4.5147491301023024e-10
in O 0 6.881649694534531e-10
the O 0 9.756164764951336e-10
literature O 0 1.1934646160227658e-08
. O 0 1.1170196323462278e-08

The O 0 6.827242771123565e-08
most O 0 4.8948685105187906e-09
common O 0 2.3801733917139245e-09
phenotypic O 0 2.4697886402691438e-08
features O 0 9.404597989259855e-09
, O 0 6.491325810209503e-10
present O 0 1.5934704944431388e-10
in O 0 3.758541922138647e-09
more O 0 8.594145534113196e-11
than O 0 1.6628994015110976e-10
a O 0 8.521611194467482e-10
third O 0 1.29463400000418e-08
of O 0 7.192520190546503e-11
our O 0 1.9602837131316164e-09
patients O 0 7.833622639452642e-09
with O 0 5.749657971954036e-10
TWIST O 0 4.7978035581763834e-05
mutations O 0 3.100132346389728e-07
, O 0 1.9823584995748433e-09
are O 0 1.3175113222629875e-09
coronal B-Disease 0 4.42409373135888e-06
synostosis I-Disease 0 5.4135616665007547e-05
, O 0 2.493716522167233e-08
brachycephaly B-Disease 0 4.30470026913099e-06
, O 0 2.520817155016175e-08
low B-Disease 0 0.020685799419879913
frontal I-Disease 1 0.9999995231628418
hairline I-Disease 1 1.0
, O 0 3.0462302902378724e-07
facial B-Disease 1 0.9417597055435181
asymmetry I-Disease 0 0.00021123341866768897
, O 0 1.076529017041139e-07
ptosis B-Disease 0 0.007221377920359373
, O 0 6.229473825669629e-08
hypertelorism B-Disease 0 0.00011213267862331122
, O 0 2.5277119064526232e-08
broad B-Disease 0 1.614094458091131e-06
great I-Disease 0 0.0001604802964720875
toes I-Disease 0 0.3444984555244446
, O 0 7.736276508296669e-09
and O 0 6.357840032222839e-09
clinodactyly B-Disease 0 3.7366962715168484e-06
. O 0 7.663143719582877e-08

Significant O 0 7.364005341514712e-06
intra O 0 0.02396721951663494
- O 0 0.0031393328681588173
and O 0 4.2306748326836896e-08
interfamilial O 0 1.5477895658477792e-06
phenotypic O 0 5.489999352903396e-07
variability O 0 6.957822762387877e-08
is O 0 3.6194783281651155e-10
present O 0 9.726803390508465e-11
for O 0 2.8153437914291146e-10
either O 0 2.4962149680618495e-08
TWIST O 0 0.0001831439440138638
mutations O 0 1.4814563655818347e-06
or O 0 3.3565817147973576e-07
FGFR O 0 7.70349579397589e-05
mutations O 0 4.158181582170073e-06
. O 0 1.8275893864938553e-07

The O 0 4.6982560064634526e-08
overlap O 0 1.6014742243442015e-07
in O 0 1.6234940503068174e-08
clinical O 0 1.9168224341115092e-08
features O 0 3.754493604901654e-09
and O 0 5.291441174115619e-10
the O 0 4.680431736625579e-11
presence O 0 2.0733126326888396e-10
, O 0 1.0037670694629242e-10
in O 0 1.4572669460033438e-10
the O 0 5.884174397730035e-11
same O 0 2.0156269708859753e-10
genes O 0 9.480812801498928e-10
, O 0 6.360004883854131e-11
of O 0 8.748497586086312e-12
mutations O 0 6.954738451803166e-10
for O 0 7.926348466469335e-11
more O 0 9.594395417034107e-11
than O 0 2.7310625982934766e-10
one O 0 1.2930390091980826e-09
craniosynostotic B-Disease 0 2.594257921373355e-06
condition I-Disease 0 2.601566848170478e-06
- O 0 1.0703332442574265e-08
such O 0 1.6371247413271561e-10
as O 0 8.22053447535609e-09
Saethre B-Disease 0 9.772336397873005e-07
- I-Disease 0 8.759665774960013e-07
Chotzen I-Disease 0 3.020783765350643e-07
, I-Disease 0 8.911021365243244e-10
Crouzon I-Disease 0 1.1559056645182864e-07
, I-Disease 0 1.3587270197845669e-09
and I-Disease 0 5.0253731842531124e-08
Pfeiffer I-Disease 0 0.0024435517843812704
syndromes I-Disease 0 4.127225838601589e-05
- O 0 5.418779380761407e-08
support O 0 9.677381118677886e-10
the O 0 1.0427880781094245e-09
hypothesis O 0 8.294084530291457e-09
that O 0 1.1273614264339926e-09
TWIST O 0 4.5999198050594714e-07
and O 0 3.246765301057053e-09
FGFRs O 0 3.118367786214549e-08
are O 0 6.256614670796523e-11
components O 0 4.1211825618781006e-10
of O 0 1.0720866902569348e-11
the O 0 6.391989021414801e-11
same O 0 4.229371852737529e-10
molecular O 0 1.122698489730567e-09
pathway O 0 1.176400754587803e-09
involved O 0 8.822168551247955e-10
in O 0 1.5456713686745616e-09
the O 0 1.1398110233429293e-09
modulation O 0 7.691449610547352e-08
of O 0 5.366965982744887e-09
craniofacial O 0 0.0005460898391902447
and O 0 3.0326037858685595e-07
limb O 0 1.324142431258224e-05
development O 0 4.948705445428914e-09
in O 0 1.076282263312578e-08
humans O 0 1.0800743410754876e-08
. O 0 5.1767607978092656e-09
. O 0 2.286630973458159e-08

Mutation O 0 2.9761586120002903e-05
analysis O 0 1.2092658607798512e-06
of O 0 9.783267529428485e-08
UBE3A O 1 0.6586360931396484
in O 1 0.9946660995483398
Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
patients O 0 0.028675690293312073
. O 0 1.21491837035137e-06

Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 0.0027040729764848948
AS B-Disease 1 0.9999924898147583
) O 0 2.6691886478857896e-09
is O 0 2.594907622111009e-10
caused O 0 1.0475490697103851e-08
by O 0 3.9624961090112265e-09
chromosome O 0 5.6686167226871476e-05
15q11 O 0 2.5567853299435228e-05
- O 0 1.7040601960616186e-05
q13 O 0 5.909991500629985e-07
deletions O 0 1.8484712427380146e-07
of O 0 8.938461637519879e-10
maternal O 0 1.7471183610950902e-08
origin O 0 4.189327107440022e-09
, O 0 7.722709693958052e-10
by O 0 1.841266694668775e-09
paternal O 0 1.7093288988689892e-05
uniparental B-Disease 0 0.008348938077688217
disomy I-Disease 0 0.002107334090396762
( O 0 1.6364073189834016e-06
UPD B-Disease 1 0.9999970197677612
) O 0 1.5351595550328057e-08
15 O 0 6.35457908515491e-09
, O 0 3.5786273944182767e-10
by O 0 1.3682454058638882e-09
imprinting O 0 0.011995415203273296
defects O 1 0.9334450364112854
, O 0 5.139598191483685e-10
and O 0 6.410684760815855e-10
by O 0 3.0157945585251866e-10
mutations O 0 2.2704336188894558e-08
in O 0 4.722682245272836e-09
the O 0 7.203840635128245e-09
UBE3A O 0 1.2857505680585746e-05
gene O 0 1.7821791971073253e-06
. O 0 1.5517667861786322e-07

UBE3A O 0 0.0004570102319121361
encodes O 0 8.263616109616123e-06
a O 0 2.175038105178828e-07
ubiquitin O 0 2.6439672637934564e-06
- O 0 1.286225824514986e-06
protein O 0 1.1291722756823219e-07
ligase O 0 1.6524711554666283e-07
and O 0 6.750880299222217e-09
shows O 0 1.994268075122818e-07
brain O 0 7.35364155843854e-05
- O 0 2.152772367480793e-06
specific O 0 1.4420587035601784e-07
imprinting O 0 1.8909164282376878e-05
. O 0 2.634543534441036e-07

Here O 0 1.8450665493219276e-06
we O 0 4.0179568117082454e-08
describe O 0 1.6334465158251987e-07
UBE3A O 0 5.5718257499393076e-05
coding O 0 2.8652388209593482e-05
- O 0 8.71932934387587e-06
region O 0 1.834565637182095e-07
mutations O 0 5.551483468480001e-07
detected O 0 1.7889345826915815e-07
by O 0 1.3493753892035443e-09
SSCP O 0 4.8545280151302e-07
analysis O 0 3.1506144360093913e-09
in O 0 6.088997306363808e-09
13 O 0 2.9031257398060006e-08
AS B-Disease 1 0.992659866809845
individuals O 0 1.916487801789657e-10
or O 0 4.177501899960134e-09
families O 0 3.996790010063478e-09
. O 0 1.427066642634145e-08

Two O 0 2.7862068918693694e-07
identical O 0 2.2286062062448764e-07
de O 0 1.0450185072841123e-06
novo O 0 6.633607881667558e-06
5 O 0 2.4926521291490644e-07
- O 0 2.4786972971924115e-06
bp O 0 4.997728410671698e-06
duplications O 0 5.385702479543397e-07
in O 0 9.096353004167668e-09
exon O 0 9.926212385380495e-08
16 O 0 1.9967528075426344e-08
were O 0 1.3015343469646723e-08
found O 0 2.427688983175358e-08
. O 0 1.2184436570805701e-08

Among O 0 1.0306696651696257e-07
the O 0 1.402127747240911e-09
other O 0 7.974300664237433e-10
11 O 0 1.675709127013647e-09
unique O 0 3.9917522065557876e-10
mutations O 0 4.0058665717879194e-08
, O 0 1.115779801885708e-09
8 O 0 6.325062251733016e-09
were O 0 2.53201601907449e-08
small O 0 2.0696073743664556e-09
deletions O 0 1.7674659602562315e-07
or O 0 1.507903846231784e-08
insertions O 0 4.822366577172943e-07
predicted O 0 3.95365077565657e-07
to O 0 2.8549336228422817e-09
cause O 0 4.632718031416516e-08
frameshifts O 0 1.4118613762548193e-06
, O 0 1.14986409283091e-09
1 O 0 1.6521324308627072e-09
was O 0 4.6639616613219914e-08
a O 0 1.8927777123423084e-09
mutation O 0 5.559937399368664e-09
to O 0 2.752235939151859e-10
a O 0 1.1253634690788772e-09
stop O 0 4.294692956818835e-08
codon O 0 6.45170956659058e-08
, O 0 1.8512173738383098e-10
1 O 0 4.970412414984082e-10
was O 0 1.4821438298895373e-08
a O 0 1.844504105008582e-09
missense O 0 1.373176360175421e-06
mutation O 0 2.0765677177791986e-08
, O 0 6.022281007211916e-10
and O 0 8.768754056198702e-10
1 O 0 2.4600270709385086e-09
was O 0 6.412475954675756e-07
predicted O 0 2.8540258156795062e-08
to O 0 1.5360630822858212e-10
cause O 0 1.7475976221703604e-09
insertion O 0 2.20179607879345e-09
of O 0 1.4572613948882207e-10
an O 0 1.1023851831382103e-09
isoleucine O 0 3.2610918765385577e-07
in O 0 1.8310648552954945e-09
the O 0 5.572515227036945e-10
hect O 0 4.445462309377035e-08
domain O 0 1.3147148925085617e-09
of O 0 7.914716104728825e-11
the O 0 7.309176597303235e-10
UBE3A O 0 2.3888210876066296e-07
protein O 0 4.7597410457456135e-09
, O 0 8.23637824609591e-11
which O 0 4.6190967717407716e-11
functions O 0 1.2297378393366643e-10
in O 0 1.2650701597394232e-09
E2 O 0 2.97919740432917e-07
binding O 0 1.610512967431532e-08
and O 0 2.220152950371812e-09
ubiquitin O 0 2.7149960502015347e-08
transfer O 0 4.358565064421782e-08
. O 0 4.693320931892231e-08

Eight O 0 1.7532482843307662e-07
of O 0 7.177846650385789e-10
the O 0 5.401180058761668e-10
cases O 0 2.0871091521712515e-09
were O 0 7.141596114479398e-08
familial O 0 1.0245250336993195e-07
, O 0 2.612758231990142e-09
and O 0 5.985022255572403e-09
five O 0 6.00446048437675e-09
were O 0 2.3008719551853574e-07
sporadic O 0 1.0981760169670451e-05
. O 0 1.2423288353602402e-07

In O 0 4.3485385958774714e-07
two O 0 3.894961153605436e-08
familial O 0 3.788011554206605e-06
cases O 0 2.3057660314407258e-07
and O 0 1.4725716646069031e-08
one O 0 9.861217620255047e-09
sporadic O 0 5.28244936504052e-06
case O 0 2.183361402785522e-07
, O 0 3.2450255815774653e-09
mosaicism O 0 4.7636260092076554e-07
for O 0 1.5738018666056064e-09
UBE3A O 0 3.069377498832182e-06
mutations O 0 2.0853561011335842e-07
was O 0 2.7590662199372673e-08
detected O 0 2.422781086863779e-08
in O 0 4.890349236674751e-10
the O 0 2.986190739129313e-10
mother O 0 1.7915914307664593e-09
of O 0 1.550453168630561e-11
three O 0 8.611449331397125e-09
AS B-Disease 1 1.0
sons O 0 7.747946284553109e-08
, O 0 1.1580800207688924e-10
in O 0 3.2790448134534245e-10
the O 0 4.987639745657191e-10
maternal O 0 2.9400597512108106e-08
grandfather O 0 1.8556415071202537e-08
of O 0 7.947784791406676e-11
two O 0 8.31172641824196e-09
AS B-Disease 1 0.9999985694885254
first O 0 4.795891683784248e-09
cousins O 0 2.828646827879311e-08
, O 0 7.412814806428969e-11
and O 0 1.4501216893947344e-10
in O 0 8.723096689422505e-10
the O 0 9.586315075083007e-10
mother O 0 3.648134239142564e-08
of O 0 5.946136638623756e-11
an O 0 2.9378384169831406e-09
AS B-Disease 1 1.0
daughter O 0 3.413828380871564e-05
. O 0 2.8032745902351053e-08

The O 0 2.430955525767331e-08
frequencies O 0 9.343400364514309e-08
with O 0 7.108498234487115e-10
which O 0 1.1552611089982179e-09
we O 0 3.850124663529186e-09
detected O 0 1.974427377149368e-08
mutations O 0 5.185565754572963e-09
were O 0 4.644208129178651e-09
5 O 0 5.927761059787429e-10
( O 0 3.3983307834439813e-10
14 O 0 5.417047921341123e-10
% O 0 2.6789530663262617e-11
) O 0 1.0689157892151968e-11
of O 0 1.651160284887876e-11
35 O 0 1.79867565286429e-09
in O 0 1.7619424808046347e-09
sporadic O 0 3.567560725059593e-06
cases O 0 9.680250911969779e-08
and O 0 1.4022328187479616e-08
8 O 0 2.431186141294006e-09
( O 0 8.968342735116153e-11
80 O 0 4.3009920625003417e-10
% O 0 6.440192823475854e-11
) O 0 3.314235691442846e-11
of O 0 2.044787776600554e-11
10 O 0 1.570410468332284e-09
in O 0 4.841985923320635e-09
familial O 0 2.582187903499289e-07
cases O 0 2.566166124040592e-08
. O 0 8.897303338528673e-09
. O 0 3.2377567293906395e-08

The O 0 1.1161270776938181e-05
hemochromatosis B-Disease 1 0.9999998807907104
845 O 0 0.00011150264617754146
G O 0 0.00028345416649244726
- O 0 1.739994331728667e-05
- O 0 6.7631785896082874e-06
> O 0 2.175526958581031e-08
A O 0 2.965424128476002e-09
and O 0 1.4547293369915337e-09
187 O 0 1.616588107822281e-08
C O 0 6.630306415900122e-06
- O 0 5.35001026946702e-06
- O 0 3.985737930634059e-05
> O 0 2.125409395148381e-07
G O 0 1.9376998352527153e-06
mutations O 0 1.900950508115784e-07
: O 0 2.32731744986836e-09
prevalence O 0 3.944498416785791e-08
in O 0 8.667259798755822e-09
non O 0 1.0371123607910704e-05
- O 0 0.0001631364575587213
Caucasian O 0 2.9497459763661027e-06
populations O 0 1.1244718933767217e-07
. O 0 7.232272736246159e-08

Hemochromatosis B-Disease 1 0.9994890689849854
, O 0 6.908641694280959e-07
the O 0 1.1428535344748525e-06
inherited B-Disease 1 1.0
disorder I-Disease 1 1.0
of I-Disease 0 1.0066709243972127e-08
iron I-Disease 1 0.77511066198349
metabolism I-Disease 0 3.177284088451415e-05
, O 0 2.1104669123417352e-09
leads O 0 2.0901487207680702e-09
, O 0 7.840884053145203e-10
if O 0 1.4465292963450338e-08
untreated O 0 1.8660750811250182e-06
, O 0 9.197360650858855e-10
to O 0 4.483181825776228e-09
progressive O 0 2.3245781903824536e-06
iron B-Disease 1 0.9976174235343933
overload I-Disease 0 0.0006599909393116832
and O 0 3.6681669257632166e-07
premature B-Disease 0 8.144335879478604e-06
death I-Disease 0 1.9044108512389357e-07
. O 0 7.177072092190429e-08

The O 0 4.296317001717398e-06
hemochromatosis B-Disease 1 0.9999997615814209
gene O 0 3.1996869438444264e-06
, O 0 1.3079798577564361e-08
HFE O 0 6.0825623222626746e-06
, O 0 1.770492530361878e-09
recently O 0 2.103676344233918e-08
has O 0 4.808456410820838e-10
been O 0 9.82601000565353e-10
identified O 0 1.1228399321439042e-09
, O 0 2.2746995259614877e-11
and O 0 6.244632588803256e-11
characterization O 0 6.258527585067952e-10
of O 0 6.5182299661958876e-12
this O 0 1.047086514716078e-10
gene O 0 3.603567888532666e-09
has O 0 4.1300746156380796e-10
shown O 0 3.1038444037179147e-10
that O 0 7.304490345916292e-11
it O 0 3.277954990776877e-11
contains O 0 1.487094301866332e-11
two O 0 2.8919810990402084e-10
mutations O 0 1.9034289699959572e-09
that O 0 1.4135634329726088e-10
result O 0 3.9359568382302257e-10
in O 0 7.901567178336677e-10
amino O 0 1.1978654734789984e-09
acid O 0 1.4470141751488086e-09
substitutions O 0 7.878425911655995e-09
- O 0 8.973056964123316e-09
cDNA O 0 2.615397143301834e-08
nucleotides O 0 5.651796186612046e-08
845 O 0 2.2505945196371613e-07
G O 0 1.8227553937322227e-06
- O 0 1.3186001979192952e-06
- O 0 1.8027898249783902e-06
> O 0 1.8104064025692423e-08
A O 0 1.3856715774807071e-08
( O 0 1.8957548864051432e-09
C282Y O 0 2.168815349534725e-08
) O 0 6.269516156232058e-11
and O 0 1.3530472575684627e-10
187 O 0 6.547384856503413e-09
C O 0 1.3706048775929958e-05
- O 0 1.74991200765362e-05
- O 0 3.630715946201235e-05
> O 0 2.5295403816016915e-07
G O 0 1.8431391026751953e-06
( O 0 1.449152708943302e-08
H63D O 0 3.540925263223471e-06
) O 0 1.0789172222303023e-08
. O 0 2.2080170580807135e-08

Although O 0 0.0002124359889421612
hemochromatosis B-Disease 1 1.0
is O 0 2.6420357457368482e-08
common O 0 5.3690136780915054e-09
in O 0 2.2919142139699034e-08
Caucasians O 0 2.1278176518535474e-06
, O 0 2.2810582311905137e-09
affecting O 0 1.407017702348412e-08
> O 0 2.7976604144441808e-08
= O 0 5.156089244451323e-08
1 O 0 1.1657713017143578e-08
/ O 0 1.78736087264042e-07
300 O 0 9.906268028103682e-10
individuals O 0 3.4928806375011945e-11
of O 0 8.368247934875672e-12
northern O 0 4.3380088410316375e-10
European O 0 8.726012801218985e-09
origin O 0 4.952782628464547e-10
, O 0 2.2447504965938947e-10
it O 0 3.101264245408686e-10
has O 0 1.6012090264805323e-10
not O 0 1.0902606595308839e-10
been O 0 3.088307387599798e-10
recognized O 0 3.608640469776603e-11
in O 0 4.2136064082320956e-10
other O 0 2.0853016535760105e-10
populations O 0 1.7831878196261641e-09
. O 0 1.0898480340415517e-08

The O 0 2.4773088469487448e-08
present O 0 1.6566320537592105e-09
study O 0 5.451615270324339e-10
used O 0 2.254977760074439e-09
PCR O 0 1.7812315888932062e-07
and O 0 8.456988997984638e-10
restriction O 0 1.7361562854034673e-08
- O 0 1.6302712069204972e-08
enzyme O 0 6.97049218345569e-09
digestion O 0 4.427521016481251e-09
to O 0 2.3021903827746826e-10
analyze O 0 1.8598821371895724e-09
the O 0 1.6004825242887932e-10
frequency O 0 1.084127987382999e-08
of O 0 1.7229459525758273e-10
the O 0 1.2332265209025195e-09
845 O 0 9.177794169090703e-08
G O 0 1.9153608263877686e-06
- O 0 1.3482410849974258e-06
- O 0 1.3467233657138422e-06
> O 0 1.4423029881527327e-08
A O 0 4.897156458127938e-09
and O 0 1.1833365398672413e-09
187 O 0 1.2874265209461555e-08
C O 0 2.8326178380666533e-06
- O 0 4.525790700427024e-06
- O 0 6.881445187900681e-06
> O 0 2.0884746732008352e-07
G O 0 7.138993964872498e-07
mutations O 0 1.4565438277713838e-07
in O 0 2.4318875802009643e-08
HLA O 0 1.839700644268305e-06
- O 0 5.5729564962803124e-08
typed O 0 3.2630509849695954e-08
samples O 0 2.000491550191441e-09
from O 0 8.269690487949788e-10
non O 0 6.019185860850484e-08
- O 0 1.2198037211419432e-06
Caucasian O 0 1.0050328569377598e-07
populations O 0 1.274819583230169e-09
, O 0 9.000044459694934e-11
comprising O 0 1.6874278363498973e-10
Australian O 0 3.279934324140754e-09
Aboriginal O 0 2.097933160527532e-09
, O 0 9.887613644510296e-11
Chinese O 0 1.6931826773980418e-10
, O 0 1.5733418734509286e-10
and O 0 5.396443292227104e-10
Pacific O 0 6.881601066766052e-09
Islanders O 0 3.6097958400205243e-07
. O 0 3.064218745407743e-08

Results O 0 2.414607706668903e-06
showed O 0 2.2841729219180706e-07
that O 0 4.372991413426064e-10
the O 0 4.966413391649382e-10
845 O 0 1.8317403771561658e-07
G O 0 8.634199730295222e-06
- O 0 5.134703314979561e-06
- O 0 1.01368905234267e-05
> O 0 3.192086595049659e-08
A O 0 8.595940848010741e-09
mutation O 0 1.2417100236916667e-08
was O 0 9.49192724419845e-09
present O 0 1.0842757247608859e-10
in O 0 2.6124580276842835e-10
these O 0 4.120654165107318e-11
populations O 0 1.62363483768857e-10
( O 0 2.687978173376848e-10
allele O 0 7.493938802838329e-09
frequency O 0 8.875862711477112e-09
0 O 0 1.6805424829513527e-09
. O 0 3.150041893995592e-10
32 O 0 1.5489738380836116e-09
% O 0 8.44931000165694e-11
) O 0 6.18645967787046e-11
, O 0 1.2445516839321158e-10
and O 0 8.344412383287647e-10
, O 0 7.96778962253164e-11
furthermore O 0 3.867389464229376e-10
, O 0 1.1996620363774468e-10
it O 0 1.6009472636469013e-09
was O 0 9.715893156680977e-07
always O 0 1.0927308835562144e-08
seen O 0 2.648729902077207e-09
in O 0 1.6082919718218847e-10
conjunction O 0 6.944147479259755e-10
with O 0 1.1124902110637436e-09
HLA O 0 1.1763270322262542e-06
haplotypes O 0 1.339619046802909e-07
common O 0 1.1326360294106053e-08
in O 0 1.4109978074827723e-08
Caucasians O 0 2.1552570217409084e-07
, O 0 3.251070246346188e-10
suggesting O 0 1.0075352996352649e-08
that O 0 1.4080558941031995e-09
845 O 0 6.568451027533229e-08
G O 0 4.087497018190334e-06
- O 0 1.3054087503405754e-05
- O 0 4.2338197090430185e-05
> O 0 4.278308551874943e-08
A O 0 6.474144953472205e-08
may O 0 6.860319672341575e-07
have O 0 1.2798334614316786e-09
been O 0 2.3638713209095386e-10
introduced O 0 1.9841124576647218e-10
into O 0 7.763052700671125e-11
these O 0 4.1320898092056524e-11
populations O 0 1.550811840056454e-10
by O 0 9.03941088647997e-10
Caucasian O 0 6.218148769221443e-07
admixture O 0 1.778120008566475e-06
. O 0 1.5214814652608766e-07

187 O 0 9.038019925355911e-06
C O 0 7.50128529034555e-05
- O 0 1.7478872905485332e-05
- O 0 1.3608251720143016e-05
> O 0 1.953825687905919e-07
G O 0 4.694775839197973e-07
was O 0 1.2137490124075612e-08
present O 0 2.0465797112567685e-10
at O 0 1.2530533277654854e-09
an O 0 1.0036751985076364e-10
allele O 0 2.0048700477559578e-08
frequency O 0 8.74377690252004e-08
of O 0 2.578922408957851e-09
2 O 0 8.582707522464261e-08
. O 0 1.8318679906315083e-07

68 O 0 2.0940593458362855e-05
% O 0 1.0989721133114472e-08
in O 0 1.668523763598273e-09
the O 0 2.2493321094607666e-10
two O 0 2.27419749698754e-10
populations O 0 1.52597393054954e-10
analyzed O 0 4.447063162160703e-09
( O 0 8.124417805177586e-10
Australian O 0 9.945899215324516e-09
Aboriginal O 0 8.69439720219134e-09
and O 0 7.681707492324108e-10
Chinese O 0 1.0118892390664769e-09
) O 0 1.4524504932111881e-09
. O 0 1.110961900252505e-08

In O 0 1.6254763579581777e-07
the O 0 5.880175457662062e-09
Australian O 0 1.5771682626564143e-08
Aboriginal O 0 5.7574962575301925e-09
samples O 0 1.6704279071078076e-09
, O 0 1.2656174719349877e-10
187 O 0 5.232231092833217e-09
C O 0 1.982119101739954e-06
- O 0 5.2367795433383435e-06
- O 0 9.583191058482043e-06
> O 0 1.3752718075465964e-07
G O 0 8.060352456595865e-07
was O 0 4.992575242113162e-08
found O 0 4.4094752849055396e-10
to O 0 5.7795841029717465e-11
be O 0 1.8919539546136122e-10
associated O 0 7.349129083067396e-10
with O 0 1.2839779239826044e-09
HLA O 0 2.0842478534177644e-06
haplotypes O 0 2.233795868278321e-07
common O 0 1.5649185058919102e-08
in O 0 1.5416473431173472e-08
Caucasians O 0 2.548524093981541e-07
, O 0 5.658078450210269e-10
suggesting O 0 8.697864650741849e-09
that O 0 3.0074598367235694e-10
it O 0 5.369482081185595e-10
was O 0 1.747388367334679e-08
introduced O 0 3.897850042733353e-09
by O 0 4.5117534708261076e-10
recent O 0 5.3636018293445886e-08
admixture O 0 1.5929547316773096e-06
. O 0 1.0465608824006267e-07

In O 0 1.6374566769172816e-07
the O 0 1.8468028217810684e-09
Chinese O 0 1.2208717370398858e-09
samples O 0 1.3755091510248008e-09
analyzed O 0 1.5994304769506584e-09
, O 0 1.104059552115011e-10
187 O 0 4.090423999514314e-09
C O 0 5.318624971550889e-07
- O 0 9.471854127696133e-07
- O 0 3.170187710566097e-06
> O 0 5.7204793790788244e-08
G O 0 5.712824417969387e-07
was O 0 4.6595332037213666e-08
present O 0 2.604517435056408e-10
in O 0 7.323805562009511e-09
association O 0 2.0093633423812207e-09
with O 0 5.911431066873973e-11
a O 0 5.576694106501634e-10
wide O 0 3.643529034036419e-09
variety O 0 6.10957684443747e-09
of O 0 1.1484482254076056e-09
HLA O 0 6.237868319658446e-07
haplotypes O 0 1.4774366263736738e-07
, O 0 1.2203640320507247e-09
showing O 0 1.552325734621718e-08
this O 0 3.3176211777785625e-10
mutation O 0 6.906897276337531e-10
to O 0 1.2257615755739693e-10
be O 0 5.351099563455364e-10
widespread O 0 5.708625794298428e-10
and O 0 4.081913473896748e-09
likely O 0 1.578534636337281e-08
to O 0 1.9933414641126745e-10
predate O 0 2.1795059979012876e-08
the O 0 3.6076580611776876e-10
more O 0 2.1315672837918243e-10
genetically O 0 3.218986632802512e-09
restricted O 0 8.032434273275157e-09
845 O 0 2.0323450655723718e-07
G O 0 4.985132818546845e-06
- O 0 5.969570338493213e-06
- O 0 2.6036914277938195e-05
> O 0 1.4464843900441338e-07
A O 0 5.024692839583622e-08
mutation O 0 4.318514186252287e-07
. O 0 5.811117986809222e-08

Genotype O 1 0.9988299012184143
- O 1 0.9995421171188354
phenotype O 0 0.0023355402518063784
correlations O 0 0.0009010509238578379
in O 0 7.63170828577131e-05
attenuated B-Disease 1 0.9998175501823425
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 0.9999910593032837
coli I-Disease 1 0.9999997615814209
. O 0 2.848676376743242e-05

Germ O 0 0.18142279982566833
- O 0 0.3597874939441681
line O 0 7.6016035563952755e-06
mutations O 0 2.2636778851392592e-07
of O 0 2.9412289270780434e-10
the O 0 4.195588321209698e-09
tumor B-Disease 0 3.0437436180363875e-06
suppressor O 0 1.138457446359098e-05
APC O 0 1.9480203263810836e-06
are O 0 1.9905735726410967e-08
implicated O 0 3.049842234759126e-06
in O 0 4.620382242137566e-06
attenuated B-Disease 1 0.999863862991333
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 0.9999997615814209
coli I-Disease 1 1.0
( O 0 0.0002908837632276118
AAPC B-Disease 1 0.9999991655349731
) O 0 7.841190097224171e-08
, O 0 1.9515951077409e-09
a O 0 4.990582613828565e-09
variant O 0 0.0009772212943062186
of O 0 1.305768728343537e-05
familial B-Disease 1 1.0
adenomatous I-Disease 1 0.9999992847442627
polyposis I-Disease 1 1.0
( O 0 4.175607318757102e-05
FAP B-Disease 0 8.873891056282446e-05
) O 0 3.6027523719894816e-07
. O 0 3.3933801546481845e-07

AAPC B-Disease 1 0.9999979734420776
is O 0 1.1111170294952899e-07
recognized O 0 2.5477300269471925e-09
by O 0 2.682594979486197e-10
the O 0 3.338352372317388e-10
occurrence O 0 7.425076109512929e-09
of O 0 8.717740973551713e-10
< O 0 2.2172982028223487e-07
100 O 0 1.0815359274829461e-08
colonic B-Disease 0 1.3101167724016705e-06
adenomas I-Disease 0 1.4538652976625599e-05
and O 0 6.233703331304241e-09
a O 0 5.966557914405257e-09
later O 0 9.505824891675729e-07
onset O 0 0.06370756775140762
of O 0 0.07036271691322327
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 1.2799641524452454e-07
age O 0 8.900057224536795e-08
> O 0 3.631306455531558e-08
40 O 0 1.4964260941496832e-08
years O 0 9.941480527686508e-09
) O 0 2.850727431891187e-09
. O 0 3.537498471928302e-08

The O 0 3.6197025821138595e-08
aim O 0 1.7709595567794167e-08
of O 0 1.6104376165948509e-10
this O 0 1.6510730282970343e-10
study O 0 1.4439559270496005e-10
was O 0 5.711144446252092e-09
to O 0 8.659192252125081e-10
assess O 0 1.1559090040691444e-07
genotype O 0 0.00011149062629556283
- O 0 0.0003258039942011237
phenotype O 0 9.384866643813439e-06
correlations O 0 1.775757482391782e-05
in O 0 2.6427119337313343e-06
AAPC B-Disease 1 0.9999983310699463
families O 0 3.666712018457474e-07
. O 0 7.903051368884917e-08

By O 0 1.632876518442572e-07
protein O 0 1.7235480527233449e-06
- O 0 1.542437757962034e-06
truncation O 0 2.8118106456531677e-06
test O 0 4.863615572503477e-07
( O 0 3.9023060338649884e-09
PTT O 0 6.667080754141352e-08
) O 0 2.697098655524144e-10
assay O 0 5.014446191609068e-09
, O 0 4.690906343918222e-11
the O 0 3.3723013964648274e-11
entire O 0 6.711206035348027e-10
coding O 0 1.4769907963341211e-08
region O 0 1.3995814507339333e-09
of O 0 2.2526724929861075e-10
the O 0 7.574263438669959e-10
APC B-Disease 0 9.576615056516857e-09
gene O 0 6.411201347589213e-09
was O 0 2.2140477895504773e-08
screened O 0 1.3127710474236665e-08
in O 0 1.9226213954226523e-09
affected O 0 4.454448809809719e-09
individuals O 0 2.430012024934314e-10
from O 0 7.497484411089772e-09
11 O 0 7.666125725336315e-07
AAPC B-Disease 1 0.9999990463256836
kindreds O 0 1.2075995073246304e-05
, O 0 4.0062539952145926e-09
and O 0 1.3810139698477997e-09
their O 0 7.645326038918654e-10
phenotypic O 0 6.160516363706847e-08
differences O 0 1.7675704100383882e-07
were O 0 3.8769621824030764e-07
examined O 0 1.6395001694036182e-06
. O 0 4.849161072684183e-08

Five O 0 3.2007932304622955e-07
novel O 0 1.7958933540285216e-07
germ O 0 0.0013120444491505623
- O 0 0.0073982710018754005
line O 0 1.485463508288376e-05
APC B-Disease 0 5.749915317210252e-07
mutations O 0 5.5801894660589824e-08
were O 0 1.2951427486029843e-08
identified O 0 1.1158398649513401e-08
in O 0 3.72239927770579e-09
seven O 0 2.2160588031283623e-08
kindreds O 0 1.6202418464672519e-06
. O 0 9.57459178607678e-08

Mutations O 0 1.5312405594158918e-05
were O 0 1.2123125259222434e-07
located O 0 4.63470373190944e-09
in O 0 1.9732142586548207e-09
three O 0 1.4651374558027896e-10
different O 0 4.208094636637405e-11
regions O 0 5.589661719596073e-11
of O 0 3.958239291890209e-11
the O 0 1.2332477261622898e-09
APC B-Disease 0 7.2963657338220855e-09
gene O 0 3.517393265539681e-09
( O 0 2.4325438885419715e-10
1 O 0 3.985627938796199e-10
) O 0 5.843196759780511e-11
at O 0 4.023929189855835e-09
the O 0 2.1712634468151748e-10
5 O 0 5.702316840938693e-09
end O 0 5.266636549094983e-08
spanning O 0 1.0866743949122792e-08
exons O 0 1.0043503806400622e-08
4 O 0 3.658424452268605e-09
and O 0 1.240707980798561e-09
5 O 0 6.656845630281794e-10
, O 0 1.0572653169615975e-10
( O 0 1.5089898774967025e-10
2 O 0 3.056580544225085e-10
) O 0 3.0869515277309745e-11
within O 0 8.231571674288674e-11
exon O 0 1.3672547538590152e-08
9 O 0 2.157107203970554e-08
, O 0 3.7683883791217454e-10
and O 0 6.97086055545526e-10
( O 0 2.556870826175839e-10
3 O 0 7.516810507368632e-10
) O 0 1.6000123448378645e-10
at O 0 3.832511641377323e-09
the O 0 3.970960227306364e-10
3 O 0 1.5067969982851537e-08
distal O 0 2.407938097803708e-07
end O 0 7.074014973795784e-08
of O 0 1.3025686085299526e-10
the O 0 1.8291310688312024e-09
gene O 0 2.149062652279099e-07
. O 0 5.996382412831736e-08

Variability O 0 1.5501471352763474e-05
in O 0 2.407032795304076e-08
the O 0 1.1549901035579069e-09
number O 0 4.629438610237457e-09
of O 0 2.274986627526232e-06
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
was O 0 7.192089469754137e-06
most O 0 8.945455487463505e-10
apparent O 0 7.176878202841408e-09
in O 0 2.0615309459515174e-09
individuals O 0 9.84517675717278e-11
with O 0 1.1752653017449433e-10
mutations O 0 3.074374310685357e-09
in O 0 7.707876004126035e-10
region O 0 3.3111873243285572e-09
1 O 0 6.0990750228029356e-09
, O 0 1.163906637735579e-09
and O 0 1.4286864313817205e-07
upper O 1 0.9994687438011169
- O 1 0.9999417066574097
gastrointestinal O 0 0.04506165534257889
manifestations O 0 3.1513006888417294e-06
were O 0 1.1782717592723202e-06
more O 0 4.391968122519074e-09
severe O 0 1.3885999123885995e-06
in O 0 4.159437683171063e-09
them O 0 3.846557738995671e-09
. O 0 1.4005594906052465e-08

In O 0 1.3193407255585043e-07
individuals O 0 1.806576555019035e-09
with O 0 6.856442080760417e-10
mutations O 0 1.3277846377945934e-08
in O 0 2.724783954022314e-09
either O 0 2.091313122676297e-09
region O 0 3.3952616274035563e-09
2 O 0 1.7264502050196029e-09
or O 0 1.5761089100507775e-09
region O 0 7.562656612059016e-10
3 O 0 3.2487661449920324e-09
, O 0 6.954761766486683e-11
the O 0 6.098033189516627e-11
average O 0 1.3770790063816207e-09
number O 0 4.593687583098749e-11
of O 0 4.3243842534623766e-11
adenomas B-Disease 0 7.858993456011376e-08
tended O 0 1.2854560971220508e-08
to O 0 4.148106302892529e-10
be O 0 1.723209686055327e-09
lower O 0 1.5876435099926312e-07
than O 0 2.0740641148986327e-10
those O 0 5.7478789089460136e-11
in O 0 1.9986179378150837e-10
individuals O 0 4.295707886625699e-12
with O 0 9.725035880758792e-12
mutations O 0 1.6678904923850268e-09
in O 0 1.1797082200004638e-09
region O 0 1.2090763945593608e-09
1 O 0 1.2848377917151765e-09
, O 0 1.6936220481600373e-10
although O 0 1.4345599153031685e-09
age O 0 1.49153649431355e-08
at O 0 3.126783454376891e-08
diagnosis O 0 7.268005788318987e-07
was O 0 4.820122967430507e-08
similar O 0 2.0361275332447804e-08
. O 0 7.764011655808645e-08

In O 0 1.7019514189087204e-06
all O 0 3.732304776349338e-07
AAPC B-Disease 1 0.9999973773956299
kindreds O 0 3.604713856475428e-05
, O 0 1.1263797894400795e-08
a O 0 4.416648824445701e-09
predominance O 0 4.2526889387772826e-07
of O 0 1.3555903954909354e-08
right O 1 0.9922742247581482
- O 1 1.0
sided O 1 1.0
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and O 0 9.229483839590102e-05
rectal B-Disease 1 0.9997206330299377
polyp I-Disease 0 8.816828631097451e-05
sparing O 0 1.4958289966671146e-06
was O 0 3.450889778378041e-07
observed O 0 6.904796379103573e-08
. O 0 3.1837441127891e-08

No O 0 4.898579936707392e-05
desmoid B-Disease 1 0.8765527606010437
tumors I-Disease 1 1.0
were O 0 9.574680461810203e-07
found O 0 1.1748809924938541e-08
in O 0 2.479600524907255e-09
these O 0 4.105682016586343e-09
kindreds O 0 3.1322595077654114e-06
. O 0 1.3718816660457378e-07

Our O 0 4.6641126516533404e-08
data O 0 7.340447361059432e-09
suggest O 0 2.8615629865669234e-09
that O 0 2.386663922049337e-10
, O 0 1.886339973111717e-10
in O 0 2.5092372624158088e-08
AAPC B-Disease 1 0.9999998807907104
families O 0 3.6057403729472526e-09
, O 0 5.801053734599826e-11
the O 0 1.62123890701249e-11
location O 0 5.267213887272248e-10
of O 0 4.1776491987999265e-11
the O 0 6.321708934109438e-09
APC B-Disease 0 5.654011374645052e-07
mutation O 0 9.514806720289926e-08
may O 0 8.764063608168726e-08
partially O 0 6.575922384399746e-08
predict O 0 1.1235328400971412e-07
specific O 0 6.959187004440537e-09
phenotypic O 0 3.78947532908569e-07
expression O 0 2.935734642051102e-07
. O 0 1.8207923346835742e-07

This O 0 4.1989927979102504e-08
should O 0 6.391982942943741e-09
help O 0 5.950394066367437e-10
in O 0 2.547194122293206e-10
the O 0 1.1454069637206743e-10
design O 0 1.1317700554513976e-08
of O 0 1.2035582253044907e-10
tailored O 0 1.130896549739191e-07
clinical O 0 5.161224180483259e-06
- O 0 0.0008013376500457525
management O 0 7.302647730966783e-08
protocols O 0 4.184992619116201e-08
in O 0 1.4641827750239145e-09
this O 0 9.777675891164961e-11
subset O 0 3.363176848125704e-09
of O 0 6.233152882728632e-10
FAP B-Disease 0 4.700259239598381e-07
patients O 0 6.091672162256145e-07
. O 0 6.2949974122261665e-09
. O 0 3.394130132505779e-08

Wilms B-Disease 1 0.9418297410011292
' I-Disease 0 0.00013302975276019424
tumor I-Disease 0 1.0007868695538491e-05
1 O 0 5.452838180985964e-08
and O 0 3.72488706545937e-08
Dax O 1 0.9998962879180908
- O 0 5.865738330612658e-07
1 O 0 7.106116139965479e-09
modulate O 0 1.8105156129877287e-07
the O 0 4.548312837471258e-09
orphan O 0 5.133382501298911e-07
nuclear O 0 9.753289731406767e-08
receptor O 0 1.0765618441155311e-07
SF O 0 4.801024988410063e-05
- O 0 1.326487790720421e-07
1 O 0 2.747983396389486e-09
in O 0 1.4278446203164208e-09
sex O 0 1.3792352149266662e-08
- O 0 8.97769680818783e-09
specific O 0 1.5254275620435465e-09
gene O 0 4.9179856631553776e-08
expression O 0 7.565029847000915e-08
. O 0 1.0699621100229706e-07

Products O 0 3.1312888495449442e-06
of O 0 3.317143537628908e-08
steroidogenic O 0 1.1675731002469547e-05
factor O 0 1.0480810885837855e-07
1 O 0 2.9231062015355747e-08
( O 0 2.122785502933766e-08
SF O 0 0.04682767018675804
- O 0 2.3471975509892218e-06
1 O 0 1.5573167644333807e-08
) O 0 4.094670380538901e-09
and O 0 6.368328087091868e-08
Wilms B-Disease 0 0.0003819853300228715
tumor I-Disease 0 4.5771394070470706e-06
1 O 0 2.569418278142166e-08
( O 0 4.723754276625414e-09
WT1 O 0 1.2731942433674703e-06
) O 0 8.577298871159655e-10
genes O 0 3.3121347886577723e-09
are O 0 2.1134712036019465e-10
essential O 0 1.4086227739795731e-09
for O 0 2.634912010801571e-10
mammalian O 0 5.21798213526381e-08
gonadogenesis O 0 2.5093814315368945e-07
prior O 0 1.184619780048024e-08
to O 0 2.877303284520849e-09
sexual O 0 2.7096261234760277e-08
differentiation O 0 2.4504009843440144e-07
. O 0 5.6515482071972656e-08

In O 0 3.1069160399965767e-07
males O 0 1.1545527911493991e-07
, O 0 9.704057113424369e-09
SF O 0 0.030251439660787582
- O 0 2.287831875946722e-06
1 O 0 4.621621751965677e-09
participates O 0 3.021784600321098e-09
in O 0 1.1624690099409918e-09
sexual O 0 5.758657439791648e-10
development O 0 1.1841261304823547e-10
by O 0 2.0639930042865018e-10
regulating O 0 5.1667381484321595e-09
expression O 0 1.6893834109410477e-09
of O 0 1.8660711864626478e-10
the O 0 2.5378410484222513e-09
polypeptide O 0 2.8593663614628895e-07
hormone O 0 1.1812053912763076e-07
Mullerian O 0 2.260093424411025e-06
inhibiting O 0 8.486597948831331e-07
substance O 0 1.572624114487553e-06
( O 0 7.178482519520912e-08
MIS O 0 4.8505102313356474e-05
) O 0 3.969600825826092e-08
. O 0 8.927072059350394e-08

Here O 0 2.0832799236814026e-06
, O 0 4.346409010480556e-09
we O 0 1.1047299741662187e-09
show O 0 5.6411200155537244e-09
that O 0 1.5664765040668271e-09
WT1 O 0 2.131075962097384e-05
- O 0 1.601422809471842e-05
KTS O 0 6.991456029936671e-05
isoforms O 0 5.675588568010426e-07
associate O 0 4.4344790950390234e-08
and O 0 1.7068474411630064e-09
synergize O 0 3.938650081636297e-07
with O 0 9.37165012260266e-09
SF O 1 0.6944372653961182
- O 0 1.0899290145971463e-06
1 O 0 5.042730233384418e-09
to O 0 2.3541446569907976e-09
promote O 0 2.549870359302986e-08
MIS O 0 2.3681082893745042e-05
expression O 0 2.47798084274109e-07
. O 0 1.1541125388703222e-07

In O 0 5.155008011570317e-07
contrast O 0 4.019861989945639e-07
, O 0 5.265009406230092e-08
WT1 O 0 5.8368466852698475e-05
missense O 0 7.128225115593523e-05
mutations O 0 2.5118624762399122e-06
, O 0 2.007294774841739e-09
associated O 0 2.3259547621279353e-09
with O 0 1.527121873401427e-09
male B-Disease 0 1.03766365100455e-06
pseudohermaphroditism I-Disease 1 0.9999998807907104
in O 0 3.331634434289299e-05
Denys B-Disease 1 0.999990701675415
- I-Disease 1 1.0
Drash I-Disease 1 0.9999995231628418
syndrome I-Disease 1 0.9999998807907104
, O 0 1.027160223543433e-08
fail O 0 5.704881118617777e-07
to O 0 4.802042763429881e-09
synergize O 0 2.1284713511704467e-06
with O 0 7.655255274130468e-08
SF O 1 0.9966474175453186
- O 0 2.060588485619519e-05
1 O 0 2.5451964802414295e-07
. O 0 1.6486838205764798e-07

Additionally O 0 7.0870999024919e-07
, O 0 4.618361693076167e-09
the O 0 1.0691615370816976e-09
X O 0 6.752440822310746e-05
- O 0 1.7255235434276983e-05
linked O 0 7.1020240284269676e-06
, O 0 3.216936717009844e-09
candidate O 0 1.4106613654973899e-08
dosage O 0 8.328896910825279e-06
- O 0 2.5552856186550343e-06
sensitive O 0 8.345373885276786e-07
sex O 0 1.7337049484922318e-07
- O 0 1.253350916385898e-07
reversal O 0 5.310546313808118e-08
gene O 0 3.510853474608666e-08
, O 0 2.5803492675890993e-09
Dax O 1 0.9925783276557922
- O 0 1.1474027417079924e-07
1 O 0 3.492777622682297e-09
, O 0 6.162414467603128e-10
antagonizes O 0 1.764220769473468e-07
synergy O 0 1.515614940217347e-07
between O 0 7.647054189874325e-08
SF O 1 0.8269882202148438
- O 0 1.7028801266860683e-06
1 O 0 8.177918786600458e-09
and O 0 5.842856865001522e-09
WT1 O 0 5.3962008905728e-07
, O 0 7.282263680963297e-10
most O 0 3.37719491261268e-10
likely O 0 9.127979483380955e-10
through O 0 7.110853572633857e-11
a O 0 1.9604509682302762e-10
direct O 0 1.6315830908553153e-09
interaction O 0 8.124080963511915e-09
with O 0 3.74096931210488e-09
SF O 1 0.887911319732666
- O 0 3.2277728223562008e-06
1 O 0 4.3668279658959364e-08
. O 0 4.195918634763984e-08

We O 0 3.268336854489462e-07
propose O 0 1.1566401525442416e-07
that O 0 1.7312612454745135e-09
WT1 O 0 2.2053104657970835e-06
and O 0 2.7220167453378963e-08
Dax O 1 0.999988317489624
- O 0 1.6611344335615286e-06
1 O 0 3.4121669933995236e-09
functionally O 0 1.3721400904387338e-08
oppose O 0 1.824924766857805e-09
each O 0 1.2147528816175424e-10
other O 0 2.780946861680178e-10
in O 0 7.483793584839304e-10
testis O 0 1.3850216085131706e-08
development O 0 3.640178991570764e-10
by O 0 1.7545981334521343e-09
modulating O 0 3.0358442018041387e-06
SF O 0 0.05993792787194252
- O 0 1.7797893860915792e-06
1 O 0 1.4229630096451729e-07
- O 0 8.257781018983223e-07
mediated O 0 3.780029373956495e-06
transactivation O 0 1.0751869012892712e-05
. O 0 2.687698774650471e-08
. O 0 2.0833120117913495e-08

A O 0 3.6486430872173514e-06
mouse O 0 1.2093732948414981e-05
model O 0 2.083269919239683e-06
for O 0 1.3959717080069822e-06
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
imprinting O 0 0.3610084652900696
- O 0 0.0697980597615242
centre O 0 1.3949595086160116e-05
mutations O 0 2.566162947914563e-05
. O 0 2.761741768608772e-07

Imprinting O 0 7.157221261877567e-05
in O 0 2.1684745377115178e-07
the O 0 3.6962241267701756e-08
15q11 O 0 7.368206297542201e-06
- O 0 6.024778485880233e-06
q13 O 0 3.752058432837657e-07
region O 0 8.05191557873286e-09
involves O 0 3.675532100899659e-09
an O 0 1.6432604166283227e-09
imprinting O 0 3.790273979120684e-07
centre O 0 1.9136503226491186e-07
( O 0 6.187150791703289e-09
IC O 0 8.661560286782333e-07
) O 0 4.458560465270267e-10
, O 0 7.068447910318909e-11
mapping O 0 9.341182272137871e-10
in O 0 4.697247590890186e-10
part O 0 7.711155602940778e-10
to O 0 6.389931361816537e-10
the O 0 5.495348065487349e-10
promoter O 0 3.0645463056089284e-08
and O 0 1.8787180700030603e-09
first O 0 4.304063772053723e-09
exon O 0 4.6787967278305587e-08
of O 0 4.895456484632632e-09
SNRPN O 0 2.8012920665787533e-05
. O 0 2.6662036134439404e-07

Deletion O 0 3.628265767474659e-05
of O 0 3.6082052901065254e-08
this O 0 2.342674676469869e-08
IC O 0 3.1362378649646416e-05
abolishes O 0 1.6139066474352148e-06
local O 0 4.235931072571475e-08
paternally O 0 7.398360821753158e-07
derived O 0 1.8479031638207744e-08
gene O 0 1.2922981795782107e-07
expression O 0 1.5661607122297028e-08
and O 0 5.861520158134681e-09
results O 0 1.8785027577905566e-07
in O 0 0.021623704582452774
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 9.016944204631727e-06
PWS B-Disease 1 0.9999994039535522
) O 0 4.798731083610619e-07
. O 0 2.142461141829699e-07

We O 0 5.07803065374901e-07
have O 0 1.9550001617574253e-09
created O 0 1.10465203650989e-09
two O 0 1.9421482200243645e-09
deletion O 0 1.209933202517277e-07
mutations O 0 5.703668648493476e-08
in O 0 1.7987003886332786e-08
mice O 0 7.256522280840727e-07
to O 0 8.29182233985648e-09
understand O 0 1.942269818755449e-06
PWS B-Disease 1 1.0
and O 0 1.1795288301641449e-08
the O 0 6.523012685555329e-10
mechanism O 0 4.4063503956692784e-09
of O 0 8.805357554209081e-10
this O 0 9.851216731249224e-09
IC O 0 1.64504144777311e-05
. O 0 4.8694118959247135e-08

Mice O 0 0.0056952363811433315
harbouring O 0 0.00019616843201220036
an O 0 1.299228102880079e-07
intragenic O 0 1.864408295659814e-05
deletion O 0 1.8463144897395978e-06
in O 0 4.6207777160134356e-08
Snrpn O 0 2.108170519932173e-06
are O 0 2.5507396195223464e-09
phenotypically O 0 2.923246711361571e-07
normal O 0 6.641088390324512e-08
, O 0 5.238958711295538e-10
suggesting O 0 1.0730600408237478e-08
that O 0 4.32498842295459e-10
mutations O 0 4.345257043070205e-09
of O 0 2.850807645504716e-10
SNRPN O 0 6.044369911251124e-07
are O 0 6.488157233697223e-10
not O 0 4.3909612057468905e-10
sufficient O 0 1.8500463383475108e-09
to O 0 5.015804660501999e-09
induce O 0 3.93334175896598e-06
PWS B-Disease 1 0.9999998807907104
. O 0 6.440890274461708e-07

Mice O 0 0.0015544506022706628
with O 0 2.5551381455102273e-08
a O 0 1.1401050770132315e-08
larger O 0 1.4129072134494436e-08
deletion O 0 9.882441531772201e-08
involving O 0 2.9893778563661044e-09
both O 0 5.3431268298709256e-09
Snrpn O 0 1.2059168739142478e-06
and O 0 4.991601354475961e-09
the O 0 6.634552462969623e-09
putative O 0 8.084471119218506e-06
PWS O 1 1.0
- O 0 0.0005551480571739376
IC O 0 7.600182925671106e-06
lack O 0 8.185175204289408e-09
expression O 0 2.1337041022917447e-09
of O 0 2.0559461078040187e-10
the O 0 1.7878569735785277e-09
imprinted O 0 4.877192054664192e-07
genes O 0 3.3694874446155154e-07
Zfp127 O 0 1.6352248621842591e-06
( O 0 1.4382784740973875e-08
mouse O 0 5.589370744019106e-07
homologue O 0 1.1031618214474292e-06
of O 0 5.566303418191865e-09
ZNF127 O 0 7.600153367093299e-06
) O 0 3.0927418404047557e-09
, O 0 2.0900290387260156e-09
Ndn O 0 6.500724225588783e-07
and O 0 4.4263664733534824e-08
Ipw O 0 2.3410913854604587e-05
, O 0 9.402803868852061e-09
and O 0 4.472378023478996e-09
manifest O 0 3.707471307734522e-08
several O 0 1.8813393065642003e-09
phenotypes O 0 1.552720192421475e-07
common O 0 1.8325721384826466e-07
to O 0 3.346980520291254e-06
PWS B-Disease 1 1.0
infants O 0 0.4645799696445465
. O 0 3.266569876814174e-07

These O 0 1.6530000479519913e-08
data O 0 5.079974663146913e-09
demonstrate O 0 1.2386154324417475e-09
that O 0 9.37772012821192e-11
both O 0 4.6849423646078137e-11
the O 0 5.0209395668909806e-11
position O 0 2.4680213428496245e-09
of O 0 9.90174348763917e-12
the O 0 1.2758795409073542e-10
IC O 0 1.4979231366396561e-07
and O 0 8.777668869530686e-11
its O 0 4.2500551689084176e-11
role O 0 7.781468247536338e-10
in O 0 1.6913107026006458e-10
the O 0 9.468267142542786e-11
coordinate O 0 3.3696731516208445e-10
expression O 0 6.233925597953771e-10
of O 0 5.248457918272109e-11
genes O 0 6.701063037795052e-10
is O 0 7.375919319763113e-11
conserved O 0 2.031389223500213e-10
between O 0 1.0249561199771051e-09
mouse O 0 4.155967303631769e-07
and O 0 3.740262766172009e-09
human O 0 3.904939704924004e-10
, O 0 3.782134605501142e-10
and O 0 1.1062439853049e-09
indicate O 0 4.656572905048506e-09
that O 0 2.2680896050175647e-10
the O 0 2.631301010413978e-10
mouse O 0 4.599217717782267e-08
is O 0 1.669108462554192e-10
a O 0 2.743069937860554e-10
suitable O 0 1.6749773790181166e-09
model O 0 6.944614661108517e-09
system O 0 1.974072683097461e-09
in O 0 9.86578485573375e-10
which O 0 3.0325161826105784e-10
to O 0 7.182334588184958e-11
investigate O 0 1.811565342180188e-10
the O 0 4.5631148165581337e-11
molecular O 0 4.5658335445786236e-10
mechanisms O 0 1.951289796409128e-09
of O 0 1.7640869320878494e-10
imprinting O 0 7.194574180857671e-08
in O 0 5.866609420479563e-09
this O 0 2.462575143802326e-10
region O 0 3.407417403789026e-10
of O 0 1.2271558769150204e-10
the O 0 9.391472044484317e-10
genome O 0 9.518760002436011e-09
. O 0 6.883701164639433e-09
. O 0 2.5541782022742154e-08

Mutations O 0 9.28420286072651e-06
of O 0 6.509803807119852e-09
the O 0 4.302569855951788e-09
ATM O 0 1.4160672208163305e-06
gene O 0 2.1014750473113963e-07
detected O 0 8.367528607777786e-07
in O 0 5.6381754376388926e-08
Japanese O 0 0.014317959547042847
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
patients O 1 0.9686501622200012
: O 0 2.0887698237714858e-09
possible O 0 2.4866431136416622e-09
preponderance O 0 8.622184566320357e-08
of O 0 2.3688223604878544e-10
the O 0 8.409538065912159e-10
two O 0 7.257987100217633e-09
founder O 0 3.332846461034933e-07
mutations O 0 3.1274103662326524e-07
4612del165 O 0 5.771264568465995e-07
and O 0 3.787097213603374e-08
7883del5 O 0 3.7521656395256286e-06
. O 0 1.5806652697847312e-07

The O 0 1.8795186917941464e-07
ATM O 0 1.9902467101928778e-05
( O 0 1.9237599246935133e-07
A O 1 0.9999998807907104
- O 1 0.9999997615814209
T O 1 1.0
, O 0 1.862950682607334e-08
mutated O 0 1.3768938345037895e-07
) O 0 1.3245967656061453e-09
gene O 0 1.7935924745415832e-08
on O 0 1.5576583578535974e-08
human O 0 1.0028132102490872e-08
chromosome O 0 1.3773017599305604e-05
11q22 O 0 1.0493174158909824e-05
. O 0 4.006886911156471e-07

3 O 0 7.36114429855661e-07
has O 0 1.912549585370016e-08
recently O 0 1.6374698930121667e-08
been O 0 2.163608181504628e-09
identified O 0 1.043609865192252e-09
as O 0 1.4438099327218623e-10
the O 0 6.05944808218517e-11
gene O 0 2.5561213146119144e-09
responsible O 0 5.722743945391073e-10
for O 0 1.590579751242771e-10
the O 0 2.088965000979215e-09
human O 0 1.7135035079718364e-07
recessive B-Disease 1 0.9999997615814209
disease I-Disease 1 0.9999998807907104
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 1 0.527620792388916
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 2.7006541358787217e-07
. O 0 1.7808815755415708e-07

In O 0 1.5596448577070987e-07
order O 0 4.343682302732077e-09
to O 0 3.8332551022257633e-10
define O 0 3.150265825979659e-09
the O 0 4.68563299271807e-10
types O 0 8.417918806458147e-09
of O 0 2.0335881867339367e-09
disease O 0 1.1818452549050562e-05
- O 0 1.528211942058988e-05
causing O 0 4.959101715940051e-07
ATM O 0 2.2351743609760888e-05
mutations O 0 5.975910255529016e-08
in O 0 6.256740459065213e-09
Japanese O 0 1.6708992234271136e-06
A B-Disease 1 0.9999998807907104
- I-Disease 1 0.9999994039535522
T I-Disease 1 1.0
patients O 0 2.7890835553989746e-05
as O 0 1.3328230741294078e-09
well O 0 5.047260387414099e-10
as O 0 1.0667308009137955e-10
to O 0 5.95884105947242e-11
look O 0 8.590384403817097e-09
for O 0 7.519130457156464e-11
possible O 0 2.762408524148441e-09
mutational O 0 3.351908333115716e-07
hotspots O 0 1.5720843293820508e-07
, O 0 9.886185203811237e-10
reverse O 0 2.1835676022874395e-07
- O 0 7.704267090957728e-08
transcribed O 0 2.0147371770917744e-08
RNA O 0 6.719342859895505e-09
derived O 0 9.150902813281903e-10
from O 0 2.908404350687732e-10
ten O 0 7.214012165412953e-10
patients O 0 3.8967110094212387e-10
belonging O 0 4.2534714639330673e-10
to O 0 1.80334983057584e-10
eight O 0 9.199220829536614e-10
unrelated O 0 1.5198059699628175e-08
Japanese O 0 2.4973353447421687e-06
A B-Disease 1 1.0
- I-Disease 1 0.9999964237213135
T I-Disease 1 1.0
families O 0 2.642116214701673e-08
was O 0 3.163357575886039e-08
analyzed O 0 1.7835143362177064e-09
for O 0 9.82960310369485e-11
mutations O 0 1.4286891669712531e-09
by O 0 1.0256322180435262e-10
the O 0 6.40679731489513e-10
restriction O 0 4.0345749852122026e-08
endonuclease O 0 3.0531221000273945e-06
fingerprinting O 0 8.262979918072233e-07
method O 0 9.97911797639972e-08
. O 0 7.532835155643625e-08

As O 0 1.406873337828074e-07
has O 0 1.6251415768664401e-09
been O 0 8.097020276487399e-10
reported O 0 1.8027696002675953e-09
by O 0 5.243865064397113e-11
others O 0 1.2851809616520882e-09
, O 0 9.421752267257943e-11
mutations O 0 1.3652814434550464e-09
that O 0 1.9111073834565673e-10
lead O 0 1.8160669634781357e-09
to O 0 1.2686802719485968e-09
exon O 0 1.905689828163304e-07
skipping O 0 2.5307929263362894e-06
or O 0 1.7335777613425307e-07
premature O 0 2.3643433166853356e-07
protein O 0 2.1568766328528e-08
truncation O 0 1.8979417859554815e-07
were O 0 9.981955173543611e-08
also O 0 4.172850953665375e-09
predominant O 0 5.470620578762464e-08
in O 0 8.116460392670888e-09
our O 0 1.473771504834076e-08
mutants O 0 5.237975528871175e-07
. O 0 4.8944041708409713e-08

Six O 0 2.796124931592203e-07
different O 0 9.605171769067056e-09
mutations O 0 2.284442501832018e-08
were O 0 6.763291704459107e-09
identified O 0 5.1979736070961735e-09
on O 0 9.858716509825172e-09
12 O 0 1.4592089758735938e-09
of O 0 3.745677726318952e-11
the O 0 7.373897603635271e-10
16 O 0 1.86651085698486e-08
alleles O 0 8.135683060572774e-08
examined O 0 2.4534551812394056e-06
. O 0 9.610360507394944e-08

Four O 0 3.0426241437453427e-07
were O 0 4.683377241576636e-08
deletions O 0 3.7280141640394504e-08
involving O 0 5.77503866949769e-09
a O 0 1.3121302266938528e-08
loss O 0 4.5710578433499904e-08
of O 0 7.922101169510753e-11
a O 0 1.2972236618224997e-09
single O 0 2.075823246627806e-08
exon O 0 1.3824435995957174e-07
exon O 0 2.2938282029372203e-07
7 O 0 1.0102451142302016e-07
, O 0 2.5690936045208446e-09
exon O 0 1.7619946390823316e-07
16 O 0 5.830480276358685e-08
, O 0 1.3789950292775188e-09
exon O 0 1.0073089384832201e-07
33 O 0 1.6744056097195426e-07
or O 0 2.4532155862289073e-08
exon O 0 6.524636546600959e-07
35 O 0 1.140484300776734e-06
. O 0 1.3876281457214645e-07

The O 0 4.564749644941912e-08
others O 0 1.949296901671005e-08
were O 0 7.59315810228145e-09
minute O 0 3.064645426320567e-08
deletions O 0 7.794904632874022e-08
, O 0 6.038406441533084e-10
4649delA O 0 2.3864252796101937e-08
in O 0 1.8052298544901646e-09
exon O 0 9.704653081143988e-08
33 O 0 5.9566115595544034e-08
and O 0 1.7781883743239746e-09
7883del5 O 0 1.1511138353625938e-07
in O 0 1.9975376019942814e-08
exon O 0 6.708409046041197e-07
55 O 0 5.906458682147786e-07
. O 0 9.05631409864327e-08

The O 0 2.1913967884756858e-07
mutations O 0 2.0398902051965706e-06
4612del165 O 0 1.111432425204839e-06
and O 0 6.569851773718938e-09
7883del5 O 0 9.028786962517188e-08
were O 0 9.284435442680206e-09
found O 0 4.716900203760588e-10
in O 0 2.2401183685794024e-10
more O 0 4.161226918597549e-11
than O 0 4.3284771600315963e-11
two O 0 4.130923728085101e-11
unrelated O 0 6.930280793682186e-10
families O 0 4.527803132425845e-11
; O 0 3.9751261310394526e-11
44 O 0 1.1114000830758641e-09
% O 0 1.7455212275585552e-10
( O 0 2.803806076201454e-10
7 O 0 2.0427821656454626e-09
of O 0 1.1540469968540634e-10
16 O 0 5.639172684368532e-09
) O 0 3.087375494148503e-11
of O 0 1.459385737256902e-11
the O 0 2.3800678095042826e-10
mutant O 0 1.394157678191732e-08
alleles O 0 1.9161607411888326e-08
had O 0 2.4520443275832804e-07
one O 0 4.938519593267188e-10
of O 0 3.9313406696717124e-11
the O 0 1.5765598826433802e-09
two O 0 3.078618249219289e-08
mutations O 0 4.5827468397874327e-07
. O 0 5.7600257008516564e-08

The O 0 1.8103172294559045e-07
4612del165 O 0 1.5251482636813307e-06
mutations O 0 2.1135100780611538e-07
in O 0 4.475125603420338e-09
three O 0 1.7660968520960552e-10
different O 0 8.938764312071967e-11
families O 0 1.836527319110104e-10
were O 0 1.4401223547011455e-09
all O 0 3.496133590963346e-11
ascribed O 0 3.762815059538127e-10
to O 0 8.876885337905094e-11
the O 0 1.2407688765314617e-10
same O 0 4.2487218188114184e-09
T O 0 1.25203450807021e-05
- O 0 5.281439143800526e-07
- O 0 3.590062078728806e-07
> O 0 6.043572309266665e-09
A O 0 1.8448311767116365e-09
substitution O 0 3.932979719678542e-09
at O 0 2.833056678142043e-09
the O 0 3.80309089775821e-10
splice O 0 1.7524658346701472e-07
donor O 0 5.0901394210711715e-09
site O 0 1.492327506014135e-08
in O 0 2.561110257204291e-08
intron O 0 1.3428923011815641e-05
33 O 0 1.7150840676549706e-06
. O 0 8.952819285923397e-08

Microsatellite O 0 0.00010644033318385482
genotyping O 0 4.3088810343761e-05
around O 0 1.0618806811635295e-07
the O 0 3.5891014604771954e-09
ATM O 0 4.907350898974983e-07
locus O 0 3.5393274089301485e-08
also O 0 5.821009896322948e-09
indicated O 0 1.4510084689334235e-08
that O 0 1.5682335985367502e-10
a O 0 1.345925704221429e-09
common O 0 3.634521306139504e-08
haplotype O 0 3.360182972755865e-06
was O 0 2.0465941474867577e-07
shared O 0 4.059317881832669e-10
by O 0 2.6229479699324543e-10
the O 0 4.507504092199355e-10
mutant O 0 3.045213148311632e-08
alleles O 0 1.100797319963931e-08
in O 0 6.125258966704905e-09
both O 0 1.8734624518401688e-08
mutations O 0 6.140656410025258e-07
. O 0 1.085626522012717e-07

This O 0 4.624066463065901e-08
suggests O 0 2.211169558563597e-08
that O 0 2.935646725710228e-10
these O 0 1.3811186916345974e-10
two O 0 8.415218522017653e-10
founder O 0 2.3313035057981324e-08
mutations O 0 1.1479335171316052e-07
may O 0 1.9244039606292063e-07
be O 0 6.454387024845687e-10
predominant O 0 1.2486831124647324e-08
among O 0 7.89575183013369e-10
Japanese O 0 2.0800719369162834e-08
ATM O 0 7.690759389333834e-07
mutant O 0 4.463466609649913e-07
alleles O 0 1.2189618701086147e-06
. O 0 1.6274570668883825e-07

W474C O 0 3.3115706173703074e-05
amino O 0 7.662105758754478e-07
acid O 0 1.3775137119864667e-07
substitution O 0 8.039887688937597e-08
affects O 0 4.807167997000761e-08
early O 0 1.762215617873153e-08
processing O 0 6.515402661833036e-10
of O 0 1.9307997908835084e-11
the O 0 4.4088340617198796e-11
alpha O 0 9.155354252499137e-10
- O 0 5.63493418592742e-10
subunit O 0 1.4688260607798043e-09
of O 0 4.8755385145815566e-11
beta O 0 2.4998456638058997e-08
- O 0 3.4298000173293985e-07
hexosaminidase O 0 4.0404131596005755e-07
A O 0 1.3570857326783425e-08
and O 0 3.5275515841703964e-09
is O 0 3.7452008161409367e-10
associated O 0 2.445832203434861e-09
with O 0 2.444885405239461e-09
subacute O 0 4.029550837003626e-05
G B-Disease 0 0.00011583624291233718
( I-Disease 0 1.2930546411382693e-08
M2 I-Disease 0 7.898643161752261e-06
) I-Disease 0 2.9287873459793445e-08
gangliosidosis I-Disease 0 6.544005827890942e-06
. O 0 1.974657806158575e-07

Mutations O 0 1.7537713574711233e-05
in O 0 6.559361764857385e-08
the O 0 7.794395351368166e-09
HEXA O 0 5.8697119129647035e-06
gene O 0 4.45455299313835e-08
, O 0 1.733394955349965e-10
encoding O 0 1.5591169466588894e-09
the O 0 2.9088650932429516e-10
alpha O 0 4.66014427047412e-09
- O 0 3.742853582622274e-09
subunit O 0 3.784077495794236e-09
of O 0 1.0048723658728775e-10
beta O 0 2.468357074292271e-08
- O 0 7.355319553425943e-07
hexosaminidase O 0 9.911329925671453e-07
A O 0 3.899153355746421e-08
( O 0 5.107927414371716e-09
Hex O 0 3.8474109231856346e-08
A O 0 5.231771904590232e-09
) O 0 2.0127917388368388e-10
, O 0 8.485163266458429e-11
that O 0 2.827991174569888e-10
abolish O 0 1.3746889848675892e-08
Hex O 0 7.521364153717514e-08
A O 0 2.9269542345389254e-09
enzyme O 0 5.025670546388028e-08
activity O 0 5.1513762855393e-07
cause O 0 8.038127270992845e-05
Tay B-Disease 1 1.0
- I-Disease 1 1.0
Sachs I-Disease 1 1.0
disease I-Disease 0 0.19000522792339325
( O 0 5.2557588503532315e-08
TSD B-Disease 0 1.7822789232013747e-05
) O 0 2.1538664185527523e-09
, O 0 3.8649042299887526e-10
the O 0 4.039439449599058e-09
fatal O 0 0.00037686392897740006
infantile B-Disease 0 0.00017404758546035737
form I-Disease 0 3.436740669826577e-08
of I-Disease 0 4.691447674787241e-09
G I-Disease 0 7.396953151328489e-06
( I-Disease 0 2.9251683297815134e-09
M2 I-Disease 0 1.5898677929726546e-06
) I-Disease 0 3.092187395026258e-09
gangliosidosis I-Disease 0 5.405214551501558e-07
, I-Disease 0 2.166217871746312e-09
Type I-Disease 0 2.457815639900218e-07
1 I-Disease 0 4.7346894405109197e-08
. O 0 7.198281082310132e-08

Less O 0 4.2850489990087226e-05
severe O 0 0.22644351422786713
, O 0 2.3877461785559717e-07
subacute O 0 0.002164235571399331
( O 0 3.26513600157341e-06
juvenile O 0 0.22486092150211334
- O 1 0.9879502058029175
onset O 0 0.03684379532933235
) O 0 2.5700359174152254e-08
and O 0 5.424393521025195e-07
chronic O 0 0.014743720181286335
( O 0 3.047857077831395e-08
adult O 0 1.3670034604729153e-05
- O 1 0.5394846200942993
onset O 0 1.3367452993406914e-05
) O 0 1.1686582812586721e-09
variants O 0 2.3929977999159746e-08
are O 0 5.377927547733918e-10
characterized O 0 8.602874523866433e-10
by O 0 3.165454565134951e-10
a O 0 5.3983817416281e-09
broad O 0 6.353890569243958e-08
spectrum O 0 5.2001382755406667e-08
of O 0 8.578722177077225e-10
clinical O 0 5.727259377863447e-08
manifestations O 0 1.648223957317896e-08
and O 0 2.631528106533665e-09
are O 0 1.0832401642346667e-10
associated O 0 3.108714397015433e-10
with O 0 2.0498418240588734e-10
residual O 0 1.8935232048988837e-07
levels O 0 3.7215777126675675e-08
of O 0 3.8037148430980494e-10
Hex O 0 1.0711811881947142e-07
A O 0 7.875901708587207e-09
enzyme O 0 5.663072144557191e-08
activity O 0 1.3093806217057136e-07
. O 0 3.298443473909174e-08

We O 0 3.442586660185043e-07
identified O 0 8.13472169625129e-08
a O 0 1.5011087484140262e-08
1422 O 0 3.9250324334716424e-05
G O 0 7.582589751109481e-05
- O 0 2.1531219317694195e-05
- O 0 1.3454214240482543e-05
> O 0 1.5121426599762344e-07
C O 0 1.7579826590008452e-06
( O 0 2.421790989970418e-09
amino O 0 4.1717052035039615e-09
acid O 0 1.6396880520019863e-09
W474C O 0 3.4018605710173233e-09
) O 0 2.548913510813655e-11
substitution O 0 4.972622313914599e-10
in O 0 2.2574035696276695e-10
the O 0 7.207750368776189e-11
first O 0 7.627817821820315e-10
position O 0 1.5079032467113507e-09
of O 0 5.1074741658219125e-11
exon O 0 4.409277920558452e-08
13 O 0 8.02404365174425e-09
of O 0 5.33481425701865e-10
HEXA O 0 2.4938985916378442e-06
of O 0 2.5770130474001007e-10
a O 0 5.788073131895999e-09
non O 0 9.654008863435593e-07
- O 0 3.4170418530266033e-06
Jewish O 0 1.430305900385065e-07
proband O 0 0.00010351015225751325
who O 0 4.118860985613537e-08
manifested O 0 3.8325278950424035e-08
a O 0 1.795050508235363e-08
subacute O 0 8.844803232932463e-06
variant O 0 7.4116196628892794e-06
of O 0 1.1949497391583463e-08
G B-Disease 0 2.198018046328798e-05
( I-Disease 0 1.652618486502888e-08
M2 I-Disease 0 1.2010105820081662e-05
) I-Disease 0 7.635146914708457e-08
gangliosidosis I-Disease 0 1.6896034139790572e-05
. O 0 1.466702599373093e-07

On O 0 6.788508244426339e-07
the O 0 1.0192679589238196e-08
second O 0 1.0240326986377113e-07
maternally O 0 1.806706131901592e-05
inherited O 0 2.3682032406213693e-05
allele O 0 1.4781131767449551e-06
, O 0 2.36936137376631e-09
we O 0 2.3406099280975923e-09
identified O 0 3.98712796112477e-09
the O 0 1.2680584360325042e-09
common O 0 4.435952632775297e-06
infantile O 1 0.9997089505195618
disease O 1 0.7041871547698975
- O 0 0.00016228994354605675
causing O 0 5.82072971155867e-06
4 O 0 6.159993972687516e-07
- O 0 2.2259890101850033e-05
bp O 0 1.9962479200330563e-05
insertion O 0 3.2178655828829505e-07
, O 0 6.478539926746407e-09
+ O 0 7.939008384028057e-08
TATC O 0 3.2901857593969908e-06
1278 O 0 2.533463884901721e-06
, O 0 1.888039946607023e-09
in O 0 5.663058466609527e-09
exon O 0 5.121422077536408e-07
11 O 0 1.4269461701132968e-07
. O 0 2.7316696460388812e-08

Pulse O 0 0.0034379155840724707
- O 0 0.00017246315837837756
chase O 0 1.54925453443866e-06
analysis O 0 1.585867792641693e-08
using O 0 1.8617642538742984e-08
proband O 0 1.2778652944689384e-06
fibroblasts O 0 1.9716263466307282e-07
revealed O 0 1.0633419833538937e-07
that O 0 3.071260745723947e-10
the O 0 3.922586699900421e-10
W474C O 0 4.7041829986937955e-08
- O 0 4.760204230791487e-09
containing O 0 8.38404123904013e-10
alpha O 0 4.918602414250017e-09
- O 0 3.528722425372166e-09
subunit O 0 1.2736391497014665e-08
precursor O 0 1.0492607671608312e-08
was O 0 1.673215699327102e-08
normally O 0 4.918356277805458e-10
synthesized O 0 1.8338608409607104e-09
, O 0 8.790150551885034e-11
but O 0 2.1248047765709543e-10
not O 0 3.5670407599885934e-11
phosphorylated O 0 2.9481994623381524e-10
or O 0 1.5948144194144476e-10
secreted O 0 2.959150979808811e-10
, O 0 1.592628945390473e-10
and O 0 1.2419480721614917e-10
the O 0 3.416059379812708e-10
mature O 0 4.2385801535260725e-09
lysosomal O 0 5.391808599597425e-08
alpha O 0 1.7185332268354614e-08
- O 0 1.6180596418280402e-08
subunit O 0 3.113821378519788e-08
was O 0 7.779041766298178e-08
not O 0 5.914143841323494e-09
detected O 0 2.3107124036414461e-07
. O 0 3.711865304012463e-08

When O 0 3.702281787809625e-07
the O 0 1.3244029872794272e-08
W474C O 0 1.7438033239614015e-07
- O 0 8.63921911786747e-09
containing O 0 1.3390532016543943e-09
alpha O 0 6.443443556491957e-09
- O 0 1.4367293132977466e-08
subunit O 0 2.9581835647718435e-08
was O 0 2.6767096983348893e-08
transiently O 0 1.3376032370615576e-07
co O 0 5.5987182889793985e-08
- O 0 1.3728024050863041e-08
expressed O 0 3.858062203043744e-10
with O 0 2.7305664673793473e-11
the O 0 1.1630384155747464e-10
beta O 0 5.1736215311848355e-09
- O 0 2.7190418805389527e-09
subunit O 0 2.2833002155664417e-09
to O 0 1.822085815561536e-10
produce O 0 1.176077679687637e-09
Hex O 0 8.473433865674451e-08
A O 0 1.434068330752325e-08
( O 0 1.1537438782127651e-09
alphabeta O 0 2.3473800681017565e-08
) O 0 2.1426709018168566e-10
in O 0 1.6031993510523534e-09
COS O 0 0.0002227933146059513
- O 0 1.0527994476206004e-07
7 O 0 2.520681441353645e-09
cells O 0 7.053461703598884e-10
, O 0 6.98384614028491e-11
the O 0 5.7864445873745396e-11
mature O 0 3.676981497058307e-10
alpha O 0 6.57416066029981e-10
- O 0 7.221886977326619e-10
subunit O 0 2.13614703703513e-09
was O 0 2.7064221974626435e-09
present O 0 4.077722881579149e-11
, O 0 4.000439216000906e-11
but O 0 1.167586027861489e-10
its O 0 4.242749554461689e-11
level O 0 4.59839100130921e-09
was O 0 1.3836986667570272e-08
much O 0 9.669722800254021e-10
lower O 0 7.459528106323887e-09
than O 0 2.569630098980813e-11
that O 0 1.4584007612672423e-11
from O 0 5.567720937071918e-11
normal O 0 1.0784023674048626e-09
alpha O 0 2.3347690447650393e-09
- O 0 4.59448079581648e-09
subunit O 0 5.44464562324265e-09
transfections O 0 4.165719857951444e-08
, O 0 7.997006529203432e-11
although O 0 8.79811709597611e-11
higher O 0 8.137833185095644e-10
than O 0 8.446023047614659e-11
in O 0 1.7849564881711188e-10
those O 0 1.0953339624197866e-10
cells O 0 3.9562939035953093e-10
transfected O 0 1.1662294241432392e-08
with O 0 1.5165670108618912e-10
an O 0 3.4026764739181203e-10
alpha O 0 1.2323079445764051e-08
- O 0 2.901365370178155e-08
subunit O 0 7.14719661232266e-08
associated O 0 3.107609103381037e-08
with O 0 3.020155148192316e-08
infantile O 0 0.001402411493472755
TSD B-Disease 0 0.002409896347671747
. O 0 7.243371555887279e-07

Furthermore O 0 3.4389836400805507e-07
, O 0 1.0460011745649922e-09
the O 0 1.0276256234842407e-10
precursor O 0 2.507877239210643e-09
level O 0 1.4143247684117455e-09
of O 0 1.0337093160617261e-11
the O 0 6.113802519802647e-11
W474C O 0 3.870431530828e-09
alpha O 0 1.0444979325896497e-09
- O 0 1.674019256547865e-09
subunit O 0 2.9470650364515905e-09
was O 0 4.346052406845047e-09
found O 0 1.8007685620435865e-10
to O 0 8.492060526998912e-11
accumulate O 0 2.3516002478629616e-09
in O 0 1.8535845081046887e-10
comparison O 0 4.788933138932805e-10
to O 0 8.734196699222707e-11
the O 0 3.0109209570028383e-10
normal O 0 6.908877026035043e-09
alpha O 0 7.648392141845761e-09
- O 0 1.3417920108338421e-08
subunit O 0 3.907745238507232e-08
precursor O 0 9.203967010762426e-08
levels O 0 5.775096667548496e-08
. O 0 4.0113103949579454e-08

We O 0 4.5067221776662336e-07
conclude O 0 1.721501377005552e-07
that O 0 9.066641326604952e-10
the O 0 1.3777856633367946e-09
1422 O 0 8.722955499251839e-06
G O 0 1.0441983249620534e-05
- O 0 6.5707145040505566e-06
- O 0 7.047711278573843e-06
> O 0 1.5370999051356193e-07
C O 0 3.1209049211611273e-06
mutation O 0 3.172632645487283e-08
is O 0 6.194255663949377e-10
the O 0 3.5788522145807633e-10
cause O 0 5.713737483148407e-09
of O 0 8.333040923957924e-10
Hex B-Disease 0 1.0647383533068933e-05
A I-Disease 0 7.964247197378427e-05
enzyme I-Disease 1 1.0
deficiency I-Disease 1 1.0
in O 0 3.4648252267288626e-08
the O 0 4.897794170233283e-08
proband O 0 1.9539018467185088e-05
. O 0 1.6496400689902657e-07

The O 0 1.7173888977595198e-07
resulting O 0 1.9975362874902203e-07
W474C O 0 4.7316831341959187e-07
substitution O 0 8.186833611034672e-08
clearly O 0 4.2693006463423444e-08
interferes O 0 3.453839170219908e-08
with O 0 1.2112685854326344e-10
alpha O 0 2.2713548819552898e-09
- O 0 2.3840944773922956e-09
subunit O 0 6.18687945319607e-09
processing O 0 2.0278287937713912e-09
, O 0 9.149746238445999e-11
but O 0 8.404531237626855e-11
because O 0 1.0629545854623501e-11
the O 0 7.962757189727832e-12
base O 0 3.5889537869371324e-11
substitution O 0 6.779043992821698e-10
falls O 0 8.641644910767354e-08
at O 0 1.4480633359070794e-09
the O 0 7.666919182858223e-11
first O 0 1.2863016207731448e-09
position O 0 1.002418703599517e-09
of O 0 3.572657794603806e-11
exon O 0 1.6740010266858008e-08
13 O 0 6.616279524251922e-09
, O 0 3.0208432977296695e-10
aberrant O 0 3.842841778123329e-08
splicing O 0 4.5032896878183237e-07
may O 0 3.7793014939779823e-07
also O 0 7.766196019609595e-10
contribute O 0 1.8052702388526853e-10
to O 0 1.438061003611324e-09
Hex B-Disease 0 2.33833225138369e-06
A I-Disease 0 6.731789653713349e-06
deficiency I-Disease 0 3.131530684186146e-05
in O 0 5.383204992881474e-09
this O 0 1.465987997661955e-09
proband O 0 4.4756995976058533e-07
. O 0 3.892619560019739e-09
. O 0 1.7382371098051408e-08

Two O 0 1.1694770591930137e-06
frequent O 0 9.551329640089534e-06
missense O 0 0.0028655764181166887
mutations O 0 0.002598007908090949
in O 0 0.023815320804715157
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 9.959738918041694e-07

Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
is O 0 9.05221895663999e-05
an O 0 0.00018862399156205356
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
disorder I-Disease 1 1.0
characterized O 0 0.008655074052512646
by O 0 3.8039149785618065e-07
early O 1 0.7278145551681519
childhood O 1 0.9998947381973267
deafness B-Disease 1 1.0
and O 0 0.46317777037620544
goiter B-Disease 1 1.0
. O 0 4.05506898459862e-06

A O 0 7.470870855286194e-07
century O 0 3.7486569226530264e-07
after O 0 8.026706410646511e-09
its O 0 1.4032158768273462e-10
recognition O 0 6.756428749810084e-10
as O 0 1.3721977332181723e-08
a O 0 1.0325314860892831e-06
syndrome O 0 0.017818236723542213
by O 0 1.3088701233954225e-09
Vaughan O 0 6.6908660301123746e-06
Pendred O 0 6.794764999540348e-07
, O 0 1.8378002453189879e-09
the O 0 7.345559271954016e-09
disease O 0 1.5686323422414716e-06
gene O 0 5.154653877070814e-07
( O 0 3.129700942849922e-08
PDS O 0 5.541123300645268e-06
) O 0 8.617310198744121e-10
was O 0 2.283998234986484e-08
mapped O 0 2.8173717581125857e-08
to O 0 9.597955319406992e-09
chromosome O 0 1.0744468454504386e-05
7q22 O 0 3.0489314667647704e-05
- O 0 3.449110590736382e-05
q31 O 0 8.306907147925813e-06
. O 0 1.5393723629131273e-07

1 O 0 3.7764550597785274e-07
and O 0 7.855947892210224e-09
, O 0 4.748521575947962e-10
recently O 0 1.2986454578367557e-08
, O 0 1.4422300853578207e-10
found O 0 3.097344880576003e-10
to O 0 8.724340000432207e-11
encode O 0 9.46029743431609e-09
a O 0 3.2608113542664796e-08
putative O 0 2.0849433894909453e-06
sulfate O 0 2.4531464077881537e-06
transporter O 0 4.5489741751225665e-05
. O 0 3.399903789613745e-07

We O 0 1.1103095403086627e-06
performed O 0 2.89806898479128e-08
mutation O 0 7.804541013456401e-09
analysis O 0 8.419488994881874e-10
of O 0 4.488507482358628e-11
the O 0 8.09326883288719e-10
PDS B-Disease 0 5.145008117324323e-07
gene O 0 2.737031046251559e-08
in O 0 1.054678211431792e-08
patients O 0 2.778203622710862e-08
from O 0 2.1579948938921234e-09
14 O 0 4.9497721477109735e-09
Pendred B-Disease 0 5.834351668454474e-08
families O 0 2.2300192248358996e-10
originating O 0 3.2221563195378167e-09
from O 0 1.196545640347324e-09
seven O 0 4.359450300750467e-10
countries O 0 2.23990478942504e-10
and O 0 5.782013201560687e-10
identified O 0 5.553662418833483e-09
all O 0 1.1568112023851995e-09
mutations O 0 8.423078412533869e-08
. O 0 3.145788340930267e-08

The O 0 1.208837545618735e-07
mutations O 0 1.813942844819394e-07
include O 0 1.2936310911371152e-09
three O 0 1.6056260765395791e-09
single O 0 4.733169856052655e-09
base O 0 2.355271977450002e-09
deletions O 0 1.3342958027351415e-07
, O 0 1.085857403992918e-09
one O 0 2.6242252815222855e-09
splice O 0 6.017377472744556e-06
site O 0 4.684051475578599e-07
mutation O 0 2.3094897017017502e-07
and O 0 4.6693465094449493e-08
10 O 0 7.990203698682308e-08
missense O 0 4.2508032493060455e-05
mutations O 0 1.624157994228881e-05
. O 0 4.6509208573297656e-07

One O 0 1.3430744729703292e-06
missense O 0 6.66033083689399e-05
mutation O 0 1.344891870758147e-06
( O 0 1.6845836725565277e-08
L236P O 0 1.0118900206634862e-07
) O 0 1.1127873067451333e-09
was O 0 1.8725334172131625e-08
found O 0 9.768436060042518e-10
in O 0 3.747172849788427e-10
a O 0 3.7863787105685276e-10
homozygous O 0 3.106185086920732e-09
state O 0 1.0984555626203374e-10
in O 0 4.2634153984977274e-09
two O 0 1.8240722265971954e-09
consanguineous O 0 2.3305995000555413e-07
families O 0 2.5274886628068316e-09
and O 0 7.802081758434554e-10
in O 0 7.719292982599768e-10
a O 0 1.97549643310424e-09
heterozygous O 0 1.316738273970941e-08
state O 0 1.7890602888037677e-10
in O 0 1.741667809973535e-09
five O 0 1.3906724660728287e-09
additional O 0 1.5527571450846267e-09
non O 0 2.1074185951874824e-06
- O 0 0.0001784166815923527
consanguineous O 0 2.6936657377518713e-05
families O 0 1.4450228036366752e-07
. O 0 5.994667162667611e-08

Another O 0 1.760860186550417e-06
missense O 0 0.00014195864787325263
mutation O 0 3.353747842993471e-06
( O 0 2.3843050200866855e-08
T416P O 0 9.540884349235057e-08
) O 0 6.694292342679375e-10
was O 0 9.55273460334638e-09
found O 0 7.549801339656881e-10
in O 0 1.9967852371571837e-10
a O 0 1.3486183003674768e-10
homozygous O 0 2.567271284448225e-09
state O 0 4.896376359919685e-11
in O 0 9.466465389351697e-10
one O 0 2.189888936854345e-09
family O 0 4.4362341578008113e-10
and O 0 3.8180270056642485e-10
in O 0 4.313084889240315e-10
a O 0 1.498224655449576e-09
heterozygous O 0 1.2770958512930974e-08
state O 0 5.203267816611401e-10
in O 0 9.775615872342769e-09
four O 0 1.5763502503318705e-08
families O 0 8.517260674523186e-09
. O 0 2.3366546031411417e-08

Pendred B-Disease 0 0.0021920425351709127
patients O 0 0.00020342734933365136
in O 0 4.379431217671481e-08
three O 0 1.2870729371172729e-08
non O 0 6.780329613320646e-07
- O 0 8.462679033982567e-06
consanguineous O 0 3.689621053126757e-06
families O 0 4.397525898980348e-09
were O 0 1.4612422383208923e-09
shown O 0 3.816388594035658e-10
to O 0 8.36522032199305e-11
be O 0 2.2695004209261072e-10
compound O 0 2.6247759521424996e-09
heterozygotes O 0 3.36066499073695e-08
for O 0 7.376865784891606e-10
L236P O 0 1.5553270316104317e-07
and O 0 1.3415463406829531e-08
T416P O 0 1.1722059980456834e-06
. O 0 5.0277606078452663e-08

In O 0 6.318938972071919e-08
total O 0 9.822317403873626e-10
, O 0 1.2492322454260574e-10
one O 0 8.559660619189557e-11
or O 0 3.650399427179707e-10
both O 0 9.498292430354383e-11
of O 0 1.0841759781610172e-11
these O 0 7.967987381007902e-11
mutations O 0 1.5007243225895195e-09
were O 0 3.412402804769954e-08
found O 0 1.8622108299837237e-09
in O 0 4.086764537891696e-10
nine O 0 6.504859983991196e-10
of O 0 2.851393426928084e-11
the O 0 1.0126479654815057e-09
14 O 0 1.5430329014520794e-08
families O 0 1.3313469215958662e-09
analyzed O 0 6.655238848907175e-08
. O 0 6.995147572297356e-08

The O 0 7.531886581091385e-08
identification O 0 1.4847979734611272e-08
of O 0 4.033755551802187e-10
two O 0 2.655888398095385e-09
frequent O 0 3.086282447384292e-07
PDS B-Disease 0 0.0006728344596922398
mutations O 0 2.0676365863891988e-07
will O 0 1.5320700263998788e-09
facilitate O 0 4.535872122346518e-09
the O 0 6.196976709560431e-09
molecular O 0 5.053161089563218e-07
diagnosis O 0 0.07119899243116379
of O 0 7.458444542862708e-06
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 3.3412081847927766e-06

Insertional O 0 0.00025962668587453663
mutation O 0 3.2444136195408646e-06
by O 0 2.3060117371187516e-08
transposable O 0 4.67014433525037e-06
element O 0 2.305137201119578e-07
, O 0 1.0249820547869604e-08
L1 O 0 4.0368181544181425e-06
, O 0 9.116948307408279e-10
in O 0 6.08638472954226e-09
the O 0 1.1442184444376835e-07
DMD B-Disease 1 1.0
gene O 0 7.823679766261193e-07
results O 0 1.2040788988088025e-07
in O 0 3.274260507168947e-08
X B-Disease 1 0.9999790191650391
- I-Disease 1 0.9999966621398926
linked I-Disease 1 0.999997615814209
dilated I-Disease 1 0.9999923706054688
cardiomyopathy I-Disease 1 1.0
. O 0 1.6736740917622228e-06

X B-Disease 1 0.9999728202819824
- I-Disease 1 0.9999994039535522
linked I-Disease 1 0.9999984502792358
dilated I-Disease 1 0.9999998807907104
cardiomyopathy I-Disease 1 1.0
( O 0 1.9200022052245913e-06
XLDCM B-Disease 0 2.700411823752802e-05
) O 0 2.927707853928041e-09
is O 0 3.416984473147977e-10
a O 0 2.7767295129876857e-09
clinical O 0 3.695124917157955e-07
phenotype O 0 1.3405523304754752e-06
of O 0 2.1133834682274255e-09
dystrophinopathy B-Disease 0 5.8953382904292084e-06
which O 0 8.193141276535698e-09
is O 0 7.670302171192134e-10
characterized O 0 4.677473963710099e-09
by O 0 4.767327421717482e-09
preferential O 0 2.201983534177998e-06
myocardial B-Disease 0 2.9185797757236287e-05
involvement I-Disease 0 1.1493653317984354e-07
without O 0 3.494883715760011e-09
any O 0 1.0568121933118846e-09
overt O 0 1.765461234981558e-07
clinical O 0 7.497915817111789e-07
signs O 0 7.200111667771125e-06
of O 0 3.4724308761724387e-07
skeletal B-Disease 1 1.0
myopathy I-Disease 1 1.0
. O 0 6.822752766311169e-06

To O 0 8.907359472232201e-08
date O 0 2.989898746363906e-07
, O 0 1.048757969357439e-09
several O 0 4.4873543769696767e-10
mutations O 0 1.9941838402814938e-08
in O 0 8.987273147909036e-09
the O 0 1.076722071502445e-07
Duchenne B-Disease 1 0.9948740601539612
muscular I-Disease 1 0.9909653663635254
dystrophy I-Disease 1 0.9489302635192871
gene O 0 7.362292308243923e-06
, O 0 5.058035412730533e-07
DMD O 1 1.0
, O 0 7.764363374462846e-09
have O 0 2.801311183020516e-09
been O 0 1.775050439967174e-09
identified O 0 1.9902459680309903e-09
in O 0 1.9193422406971195e-09
patients O 0 5.814463133191339e-09
with O 0 3.0604191403327263e-10
XLDCM B-Disease 0 0.00012141237675677985
, O 0 1.874240540544747e-09
but O 0 2.4143147481225924e-09
a O 0 8.024942377282684e-10
pathogenic O 0 3.595296504954604e-08
correlation O 0 4.8276649344813904e-09
of O 0 1.5906101435980702e-10
these O 0 5.35666511147781e-10
cardiospecific O 0 1.4237044752007932e-06
mutations O 0 3.323933412957558e-07
in O 0 3.005903579378355e-07
DMD O 1 1.0
with O 0 9.758328367581726e-09
the O 0 2.379716157463463e-08
XLDCM B-Disease 0 0.0016025527147576213
phenotype O 0 5.81883159611607e-06
has O 0 3.3121555276238723e-08
remained O 0 1.2028141327391495e-07
to O 0 8.476997992445945e-10
be O 0 5.007765313536083e-09
elucidated O 0 5.711930839424895e-07
. O 0 5.780904643870599e-08

We O 0 4.3797743387585797e-07
report O 0 2.4164030776319123e-08
here O 0 1.0559155771971973e-09
the O 0 5.0266790729835975e-11
identification O 0 2.6751656445611616e-10
of O 0 9.932178343663445e-12
a O 0 1.891481277160878e-10
unique O 0 7.99001309559344e-10
de O 0 9.861371808028707e-08
novo O 0 1.2956735417901655e-06
L1 O 0 1.422294417352532e-06
insertion O 0 3.2456771492661574e-08
in O 0 2.3270907423267317e-09
the O 0 1.4388484848026906e-09
muscle O 0 1.3855387237526884e-07
exon O 0 1.8274847946031514e-07
1 O 0 4.5271708160044e-08
in O 0 1.8108988797393977e-06
DMD O 1 1.0
in O 0 3.1485200224778964e-07
three O 0 1.9483229252159617e-08
XLDCM B-Disease 0 6.148204556666315e-05
patients O 0 1.5305262479614612e-07
from O 0 2.1369825908834628e-09
two O 0 8.323001732257751e-10
unrelated O 0 5.2876934830692335e-08
Japanese O 0 2.844033417659375e-07
families O 0 1.992453846355602e-08
. O 0 2.3856788544662777e-08

The O 0 8.843758791954315e-08
insertion O 0 7.138211230994784e-07
was O 0 1.6753608633734984e-07
a O 0 4.51483783692197e-09
5 O 0 2.190324543960287e-08
- O 0 8.036667509259132e-08
truncated O 0 2.0439797410176652e-08
form O 0 2.7778948030743322e-09
of O 0 2.6068333602857763e-10
human O 0 7.723224837441478e-10
L1 O 0 3.9548575614389847e-07
inversely O 0 1.606766630857237e-08
integrated O 0 3.334652021180773e-08
in O 0 1.185229958622358e-08
the O 0 4.12340206423778e-09
5 O 0 3.192786479644383e-08
- O 0 9.720934031065553e-07
untranslated O 0 1.3265007510199212e-06
region O 0 1.2005330063402653e-08
in O 0 1.1716160486230365e-08
the O 0 1.1343260775120712e-09
muscle O 0 1.0036076503183722e-07
exon O 0 1.831146079211976e-08
1 O 0 1.66384561683941e-09
, O 0 8.202218071406975e-11
which O 0 1.3348984417849152e-10
affected O 0 4.5925860336915036e-10
the O 0 1.0141628509208189e-10
transcription O 0 6.9079808540095655e-09
or O 0 8.10652378557819e-10
the O 0 3.139682958064327e-10
stability O 0 6.531328811121284e-10
of O 0 1.3155212162663243e-11
the O 0 1.3066843440601161e-10
muscle O 0 1.0020923646436586e-08
form O 0 2.5569979467121584e-10
of O 0 1.3751097482916919e-10
dystrophin O 0 8.446229315950404e-08
transcripts O 0 7.601566665016435e-08
but O 0 2.2832260526683967e-09
not O 0 3.3069819105335796e-10
that O 0 1.750638349562461e-11
of O 0 7.966144237314676e-12
the O 0 9.282199453508611e-10
brain O 0 4.4746155936081777e-07
or O 0 5.835728789094219e-09
Purkinje O 0 1.2766932400154474e-07
cell O 0 5.672985139426601e-07
form O 0 3.969267936554388e-08
, O 0 1.2596557574795497e-08
probably O 0 8.617652724751679e-07
due O 0 1.6896541943367538e-09
to O 0 1.8169217519403702e-10
its O 0 5.3209707473467205e-11
unique O 0 1.2992239228903912e-10
site O 0 2.1185575516113886e-09
of O 0 9.765319802790273e-11
integration O 0 8.790829397753441e-09
. O 0 1.0508450110080503e-08

We O 0 3.035806912521366e-07
speculate O 0 1.7048969880306686e-07
that O 0 1.8231008369617996e-10
this O 0 3.243827775833985e-11
insertion O 0 1.5333123659644343e-09
of O 0 2.7518723411112944e-11
an O 0 2.1465078325899611e-10
L1 O 0 5.995776746203774e-07
sequence O 0 1.1441395386668773e-08
in O 0 9.276753303311125e-07
DMD O 1 1.0
is O 0 1.5442774836671447e-09
responsible O 0 1.2139005078903864e-10
for O 0 1.750404682310247e-11
some O 0 2.5905694256422862e-11
of O 0 4.6210418304382106e-12
the O 0 1.6518944198629093e-11
population O 0 9.109707779786369e-12
of O 0 2.294898472643414e-11
Japanese O 0 6.462067148049755e-08
patients O 0 8.175564225609833e-09
with O 0 6.094281190804907e-10
XLDCM B-Disease 0 5.885069640498841e-06
. O 0 7.031033977256129e-09
. O 0 2.390443221145233e-08

Severe O 1 0.9985606074333191
early O 1 0.9083564281463623
- O 1 0.999998927116394
onset O 1 0.999985933303833
obesity B-Disease 1 1.0
, O 0 2.095803756674286e-05
adrenal B-Disease 1 0.9999996423721313
insufficiency I-Disease 1 1.0
and O 0 2.643971129145939e-05
red O 0 0.007811283227056265
hair O 1 0.9999995231628418
pigmentation O 1 0.9612635970115662
caused O 0 1.1238088518439326e-05
by O 0 5.7591581281712934e-08
POMC O 0 0.00023081109975464642
mutations O 0 9.132112381848856e-07
in O 0 1.60737947396683e-08
humans O 0 1.0608037115389379e-07
. O 0 5.9258788098759396e-08

Sequential O 0 2.406900421192404e-05
cleavage O 0 9.346888873551507e-06
of O 0 5.571784367219834e-09
the O 0 2.254960440595255e-09
precursor O 0 7.331244233910184e-08
protein O 0 8.090220404710635e-08
pre O 0 1.53207583935e-05
- O 0 2.6745066861622036e-05
pro O 0 2.5180355805787258e-05
- O 0 0.00013200522516854107
opiomelanocortin O 0 2.9158532925066538e-05
( O 0 1.803423899104928e-08
POMC O 0 1.3269690271044965e-06
) O 0 9.564216085777844e-10
generates O 0 4.972691147742125e-09
the O 0 3.2546334516325715e-09
melanocortin O 0 4.443468242243398e-06
peptides O 0 6.106352543611138e-07
adrenocorticotrophin O 0 3.867161467496771e-06
( O 0 1.606594857150867e-08
ACTH O 0 3.5357587080397934e-07
) O 0 9.032275483100705e-10
, O 0 9.71044022968215e-10
melanocyte O 0 3.150188831568812e-06
- O 0 4.8393059842055663e-05
stimulating O 0 2.3724298898741836e-06
hormones O 0 2.9772886023238243e-07
( O 0 2.445142088802754e-09
MSH O 0 9.310281825491984e-07
) O 0 2.224170014830662e-10
alpha O 0 1.2722326525604899e-09
, O 0 6.104864530565024e-11
beta O 0 3.744693444218683e-10
and O 0 6.702286642346067e-11
gamma O 0 9.293537051036083e-10
as O 0 2.321415421002726e-10
well O 0 1.6972502570045123e-10
as O 0 3.6680977699710127e-11
the O 0 6.822833270581086e-11
opioid O 0 3.7034340039099334e-09
- O 0 4.859555868819143e-09
receptor O 0 1.1574275760040109e-08
ligand O 0 7.507003374485066e-08
beta O 0 1.5897888943072758e-06
- O 0 9.685763870947994e-06
endorphin O 0 7.975875632837415e-05
. O 0 2.5549462634444353e-07

While O 0 2.7736959395952e-07
a O 0 1.430205820440733e-08
few O 0 6.426406962134479e-09
cases O 0 1.930219983847792e-09
of O 0 3.7481234782532624e-10
isolated O 0 9.862974548013881e-05
ACTH B-Disease 1 0.8700749278068542
deficiency I-Disease 0 0.0001036563262459822
have O 0 3.007736726345911e-09
been O 0 6.380752370915843e-09
reported O 0 1.4754019161955512e-07
( O 0 7.2061632216957605e-09
OMIM O 0 7.120022473827703e-06
201400 O 0 1.0553527118872807e-07
) O 0 6.960590437365965e-10
, O 0 2.0095157482469261e-10
an O 0 8.782747307201078e-10
inherited O 0 0.0019007609225809574
POMC O 1 0.7746652364730835
defect O 0 0.0004978857468813658
has O 0 1.9566648745694692e-08
not O 0 8.812653717882313e-09
been O 0 1.2597134002589883e-08
described O 0 2.1007492634339542e-08
so O 0 8.7131732939838e-09
far O 0 2.0974301406795348e-08
. O 0 1.2829185713769675e-08

Recent O 0 1.0052722245745827e-06
studies O 0 9.084167373885066e-08
in O 0 3.5187486258081435e-09
animal O 0 9.033210623954346e-09
models O 0 5.4414925898527144e-08
elucidated O 0 9.156166669299637e-08
a O 0 2.1326747035033122e-09
central O 0 2.076297356268242e-09
role O 0 3.1988747206668222e-09
of O 0 1.6770225486073542e-10
alpha O 0 4.186820845575312e-08
- O 0 5.002322041036678e-07
MSH O 0 6.296696483332198e-06
in O 0 4.403837738919947e-09
the O 0 5.671627612002794e-10
regulation O 0 7.936098889160803e-09
of O 0 1.7365973242755572e-11
food O 0 5.220107124337403e-10
intake O 0 1.3009305854794206e-09
by O 0 5.321915130807042e-11
activation O 0 9.439853343451432e-10
of O 0 9.24935891766232e-11
the O 0 3.5782672380690883e-09
brain O 0 3.467970373094431e-06
melanocortin O 0 5.785250323242508e-06
- O 0 5.776638545285095e-07
4 O 0 2.598610393533818e-08
- O 0 7.979953409176233e-08
receptor O 0 7.083816910835594e-08
( O 0 1.0269682881869358e-08
MC4 O 0 3.6208133678883314e-05
- O 0 3.4775680433085654e-06
R O 0 3.6034778077009832e-06
; O 0 3.299284845326156e-09
refs O 0 3.074853111684206e-06
3 O 0 2.3496555812130282e-08
- O 0 1.9711676202405215e-07
5 O 0 2.8008357855213717e-09
) O 0 1.3533826836997775e-10
and O 0 2.2040765046416055e-10
the O 0 1.8454322792127442e-10
linkage O 0 5.424207927262614e-08
of O 0 2.1523705040493724e-10
human O 0 1.2403678972816579e-08
obesity B-Disease 1 0.9999953508377075
to O 0 6.749502734493262e-09
chromosome O 0 1.1345261441420007e-07
2 O 0 2.127465981160981e-09
in O 0 2.3697186435356343e-09
close O 0 1.0456526311486414e-08
proximity O 0 5.413415049559944e-09
to O 0 2.8273292596026067e-09
the O 0 5.869463137742059e-09
POMC O 0 9.354871508548968e-07
locus O 0 1.254536652339766e-08
, O 0 4.899498584620687e-10
led O 0 3.2958805129545965e-10
to O 0 1.0838581421257487e-10
the O 0 1.3235505746944654e-10
proposal O 0 1.7277316244346252e-09
of O 0 4.537684811234399e-11
an O 0 1.919066572320105e-10
association O 0 1.935986482237695e-09
of O 0 2.4012894450642364e-10
POMC O 0 1.5607474779244512e-06
with O 0 3.979939933174137e-09
human O 0 1.643318370270208e-07
obesity B-Disease 1 0.9999990463256836
. O 0 8.646382525512308e-07

The O 0 5.0463896172914247e-08
dual O 0 1.1234858021680338e-07
role O 0 1.9869435874397823e-08
of O 0 5.696845772895642e-10
alpha O 0 7.710927008020008e-08
- O 0 1.6490248526679352e-06
MSH O 0 3.4293792850803584e-05
in O 0 5.793971524781227e-09
regulating O 0 4.409749010392261e-08
food O 0 8.948958019061592e-09
intake O 0 5.276399406284327e-08
and O 0 5.808023395559303e-09
influencing O 0 3.4564035900075396e-07
hair O 1 0.9602136611938477
pigmentation O 0 0.0003857665287796408
predicts O 0 8.012711987248622e-07
that O 0 1.1483234363396377e-09
the O 0 6.59556242954551e-10
phenotype O 0 5.82682275762636e-08
associated O 0 2.6059150393109576e-09
with O 0 8.456376154875045e-10
a O 0 3.866317115353013e-07
defect O 0 3.5653396480483934e-05
in O 0 3.680002080841405e-08
POMC O 0 5.972805411147419e-06
function O 0 8.299861242733186e-09
would O 0 1.0511175929650562e-08
include O 0 1.972985685938511e-08
obesity B-Disease 1 0.9999991655349731
, O 0 1.0387666726785483e-08
alteration O 0 6.815058100073657e-07
in O 0 4.5635933929588646e-06
pigmentation O 1 0.5931088924407959
and O 0 5.9321740991435945e-05
ACTH B-Disease 0 0.08972074091434479
deficiency I-Disease 0 0.0007093315944075584
. O 0 1.4345118870551232e-07

The O 0 1.0442499132068406e-07
observation O 0 2.2359314755249216e-07
of O 0 7.966760584565691e-10
these O 0 4.735987602089153e-09
symptoms O 0 1.1974055951213813e-06
in O 0 1.120685944044908e-08
two O 0 6.351234649315529e-09
probands O 0 4.2097104824279086e-07
prompted O 0 2.4331033188218498e-08
us O 0 5.7700071387500884e-09
to O 0 1.439586089224676e-10
search O 0 1.4126289027416306e-09
for O 0 2.5925678270866115e-10
mutations O 0 6.119478701549497e-09
within O 0 7.644465616074569e-10
their O 0 6.552881792742937e-09
POMC O 0 9.053444046003278e-06
genes O 0 8.291357858070114e-07
. O 0 1.473412396535423e-07

Patient O 0 0.00016835774295032024
1 O 0 2.0358018559818447e-07
was O 0 1.0302293418362751e-07
found O 0 8.408094775980146e-10
to O 0 5.611699646634882e-11
be O 0 1.936635574129042e-10
a O 0 3.051931762865223e-10
compound O 0 3.84122733620984e-09
heterozygote O 0 5.4782638869710354e-08
for O 0 2.4648072471933347e-10
two O 0 9.579588233776803e-10
mutations O 0 1.1752508299878173e-08
in O 0 3.148349803083761e-09
exon O 0 8.010528773638725e-08
3 O 0 3.0749447432754096e-08
( O 0 8.842152787735813e-09
G7013T O 0 3.7851555134693626e-07
, O 0 1.4377373735996457e-09
C7133delta O 0 5.020602245053851e-08
) O 0 1.4370347967140873e-10
which O 0 1.151373510421827e-10
interfere O 0 2.4145541122067016e-09
with O 0 2.6345500780955433e-10
appropriate O 0 2.6753252946321027e-09
synthesis O 0 3.848399376948919e-09
of O 0 4.466578773509866e-10
ACTH O 0 1.4786107271902438e-07
and O 0 4.923407903589805e-09
alpha O 0 2.0254859123269853e-07
- O 0 4.1019766285899095e-06
MSH O 0 0.00039849980385042727
. O 0 2.2152309497869282e-07

Patient O 0 0.0003759256505873054
2 O 0 3.795967984387971e-07
was O 0 5.735917341098684e-08
homozygous O 0 4.435451472772911e-08
for O 0 3.924742197902731e-10
a O 0 3.4417177996459714e-09
mutation O 0 4.9556220460544864e-08
in O 0 1.3599204429226575e-08
exon O 0 4.365766699265805e-07
2 O 0 8.343178592440381e-08
( O 0 1.752331435511678e-08
C3804A O 0 4.99542352372373e-07
) O 0 4.266571540512132e-09
which O 0 2.462413206671954e-08
abolishes O 0 5.1821953093167394e-06
POMC O 0 7.789502706145868e-05
translation O 0 5.4404822549258824e-06
. O 0 4.1606389800108445e-07

These O 0 7.637491705736466e-08
findings O 0 2.1160790453222944e-08
represent O 0 4.411098708523298e-10
the O 0 1.8314026684063123e-10
first O 0 2.705584645212866e-10
examples O 0 1.149618511497863e-09
of O 0 2.1207881284457386e-10
a O 0 6.07771596605744e-07
genetic B-Disease 1 1.0
defect I-Disease 1 0.9999979734420776
within O 0 2.9783084887213818e-09
the O 0 4.818686338836642e-09
POMC O 0 3.155721515213372e-06
gene O 0 1.0840704334214024e-07
and O 0 3.900847200810631e-09
define O 0 1.799602955543378e-08
a O 0 7.344974051193276e-08
new O 0 9.369476174470037e-06
monogenic B-Disease 1 0.9998660087585449
endocrine I-Disease 1 0.9927728772163391
disorder I-Disease 0 0.0002244200004497543
resulting O 0 3.542589510630023e-08
in O 0 5.3734829918994365e-08
early O 0 0.33861440420150757
- O 1 0.9999971389770508
onset O 1 0.9999918937683105
obesity B-Disease 1 1.0
, O 0 1.5136349247768521e-05
adrenal B-Disease 1 0.9999992847442627
insufficiency I-Disease 1 1.0
and O 0 7.028849722701125e-06
red O 0 5.9597714425763115e-05
hair O 1 0.9999148845672607
pigmentation O 0 0.0010664580622687936
. O 0 8.255545935753617e-08
. O 0 1.0234899150418642e-07

A O 0 1.1043818631151225e-05
European O 0 2.284862148371758e-06
multicenter O 0 8.923732821131125e-06
study O 0 1.6923134182889044e-07
of O 0 3.1898412089503836e-07
phenylalanine B-Disease 1 1.0
hydroxylase I-Disease 1 1.0
deficiency I-Disease 1 1.0
: O 0 7.39734531407521e-08
classification O 0 3.252084823657242e-08
of O 0 2.390677933394869e-10
105 O 0 7.742037411162528e-08
mutations O 0 9.083682073196542e-08
and O 0 2.279170852048651e-09
a O 0 6.20014206642594e-10
general O 0 6.242290573332809e-10
system O 0 3.831766015593985e-09
for O 0 1.603486787793429e-09
genotype O 0 1.9330414033902343e-06
- O 0 1.07988785202906e-06
based O 0 1.1585355963461552e-07
prediction O 0 2.6745517516246764e-06
of O 0 1.827656781472342e-08
metabolic O 0 0.00015015248209238052
phenotype O 0 3.065012424485758e-05
. O 0 3.381549618097779e-07

Phenylketonuria B-Disease 1 0.9995496869087219
( O 0 0.00011908489250345156
PKU B-Disease 0 0.43549659848213196
) O 0 2.726402783537196e-07
and O 0 1.2370929880489712e-06
mild B-Disease 1 0.999982476234436
hyperphenylalaninemia I-Disease 1 1.0
( O 0 0.141410231590271
MHP B-Disease 1 1.0
) O 0 5.3526463261732715e-08
are O 0 4.221606531018551e-08
allelic B-Disease 0 0.00017118458345066756
disorders I-Disease 1 0.9580207467079163
caused O 0 1.9656860672512266e-07
by O 0 3.2532554428144067e-09
mutations O 0 1.778568190502483e-07
in O 0 5.42186784358023e-09
the O 0 5.084637599850339e-09
gene O 0 5.186835210224672e-07
encoding O 0 2.3633340333617525e-06
phenylalanine O 0 9.141471673501655e-05
hydroxylase O 0 0.0011967733735218644
( O 0 7.334935503422457e-07
PAH O 0 1.788486770237796e-05
) O 0 2.629016115918148e-08
. O 0 7.017438008460886e-08

Previous O 0 1.4353647657117108e-06
studies O 0 9.659463984235117e-08
have O 0 3.818851901371545e-09
suggested O 0 4.902436678833055e-09
that O 0 1.0688673557357475e-10
the O 0 1.794459858484032e-10
highly O 0 9.7261816378591e-09
variable O 0 2.1959722573683393e-07
metabolic O 0 6.395342643372715e-05
phenotypes O 0 9.104701348405797e-06
of O 0 2.7634907837637e-06
PAH B-Disease 1 0.9984083771705627
deficiency I-Disease 1 0.5626906752586365
correlate O 0 3.690247467602603e-06
with O 0 4.5141248961044766e-07
PAH O 0 0.010118263773620129
genotypes O 0 0.00011401035590097308
. O 0 6.380048489518231e-07

We O 0 4.5765929712615616e-07
identified O 0 8.034062659589836e-08
both O 0 2.7617867992546508e-09
causative O 0 2.8097602466914395e-07
mutations O 0 2.0929289235027682e-07
in O 0 3.503093992662798e-08
686 O 0 3.148077439618646e-06
patients O 0 8.570648333261488e-07
from O 0 4.930079899878592e-09
seven O 0 7.877253516141991e-09
European O 0 4.6676994713834574e-08
centers O 0 3.970176720713425e-08
. O 0 3.276759841241983e-08

On O 0 1.9500524217619386e-07
the O 0 7.213090125191002e-10
basis O 0 5.907309086339296e-10
of O 0 6.090710574779834e-11
the O 0 4.09801248490993e-10
phenotypic O 0 3.047525609645163e-08
characteristics O 0 6.488111381486306e-09
of O 0 6.293241483490419e-10
297 O 0 5.029640988141182e-07
functionally O 0 1.6439860246464377e-06
hemizygous O 0 1.5181713933998253e-05
patients O 0 1.0078852028527763e-06
, O 0 5.189778051750693e-10
105 O 0 2.7738815688849172e-09
of O 0 3.619062341475576e-11
the O 0 2.229517265250891e-10
mutations O 0 2.695058620716395e-09
were O 0 4.287929566970661e-09
assigned O 0 6.579642386483897e-10
to O 0 1.448162006978393e-10
one O 0 5.7020421717624e-10
of O 0 9.513468485211618e-11
four O 0 1.1290076651349068e-09
arbitrary O 0 9.660215738449551e-09
phenotype O 0 4.1292369701295684e-07
categories O 0 1.035813284033793e-07
. O 0 3.679461713090859e-08

We O 0 2.0651611976063577e-07
proposed O 0 9.15635478548893e-09
and O 0 4.407661347016756e-09
tested O 0 5.310026640614751e-09
a O 0 4.0000672218987177e-10
simple O 0 6.475262548377714e-10
model O 0 2.1111998815825928e-09
for O 0 7.424105774589407e-11
correlation O 0 6.9258971890917564e-09
between O 0 6.0435025872607184e-09
genotype O 0 9.744240969666862e-07
and O 0 1.2251224923431892e-08
phenotypic O 0 6.618300858463044e-07
outcome O 0 7.852945032027492e-07
. O 0 1.062595842427072e-07

The O 0 1.6329731522546354e-07
observed O 0 1.7210565772529662e-07
phenotype O 0 1.0990371492880513e-06
matched O 0 2.3543532279290957e-07
the O 0 1.2292865392282692e-08
predicted O 0 2.3429395241691964e-06
phenotype O 0 4.961197532793449e-07
in O 0 1.0145237538949914e-08
79 O 0 6.656343742861281e-08
% O 0 1.1233534241705811e-10
of O 0 1.1888915199542716e-11
the O 0 2.940819532337713e-10
cases O 0 5.026722593726163e-09
, O 0 1.0530535332620161e-09
and O 0 1.6017719373095929e-09
in O 0 4.3968947927019997e-10
only O 0 2.2739893301704228e-10
5 O 0 8.503665827053197e-11
of O 0 3.7053381196638924e-11
184 O 0 6.120692397360017e-09
patients O 0 8.809750084992629e-08
was O 0 1.9105813464648236e-07
the O 0 1.1997541848884907e-09
observed O 0 9.468547723656684e-09
phenotype O 0 5.478253584101367e-08
more O 0 5.114242362935784e-10
than O 0 3.0881072698996093e-10
one O 0 3.6307623574316494e-10
category O 0 3.383527902300898e-09
away O 0 3.610626686523233e-09
from O 0 7.946515112600139e-10
that O 0 1.2076935007598877e-09
expected O 0 4.20578167847907e-08
. O 0 1.0218373702741701e-08

Among O 0 6.14083148775535e-08
the O 0 1.8388065514685081e-09
seven O 0 3.9867989465314224e-10
contributing O 0 1.8488637010261044e-10
centers O 0 3.8225736465058446e-10
, O 0 5.444743961247056e-11
the O 0 3.849783339338053e-11
proportion O 0 6.191751000805823e-10
of O 0 6.506097743885775e-11
patients O 0 3.2512332825973544e-09
for O 0 1.0251471893596431e-10
whom O 0 1.4908416723358187e-09
the O 0 5.681946579905173e-10
observed O 0 9.179314197638178e-09
phenotype O 0 6.59131771385546e-08
did O 0 4.764475747265351e-08
not O 0 2.802978738003503e-09
match O 0 2.9466168172120888e-08
the O 0 1.060651011464131e-09
predicted O 0 1.6804009419502108e-06
phenotype O 0 1.6790973234037665e-07
was O 0 3.141351356816813e-08
4 O 0 2.1694679386285998e-09
% O 0 1.4389116564927917e-09
- O 0 2.1856342868886713e-07
23 O 0 6.604934554843567e-08
% O 0 2.2864203863548482e-09
( O 0 4.1051024801674885e-09
P O 0 4.2543557356111705e-05
< O 0 5.056284280158252e-08
. O 0 6.521868045616941e-10
0001 O 0 2.2534918286964967e-07
) O 0 1.5309210843472698e-10
, O 0 5.755338913782104e-11
suggesting O 0 4.608488257673571e-09
that O 0 3.178753094079667e-10
differences O 0 9.788373445118737e-10
in O 0 1.3943105003910716e-10
methods O 0 4.790677854416003e-10
used O 0 7.177025085347566e-10
for O 0 3.8035405380831833e-10
mutation O 0 8.958966013494774e-09
detection O 0 4.241501727619834e-08
or O 0 4.0843536908141687e-07
phenotype O 0 7.884644219302572e-06
classification O 0 3.366458543041517e-07
may O 0 1.577499944005467e-07
account O 0 1.485709222315279e-09
for O 0 1.2611786615046583e-10
a O 0 6.98226476636421e-10
considerable O 0 3.418524796572342e-09
proportion O 0 1.7604518731673124e-08
of O 0 1.0356271396005923e-08
genotype O 0 0.4565575122833252
- O 1 0.9727941155433655
phenotype O 0 0.0003850278735626489
inconsistencies O 0 8.50317082949914e-05
. O 0 4.905160722046276e-07

Our O 0 9.674621281874352e-08
data O 0 2.588755698695877e-08
indicate O 0 9.846501392019036e-09
that O 0 3.5480227089657035e-10
the O 0 8.13653322495611e-09
PAH O 0 0.0002736455062404275
- O 0 2.18415807466954e-05
mutation O 0 6.72782221045054e-07
genotype O 0 1.9808794604614377e-06
is O 0 1.449655173679787e-09
the O 0 6.395345364396121e-10
main O 0 7.355107189965793e-09
determinant O 0 8.797056239018275e-08
of O 0 4.8481223480223434e-09
metabolic O 0 0.0007422814378514886
phenotype O 0 5.172152668819763e-06
in O 0 5.6488001831667134e-08
most O 0 2.1524243720705272e-07
patients O 0 1.725307993183378e-05
with O 0 4.687855380325345e-06
PAH B-Disease 1 0.9998217225074768
deficiency I-Disease 1 0.8485261797904968
. O 0 5.130974614075967e-07

In O 0 9.607593653981894e-08
the O 0 2.0345698459323103e-09
present O 0 3.840016915557243e-10
study O 0 5.660258928230633e-10
, O 0 1.0345205248007971e-10
the O 0 2.0748475160203839e-10
classification O 0 4.545667842137391e-09
of O 0 2.786240405061591e-10
105 O 0 3.290599806859973e-06
PAH O 0 1.1214469850528985e-05
mutations O 0 1.6710318107016064e-07
may O 0 1.692209394832389e-08
allow O 0 4.5668435699752763e-10
the O 0 8.252216687765213e-10
prediction O 0 3.150544003460709e-08
of O 0 8.025581588189112e-11
the O 0 1.2372270985494538e-09
biochemical O 0 8.606064056948526e-07
phenotype O 0 5.901937356611597e-07
in O 0 3.542981730220163e-08
> O 0 4.7444164152921076e-08
10 O 0 2.5798474467819688e-09
, O 0 1.9911412796336236e-10
000 O 0 1.4979617546373447e-09
genotypes O 0 2.8407471930336214e-08
, O 0 3.3126004717054514e-10
which O 0 6.38612995818022e-10
may O 0 1.9909229820314067e-08
be O 0 2.0961041236056133e-10
useful O 0 3.839482343170886e-10
for O 0 5.5681032701260236e-11
the O 0 6.067731872505533e-10
management O 0 1.1710776348650143e-08
of O 0 1.0689473750602474e-09
hyperphenylalaninemia B-Disease 1 0.9999988079071045
in O 0 2.2666533823212376e-06
newborns O 0 1.0402961379440967e-05
. O 0 6.218172643457365e-08

Somatic O 0 0.00029083999106660485
instability O 0 1.2880454960395582e-05
of O 0 1.2830335904823187e-08
the O 0 1.7305490374042165e-08
CTG O 0 7.646931408089586e-06
repeat O 0 1.025427764034248e-06
in O 0 4.0097727804777605e-08
mice O 0 6.512576078421262e-07
transgenic O 0 2.1755796808520245e-07
for O 0 5.048919060612889e-09
the O 0 5.195092285248393e-07
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
region O 0 4.0303072523784067e-07
is O 0 1.1890612050535765e-08
age O 0 2.9264797252182007e-09
dependent O 0 1.58897039970185e-09
but O 0 1.5234911110439953e-09
not O 0 1.1742391781144335e-10
correlated O 0 2.8951710473457126e-10
to O 0 7.550920305687825e-11
the O 0 2.736527393576438e-10
relative O 0 1.4026474204342776e-08
intertissue O 0 2.389183464401867e-07
transcription O 0 1.8930519729565276e-07
levels O 0 1.9609615264926106e-08
and O 0 8.222887259989875e-09
proliferative O 0 1.895090281323064e-05
capacities O 0 1.0579419722489547e-06
. O 0 1.9911192339350237e-07

A O 0 3.7850682019779924e-06
( O 0 1.0559890029071539e-07
CTG O 0 2.0873883386229863e-06
) O 0 6.5573324548040546e-09
nexpansion O 0 2.0404552003583376e-07
in O 0 3.49922579800932e-09
the O 0 3.4335019272191403e-09
3 O 0 1.121220876143525e-07
- O 0 2.030642281170003e-05
untranslated O 0 2.7228763428865932e-05
region O 0 1.9774847714870702e-07
( O 0 1.3193426795510277e-08
UTR O 0 4.475409411952569e-07
) O 0 8.95296503600207e-10
of O 0 1.9454060584678246e-10
the O 0 1.907667623868292e-08
DM O 1 1.0
protein O 0 3.0978034715190006e-07
kinase O 0 1.3620044683193555e-06
gene O 0 2.384762751717062e-07
( O 0 5.94812732401806e-09
DMPK O 0 1.3346575542527717e-06
) O 0 9.329627070897573e-10
is O 0 2.146049310480791e-10
responsible O 0 3.093709510793019e-09
for O 0 1.6143172132387917e-08
causing O 0 0.002210371196269989
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 0.0004095436306670308
DM B-Disease 1 1.0
) O 0 2.722702845403546e-07
. O 0 1.3052962799520174e-07

Major O 0 3.826309239229886e-06
instability O 0 1.8528975488152355e-05
, O 0 8.192890810221343e-09
with O 0 3.0536784212387147e-10
very O 0 1.786755743360402e-09
large O 0 7.118887423995801e-11
expansions O 0 1.1390986820458693e-08
between O 0 6.445012856737264e-10
generations O 0 1.776174762824212e-09
and O 0 1.360166090869086e-09
high O 0 4.191053726287919e-09
levels O 0 7.716628447340668e-10
of O 0 5.6648567781092396e-11
somatic O 0 7.065789020543889e-08
mosaicism O 0 1.6201661310333293e-06
, O 0 1.496508139631203e-09
is O 0 3.4729730202798237e-10
observed O 0 3.0911260218147163e-09
in O 0 2.2341767547118252e-08
patients O 0 2.2075103345287062e-07
. O 0 3.401232717692437e-08

There O 0 1.585798941050598e-07
is O 0 3.08200687193505e-09
a O 0 1.3314459534896628e-09
good O 0 2.1011016926308912e-08
correlation O 0 1.1312347503178444e-08
between O 0 5.226914456812892e-09
repeat O 0 2.3828280859561346e-07
size O 0 9.813016177417921e-09
( O 0 9.131375100501771e-10
at O 0 1.653052694727819e-09
least O 0 3.4638306112277917e-10
in O 0 1.1900226359884414e-09
leucocytes O 0 1.0698600760861154e-07
) O 0 1.8130066892219077e-10
, O 0 1.3283152355825223e-10
clinical O 0 2.054388126282447e-08
severity O 0 1.1679601357172942e-06
and O 0 5.1562469849386616e-08
age O 0 4.9594895301652286e-08
of O 0 1.333024024496865e-09
onset O 0 2.339521188332583e-06
. O 0 1.0556627927371665e-07

The O 0 1.4876702607580228e-06
trinucleotide O 0 0.00035559688694775105
repeat O 0 3.42924176948145e-05
instability O 0 8.695577093931206e-07
mechanisms O 0 7.778715627182464e-08
involved O 0 4.8925375750741296e-08
in O 0 4.26332235292648e-06
DM B-Disease 1 1.0
and O 0 2.691546185928928e-08
other O 0 3.5808618292776373e-09
human O 0 1.6130144331327756e-07
genetic B-Disease 1 1.0
diseases I-Disease 1 1.0
are O 0 3.132448256337739e-08
unknown O 0 2.710179956011416e-07
. O 0 7.315334471513779e-08

We O 0 8.926218697524746e-07
studied O 0 4.811442977370461e-07
somatic O 0 1.0240752317258739e-06
instability O 0 2.1772275715647993e-07
by O 0 1.4913194013033149e-09
measuring O 0 6.989972689552815e-08
the O 0 5.2757327395625e-09
CTG O 0 3.0994219741842244e-06
repeat O 0 2.547790245444048e-07
length O 0 3.010085336541124e-08
at O 0 1.4656840185978126e-08
several O 0 4.255962804400326e-10
ages O 0 4.458817759456224e-09
in O 0 3.925513247793333e-10
various O 0 1.5847353984632662e-10
tissues O 0 2.848689062417975e-09
of O 0 1.7315311684473755e-10
transgenic O 0 8.050952260418853e-08
mice O 0 2.3931033865665086e-07
carrying O 0 1.0305591047199414e-08
a O 0 6.3053193777307115e-09
( O 0 1.0149843632234479e-08
CTG O 0 8.330217724505928e-07
) O 0 1.6306248573627613e-09
55expansion O 0 7.952299796443185e-08
surrounded O 0 2.531604037514512e-09
by O 0 3.5085936933576534e-10
45 O 0 2.769430240689985e-09
kb O 0 5.278191039792546e-08
of O 0 1.082738135260719e-10
the O 0 2.269683330169414e-09
human O 0 1.0146556661538852e-07
DM B-Disease 1 1.0
region O 0 3.738238874007038e-08
, O 0 3.388324620878791e-10
using O 0 1.5584836754456433e-09
small O 0 3.548222693439129e-08
- O 0 2.3954969492478995e-06
pool O 0 3.90280717965652e-07
PCR O 0 5.470919859362766e-06
. O 0 5.1453415750302156e-08

These O 0 1.738998918199286e-07
mice O 0 1.5052005437610205e-06
have O 0 2.718341995944229e-09
been O 0 5.458618002052162e-10
shown O 0 2.46618031551904e-10
to O 0 1.2366532797791763e-10
reproduce O 0 5.452252427318172e-09
the O 0 6.584638945206223e-10
intergenerational O 0 3.573958196056992e-08
and O 0 1.6812123915244115e-09
somatic O 0 5.564862703977269e-08
instability O 0 2.3735331922125624e-08
of O 0 1.4285740645991751e-10
the O 0 1.242597802431078e-09
55 O 0 2.575306012886358e-08
CTG O 0 1.2257474963917048e-06
repeat O 0 2.1763432300758723e-07
suggesting O 0 4.386830099178951e-08
that O 0 1.856740872163698e-10
surrounding O 0 2.0138439527084273e-10
sequences O 0 1.858736831117369e-09
and O 0 8.399391182578597e-10
the O 0 2.526200915120569e-10
chromatin O 0 9.948896817491004e-09
environment O 0 1.270341387638041e-09
are O 0 7.093244047684522e-11
involved O 0 5.797760049830458e-10
in O 0 4.78747441690075e-09
instability O 0 8.128161255172017e-08
mechanisms O 0 2.1414744821868226e-07
. O 0 7.322691430999839e-08

As O 0 5.334128161393892e-08
observed O 0 4.983144563652786e-09
in O 0 4.883992099635748e-10
some O 0 5.2257431021329737e-11
of O 0 6.808088381243804e-12
the O 0 1.637009278132595e-10
tissues O 0 9.26179488658363e-09
of O 0 1.528194992772569e-08
DM B-Disease 1 1.0
patients O 0 4.633349453797564e-05
, O 0 4.919913365597495e-10
there O 0 7.913693589323145e-10
is O 0 1.0853413306977089e-10
a O 0 1.2748415656460566e-09
tendency O 0 3.120914726650881e-08
for O 0 1.1205443239958868e-09
repeat O 0 6.679809416709759e-08
length O 0 8.433024945020406e-09
and O 0 1.537544203067398e-09
somatic O 0 1.6755567600057475e-08
mosaicism O 0 7.03928861867098e-08
to O 0 3.276456328471511e-10
increase O 0 3.4098229795276325e-10
with O 0 9.053952726434389e-11
the O 0 7.759474174307002e-10
age O 0 5.409018122293219e-09
of O 0 6.939959718010869e-11
the O 0 3.3736748950019546e-09
mouse O 0 1.9894046090485062e-06
. O 0 1.0637720038175758e-07

Furthermore O 0 9.454039400225156e-07
, O 0 1.0400453831493905e-08
we O 0 1.51272550041881e-09
observed O 0 3.647218915769912e-10
no O 0 2.0547387402647388e-10
correlation O 0 1.8387223965632415e-09
between O 0 4.834149192056714e-10
the O 0 1.6607607511431866e-09
somatic O 0 2.496896627235401e-07
mutation O 0 1.5700749145253212e-07
rate O 0 1.5386060567834647e-06
and O 0 1.1528315191355887e-08
tissue O 0 1.465311498805022e-07
proliferation O 0 3.6668654956883984e-07
capacity O 0 9.198859629577782e-08
. O 0 5.976754380299099e-08

The O 0 5.553505957323068e-07
somatic O 0 1.0300244866812136e-05
mutation O 0 2.355741571591352e-06
rates O 0 1.491709099354921e-06
in O 0 1.7163966914424122e-09
different O 0 1.7870140089915054e-10
tissues O 0 4.048649415722139e-09
were O 0 1.3913258101183601e-08
also O 0 2.9603985929327337e-10
not O 0 1.4453087338051063e-10
correlated O 0 2.8593680201360883e-10
to O 0 1.119616552247571e-10
the O 0 2.1039148201396074e-10
relative O 0 6.886485603985193e-09
inter O 0 5.764603884017561e-06
- O 0 2.4675955501152202e-06
tissue O 0 8.240302662443355e-08
difference O 0 4.293650768261159e-09
in O 0 7.059262618902551e-10
transcriptional O 0 2.260990861202572e-08
levels O 0 2.1988793008631546e-09
of O 0 1.660296553018803e-11
the O 0 1.1460756649261938e-10
three O 0 5.139020320399368e-10
genes O 0 5.727791574372532e-09
( O 0 2.3091399903307774e-09
DMAHP O 0 3.3084033930208534e-06
, O 0 3.4847260632631105e-09
DMPK O 0 2.605459940241417e-06
and O 0 4.429768107883092e-09
59 O 0 8.509125848377153e-09
) O 0 7.582382638426921e-11
surrounding O 0 2.371304264059404e-10
the O 0 3.45396911072271e-09
repeat O 0 3.097921705830231e-07
. O 0 4.133434039488293e-09
. O 0 1.983914010850185e-08

A O 0 2.65237190433254e-06
novel O 0 3.562558958947193e-07
missense O 0 4.396008080220781e-05
mutation O 0 1.4354756103784894e-06
in O 0 4.289199750928674e-08
patients O 0 2.2828706391919695e-07
from O 0 3.829544681366315e-09
a O 0 1.593897636098518e-08
retinoblastoma B-Disease 0 6.817744724685326e-05
pedigree O 0 4.093992174603045e-05
showing O 0 6.429364702853491e-07
only O 0 1.1738708671771292e-08
mild O 0 1.9872711618518224e-06
expression O 0 1.0036398379043021e-08
of O 0 2.814533051065382e-10
the O 0 1.6094810817435246e-08
tumor B-Disease 0 1.3049472727288958e-05
phenotype O 0 7.301482128241332e-06
. O 0 1.7593499990198325e-07

We O 0 1.5380237528006546e-07
have O 0 1.846866104493472e-09
used O 0 7.402108370690996e-10
single O 0 4.810834841606493e-09
strand O 0 6.034797479514964e-07
conformation O 0 4.1950382723143775e-08
polymorphism O 0 3.6500136246786496e-08
analysis O 0 1.195363918959913e-09
to O 0 2.7312291317471704e-10
study O 0 5.657096457944988e-10
the O 0 5.484991350002133e-10
27 O 0 9.910015030811792e-09
exons O 0 1.9276849005933627e-09
of O 0 7.103249238804565e-11
the O 0 1.0567093866598043e-09
RB1 O 0 3.7960654708513175e-07
gene O 0 7.101183641111675e-09
in O 0 8.784120653082539e-10
individuals O 0 3.5249251434388285e-11
from O 0 2.2017908329896585e-10
a O 0 4.873470071942165e-09
family O 0 1.1224572382673159e-08
showing O 0 1.0092971933772787e-06
mild O 0 5.032250101066893e-06
expression O 0 6.246342998394994e-09
of O 0 3.7547279174710013e-10
the O 0 2.0673084577538248e-08
retinoblastoma B-Disease 0 4.101162267033942e-05
phenotype O 0 1.6338501154677942e-05
. O 0 2.6288665821994073e-07

In O 0 3.0866092970427417e-07
this O 0 4.9320929562668425e-09
family O 0 4.612199067111078e-09
affected O 0 1.9358390446200247e-09
individuals O 0 1.807764909989018e-10
developed O 0 6.832375731846696e-08
unilateral B-Disease 0 0.09721863269805908
tumors I-Disease 1 1.0
and O 0 4.5930462988508225e-08
, O 0 1.9415989649385068e-10
as O 0 1.955883094373334e-10
a O 0 2.1126046745312266e-10
result O 0 1.0437133379781471e-09
of O 0 1.0149640849999031e-10
linkage O 0 1.2562276197058964e-07
analysis O 0 4.467475278602251e-09
, O 0 1.014687667222347e-09
unaffected O 0 1.1455352932898677e-07
mutation O 0 9.024599734175354e-09
carriers O 0 1.5083900350987278e-08
were O 0 8.121121553017474e-09
also O 0 2.3846619123801815e-10
identified O 0 4.879885384667659e-10
within O 0 2.348035932353554e-10
the O 0 1.1799653698574275e-08
pedigree O 0 3.1538261282548774e-06
. O 0 9.94984930002829e-08

A O 0 1.9742371932807146e-06
single O 0 8.225526215710488e-08
band O 0 5.13667330892531e-08
shift O 0 3.141638771353428e-08
using O 0 9.789050459119153e-09
SSCP O 0 2.5869203454931267e-06
was O 0 5.974714412104731e-08
identified O 0 3.6978651252184136e-09
in O 0 7.616390851339361e-10
exon O 0 3.090608657885241e-08
21 O 0 1.944261818209725e-08
which O 0 5.661586754968084e-10
resulted O 0 1.0281280271584592e-09
in O 0 1.404954708128514e-09
a O 0 1.1487248485764212e-08
missense O 0 3.51839935319731e-06
mutation O 0 7.571150462126752e-08
converting O 0 9.009039558804943e-08
a O 0 1.2300820628752263e-07
cys O 0 0.3608672320842743
- O 0 6.001644942443818e-05
- O 0 1.0260234375891741e-05
> O 0 1.0262010619044304e-07
arg O 0 1.3004206778077787e-07
at O 0 5.7773195116794795e-09
nucleotide O 0 8.442294863186817e-09
position O 0 1.50770258500188e-08
28 O 0 6.314984091204678e-09
in O 0 5.849990492023949e-10
the O 0 4.610106074665055e-09
exon O 0 1.2506671964729321e-06
. O 0 1.2094440648979798e-07

The O 0 2.902617382005701e-07
mutation O 0 4.558450541480852e-07
destroyed O 0 2.766869329207111e-07
an O 0 4.69216354659352e-09
NdeI O 0 8.956839678830875e-07
restriction O 0 3.804328514434019e-07
enzyme O 0 2.7865416996064596e-07
site O 0 1.9035573473047407e-07
. O 0 6.796994966862258e-08

Analysis O 0 1.5290410715351754e-07
of O 0 1.2341065946941399e-09
all O 0 4.621936722237763e-10
family O 0 3.0522112615116725e-10
members O 0 6.082305492594031e-11
demonstrated O 0 9.378547938254655e-10
that O 0 1.658705395257698e-10
the O 0 2.908077112451224e-10
missense O 0 7.549908218607015e-07
mutation O 0 1.1063947624734283e-07
co O 0 3.2643495728734706e-07
- O 0 1.034251226883498e-06
segregated O 0 5.730417385052533e-08
with O 0 1.379715897087408e-09
patients O 0 7.729177013970912e-07
with O 0 2.587615277604982e-08
tumors B-Disease 1 1.0
or O 0 1.8709325786403497e-06
who O 0 3.0404805784201017e-07
, O 0 1.5985726631306818e-10
as O 0 3.456175068361489e-10
a O 0 3.066577825006078e-10
result O 0 1.1489083018290103e-09
of O 0 1.2736887933240126e-10
linkage O 0 9.796917765925173e-08
analysis O 0 8.002461804323957e-09
had O 0 8.301145157929568e-07
been O 0 6.123179741024387e-09
predicted O 0 1.4327668829139384e-08
to O 0 1.5081180748666156e-10
carry O 0 5.500845556838385e-09
the O 0 4.606221182257286e-09
predisposing O 0 9.821546882449184e-07
mutation O 0 4.907528250441828e-07
. O 0 1.414498598251157e-07

These O 0 2.995109582570876e-08
observations O 0 3.7281353115758975e-08
point O 0 1.8520172062608253e-08
to O 0 4.5919465452293196e-10
another O 0 5.926663604327587e-10
region O 0 6.919318451537038e-10
of O 0 1.2299725127284944e-10
the O 0 1.51950085847119e-09
RB1 O 0 3.836719599803473e-07
gene O 0 1.1865622262519082e-08
where O 0 6.463478641194342e-10
mutations O 0 9.194593530992279e-09
only O 0 5.577204253981449e-10
modify O 0 8.969258225022259e-09
the O 0 4.194737890372835e-10
function O 0 2.2532482824022537e-10
of O 0 4.4121567510657655e-11
the O 0 1.946493521920445e-10
gene O 0 8.746808610737844e-09
and O 0 5.266633795741882e-09
raise O 0 3.949028215544104e-09
important O 0 2.982543545471117e-09
questions O 0 2.2451496217712474e-09
for O 0 1.7607254543250406e-10
genetic O 0 1.2667465298932257e-08
counseling O 0 3.374809054434991e-08
in O 0 2.655868192036337e-09
families O 0 5.159527249887219e-10
with O 0 1.263545518215281e-10
these O 0 8.996204337030633e-10
distinctive O 0 1.2208809607727744e-07
phenotypes O 0 1.8262808509916795e-07
. O 0 1.2709527652532415e-08
. O 0 5.0953968155909024e-08

Maternal B-Disease 0 0.005686168093234301
disomy I-Disease 0 0.18880455195903778
and O 0 0.22621846199035645
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
consistent O 0 2.7137436973134754e-06
with O 0 3.356448008418056e-09
gamete O 0 6.850461318208545e-07
complementation O 0 7.222099520731717e-05
in O 0 1.2394242965285684e-08
a O 0 1.1783236608664538e-08
case O 0 2.0831729230508245e-08
of O 0 8.359403169677648e-10
familial O 0 1.2923675285492209e-06
translocation O 0 1.877703425634536e-06
( O 0 1.926057713319551e-08
3 O 0 8.827525377341772e-09
; O 0 2.2472146365970502e-09
15 O 0 7.50960627016184e-09
) O 0 6.094734161798954e-10
( O 0 1.2320511277863488e-09
p25 O 0 1.8136141477498313e-07
; O 0 1.5160153132853793e-09
q11 O 0 8.303743470605696e-08
. O 0 8.775847826214545e-10
2 O 0 3.572634188486745e-09
) O 0 3.739634824029281e-09
. O 0 2.439390378583539e-08

Maternal B-Disease 0 0.09913293272256851
uniparental I-Disease 1 0.9567098617553711
disomy I-Disease 0 0.3993026614189148
( I-Disease 0 2.8172322345199063e-05
UPD I-Disease 1 0.9999932050704956
) I-Disease 0 8.829882602867656e-09
for I-Disease 0 7.683920166812186e-10
chromosome I-Disease 0 6.973206723159819e-07
15 I-Disease 0 1.0702393637984642e-08
is O 0 1.0299763819610064e-10
responsible O 0 1.3539559751141184e-10
for O 0 6.956658860080012e-11
an O 0 7.80953704482279e-11
estimated O 0 4.690908772531088e-10
30 O 0 6.798726581713765e-10
% O 0 4.564655597949496e-11
of O 0 3.069695539426043e-11
cases O 0 8.625141489915222e-09
of O 0 1.7508335076854564e-05
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 1.309639719693223e-05
PWS B-Disease 1 0.9999994039535522
) O 0 2.613198830658803e-07
. O 0 1.456018736689657e-07

We O 0 3.985104228831915e-07
report O 0 2.7871788432776157e-08
on O 0 2.102263252368175e-09
an O 0 1.5652512619368508e-10
unusual O 0 1.1544835087917704e-09
case O 0 3.1702296343638636e-09
of O 0 1.2881350153204352e-10
maternal B-Disease 0 7.547590996637155e-08
disomy I-Disease 0 3.187632046319777e-06
15 I-Disease 0 1.5956132415340107e-08
in O 0 1.2683088357334782e-07
PWS B-Disease 1 1.0
that O 0 7.287728642779712e-09
is O 0 1.7566867405172104e-10
most O 0 3.760081412895744e-10
consistent O 0 4.433410971671492e-09
with O 0 4.666535213804224e-11
adjacent O 0 3.2876006361703958e-09
- O 0 4.04343126092499e-07
1 O 0 3.6642553435939362e-09
segregation O 0 1.3670436338486525e-08
of O 0 4.059129768418934e-11
a O 0 2.3674551208330286e-09
paternal O 0 9.362806281387748e-07
t O 0 7.189607003965648e-06
( O 0 2.6484117121583495e-09
3 O 0 3.313613161637363e-09
; O 0 3.6012570703292113e-10
15 O 0 3.1625715379846042e-09
) O 0 4.189900093543031e-10
( O 0 9.859990601768231e-10
p25 O 0 1.0209104317482343e-07
; O 0 9.783539534069519e-10
q11 O 0 4.6285226318332207e-08
. O 0 4.223486838039747e-10
2 O 0 7.730166506902947e-10
) O 0 4.368162428991518e-11
with O 0 5.927079660406065e-11
simultaneous O 0 5.524537982637412e-08
maternal O 0 1.8205543028670945e-06
meiotic O 0 8.659175364300609e-06
nondisjunction O 0 3.56979330717877e-06
for O 0 9.399128586551342e-09
chromosome O 0 2.21928758037393e-06
15 O 0 2.069218538736095e-07
. O 0 7.065977314368865e-08

The O 0 1.8403447654691263e-07
patient O 0 1.5424817547682323e-06
( O 0 8.54011616979733e-09
J O 0 9.648997547628824e-06
. O 0 6.16785900131589e-10
B O 0 8.852264699044099e-08
. O 0 1.2423792550286805e-10
) O 0 3.4406050924973286e-11
, O 0 2.7663970073033006e-11
a O 0 1.007342653736032e-09
17 O 0 2.2326692317164998e-07
- O 0 7.380826332337165e-07
year O 0 7.968588988660485e-07
- O 0 1.3234051039034966e-05
old O 0 0.0005298882024362683
white O 0 4.3007013061924226e-08
male O 0 1.3582303282078101e-08
with O 0 2.596651782482695e-09
PWS B-Disease 1 1.0
, O 0 8.246870741857038e-09
was O 0 3.0713341203636446e-08
found O 0 5.592042384705564e-10
to O 0 1.0939810862753419e-10
have O 0 4.672923714643673e-10
47 O 0 7.155183112672603e-10
chromosomes O 0 7.321343531430102e-10
with O 0 8.31798241396342e-11
a O 0 1.1707426139651034e-08
supernumerary O 0 3.514621130307205e-05
, O 0 2.4478623572576907e-09
paternal O 0 4.7596390118087584e-07
der O 0 0.28616851568222046
( O 0 1.8014806313360054e-09
15 O 0 8.046875943357179e-10
) O 0 2.1006698117109757e-11
consisting O 0 1.641369852534158e-11
of O 0 3.504485590610784e-11
the O 0 4.231019534728375e-09
short O 0 1.7816299077821895e-05
arm O 1 0.9033474326133728
and O 0 8.566512832430817e-09
the O 0 1.3067822379753125e-09
proximal O 0 3.0933979360270314e-06
long O 0 2.872454842872685e-06
arm O 0 0.0025232862681150436
of O 0 1.633956081548149e-09
chromosome O 0 2.8196782295708545e-06
15 O 0 1.6519416590199398e-07
, O 0 5.974415628884344e-09
and O 0 4.977390588578601e-08
distal O 0 0.000188717371202074
chromosome O 0 0.090042345225811
arm O 1 0.9912848472595215
3p O 0 0.004466662183403969
. O 0 1.3263111213746015e-06

The O 0 2.1902268088069832e-07
t O 0 5.825049811392091e-06
( O 0 8.415029562058862e-09
3 O 0 8.224403935663815e-10
; O 0 1.5123438612540951e-10
15 O 0 1.1131694455102092e-09
) O 0 5.424841131862479e-11
was O 0 4.413432286298757e-09
present O 0 4.6496632932768733e-11
in O 0 7.642089738801872e-10
the O 0 2.2663296239677777e-10
balanced O 0 6.489617732086117e-10
state O 0 1.3085051098205014e-10
in O 0 2.5559556693366403e-09
the O 0 5.8549165515842105e-09
patients O 0 3.73603654679755e-08
father O 0 1.2686881767365321e-08
and O 0 2.1267438921057646e-09
a O 0 2.2039442271193366e-08
sister O 0 6.076242698327405e-06
. O 0 1.2403755533796357e-07

Fluorescent O 0 1.9490240447339602e-05
in O 0 1.1643562913832284e-07
situ O 0 2.806089014484314e-07
hybridization O 0 4.6266247721860054e-08
analysis O 0 9.862930028248229e-09
demonstrated O 0 1.054808951295172e-08
that O 0 1.133739879755069e-09
the O 0 9.365271225192373e-09
PWS B-Disease 1 0.9999996423721313
critical O 0 3.399112102897561e-08
region O 0 7.19967863105353e-09
resided O 0 3.0526450700563146e-08
on O 0 3.0816365015340352e-09
the O 0 2.5513563484125257e-10
derivative O 0 2.1589510623698516e-08
chromosome O 0 3.530434256049375e-08
3 O 0 1.7385777262290958e-09
and O 0 7.020671821678093e-10
that O 0 3.467895970388213e-10
there O 0 3.0315578936068732e-09
was O 0 1.238297784311726e-07
no O 0 9.260589517445794e-10
deletion O 0 3.784423885377919e-09
of O 0 5.476772160784016e-11
the O 0 1.4440757922784542e-08
PWS B-Disease 1 0.9999998807907104
region O 0 4.738393499792437e-08
on O 0 1.2949506356108031e-07
the O 0 2.2421371426162295e-09
normal O 0 4.3209610112171504e-08
pair O 0 3.6842020989524826e-08
of O 0 4.1019224128469034e-10
15s O 0 4.3121762161035804e-08
present O 0 1.1812528732946248e-09
in O 0 4.2177433101642237e-08
J O 0 0.01294268760830164
. O 0 1.1942279343202244e-07

B O 0 0.003719667438417673
. O 0 5.9299877648300026e-06

Methylation O 0 8.269907084468286e-06
analysis O 0 1.3735677839576965e-07
at O 0 2.0363838615367058e-08
exon O 0 4.465390190944163e-08
alpha O 0 7.394350909351033e-09
of O 0 1.0398619465501469e-10
the O 0 2.995489134516305e-10
small O 0 2.2838575475248035e-09
nuclear O 0 2.3344643977907253e-06
ribonucleoprotein O 0 1.6573951143072918e-05
- O 0 8.253655323642306e-07
associated O 0 4.3232855517771895e-08
polypeptide O 0 5.947988483967492e-07
N O 0 2.6867152769227687e-07
( O 0 1.7762967763346182e-09
SNRPN O 0 2.3899968937257654e-07
) O 0 2.849742108956832e-10
gene O 0 1.3589558811588631e-08
showed O 0 2.277225803481997e-07
a O 0 4.1039589504521246e-09
pattern O 0 2.8392719286784995e-07
characteristic O 0 1.483818312664198e-08
of O 0 1.764776935697654e-10
only O 0 2.062266579727634e-09
the O 0 3.1084967933026064e-09
maternal O 0 1.6816117920370743e-07
chromosome O 0 1.414168423252704e-06
15 O 0 9.435379411115719e-08
in O 0 1.0082008117251462e-07
J O 0 0.19006851315498352
. O 0 3.594632005388121e-07

B O 0 0.0033000889234244823
. O 0 6.713735274388455e-06

Maternal B-Disease 0 0.0013488437980413437
disomy I-Disease 0 0.0012293743202462792
was O 0 3.1059641969477525e-06
confirmed O 0 2.7522229828491618e-08
by O 0 5.338030573120989e-10
polymerase O 0 5.730165852924074e-08
chain O 0 4.1181223764397146e-08
reaction O 0 6.038386679563246e-09
analysis O 0 2.341060900690195e-09
of O 0 3.438854756510068e-10
microsatellite O 0 1.347939786455754e-07
repeats O 0 1.1370879349215102e-07
at O 0 1.284676720558764e-08
the O 0 2.0563275526797042e-09
gamma O 0 2.699279093576479e-07
- O 0 1.652308696975524e-06
aminobutyric O 0 1.2329425089774304e-06
acid O 0 6.391887552581466e-08
receptor O 0 3.148285188103728e-08
beta3 O 0 3.167173474594165e-07
subunit O 0 1.935862599111715e-07
( O 0 1.2901230306283651e-08
GABRB3 O 0 1.1136264674860286e-06
) O 0 5.1942268264326685e-09
locus O 0 1.8000464763190394e-07
. O 0 7.513778399470539e-08

A O 0 3.5163870961696375e-06
niece O 0 8.122540748445317e-06
( O 0 1.2247813430121823e-08
B O 0 9.764774233644857e-08
. O 0 1.7878423741457539e-10
B O 0 2.969404633290651e-08
. O 0 4.363365918580442e-11
) O 0 2.5004330203581837e-11
with O 0 2.7039840852505215e-11
45 O 0 4.4118814157556585e-10
chromosomes O 0 1.9849499821589234e-09
and O 0 6.450375233946204e-10
the O 0 5.225626042992815e-10
derivative O 0 5.472561426245193e-08
3 O 0 3.0034370546161426e-09
but O 0 2.276368649134497e-09
without O 0 5.004735514901881e-10
the O 0 8.765191905624192e-10
der O 0 0.0009723780676722527
( O 0 6.968627341841227e-10
15 O 0 4.902864225719838e-10
) O 0 6.780204869771822e-11
demonstrated O 0 1.0512735126866346e-09
a O 0 7.308483152002054e-09
phenotype O 0 2.0872997197329823e-07
consistent O 0 2.864715220596281e-08
with O 0 2.442111235456679e-10
that O 0 6.915175654320649e-10
reported O 0 6.140268737908627e-08
for O 0 4.34109637126312e-10
haploinsufficiency O 0 2.0875029349554097e-07
of O 0 1.186491571658621e-09
distal O 0 5.026350663683843e-06
3 O 0 4.5960172201375826e-07
p O 0 5.156283077667467e-05
. O 0 1.008160452897755e-07

Uniparental B-Disease 1 0.9999983310699463
disomy I-Disease 1 0.9999862909317017
associated O 0 3.7416923532873625e-06
with O 0 4.996147495717196e-08
unbalanced O 0 0.00015382382844109088
segregation O 0 4.0091691744237323e-07
of O 0 1.0432734676157907e-09
non O 0 5.045350235377555e-07
- O 0 1.5712937965872698e-05
Robertsonian O 0 3.7472668736882042e-06
translocations O 0 5.16133241035277e-06
has O 0 1.4271456905134983e-08
been O 0 3.894172095897375e-09
reported O 0 1.2818667904923586e-08
previously O 0 1.0103964331875659e-09
but O 0 1.3309254809357185e-09
has O 0 8.432228526533692e-11
not O 0 6.974062299880401e-11
, O 0 5.885877722711097e-12
to O 0 1.4270943801686364e-11
our O 0 7.996030920720543e-11
knowledge O 0 1.4143483606510188e-10
, O 0 4.887605251080451e-11
been O 0 6.652479678237455e-10
observed O 0 2.352222583379415e-10
in O 0 5.147388071335968e-10
a O 0 3.4336264942425032e-09
case O 0 1.9368737724789753e-08
of O 0 1.1075999672982562e-08
PWS B-Disease 1 0.9999995231628418
. O 0 2.104969070160223e-07

Furthermore O 0 1.6255659147645929e-06
, O 0 9.488958951919813e-09
our O 0 1.636313973207848e-09
findings O 0 9.384488741659425e-10
are O 0 9.467798073314881e-11
best O 0 4.0450581773043837e-10
interpreted O 0 1.905023250259319e-09
as O 0 5.074345943434366e-10
true O 0 1.6094864330185032e-09
gamete O 0 1.434676164535631e-07
complementation O 0 1.7344949583275593e-06
resulting O 0 4.9058158424486464e-08
in O 0 1.358684329488824e-07
maternal B-Disease 0 0.0004155983042437583
UPD I-Disease 1 0.9999998807907104
15 I-Disease 0 2.2889842512086034e-05
and O 0 1.2602689821505919e-05
PWS B-Disease 1 0.9999995231628418

Schwartz B-Disease 1 0.9997991919517517
- I-Disease 1 0.9999995231628418
Jampel I-Disease 1 0.9999822378158569
syndrome I-Disease 1 0.9999986886978149
type I-Disease 0 1.1968281796725933e-05
2 I-Disease 0 5.522167612070916e-08
and O 0 9.65867243962748e-08
Stuve B-Disease 1 0.9995416402816772
- I-Disease 1 1.0
Wiedemann I-Disease 1 1.0
syndrome I-Disease 1 0.9999997615814209
: O 0 1.4283786375912655e-09
a O 0 1.1497895968659577e-09
case O 0 8.835559839326379e-09
for O 0 5.521866852653545e-10
" O 0 1.5636205219493604e-08
lumping O 0 6.879542979731923e-08
" O 0 4.692345356716032e-08
. O 0 1.921757153411363e-08

Recent O 0 2.258694280499185e-07
studies O 0 2.5293131145076586e-08
demonstrated O 0 3.0244311499671994e-09
the O 0 1.3788813146842216e-10
existence O 0 6.304293753700563e-10
of O 0 5.276753686778157e-11
a O 0 6.31247609739205e-10
genetically O 0 9.430050518233202e-09
distinct O 0 3.0959348418235777e-09
, O 0 6.520860518222094e-10
usually O 0 3.012868288188031e-10
lethal O 0 2.573703916652903e-09
form O 0 1.019613504738004e-09
of O 0 1.7861587209289098e-10
the O 0 5.984259843216932e-08
Schwartz B-Disease 1 0.9986987113952637
- I-Disease 1 0.9999991655349731
Jampel I-Disease 1 0.9999985694885254
syndrome I-Disease 1 0.9999998807907104
( O 0 4.388412264688668e-07
SJS B-Disease 1 0.9028048515319824
) O 0 3.0623477087488027e-09
of O 0 2.563586676274099e-09
myotonia B-Disease 1 0.772031843662262
and O 0 0.00023368909023702145
skeletal B-Disease 1 0.999982476234436
dysplasia I-Disease 1 0.999998927116394
, O 0 6.058205936909644e-09
which O 0 2.4365480744137358e-09
we O 0 1.774963287459741e-08
called O 0 7.201274598855889e-08
SJS B-Disease 1 0.9258041977882385
type I-Disease 0 2.317384769412456e-06
2 I-Disease 0 1.1633274255018478e-07
. O 0 1.3975500223750714e-07

This O 0 3.911208295903634e-06
disorder O 0 0.0117021594196558
is O 0 9.626226038506047e-09
reminiscent O 0 1.0013896201144235e-07
of O 0 3.6719424723052896e-10
another O 0 4.877477532971852e-09
rare O 0 8.621625369187313e-08
condition O 0 5.4777274272055365e-06
, O 0 5.799540847561957e-10
the O 0 5.4378790359521645e-09
Stuve B-Disease 1 0.9996278285980225
- I-Disease 1 1.0
Wiedemann I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 2.0098383402000763e-07
SWS B-Disease 0 0.0002535278908908367
) O 0 4.822251487013318e-10
, O 0 8.362062431377382e-11
which O 0 5.681412285074572e-11
comprises O 0 2.0497518959938787e-10
campomelia B-Disease 0 6.786476092202065e-07
at O 0 1.4188788100000238e-07
birth O 0 1.3327149872566224e-07
with O 0 3.219417976652039e-08
skeletal B-Disease 1 0.9993405938148499
dysplasia I-Disease 1 0.9999991655349731
, O 0 4.5323375275074795e-08
contractures B-Disease 0 7.185526192188263e-05
, O 0 1.87649131788703e-08
and O 0 2.0055662020013187e-08
early B-Disease 0 1.0645189831848256e-05
death I-Disease 0 4.285405452719715e-07
. O 0 3.0196829925444035e-08

To O 0 1.2200975163523253e-07
test O 0 7.154861947356039e-08
for O 0 1.9022809716329192e-10
possible O 0 3.0100666403853893e-09
nosologic O 0 6.162309205137717e-07
identity O 0 2.0491206953465735e-08
between O 0 1.2933061732667284e-08
these O 0 5.786828793929999e-08
disorders O 0 0.0001691055513219908
, O 0 3.357170097473272e-10
we O 0 5.940924419078897e-10
reviewed O 0 4.110921880684515e-10
the O 0 2.787748504262666e-11
literature O 0 1.4258789982068976e-10
and O 0 5.2552795448690404e-11
obtained O 0 8.79476144688418e-11
a O 0 2.329207937634692e-10
follow O 0 3.535587600467238e-09
- O 0 6.439513811073994e-08
up O 0 1.9441941390141437e-09
of O 0 8.557289425670245e-12
the O 0 4.2070832928509105e-11
only O 0 2.353487960071732e-10
two O 0 8.663653128238025e-10
surviving O 0 2.014080280332564e-08
patients O 0 8.934307516028639e-09
, O 0 5.679700459948478e-11
one O 0 1.7956855447032183e-10
with O 0 9.907232811912081e-10
SJS B-Disease 1 0.9629969596862793
type I-Disease 0 1.8562525383458706e-06
2 I-Disease 0 1.9825710850795986e-08
at O 0 3.7629629900948203e-07
age O 0 2.871066229204189e-08
10 O 0 2.0031376557483327e-09
years O 0 3.602741160957379e-10
and O 0 2.9699398496063623e-10
another O 0 8.253727701301727e-10
with O 0 3.00523628204985e-09
SWS B-Disease 0 0.03989904373884201
at O 0 5.439182473310211e-07
age O 0 4.6909669038086577e-08
7 O 0 1.2620053446710244e-08
years O 0 1.1934009336300733e-08
. O 0 1.526761472803173e-08

Patients O 0 0.0012802649289369583
reported O 0 3.1709498671261827e-06
as O 0 1.2613266875405316e-08
having O 0 2.963469292183163e-08
either O 0 1.1326422963975347e-06
neonatal O 1 0.9999998807907104
SJS B-Disease 1 0.9999996423721313
or O 0 4.212487965560285e-06
SWS B-Disease 0 0.007256117183715105
presented O 0 1.3980454127704434e-08
a O 0 2.4252346797482005e-09
combination O 0 3.209705923268302e-08
of O 0 8.549858043771508e-10
a O 0 3.4050234631877174e-08
severe O 0 0.0004701815196312964
, O 0 7.76128743495974e-08
prenatal O 1 0.99910968542099
- O 1 0.9999948740005493
onset O 1 0.9999797344207764
neuromuscular B-Disease 1 0.9999997615814209
disorder I-Disease 1 0.9999845027923584
( O 0 1.8061180639961094e-07
with O 0 9.349796528113075e-07
congenital B-Disease 1 1.0
joint I-Disease 0 0.35706034302711487
contractures I-Disease 1 0.9999953508377075
, O 0 0.0005841252277605236
respiratory O 1 0.9999721050262451
and O 0 7.287675316547393e-07
feeding O 0 2.884952152726328e-07
difficulties O 0 9.440857411391335e-07
, O 0 1.1969405466771832e-09
tendency O 0 3.93855934532894e-08
to O 0 2.0509309806016063e-08
hyperthermia B-Disease 0 0.000236518622841686
, O 0 2.557535516700682e-09
and O 0 1.6459047458283749e-09
frequent O 0 1.9631769987427106e-08
death O 0 2.2090287643550255e-07
in O 0 3.4038620810861175e-07
infancy O 0 5.9564567891357e-06
) O 0 1.1536772925868632e-10
with O 0 6.040304367793681e-11
a O 0 9.812940682252247e-09
distinct O 0 1.31497685629256e-07
campomelic B-Disease 1 0.9277868270874023
- I-Disease 1 0.9907282590866089
metaphyseal I-Disease 1 0.9427912831306458
skeletal I-Disease 1 0.9996254444122314
dysplasia I-Disease 1 0.9999756813049316
. O 0 9.26612528928672e-07

The O 0 4.008411380596044e-08
similarity O 0 4.073732995379942e-08
of O 0 2.0317068860631338e-10
the O 0 1.183038556007432e-09
clinical O 0 2.143547916944044e-08
and O 0 1.818692041410941e-08
radiographic O 0 1.4532608474837616e-05
findings O 0 3.8465307738988486e-07
is O 0 3.4083229571990614e-09
so O 0 8.973343734730577e-10
extensive O 0 4.5232131928862884e-10
that O 0 1.0122888083330395e-09
these O 0 3.4497884549011815e-09
disorders O 0 1.3803557976643788e-06
appear O 0 1.2912432012512909e-08
to O 0 3.521802016681619e-10
be O 0 7.144436708905744e-10
a O 0 1.4979274487458838e-09
single O 0 1.724348130949238e-08
entity O 0 2.274371837529543e-07
. O 0 2.3570804330574902e-07

The O 0 4.6600046488265434e-08
follow O 0 7.081926156615737e-08
- O 0 1.3332835351320682e-06
up O 0 5.903201483192788e-09
observation O 0 9.001976053468752e-09
of O 0 3.6932162189584616e-11
an O 0 1.0092172236797481e-10
identical O 0 8.62221405384389e-09
and O 0 3.6369813827263897e-09
unique O 0 2.2893835716075728e-09
pattern O 0 5.614889232674614e-06
of O 0 7.181002104061918e-08
progressive O 0 0.07003285735845566
bone B-Disease 1 0.9999998807907104
dysplasia I-Disease 1 0.9999995231628418
in O 0 1.4026561245827907e-07
the O 0 2.577998037267548e-09
two O 0 6.184059486713522e-09
patients O 0 4.797019315105899e-08
( O 0 4.4512871166801915e-10
one O 0 1.5691259402927926e-09
with O 0 4.646210527425865e-09
SJS B-Disease 1 0.999588668346405
type I-Disease 0 4.544076546153519e-06
2 I-Disease 0 2.256708420134146e-08
, O 0 1.1160351531813717e-09
one O 0 2.0915924547892928e-09
with O 0 3.259945424716193e-09
SWS B-Disease 0 0.0006774936919100583
) O 0 9.4697161223678e-10
surviving O 0 5.528530522269648e-09
beyond O 0 4.2819412016115166e-08
infancy O 0 1.1447307315393118e-06
adds O 0 5.555337079243827e-09
to O 0 4.930723537799331e-11
the O 0 1.097915092174162e-10
evidence O 0 5.079304199462342e-10
in O 0 6.844851907494842e-10
favor O 0 1.613454481130816e-09
of O 0 3.079848598375179e-10
identity O 0 5.991557827655924e-08
. O 0 1.9379935878305332e-08

The O 0 3.0813330909040815e-07
hypothesis O 0 1.1024445711882436e-06
that O 0 4.7921819401608445e-08
SWS B-Disease 0 0.05930445343255997
and O 0 2.8423576736713585e-07
SJS B-Disease 1 0.9905994534492493
type I-Disease 0 2.7280775611870922e-06
2 I-Disease 0 3.556486882771992e-09
are O 0 4.503817596646087e-10
the O 0 9.969730596637305e-10
same O 0 1.9071461565545178e-07
disorder O 0 5.829284873470897e-06
should O 0 3.2843916475400192e-09
be O 0 3.16237702691069e-10
testable O 0 6.5524070613776075e-09
by O 0 5.049051177152819e-10
molecular O 0 6.835397137194832e-09
methods O 0 4.39638760951766e-08
. O 0 8.159860342971115e-09
. O 0 2.2585988190826356e-08

A O 0 6.618062798224855e-06
mouse O 0 3.428365380386822e-05
model O 0 1.3610423366117175e-06
of O 0 5.809732783745858e-08
severe O 1 0.9999802112579346
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
: O 0 0.04661095142364502
defects O 1 0.9994226694107056
in O 0 6.475219151980127e-07
hemostasis O 0 0.01818888448178768
and O 0 9.610938832338434e-06
thrombosis B-Disease 0 0.07175454497337341
. O 0 4.732237925964e-07

von B-Disease 1 0.9535489082336426
Willebrand I-Disease 1 0.9578599333763123
factor I-Disease 0 0.00014271587133407593
( I-Disease 0 1.0274040505464654e-05
vWf I-Disease 0 0.004635133780539036
) I-Disease 0 0.00016070602578110993
deficiency I-Disease 1 0.9999710321426392
causes O 0 0.0009916593553498387
severe O 1 1.0
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
in O 0 4.478374830796383e-05
humans O 0 4.074311618751381e-06
. O 0 7.547791938122828e-07

We O 0 3.884367174578074e-07
generated O 0 1.9902699932572432e-08
a O 0 8.606472867711545e-09
mouse O 0 3.666306156446808e-07
model O 0 2.5849416829260008e-08
for O 0 8.406843554631394e-10
this O 0 2.456042258458524e-09
disease O 0 1.9315541166520234e-08
by O 0 1.1828665824609175e-10
using O 0 3.2735472110800856e-09
gene O 0 1.337363357833965e-07
targeting O 0 4.993308948542108e-07
. O 0 1.8137491508696257e-07

vWf B-Disease 0 0.29219168424606323
- I-Disease 1 0.9999393224716187
deficient I-Disease 1 0.9814351797103882
mice O 0 0.00018113342230208218
appeared O 0 1.8151954463974107e-06
normal O 0 9.432751824078878e-08
at O 0 2.1081588030824605e-08
birth O 0 2.8507765037488753e-09
; O 0 5.613273040827593e-11
they O 0 3.7798486562934386e-10
were O 0 6.290292287047805e-09
viable O 0 4.866348035648116e-08
and O 0 6.4852656578295864e-09
fertile O 0 3.256951330854463e-08
. O 0 4.5499550793692833e-08

Neither O 0 3.0614715797128156e-05
vWf O 0 0.0004455002781469375
nor O 0 3.1804949685465544e-05
vWf O 0 0.0001982303219847381
propolypeptide O 0 0.0002948843175545335
( O 0 5.11240443756833e-07
von B-Disease 0 0.000901591032743454
Willebrand I-Disease 0 0.0007833216222934425
antigen O 0 3.280341616118676e-06
II O 0 5.019576747145038e-06
) O 0 3.5936087439125686e-09
were O 0 3.6595269037320577e-09
detectable O 0 3.048764085633593e-08
in O 0 1.4400373116174592e-09
plasma O 0 1.5519991336532257e-07
, O 0 4.002702613803422e-09
platelets O 0 6.106771621716689e-08
, O 0 5.751423781674703e-10
or O 0 2.7274356106943287e-09
endothelial O 0 1.1368000762956854e-08
cells O 0 4.723691215957615e-09
of O 0 2.6606225556058405e-10
the O 0 2.65987276648616e-09
homozygous O 0 7.924271585579845e-07
mutant O 0 2.8351880700938636e-06
mice O 0 2.9566790544777177e-05
. O 0 1.8694152004172793e-07

The O 0 2.6127554519916885e-07
mutant O 0 1.988931580854114e-05
mice O 0 0.004870083648711443
exhibited O 0 0.002930236281827092
defects O 1 0.6925345063209534
in O 0 9.317683691278944e-08
hemostasis O 0 1.1880264537467156e-05
with O 0 2.59819254999627e-09
a O 0 4.716716262009868e-08
highly O 0 3.481895873846952e-06
prolonged O 0 0.06367211043834686
bleeding O 1 0.9998656511306763
time O 0 7.592639406084345e-08
and O 0 1.116998227246313e-08
spontaneous O 0 7.298081072804052e-08
bleeding O 0 9.001528087537736e-05
events O 0 1.4422197880392673e-09
in O 0 9.736905726143164e-10
approximately O 0 5.870993691203807e-10
10 O 0 1.134722094064955e-09
% O 0 2.9730512496328743e-10
of O 0 1.3163157230877687e-09
neonates O 0 7.880966563789116e-07
. O 0 4.4952315647606156e-08

As O 0 9.606603157408244e-08
in O 0 4.151915700134623e-09
the O 0 7.155783188217413e-10
human O 0 1.8452465111451488e-09
disease O 0 8.766421188965978e-08
, O 0 1.168408148011224e-10
the O 0 9.199514067192993e-11
factor O 0 3.1194846705773216e-09
VIII O 0 2.6047641767945606e-06
level O 0 1.602176169512859e-08
in O 0 1.363215318406219e-09
these O 0 6.923291939742171e-10
mice O 0 1.5326530444781383e-07
was O 0 7.017478509396824e-08
reduced O 0 1.6078663955809702e-09
strongly O 0 1.0751635137751236e-09
as O 0 8.647126903404967e-10
a O 0 2.8170679677863575e-10
result O 0 4.4725462222672263e-10
of O 0 3.2932330473745e-11
the O 0 4.970308054019767e-10
lack O 0 1.8873196339086462e-09
of O 0 4.809370610092678e-11
protection O 0 4.957281252160328e-10
provided O 0 9.60837298613626e-10
by O 0 4.614099768929236e-09
vWf O 0 2.8610868412215495e-06
. O 0 1.3298938483785605e-07

Defective O 1 0.9973893761634827
thrombosis B-Disease 1 0.9690690040588379
in O 0 3.194096791503398e-07
mutant O 0 3.0381552278413437e-06
mice O 0 3.633733285823837e-05
was O 0 4.268910061000497e-07
also O 0 2.302894319683446e-09
evident O 0 3.2954734496826177e-09
in O 0 8.604761347896783e-10
an O 0 1.1662705523551864e-10
in O 0 9.655422017473825e-10
vivo O 0 8.328646572408616e-08
model O 0 4.040882473077545e-08
of O 0 1.5004589570821736e-08
vascular B-Disease 1 0.9135265946388245
injury I-Disease 1 0.847627580165863
. O 0 2.3535113768957672e-07

In O 0 4.2737251959579226e-08
this O 0 4.507487161298229e-10
model O 0 6.0864429052287505e-09
, O 0 4.0563150061068143e-10
the O 0 7.655978628839932e-10
exteriorized O 0 1.6593356804150972e-06
mesentery O 0 4.267943495506188e-06
was O 0 9.86546979220293e-07
superfused O 0 5.837367780259228e-07
with O 0 1.5881432835485043e-09
ferric O 0 6.255776270336355e-07
chloride O 0 6.536818375479925e-08
and O 0 6.873624780467935e-09
the O 0 7.164496218514671e-10
accumulation O 0 7.979447325112687e-09
of O 0 2.788765884886857e-10
fluorescently O 0 2.617017003103683e-07
labeled O 0 4.632704815321631e-07
platelets O 0 1.6148273971339222e-06
was O 0 2.55331684684279e-07
observed O 0 5.724602569756598e-09
by O 0 1.971675711587295e-09
intravital O 0 1.5369694210676244e-06
microscopy O 0 9.491050150245428e-07
. O 0 1.0039695297336948e-07

We O 0 9.825208735492197e-07
conclude O 0 8.07149092452164e-07
that O 0 1.5013427168142357e-09
these O 0 8.943305540576318e-10
mice O 0 2.125468228086902e-07
very O 0 1.0801402439142294e-08
closely O 0 3.386060498655752e-08
mimic O 0 3.7047541354695568e-06
severe O 0 0.00030191175756044686
human O 0 2.4476382805005414e-06
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
and O 0 0.0003738235973287374
will O 0 1.2605167398760386e-07
be O 0 2.8127848938908073e-09
very O 0 9.567865388859786e-10
useful O 0 2.0930679411890196e-10
for O 0 2.6710751666048083e-11
investigating O 0 2.2100794805357538e-10
the O 0 3.879518581384467e-11
role O 0 3.225954781083118e-10
of O 0 4.6665258462974535e-11
vWf O 0 1.3828201694821018e-08
in O 0 4.142123533057429e-09
normal O 0 2.549170687871083e-07
physiology O 0 7.799737744562663e-08
and O 0 1.224865453508528e-08
in O 0 7.631361853555063e-08
disease O 0 7.244325388455763e-07
models O 0 1.25351348856384e-07
. O 0 6.35845820440295e-09
. O 0 1.6624126075726053e-08

Oral O 0 3.272866160841659e-05
contraceptives O 0 0.00031925225630402565
and O 0 6.904348737180044e-08
the O 0 7.925116563001211e-09
risk O 0 5.979827619739808e-07
of O 0 3.653127294001024e-07
hereditary B-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
. O 0 2.205674036304117e-06

Hereditary B-Disease 1 0.9999998807907104
Ovarian I-Disease 1 0.9999984502792358
Cancer I-Disease 0 0.2037850022315979
Clinical O 0 1.1363533303665463e-05
Study O 0 3.974291189479118e-07
Group O 0 4.6127294694997545e-07
. O 0 1.8067295570745046e-07

BACKGROUND O 0 0.00011964875739067793
Women O 0 3.6333887010187027e-07
with O 0 3.0794506944431532e-09
mutations O 0 6.177530309514623e-08
in O 0 1.9121839667235463e-09
either O 0 5.634066546633676e-09
the O 0 6.2816840618040715e-09
BRCA1 O 0 2.096067873935681e-06
or O 0 1.634655255600137e-08
the O 0 2.7284607906352676e-09
BRCA2 O 0 6.073944405216025e-07
gene O 0 3.884596466718904e-08
have O 0 4.074756532190804e-09
a O 0 3.106635615424125e-09
high O 0 1.455388485283038e-07
lifetime O 0 4.79486068627466e-08
risk O 0 5.501548457687022e-06
of O 0 7.93622893979773e-06
ovarian B-Disease 1 1.0
cancer I-Disease 1 0.9999992847442627
. O 0 8.888587217370514e-07

Oral O 0 5.092619176139124e-05
contraceptives O 0 0.0017415331676602364
protect O 0 8.453491318505257e-06
against O 1 0.9212384819984436
ovarian B-Disease 1 1.0
cancer I-Disease 1 0.9999969005584717
in O 0 9.503829723200852e-09
general O 0 8.528684425357369e-10
, O 0 3.6321337604228177e-10
but O 0 1.1492239382349112e-09
it O 0 1.1194777743694928e-10
is O 0 1.9842023857297164e-11
not O 0 2.6901167404780324e-10
known O 0 2.566721835073338e-10
whether O 0 2.899448181548081e-10
they O 0 6.015783426960297e-10
also O 0 2.1906983171948724e-10
protect O 0 2.347959882076367e-10
against O 0 9.936569789203986e-09
hereditary B-Disease 0 4.428116426424822e-06
forms I-Disease 0 3.205668690497987e-07
of I-Disease 0 0.00012417655671015382
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999990463256836
. O 0 4.460692082375317e-07

METHODS O 0 3.221223096261383e-06
We O 0 9.519562382820368e-08
enrolled O 0 8.016827024448503e-08
207 O 0 5.650340426655021e-07
women O 0 4.178571799684505e-08
with O 0 3.3199290783159086e-07
hereditary B-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 2.9775488741279332e-08
161 O 0 2.6347690251782296e-08
of O 0 9.128566652583103e-11
their O 0 9.852865190396187e-10
sisters O 0 1.3556860523067371e-08
as O 0 7.281347746967981e-10
controls O 0 5.825078375210069e-08
in O 0 4.953965682119588e-09
a O 0 2.5109558876579285e-08
case O 0 5.297637244439102e-07
- O 0 2.3623290417162934e-06
control O 0 1.1586973869270878e-06
study O 0 6.838399002617734e-08
. O 0 7.63934266956312e-08

All O 0 4.294095035106693e-08
the O 0 7.098854393206011e-09
patients O 0 5.105086131607095e-08
carried O 0 1.014359263251663e-08
a O 0 8.280838237340049e-09
pathogenic O 0 1.0006771162807127e-06
mutation O 0 5.542427317095644e-08
in O 0 8.135042861567854e-09
either O 0 3.518603008956234e-08
BRCA1 O 0 5.073459306004224e-06
( O 0 7.1300649828742735e-09
179 O 0 5.583724416169389e-08
women O 0 1.4159422079274009e-08
) O 0 9.734528738647441e-10
or O 0 3.7302616107126596e-08
BRCA2 O 0 0.00011832852032966912
( O 0 2.9166015380610588e-08
28 O 0 1.5329570146604965e-07
women O 0 2.3046530017722944e-08
) O 0 5.4239466251715385e-09
. O 0 3.494844946771991e-08

The O 0 3.0737837164451776e-08
control O 0 1.3792843844839808e-07
women O 0 1.639276270282153e-08
were O 0 5.340895281591429e-09
enrolled O 0 4.615998971946311e-10
regardless O 0 1.5542082898445386e-10
of O 0 5.698296001721559e-12
whether O 0 2.667604193096196e-10
or O 0 1.349879874545934e-09
not O 0 8.587615951682892e-09
they O 0 4.142076015511975e-09
had O 0 1.676419714158328e-08
either O 0 5.1465560702013136e-09
mutation O 0 3.646144719482436e-08
. O 0 1.9278072471706764e-08

Lifetime O 0 8.682668521942105e-06
histories O 0 3.1957406463334337e-06
of O 0 7.32768956623886e-09
oral O 0 5.704940804207581e-07
- O 0 2.461937583575491e-06
contraceptive O 0 1.446437522645283e-06
use O 0 1.0272112049847237e-08
were O 0 9.697137315356485e-09
obtained O 0 5.240957667851376e-10
by O 0 2.2758725459759432e-10
interview O 0 6.197097235371984e-08
or O 0 7.122802903047898e-10
by O 0 5.5983467861508984e-11
written O 0 4.0445874427419426e-10
questionnaire O 0 8.204365520292356e-10
and O 0 1.0165934066774795e-10
were O 0 1.1957334011825083e-09
compared O 0 1.5505671191462511e-09
between O 0 7.07942093836067e-10
patients O 0 7.548336178331283e-09
and O 0 4.826926081058502e-10
control O 0 1.2136794680372986e-08
women O 0 1.3280479826960345e-08
, O 0 1.601639793014087e-10
after O 0 1.1095679930406277e-09
adjustment O 0 3.4819620520210037e-09
for O 0 3.8696601478704906e-11
year O 0 4.080868143407912e-10
of O 0 5.2859105981184484e-11
birth O 0 1.9357216274329403e-08
and O 0 1.2178464459111638e-08
parity O 0 7.366389809249085e-07
. O 0 4.2836241220811644e-08

RESULTS O 0 1.1607376109168399e-05
The O 0 2.0028442904163057e-08
adjusted O 0 2.585403535704245e-06
odds O 0 6.059230145183392e-06
ratio O 0 4.9665963160805404e-05
for O 0 0.0003706585557665676
ovarian B-Disease 1 1.0
cancer I-Disease 1 0.9999996423721313
associated O 0 3.353979849407551e-08
with O 0 3.317393304502758e-10
any O 0 9.266491463044702e-10
past O 0 1.2895245982136316e-09
use O 0 1.1140403044507252e-09
of O 0 4.03841293739049e-10
oral O 0 3.4948850924365615e-08
contraceptives O 0 4.2078096157638356e-05
was O 0 2.8987915356992744e-07
0 O 0 2.8960025488800056e-08
. O 0 2.1555690565833174e-08

5 O 0 2.1516302695090417e-07
( O 0 7.53217133109274e-09
95 O 0 4.224208183245537e-08
percent O 0 6.338735261124384e-07
confidence O 0 9.586250371285132e-08
interval O 0 3.72642716683913e-09
, O 0 5.36155807251415e-11
0 O 0 1.216009376525662e-10
. O 0 2.3776302107703096e-11
3 O 0 1.1645123754178144e-10
to O 0 1.0700769437210766e-10
0 O 0 1.1172811564819085e-09
. O 0 4.597844882603397e-10
8 O 0 1.1183947101756075e-08
) O 0 3.808566351182208e-09
. O 0 1.4953391413996542e-08

The O 0 1.8448150740368874e-07
risk O 0 3.248622704177251e-07
decreased O 0 6.627573867490355e-08
with O 0 1.1111896819349099e-10
increasing O 0 3.538851434115031e-10
duration O 0 6.828643206446827e-10
of O 0 1.914769558186702e-11
use O 0 8.480507407426785e-10
( O 0 1.422335027534416e-09
P O 0 1.0544589486016775e-06
for O 0 2.7711516414896664e-10
trend O 0 1.012030992342261e-07
, O 0 9.365266340211065e-10
< O 0 8.133228313056406e-09
0 O 0 4.828307198501136e-10
. O 0 1.1812026357027605e-10
001 O 0 5.61699531331783e-09
) O 0 1.3664471464058803e-11
; O 0 4.022227429595349e-12
use O 0 1.089566353806859e-10
for O 0 1.5160751820619822e-10
six O 0 3.8050643191844813e-10
or O 0 4.5451972741084035e-10
more O 0 2.0726245719693281e-10
years O 0 1.0613896428424141e-09
was O 0 6.823321907489799e-09
associated O 0 6.520434192580638e-11
with O 0 1.170948581152853e-11
a O 0 8.101052051401325e-10
60 O 0 7.721210337763296e-09
percent O 0 1.248387206942425e-07
reduction O 0 6.218621173559313e-09
in O 0 1.5566783417853003e-08
risk O 0 1.1020960499763532e-07
. O 0 2.6789059859311237e-08

Oral O 0 8.196205453714356e-05
- O 0 6.751134060323238e-05
contraceptive O 0 2.4409913748968393e-05
use O 0 1.088925927206219e-07
protected O 0 2.2356316549121402e-06
against O 1 0.7634648084640503
ovarian B-Disease 1 1.0
cancer I-Disease 1 0.9995457530021667
both O 0 9.738392314773137e-10
for O 0 8.21830034580806e-11
carriers O 0 2.9479083618610957e-09
of O 0 3.208648624575261e-11
the O 0 2.4046318269910216e-09
BRCA1 O 0 1.1032018846890423e-05
mutation O 0 4.710863521495412e-08
( O 0 2.2132360388837924e-09
odds O 0 1.0543065087631476e-07
ratio O 0 7.577348526410788e-08
, O 0 2.1437786268396763e-10
0 O 0 3.160579853389578e-10
. O 0 7.603382506937706e-11
5 O 0 2.3419441386174356e-10
; O 0 7.271836605093895e-11
95 O 0 3.4700832429734874e-08
percent O 0 3.452569217188284e-05
confidence O 0 1.7176180335809477e-06
interval O 0 3.1299025593511942e-09
, O 0 3.8231914162301095e-11
0 O 0 5.055206253601341e-11
. O 0 1.680095125522474e-11
3 O 0 3.5581256691008534e-11
to O 0 3.661010383737562e-11
0 O 0 5.154176530020038e-10
. O 0 1.44731157614153e-10
9 O 0 1.9082562197070274e-09
) O 0 2.9666546996764964e-11
and O 0 7.018526038127249e-11
for O 0 3.746213408928334e-11
carriers O 0 4.259668173745013e-09
of O 0 6.610167274656575e-11
the O 0 4.255672703123992e-09
BRCA2 O 0 1.2923569556733128e-05
mutation O 0 8.456545685930905e-08
( O 0 3.0131284134427005e-09
odds O 0 2.80726681012311e-07
ratio O 0 6.045429756795784e-08
, O 0 2.8906244065041165e-10
0 O 0 4.0466399675587184e-10
. O 0 7.556712200429416e-11
4 O 0 2.246073882439248e-10
; O 0 1.1079410999759176e-10
95 O 0 3.133786918851911e-08
percent O 0 2.5880510293063708e-05
confidence O 0 1.8534875607656431e-06
interval O 0 3.1332714200971168e-09
, O 0 8.49894668530915e-11
0 O 0 1.1795950327631033e-10
. O 0 1.9227404390864677e-11
2 O 0 8.186182287595045e-11
to O 0 2.8785093753036506e-10
1 O 0 1.636432545026878e-09
. O 0 8.800387640839347e-10
1 O 0 4.3042116537606034e-09
) O 0 1.6421511928044197e-09
. O 0 1.1434522662057134e-08

CONCLUSIONS O 0 2.996052717207931e-05
Oral O 0 9.225484063790645e-06
- O 0 3.424542956054211e-05
contraceptive O 0 1.5728501239209436e-05
use O 0 8.74084236102135e-08
may O 0 2.2329588489355956e-07
reduce O 0 6.76745948169355e-09
the O 0 3.0088038727171806e-09
risk O 0 1.2955796364622074e-06
of O 0 7.4375980148033705e-06
ovarian B-Disease 1 1.0
cancer I-Disease 1 0.9999992847442627
in O 0 8.234331971834763e-08
women O 0 9.903420306045518e-09
with O 0 4.857913515898815e-10
pathogenic O 0 3.1328639238381584e-07
mutations O 0 7.92505971958235e-08
in O 0 1.6606380270900445e-08
the O 0 1.9584122767923873e-08
BRCA1 O 0 3.3850308682303876e-05
or O 0 1.1602631957430276e-06
BRCA2 O 0 0.000574264326132834
gene O 0 0.00018705274851527065

A O 0 1.1877690440087463e-06
Japanese O 0 7.023583634691022e-07
family O 0 5.425553339932776e-08
with O 0 9.602350026227668e-09
adrenoleukodystrophy B-Disease 1 1.0
with O 0 7.916792554851781e-09
a O 0 7.552458214377111e-08
codon O 0 4.15675413023564e-06
291 O 0 3.0385527338694374e-07
deletion O 0 1.5739684045001923e-07
: O 0 6.844800282124197e-10
a O 0 1.2751917299880233e-09
clinical O 0 4.425725208534459e-08
, O 0 1.1219557505270927e-09
biochemical O 0 1.6847867811975448e-07
, O 0 5.660067081691977e-09
pathological O 0 2.3691245587542653e-06
, O 0 7.680671210152923e-09
and O 0 5.569075423039749e-09
genetic O 0 1.222473571260707e-07
report O 0 2.4308030788233737e-07
. O 0 4.231223726947064e-08

We O 0 6.029895871506596e-07
report O 0 2.3238719393248175e-08
a O 0 1.6372817546184137e-09
Japanese O 0 5.106917200237149e-08
family O 0 7.616714370328737e-09
with O 0 5.888023224542849e-08
adrenoleukodystrophy B-Disease 1 1.0
( O 0 0.0008259072783403099
ALD B-Disease 1 1.0
) O 0 2.269553434075533e-09
with O 0 2.1877170908179977e-10
a O 0 3.1428779578845933e-09
three O 0 2.763130391159052e-09
base O 0 4.84534901090683e-09
pair O 0 3.9076266489246336e-07
deletion O 0 8.965068900579354e-07
( O 0 6.622529191702142e-09
delGAG O 0 1.0514027337649168e-07
291 O 0 6.749582581733193e-08
) O 0 9.233710462908107e-10
in O 0 5.835862459946384e-09
the O 0 2.200351474357376e-07
ALD B-Disease 1 0.9999985694885254
gene O 0 4.621677817340242e-06
. O 0 2.1105552150402218e-07

A O 0 4.771223416355497e-07
variety O 0 2.9170799109579093e-08
of O 0 5.321704188432363e-10
phenotypes O 0 6.331920587854256e-08
were O 0 2.965154166645334e-08
observed O 0 7.277292657370538e-10
within O 0 2.6883625880991247e-10
this O 0 7.075087182784046e-10
family O 0 1.8968590254075934e-08
. O 0 2.1540975225775583e-08

While O 0 3.708695714976784e-07
the O 0 1.6438567840282303e-08
proband O 0 2.8507997740234714e-06
( O 0 9.06391406374496e-09
patient O 0 2.0215079388208324e-08
1 O 0 1.5021848209784139e-09
) O 0 5.405828562565773e-10
was O 0 4.1912795012422066e-08
classified O 0 3.024927197614602e-09
as O 0 1.3369937379437147e-09
having O 0 9.432510328366561e-10
a O 0 6.413534148208555e-10
rare O 0 9.419102831031978e-09
intermediate O 0 1.712133901321522e-08
type O 0 1.0290509777632906e-07
of O 0 1.2932758197692351e-09
adult O 0 2.603391067168559e-07
cerebral O 0 7.435450970660895e-05
and O 0 3.847095740638906e-06
cerebello O 1 0.9721017479896545
- O 1 0.9530618190765381
brain O 0 0.0002108752087224275
stem O 0 9.140775603100337e-08
forms O 0 1.6903964450420972e-08
, O 0 7.034401061645212e-09
his O 0 8.720139277329508e-09
younger O 0 1.2850962605170935e-07
brother O 0 2.64764032920084e-08
( O 0 1.758199363877111e-09
patient O 0 1.1712072200964485e-08
2 O 0 1.0657592586227338e-09
) O 0 4.189085467398712e-10
and O 0 1.7264740748146323e-08
nephew O 0 3.584209707696573e-06
( O 0 7.053088335595703e-09
patient O 0 3.3518890063533036e-07
3 O 0 1.3655893305042355e-08
) O 0 1.3845744550877725e-09
had O 0 1.4577543652194436e-06
a O 0 5.666366860168637e-07
childhood O 0 0.0005166669143363833
ALD B-Disease 1 0.9999995231628418
type O 0 9.495481936028227e-05
. O 0 4.410060512327618e-07

Another O 0 3.0979738312453264e-06
nephew O 0 4.314974648877978e-05
( O 0 1.4396431424756884e-07
patient O 0 3.0939801831664226e-07
4 O 0 5.426368243632851e-09
) O 0 2.7611690711637493e-10
of O 0 6.511796657449054e-11
patient O 0 4.859725066808096e-08
1 O 0 9.595868988299117e-09
was O 0 6.773814789085009e-07
classified O 0 1.2042758790187236e-08
as O 0 3.0580633580967742e-09
having O 0 1.0301778985422061e-08
an O 0 2.561323819705308e-09
adolescent O 0 2.3197054588308674e-07
form O 0 7.435722437776349e-08
. O 0 2.2199726856797497e-07

The O 0 1.0582291309901848e-07
tau O 0 1.5031234568141372e-07
level O 0 1.0990685694878266e-08
in O 0 1.9168726606011433e-09
the O 0 6.9711831862662166e-09
cerebrospinal O 0 6.30091963103041e-05
fluid O 0 2.3766738195263315e-06
( O 0 4.310276580099526e-08
CSF O 0 0.019017912447452545
) O 0 4.2904554908851367e-10
in O 0 2.8769409077256114e-09
patient O 0 6.964209120496889e-08
1 O 0 2.80837841870607e-09
was O 0 6.495419029306504e-07
as O 0 3.186366948071395e-09
high O 0 8.525143257998025e-09
as O 0 5.193114827051204e-10
that O 0 1.6195583762979027e-10
of O 0 3.4645639135355566e-10
patients O 0 2.409555293070298e-07
with O 0 1.1419292178516116e-07
Alzheimers B-Disease 1 0.9998728036880493
disease I-Disease 0 0.0008572905790060759
( O 0 1.5946335807370815e-08
AD B-Disease 0 8.201905075111426e-06
) O 0 1.8148732294775982e-08
. O 0 3.010860538665838e-08

His O 0 5.6734033933025785e-06
brain O 0 2.43556423811242e-05
magnetic O 0 6.310928597486054e-07
resonance O 0 2.0281488559703575e-06
image O 0 1.589500925547327e-06
( O 0 6.878808278543147e-08
MRI O 0 0.015330845490098
) O 0 9.502832298835528e-09
showed O 0 0.0002697626769077033
abnormalities B-Disease 0 0.052307676523923874
in I-Disease 0 4.3179930742098804e-09
the I-Disease 0 1.8844132920747825e-09
bilateral I-Disease 0 1.2796703003914445e-06
cerebellar I-Disease 0 2.469877654220909e-05
hemispheres I-Disease 0 0.0005384576506912708
and O 0 2.2678511868434725e-06
brain O 0 1.4697631741000805e-05
stem O 0 6.865779056397514e-08
, O 0 9.430135561316888e-10
but O 0 1.2065514143344558e-09
not O 0 3.133747983330437e-10
in O 0 9.66144608760544e-10
the O 0 2.1390064830484334e-08
cerebral O 0 0.005899485666304827
white O 0 4.910154984827386e-07
matter O 0 2.215298167129731e-08
, O 0 1.082585340816955e-10
where O 0 5.438786226941161e-11
marked O 0 1.0288224716603622e-09
reductions O 0 1.1730985960412e-08
of O 0 4.820520024817476e-11
the O 0 1.1231590102411815e-09
cerebral O 0 4.996014126845694e-07
blood O 0 1.9414159169173217e-08
flow O 0 5.751854548208257e-09
and O 0 7.57100249160203e-09
oxygen O 0 1.2571188534593603e-08
metabolism O 0 6.372520289232853e-08
were O 0 1.1230482321877844e-08
clearly O 0 4.942243947425595e-09
demonstrated O 0 2.1313082410046036e-09
by O 0 9.781450094337174e-10
positron O 0 5.7888764786184765e-06
emission O 0 4.513489329838194e-06
tomography O 0 0.00023324057110585272
( O 0 3.4396725823171437e-07
PET O 0 5.075763056083815e-06
) O 0 4.973471590119516e-08
. O 0 7.5368880914084e-08

In O 0 8.150552730512572e-07
patients O 0 2.2724905193172162e-06
2 O 0 1.3620567784755622e-08
and O 0 2.4498008066586863e-09
3 O 0 4.476380155438164e-09
, O 0 8.571672260870855e-10
the O 0 5.009781034459593e-09
autopsy O 0 0.0004925235407426953
findings O 0 7.823099679171719e-08
showed O 0 7.553537670901278e-07
massive O 0 1.3881734162168868e-07
demyelination B-Disease 1 0.9999892711639404
of I-Disease 0 4.064828917904606e-09
the I-Disease 0 8.128982642574556e-08
cerebral I-Disease 0 0.0682096853852272
white I-Disease 0 1.5639569710401702e-06
matter I-Disease 0 3.0331385403314925e-08
with O 0 1.9720582111748541e-10
sparing O 0 4.560022581756584e-09
of O 0 1.7329519763631396e-10
the O 0 2.4746913407369675e-09
U O 0 2.6779594918480143e-05
- O 0 4.227039880788652e-06
fibers O 0 1.1719869235093938e-06
, O 0 3.5689681765482817e-10
compatible O 0 8.31172641824196e-09
with O 0 2.1991340692917305e-10
the O 0 1.5595303937132599e-09
findings O 0 2.0210876527926303e-08
of O 0 1.1663472854195334e-08
childhood O 0 5.117701584822498e-05
ALD B-Disease 1 0.9999983310699463
. O 0 5.664541049554828e-07

Oleic O 0 0.01182575710117817
and O 0 8.9930443891717e-07
erucic O 0 0.00011640138836810365
acids O 0 3.8213096331674024e-07
( O 0 5.5849249669392975e-09
Lorenzos O 0 6.801067087280899e-08
Oil O 0 1.1920405107446186e-08
) O 0 9.191971489519446e-11
were O 0 1.8314237626437802e-10
administered O 0 9.066290773684926e-11
to O 0 1.9250862015596226e-10
patients O 0 1.7779442362808595e-09
1 O 0 2.419956735000284e-10
and O 0 8.647143556750336e-10
4 O 0 6.328364499097461e-10
, O 0 7.83793446812453e-11
but O 0 6.582990402792532e-11
sufficient O 0 6.287310949648628e-11
effectiveness O 0 5.54377788120064e-09
was O 0 2.8957041209309864e-08
not O 0 8.333057022191781e-10
obtained O 0 5.281199477735754e-09
. O 0 1.9112004423504914e-08

The O 0 9.049355043089236e-08
findings O 0 3.7444902289962556e-08
in O 0 1.5551461229890151e-09
this O 0 1.2465567467145888e-10
family O 0 4.307625922628233e-10
suggest O 0 1.3639305240786825e-09
that O 0 2.057770481789234e-10
delGAG291 O 0 1.9518342497804042e-08
is O 0 7.557663522783642e-11
part O 0 2.362325335347748e-10
of O 0 5.6154362410021363e-11
the O 0 9.365462849686423e-10
cause O 0 8.845897347953269e-09
of O 0 2.1687109885704103e-09
Japanese O 0 2.6619010895956308e-05
ALD B-Disease 1 0.9999797344207764
with O 0 3.823268368563504e-09
phenotypic O 0 3.672682282740425e-07
variations O 0 1.1013055427611107e-06
. O 0 1.3570435442034068e-07

Moreover O 0 1.5784207789693028e-06
, O 0 5.486239462726417e-09
although O 0 1.0695326846388298e-09
the O 0 1.4997449115927708e-10
scale O 0 2.1763641999683614e-09
of O 0 2.4848010801714615e-11
the O 0 1.8181316174814555e-10
study O 0 1.270391708496632e-10
is O 0 3.3780499231195193e-11
limited O 0 1.6854111162256658e-10
, O 0 2.140906202319215e-10
there O 0 1.3623393524397898e-09
is O 0 7.575357702238605e-11
a O 0 9.845590315249453e-11
possibility O 0 1.3754855032743762e-09
that O 0 1.5019154808726398e-09
PET O 0 9.744791640287076e-08
can O 0 5.4248467939999045e-09
detect O 0 5.336153208190808e-07
an O 0 1.191008713874453e-08
insidious B-Disease 0 0.0001006427628453821
lesion I-Disease 0 0.0007938463240861893
which O 0 4.161937461333309e-09
is O 0 6.702073340747461e-10
undetectable O 0 1.4444668572366481e-08
by O 0 2.6456234425431546e-10
computed O 0 4.5555996308621616e-08
tomogram O 0 8.086777825155878e-07
( O 0 5.777649914051608e-09
CT O 0 0.14564432203769684
) O 0 1.4001128034735189e-09
or O 0 3.430863815268026e-09
MRI O 0 1.3539978681365028e-05
analysis O 0 1.6127714719260666e-09
, O 0 7.843737465096368e-11
and O 0 2.1178253595266483e-10
that O 0 2.8918581071457616e-11
the O 0 6.86917467351833e-11
higher O 0 4.587405566525149e-09
level O 0 8.460829259426816e-10
of O 0 1.3413191564393134e-11
tau O 0 6.246697048517547e-10
reflects O 0 3.375694446194899e-10
the O 0 6.117033268804306e-11
process O 0 5.961310889368576e-10
of O 0 8.609686852345533e-10
neuronal B-Disease 0 7.481290140276542e-06
degeneration I-Disease 0 0.0023711288813501596
in O 0 1.4356893188960385e-05
ALD B-Disease 1 0.9999991655349731
. O 0 9.858322300715372e-07

Lorenzos O 0 4.380441168905236e-05
Oil O 0 7.746969572508533e-07
should O 0 6.7047993823621255e-09
be O 0 2.312056379683014e-10
given O 0 3.55958457154415e-11
in O 0 1.712174430013036e-10
the O 0 2.6060131830263344e-10
early O 0 1.6315100026531582e-07
stage O 0 4.0420925273565445e-08
. O 0 1.945759553478865e-09
. O 0 7.136800483920069e-09

Nonsense O 0 0.0006160249467939138
mutation O 0 4.153528607275803e-06
in O 0 4.1839548714506236e-08
exon O 0 2.265230421016895e-07
4 O 0 9.683663648729635e-09
of O 0 1.9953345919976329e-10
human O 0 1.3854516422995289e-09
complement O 0 3.360357325732366e-08
C9 O 0 6.60599471302703e-06
gene O 0 2.4514574192835425e-07
is O 0 2.560014866759275e-09
the O 0 6.364169746753134e-10
major O 0 8.48306758172157e-09
cause O 0 2.6054442159306745e-08
of O 0 2.580506697213991e-09
Japanese O 0 2.1688522338081384e-06
complement B-Disease 0 4.28102066507563e-06
C9 I-Disease 0 0.2974627912044525
deficiency I-Disease 0 0.03286074846982956
. O 0 5.615830218630435e-07

Deficiency B-Disease 1 0.9978020787239075
of I-Disease 0 6.296005938821736e-09
the I-Disease 0 4.879739279317619e-09
ninth I-Disease 0 4.0974693860107436e-08
component I-Disease 0 5.763165500383138e-09
of I-Disease 0 7.529923212734602e-11
human I-Disease 0 3.236864110078841e-10
complement I-Disease 0 3.8130892221488466e-08
( O 0 1.2216596623204623e-08
C9 O 0 1.6874961374924169e-06
) O 0 8.166240461626728e-10
is O 0 1.4740286768955002e-10
the O 0 4.1392858585176384e-10
most O 0 2.671047383273617e-09
common O 0 2.8389064254952245e-07
complement B-Disease 1 1.0
deficiency I-Disease 1 1.0
in O 0 3.403685866487649e-08
Japan O 0 9.085085395099668e-08
but O 0 5.800263380706383e-09
is O 0 1.0365193425787567e-10
rare O 0 4.1209941015196705e-10
in O 0 1.6257120094564925e-09
other O 0 1.166346907943705e-09
countries O 0 2.327463777263006e-09
. O 0 2.0326858418684424e-08

We O 0 9.22897072541673e-07
studied O 0 6.415019981886871e-08
the O 0 2.4443864710121943e-09
molecular O 0 6.083703762982395e-09
basis O 0 4.4552561639932264e-09
of O 0 2.1576132880340992e-08
C9 B-Disease 1 0.9991737008094788
deficiency I-Disease 0 0.3728981614112854
in O 0 1.968133389596005e-08
four O 0 1.4198446862678793e-08
Japanese O 0 3.277379221344745e-07
C9 B-Disease 0 0.004697419703006744
- I-Disease 1 0.8739960789680481
deficient I-Disease 0 0.4779162108898163
patients O 0 0.0001149005038314499
who O 0 5.194596610635926e-07
had O 0 9.751624929776881e-06
suffered O 1 0.7512354850769043
from O 0 9.546429282636382e-06
meningococcal B-Disease 1 1.0
meningitis I-Disease 1 1.0
. O 0 2.8783340439986205e-06

Direct O 0 6.986533662711736e-07
sequencing O 0 4.7272359893213434e-07
of O 0 8.472217594146514e-09
amplified O 0 5.938075560152356e-07
C9 O 0 3.834542894765036e-06
cDNA O 0 2.601869368845655e-07
and O 0 1.0871386457722565e-08
DNA O 0 9.311288096114367e-08
revealed O 0 8.914293658790484e-08
a O 0 8.070212054178683e-09
nonsense O 0 6.785944606235716e-07
substitution O 0 7.157441928029584e-08
( O 0 7.234739474171192e-09
CGA O 0 4.115824140171753e-06
- O 0 2.9461107260431163e-06
- O 0 2.674493089216412e-06
> O 0 7.336279850278515e-08
TGA O 0 5.896541779293329e-07
) O 0 5.779300371600016e-10
at O 0 6.211979264314493e-10
codon O 0 8.841679388638113e-09
95 O 0 9.139860535078981e-10
in O 0 6.002373598157362e-10
exon O 0 1.5696775435003474e-08
4 O 0 3.124468683779469e-09
in O 0 3.764489608926169e-09
the O 0 6.386705830863093e-09
four O 0 1.8713130600644945e-07
C9 B-Disease 0 0.02310754545032978
- I-Disease 0 0.08559601753950119
deficient I-Disease 0 0.00023106805747374892
individuals O 0 2.3902609669335106e-08
. O 0 4.9975675153746124e-08

An O 0 1.594339238408793e-07
allele O 0 3.3106507544289343e-06
- O 0 5.651655214933271e-07
specific O 0 6.550407327665653e-09
polymerase O 0 1.8994663264493283e-07
chain O 0 8.608414248101326e-08
reaction O 0 4.681954823837486e-09
system O 0 9.222761998550766e-10
designed O 0 6.379522687893768e-09
to O 0 9.431555536565384e-10
detect O 0 1.8854642291898926e-08
exclusively O 0 1.1062777360848486e-09
only O 0 3.508165424825904e-10
one O 0 1.1130584648411102e-10
of O 0 7.807373671175899e-12
the O 0 2.5458876673489783e-10
normal O 0 4.541091946919096e-09
and O 0 1.6800808522177135e-09
mutant O 0 1.3803510334753355e-08
alleles O 0 1.616122702330358e-08
indicated O 0 7.090196874059984e-08
that O 0 4.321978608334831e-10
all O 0 9.21090911876199e-11
the O 0 9.74925903896029e-11
four O 0 8.81180961531669e-10
patients O 0 2.0908625941729042e-09
were O 0 1.3467141846135178e-09
homozygous O 0 1.381485481566358e-09
for O 0 4.0017822389160074e-11
the O 0 8.987864619225405e-11
mutation O 0 1.34798883166809e-09
in O 0 1.2519854042380985e-09
exon O 0 1.341996824777425e-08
4 O 0 5.634302802093316e-09
and O 0 3.013260752027236e-09
that O 0 1.9682702689927112e-10
the O 0 2.6974281142067014e-10
parents O 0 1.0563909746963418e-09
of O 0 7.870727680714396e-11
patient O 0 3.83578964147091e-08
2 O 0 6.847271638577013e-09
were O 0 7.102553922777588e-07
heterozygous O 0 2.5461292807449354e-06
. O 0 9.789427934947526e-08

The O 0 7.739733831613194e-08
common O 0 5.467657970825712e-08
mutation O 0 8.631415937543352e-08
at O 0 1.1911222230764906e-08
codon O 0 6.01891017026901e-08
95 O 0 5.78146419627501e-09
in O 0 1.6876895436723771e-09
exon O 0 5.491309096328223e-08
4 O 0 1.7995962053873882e-08
might O 0 1.1698981694507893e-07
be O 0 6.994660961545662e-10
responsible O 0 5.363402499902747e-10
for O 0 2.530246567822303e-10
most O 0 6.5854965924927455e-09
Japanese O 0 2.6961195089825196e-06
C9 B-Disease 0 0.0017490689642727375
deficiency I-Disease 0 7.605220162076876e-05
. O 0 8.547155871951873e-09
. O 0 3.074569576710928e-08

BRCA1 O 0 0.00014701695181429386
required O 0 1.609365227750459e-07
for O 0 8.658899375291185e-09
transcription O 0 8.437164979113732e-06
- O 0 0.00010815759742399678
coupled O 0 2.5929371076927055e-06
repair O 0 0.0005002819816581905
of O 0 4.895092775569765e-09
oxidative O 0 2.2195789028955915e-07
DNA O 0 1.8751087509372155e-06
damage O 0 3.858474883600138e-06
. O 0 2.0268250011667988e-07

The O 0 6.983952334849164e-05
breast B-Disease 1 0.9999978542327881
and I-Disease 1 0.9999740123748779
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999996423721313
susceptibility O 0 1.971996243810281e-05
gene O 0 7.202536835393403e-06
BRCA1 O 0 3.6448807804845273e-05
encodes O 0 5.124451263327501e-07
a O 0 1.0762128965779993e-07
zinc O 0 9.82070341706276e-05
finger O 0 0.00017222239694092423
protein O 0 5.2004853756670855e-08
of O 0 5.635933386649583e-10
unknown O 0 3.620696986672556e-08
function O 0 2.6294623367562053e-08
. O 0 3.6804234326837104e-08

Association O 0 2.1498949820397684e-07
of O 0 5.91450166620433e-10
the O 0 4.430492361873206e-10
BRCA1 O 0 8.340665402783998e-08
protein O 0 3.3752902695027842e-09
with O 0 1.0074555079064851e-10
the O 0 5.26488352914356e-10
DNA O 0 1.0949761986012163e-07
repair O 0 3.944915533793392e-06
protein O 0 3.8741415409049296e-08
Rad51 O 0 1.0117663578057545e-06
and O 0 2.694256817648011e-09
changes O 0 7.06443514797428e-10
in O 0 1.4738092690702587e-10
the O 0 4.5617135069342396e-11
phosphorylation O 0 9.582731275159517e-10
and O 0 6.401154606372472e-10
cellular O 0 5.097350808114243e-08
localization O 0 2.1892720525329423e-08
of O 0 4.0123755012944073e-11
the O 0 7.237920679470378e-11
protein O 0 7.184996486664375e-10
after O 0 2.9892297526146194e-09
exposure O 0 8.362707859532748e-09
to O 0 6.869401714126866e-10
DNA O 0 1.3431112222406227e-07
- O 0 2.3035528329273802e-07
damaging O 0 1.16361697166667e-07
agents O 0 1.1042502023883571e-08
are O 0 2.5407748127648233e-10
consistent O 0 1.2254022241364737e-09
with O 0 3.0325266603403733e-11
a O 0 3.6136424408361734e-10
role O 0 1.0700182961898008e-09
for O 0 1.486326478561395e-10
BRCA1 O 0 1.2020572626170178e-07
in O 0 1.108314240383379e-08
DNA O 0 1.2635415487238788e-06
repair O 0 0.0003070467500947416
. O 0 1.9516151894549694e-07

Here O 0 9.075557159121672e-07
, O 0 2.120732700561234e-09
it O 0 1.4625854694028106e-10
is O 0 2.166058651886793e-11
shown O 0 3.1908900521848693e-10
that O 0 4.3344358657826376e-10
mouse O 0 3.1287825663639524e-07
embryonic O 0 3.1132040589909593e-07
stem O 0 4.377506854780222e-07
cells O 0 3.782103021876537e-07
deficient B-Disease 0 8.234493179770652e-06
in I-Disease 0 1.083286704783859e-08
BRCA1 I-Disease 0 1.160181341219868e-06
are O 0 2.2051878101336797e-09
defective O 0 4.796480084223731e-07
in O 0 4.468660108614131e-09
the O 0 7.186750639043282e-10
ability O 0 2.1552224449550295e-09
to O 0 2.8160257459219906e-10
carry O 0 7.722948502930649e-09
out O 0 1.948754224656568e-08
transcription O 0 1.2099407058485667e-06
- O 0 5.526225777430227e-06
coupled O 0 5.337588504517043e-07
repair O 0 6.997618766035885e-05
of O 0 1.9149795082995524e-09
oxidative O 0 6.563742260823346e-08
DNA O 0 4.2164083424722776e-07
damage O 0 1.7485073158240994e-06
, O 0 2.1261070681788397e-09
and O 0 4.645714035689252e-09
are O 0 2.7578861416799327e-09
hypersensitive O 0 6.59589488805068e-07
to O 0 3.2065838873052144e-09
ionizing O 0 3.4672984838834964e-07
radiation O 0 2.1843352442374453e-06
and O 0 1.388420400871837e-08
hydrogen O 0 6.998537571689667e-08
peroxide O 0 1.6937106920522638e-05
. O 0 3.487138542368484e-07

These O 0 1.2065639509728499e-07
results O 0 1.3535834852973494e-07
suggest O 0 2.01204901628671e-08
that O 0 2.5386106550229215e-09
BRCA1 O 0 2.6353401949563704e-07
participates O 0 3.741697174319825e-09
, O 0 1.3743493842977017e-10
directly O 0 2.2454528514348482e-10
or O 0 1.0962499796818292e-09
indirectly O 0 1.918343039974957e-09
, O 0 2.331461412818925e-10
in O 0 3.066321863087751e-09
transcription O 0 1.331060389020422e-06
- O 0 6.013195616105804e-06
coupled O 0 6.943417929505813e-07
repair O 0 6.524432683363557e-05
of O 0 1.567310392580623e-09
oxidative O 0 5.497250654684649e-08
DNA O 0 4.380283940008667e-07
damage O 0 1.157175688604184e-06
. O 0 1.4617698163021942e-08
. O 0 3.683274485410948e-08

Truncation O 0 0.00015634061128366739
mutations O 0 1.2064242582709994e-05
in O 0 8.314616195548297e-08
the O 0 5.873618480478626e-09
transactivation O 0 2.34207709581824e-06
region O 0 5.14743234703019e-08
of O 0 1.8513348631898907e-09
PAX6 O 0 4.7966268539312296e-06
result O 0 4.9056943396408315e-08
in O 0 1.6898484389571422e-08
dominant O 0 9.015456271299627e-06
- O 0 1.5321867977036163e-05
negative O 0 1.7466057897763676e-06
mutants O 0 3.46013393937028e-06
. O 0 1.5185069912604376e-07

PAX6 O 0 0.0005843004328198731
is O 0 8.273026708138786e-08
a O 0 1.2848678565546834e-08
transcription O 0 9.313507831620882e-08
factor O 0 6.173170419287999e-09
with O 0 2.0114945820104424e-10
two O 0 1.2613958766394262e-09
DNA O 0 1.4788983548896795e-07
- O 0 3.208234602425364e-07
binding O 0 5.1383196364440664e-08
domains O 0 8.616479618694939e-08
( O 0 3.7147391829250864e-09
paired O 0 1.0157826579870743e-07
box O 0 1.9955503205437708e-07
and O 0 1.1771959407269605e-08
homeobox O 0 1.90853072012942e-07
) O 0 4.967607436512367e-10
and O 0 8.076090352027165e-10
a O 0 7.589350481396195e-09
proline O 0 2.455772573739523e-06
- O 0 3.791116398588201e-07
serine O 0 5.223955213295994e-06
- O 0 2.270287723149522e-06
threonine O 0 9.228590897691902e-06
( O 0 2.3876818744383854e-08
PST O 0 6.953822776267771e-06
) O 0 6.050538292612373e-09
- O 0 9.081793450604891e-08
rich O 0 2.9016421265737335e-08
transactivation O 0 6.887913059472339e-06
domain O 0 9.364021025248803e-07
. O 0 1.630663746254868e-07

PAX6 O 0 0.003771288553252816
regulates O 0 0.00010822981130331755
eye O 0 0.03529812768101692
development O 0 7.322551454080894e-08
in O 0 1.6791110724057035e-08
animals O 0 2.282834143940704e-09
ranging O 0 7.971689086616607e-09
from O 0 2.058984538422237e-09
jellyfish O 0 3.6064076169850523e-09
to O 0 6.394491047778672e-10
Drosophila O 0 7.820216474385688e-09
to O 0 2.1856283449750435e-09
humans O 0 2.339499793890809e-08
. O 0 4.953250254402519e-08

Heterozygous O 0 0.00018131019896827638
mutations O 0 5.744923782913247e-06
in O 0 1.4679978121989734e-08
the O 0 2.1108896852695125e-09
human O 0 4.151701649135475e-09
PAX6 O 0 3.1038944143801928e-06
gene O 0 1.7676092056717607e-07
result O 0 2.280533095699866e-08
in O 0 2.4473536530678075e-09
various O 0 1.393670401306224e-09
phenotypes O 0 9.700988812255673e-08
, O 0 1.278469663468229e-09
including O 0 1.6884373010839226e-08
aniridia B-Disease 1 1.0
, O 0 5.531283750315197e-05
Peters B-Disease 1 1.0
anomaly I-Disease 1 1.0
, O 0 1.3440622979032923e-06
autosomal B-Disease 0 0.18976141512393951
dominant I-Disease 0 0.05506475642323494
keratitis I-Disease 1 0.9998331069946289
, O 0 2.0993796567836398e-07
and O 0 6.631562996517459e-07
familial B-Disease 0 0.060004573315382004
foveal I-Disease 1 0.9990492463111877
dysplasia I-Disease 1 0.9999977350234985
. O 0 2.0907953057758277e-06

It O 0 9.487641250416345e-08
is O 0 8.553968644520182e-10
believed O 0 2.356808748160688e-09
that O 0 1.8117449207544212e-10
the O 0 2.859869840943219e-10
mutated O 0 9.225180264138544e-08
allele O 0 1.1505584751603237e-07
of O 0 1.1973926294928106e-09
PAX6 O 0 1.7520092114864383e-06
produces O 0 1.4756251331959902e-08
an O 0 2.01626626505913e-09
inactive O 0 8.019640773682113e-08
protein O 0 4.9395513457284324e-08
and O 0 2.534495422423788e-07
aniridia B-Disease 1 1.0
is O 0 6.332509627782201e-09
caused O 0 4.092798278065857e-08
due O 0 1.5668538466684367e-08
to O 0 4.189998570325315e-09
genetic O 0 6.525469871121459e-07
haploinsufficiency O 0 1.7827142073656432e-05
. O 0 1.0673144146267077e-07

However O 0 4.4977272750656994e-07
, O 0 3.06993852561277e-09
several O 0 7.804001334044131e-10
truncation O 0 2.57697251981881e-07
mutations O 0 5.98564113829525e-08
have O 0 1.2272759475351336e-09
been O 0 4.3323120091365297e-10
found O 0 1.760097484426737e-10
to O 0 3.7632008620391844e-11
occur O 0 4.8131703483944577e-11
in O 0 1.3562174994152798e-10
the O 0 6.829555254661557e-10
C O 0 3.4835418773582205e-05
- O 0 1.7556040177169052e-07
terminal O 0 9.119008126390327e-08
half O 0 4.994296531890541e-09
of O 0 1.531157700629393e-10
PAX6 O 0 6.177307341204141e-07
in O 0 2.4309695589863622e-08
patients O 0 1.231765480724789e-07
with O 0 4.1169738729252e-09
Aniridia B-Disease 1 0.9999974966049194
resulting O 0 4.787009011408827e-09
in O 0 9.570383374679636e-10
mutant O 0 6.321202672410209e-09
proteins O 0 7.686661307459985e-10
that O 0 1.4500414757812052e-10
retain O 0 1.439938390745965e-09
the O 0 5.509810385717628e-10
DNA O 0 2.615157690399883e-08
- O 0 4.53391102439582e-08
binding O 0 9.749621554533405e-09
domains O 0 1.2695982931631988e-08
but O 0 2.5081844157170963e-08
have O 0 3.9828558229260125e-09
lost O 0 2.3548015093410868e-08
most O 0 1.0182448634266095e-10
of O 0 2.3314291469622717e-11
the O 0 8.724344580102183e-10
transactivation O 0 1.1484573860798264e-06
domain O 0 2.2291121126727376e-07
. O 0 7.027805537518361e-08

It O 0 1.670915423801489e-07
is O 0 2.440338375819806e-09
not O 0 8.184422584101014e-10
clear O 0 1.0452473331312717e-09
whether O 0 3.1203817307812187e-10
such O 0 2.3232403500994536e-10
mutants O 0 2.389896565091476e-07
really O 0 1.8587501244837767e-06
behave O 0 9.852136884092033e-09
as O 0 1.7988197598128863e-09
loss O 0 9.28110654996317e-09
- O 0 9.975497761161023e-09
of O 0 1.8848582417074766e-10
- O 0 5.3572932756651426e-08
function O 0 1.8452817052150294e-09
mutants O 0 5.869588903806289e-08
as O 0 7.278185165660034e-09
predicted O 0 1.3834717371707939e-08
by O 0 2.1410788697551197e-09
haploinsufficiency O 0 4.187262675259262e-06
. O 0 7.974841054192439e-08

Contrary O 0 6.964680210330698e-07
to O 0 5.775357969639572e-09
this O 0 1.498606794214652e-10
theory O 0 6.159465160138211e-10
, O 0 5.687321100178444e-11
our O 0 8.630859915648159e-11
data O 0 1.1520375764462187e-09
showed O 0 1.0829458219063781e-08
that O 0 3.726210312526845e-11
these O 0 4.684745646965638e-11
mutants O 0 5.707311512281876e-09
are O 0 3.2891797618894714e-10
dominant O 0 6.077640790635996e-08
- O 0 7.614713837256204e-08
negative O 0 1.939036309295261e-08
in O 0 4.512753726260144e-09
transient O 0 2.0440849013425577e-08
transfection O 0 3.244436754812341e-07
assays O 0 1.626406742616382e-07
when O 0 2.5273971804296025e-09
they O 0 1.0395292404652423e-09
are O 0 1.6405224401161433e-10
coexpressed O 0 2.1545002226730503e-08
with O 0 4.151660126794354e-10
wild O 0 5.087443355478172e-08
- O 0 2.1006482711527497e-05
type O 0 1.541129131510388e-05
PAX6 O 0 0.00011689548409776762
. O 0 2.1156134266675508e-07

We O 0 3.0037369924684754e-07
found O 0 6.983893463541335e-09
that O 0 1.86021115178292e-10
the O 0 1.9751637825304869e-10
dominant O 0 2.3239944368924625e-07
- O 0 8.956958481576294e-07
negative O 0 6.26665581648922e-08
effects O 0 4.466702208105744e-08
result O 0 1.2055806353217235e-09
from O 0 6.208043801247953e-11
the O 0 3.1843284953314566e-11
enhanced O 0 1.6039181094384958e-09
DNA O 0 2.9507378762616554e-09
binding O 0 1.1786893683307653e-09
ability O 0 1.954687078864481e-09
of O 0 1.7060491908083009e-10
these O 0 1.1618971340610074e-09
mutants O 0 2.764479631878203e-07
. O 0 2.9229612508174796e-08

Kinetic O 0 9.292602953792084e-07
studies O 0 1.017523914015328e-07
of O 0 8.169231957566581e-10
binding O 0 2.5434440331650876e-08
and O 0 7.210480212904713e-09
dissociation O 0 2.841874469083905e-08
revealed O 0 3.717079977150206e-08
that O 0 1.490386009050937e-10
various O 0 1.1062222665669807e-10
truncation O 0 2.449144176353002e-07
mutants O 0 3.4692561712290626e-07
have O 0 1.1025707458145462e-08
3 O 0 2.64723998277816e-09
- O 0 2.0038650916376355e-07
5 O 0 4.395322505956756e-08
- O 0 8.57411464494362e-07
fold O 0 1.9727410816017255e-08
higher O 0 5.0088253544799954e-09
affinity O 0 1.01256880657985e-09
to O 0 1.2273430882725478e-10
various O 0 1.935191729085517e-10
DNA O 0 6.581980738218363e-09
- O 0 3.985059837674498e-09
binding O 0 1.2853133002366235e-09
sites O 0 2.6455238000266945e-09
when O 0 1.1760731277732361e-09
compared O 0 2.221720363237978e-09
with O 0 4.854956020539092e-11
the O 0 9.54766710137278e-10
wild O 0 2.2087458972919194e-08
- O 0 4.3032878238591366e-06
type O 0 6.231759471120313e-06
PAX6 O 0 7.987993012648076e-05
. O 0 2.3010694860658987e-07

These O 0 1.398736770852338e-07
results O 0 2.3896864931316486e-08
provide O 0 4.0494196884566236e-10
a O 0 2.8837587873198345e-09
new O 0 4.537025333206657e-08
insight O 0 4.275412734955353e-08
into O 0 1.167695717896322e-09
the O 0 5.404498515382272e-10
role O 0 1.574762653611117e-09
of O 0 2.95847374376379e-10
mutant O 0 1.172042303210219e-07
PAX6 O 0 3.89261003874708e-06
in O 0 4.8281648901138396e-08
causing O 0 1.0956694040942239e-06
aniridia B-Disease 1 0.9999996423721313
. O 0 4.570970446593492e-08
. O 0 5.3621800333303327e-08

Reversal O 0 0.0005953182699158788
of O 0 1.1070402479163022e-06
severe O 1 0.9996627569198608
hypertrophic B-Disease 1 0.999998927116394
cardiomyopathy I-Disease 1 1.0
and O 0 3.431793174968334e-06
excellent O 0 3.465457666607108e-06
neuropsychologic O 0 4.151902248850092e-05
outcome O 0 5.138780352353933e-07
in O 0 1.1818466560953311e-07
very B-Disease 0 8.121393875626381e-06
- I-Disease 0 1.8216749595012516e-05
long I-Disease 0 3.442699380684644e-06
- I-Disease 0 4.9225982365896925e-06
chain I-Disease 0 2.4150283934432082e-05
acyl I-Disease 0 2.2561082005267963e-05
- I-Disease 0 2.7332623631082242e-06
coenzyme I-Disease 0 8.239970838985755e-07
A I-Disease 0 7.714920116086432e-07
dehydrogenase I-Disease 0 0.0005244148778729141
deficiency I-Disease 0 0.0019666466396301985
. O 0 3.906124845798331e-07

Very B-Disease 0 0.0003736521757673472
- I-Disease 0 0.0011597051052376628
long I-Disease 0 7.089052814990282e-06
- I-Disease 0 1.8888293197960593e-05
chain I-Disease 0 1.4966571143304463e-05
acyl I-Disease 0 1.038820937537821e-05
- I-Disease 0 8.744483466216479e-07
coenzyme I-Disease 0 2.0094225305911095e-07
A I-Disease 0 4.515666418569708e-08
dehydrogenase I-Disease 0 2.9323928174562752e-06
( I-Disease 0 3.6706225614580035e-08
VLCAD I-Disease 0 7.503802771680057e-05
) I-Disease 0 7.542352875589131e-08
deficiency I-Disease 0 2.7263684387435205e-05
is O 0 1.098470758797987e-09
a O 0 2.8517677108652606e-08
disorder O 0 9.706903256301302e-06
of O 0 6.66801613924406e-10
fatty O 0 6.702450150442019e-08
acid O 0 4.123653862819765e-09
beta O 0 1.1536779309651024e-09
oxidation O 0 3.571133666557813e-10
that O 0 1.8132384482782982e-10
reportedly O 0 2.6667930086432534e-08
has O 0 2.4234128037647906e-09
high O 0 2.2776205810259853e-08
rates O 0 8.058722755777126e-07
of O 0 1.779531966228376e-09
morbidity O 0 1.4667079085484147e-05
and O 0 3.7144582165637985e-07
mortality O 0 1.2288936659388128e-06
. O 0 7.551277292350278e-08

We O 0 2.2573698288397281e-07
describe O 0 2.6709569667104915e-08
the O 0 1.1825355139549742e-09
outcome O 0 4.676840248407643e-09
of O 0 5.661983729088327e-11
a O 0 1.7254329076621389e-09
5 O 0 7.0724870404603735e-09
- O 0 6.422336014111352e-07
year O 0 3.736913640750572e-07
- O 0 7.259835001605097e-06
old O 0 0.007708544842898846
girl O 0 7.066810212563723e-05
with O 0 6.694579468558004e-08
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
who O 0 1.9386486371786305e-07
was O 0 9.387214561229484e-09
first O 0 7.13710979205473e-10
seen O 0 1.552367123736076e-08
at O 0 2.3236135238136058e-09
5 O 0 6.119568740636794e-10
months O 0 9.991450999891072e-10
of O 0 4.871820308283148e-11
age O 0 1.026455187513875e-08
with O 0 1.6313691730829305e-08
severe O 1 0.9999794960021973
hypertrophic B-Disease 1 0.9999997615814209
cardiomyopathy I-Disease 1 1.0
, O 0 0.0007593962363898754
hepatomegaly B-Disease 1 1.0
, O 0 5.349433558876626e-05
encephalopathy B-Disease 0 0.2384512722492218
, O 0 5.0553200736658255e-08
and O 0 1.5797429853137146e-07
hypotonia B-Disease 0 0.0036166193895041943
. O 0 6.231624638530775e-07

Biochemical O 0 0.0001639423571759835
studies O 0 5.552243237616494e-05
indicated O 1 0.9998303651809692
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
caused O 0 2.666798764039413e-06
by O 0 3.287638605797838e-09
a O 0 3.811402393694152e-08
stable O 0 2.557716015871847e-06
yet O 0 1.872167985084161e-07
inactive O 0 3.607201222166623e-07
enzyme O 0 2.7904641797249496e-07
. O 0 5.549715709207703e-08

Molecular O 0 2.2317760794976493e-06
genetic O 0 1.3773154705631896e-06
analysis O 0 4.641482931333485e-08
of O 0 5.214397802433268e-09
her O 0 2.544769586165785e-07
VLCAD O 0 0.00012074286496499553
gene O 0 2.3723960111965425e-06
revealed O 0 1.4372029681908316e-06
a O 0 9.464921646440416e-08
T1372C O 0 4.296423412597505e-06
( O 0 3.4361374190439165e-08
F458L O 0 1.0309266826880048e-06
) O 0 1.096443025261351e-08
missense O 0 4.740540134662297e-06
mutation O 0 8.832916478240804e-07
and O 0 3.701691397850482e-08
a O 0 4.952593712914677e-07
1668 O 0 0.08153031021356583
ACAG O 0 0.0007970853475853801
1669 O 0 8.683899068273604e-05
splice O 0 9.684778342489153e-05
site O 0 2.7036378469347255e-06
mutation O 0 1.3332390153664164e-05
. O 0 6.194858315211604e-07

After O 0 3.866973656840855e-07
initial O 0 7.165008497622694e-08
treatment O 0 6.021459597604917e-08
with O 0 4.757242377806392e-10
intravenous O 0 2.0417749624357384e-07
glucose O 0 1.6443747881567106e-05
and O 0 3.686317739948208e-08
carnitine O 0 2.2752765005407127e-07
, O 0 4.411056797604118e-10
the O 0 7.011732305883811e-10
patient O 0 6.202371594099532e-08
has O 0 1.403120286624926e-09
thrived O 0 3.0601537304164594e-08
on O 0 5.478605569209094e-09
a O 0 1.0105318359876492e-08
low O 0 0.0004028009425383061
- O 0 4.04818456445355e-05
fat O 0 4.622206120075134e-07
diet O 0 7.985979877389582e-09
supplemented O 0 1.7428972709510049e-09
with O 0 2.642143726028223e-10
medium O 0 4.799573162017623e-06
- O 0 7.311790568564902e-07
chain O 0 1.267181005459861e-06
triglyceride O 0 9.351812764180067e-07
oil O 0 1.6852045803261717e-07
and O 0 6.418065634505865e-09
carnitine O 0 1.4286182192790875e-07
and O 0 6.31616448032446e-09
avoidance O 0 1.2435094731699792e-07
of O 0 2.4458228775614543e-09
fasting O 0 2.5719957648107084e-06
. O 0 9.016378754722609e-08

Her O 0 0.0001821631012717262
ventricular O 1 0.905048131942749
hypertrophy O 0 0.007049317937344313
resolved O 0 7.365508736256743e-06
significantly O 0 2.605802933430823e-07
over O 0 2.6173569978027444e-09
1 O 0 3.154288163997876e-09
year O 0 4.2738941274933495e-09
, O 0 1.464134508077919e-10
and O 0 8.848929922145032e-10
cognitively O 0 3.908647840944468e-07
, O 0 5.253919521663875e-10
she O 0 6.121673390424576e-09
is O 0 3.5098035588987386e-11
in O 0 2.128057591255228e-10
the O 0 1.6153442472521817e-10
superior O 0 7.861268969122648e-09
range O 0 1.0638487424330378e-08
for O 0 9.478033469179081e-09
age O 0 8.044336397006191e-08
. O 0 2.4616243265995763e-08

Clinical O 0 1.5579944374621846e-05
recognition O 0 3.1805035405341187e-07
of O 0 1.9314711607876234e-06
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
is O 0 6.165556953874329e-09
important O 0 1.4777085111106203e-09
because O 0 1.802102689296703e-09
it O 0 2.0629145613959565e-10
is O 0 2.320440367631349e-11
one O 0 6.75507219605187e-11
of O 0 1.0710422132520492e-11
the O 0 6.106976035979983e-10
few O 0 3.550720606426694e-08
directly O 0 2.4930365327691106e-08
treatable O 0 6.826260687375907e-06
causes O 0 1.9735916012564303e-08
of O 0 1.9468073375605854e-08
cardiomyopathy B-Disease 1 1.0
in O 0 2.58265089314591e-07
children O 0 3.307906482064027e-08
. O 0 3.299624573571691e-09
. O 0 2.0544350221030072e-08

Cloning O 0 2.3497957499785116e-06
of O 0 5.960131499449517e-09
a O 0 9.668731593137636e-09
novel O 0 1.4292568017992835e-08
member O 0 4.985682977576289e-09
of O 0 1.3440677737452944e-10
the O 0 1.7604443458552055e-09
low O 0 1.9166094716638327e-05
- O 0 2.8272177132748766e-06
density O 0 1.956709638761822e-08
lipoprotein O 0 3.178943416060065e-06
receptor O 0 2.8634158866225334e-07
family O 0 1.460842327105638e-07
. O 0 8.824583375144357e-08

A O 0 1.181023549179372e-06
gene O 0 6.79249751556199e-07
encoding O 0 1.2878739141797269e-07
a O 0 1.1649600395458037e-08
novel O 0 2.8636717885888174e-08
transmembrane O 0 5.09520283742404e-08
protein O 0 4.024829536319885e-08
was O 0 3.16878043804536e-08
identified O 0 2.0559274283016293e-09
by O 0 4.187597144045263e-11
DNA O 0 2.557935641078757e-09
sequence O 0 6.129661778153661e-10
analysis O 0 4.334601289013307e-10
within O 0 2.473637961131203e-10
the O 0 8.233480564001638e-09
insulin B-Disease 1 0.9930005073547363
- I-Disease 1 0.9999992847442627
dependent I-Disease 1 0.9999954700469971
diabetes I-Disease 1 1.0
mellitus I-Disease 1 1.0
( O 0 2.0864151792920893e-06
IDDM B-Disease 0 8.470530883641914e-05
) O 0 1.706669294776475e-08
locus O 0 3.3863776138787216e-07
IDDM4 O 0 1.892731415864546e-05
on O 0 1.104648390537477e-06
chromosome O 0 4.625253495760262e-05
11q13 O 0 1.5347548469435424e-05
. O 0 3.241600552428281e-07

Based O 0 2.2269659893936478e-07
on O 0 5.058204166630276e-08
its O 0 5.476286535355257e-09
chromosomal O 0 1.9602680367825087e-06
position O 0 2.9168361947995436e-07
, O 0 5.771104705232233e-10
this O 0 1.2963352613581947e-10
gene O 0 6.578127376144494e-09
is O 0 2.9300584181157774e-10
a O 0 7.003752577894318e-10
candidate O 0 1.7821202291656846e-09
for O 0 4.5179104901649225e-10
conferring O 0 2.855566805237686e-08
susceptibility O 0 3.0957775720708014e-07
to O 0 4.6809745413156634e-07
diabetes B-Disease 0 0.17349769175052643
. O 0 4.7010885850795603e-07

The O 0 4.4466158755085416e-08
gene O 0 2.0604399253443262e-07
, O 0 2.9972053727789216e-09
termed O 0 9.684369217666244e-08
low O 0 5.922181298956275e-05
- O 0 7.469150204997277e-06
density O 0 1.6694794879867914e-08
lipoprotein O 0 3.288393202183215e-07
receptor O 0 2.1883620249241176e-08
related O 0 2.8044293998163994e-08
protein O 0 4.767511896375254e-08
5 O 0 1.240533542556932e-08
( O 0 3.2590996568160335e-09
LRP5 O 0 5.015338047087425e-07
) O 0 1.1312465547641537e-10
, O 0 1.9650696000961254e-11
encodes O 0 2.408307164802892e-10
a O 0 1.6339553321476075e-10
protein O 0 3.598814801719641e-09
of O 0 4.392778918393958e-10
1615 O 0 1.041456698658294e-06
amino O 0 1.6977821371000346e-09
acids O 0 4.232430239614615e-10
that O 0 1.355549613529794e-11
contains O 0 1.4690375652048893e-11
conserved O 0 2.440104507339669e-10
modules O 0 1.0987201148893178e-09
which O 0 3.27776916719813e-10
are O 0 9.18878167999182e-11
characteristic O 0 2.340836691150372e-10
of O 0 5.695756366552729e-11
the O 0 2.1320725185347555e-09
low O 0 0.0011711533879861236
- O 0 4.5877208322053775e-05
density O 0 2.809649757296029e-08
lipoprotein O 0 1.3230404874775559e-05
( O 0 4.601121617042736e-08
LDL O 0 4.084220108779846e-06
) O 0 3.6222909116645496e-09
receptor O 0 3.6303298145412555e-08
family O 0 6.641975147658741e-08
. O 0 5.723000384705301e-08

These O 0 7.653036249166689e-08
modules O 0 6.13371398117124e-08
include O 0 1.8493407916153615e-09
a O 0 3.865621600596114e-09
putative O 0 8.039427257244824e-08
signal O 0 1.6994070506370917e-07
peptide O 0 6.127701013269871e-09
for O 0 1.5163674482732148e-10
protein O 0 9.524494526402805e-10
export O 0 1.79153420987177e-08
, O 0 5.710814598991476e-10
four O 0 2.1515671466687536e-09
epidermal O 0 1.0093899760477143e-07
growth O 0 3.142490001550868e-08
factor O 0 1.3656127784145156e-08
( O 0 2.2186883441577265e-09
EGF O 0 1.3220902417288016e-07
) O 0 5.604343655818411e-10
repeats O 0 4.7087858057182075e-09
with O 0 1.9369385262368866e-10
associated O 0 1.9194345668438473e-08
spacer O 0 5.296750259731198e-06
domains O 0 7.32895060195915e-08
, O 0 9.097128605972671e-10
three O 0 1.6129836355460725e-09
LDL O 0 1.6668377611495089e-06
- O 0 1.0809568351533017e-07
receptor O 0 2.9780656163325148e-08
( O 0 5.139709102763845e-09
LDLR O 0 4.684194720994128e-07
) O 0 4.433594880115521e-10
repeats O 0 6.195086221794099e-09
, O 0 2.7296928606368454e-10
a O 0 6.44404196670223e-10
single O 0 8.401654483236598e-09
transmembrane O 0 1.4466809084012766e-08
spanning O 0 1.3967446754747925e-08
domain O 0 1.0244523451774512e-08
, O 0 8.090459413523376e-10
and O 0 4.909808115627357e-10
a O 0 3.748647614543188e-09
cytoplasmic O 0 3.4447083407940227e-07
domain O 0 3.518757978326903e-07
. O 0 1.0338315803437581e-07

The O 0 1.5185078083845838e-08
encoded O 0 4.60525697576486e-08
protein O 0 4.9179856631553776e-08
has O 0 1.5726314694930466e-09
a O 0 2.830079504079208e-10
unique O 0 2.9912528010100914e-10
organization O 0 1.4538196202451559e-09
of O 0 3.555454264336788e-10
EGF O 0 3.790639198086865e-07
and O 0 1.7913498240318404e-08
LDLR O 0 6.2754147620580625e-06
repeats O 0 6.428911092370981e-08
; O 0 6.702942645375742e-10
therefore O 0 1.3201122417427769e-09
, O 0 6.775437433326204e-10
LRP5 O 0 3.313515662739519e-06
likely O 0 6.06648740131277e-08
represents O 0 4.04969002776312e-10
a O 0 4.252481700106614e-10
new O 0 2.3501698365180346e-09
category O 0 1.718451336785165e-08
of O 0 7.726197459589912e-11
the O 0 5.0881783231204736e-09
LDLR O 0 2.435749956930522e-05
family O 0 4.9829093740072494e-08
. O 0 4.324596858396035e-08

Both O 0 1.455437086406164e-07
human O 0 1.3928339370750109e-08
and O 0 2.4177907675948518e-08
mouse O 0 4.800754595635226e-06
LRP5 O 0 7.311018271138892e-05
cDNAs O 0 7.840671969461255e-07
have O 0 7.159008941215461e-09
been O 0 2.65551847178358e-09
isolated O 0 2.8596205403630393e-09
and O 0 2.5956897742318574e-10
the O 0 6.404252822500567e-11
encoded O 0 1.0070794198568933e-09
mature O 0 1.0546273854217247e-09
proteins O 0 2.3607757415611275e-10
are O 0 7.156394227214591e-11
95 O 0 4.49392384416214e-10
% O 0 5.591943574856373e-11
identical O 0 1.1887477668892643e-09
, O 0 2.8934377116485166e-10
indicating O 0 3.34813137214951e-08
a O 0 8.943565887875593e-09
high O 0 2.1863734218641184e-06
degree O 0 5.995353546950355e-08
of O 0 1.5902400229972358e-10
evolutionary O 0 2.0221124774622012e-09
conservation O 0 4.2454392779056604e-10
. O 0 2.016346867250718e-09
. O 0 1.4734117037562555e-08

The O 0 3.2162427032744745e-07
APC B-Disease 0 3.70664861293335e-06
variants O 0 1.843279733293457e-06
I1307K O 0 1.4614934116252698e-06
and O 0 7.314703509564424e-09
E1317Q O 0 9.520506694116193e-08
are O 0 4.0915923427142786e-10
associated O 0 6.130988339236865e-08
with O 1 0.9210351705551147
colorectal B-Disease 1 1.0
tumors I-Disease 1 1.0
, O 0 9.808884016138109e-08
but O 0 1.3596428871665012e-08
not O 0 5.1879300855262045e-09
always O 0 4.433259093161723e-09
with O 0 4.27475381481468e-11
a O 0 9.80721548415886e-09
family O 0 1.7389069739692786e-08
history O 0 3.66729153711276e-08
. O 0 4.908062223307752e-08

Classical O 1 0.8735955953598022
familial B-Disease 1 1.0
adenomatous I-Disease 1 0.9999992847442627
polyposis I-Disease 1 1.0
( O 0 6.031025623087771e-05
FAP B-Disease 0 1.2747475921059959e-05
) O 0 1.8638463217257595e-08
is O 0 1.4822928440239025e-09
a O 0 2.608766003220353e-08
high O 1 0.9626995921134949
- O 1 1.0
penetrance O 1 0.9999743700027466
autosomal B-Disease 1 0.999990701675415
dominant I-Disease 1 0.9995293617248535
disease I-Disease 1 0.6374664902687073
that O 0 2.1819182904891932e-08
predisposes O 0 2.70193709184241e-07
to O 0 1.813844519027441e-09
hundreds O 0 1.5996104441029502e-09
or O 0 4.732104930127434e-09
thousands O 0 7.470362994865809e-09
of O 0 1.93565028894227e-05
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 1 0.9861248135566711
carcinoma I-Disease 1 1.0
and O 0 2.3717047881177677e-08
that O 0 9.23430887311838e-10
results O 0 7.071273344649853e-09
from O 0 7.922241196389734e-10
truncating O 0 7.339582452914328e-08
mutations O 0 7.884291619575379e-08
in O 0 8.906132720198912e-09
the O 0 1.295288587499499e-08
APC B-Disease 0 4.938774509355426e-07
gene O 0 8.07768230970396e-07
. O 0 5.7297615541074265e-08

A O 0 3.0184389743226347e-06
variant O 0 4.776929927174933e-05
of O 0 7.908570154313566e-08
FAP B-Disease 0 4.9079641030402854e-05
is O 0 8.762506809034676e-07
attenuated B-Disease 1 0.9830201268196106
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 0.999996542930603
coli I-Disease 1 1.0
, O 0 5.368873345901193e-08
which O 0 1.3469865223214583e-09
results O 0 2.6077893178211298e-09
from O 0 1.1926084564350958e-09
germ O 0 0.00040026905480772257
- O 0 6.462744931923226e-05
line O 0 2.9831876418029424e-06
mutations O 0 2.8065377577490835e-08
in O 0 2.7059783302973983e-09
the O 0 4.66999217074715e-10
5 O 0 8.703236464846498e-10
and O 0 6.32184971038896e-10
3 O 0 3.076549015545993e-10
regions O 0 2.702217061223422e-10
of O 0 1.8931307910197148e-10
the O 0 6.5608483090784375e-09
APC B-Disease 0 2.842265587332804e-07
gene O 0 5.06546484757564e-07
. O 0 6.384844652984611e-08

Attenuated B-Disease 1 0.9999643564224243
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 0.9999995231628418
coli I-Disease 1 1.0
patients O 1 0.9998840093612671
have O 0 1.2172703236501548e-06
" O 0 1.043881496798349e-07
multiple O 0 2.3253630843100837e-06
" O 1 0.99998939037323
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
( O 0 2.242437524557772e-08
typically O 0 4.111520013339032e-09
fewer O 0 2.3597190867974405e-09
than O 0 3.54944407199298e-10
100 O 0 3.0650457172320955e-10
) O 0 9.966739933364721e-11
without O 0 1.1646439368462325e-09
the O 0 6.289548437621306e-09
florid O 0 2.9775725124636665e-05
phenotype O 0 1.0120751312570064e-06
of O 0 7.167835658350441e-09
classical O 0 9.063050470103917e-07
FAP B-Disease 0 5.679910373146413e-06
. O 0 2.4354696392947517e-07

Another O 0 4.866051313001662e-07
group O 0 3.389375180518073e-08
of O 0 8.659952199785437e-10
patients O 0 3.751760857539921e-08
with O 0 6.762578830254995e-10
multiple O 0 1.1361047569380389e-07
adenomas B-Disease 0 0.0006893243989907205
has O 0 3.366695366935346e-08
no O 0 5.8784483947249555e-09
mutations O 0 8.025772935127407e-09
in O 0 1.414367845065101e-09
the O 0 1.061169041527421e-09
APC B-Disease 0 1.6746268372003215e-08
gene O 0 9.363287922781183e-09
, O 0 4.189293079104317e-10
and O 0 5.108908851525484e-10
their O 0 2.457330783300904e-09
phenotype O 0 1.5887265192304767e-07
probably O 0 5.836611194354191e-07
results O 0 8.86579520908981e-09
from O 0 7.151308434316661e-10
variation O 0 1.1638850772044407e-08
at O 0 2.251738173697504e-08
a O 0 8.172255094862635e-10
locus O 0 7.079856256808625e-09
, O 0 3.8819336634077217e-10
or O 0 1.1425360657568717e-09
loci O 0 5.5360014350469555e-09
, O 0 3.5924485608518353e-10
elsewhere O 0 1.3912595520082505e-08
in O 0 4.066573744410107e-09
the O 0 3.1837181779792445e-09
genome O 0 2.7778961353419618e-08
. O 0 6.743920266671921e-08

Recently O 0 3.918313268513884e-06
, O 0 4.989278767908445e-09
however O 0 1.336835642185008e-09
, O 0 9.138252654583567e-11
a O 0 6.796444518286648e-10
missense O 0 9.301655268245668e-07
variant O 0 1.8114033082383685e-06
of O 0 7.76310071781694e-10
APC B-Disease 0 1.6698926685876359e-07
( O 0 2.6679620734881837e-09
I1307K O 0 1.002471279321071e-07
) O 0 1.0162644059619197e-09
was O 0 4.5176825835824275e-08
described O 0 3.927320246788213e-09
that O 0 4.274918752322776e-10
confers O 0 1.087648304753941e-09
an O 0 1.165207791364864e-10
increased O 0 6.168288280150591e-08
risk O 0 4.637239544535987e-05
of O 0 0.30447903275489807
colorectal B-Disease 1 1.0
tumors I-Disease 1 1.0
, O 0 1.829976348233231e-08
including O 0 1.13908293908338e-09
multiple O 0 1.185266569336818e-07
adenomas B-Disease 0 0.00014079821994528174
, O 0 1.592733767097343e-08
in O 0 4.8297767563099114e-08
Ashkenazim O 0 0.00023427314590662718
. O 0 1.7508823191292322e-07

We O 0 3.637098302533559e-07
have O 0 5.6313163021570745e-09
studied O 0 1.4576492013418374e-08
a O 0 1.528596471622734e-09
set O 0 8.742071955225583e-09
of O 0 6.894814164049023e-10
164 O 0 3.0446850018961413e-07
patients O 0 2.6415173692839744e-07
with O 0 2.6398998542731533e-08
multiple O 1 0.9999845027923584
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 0 0.001992037519812584
/ I-Disease 1 0.9947201013565063
or I-Disease 0 0.26611870527267456
carcinoma I-Disease 1 1.0
and O 0 2.7650466449813393e-07
analyzed O 0 7.153783485591703e-07
codons O 0 4.722765879705548e-06
1263 O 0 2.7319692890159786e-05
- O 0 2.56726943916874e-05
1377 O 0 2.0588384359143674e-05
( O 0 3.6406962777846275e-08
exon O 0 8.016013453016058e-07
15G O 0 1.2842696150983102e-06
) O 0 1.5398098351937506e-09
of O 0 8.2068810081104e-11
the O 0 6.247102279921535e-10
APC B-Disease 0 2.2528379162167766e-08
gene O 0 1.674275473817488e-08
for O 0 1.4301833051177937e-09
germ O 0 9.481784218223765e-05
- O 0 4.574483318720013e-05
line O 0 7.829085006960668e-06
variants O 0 2.6224010980513413e-06
. O 0 1.2483359057569032e-07

Three O 0 7.120106033653428e-07
patients O 0 4.820885806111619e-07
with O 0 4.764461603024017e-10
the O 0 2.1932455851469967e-09
I1307K O 0 4.816005798602419e-07
allele O 0 3.1256033139470674e-07
were O 0 5.23476906266751e-08
detected O 0 9.550115009915316e-08
, O 0 4.3940778793327695e-10
each O 0 1.0546148676571221e-10
of O 0 5.764603239200028e-10
Ashkenazi O 0 4.513200565270381e-06
descent O 0 8.022468591661891e-07
. O 0 5.058020491333082e-08

Four O 0 1.7008188706313376e-06
patients O 0 3.9017827475618105e-06
had O 0 7.403400559269357e-08
a O 0 1.8348240260479542e-08
germ O 0 0.01030138973146677
- O 0 0.00033398359664715827
line O 0 5.386748398450436e-06
E1317Q O 0 1.6194293266380555e-06
missense O 0 8.486921956318838e-07
variant O 0 3.399501906642399e-07
of O 0 4.259065045086885e-10
APC O 0 1.4097415679259484e-08
that O 0 2.03832090095446e-10
was O 0 4.2785917031551435e-09
not O 0 5.6374790252666784e-11
present O 0 9.156358830864075e-12
in O 0 3.5150440891307255e-10
controls O 0 2.2803945398663927e-07
; O 0 5.297658839387154e-11
one O 0 9.347505408596746e-11
of O 0 4.132426605768513e-12
these O 0 2.548009372937976e-11
individuals O 0 3.8903668481138354e-11
had O 0 5.355751113711449e-07
an O 0 1.1421324302984814e-10
unusually O 0 8.701448450665339e-09
large O 0 4.15574824552678e-10
number O 0 1.3310142987776885e-09
of O 0 1.0086923518670687e-09
metaplastic B-Disease 0 9.059801413968671e-06
polyps I-Disease 0 1.804114333481266e-07
of I-Disease 0 2.6124780116987267e-10
the I-Disease 0 4.292430411112491e-09
colorectum I-Disease 0 2.37085578191909e-06
. O 0 8.149878993890525e-08

There O 0 1.3351383643112058e-07
is O 0 6.805018215594316e-10
increasing O 0 7.517882844032542e-11
evidence O 0 2.749397376433649e-10
that O 0 7.566635512601394e-11
there O 0 9.602816458675889e-11
exist O 0 2.708713808807772e-10
germ O 0 1.2767009138769936e-06
- O 0 1.0561461039060305e-07
line O 0 6.795401219505948e-08
variants O 0 1.1663829901920053e-08
of O 0 1.1253543236167118e-10
the O 0 7.573916493974764e-10
APC B-Disease 0 1.2723813114234872e-08
gene O 0 4.343392312478045e-09
that O 0 5.359199195531517e-10
predispose O 0 9.232658193525367e-09
to O 0 2.571577673027292e-10
the O 0 2.7288390991309086e-10
development O 0 1.908358138180688e-09
of O 0 5.96560223442566e-09
multiple O 1 0.9995947480201721
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 1 0.9974963068962097
carcinoma I-Disease 1 1.0
, O 0 2.204583182674469e-08
but O 0 6.473451108490735e-09
without O 0 1.0478302669980621e-09
the O 0 1.1927905330111344e-09
florid O 0 1.8793673007166944e-05
phenotype O 0 5.320248419593554e-07
of O 0 3.402929604767735e-10
classical O 0 7.744223040617726e-08
FAP B-Disease 0 1.0059726207600761e-07
, O 0 5.308524730907038e-10
and O 0 1.7562311327434799e-10
possibly O 0 1.6831247506843283e-09
with O 0 2.0373221165659317e-10
importance O 0 4.5301252526996905e-08
for O 1 0.6514447927474976
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
risk O 0 3.707139910602564e-07
in O 0 2.8612898717028656e-09
the O 0 2.7386262702044917e-10
general O 0 1.5999573887981455e-10
population O 0 1.0525931515292797e-10
. O 0 9.050780125363644e-10
. O 0 1.545489247689602e-08

Genomic O 0 5.2690861593873706e-06
structure O 0 6.795957006033859e-07
of O 0 4.140361831161954e-09
the O 0 3.357013156346511e-08
human O 0 8.163137863448355e-06
congenital B-Disease 1 1.0
chloride I-Disease 1 0.9999980926513672
diarrhea I-Disease 1 1.0
( O 0 2.0277841031202115e-05
CLD B-Disease 0 0.0077673583291471004
) O 0 7.008382851836359e-08
gene O 0 1.505471914242662e-06
. O 0 2.1238187741801084e-07

Congenital B-Disease 1 1.0
chloride I-Disease 1 0.9999991655349731
diarrhea I-Disease 1 1.0
( O 0 0.0007108332356438041
CLD B-Disease 1 0.9417659640312195
) O 0 3.579613760962275e-08
is O 0 2.351631556152256e-09
caused O 0 2.3698598639043666e-08
by O 0 1.649242076240398e-09
mutations O 0 6.520480866356593e-08
in O 0 5.1327924133204306e-09
a O 0 2.539124022149508e-09
gene O 0 2.5817882942646975e-08
which O 0 4.165821021473448e-09
encodes O 0 7.701564186390897e-08
an O 0 3.111143698220076e-08
intestinal O 0 5.540955680771731e-05
anion O 0 7.804173037584405e-06
transporter O 0 0.00020443342509679496
. O 0 4.4399126863936544e-07

We O 0 6.855852916487493e-07
report O 0 2.7634904142814776e-08
here O 0 1.9216315205738965e-09
the O 0 9.994914618172146e-11
complete O 0 5.431138316858153e-10
genomic O 0 2.72214495389278e-09
organization O 0 5.166972405490355e-10
of O 0 2.2445406644422405e-10
the O 0 2.6493867100185753e-09
human O 0 8.972475207258412e-09
CLD B-Disease 0 1.0711862159951124e-05
gene O 0 1.0654879645244364e-07
which O 0 4.0458241201690726e-09
spans O 0 1.8541697954788106e-08
approximately O 0 2.3756832057131305e-09
39kb O 0 1.3692900893147453e-06
, O 0 2.3744239907586007e-09
and O 0 2.072819249576696e-09
comprises O 0 1.4630159306250334e-09
21 O 0 5.392024959860464e-08
exons O 0 4.780040399054997e-07
. O 0 8.157778808026706e-08

All O 0 1.2399685545005923e-07
exon O 0 2.570482820374309e-06
/ O 0 1.2771843103109859e-06
intron O 0 3.834605195152108e-06
boundaries O 0 2.2304176638954232e-07
conform O 0 6.232647251636081e-07
to O 0 3.796982728232479e-09
the O 0 2.0792985111484086e-08
GT O 0 5.2903516916558146e-05
/ O 0 6.771366315660998e-05
AG O 1 0.990122377872467
rule O 0 1.3679273251909763e-06
. O 0 1.5901892425063124e-07

An O 0 1.894147416692249e-08
analysis O 0 7.4228951874033555e-09
of O 0 3.0308164311598773e-10
the O 0 1.721570441759468e-09
putative O 0 9.02360497434529e-08
promoter O 0 3.905018957084394e-07
region O 0 1.8862339246084048e-08
sequence O 0 1.468176957786227e-08
shows O 0 3.2549827722050395e-08
a O 0 2.0529622446474605e-08
putative O 0 1.0862639783226768e-06
TATA O 0 4.834715946344659e-05
box O 0 4.2963890223290946e-07
and O 0 9.087924190964713e-09
predicts O 0 6.027963195265329e-08
multiple O 0 6.170345123734933e-09
transcription O 0 9.428057268223711e-08
factor O 0 1.174016350802276e-08
binding O 0 3.766164624607882e-08
sites O 0 2.1006715655857988e-07
. O 0 8.458093958552126e-08

The O 0 2.9159339831608122e-08
genomic O 0 1.2337405053131079e-07
structure O 0 1.0004445982758625e-07
was O 0 4.83229243286587e-08
determined O 0 1.2515700698045862e-09
using O 0 1.5565111421977917e-09
DNA O 0 1.145316286255138e-08
from O 0 2.899746831541705e-10
several O 0 1.6227587329442628e-10
sources O 0 6.906054061950329e-10
including O 0 6.752225861772487e-11
multiple O 0 8.858116462562293e-10
large O 0 8.456348510321732e-09
- O 0 0.0018324152333661914
insert O 0 1.9407962099649012e-05
libaries O 0 2.338885224162368e-06
and O 0 3.1915734499676773e-09
genomic O 0 3.126359970906378e-08
DNA O 0 1.1219974282994372e-07
from O 0 2.0066874384383482e-08
Finnish O 0 1.711938966764137e-05
CLD B-Disease 0 0.002925099804997444
patients O 0 6.5827507569338195e-06
and O 0 4.291998578764833e-08
controls O 0 3.7084023460920434e-06
. O 0 2.4703311396478966e-07

Exon O 0 5.234792843111791e-05
- O 0 7.3059190981439315e-06
specific O 0 3.8766174270676856e-08
primers O 0 1.48199899285828e-06
developed O 0 1.0134527173022434e-07
in O 0 1.6661584112398486e-08
this O 0 2.329998693983981e-10
study O 0 1.494442208871405e-10
will O 0 1.239151281584583e-10
facilitate O 0 7.861459261349069e-10
mutation O 0 5.1948516599509276e-09
screening O 0 9.279690793562168e-09
studies O 0 2.169997737055951e-09
of O 0 2.6416702159082206e-10
patients O 0 1.9211046975442514e-08
with O 0 6.351316139685537e-10
the O 0 1.3611276017400087e-07
disease O 0 3.602675496949814e-05
. O 0 2.237930516457709e-07

Genomic O 0 1.0299528184987139e-05
sequencing O 0 1.0839119113370543e-06
of O 0 8.085126346202287e-09
a O 0 6.33268086858152e-08
BAC O 0 0.001226471271365881
clone O 0 6.683324318146333e-05
H O 1 1.0
_ O 0 1.0338236933193912e-07
RG364P16 O 0 2.0878870543583616e-07
revealed O 0 2.892292982892286e-08
the O 0 1.1580556652512897e-10
presence O 0 1.4711803997258244e-10
of O 0 1.1428138817215494e-11
another O 0 3.510026158615176e-10
, O 0 6.273619124197438e-11
highly O 0 2.4309670942912476e-10
homologous O 0 1.8267914958514098e-09
gene O 0 1.0298164099253881e-08
3 O 0 3.852137719917437e-09
of O 0 2.505036178490627e-10
the O 0 1.2156927908790749e-08
CLD B-Disease 0 2.3998825781745836e-05
gene O 0 4.2089677521062185e-08
, O 0 7.291200421200017e-10
with O 0 4.396691344332737e-11
a O 0 7.694656023460311e-10
similar O 0 2.8569928645083564e-09
genomic O 0 2.53201601907449e-08
structure O 0 6.535035623755903e-08
, O 0 7.909438104469757e-10
recently O 0 1.3451129987629429e-08
identified O 0 1.1746815964386315e-08
as O 0 1.1877057559672721e-08
the O 0 5.311930181051139e-06
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
gene O 0 1.1785834431066178e-05
( O 0 1.3001913146126753e-07
PDS B-Disease 0 9.689551916380879e-06
) O 0 4.4515271468981155e-09
. O 0 7.288367687152686e-09
. O 0 3.304961282424301e-08

The O 0 2.7698365556716453e-07
APCI1307K O 0 0.00019004331261385232
allele O 0 3.158071922371164e-05
and O 0 6.040336302248761e-07
cancer B-Disease 0 5.198905910219764e-06
risk O 0 6.178862577144173e-08
in O 0 1.9102264214865272e-09
a O 0 2.1349211287713388e-09
community O 0 2.241410168579705e-09
- O 0 1.0356591673144067e-07
based O 0 3.681446703041047e-09
study O 0 2.86377965785789e-09
of O 0 1.348906986109455e-09
Ashkenazi O 0 5.075532385490078e-07
Jews O 0 4.7023078764141246e-08
. O 0 3.534692893936153e-08

Mutations O 0 0.00013046625826973468
in O 0 5.048681259722798e-07
APC O 0 4.7170856305456255e-06
are O 0 1.1546361200487354e-08
classically O 0 3.4911310649476945e-05
associated O 0 1.2253489103386528e-06
with O 0 1.7703532648738474e-05
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 0 1.1145678399770986e-05
FAP B-Disease 0 5.793029686174123e-06
) O 0 1.6903447530580706e-08
, O 0 1.6528951540806247e-09
a O 0 5.330629093691641e-08
highly O 0 0.0014591340441256762
penetrant O 1 0.9999961853027344
autosomal B-Disease 1 1.0
dominant I-Disease 1 1.0
disorder I-Disease 1 1.0
characterized O 0 0.0001740598672768101
by O 0 2.1076104417261377e-07
multiple O 0 6.288314034463838e-05
intestinal O 1 0.9944063425064087
polyps B-Disease 0 0.0002121056750183925
and O 0 2.9648658639302994e-08
, O 0 6.180058687021983e-10
without O 0 8.745770774254424e-10
surgical O 0 3.447390781730064e-06
intervention O 0 2.0215124152400676e-07
, O 0 1.0083192059084922e-09
the O 0 4.0706843451587815e-10
development O 0 2.2556756462677185e-08
of O 0 0.008590864948928356
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 4.7388454049723805e-07
CRC B-Disease 0 9.152548045676667e-06
) O 0 3.262752201749208e-08
. O 0 1.2766724921675632e-07

APC B-Disease 0 0.00015527154027950019
is O 0 2.280729347603483e-07
a O 0 1.1098468348791357e-06
tumour O 1 1.0
- O 0 0.00144227035343647
suppressor O 0 1.1383642231521662e-05
gene O 0 1.0721925036705215e-06
, O 0 5.90147886114778e-09
and O 0 7.151271130823034e-09
somatic O 0 1.01637715488323e-06
loss O 0 6.056018264644081e-06
occurs O 0 1.5257171526172897e-07
in O 0 2.2299036572803743e-06
tumours B-Disease 1 0.9999998807907104
. O 0 1.456763470741862e-06

The O 0 2.852717670975835e-07
germline O 0 3.8496542401844636e-05
T O 0 6.362215935951099e-05
- O 0 1.4841333495496656e-06
to O 0 1.2913490721189191e-08
- O 0 7.09725213710044e-07
A O 0 4.3309444919259477e-08
transversion O 0 2.698288312785735e-07
responsible O 0 2.618989913827363e-09
for O 0 2.886107186572673e-10
the O 0 1.2839239671436076e-09
APC O 0 1.0199334354865641e-07
I1307K O 0 6.096216509376973e-08
allele O 0 1.2454867714950524e-07
converts O 0 3.8063095786355916e-08
the O 0 1.8292914960582607e-09
wild O 0 1.3537223786386221e-08
- O 0 2.323872507759006e-07
type O 0 9.514570820101653e-08
sequence O 0 2.586587610764468e-09
to O 0 9.624421259957217e-10
a O 0 3.7322401169603836e-08
homopolymer O 0 0.0002639012527652085
tract O 0 0.00010008824028773233
( O 0 1.7378757988240068e-08
A8 O 0 9.179760127153713e-06
) O 0 4.2182859982808907e-10
that O 0 3.879387366900744e-10
is O 0 6.200603364092672e-10
genetically O 0 1.5843778555790777e-07
unstable O 0 0.0001199556136270985
and O 0 2.625554316182388e-07
prone O 0 7.260897518790443e-07
to O 0 7.602214857627132e-09
somatic O 0 1.8362475202593487e-06
mutation O 0 2.0966756437701406e-06
. O 0 3.020749090865138e-07

The O 0 3.0034792075639416e-07
I1307K O 0 2.536284910092945e-06
allele O 0 1.7340699969281559e-06
was O 0 3.26785993820522e-07
found O 0 1.7122415485459896e-08
in O 0 8.848343391321123e-09
6 O 0 4.305921663672052e-08
. O 0 2.290485134892606e-08

1 O 0 3.1609604889126786e-07
% O 0 6.526413187657454e-09
of O 0 7.222658582328734e-10
unselected O 0 2.7997055440209806e-05
Ashkenazi O 0 5.246061391517287e-06
Jews O 0 1.3978000978909222e-08
and O 0 2.5873867492975933e-09
higher O 0 2.1798758353952508e-08
proportions O 0 1.1873840577436567e-08
of O 0 1.0919489756844314e-09
Ashkenazim O 0 3.055988418054767e-05
with O 0 2.0162740366203025e-09
family O 0 3.232879963732671e-09
or O 0 4.125730868054234e-09
personal O 0 2.6324983082304243e-08
histories O 0 2.7895168841496343e-07
of O 0 2.541822974322372e-09
CRC B-Disease 0 4.180567430012161e-06
( O 0 1.0240810865980166e-08
ref O 0 6.2659778450324666e-06
. O 0 2.4800024256421693e-09
2 O 0 5.57831336678305e-09
) O 0 3.891677202716437e-09
. O 0 2.2945386035644333e-08

To O 0 6.811855257637944e-08
evaluate O 0 2.6871758151969516e-08
the O 0 6.667621454958805e-10
role O 0 2.137316768013875e-09
of O 0 1.1392713161750834e-10
I1307K O 0 8.799640482948234e-08
in O 0 4.2443584646889576e-08
cancer B-Disease 0 5.655839458995615e-07
, O 0 1.7876080615764067e-09
we O 0 6.842075794821767e-09
genotyped O 0 1.4030334227754793e-07
5 O 0 4.14526102332502e-09
, O 0 4.1840086950628574e-09
081 O 0 2.0074758140253834e-06
Ashkenazi O 0 4.810442533198511e-07
volunteers O 0 2.020477785080743e-09
in O 0 7.719322403509921e-10
a O 0 4.1247631976659704e-09
community O 0 3.0007802909182146e-09
survey O 0 1.6334605845713668e-07
. O 0 2.1059605614937027e-08

Risk O 0 7.626291790074902e-06
of O 0 9.388074317939754e-09
developing O 0 0.0002434321359032765
colorectal B-Disease 1 1.0
, I-Disease 0 4.244303909217706e-06
breast I-Disease 0 0.00025592881138436496
and I-Disease 0 2.1852341092198913e-07
other I-Disease 0 1.141640737500893e-07
cancers I-Disease 0 1.6437930753454566e-05
were O 0 7.581873262552108e-08
compared O 0 9.268758205394079e-09
between O 0 3.845750384812163e-09
genotyped O 0 1.2894755627712584e-06
I1307K O 0 1.032302563430676e-07
carriers O 0 2.209057647917234e-08
and O 0 5.681111692190655e-10
non O 0 1.8322291239769584e-08
- O 0 4.853195179066461e-08
carriers O 0 1.6372919020568588e-08
and O 0 2.1081326961880364e-10
their O 0 1.5216201909584726e-10
first O 0 3.3925040554549923e-09
- O 0 1.4552524874034134e-07
degree O 0 1.1615657768970777e-07
relatives O 0 1.4461464559190063e-07
. O 0 3.453219932225693e-08

Sperm O 0 4.1083894757321104e-06
DNA O 0 1.0750615047072642e-06
analysis O 0 4.684171983626584e-08
in O 0 7.6097741441572e-09
a O 0 2.2417134459828958e-07
Friedreich B-Disease 0 0.21559587121009827
ataxia I-Disease 1 0.9949222207069397
premutation O 0 0.002268455224111676
carrier O 0 1.890781095426064e-05
suggests O 0 1.1376052810874171e-07
both O 0 3.4872194021318137e-09
meiotic O 0 7.411608748952858e-07
and O 0 6.224625703765696e-09
mitotic O 0 1.2225237355778518e-07
expansion O 0 3.099298240272219e-08
in O 0 6.023364029772438e-09
the O 0 5.515712331316536e-09
FRDA B-Disease 0 1.9335354863869725e-06
gene O 0 6.810425929870689e-07
. O 0 1.3388194020080846e-07

Friedreich B-Disease 1 0.9993118047714233
ataxia I-Disease 1 0.9999570846557617
is O 0 2.518309656807105e-06
usually O 0 1.1053000292804427e-07
caused O 0 1.9432681241937644e-08
by O 0 1.954838929618674e-10
an O 0 1.346528583079376e-10
expansion O 0 8.080038860214245e-09
of O 0 4.1715361720484623e-10
a O 0 3.979410578835996e-08
GAA O 0 3.077434939768864e-06
trinucleotide O 0 1.8246303170599276e-06
repeat O 0 2.995489865043055e-07
in O 0 9.657857624745247e-09
intron O 0 4.285642773993459e-07
1 O 0 2.4370916396065923e-09
of O 0 3.2838703978299577e-10
the O 0 3.5309983825726476e-09
FRDA B-Disease 0 3.2987190934363753e-06
gene O 0 4.338497774369898e-07
. O 0 9.816501744808193e-08

Occasionally O 0 3.4428469462000066e-06
, O 0 6.484016434882278e-09
a O 0 9.09445685426391e-10
fully O 0 3.131550574408948e-09
expanded O 0 8.450011357297171e-09
allele O 0 7.246301692021007e-08
has O 0 1.3921745978251465e-09
been O 0 9.730036776289808e-10
found O 0 3.568580153601175e-10
to O 0 1.0126629396145503e-10
arise O 0 3.69724278970196e-10
from O 0 3.606474285877681e-10
a O 0 3.728574338168755e-09
premutation O 0 1.9776167903273745e-07
of O 0 1.723238357564938e-10
100 O 0 1.6663070923073064e-09
or O 0 6.975745758808216e-09
less O 0 7.841818927545319e-08
triplet O 0 7.702614311710931e-06
repeats O 0 1.9366580090718344e-06
. O 0 1.5833718691737886e-07

We O 0 3.4919875702144054e-07
have O 0 5.070516895244737e-09
examined O 0 1.0002362493821693e-08
the O 0 2.4677707100018154e-10
sperm O 0 8.185737421229078e-09
DNA O 0 1.3950140598240068e-08
of O 0 2.0686830026761527e-10
a O 0 6.34308694458241e-09
premutation O 0 6.549812951561762e-06
carrier O 0 5.783479537058156e-06
. O 0 1.4646799684214784e-07

This O 0 1.4299472184120532e-07
mans O 0 4.6670547817484476e-06
leucocyte O 0 6.361278792610392e-06
DNA O 0 8.916501883504679e-07
showed O 0 3.346443122609344e-07
one O 0 2.6806119546307627e-09
normal O 0 1.5273002418325632e-08
allele O 0 1.842536505591852e-07
and O 0 2.4459443359603483e-09
one O 0 6.126131824046865e-10
allele O 0 1.8846911586933857e-08
of O 0 1.3914995544705988e-10
approximately O 0 1.2326057952094516e-09
100 O 0 1.4916473389803286e-08
repeats O 0 5.743722226725367e-07
. O 0 9.750183238566024e-08

His O 0 4.2244906239830016e-07
sperm O 0 6.016815632392536e-07
showed O 0 1.1867177818203345e-07
an O 0 3.6762526356426406e-10
expanded O 0 4.4858072811848615e-09
allele O 0 2.2517774311836547e-07
in O 0 2.4398742581865918e-08
a O 0 4.355506888487071e-08
tight O 0 1.7553828001837246e-05
range O 0 3.4086365729990575e-08
centering O 0 6.58776002637751e-08
on O 0 8.768444814677423e-08
a O 0 2.4737709658495532e-09
size O 0 3.0990483512738365e-09
of O 0 2.739838356191626e-10
approximately O 0 7.751549624401832e-09
320 O 0 2.861474968085531e-07
trinucleotide O 0 1.2925738701596856e-05
repeats O 0 5.742721441492904e-06
. O 0 2.672104528755881e-07

His O 0 3.024172883669962e-06
affected O 0 1.9239780613133917e-06
son O 0 5.0356684369035065e-06
has O 0 5.205732289681464e-09
repeat O 0 4.738555858807558e-08
sizes O 0 6.163396193414883e-08
of O 0 1.4278065396666761e-09
1040 O 0 5.533939315682801e-07
and O 0 2.0190457306057397e-08
540 O 0 9.111981853493489e-07
. O 0 6.147722331206751e-08

These O 0 3.0318947352725445e-08
data O 0 7.710820426609644e-09
suggest O 0 1.4517524959956063e-09
that O 0 7.806334745286136e-11
expansion O 0 1.4899319555894408e-09
occurs O 0 2.026598194815321e-10
in O 0 1.1742569416828275e-10
two O 0 1.2400165616544e-10
stages O 0 1.536655802603093e-09
, O 0 7.277594499255358e-11
the O 0 6.153485360149702e-11
first O 0 1.3685795829943004e-09
during O 0 1.1897774987446041e-09
meiosis O 0 1.0730513144707743e-09
followed O 0 2.8606117474794246e-10
by O 0 1.40483888411147e-10
a O 0 2.780895291820684e-09
second O 0 4.013085685983242e-08
mitotic O 0 4.6387040697482007e-07
expansion O 0 3.7329240853978263e-07
. O 0 1.0029015840018474e-07

We O 0 2.5587428353901487e-07
also O 0 5.016474347030453e-09
show O 0 6.3084351076270195e-09
that O 0 1.4636822309732622e-10
in O 0 2.5552132632000735e-10
all O 0 1.3324513714607633e-10
informative O 0 3.3534790500056033e-09
carrier O 0 2.148426858639141e-08
father O 0 3.2740281596943532e-09
to O 0 3.8802014379335503e-10
affected O 0 3.6849310269815305e-09
child O 0 3.713564922236401e-08
transmissions O 0 1.1313469485685346e-06
, O 0 4.163515643362814e-10
with O 0 2.5113593496439712e-11
the O 0 6.775111027756964e-11
notable O 0 3.3150657219316315e-10
exception O 0 6.601326152377851e-10
of O 0 5.4733991644573265e-11
the O 0 7.456493755775284e-10
premutation O 0 2.976828454848146e-07
carrier O 0 5.049875184681696e-08
, O 0 2.8999572188048717e-10
the O 0 1.2771797508470684e-10
expansion O 0 4.245392926094382e-09
size O 0 7.802874790741043e-09
decreases O 0 1.2163862805891767e-08
. O 0 2.395608600380683e-09
. O 0 1.597833509947577e-08

The O 0 2.758593495855166e-07
R496H O 0 3.7856134440517053e-06
mutation O 0 2.2774561614369304e-07
of O 0 1.0028738950396132e-09
arylsulfatase O 0 2.5917602215486113e-06
A O 0 2.968278636217292e-07
does O 0 1.2083648925909074e-07
not O 0 3.0811656870355364e-07
cause O 0 7.928300874482375e-06
metachromatic B-Disease 1 1.0
leukodystrophy I-Disease 1 0.9999971389770508
. O 0 2.2281776637100847e-06

Deficiency B-Disease 1 0.9999129772186279
of I-Disease 0 7.719830108499082e-08
arylsulfatase I-Disease 0 9.798627434065565e-05
A I-Disease 0 1.1509836213008384e-06
( O 0 6.344783542999721e-08
ARSA O 0 5.014496491639875e-05
) O 0 1.9528322070527793e-08
enzyme O 0 5.421202899924538e-07
activity O 0 2.907392627093941e-06
causes O 0 1.3649076208821498e-05
metachromatic B-Disease 1 1.0
leukodystrophy I-Disease 1 1.0
( O 0 0.00013939847121946514
MLD B-Disease 1 0.9999967813491821
) O 0 4.0169152271118946e-07
. O 0 2.325393353430627e-07

A O 0 8.6799343534949e-07
number O 0 2.1870349087294016e-08
of O 0 5.891087173637288e-09
ARSA O 0 0.00013828084047418088
gene O 0 1.010503069664992e-06
mutations O 0 4.857585054196534e-07
responsible O 0 1.9653423777299395e-08
for O 0 1.6956471782236804e-08
MLD B-Disease 1 0.9999998807907104
have O 0 7.904046128714981e-08
been O 0 3.8515665323757275e-08
identified O 0 6.01709686520735e-08
. O 0 1.5765307281867535e-08

Recently O 0 3.023890030817711e-06
, O 0 6.405261654407468e-09
the O 0 9.590759297850582e-10
R496H O 0 6.261135609975099e-08
mutation O 0 1.1245679942817333e-08
of O 0 5.007504411125296e-10
ARSA O 0 1.9322715161251836e-05
was O 0 2.045114477766674e-08
proposed O 0 3.0177335630376945e-10
to O 0 1.17664475385304e-10
be O 0 1.1100950159104173e-09
a O 0 2.994479553208862e-09
cause O 0 6.426471088616381e-08
of O 0 2.1089268997798172e-08
MLD B-Disease 1 0.9999998807907104
( O 0 2.584123315330089e-08
Draghia O 0 5.747185127802368e-07
et O 0 2.1225592661267e-07
al O 0 1.245096541424573e-06
. O 0 4.275084286575748e-09
, O 0 5.704630656744314e-10
1997 O 0 2.033506918408534e-09
) O 0 1.9742758539109673e-09
. O 0 1.0268272454538874e-08

We O 0 2.537325087814679e-07
have O 0 8.3887963242546e-09
investigated O 0 1.3716900504334717e-08
the O 0 5.91781901260191e-10
R496H O 0 5.3023576640498504e-08
mutation O 0 1.0725035082259637e-08
and O 0 3.476445797900851e-10
found O 0 7.039605010028538e-10
this O 0 3.906115014773448e-11
mutation O 0 1.2432711526955131e-09
at O 0 1.4287110383648383e-09
a O 0 4.4689985045920366e-10
relatively O 0 4.529120189999958e-09
high O 0 5.092207544521443e-09
frequency O 0 1.600013987967941e-08
in O 0 2.106521845846032e-09
an O 0 1.4999623765277192e-10
African O 0 3.364278577944191e-10
American O 0 4.5819992244844343e-10
population O 0 3.449817861933546e-11
( O 0 2.682559174793653e-10
f O 0 4.989071911154497e-08
= O 0 8.005026863600051e-09
0 O 0 2.0003771972199047e-09
. O 0 1.1969838453751436e-09
09 O 0 5.450518969496443e-08
, O 0 5.124064506034642e-10
n O 0 2.420337708031184e-08
= O 0 9.192773831045997e-08
61 O 0 9.152255131539277e-08
subjects O 0 1.115774352911103e-07
) O 0 1.1321414028486743e-08
. O 0 3.782924551387623e-08

The O 0 7.533495249845146e-07
ARSA O 0 9.433209197595716e-05
enzyme O 0 4.700559372849966e-07
activity O 0 1.4018215210853668e-07
in O 0 2.664412468433852e-09
subjects O 0 4.00555144608461e-09
with O 0 1.540808036715191e-10
and O 0 4.588786017833968e-10
without O 0 3.748874266573665e-10
the O 0 6.459707768691203e-10
R496H O 0 7.251154698906248e-08
mutation O 0 5.0082329394740555e-09
was O 0 3.7687804876895825e-08
determined O 0 4.629032268610445e-09
and O 0 6.885352288321656e-10
found O 0 1.3740092397185322e-09
to O 0 2.7958971249297804e-10
be O 0 2.5339037534877207e-09
normal O 0 5.096407917903889e-08
. O 0 3.898156819559517e-08

It O 0 1.6408284864155576e-07
is O 0 1.8076313779147313e-09
therefore O 0 7.600312046385227e-10
concluded O 0 2.4657111907799845e-09
that O 0 9.521110982957381e-11
the O 0 2.0827219116004159e-10
R496H O 0 5.368913846837131e-08
mutation O 0 7.98014809788583e-09
of O 0 2.54142928923784e-10
ARSA O 0 3.2055754672910552e-06
does O 0 7.520371880787025e-09
not O 0 1.256940662663908e-09
negatively O 0 2.920407471407316e-09
influence O 0 1.0738825384493111e-09
the O 0 3.485987332130236e-10
activity O 0 8.742005341844106e-09
of O 0 1.822913209270638e-10
ARSA O 0 2.553200147303869e-06
and O 0 2.1211574718904558e-09
is O 0 2.1314412734785293e-10
not O 0 5.661619506547311e-10
a O 0 6.1565672559993345e-09
cause O 0 1.7932526930053427e-07
of O 0 1.7739047564191424e-07
MLD B-Disease 1 0.9999978542327881

Down O 0 0.0004887830000370741
- O 0 4.489860657486133e-05
regulation O 0 1.1890292626048904e-06
of O 0 1.0338410127985753e-08
transmembrane O 0 2.5987349090428324e-06
carbonic O 0 5.323236473486759e-05
anhydrases O 0 9.470414079260081e-05
in O 0 2.9237613489385694e-05
renal B-Disease 1 0.9999973773956299
cell I-Disease 1 0.9999995231628418
carcinoma I-Disease 1 1.0
cell O 0 0.0002192498359363526
lines O 0 1.016655346575135e-06
by O 0 7.1155281666790415e-09
wild O 0 2.5234950840058445e-07
- O 0 6.424886669265106e-05
type O 0 0.07726075500249863
von B-Disease 1 0.9999755620956421
Hippel I-Disease 1 0.995674192905426
- I-Disease 1 0.7539387941360474
Lindau I-Disease 0 0.38043636083602905
transgenes O 0 0.0010115987388417125
. O 0 3.1791678338777274e-06

To O 0 1.753924010472474e-07
discover O 0 2.7439108407634194e-07
genes O 0 1.0451126541966005e-07
involved O 0 3.479348009705063e-08
in O 0 1.7766305404620653e-07
von B-Disease 1 0.9991375207901001
Hippel I-Disease 1 0.999506950378418
- I-Disease 1 0.9999237060546875
Lindau I-Disease 1 0.9993420243263245
( O 0 3.3514606911921874e-07
VHL B-Disease 0 5.484223220264539e-05
) O 0 2.9738540519019807e-08
- O 0 7.595545412186766e-06
mediated O 0 1.9320725186844356e-05
carcinogenesis O 0 0.00016028394747991115
, O 0 2.059547377086801e-08
we O 0 1.2912603430947911e-08
used O 0 2.979769988087355e-06
renal B-Disease 1 0.9999872446060181
cell I-Disease 1 0.9999994039535522
carcinoma I-Disease 1 1.0
cell O 0 0.03389871120452881
lines O 0 4.72191022709012e-05
stably O 0 4.858634201809764e-05
transfected O 0 8.301831257995218e-06
with O 0 4.89798068770142e-08
wild O 0 3.6971093209103856e-07
- O 0 0.005205768626183271
type O 1 0.7342526912689209
VHL O 1 0.7629455924034119
- O 0 0.0001694180245976895
expressing O 0 6.975375299589359e-07
transgenes O 0 9.414606756763533e-05
. O 0 8.792155199444096e-07

Large O 0 9.97264578472823e-07
- O 0 9.9510343716247e-06
scale O 0 4.4645560137723805e-07
RNA O 0 2.3036538721044053e-07
differential O 0 1.1079553274839782e-07
display O 0 2.373469598637712e-08
technology O 0 3.3284123901466955e-07
applied O 0 5.658145951770166e-09
to O 0 2.573614099610211e-10
these O 0 3.3339236926721583e-10
cell O 0 1.044660251636742e-07
lines O 0 1.1185593962181883e-07
identified O 0 1.0159237895379647e-08
several O 0 5.279646164702001e-10
differentially O 0 1.0806925132555989e-08
expressed O 0 6.727970403019867e-10
genes O 0 3.6207918885367008e-09
, O 0 1.4835112305267018e-10
including O 0 1.1061336568918279e-10
an O 0 7.424789671972576e-10
alpha O 0 9.291241553910368e-08
carbonic O 0 8.645096727377677e-07
anhydrase O 0 3.163320343446685e-06
gene O 0 1.1368736068106955e-06
, O 0 2.0934853850462787e-08
termed O 0 1.6326350760209607e-06
CA12 O 0 0.00011016728240065277
. O 0 2.889178460918629e-07

The O 0 5.034420524907546e-08
deduced O 0 7.247795252851574e-08
protein O 0 2.7369580379854597e-08
sequence O 0 5.067374964085047e-09
was O 0 2.5134092140888242e-08
classified O 0 4.056842861643872e-09
as O 0 6.377293138015716e-10
a O 0 1.1705366675940354e-09
one O 0 3.8987071349083635e-08
- O 0 8.00534962763777e-06
pass O 0 5.606785862255492e-07
transmembrane O 0 1.7321943346360058e-07
CA O 0 7.464283271474415e-07
possessing O 0 5.794612345511041e-09
an O 0 3.536395065673048e-10
apparently O 0 5.707096661922151e-08
intact O 0 1.7506575744619113e-08
catalytic O 0 1.9820417307414573e-08
domain O 0 2.4718751490127033e-09
in O 0 8.491189973369728e-10
the O 0 3.203099341320126e-09
extracellular O 0 1.2556574802147225e-07
CA O 0 8.61259686644189e-05
module O 0 7.90873457390262e-07
. O 0 5.08619173444913e-08

Reintroduced O 0 3.744241621461697e-05
wild O 0 4.683457973442273e-06
- O 0 0.0010241458658128977
type O 0 6.291997851803899e-05
VHL B-Disease 0 6.613849836867303e-05
strongly O 0 1.4543007864631363e-07
inhibited O 0 2.756831349870481e-07
the O 0 1.733306498330478e-09
overexpression O 0 2.2463160220809186e-08
of O 0 1.3343129379173035e-10
the O 0 6.252752760005365e-10
CA12 O 0 3.522847578096844e-07
gene O 0 3.1506520059565446e-08
in O 0 1.0397637417725036e-08
the O 0 6.397010565706296e-08
parental O 0 0.000452410924481228
renal B-Disease 1 0.9998829364776611
cell I-Disease 1 0.9999947547912598
carcinoma I-Disease 1 1.0
cell O 0 0.03053097240626812
lines O 0 0.00018341484246775508
. O 0 1.42457236051996e-06

Similar O 0 3.6859316310255963e-07
results O 0 1.4549749494108255e-07
were O 0 4.05104394474165e-09
obtained O 0 7.70032315688951e-10
with O 0 2.2886487149875734e-10
CA9 O 0 1.5924633771646768e-05
, O 0 4.4914560959341543e-10
encoding O 0 3.3961491396894417e-09
another O 0 6.9484307196887585e-09
transmembrane O 0 7.74661543800903e-08
CA O 0 7.2685575105424505e-06
with O 0 6.447496425643351e-10
an O 0 2.6049209456147082e-09
intact O 0 1.52292884081362e-07
catalytic O 0 7.508392059207836e-07
domain O 0 3.904940513166366e-07
. O 0 9.857591720674463e-08

Although O 0 3.356738318416319e-07
both O 0 6.5646159619348055e-09
domains O 0 1.1480436157285112e-08
of O 0 1.6669514379952233e-10
the O 0 1.5974700451337753e-09
VHL B-Disease 0 5.211298912399798e-07
protein O 0 8.615145041801497e-09
contribute O 0 1.3364990225639417e-09
to O 0 4.6536935416341407e-10
regulation O 0 3.489230238074015e-08
of O 0 3.623132072139157e-10
CA12 O 0 4.538427447187132e-07
expression O 0 6.45285158640263e-09
, O 0 4.2761746921193833e-10
the O 0 5.828750815339845e-10
elongin O 0 1.1454369541752385e-07
binding O 0 1.5562269695124087e-08
domain O 0 1.6639607025581427e-08
alone O 0 1.577210362313508e-08
could O 0 2.0090119789983873e-08
effectively O 0 5.3738112626433576e-08
regulate O 0 1.0880991112571792e-06
CA9 O 0 0.00010174550698138773
expression O 0 4.1819487250904785e-07
. O 0 2.271352457228204e-07

We O 0 2.1068137812108034e-06
mapped O 0 5.06868127558846e-06
CA12 O 0 7.564167026430368e-05
and O 0 6.990106271587138e-08
CA9 O 0 2.700919321796391e-05
loci O 0 3.643100399131072e-07
to O 0 3.4554073380377304e-08
chromosome O 0 5.3536746236204635e-06
bands O 0 2.2765359517507022e-06
15q22 O 0 3.2512152756680734e-06
and O 0 1.0574845532573818e-07
17q21 O 0 5.247487479209667e-06
. O 0 1.3458422642997903e-07

2 O 0 4.1938542949537805e-07
respectively O 0 5.923449108991008e-08
, O 0 9.172588799621906e-10
regions O 0 3.57143514762015e-09
prone O 0 3.1513346243627893e-07
to O 0 1.3313037339202083e-09
amplification O 0 6.505759841957115e-08
in O 0 3.965165085162425e-09
some O 0 3.1487279450459482e-09
human O 0 2.3293035056326516e-08
cancers B-Disease 0 6.355631194310263e-05
. O 0 8.921284688767628e-08

Additional O 0 7.82172691060623e-08
experiments O 0 1.036056289649423e-07
are O 0 9.36880351076752e-10
needed O 0 2.1358375068558644e-09
to O 0 1.3807262277953924e-10
define O 0 1.5980612388943882e-09
the O 0 3.5863417791048846e-10
role O 0 2.9248725663677533e-09
of O 0 6.893420834153119e-10
CA O 0 8.862652975949459e-06
IX O 0 6.286366556196299e-07
and O 0 1.4267918402310897e-08
CA O 0 1.3956068869447336e-06
XII O 0 7.465978768550485e-08
enzymes O 0 2.9590507821808387e-09
in O 0 3.4110783642127274e-10
the O 0 2.6749616410803867e-10
regulation O 0 1.3191741032869686e-08
of O 0 1.2279097183487409e-10
pH O 0 3.2456568543892672e-09
in O 0 3.768215739441416e-10
the O 0 7.130075418970705e-10
extracellular O 0 6.0145355362806185e-09
microenvironment O 0 6.395875828957287e-08
and O 0 5.275860304188029e-10
its O 0 1.647147557237716e-10
potential O 0 1.8004399082727218e-09
impact O 0 1.4912803436573085e-08
on O 0 4.7135057457126095e-07
cancer B-Disease 0 6.619260375373415e-07
cell O 0 8.77578895597253e-06
growth O 0 1.6090290273496066e-06
. O 0 7.746527330709796e-08

A O 0 5.155823714630969e-07
gene O 0 7.461771360794955e-07
encoding O 0 1.7133204721631046e-07
a O 0 1.1033260527426592e-08
transmembrane O 0 8.483686286808734e-08
protein O 0 4.4778513341725557e-08
is O 0 1.6525105728248946e-09
mutated O 0 4.6849851287333877e-07
in O 0 3.401765695798531e-07
patients O 0 6.320767715806141e-05
with O 0 0.0001621816772967577
diabetes B-Disease 1 1.0
mellitus I-Disease 1 1.0
and O 1 0.9516953229904175
optic B-Disease 1 1.0
atrophy I-Disease 1 0.9999927282333374
( O 0 0.2798590660095215
Wolfram B-Disease 1 1.0
syndrome I-Disease 1 1.0
) O 0 4.4160873358123354e-07
. O 0 3.364700091879058e-07

Wolfram B-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 0.0003441662702243775
WFS B-Disease 0 0.26853299140930176
; O 0 1.0910814580711303e-06
OMIM O 0 0.0014276093570515513
222300 O 0 1.3066132851236034e-05
) O 0 2.6682789311394117e-08
is O 0 2.6847168044241698e-08
an O 0 1.2971234752967575e-07
autosomal B-Disease 1 0.9999997615814209
recessive I-Disease 1 1.0
neurodegenerative I-Disease 1 1.0
disorder I-Disease 1 0.9990348815917969
defined O 0 1.6634712096674775e-07
by O 0 3.5596578129570844e-08
young O 0 1.6136164049385116e-05
- O 0 0.00017019404913298786
onset O 0 8.226792851928622e-05
non O 0 4.259767956682481e-05
- O 0 0.0023093337658792734
immune O 0 0.00039828522130846977
insulin B-Disease 1 0.9988467693328857
- I-Disease 1 0.9999299049377441
dependent I-Disease 1 0.9997010827064514
diabetes I-Disease 1 1.0
mellitus I-Disease 1 1.0
and O 0 7.4403164035175e-05
progressive O 0 0.00037697143852710724
optic B-Disease 1 0.9999831914901733
atrophy I-Disease 0 0.025202753022313118
. O 0 3.3495607567601837e-06

Linkage O 0 3.559509423212148e-05
to O 0 4.960303101597674e-08
markers O 0 5.760282988376275e-07
on O 0 3.19543744353723e-07
chromosome O 0 5.3962583479005843e-05
4p O 0 0.00019061332568526268
was O 0 1.013656174109201e-06
confirmed O 0 7.509223109991581e-08
in O 0 7.669033408319592e-09
five O 0 4.971761669025909e-09
families O 0 2.5284241367273808e-09
. O 0 1.2417361361372059e-08

On O 0 1.9742115853205178e-07
the O 0 2.929869902246196e-09
basis O 0 6.46929132486207e-09
of O 0 1.48192258464519e-09
meiotic O 0 1.6912670616875403e-05
recombinants O 0 0.00014514430949930102
and O 0 8.653320833218459e-07
disease O 0 3.0342660465976223e-05
- O 0 6.49750245429459e-06
associated O 0 1.9605226952990051e-07
haplotypes O 0 5.503878583112964e-06
, O 0 6.289788689883835e-09
the O 0 5.7495732619372575e-09
WFS B-Disease 0 9.510544259683229e-06
gene O 0 6.028572840932611e-08
was O 0 1.3349354510694411e-08
localized O 0 1.2702038532097504e-08
to O 0 3.3251996711669563e-09
a O 0 6.994881118771445e-08
BAC O 0 0.04611100256443024
/ O 0 2.8984426535316743e-05
P1 O 0 0.00018182920757681131
contig O 0 1.1586001846808358e-06
of O 0 5.12281328468589e-10
less O 0 2.9717088789738e-09
than O 0 2.6562732013957202e-09
250 O 0 2.1395164750970252e-08
kb O 0 4.490613719099201e-06
. O 0 1.3250047459223424e-07

Mutations O 0 4.176284346613102e-05
in O 0 8.456142808199729e-08
a O 0 1.0250426285551839e-08
novel O 0 3.179775021067144e-08
gene O 0 2.533217298150703e-07
( O 0 8.149548591518396e-09
WFS1 O 0 5.842258019583824e-07
) O 0 6.66473487509478e-10
encoding O 0 4.032080447302633e-09
a O 0 1.933916138341374e-09
putative O 0 2.58980765721617e-08
transmembrane O 0 1.642192870576764e-08
protein O 0 7.361366627378629e-09
were O 0 3.441811458060329e-08
found O 0 2.0226218477858993e-09
in O 0 8.198983714180486e-10
all O 0 1.455627979263241e-10
affected O 0 3.025658612543225e-10
individuals O 0 2.853972266847471e-11
in O 0 1.6141131764513261e-09
six O 0 4.7189299579031285e-08
WFS B-Disease 0 8.306439667649101e-06
families O 0 6.261990370681758e-10
, O 0 5.574840589162022e-11
and O 0 8.886033575628005e-11
these O 0 5.245005124665525e-11
mutations O 0 1.971792062960276e-09
were O 0 6.1200506884517836e-09
associated O 0 2.3012960426171958e-09
with O 0 9.468000827794754e-10
the O 0 2.3074467492278927e-07
disease O 0 0.0001226751774083823
phenotype O 0 1.4280613868322689e-05
. O 0 3.4997822240256937e-07

WFS1 O 0 0.0003330363833811134
appears O 0 8.547564789296302e-07
to O 0 4.452605395499631e-09
function O 0 9.246082233183017e-10
in O 0 2.486761685460692e-09
survival O 0 3.1830758473461174e-08
of O 0 2.2005186561813161e-10
islet O 0 2.5364008138240024e-07
beta O 0 1.874420831882162e-07
- O 0 1.4998487358752755e-06
cells O 0 4.909812645337297e-08
and O 0 3.4107745516820387e-09
neurons O 0 2.458583736597575e-08
. O 0 2.0731196759271597e-09
. O 0 2.0020728186409542e-08

Stable O 0 7.958784408401698e-06
interaction O 0 6.739831093227622e-08
between O 0 6.286430487278949e-09
the O 0 7.818259373237879e-10
products O 0 6.228544791042623e-09
of O 0 4.23077337052824e-11
the O 0 1.4263475955900162e-09
BRCA1 O 0 5.453489848150639e-06
and O 0 1.0441901565627631e-07
BRCA2 O 0 3.381613714736886e-05
tumor B-Disease 0 2.459555844325223e-06
suppressor O 0 1.5396951766888378e-06
genes O 0 2.2493050266803039e-07
in O 0 2.966726775355255e-08
mitotic O 0 1.7344552816211944e-06
and O 0 3.3281580158472934e-08
meiotic O 0 9.031385161506478e-06
cells O 0 1.4091011735217762e-06
. O 0 1.5773794359574822e-07

BRCA1 O 0 0.005838585551828146
and O 0 1.4558743544057506e-07
BRCA2 O 0 2.2761214495403692e-06
account O 0 4.199487424472181e-09
for O 0 3.0411703710875315e-10
most O 0 2.1913879044710427e-10
cases O 0 3.3994979053986185e-10
of O 0 9.456319755019038e-11
familial O 0 3.973760556164052e-07
, O 0 1.0256351323789659e-08
early O 0 0.0004684368323069066
onset O 0 0.003989124204963446
breast B-Disease 0 0.005724533926695585
and I-Disease 0 9.895928087644279e-05
/ I-Disease 1 0.9999991655349731
or I-Disease 1 0.9999992847442627
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999995231628418
and O 0 3.211143351222745e-09
encode O 0 3.416712690551549e-09
products O 0 6.646258299269903e-08
that O 0 2.830036205381248e-10
each O 0 9.871822109763784e-11
interact O 0 1.3198000470282523e-09
with O 0 1.0931389127222246e-09
hRAD51 O 0 2.257054575238726e-06
. O 0 1.0655082860466791e-07

Results O 0 2.50246080213401e-06
presented O 0 4.855722934848927e-08
here O 0 1.1220419260382641e-08
show O 0 1.6923804579960233e-08
that O 0 1.9051105137890545e-09
BRCA1 O 0 9.802232625588658e-07
and O 0 6.2514438070593314e-09
BRCA2 O 0 7.034751661194605e-07
coexist O 0 1.4405655335281153e-08
in O 0 2.353852890379926e-09
a O 0 2.9642877041879956e-09
biochemical O 0 9.27383752014066e-08
complex O 0 2.4598501013883833e-08
and O 0 1.4629663702692142e-08
colocalize O 0 4.0471155671184533e-07
in O 0 1.0226562707771336e-08
subnuclear O 0 8.380481517633598e-07
foci O 0 3.226537046430167e-07
in O 0 2.7168958194323523e-09
somatic O 0 5.4933099846721234e-08
cells O 0 2.590642544930688e-08
and O 0 4.540866793689702e-09
on O 0 5.571338501653145e-09
the O 0 3.1480176798659443e-10
axial O 0 3.89066023842588e-09
elements O 0 5.952440318424124e-09
of O 0 1.5554664223316195e-09
developing O 0 9.383315102695633e-08
synaptonemal O 0 4.691285539593082e-06
complexes O 0 1.173674718302209e-06
. O 0 1.1810984545945757e-07

Like O 0 7.18633009455516e-06
BRCA1 O 0 0.00015250446449499577
and O 0 2.3299750750993553e-07
RAD51 O 0 0.0001094993858714588
, O 0 2.939700749493568e-08
BRCA2 O 0 4.584448106470518e-06
relocates O 0 9.32964894673205e-07
to O 0 2.884998195895605e-08
PCNA O 0 7.674803782720119e-06
+ O 0 4.651577256709061e-08
replication O 0 1.8724621853039025e-08
sites O 0 5.981370954089016e-09
following O 0 2.7482454090232977e-09
exposure O 0 3.138051596351943e-08
of O 0 2.693428258204733e-10
S O 0 1.4789337399179203e-07
phase O 0 1.0104990622039622e-08
cells O 0 6.153749509962836e-09
to O 0 4.009670817595179e-09
hydroxyurea O 0 6.888437837915262e-07
or O 0 2.253929487494588e-08
UV O 0 3.248168923164485e-06
irradiation O 0 2.4186085738620022e-06
. O 0 2.3006877825082483e-07

Thus O 0 6.233705107661081e-07
, O 0 6.045418388112012e-08
BRCA1 O 0 2.072268898700713e-06
and O 0 6.126871454625871e-09
BRCA2 O 0 5.036255288359825e-07
participate O 0 2.952145417012275e-09
, O 0 5.0818721453183e-10
together O 0 2.0304208314669836e-10
, O 0 1.255995862869952e-10
in O 0 4.931676178543398e-10
a O 0 3.1793609966968006e-09
pathway O 0 1.1374139852193821e-08
( O 0 1.311904362921723e-09
s O 0 2.3322421327520715e-08
) O 0 4.4444978947177916e-11
associated O 0 1.5405904330023645e-10
with O 0 2.988018166227846e-11
the O 0 2.675145382990962e-10
activation O 0 2.5386250879222416e-09
of O 0 2.5570318085144095e-10
double O 0 2.305131374669145e-06
- O 0 0.0014221557648852468
strand O 0 0.008141749538481236
break O 0 0.021285146474838257
repair O 1 0.7893968820571899
and O 0 1.100075692761493e-07
/ O 0 3.310583167603909e-07
or O 0 2.0884442619717447e-08
homologous O 0 3.277206985785597e-07
recombination O 0 1.9418771444179583e-06
. O 0 4.5476082277673413e-07

Dysfunction O 0 0.00033653833088465035
of O 0 3.943503301684359e-09
this O 0 7.672028567995426e-10
pathway O 0 8.63818083729484e-09
may O 0 2.2242145902851007e-08
be O 0 1.3196735371145962e-10
a O 0 1.2897427570379705e-10
general O 0 1.1435339480891926e-10
phenomenon O 0 5.340681230592281e-09
in O 0 1.8183129446569524e-09
the O 0 2.4795471231797706e-10
majority O 0 2.0457874283508204e-10
of O 0 1.0695647839620293e-10
cases O 0 2.8126454498789144e-09
of O 0 4.554172594595229e-09
hereditary B-Disease 1 0.9913225173950195
breast I-Disease 1 0.8574908375740051
and I-Disease 0 0.008435338735580444
/ I-Disease 1 0.9999984502792358
or I-Disease 1 0.9999995231628418
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999996423721313
. O 0 5.0135881224377954e-08
. O 0 6.61712746818921e-08

A O 0 2.3481111384171527e-06
novel O 0 5.779338607680984e-07
Arg362Ser O 0 9.389539627591148e-06
mutation O 0 2.4671996357028547e-07
in O 0 3.5935605602333e-09
the O 0 1.2850001951392187e-08
sterol O 0 3.609140549087897e-05
27 O 0 2.3608612536918372e-05
- O 0 1.822971535148099e-05
hydroxylase O 0 2.5481562261120416e-05
gene O 0 6.386002269209712e-07
( O 0 1.683623196413464e-08
CYP27 O 0 1.4134726598058478e-06
) O 0 7.397761847549589e-10
: O 0 7.67433755433089e-11
its O 0 9.50338488459046e-11
effects O 0 6.2254330579492034e-09
on O 0 3.0228580527591475e-08
pre O 0 1.9631941086117877e-06
- O 0 7.65043850492475e-08
mRNA O 0 1.2781168123865427e-08
splicing O 0 1.0312025011671722e-07
and O 0 2.015935418597792e-09
enzyme O 0 2.0095178854262485e-08
activity O 0 5.866030150514234e-08
. O 0 1.3305808899133353e-08

A O 0 4.49600776164516e-07
novel O 0 1.2926211923058872e-07
C O 0 4.218067715555662e-06
to O 0 1.1149032808077664e-09
A O 0 1.5966362454378213e-08
mutation O 0 1.4719510943450587e-08
in O 0 1.6868977326112145e-09
the O 0 2.8197573165300582e-09
sterol O 0 1.5872585208853707e-05
27 O 0 1.1776957762776874e-05
- O 0 4.764212462760042e-06
hydroxylase O 0 6.315074188023573e-06
gene O 0 3.949724032281665e-07
( O 0 1.3328619097308092e-08
CYP27 O 0 2.7209061954636127e-06
) O 0 1.0099898695159482e-09
was O 0 5.252118295828723e-09
identified O 0 6.413669040306047e-10
by O 0 1.288901763096817e-10
sequencing O 0 1.3683400190700468e-08
amplified O 0 1.5809789033482957e-07
CYP27 O 0 5.131835791871708e-07
gene O 0 5.475714814906496e-08
products O 0 3.9000905616148884e-08
from O 0 2.558003808772469e-09
a O 0 3.3621653017235076e-08
patient O 0 6.0935012697882485e-06
with O 0 2.1822435769536241e-07
cerebrotendinous B-Disease 1 1.0
xanthomatosis I-Disease 1 0.9999998807907104
( O 0 3.9598239709448535e-07
CTX B-Disease 0 0.0004577025829348713
) O 0 1.0087124024948935e-07
. O 0 1.0292728802596685e-07

The O 0 2.731582071646699e-07
mutation O 0 1.5093115734998719e-06
changed O 0 2.248723802722452e-07
the O 0 9.675705570089121e-09
adrenodoxin O 0 1.4062766240385827e-06
cofactor O 0 1.5394705314975e-06
binding O 0 1.2672086313614273e-07
residue O 0 7.44084388770716e-07
362Arg O 0 2.716208769015793e-07
to O 0 4.895624350353955e-09
362Ser O 0 6.137634613878618e-07
( O 0 7.0646675176533336e-09
CGT O 0 1.2250310419403831e-06
362Arg O 0 3.3902551876963116e-07
to O 0 1.746968436577845e-08
AGT O 0 3.930757884518243e-06
362Ser O 0 1.804967837415461e-07
) O 0 5.968524008359566e-10
, O 0 1.5328788238733182e-10
and O 0 1.8122910117046587e-10
was O 0 9.552716839777986e-09
responsible O 0 2.0163892777702586e-09
for O 0 2.3152435524309567e-09
deficiency O 0 1.3160307332782395e-07
in O 0 2.2378891795238331e-10
the O 0 1.1123861831663362e-09
sterol O 0 3.026671492989408e-06
27 O 0 2.113370101142209e-06
- O 0 7.679801683480036e-07
hydroxylase O 0 1.0350959200877696e-06
activity O 0 5.4017213813040144e-08
, O 0 1.0674411354827384e-10
as O 0 2.035547008727434e-10
confirmed O 0 5.391042612323815e-10
by O 0 1.4669794892729904e-11
expression O 0 2.4798310627183184e-10
of O 0 3.748829718874802e-11
mutant O 0 5.874066122402155e-09
cDNA O 0 1.718117204063674e-08
into O 0 1.812759364838712e-08
COS O 0 0.00010671188647393137
- O 0 6.903122766743763e-07
1 O 0 2.412704880327965e-08
cells O 0 8.438580323399947e-08
. O 0 3.0324962096983654e-08

Quantitative O 0 2.5905271741066827e-06
analysis O 0 9.56460723955388e-08
showed O 0 5.656918844465508e-08
that O 0 1.583632391888301e-10
the O 0 4.6712994583586465e-11
expression O 0 9.636526021594705e-10
of O 0 9.055593080953273e-11
CYP27 O 0 1.3116603270191263e-07
gene O 0 1.751917011461046e-08
mRNA O 0 5.343228526299981e-09
in O 0 1.786629733047107e-09
the O 0 9.42916411617034e-10
patient O 0 4.415168675109271e-08
represented O 0 8.416185082182892e-09
52 O 0 1.6147289727541647e-07
. O 0 4.291270272460679e-08

5 O 0 8.722495294932742e-07
% O 0 1.4121259717114754e-08
of O 0 5.379589551601782e-10
the O 0 3.3657052700419854e-09
normal O 0 2.2929206977551075e-07
level O 0 5.395655762185925e-07
. O 0 6.92761688014798e-08

As O 0 7.435396298660635e-08
the O 0 4.315012347433367e-09
mutation O 0 1.9485423052856277e-08
occurred O 0 4.3546926065118896e-08
at O 0 2.7564084348341567e-09
the O 0 3.1557789714753426e-10
penultimate O 0 1.0175783415888873e-07
nucleotide O 0 1.4189946107023843e-08
of O 0 2.6361435256916366e-10
exon O 0 7.433765603082065e-08
6 O 0 2.141484323203713e-08
( O 0 3.1984352943936756e-09
- O 0 8.936936524150951e-08
2 O 0 5.289435556221633e-09
position O 0 9.041140280885429e-09
of O 0 4.69254635149241e-10
exon O 0 1.6371021160921373e-07
6 O 0 6.790853035454347e-08
- O 0 3.1212960038828896e-07
intron O 0 3.025759497177205e-06
6 O 0 3.453160957178625e-08
splice O 0 7.602804430462129e-07
site O 0 6.891031301137218e-09
) O 0 8.29739887908687e-11
of O 0 8.900429872282789e-12
the O 0 1.0429784813581477e-10
gene O 0 7.794128009663837e-09
, O 0 3.3255151410394035e-10
we O 0 9.45376332772696e-10
hypothesized O 0 1.667193938459377e-09
that O 0 7.31768187711701e-11
the O 0 4.2855646809059067e-10
mutation O 0 2.2340403305065593e-08
may O 0 3.563733841360772e-08
partially O 0 1.2573226904066814e-08
affect O 0 4.218030813518681e-09
the O 0 3.503183854114411e-10
normal O 0 7.011080604968356e-09
splicing O 0 4.644972406708803e-08
efficiency O 0 1.2096352364210361e-08
in O 0 5.30087884698105e-09
exon O 0 6.166464316947895e-08
6 O 0 1.8574510818325507e-08
and O 0 1.9429855502295368e-09
cause O 0 1.7721514256052728e-09
alternative O 0 2.6299977751165216e-09
splicing O 0 3.5192471159462e-08
elsewhere O 0 7.102812560333405e-08
, O 0 2.6412369513728606e-10
which O 0 3.444373952721236e-11
resulted O 0 2.0226399721767763e-10
in O 0 7.961930004185547e-10
decreased O 0 1.837993934827864e-08
transcript O 0 3.873106990681663e-08
in O 0 2.510978758252236e-09
the O 0 1.0561618246640592e-08
patient O 0 4.832273816646193e-07
. O 0 3.6819962190293154e-08

Transfection O 0 9.467489871894941e-05
of O 0 3.2928110016428036e-08
constructed O 0 6.799315315220156e-07
minigenes O 0 2.7394306016503833e-05
, O 0 1.3315145652725846e-09
with O 0 1.1928967535990154e-10
or O 0 1.8955668146247717e-09
without O 0 5.707438965885103e-10
the O 0 3.7036160249748207e-10
mutation O 0 4.453251101210753e-09
, O 0 1.890442524743463e-10
into O 0 4.446876644692566e-09
COS O 0 0.0006015015533193946
- O 0 1.7996791257246514e-07
1 O 0 3.0246618543117165e-09
cells O 0 4.599530978310895e-09
confirmed O 0 2.278645894193687e-08
that O 0 1.0972409786313975e-10
the O 0 1.2479414723820526e-10
mutant O 0 2.9093785158806895e-08
minigene O 0 3.592336099700333e-07
was O 0 2.1795559135284748e-08
responsible O 0 4.21584100962491e-10
for O 0 4.4783485947386126e-11
a O 0 3.806109594162166e-10
mRNA O 0 4.82221684805495e-09
species O 0 6.919420592055303e-11
alternatively O 0 5.180592843601062e-09
spliced O 0 7.84385122187814e-07
at O 0 5.813213377336979e-08
an O 0 1.535697791155144e-09
activated O 0 1.737041372962267e-07
cryptic O 0 4.3430057417026546e-07
5 O 0 1.4186915642255826e-08
splice O 0 1.9752237676584627e-06
site O 0 1.3397402653936297e-07
88 O 0 9.809800616267239e-08
bp O 0 7.085668016770796e-07
upstream O 0 2.2042257796783815e-08
from O 0 1.2751016909007262e-09
the O 0 5.650658274625187e-10
3 O 0 2.158875966884466e-09
end O 0 1.0376676407020113e-08
of O 0 2.7835048155289144e-10
exon O 0 1.0947340456368693e-07
6 O 0 8.786173566477373e-08
. O 0 5.4374254432332236e-08

Our O 0 8.356828118394333e-08
data O 0 1.049667108787844e-08
suggest O 0 2.2319224246558633e-09
that O 0 5.189508545111465e-11
the O 0 7.153665160242184e-11
C O 0 9.389384558744496e-08
to O 0 1.860342435655582e-10
A O 0 1.0083292423246348e-08
mutation O 0 7.628142562055018e-09
at O 0 3.282926153147514e-09
the O 0 2.928868259033379e-10
penultimate O 0 5.450799989148436e-08
nucleotide O 0 3.311143137452177e-09
of O 0 6.790584067273286e-11
exon O 0 1.2574616903293645e-08
6 O 0 2.2851995851169704e-09
of O 0 1.4906531564662373e-10
the O 0 1.6053688378647735e-09
CYP27 O 0 7.675159849895863e-07
gene O 0 1.4520468383238949e-08
not O 0 2.3577666485863347e-09
only O 0 5.308727901720545e-10
causes O 0 4.4438497326382276e-09
the O 0 6.559161391805901e-08
deficiency B-Disease 0 3.930323146050796e-06
in I-Disease 0 1.5972201339309322e-09
the I-Disease 0 2.1133916838778077e-09
sterol I-Disease 0 5.441644589154748e-06
27 I-Disease 0 1.720631303214759e-06
- I-Disease 0 9.348673302156385e-07
hydroxylase I-Disease 0 1.5365253602794837e-06
activity I-Disease 0 3.6893112564939656e-07
, O 0 4.650720919485707e-10
but O 0 2.1048469633910827e-09
also O 0 4.128467845365691e-10
partially O 0 2.464272563784675e-09
leads O 0 4.3533512905646887e-10
to O 0 1.1217048123679518e-10
alternative O 0 4.330149572240316e-09
pre O 0 4.2579321757330035e-07
- O 0 3.111962953994407e-08
mRNA O 0 5.141218561988126e-09
splicing O 0 2.7405780755884734e-08
of O 0 2.906579976702517e-10
the O 0 1.2073225752473604e-09
gene O 0 1.4072880105686636e-07
. O 0 2.8195437096201204e-08

To O 0 2.5538907877376005e-08
our O 0 2.832807988184527e-09
knowledge O 0 8.483840852058222e-10
, O 0 1.2979629870901732e-10
this O 0 3.7174999190092706e-11
is O 0 4.033430187067033e-11
the O 0 5.975457628704106e-11
first O 0 1.239123470497816e-09
report O 0 1.1885822326362927e-09
regarding O 0 2.1751681011927815e-10
effects O 0 1.7574518507146308e-09
on O 0 4.1823171592625386e-09
pre O 0 5.7933220887207426e-08
- O 0 4.725592805954193e-09
mRNA O 0 1.5501826489128234e-09
splicing O 0 5.97496230270167e-09
of O 0 3.0615385226973046e-11
a O 0 6.673868679918371e-10
mutation O 0 2.4140247578685603e-09
at O 0 3.2622218260058844e-09
the O 0 7.257083822764798e-10
- O 0 3.33586143597131e-07
2 O 0 5.3850230941066e-09
position O 0 1.6759944543309757e-08
of O 0 1.020064310797153e-10
a O 0 4.728874625214985e-09
5 O 0 1.285772466275148e-08
splice O 0 5.30147599420161e-06
site O 0 5.107033871354361e-07
. O 0 1.146252159855976e-07

ATM O 0 0.0011048944434151053
germline O 0 0.0002779861679300666
mutations O 0 1.0602312613627873e-05
in O 0 1.6569369165608805e-07
classical O 0 0.02532198093831539
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
patients O 1 0.9988903403282166
in O 0 1.1556301870996322e-07
the O 0 7.875541108148809e-09
Dutch O 0 4.581716893881094e-06
population O 0 5.4841993168963654e-09
. O 0 2.003157639762776e-08

Germline O 0 0.0005248616798780859
mutations O 0 7.512484444305301e-06
in O 0 2.210452620943215e-08
the O 0 1.9834061060208796e-09
ATM O 0 2.310181344000739e-07
gene O 0 1.513773995043266e-08
are O 0 1.4772287559861041e-10
responsible O 0 1.1126259913396552e-09
for O 0 2.3530899451174037e-09
the O 0 0.0007436780724674463
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
disorder I-Disease 1 1.0
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 0 0.1952553242444992
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 2.1662381755049864e-07
. O 0 8.781047000638864e-08

In O 0 1.932179287678082e-07
our O 0 5.079315634759496e-09
study O 0 2.0436123904232772e-09
, O 0 2.2373855546042876e-10
we O 0 1.560454959692592e-10
have O 0 4.1581960097403226e-11
determined O 0 4.6310166812446596e-10
the O 0 5.467818975368743e-10
ATM O 0 4.955923486704705e-06
mutation O 0 5.798814317614642e-09
spectrum O 0 1.3264987330785516e-08
in O 0 1.0593252497415051e-08
19 O 0 3.113696322998294e-08
classical O 0 2.0656668766605435e-06
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 0.00010503380326554179
, O 0 2.2443437386332477e-10
including O 0 4.516865700909811e-11
some O 0 5.247857357004726e-11
immigrant O 0 2.15239204237605e-09
populations O 0 8.387060490555598e-11
, O 0 9.273772028084437e-11
as O 0 2.167741958158942e-10
well O 0 8.458022060509052e-10
as O 0 1.5640582162745886e-09
12 O 0 1.1446802394843303e-09
of O 0 7.612117880473335e-11
Dutch O 0 3.6235991274224943e-07
ethnic O 0 1.6499971389194457e-09
origin O 0 4.9069853957917076e-08
. O 0 8.938521744994432e-08

Both O 0 6.315323730632372e-08
the O 0 4.415015020242663e-09
protein O 0 2.6271965936075503e-08
truncation O 0 2.0393444799537974e-07
test O 0 4.1712067400112574e-07
( O 0 4.323662761152036e-09
PTT O 0 7.513664712632817e-08
) O 0 2.1991214405048254e-10
and O 0 1.2873097032795044e-10
the O 0 3.339078458175493e-10
restriction O 0 3.5806721143671894e-08
endonuclease O 0 4.69921542389784e-06
fingerprinting O 0 1.529363430563535e-06
( O 0 4.2391135046671025e-09
REF O 0 3.3645042663010827e-07
) O 0 7.739043433874215e-11
method O 0 3.7885963810602163e-10
were O 0 1.5410467346654855e-09
used O 0 7.199276730318616e-10
and O 0 8.45411851635447e-10
compared O 0 6.939844254816308e-10
for O 0 1.589050765971045e-11
their O 0 4.258656621791701e-11
detection O 0 7.273407431895862e-10
efficiency O 0 1.4039930329445838e-09
, O 0 6.130687624228415e-11
identifying O 0 7.609421426302276e-10
76 O 0 4.7009605097514395e-09
% O 0 7.706666554918584e-11
and O 0 1.2161531504073508e-10
60 O 0 7.26949667129162e-10
% O 0 3.6677758052938714e-11
of O 0 2.867794196559359e-11
the O 0 2.0071455608672295e-09
mutations O 0 6.693123566492432e-08
, O 0 2.7468776142569595e-09
respectively O 0 5.086735299641987e-08
. O 0 4.323722535559682e-08

Most O 0 5.928093855800398e-07
patients O 0 1.2782724070348195e-06
were O 0 9.856329086233018e-09
found O 0 1.2219386613665506e-09
to O 0 3.1595190352895486e-10
be O 0 1.8140278168488067e-09
compound O 0 3.447126317723814e-08
heterozygote O 0 3.5660912089952035e-06
. O 0 9.137010437143545e-08

Seventeen O 0 9.790212061489001e-06
mutations O 0 6.604845452784502e-07
were O 0 1.1576814173963612e-08
distinct O 0 7.37847005716219e-10
, O 0 1.297792290300137e-10
of O 0 9.639660597526856e-12
which O 0 4.1055150945545904e-10
10 O 0 9.132559708469046e-10
were O 0 2.4151082911316735e-08
not O 0 2.8114655048483428e-09
reported O 0 7.33870066937925e-08
previously O 0 4.585343660323815e-08
. O 0 2.9455492267516092e-08

Mutations O 0 5.666255310643464e-05
are O 0 2.4833124001588658e-08
small O 0 1.8280402969139686e-08
deletions O 0 1.4466279480984667e-06
or O 0 2.4692334932296944e-07
point O 0 5.325903771336016e-07
mutations O 0 3.065394196255511e-07
frequently O 0 5.731936525421588e-08
affecting O 0 1.1819164313919828e-07
splice O 0 2.7618320018518716e-05
sites O 0 1.3874060869056848e-06
. O 0 5.488701049216616e-07

Moreover O 0 3.835347797576105e-06
, O 0 3.1234392849910364e-08
a O 0 2.723252556791067e-08
16 O 0 2.0854416504789697e-07
. O 0 5.963192961644381e-08

7 O 0 1.2268840691831429e-05
- O 0 1.1458949302323163e-05
kb O 0 3.156651473545935e-06
genomic O 0 3.6830292060585634e-07
deletion O 0 1.7478208746979362e-07
of O 0 3.501700873709268e-10
the O 0 6.374034633438441e-10
3 O 0 3.3937206378453766e-09
end O 0 5.434809935422891e-09
of O 0 3.3558367890096363e-11
the O 0 1.587912301648231e-10
gene O 0 6.120867368508698e-09
, O 0 2.0290076563345139e-10
most O 0 2.985057478976927e-10
likely O 0 9.412942425512938e-09
a O 0 6.232356297708463e-10
result O 0 1.4310618245971796e-09
of O 0 5.822747839445697e-11
recombination O 0 4.173352330383295e-09
between O 0 4.842309220265406e-09
two O 0 4.930775787670427e-09
LINE O 0 1.131670614995528e-06
elements O 0 1.0740224709593349e-08
, O 0 3.439965201579298e-09
was O 0 1.5192530611329857e-07
identified O 0 7.737578755495633e-08
. O 0 3.146226390526863e-08

The O 0 4.545765364127874e-08
most O 0 4.419952848166986e-09
frequently O 0 6.248058959101854e-09
found O 0 7.862393403001988e-09
mutation O 0 3.790419977889314e-09
, O 0 1.1276361094880727e-10
identified O 0 1.606217270300192e-09
in O 0 1.051008835517564e-09
three O 0 9.878664553042427e-10
unrelated O 0 3.2588776122111085e-08
Turkish O 0 1.1227612048969604e-06
A B-Disease 1 1.0
- I-Disease 1 0.9999986886978149
T I-Disease 1 1.0
individuals O 0 4.227647565357984e-09
, O 0 1.015696526884824e-09
was O 0 2.378581775985822e-08
previously O 0 2.0961612445802302e-09
described O 0 1.8551771230335135e-09
to O 0 1.1975495595173413e-10
be O 0 3.632833756039844e-10
a O 0 1.1371573682694702e-09
Turkish O 0 2.71608968205328e-07
A B-Disease 1 1.0
- I-Disease 1 0.9999216794967651
T I-Disease 1 1.0
founder O 0 4.8464094106748234e-06
mutation O 0 1.5130976862565149e-06
. O 0 5.800255209464922e-08

The O 0 1.2735418941645094e-08
presence O 0 1.3980001156710387e-08
of O 0 2.603767479403274e-10
a O 0 5.022927407338784e-09
founder O 0 2.2323690984649147e-07
mutation O 0 3.6538168046718056e-08
among O 0 2.142745758604292e-09
relatively O 0 2.379043406719461e-09
small O 0 6.983143507888201e-10
ethnic O 0 3.5041328172447095e-10
population O 0 2.918756208947215e-11
groups O 0 4.764886055164119e-11
in O 0 2.2578988678745304e-10
Western O 0 2.370794449646496e-09
Europe O 0 5.62421234917565e-07
could O 0 6.382008166383457e-08
indicate O 0 2.8394673279308336e-09
a O 0 7.906391652490186e-10
high O 0 3.046584140520281e-08
carrier O 0 4.37481446624588e-08
frequency O 0 4.444182621909931e-08
in O 0 2.9473010698666258e-09
such O 0 9.226456820776718e-10
communities O 0 5.926147572665741e-09
. O 0 2.6163501587461724e-08

In O 0 8.679073175699159e-07
patients O 0 6.117100497249339e-07
of O 0 4.524766394897739e-10
Dutch O 0 5.162161187399761e-07
ethnic O 0 3.206043763803734e-10
origin O 0 1.122405168807461e-09
, O 0 2.2149579392838348e-10
however O 0 4.721401047902418e-10
, O 0 3.1041922504693176e-11
no O 0 2.1826737639507598e-10
significant O 0 5.60013313499752e-10
founder O 0 1.8852844618777453e-08
effect O 0 1.5936910457980957e-08
could O 0 3.2156378892977955e-08
be O 0 1.7849505207223615e-09
identified O 0 2.3862568809818185e-08
. O 0 9.69366009684336e-09

The O 0 9.767512665348477e-08
observed O 0 4.1113576543239105e-08
genetic O 0 4.9646285305016136e-08
heterogeneity O 0 2.601580995076347e-08
including O 0 2.067713777975655e-09
the O 0 1.3466217030355665e-09
relative O 0 3.520885272223495e-08
high O 0 5.998556389386067e-07
percentage O 0 6.20952107510675e-08
of O 0 6.945327091223419e-10
splice O 0 0.0002711864362936467
- O 0 2.525497620808892e-05
site O 0 2.1268307648369955e-07
mutations O 0 6.259512019823887e-07
had O 0 2.472924279572908e-06
no O 0 8.633551651371363e-09
reflection O 0 7.865272877438656e-09
on O 0 8.147609520392507e-08
the O 0 3.350769617327387e-08
phenotype O 0 4.223074938636273e-06
. O 0 1.274176497645385e-07

All O 0 3.4553883665466856e-07
patients O 0 7.818205745024898e-07
manifested O 0 1.4021317440437997e-07
classical O 0 4.7844832806731574e-06
A B-Disease 1 1.0
- I-Disease 1 0.9999979734420776
T I-Disease 1 1.0
and O 0 1.9833390041412713e-08
increased O 0 1.2660557047183829e-08
cellular O 0 3.453991439528181e-07
radioresistant O 0 5.123351911606733e-07
DNA O 0 9.714653970149811e-08
synthesis O 0 1.6655108936447505e-07
. O 0 4.619500160174539e-08

Determination O 0 7.979532483659568e-07
of O 0 1.5374091999476036e-09
the O 0 5.115295409474641e-10
genomic O 0 1.4218284327682795e-08
structure O 0 1.2464916210319643e-08
of O 0 2.2658065701453012e-10
the O 0 2.2938067001376794e-09
COL4A4 O 0 1.2699284752670792e-06
gene O 0 5.7578066758878776e-08
and O 0 2.6523749863116564e-09
of O 0 3.904433443224775e-10
novel O 0 3.629752427514177e-07
mutations O 0 0.000701217504683882
causing O 0 0.007833866402506828
autosomal B-Disease 1 0.9999997615814209
recessive I-Disease 1 1.0
Alport I-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 2.1625241060974076e-05

Autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
Alport I-Disease 1 1.0
syndrome I-Disease 1 1.0
is O 0 4.095823896932416e-06
a O 0 1.9447534214123152e-06
progressive O 0 0.004851522855460644
hematuric B-Disease 1 0.9999336004257202
glomerulonephritis I-Disease 1 1.0
characterized O 0 2.2841279132990167e-05
by O 0 9.794395339213224e-08
glomerular B-Disease 0 0.0010959337232634425
basement I-Disease 1 0.7525836825370789
membrane I-Disease 0 0.01626482978463173
abnormalities I-Disease 1 0.9990033507347107
and O 0 1.042913932991496e-08
associated O 0 2.7875759478490636e-09
with O 0 4.482811899464423e-10
mutations O 0 5.546446146809103e-08
in O 0 9.365610509348699e-09
either O 0 1.617695488675963e-08
the O 0 1.0568752095707623e-08
COL4A3 O 0 1.6962316067292704e-06
or O 0 5.33331112606561e-09
the O 0 1.9006389795350742e-09
COL4A4 O 0 2.6396133989692316e-07
gene O 0 1.181907016700734e-08
, O 0 2.8939067808764207e-10
which O 0 6.81809816938106e-11
encode O 0 3.5607088388900365e-09
the O 0 5.3093178742358305e-09
alpha3 O 0 2.0998613763367757e-06
and O 0 3.5423600053263726e-08
alpha4 O 0 2.442527147650253e-06
type O 0 1.3194882740208413e-05
IV O 0 0.00011535982775967568
collagen O 0 1.64431673965737e-06
chains O 0 4.5314227463677526e-06
, O 0 3.3440323843336728e-09
respectively O 0 1.603301136299251e-08
. O 0 2.3268391657893517e-08

To O 0 1.0442339970495595e-07
date O 0 3.2168131269827427e-07
, O 0 1.6090198062812533e-09
mutation O 0 8.338625789860998e-09
screening O 0 2.214575722803147e-08
in O 0 1.7692738385477469e-09
the O 0 1.4765526301641074e-10
two O 0 5.367024602520587e-10
genes O 0 3.3692058032386285e-09
has O 0 4.321832669518244e-09
been O 0 4.3578502584296075e-08
hampered O 0 8.537821258869371e-07
by O 0 2.2961474388516478e-10
the O 0 3.540978343874457e-10
lack O 0 1.5154573151932027e-09
of O 0 1.2615829214635e-10
genomic O 0 1.1890839424211208e-08
structure O 0 2.5367242528773204e-08
information O 0 4.86362914386973e-08
. O 0 7.710706739771922e-08

We O 0 3.456218848896242e-07
report O 0 1.7774500093992174e-08
here O 0 4.398119368698161e-10
the O 0 4.38800350222035e-11
complete O 0 1.0381655257685196e-10
characterization O 0 1.2315858333167284e-09
of O 0 1.4462732227105146e-11
the O 0 1.7450385580985994e-10
48 O 0 8.5659845883157e-10
exons O 0 2.0688812885083507e-09
of O 0 3.212230828553153e-11
the O 0 8.055291433883838e-10
COL4A4 O 0 4.870080942964705e-07
gene O 0 2.0749089557625666e-08
, O 0 4.3259537618745014e-10
a O 0 4.6228096350908743e-10
comprehensive O 0 4.46188064273656e-09
gene O 0 3.433241602124326e-08
screen O 0 1.0934627425740473e-06
, O 0 2.1884858369958238e-09
and O 0 3.6310393580762934e-10
the O 0 1.0771313702084839e-10
subsequent O 0 3.252013103249851e-10
detection O 0 2.7597386598188223e-09
of O 0 5.719859655362036e-11
10 O 0 4.646208140446362e-10
novel O 0 1.182666298227275e-09
mutations O 0 3.6123367408436025e-08
in O 0 2.305580792949513e-08
eight O 0 1.4706286037835525e-06
patients O 0 0.0004928293055854738
diagnosed O 0 0.2374432533979416
with O 0 3.944558557122946e-06
autosomal B-Disease 1 0.9999997615814209
recessive I-Disease 1 1.0
Alport I-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 1.3593957191915251e-05

Furthermore O 0 9.347353966404626e-07
, O 0 1.3295205825158973e-08
we O 0 1.5723256030497623e-09
identified O 0 8.307633470039377e-10
a O 0 1.5460656366261816e-10
glycine O 0 8.35905655804936e-09
to O 0 3.2633901136946974e-10
alanine O 0 1.4098787026739501e-08
substitution O 0 2.456032932585117e-09
in O 0 1.406606386922249e-09
the O 0 5.572494132799477e-10
collagenous O 0 6.228690097032086e-08
domain O 0 2.215977401576197e-09
that O 0 1.5674321562908489e-10
is O 0 6.739268865185721e-11
apparently O 0 1.2844758146002277e-08
silent O 0 1.10004796383123e-08
in O 0 7.776008725812744e-10
the O 0 3.5355790517499486e-10
heterozygous O 0 8.231863191099364e-09
carriers O 0 1.732173871005216e-08
, O 0 4.976692391522874e-10
in O 0 2.4733699532930586e-09
11 O 0 4.73308219284263e-08
. O 0 3.244402080326836e-08

5 O 0 2.350512460225218e-07
% O 0 3.3392075771132568e-09
of O 0 8.483479890797341e-11
all O 0 1.2493775458644052e-10
control O 0 3.448617391654807e-09
individuals O 0 2.213184219224118e-10
, O 0 4.956524635169046e-10
and O 0 1.9708747966973306e-09
in O 0 3.1518345711134543e-09
one O 0 1.2412714189835583e-09
control O 0 2.4474891002768118e-09
individual O 0 1.8370738263939757e-10
homozygous O 0 7.3135590916706406e-09
for O 0 1.9842563703242888e-10
this O 0 3.311349805468211e-10
glycine O 0 8.67781722035943e-08
substitution O 0 6.445633715657095e-08
. O 0 3.601137166242552e-08

There O 0 3.9721277289572754e-07
has O 0 6.586865719526713e-09
been O 0 2.121566033963518e-09
no O 0 2.757900852135009e-10
previous O 0 2.670837162543904e-10
finding O 0 1.8310393479215037e-10
of O 0 1.1524209538038566e-11
a O 0 2.010742544689137e-10
glycine O 0 6.658182449825745e-09
substitution O 0 1.688468698191059e-09
that O 0 2.7700841620514893e-10
is O 0 4.016916313465124e-11
not O 0 8.552399066719119e-11
associated O 0 1.17384948983279e-10
with O 0 2.309049479398695e-11
any O 0 2.111433250462369e-09
obvious O 0 1.1932078791687672e-07
phenotype O 0 2.6739627401184407e-07
in O 0 1.2475809718637265e-08
homozygous O 0 3.249508893077291e-07
individuals O 0 1.0871968214587469e-08
. O 0 3.33128902241242e-08

Founder O 0 0.00014533044304698706
BRCA1 O 0 0.0015091067180037498
and O 0 7.07234107721888e-07
BRCA2 O 0 5.648441219818778e-05
mutations O 0 6.710930620101863e-07
in O 0 3.094737976994111e-08
French O 0 8.843428076943383e-06
Canadian O 0 0.00041226166649721563
breast B-Disease 1 0.999993085861206
and I-Disease 1 0.9999809265136719
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999994039535522
families O 0 3.492993130294053e-07
. O 0 1.78463395172912e-07

We O 0 5.70022052670538e-07
have O 0 7.025618309342008e-09
identified O 0 5.77503866949769e-09
four O 0 6.792194029436871e-10
mutations O 0 3.1079629980723666e-09
in O 0 3.619934074716724e-10
each O 0 5.072669020944609e-11
of O 0 2.1073286171624517e-10
the O 0 7.105148824848584e-07
breast B-Disease 1 0.9907095432281494
cancer I-Disease 0 0.001745428773574531
- O 0 7.035114686004817e-05
susceptibility O 0 1.6970082015177468e-06
genes O 0 4.498036219047208e-07
, O 0 1.4949684157272713e-08
BRCA1 O 0 4.052107669849647e-06
and O 0 2.7020083948059437e-08
BRCA2 O 0 2.396262516413117e-06
, O 0 1.0520236903843738e-09
in O 0 2.311096425344772e-09
French O 0 3.762718552025035e-05
Canadian O 0 0.0048997411504387856
breast B-Disease 1 0.999800980091095
cancer I-Disease 1 0.7274481654167175
and O 1 0.8880963921546936
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 1.2531644699720346e-07
from O 0 4.805609421509871e-08
Quebec O 0 1.4180416201270418e-06
. O 0 1.6699229377081792e-07

To O 0 7.812721491973207e-08
identify O 0 1.345996309964903e-07
founder O 0 1.2086968581570545e-07
effects O 0 8.170623573278135e-07
, O 0 7.3703581016104636e-09
we O 0 6.554356613008849e-09
examined O 0 1.562943729993549e-08
independently O 0 3.4175990926144095e-09
ascertained O 0 4.425311317390879e-08
French O 0 1.076268247857115e-07
Canadian O 0 4.990232937984729e-08
cancer B-Disease 0 5.4163610485602476e-08
families O 0 1.8104047427858205e-10
for O 0 2.1173030342880317e-11
the O 0 3.709757848135986e-11
distribution O 0 3.236345358370585e-10
of O 0 1.516023279135581e-10
these O 0 1.3311158841844417e-09
eight O 0 3.047827945579229e-08
mutations O 0 3.2596241794635716e-07
. O 0 6.917160533248534e-08

Mutations O 0 3.1890428999759024e-06
were O 0 6.004565733519485e-08
found O 0 2.6202742198222495e-09
in O 0 1.0311504983206987e-09
41 O 0 6.619082171255286e-09
of O 0 1.3532124032433757e-10
97 O 0 4.1732750588607814e-08
families O 0 4.421419674827121e-09
. O 0 1.8618353081478745e-08

Six O 0 2.2835304491763964e-07
of O 0 1.239714442213824e-09
eight O 0 4.303128076088569e-09
mutations O 0 2.6876064040948222e-08
were O 0 3.3970771085023443e-08
observed O 0 2.109336261213457e-09
at O 0 7.98666466295117e-09
least O 0 3.7127276808490706e-09
twice O 0 8.703494103201592e-08
. O 0 2.9515160093751547e-08

The O 0 1.0487084409760428e-06
BRCA1 O 0 0.00023158814292401075
C4446T O 0 1.4446246495936066e-05
mutation O 0 1.1906315648957388e-06
was O 0 8.892828873285907e-08
the O 0 6.891329729086237e-10
most O 0 1.0728425925421448e-09
common O 0 1.0011887319194557e-08
mutation O 0 1.482369960115193e-08
found O 0 9.767788355929952e-09
, O 0 3.719168306659526e-10
followed O 0 9.736051964637227e-10
by O 0 5.820785520249672e-10
the O 0 1.2260435333644182e-08
BRCA2 O 0 2.4426937670796178e-05
8765delAG O 0 3.880726580973715e-06
mutation O 0 2.047782345471205e-06
. O 0 2.858608638689475e-07

Together O 0 1.780232992132369e-07
, O 0 2.258236042607109e-09
these O 0 2.0473292505762686e-10
mutations O 0 2.2377153463537525e-09
were O 0 3.2090985424559904e-09
found O 0 3.7432296151607147e-10
in O 0 2.522017039652269e-10
28 O 0 1.1623337847765924e-09
of O 0 1.5119450830214376e-11
41 O 0 2.8222000292288385e-09
families O 0 9.920746862901453e-11
identified O 0 2.0516617293964146e-09
to O 0 2.686553202124742e-10
have O 0 5.9831046783642705e-09
a O 0 1.2276393235310934e-08
mutation O 0 3.013412026575679e-07
. O 0 6.060161439336298e-08

The O 0 1.250361378879461e-07
odds O 0 4.344621515883773e-07
of O 0 3.2668778793265574e-10
detection O 0 7.618502273487593e-09
of O 0 5.944583020278671e-11
any O 0 3.165853135200791e-10
of O 0 4.223211017007067e-11
the O 0 1.194835119733284e-09
four O 0 2.0623895480298415e-08
BRCA1 O 0 6.347485850710655e-06
mutations O 0 7.693678298892337e-07
was O 0 3.214588105038274e-06
18 O 0 7.561914117104607e-08
. O 0 4.170060208252835e-08

7x O 0 0.0032784659415483475
greater O 0 7.06868604538613e-07
if O 0 5.7561489796853493e-08
one O 0 1.5666558050853041e-09
or O 0 1.0570299080470136e-09
more O 0 6.396138618747216e-10
cases O 0 1.5730885039033637e-08
of O 0 5.1081328820146155e-06
ovarian B-Disease 1 1.0
cancer I-Disease 1 0.9999985694885254
were O 0 2.0463443206608645e-07
also O 0 3.0881486257072766e-10
present O 0 7.002853852355884e-11
in O 0 1.2201104571119004e-09
the O 0 2.713141267207675e-09
family O 0 2.1014464834934188e-08
. O 0 3.718866992130643e-08

The O 0 4.8542503350290644e-08
odds O 0 1.957834001586889e-07
of O 0 1.9168898413024493e-10
detection O 0 3.3935136922735865e-09
of O 0 6.103176991567594e-11
any O 0 1.9175298848761457e-10
of O 0 3.048265459493216e-11
the O 0 1.4646520662964235e-09
four O 0 2.2719151004935156e-08
BRCA2 O 0 3.3088770123868017e-06
mutations O 0 2.835151065028185e-07
was O 0 5.623568881674146e-07
5 O 0 2.4878684001805595e-08
. O 0 5.5826379963264117e-08

3x O 0 0.0003071668033953756
greater O 0 1.102937190466946e-07
if O 0 3.778209034521751e-08
there O 0 1.6117013279526304e-09
were O 0 6.42450759258395e-09
at O 0 8.337651680179192e-10
least O 0 7.982971228503999e-11
five O 0 2.377731067593203e-10
cases O 0 1.1230604224365948e-09
of O 0 3.9771395066168225e-09
breast B-Disease 0 0.010857237502932549
cancer I-Disease 0 3.2018542697187513e-06
in O 0 3.6337450382006864e-08
the O 0 1.0559079832717089e-08
family O 0 6.07173120670268e-08
. O 0 4.8897387472379705e-08

Interestingly O 0 8.115641321637668e-06
, O 0 4.012402410324967e-09
the O 0 2.1460656862704042e-10
presence O 0 8.254326111512e-10
of O 0 2.9519522937171416e-10
a O 0 2.988108747103979e-07
breast B-Disease 0 0.051220785826444626
cancer I-Disease 0 1.4683248537039617e-06
case O 0 3.0118197713591144e-08
< O 0 6.21947719992022e-08
36 O 0 5.338929742748633e-09
years O 0 7.891882147781359e-10
of O 0 5.812162556795286e-11
age O 0 2.7524789114607984e-09
was O 0 2.377763985705883e-09
strongly O 0 2.7564597826490456e-10
predictive O 0 3.4198290865816716e-09
of O 0 4.3232792346081794e-11
the O 0 6.363219673399811e-11
presence O 0 8.926003686182682e-11
of O 0 9.446777561594732e-12
any O 0 1.1731936255809927e-10
of O 0 4.935550926288279e-11
the O 0 1.5714741730121773e-09
eight O 0 1.1117525566817221e-08
mutations O 0 8.146770369421574e-08
screened O 0 8.456527211819775e-07
. O 0 8.90983997692274e-08

Carriers O 0 1.0373371424066136e-06
of O 0 4.723634816627964e-10
the O 0 2.143096117235288e-10
same O 0 7.691515757635159e-10
mutation O 0 1.8290019498934385e-09
, O 0 4.5810532450785146e-11
from O 0 1.0525449956055866e-10
different O 0 1.830082752007911e-10
families O 0 2.0241025522338418e-10
, O 0 2.956565547940215e-11
shared O 0 1.3836445877934977e-10
similar O 0 1.7507469918243146e-09
haplotypes O 0 1.322384122204312e-07
, O 0 6.816086028926804e-10
indicating O 0 1.348874256734689e-08
that O 0 1.6673902536457064e-10
the O 0 9.395731415118291e-11
mutant O 0 7.96317944917746e-09
alleles O 0 4.950461374164661e-09
were O 0 6.563492149780359e-08
likely O 0 1.873512367467356e-08
to O 0 2.0527486654930982e-10
be O 0 2.659678588479153e-10
identical O 0 8.521074956746588e-10
by O 0 4.5515302637966215e-10
descent O 0 9.871379269554836e-09
for O 0 7.071036811634457e-11
a O 0 1.0314415987977554e-09
mutation O 0 4.395873887119706e-09
in O 0 4.59839100130921e-09
the O 0 1.2601141241574965e-09
founder O 0 1.5134533626337543e-08
population O 0 1.2543421856747727e-09
. O 0 1.517011227747389e-08

The O 0 7.887285136121136e-08
identification O 0 3.435849293964566e-08
of O 0 1.127238857812074e-09
common O 0 6.420112441674064e-08
BRCA1 O 0 8.63651221152395e-05
and O 0 2.005283761263854e-07
BRCA2 O 0 1.9236225853092037e-05
mutations O 0 3.3283870948253025e-07
will O 0 3.435401740858879e-09
facilitate O 0 1.0535060823713138e-08
carrier O 0 1.161279996608755e-07
detection O 0 4.221204008558743e-08
in O 0 2.115570474359174e-08
French O 0 4.1743092879187316e-05
Canadian O 0 9.625154780223966e-05
breast B-Disease 1 0.995797872543335
cancer I-Disease 0 0.4561251997947693
and O 0 0.30292224884033203
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
families O 0 1.6568847058806568e-06
. O 0 2.4297392542393936e-07

Are O 0 7.634665166733612e-07
Dp71 O 0 5.342128497431986e-05
and O 0 3.7280716469467734e-07
Dp140 O 0 2.051346018561162e-05
brain O 0 1.4428347640205175e-05
dystrophin O 0 4.427077328728046e-06
isoforms O 0 5.230248234511237e-07
related O 0 5.6895544275903376e-08
to O 0 2.0958704993745414e-08
cognitive B-Disease 0 3.971437763539143e-06
impairment I-Disease 0 0.00027084891917183995
in O 0 7.369063951045973e-06
Duchenne B-Disease 1 0.9999808073043823
muscular I-Disease 1 0.9999837875366211
dystrophy I-Disease 1 0.9999737739562988
? O 0 0.0001780954480636865

Molecular O 0 5.854210030520335e-06
study O 0 3.4018111705336196e-07
and O 0 3.217380140085879e-08
neuropsychological O 0 4.761109835271782e-07
analysis O 0 1.1034375191343315e-08
were O 0 4.723936797290662e-08
performed O 0 1.4399008207988118e-08
concurrently O 0 2.748958394249712e-09
on O 0 4.28125517260014e-08
49 O 0 5.768117148363672e-07
patients O 0 4.4397603460311075e-07
with O 0 2.1055534205061122e-07
Duchenne B-Disease 1 0.999997615814209
muscular I-Disease 1 0.9999996423721313
dystrophy I-Disease 1 0.9999992847442627
( O 0 1.4046525393496267e-05
DMD B-Disease 1 1.0
) O 0 9.171299275578804e-09
in O 0 3.3731539783588005e-09
order O 0 6.572029587204042e-10
to O 0 4.947410259248386e-10
find O 0 4.8801482854798905e-09
a O 0 8.972385612260325e-10
molecular O 0 4.181671009462207e-09
explanation O 0 4.606818482244535e-09
for O 0 2.63661120714076e-10
the O 0 1.6246022305210772e-09
cognitive B-Disease 0 5.067774395683955e-07
impairment I-Disease 0 2.569159278209554e-06
observed O 0 1.371093638624643e-08
in O 0 2.301463908338519e-08
most O 0 2.243962399006705e-06
DMD B-Disease 1 1.0
patients O 0 0.00045614413102157414
. O 0 3.029100525964168e-07

Complete O 0 3.621077553361829e-07
analysis O 0 2.8609530744461154e-08
of O 0 3.225081313118494e-10
the O 0 6.302382504763671e-10
dystrophin O 0 1.404476392963261e-07
gene O 0 1.3720817548801278e-07
was O 0 6.744112965861859e-07
performed O 0 5.462161833946766e-09
to O 0 1.483426298465318e-10
define O 0 2.2972743707327936e-09
the O 0 6.136188779315432e-10
localization O 0 5.012134707271798e-08
of O 0 2.4036445056552225e-10
deletions O 0 5.5321510927797135e-08
and O 0 2.7508937350262386e-09
duplications O 0 7.238193688863248e-08
in O 0 2.97478863764411e-09
relation O 0 3.778350965433219e-09
to O 0 4.663930353032697e-10
the O 0 1.8058428086220601e-09
different O 0 1.27092789625749e-07
DMD B-Disease 1 1.0
promoters O 0 2.762121584964916e-05
. O 0 2.2409054167837894e-07

Qualitative O 0 2.9895445550209843e-06
analysis O 0 7.203197327498856e-08
of O 0 5.794200119701998e-10
the O 0 8.946683949240253e-10
Dp71 O 0 2.0868837680154684e-07
transcript O 0 3.534511279212893e-07
and O 0 1.7096626336865484e-09
testing O 0 2.118686781571455e-09
for O 0 2.012510470772444e-11
the O 0 3.6709673495449735e-11
specific O 0 6.569118166099841e-11
first O 0 1.227917434398762e-09
exon O 0 1.0214203705061209e-08
of O 0 4.053940239057141e-10
Dp140 O 0 9.7751907901511e-08
were O 0 7.595899376156012e-08
also O 0 1.8080312802482013e-09
carried O 0 1.104869706836098e-08
out O 0 1.6715379302922884e-08
. O 0 1.3446332047806209e-08

Neuropsychological O 0 0.00032699081930331886
analysis O 0 1.619440126887639e-06
assessed O 0 2.1314469904609723e-06
verbal O 0 3.825148723990424e-06
and O 0 4.1737607148206735e-08
visuospatial O 0 2.6919728952634614e-06
intelligence O 0 2.408602028936002e-07
, O 0 3.929523373358279e-09
verbal O 0 1.576254646806774e-07
memory O 0 8.5489695322849e-08
, O 0 3.4077118904463077e-09
and O 0 7.594143092148897e-09
reading O 0 1.2805821825168096e-06
skills O 0 1.1488319842101191e-06
. O 0 3.8154535531020883e-08

Comparison O 0 9.105448839363817e-07
of O 0 4.946742571121376e-09
molecular O 0 3.578289664574186e-08
and O 0 3.4891487477040073e-09
psychometric O 0 2.738110254085768e-07
findings O 0 1.0625022639487725e-08
demonstrated O 0 6.544663033736242e-09
that O 0 6.258742413223217e-10
deletions O 0 2.737824722487403e-08
and O 0 2.3418111894102367e-09
duplications O 0 2.994549674895097e-08
that O 0 2.925122088992538e-10
were O 0 2.042334079632724e-09
localized O 0 2.6625477378416917e-09
in O 0 3.6543583714632177e-09
the O 0 8.32774960102256e-10
distal O 0 3.292472072757846e-08
part O 0 1.2265527482568928e-09
of O 0 5.949301468133328e-11
the O 0 2.646632912828295e-10
gene O 0 1.0116870896581531e-08
seemed O 0 2.0718822213439125e-07
to O 0 3.8996106344058035e-10
be O 0 4.6259318597918764e-10
preferentially O 0 2.975719004538746e-09
associated O 0 4.617692006547713e-09
with O 0 2.6249862283833636e-09
cognitive B-Disease 0 3.907018253812566e-06
impairment I-Disease 0 4.435853770701215e-05
. O 0 1.5025516120203974e-07

Two O 0 4.789093850376958e-07
altered O 0 2.413645233900752e-06
Dp71 O 0 3.202706238880637e-06
transcripts O 0 4.502722674715187e-07
and O 0 4.582490831239738e-09
two O 0 6.080568826227761e-10
deleted O 0 1.7484186543015312e-08
Dp140 O 0 1.774272817556266e-08
DNA O 0 3.346131371984029e-09
sequences O 0 1.0318075283066719e-09
were O 0 1.0876566314266256e-09
found O 0 4.2167741520771074e-10
in O 0 5.627254218154576e-10
four O 0 6.810618735642038e-09
patients O 0 4.681340826095948e-08
with O 0 1.5317842994022612e-08
severe O 1 0.9853796362876892
cerebral B-Disease 1 0.9997039437294006
dysfunction I-Disease 0 0.007562417536973953
. O 0 5.52548613086401e-07

These O 0 4.04299491663096e-08
findings O 0 2.628544848448655e-08
suggest O 0 5.859877028058236e-09
that O 0 7.2723778388184e-11
some O 0 1.7361733578580285e-11
sequences O 0 1.204219501893533e-10
located O 0 2.239050472807591e-10
in O 0 1.0261590466242865e-09
the O 0 5.064212937888612e-10
distal O 0 2.004342469774656e-08
part O 0 8.857238276149815e-10
of O 0 2.234488809260693e-11
the O 0 8.921068050948833e-11
gene O 0 4.304769873897385e-09
and O 0 3.104947188248275e-09
, O 0 6.841598815254812e-11
in O 0 1.9479941271161039e-10
particular O 0 1.1753353845733727e-09
, O 0 4.699308719935402e-10
some O 0 4.765545735807564e-09
DMD B-Disease 1 0.9999995231628418
isoforms O 0 3.502886869455324e-08
expressed O 0 3.3116148712153404e-10
in O 0 1.3573749901851784e-09
the O 0 3.965044292897346e-09
brain O 0 3.045293669856619e-05
may O 0 1.0914273929074625e-07
be O 0 2.805298493502306e-10
related O 0 4.780418838556955e-10
to O 0 2.654762520926113e-10
the O 0 3.710250107147317e-09
cognitive B-Disease 0 5.314776672094013e-07
impairment I-Disease 0 1.6870809531610576e-06
associated O 0 2.2006091171533626e-08
with O 0 6.156252396749551e-08
DMD B-Disease 1 1.0
. O 0 2.6668038799471105e-07
. O 0 1.4194107222920138e-07

I1307K O 0 0.0005786559777334332
APC O 0 4.376808283268474e-05
and O 0 5.8272561886951735e-08
hMLH1 O 0 1.0640374057402369e-06
mutations O 0 1.583790236736604e-07
in O 0 4.13148715239231e-09
a O 0 5.008710779463854e-09
non O 0 3.0807041184743866e-07
- O 0 4.88043951918371e-07
Jewish O 0 4.099470629626012e-08
family O 0 2.4392461384081798e-08
with O 0 6.624474746530495e-09
hereditary B-Disease 1 0.9694443941116333
non I-Disease 1 0.9999984502792358
- I-Disease 1 1.0
polyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 3.410078306842479e-06

We O 0 2.8150708430985105e-07
describe O 0 8.74741346024166e-08
a O 0 8.352171398939845e-09
French O 0 7.226364004964125e-07
Canadian O 0 3.1657589261158137e-06
hereditary B-Disease 1 0.9991857409477234
non I-Disease 1 0.9999990463256836
- I-Disease 1 1.0
polyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 9.573946044838522e-06
HNPCC B-Disease 0 0.0019271289929747581
) O 0 2.8980910116160885e-08
kindred O 0 5.310016149451258e-06
which O 0 1.827224593853316e-08
carries O 0 6.968806331997257e-08
a O 0 1.659656412300592e-08
novel O 0 9.783641274907495e-08
truncating O 0 5.006658739148406e-06
mutation O 0 2.082495257127448e-06
in O 0 2.795367777252977e-07
hMLH1 O 0 1.363814590149559e-05
. O 0 4.461249147880153e-07

Interestingly O 0 1.328881444351282e-05
, O 0 1.8719228833674606e-08
the O 0 4.807486853053433e-09
I1307K O 0 5.278181447465613e-07
APC O 0 3.0122222938189225e-07
polymorphism O 0 4.684775092300697e-07
, O 0 3.4151861894038404e-10
associated O 0 5.399851676912704e-10
with O 0 4.0940573847736417e-11
an O 0 9.070943995936886e-11
increased O 0 1.499187902709309e-07
risk O 0 3.309613384772092e-05
of O 0 0.011337203904986382
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, O 0 7.727221529307826e-09
is O 0 1.4897579003747552e-10
also O 0 3.4820865635332154e-10
present O 0 3.875059301217121e-11
in O 0 1.1375614228370523e-08
this O 0 3.1426798940970002e-09
family O 0 1.3836829459989985e-08
. O 0 1.3961613198887335e-08

The O 0 1.747515909755748e-07
I1307K O 0 2.6403010906506097e-06
polymorphism O 0 2.456644097037497e-06
has O 0 5.0830277764646326e-09
previously O 0 1.3098165885239155e-09
only O 0 8.90840040623786e-11
been O 0 2.8350932712584154e-10
identified O 0 3.380127011620715e-10
in O 0 6.13094505719225e-11
individuals O 0 7.731500335783625e-12
of O 0 2.196395669507023e-11
self O 0 3.523424751961102e-08
- O 0 4.1211819734598976e-06
reported O 0 1.3039370969636366e-05
Ashkenazi O 0 5.292698119774286e-07
Jewish O 0 1.986636632977934e-08
origins O 0 3.016100436070701e-07
. O 0 5.2673193806640484e-08

In O 0 3.584991148386507e-08
addition O 0 2.946435539996628e-09
, O 0 4.021939725706858e-10
in O 0 6.539867536403676e-10
this O 0 2.319923697591264e-10
family O 0 1.2085713541054588e-09
, O 0 1.0009032491709036e-10
there O 0 4.143085319263662e-10
appears O 0 5.074019426842824e-09
to O 0 2.3479376776158745e-10
be O 0 1.2936902660243277e-09
no O 0 1.1260934407175682e-09
relationship O 0 8.667289108643672e-10
between O 0 3.598394082704459e-10
the O 0 4.96738983279954e-10
I1307K O 0 2.70213220687765e-08
polymorphism O 0 1.4670320958032335e-08
and O 0 1.853450309896587e-10
the O 0 5.18673749783094e-11
presence O 0 8.486009117625315e-10
or O 0 4.142147069785551e-09
absence O 0 7.176727656599269e-09
of O 0 6.501126859070894e-10
cancer B-Disease 0 1.4603116937905725e-07
. O 0 4.670431152931087e-09
. O 0 2.081826444566559e-08

Identification O 0 4.2862640725616075e-07
of O 0 1.5621323123937714e-09
a O 0 3.596577924369626e-09
novel O 0 1.3107544383217373e-08
mutation O 0 1.702101926071009e-08
of O 0 1.5194391578265964e-10
the O 0 8.747004787146295e-10
CPO O 0 2.7305611638439586e-07
gene O 0 1.0155168261860581e-08
in O 0 3.3433051882525433e-09
a O 0 1.439719454765509e-08
Japanese O 0 3.1790102639206452e-06
hereditary B-Disease 0 0.00020272372057661414
coproporphyria I-Disease 0 5.7655939599499106e-05
family O 0 2.4655767560943787e-07
. O 0 7.407722790730986e-08

Hereditary B-Disease 1 0.9998459815979004
coproporphyria I-Disease 0 0.4596230387687683
( O 0 9.122779374592938e-06
HCP B-Disease 0 0.00038250169018283486
) O 0 1.2017289385823915e-08
is O 0 2.731694426216791e-09
an O 0 1.446294728424391e-08
autosomal B-Disease 1 0.999847412109375
dominant I-Disease 1 0.9999880790710449
disease I-Disease 1 0.9933274984359741
characterized O 0 7.992456403371762e-07
by O 0 2.652275377101887e-08
a O 0 7.134616225812351e-06
deficiency B-Disease 0 0.0014918097294867039
of I-Disease 0 1.9924644156787963e-09
coproporphyrinogen I-Disease 0 3.997000931121875e-06
oxidase I-Disease 0 1.3810523569190991e-06
( O 0 1.2586231612488064e-08
CPO O 0 1.0149010449822526e-06
) O 0 6.927056706018675e-10
caused O 0 1.917157765873867e-09
by O 0 1.6741621977622856e-10
a O 0 3.872617782008092e-09
mutation O 0 2.601675141988835e-08
in O 0 8.597941025811906e-09
the O 0 7.632799281509506e-09
CPO O 0 2.8156584903626936e-06
gene O 0 4.948868763676728e-07
. O 0 1.1750270800803264e-07

Only O 0 2.7620629339253355e-07
11 O 0 3.008788240776994e-08
mutations O 0 8.092932546333031e-09
of O 0 4.3168683905303595e-11
the O 0 2.688536893113991e-10
gene O 0 1.3202085646923933e-08
have O 0 3.7501921568150465e-09
been O 0 9.296662106805798e-09
reported O 0 1.546346624081707e-07
in O 0 1.1091669449569963e-07
HCP B-Disease 0 0.0004553590260911733
patients O 0 3.054461785723106e-06
. O 0 5.0338055501697454e-08

We O 0 7.242238666549383e-07
report O 0 3.7619859227788766e-08
another O 0 2.2169497349011635e-09
mutation O 0 1.0434272113002407e-08
in O 0 2.903240536866747e-09
a O 0 7.215157804552064e-09
Japanese O 0 2.6798497287927603e-07
family O 0 1.4172364615205879e-08
. O 0 2.168314949813066e-08

Polymerase O 0 7.087090489221737e-05
chain O 0 8.819273716653697e-06
reaction O 0 9.669710152593325e-07
- O 0 3.3136102501885034e-06
single O 0 6.456732393189668e-08
strand O 0 1.6491239875904284e-06
conformational O 0 1.5886112691987364e-07
polymorphism O 0 3.386138871519506e-07
and O 0 4.5686820993040556e-10
direct O 0 1.9434935882856053e-09
sequence O 0 4.81558082299216e-09
analyses O 0 1.1653067844008547e-08
demonstrated O 0 2.0282620027956e-09
a O 0 1.5809623610252288e-09
C O 0 1.9668655681925884e-07
to O 0 1.0408207629097888e-09
T O 0 1.3447017011003481e-07
substitution O 0 3.015318661425681e-09
in O 0 1.688929329723976e-09
exon O 0 1.1974640834466754e-08
1 O 0 4.1639602876841764e-10
of O 0 4.001263209651995e-11
the O 0 2.440872504116953e-10
CPO O 0 3.679763338482189e-08
gene O 0 7.264219892277879e-09
at O 0 2.078595517929216e-09
nucleotide O 0 3.432578887796467e-09
position O 0 8.559702280308557e-09
85 O 0 1.936492521892319e-09
, O 0 1.8276967439501135e-10
which O 0 2.2137076893802288e-10
lies O 0 8.906569926026009e-10
in O 0 1.4733632092145399e-09
the O 0 1.0710066167263221e-09
putative O 0 2.842297242011682e-08
presequence O 0 7.699948412209778e-08
for O 0 2.3031214435587088e-10
targeting O 0 6.35144026261969e-09
to O 0 4.1662344685278185e-09
mitochondria O 0 1.0381714901086525e-06
. O 0 9.891324026511938e-08

This O 0 1.797243527335013e-07
mutation O 0 2.552917237608199e-07
changes O 0 2.265000986767518e-08
the O 0 2.0039057080367684e-09
codon O 0 1.0906573777447193e-07
for O 0 3.008722160302568e-10
glutamine O 0 1.2796292025996081e-08
to O 0 6.663693485897682e-10
a O 0 3.832555606209098e-09
termination O 0 1.8687609326661914e-07
codon O 0 2.300154591239334e-07
at O 0 1.4661369007740177e-08
amino O 0 6.275217234730235e-09
acid O 0 1.954669315296087e-08
position O 0 5.985162232491348e-08
29 O 0 1.3619624894545268e-07
. O 0 1.3154554778793681e-08

MaeI O 0 9.515569399809465e-05
restriction O 0 6.085307973080489e-07
analysis O 0 4.8197364321822533e-08
showed O 0 5.3579476855247776e-08
two O 0 2.363609585831483e-10
other O 0 4.7131028246827356e-11
carriers O 0 2.3068242871460143e-09
in O 0 1.4642554946320274e-09
the O 0 3.1651181675584894e-09
family O 0 2.2101280805486567e-08
. O 0 1.798127513552572e-08

The O 0 4.680769336573576e-07
C O 0 0.2336396723985672
- O 1 0.649715006351471
T O 0 0.0005595131078734994
mutation O 0 5.0708486298844946e-08
is O 0 3.610590437741479e-10
located O 0 6.020305920451108e-10
within O 0 3.3399447096904566e-10
a O 0 2.3489552525290947e-09
recently O 0 3.902709977410268e-08
proposed O 0 1.9462420564053673e-09
putative O 0 7.539357582686534e-09
alternative O 0 6.0067284479714544e-09
translation O 0 7.51248947494787e-08
initiation O 0 7.671450674706648e-08
codon O 0 4.0374854393121495e-07
( O 0 9.049006877148713e-09
TIC O 0 9.922547178575769e-06
- O 0 5.966787597344592e-08
1 O 0 1.2707993546356988e-09
) O 0 7.316104666532652e-11
, O 0 1.914192589158592e-11
supporting O 0 2.1088483737052854e-10
that O 0 2.883093319638874e-09
TIC O 0 4.159776653978042e-05
- O 0 3.260494096934963e-08
1 O 0 1.3705884205350571e-09
is O 0 1.989911152522339e-10
the O 0 1.697969126412957e-10
real O 0 8.442234644689961e-08
TIC O 0 1.7993614847000572e-06
rather O 0 1.6040894168511954e-09
than O 0 2.253515596351008e-09
TIC O 0 6.312749974313192e-06
- O 0 4.086417604298731e-08
2 O 0 4.0989212024555854e-09
. O 0 2.0482520124431858e-09
. O 0 1.278326511311434e-08

Human B-Disease 0 4.875955141869781e-07
complement I-Disease 0 4.861129582423018e-06
factor I-Disease 0 9.598371980246156e-05
H I-Disease 1 1.0
deficiency I-Disease 1 0.9999359846115112
associated O 0 3.900896990671754e-05
with O 0 0.0003757108934223652
hemolytic B-Disease 1 1.0
uremic I-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 7.496481430280255e-06

This O 0 3.4303944573821354e-08
study O 0 6.448287237503791e-09
reports O 0 6.996479395837696e-09
on O 0 2.935037990425826e-09
six O 0 4.403703179889362e-09
cases O 0 3.084765110017429e-09
of O 0 2.727909231836634e-09
deficiency B-Disease 0 3.99268446926726e-06
in I-Disease 0 1.2423418960239019e-09
the I-Disease 0 2.3898388823440087e-10
human I-Disease 0 1.8257907685725883e-10
complement I-Disease 0 3.5956175814533253e-09
regulatory I-Disease 0 7.454055150901695e-08
protein I-Disease 0 2.866092607689552e-08
Factor I-Disease 0 1.0353194568324398e-07
H I-Disease 1 0.9999995231628418
( O 0 3.1765743813139125e-08
FH O 0 8.323139809363056e-06
) O 0 4.4102826946001983e-10
in O 0 3.2098254609813637e-10
the O 0 1.1036006136722065e-10
context O 0 4.636578232464217e-09
of O 0 1.1577360181647123e-09
an O 0 2.724432874856575e-07
acute B-Disease 1 0.9999939203262329
renal I-Disease 1 1.0
disease I-Disease 1 1.0
. O 0 3.203665528417332e-06

Five O 0 8.746913238155685e-08
of O 0 3.525753855537772e-10
the O 0 8.484229430116841e-10
cases O 0 1.2661878212583133e-09
were O 0 6.315345579821496e-09
observed O 0 8.672713103230478e-10
in O 0 2.5267656855731957e-09
children O 0 3.6450442664204274e-09
presenting O 0 1.0423654828173312e-07
with O 0 1.292443266720511e-05
idiopathic O 1 0.9999998807907104
hemolytic B-Disease 1 1.0
uremic I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 0.000198940557311289
HUS B-Disease 1 0.9999988079071045
) O 0 6.960416953916138e-07
. O 0 4.7213788434419257e-07

Two O 0 4.191639035866501e-08
of O 0 5.726630281088774e-10
the O 0 7.796860379549742e-10
children O 0 5.694762883479143e-09
exhibited O 0 2.1263682015160157e-07
a O 0 1.6078417957032798e-06
homozygous O 1 0.9098940491676331
deficiency O 0 0.03948957100510597
characterized O 0 5.550898851680586e-09
by O 0 4.973978451339178e-10
the O 0 1.9463981537626296e-09
absence O 0 4.6721062574306416e-09
of O 0 3.9822596609173644e-11
the O 0 4.67104355195147e-10
150 O 0 3.882306032210181e-09
- O 0 5.868581709478349e-08
kD O 0 9.898155184373536e-08
form O 0 1.869652654917786e-09
of O 0 2.064414056368591e-10
Factor O 0 1.9048316701741896e-08
H O 1 0.9999996423721313
and O 0 1.7720465095294458e-09
the O 0 6.786169542971621e-11
presence O 0 4.0540565349189706e-10
, O 0 6.542060643210945e-11
upon O 0 6.697482152207002e-11
immunoblotting O 0 3.475607357472654e-08
, O 0 6.890998188735509e-11
of O 0 1.3421124454848776e-11
the O 0 2.9380609056772755e-10
42 O 0 3.0830605624032614e-08
- O 0 5.586984386241056e-08
kD O 0 5.862461875949521e-07
Factor O 0 3.1280062984251344e-08
H O 1 0.9999980926513672
- O 0 1.801430471459753e-07
like O 0 6.520453510461266e-09
protein O 0 8.74412364737509e-09
1 O 0 5.075006637156321e-09
( O 0 3.021686456605721e-09
FHL O 0 3.3302330848528072e-06
- O 0 8.921404059947236e-08
1 O 0 2.15739826003869e-09
) O 0 8.719149707792084e-11
and O 0 1.3756080996518705e-10
other O 0 1.0135871031380361e-09
FH O 0 0.00046149169793352485
- O 0 7.891844688856509e-08
related O 0 2.2603614979743725e-08
protein O 0 2.8457526113356835e-08
( O 0 3.0733540157257266e-09
FHR O 0 8.9271890146847e-07
) O 0 1.7041280608864895e-09
bands O 0 9.697214409243315e-08
. O 0 2.833474432861749e-08

Southern O 0 5.206835339777172e-06
blot O 0 7.279537385329604e-05
and O 0 2.835020218583395e-08
PCR O 0 5.954429980192799e-07
analysis O 0 2.921677788592092e-09
of O 0 7.911590826914505e-11
DNA O 0 4.189790292485895e-09
of O 0 9.286586777346173e-11
one O 0 1.3668107756714676e-09
patient O 0 4.0449922522611814e-08
with O 0 2.5862667563103514e-09
homozygous O 0 0.0018811256159096956
deficiency O 0 0.035390324890613556
ruled O 0 4.029592162169138e-07
out O 0 4.949413323629415e-09
the O 0 1.5514360629520496e-10
presence O 0 4.817085064168225e-10
of O 0 7.352476266708763e-11
a O 0 6.734582336243022e-10
large O 0 8.487433533765909e-10
deletion O 0 2.8371841764851524e-08
of O 0 9.02433267002678e-11
the O 0 1.563482676658623e-09
FH O 0 5.14812791152508e-06
gene O 0 2.194640025265926e-08
as O 0 4.523716068405292e-09
the O 0 1.5430469124666502e-09
underlying O 0 3.2707501418371976e-07
defect O 0 2.3984887320693815e-07
for O 0 2.551075350964993e-09
the O 0 1.791941457440771e-07
deficiency O 0 0.00010491347347851843
. O 0 1.050524716106338e-07

The O 0 5.484976028924393e-08
other O 0 2.7385336220930867e-09
four O 0 1.2545289251875147e-09
children O 0 1.2512263447561622e-09
presented O 0 3.006211279910076e-09
with O 0 1.1114896558694909e-08
heterozygous O 0 0.22738273441791534
deficiency O 0 0.04416634514927864
and O 0 1.2091784462597843e-08
exhibited O 0 9.394203459578421e-08
a O 0 1.3827595068960363e-08
normal O 0 2.569389607742778e-07
immunoblotting O 0 2.763712245723582e-06
pattern O 0 6.632227211866848e-08
of O 0 1.6783921474861074e-10
proteins O 0 5.086652765662336e-10
of O 0 2.322106257279799e-10
the O 0 1.6197269303575013e-08
FH O 0 0.0008318197214975953
family O 0 9.30585457581401e-08
. O 0 1.4520806246309803e-07

Factor B-Disease 0 0.028286747634410858
H I-Disease 1 1.0
deficiency I-Disease 1 0.9995946288108826
is O 0 1.7443015920548532e-08
the O 0 3.239410517608121e-09
only O 0 3.6242246892470575e-07
complement B-Disease 1 1.0
deficiency I-Disease 1 1.0
associated O 0 6.179888032420422e-07
with O 0 1.3164638801299589e-07
HUS B-Disease 1 0.9999942779541016
. O 0 2.0018590021209093e-06

These O 0 5.3616890482999224e-08
observations O 0 6.823233178465671e-08
suggest O 0 1.7448305911216266e-08
a O 0 2.5139976767007965e-09
role O 0 4.223545513326599e-09
for O 0 1.991301790127409e-09
FH O 0 4.836731750401668e-05
and O 0 8.690335562278051e-09
/ O 0 4.5736521769867977e-07
or O 0 1.490518286573206e-08
FH O 0 6.845080861239694e-06
receptors O 0 1.189483089802934e-08
in O 0 1.9988668498172046e-09
the O 0 1.573651764452677e-09
pathogenesis O 0 1.4055295594062045e-07
of O 0 1.01283390563367e-08
idiopathic O 0 0.0019810344092547894
HUS B-Disease 1 0.999994158744812
. O 0 2.156110099349462e-07
. O 0 1.5878539727509633e-07

Further O 0 3.088461539846321e-07
evidence O 0 1.4360445277361578e-08
for O 0 4.241441087238229e-10
a O 0 1.8185835060080535e-09
major O 0 6.95340229839303e-09
ancient O 0 7.706075422220238e-08
mutation O 0 1.546315434097778e-05
underlying O 0 0.011258629150688648
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
from O 0 1.9426053654569841e-07
linkage O 0 1.262840123672504e-05
disequilibrium O 0 2.6738360247691162e-05
studies O 0 7.112437572232011e-08
in O 0 2.569181756229e-09
the O 0 7.149890124402702e-10
Japanese O 0 2.1205153188930126e-08
population O 0 9.789344890265284e-10
. O 0 8.56863646703232e-09

The O 0 5.691344995284453e-05
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.5449934601783752
DM B-Disease 1 1.0
) O 0 1.005493004413438e-07
mutation O 0 5.46944143309247e-08
is O 0 1.6761887433602851e-09
an O 0 2.5617634680230594e-09
unstable O 0 1.6771553418948315e-05
( O 0 1.4969000261544352e-08
CTG O 0 1.286953533963242e-06
) O 0 1.2026225570949123e-09
n O 0 2.4997120817715768e-08
repeat O 0 1.6476967346079618e-07
, O 0 3.827907157916144e-10
present O 0 6.549338849026753e-11
at O 0 2.598737669501361e-09
a O 0 2.686394162676464e-10
copy O 0 9.019265334586635e-09
number O 0 2.346155769661351e-10
of O 0 5.03765917869714e-11
5 O 0 5.407996717110564e-09
- O 0 2.1242421155420743e-07
37 O 0 2.4073450788364426e-08
repeats O 0 1.636758106826619e-08
on O 0 1.4439931028675801e-08
normal O 0 9.290900493397203e-09
chromosomes O 0 1.048126652136716e-08
but O 0 2.0345269913235597e-09
amplified O 0 1.2243772218312188e-08
to O 0 9.569526282504626e-10
50 O 0 6.828646537115901e-09
- O 0 2.3218872158281556e-08
3000 O 0 1.333540833314828e-08
copies O 0 8.488121494565348e-08
on O 0 2.5488076062174514e-05
DM B-Disease 1 1.0
chromosomes O 0 1.986858023883542e-06
. O 0 1.1266251220831691e-07

Previous O 0 2.349849410165916e-06
findings O 0 1.8616154306982935e-07
in O 0 9.253126265207356e-09
Caucasian O 0 2.2262609888912266e-07
populations O 0 4.190861879749264e-09
of O 0 8.996342004685687e-10
a O 0 2.8321776426309953e-06
DM B-Disease 1 1.0
founder O 0 2.419083557470003e-06
chromosome O 0 3.8005025544407545e-06
raise O 0 9.604313788713625e-08
a O 0 1.147220629604817e-08
question O 0 2.382363817332589e-08
about O 0 6.900287008448913e-10
the O 0 1.2873464794171952e-10
molecular O 0 8.792552241843055e-10
events O 0 3.8594163975780305e-10
involved O 0 1.7785308781270714e-09
in O 0 1.2803705873309923e-09
the O 0 7.661749013010422e-10
expansion O 0 8.81904753669005e-08
mutation O 0 2.559436040883156e-07
. O 0 4.607611714391169e-08

To O 0 1.309430643914311e-07
investigate O 0 4.430970079738472e-08
whether O 0 1.050440179284351e-08
a O 0 4.7070796149739635e-09
founder O 0 4.210308546248598e-08
chromosome O 0 2.0785340382190043e-07
for O 0 1.5425641874955431e-09
the O 0 7.966463755337827e-08
DM B-Disease 1 1.0
mutation O 0 6.26025240535455e-08
exists O 0 8.231261783286925e-10
in O 0 8.270447660052582e-10
the O 0 1.286291212432289e-10
Japanese O 0 6.064611035583312e-09
population O 0 1.7997306769879096e-11
, O 0 9.13340861274925e-11
we O 0 2.5593607233531657e-09
genotyped O 0 2.0372580067373747e-08
families O 0 2.347910477151771e-10
using O 0 3.5921077223832754e-09
polymorphic O 0 2.0344667461813515e-07
markers O 0 2.2049475489893666e-07
near O 0 1.258701587403266e-07
the O 0 9.064172523665093e-09
( O 0 1.0710296649563134e-08
CTG O 0 8.399684929827345e-07
) O 0 1.842492824977171e-09
n O 0 7.566083581878047e-08
repeat O 0 1.9821823116217274e-07
region O 0 2.5846015105912556e-08
and O 0 1.4788088087414053e-08
constructed O 0 1.434673322364688e-07
haplotypes O 0 5.85164252697723e-06
. O 0 8.913851701208841e-08

Six O 0 4.4826967382505245e-07
different O 0 2.2339337490961952e-08
haplotypes O 0 7.634686767232779e-07
were O 0 1.3013423938446067e-07
found O 0 3.788513680547112e-08
and O 0 1.4500603811029578e-06
DM B-Disease 1 1.0
alleles O 0 5.08537766563677e-07
were O 0 1.610803678886441e-06
always O 0 2.49785870209962e-07
haplotype O 0 2.0001928078272613e-06
A O 0 4.6405668285842694e-07
. O 0 3.5966553468824713e-07

To O 0 5.2840032793710634e-08
find O 0 1.4392856684253275e-08
an O 0 1.3206581661595607e-10
origin O 0 3.022993244616856e-10
of O 0 2.869621901213648e-11
the O 0 5.2602866507101e-10
( O 0 1.9805217466029035e-09
CTG O 0 1.5740855019430455e-07
) O 0 6.482541170527156e-10
n O 0 1.6588904472314425e-08
repeat O 0 1.3726406677960767e-07
mutation O 0 8.496572334593111e-09
and O 0 8.353776004277336e-10
to O 0 1.0442006287414429e-10
investigate O 0 7.195707363294446e-10
the O 0 2.917421859649494e-10
mechanism O 0 1.2444361097152523e-09
of O 0 1.2324517274786562e-11
the O 0 3.955386365661617e-11
expansion O 0 7.683568781224892e-10
mutation O 0 6.860458312551998e-10
in O 0 1.3372099261221848e-10
the O 0 6.0411911584346e-11
Japanese O 0 2.4434076983936848e-09
population O 0 9.54408774234139e-12
we O 0 2.0391920096951566e-10
have O 0 9.659562039132652e-11
studied O 0 7.336538598856635e-10
90 O 0 7.301596549602607e-10
Japanese O 0 9.300058536609868e-07
DM B-Disease 1 1.0
families O 0 8.749190816281782e-10
comprising O 0 3.7132497077152493e-10
190 O 0 4.718927471003553e-09
affected O 0 5.175506689880649e-09
and O 0 1.3460823566902036e-09
130 O 0 1.4208145771021918e-08
unaffected O 0 8.295502311739256e-07
members O 0 1.3181002067597092e-08
. O 0 2.6493880866951258e-08

The O 0 4.906180706143459e-08
results O 0 7.09842424839735e-08
suggest O 0 1.0253867976928177e-08
that O 0 2.3069639254469365e-10
a O 0 2.8803492924112106e-10
few O 0 1.3651797470259908e-09
common O 0 6.725519585693007e-10
ancestral O 0 4.54715021191987e-09
mutations O 0 9.762070263263922e-09
in O 0 1.2048957387378323e-09
both O 0 1.8081899311184202e-09
Caucasian O 0 9.002220480169854e-08
and O 0 1.032337104689418e-09
Japanese O 0 2.1968209473754996e-09
populations O 0 3.1229938773913446e-11
have O 0 4.1039630027661644e-11
originated O 0 2.5721713647897104e-10
by O 0 1.6021430709889373e-11
expansion O 0 3.482810428945271e-10
of O 0 1.3611431426419074e-11
an O 0 6.57568652306928e-11
ancestral O 0 1.6002207336995866e-09
n O 0 4.682296150804177e-08
= O 0 4.3320433462668007e-08
5 O 0 5.403140601600853e-09
repeat O 0 4.3374754454816866e-08
to O 0 1.235366586804787e-09
n O 0 5.4018659767507415e-08
= O 0 8.887267455293113e-08
19 O 0 1.467085866124762e-07
- O 0 2.746856182511692e-07
37 O 0 1.1400315713672171e-07
copies O 0 2.98437782930705e-07
. O 0 6.5250212344381e-08

These O 0 4.450901158747911e-08
data O 0 1.6576633399267848e-08
support O 0 9.643825737981615e-10
multistep O 0 1.7133007190750504e-07
models O 0 1.1405328592672959e-07
of O 0 1.358149259722552e-09
triplet O 0 1.2624478813449969e-06
repeat O 0 1.0882013157242909e-07
expansion O 0 8.510067317502035e-09
that O 0 4.3068040800342544e-10
have O 0 1.319406667255052e-10
been O 0 1.0488015317333677e-10
proposed O 0 1.0951334977749028e-10
for O 0 2.9442992488526443e-10
both O 0 2.3267153892447823e-07
DM B-Disease 1 1.0
and O 0 2.9074094527459238e-06
Friedreichs B-Disease 0 4.36348891525995e-05
ataxia I-Disease 0 6.736670184182003e-05
. O 0 3.099014378449283e-08
. O 0 4.812892484551412e-08

The O 0 2.4990351121800813e-08
molecular O 0 5.097477284721208e-08
basis O 0 5.278010206666295e-08
of O 0 4.275284481991548e-06
C6 B-Disease 1 1.0
deficiency I-Disease 1 1.0
in O 0 1.2045285657791283e-08
the O 0 5.343878117791689e-10
western O 0 1.3089157313572741e-08
Cape O 0 8.505137572001331e-08
, O 0 1.1131778832051964e-09
South O 0 7.120755096678977e-09
Africa O 0 3.8545280744983756e-08
. O 0 3.104717904989229e-08

Deficiency B-Disease 1 0.9972158670425415
of I-Disease 0 3.702904427527187e-09
the I-Disease 0 2.9090883035820525e-09
sixth I-Disease 0 2.874649673856311e-08
component I-Disease 0 2.6229542982036946e-09
of I-Disease 0 3.3790553688461955e-11
human I-Disease 0 2.3050462927276527e-10
complement I-Disease 0 1.3538049792316542e-08
( O 0 8.96857343946067e-09
C6 O 0 1.0437913715577452e-06
) O 0 2.4452434521649025e-10
has O 0 3.231102885248305e-10
been O 0 1.4081283916667076e-09
reported O 0 2.3669688431482427e-08
in O 0 4.0629197228803093e-10
a O 0 6.524589202250297e-11
number O 0 2.6314502660218508e-11
of O 0 8.456174128979033e-12
families O 0 1.686358865049531e-11
from O 0 7.775589200287314e-11
the O 0 5.330499236455566e-11
western O 0 3.779143664672802e-09
Cape O 0 4.842173595420718e-08
, O 0 7.207038854595282e-10
South O 0 3.751944976926325e-09
Africa O 0 3.379988555707314e-08
. O 0 2.7445640427004037e-08

Meningococcal B-Disease 1 0.9999622106552124
disease I-Disease 1 0.9836375117301941
is O 0 9.548366364242611e-08
endemic O 0 2.720853942150825e-08
in O 0 3.238483925471769e-09
the O 0 1.7092713910926705e-09
Cape O 0 5.3209788575259154e-08
and O 0 1.8194890039069378e-09
almost O 0 6.785227379957348e-10
all O 0 1.7834148047235487e-10
pedigrees O 0 3.138536541769099e-08
of O 0 7.758911846345029e-10
total O 0 1.6439546016044915e-05
C6 B-Disease 1 1.0
deficiency I-Disease 1 1.0
( O 0 3.043331986418707e-08
C6Q0 O 0 2.0451436739676865e-06
) O 0 4.75405881328328e-10
have O 0 1.2787501058042494e-09
been O 0 4.608005088613254e-09
ascertained O 0 3.034145024116697e-08
because O 0 3.7250200701777203e-09
of O 0 2.0817658707983355e-09
recurrent O 0 0.00011169737990712747
disease O 0 0.0007925613899715245
. O 0 4.384546627989039e-07

We O 0 2.620745931380952e-07
have O 0 2.3781088209773316e-09
sequenced O 0 7.235691601437111e-09
the O 0 1.9479420854118246e-10
expressed O 0 4.05513900236798e-10
exons O 0 3.293449957197936e-09
of O 0 1.192066584332352e-10
the O 0 1.5337364711598411e-09
C6 O 0 6.059549377823714e-07
gene O 0 8.790729033592015e-09
from O 0 3.977858598069872e-10
selected O 0 6.21820261947903e-10
cases O 0 8.937166562361654e-10
and O 0 1.2500382950975109e-09
have O 0 5.699250404944678e-09
found O 0 7.971597604239378e-09
three O 0 1.5716179468938662e-09
molecular O 0 1.5871697200964263e-07
defects O 0 2.9874194297008216e-05
leading O 0 1.5585113644078774e-08
to O 0 1.5891492566311172e-09
total O 0 5.3847585945732135e-08
deficiency O 0 0.00018710411677602679
879delG O 0 3.175096878749173e-07
, O 0 3.1513941456395855e-10
which O 0 1.659749698790236e-10
is O 0 7.860721101815571e-11
the O 0 2.646627639268928e-10
common O 0 3.724005992467028e-08
defect O 0 1.3241597685009765e-07
in O 0 1.4331542619316906e-09
the O 0 1.3730085957064375e-09
Cape O 0 1.5670272190959622e-08
and O 0 1.3302529078274006e-09
hitherto O 0 1.901622681543813e-08
unreported O 0 1.603784305359568e-08
, O 0 1.82476381227481e-10
and O 0 4.1454964461173915e-10
1195delC O 0 1.6914414757707164e-08
and O 0 6.729009571770916e-10
1936delG O 0 3.262403680537318e-08
, O 0 1.3910696206043127e-10
which O 0 7.071765395494367e-11
have O 0 1.0086533691611166e-10
been O 0 2.521079178752217e-10
previously O 0 4.155518429360683e-10
reported O 0 1.0398629513019841e-08
in O 0 1.5440390077614552e-09
African O 0 4.472198611438216e-09
- O 0 2.1685305284790957e-07
Americans O 0 2.7559526216691665e-08
. O 0 1.9660998162862597e-08

We O 0 1.7709923838538089e-07
also O 0 2.14954898325459e-09
show O 0 2.0167778558288774e-09
that O 0 1.113349343273562e-10
the O 0 4.31101210285334e-10
879delG O 0 3.552598002443119e-07
and O 0 3.9098996040820566e-08
1195delC O 0 2.748369297478348e-05
defects O 0 0.00024408615718130022
are O 0 3.983021135134379e-10
associated O 0 1.737122667933022e-09
with O 0 1.7836505605828279e-09
characteristic O 0 1.9772405721596442e-05
C6 O 1 0.9842768907546997
/ O 0 0.0004898809711448848
C7 O 0 1.813863855204545e-05
region O 0 7.942401225591311e-08
DNA O 0 3.701960622493061e-07
marker O 0 3.6063445918443904e-07
haplotypes O 0 1.1128747701150132e-06
, O 0 4.25940838155725e-09
although O 0 1.8314489924620148e-09
small O 0 7.598862650226579e-10
variations O 0 2.768322637791698e-08
were O 0 4.6173511236702325e-07
observed O 0 3.02644060923285e-08
. O 0 2.6282689802314962e-08

The O 0 2.8002824592476827e-07
1936delG O 0 1.4144990927889012e-05
defect O 0 4.975927822670201e-06
was O 0 2.227934103871121e-08
observed O 0 4.373950923675096e-10
only O 0 6.646844880053848e-11
once O 0 5.70021529977538e-10
in O 0 4.3937423144235765e-10
the O 0 3.1215305340559496e-10
Cape O 0 8.007455143399511e-09
, O 0 2.7605584485002055e-10
but O 0 3.245104185367609e-10
its O 0 1.0958062235388866e-10
associated O 0 3.8991512241182136e-09
haplotype O 0 8.870727583598637e-07
could O 0 2.6374948447482893e-07
be O 0 7.708967686426149e-09
deduced O 0 2.404152326107578e-07
. O 0 4.6566281497462114e-08

The O 0 8.468587253673832e-08
data O 0 2.420203770725493e-08
from O 0 1.3964776002239887e-09
the O 0 5.409521164345676e-10
haplotypes O 0 8.343656787701548e-08
indicate O 0 4.5639399814945136e-08
that O 0 6.419127451806617e-10
these O 0 2.5873805875598066e-10
three O 0 1.5815021514598016e-09
molecular O 0 8.155243591545513e-08
defects O 0 4.048121809319127e-06
account O 0 1.961656392879263e-09
for O 0 7.10288716732066e-10
the O 0 4.750936355435442e-08
defects O 0 0.002508732723072171
in O 0 3.2030382790537715e-09
all O 0 5.961459104142364e-10
the O 0 9.55355017318027e-10
38 O 0 1.8660445633145173e-08
unrelated O 0 4.847616708048008e-08
C6Q0 O 0 1.8591543948787148e-06
individuals O 0 5.605262920482801e-10
we O 0 1.2895171597193666e-09
have O 0 2.5817067927924597e-10
studied O 0 1.4956607063965066e-09
from O 0 4.873290659901386e-10
the O 0 1.7997394685664858e-09
Cape O 0 7.746187691282103e-08
. O 0 2.4327968972670533e-08

We O 0 2.7909828759220545e-07
have O 0 3.584100571885074e-09
also O 0 4.021034616386032e-10
observed O 0 4.619292726104618e-10
the O 0 9.192011596326211e-10
879delG O 0 6.406888815035927e-07
defect O 0 4.119655159229296e-07
in O 0 3.11849723821922e-09
two O 0 3.972517248485019e-08
Dutch O 1 0.9999428987503052
C6 B-Disease 1 1.0
- I-Disease 1 0.9999985694885254
deficient I-Disease 1 1.0
kindreds O 0 2.3696853531873785e-05
, O 0 1.266484916939703e-09
but O 0 4.1137768191923385e-10
the O 0 1.260673648806332e-10
879delG O 0 8.676609297708637e-08
defect O 0 2.86851538078281e-08
in O 0 4.115691953909817e-10
the O 0 2.7851509987186773e-10
Cape O 0 1.298665353033357e-08
probably O 0 7.240830086630012e-07
did O 0 8.430355080690788e-09
not O 0 2.0812922219004548e-10
come O 0 1.9781649929218048e-10
from O 0 8.485292329885041e-11
The O 0 2.711815494382819e-10
Netherlands O 0 1.4014845817200694e-07
. O 0 2.9697937442563216e-09
. O 0 1.0174226794390506e-08

Complement B-Disease 1 0.999750554561615
C7 I-Disease 1 1.0
deficiency I-Disease 1 1.0
: O 0 7.602842089227124e-08
seven O 0 1.0778764547580977e-08
further O 0 6.110450812002455e-09
molecular O 0 1.0601073654470383e-06
defects O 0 0.013150595128536224
and O 0 4.56661064518471e-09
their O 0 4.8430486287998065e-09
associated O 0 9.232485354004893e-08
marker O 0 2.903546828747494e-06
haplotypes O 0 1.8936125343316235e-05
. O 0 4.141114970934723e-07

Seven O 0 3.4436342843946477e-07
further O 0 2.8310056521263505e-08
molecular O 0 3.739408782621467e-08
bases O 0 4.151426580278894e-08
of O 0 1.0646260761859594e-06
C7 B-Disease 1 1.0
deficiency I-Disease 1 1.0
are O 0 6.41497166498084e-08
described O 0 7.740301271041972e-07
. O 0 1.1957367007653374e-07

All O 0 1.704879970532147e-08
these O 0 1.336058153000863e-09
new O 0 9.651965449108957e-09
molecular O 0 5.556160544983868e-07
defects O 0 2.8233051125425845e-05
involve O 0 3.4638718560131565e-09
single O 0 3.7591313173379604e-08
- O 0 3.676715891742788e-07
nucleotide O 0 1.987394604441306e-08
events O 0 4.625273053449064e-09
, O 0 1.3790607544805766e-09
deletions O 0 3.988331442883464e-08
and O 0 2.475210703067887e-09
substitutions O 0 1.4720015428792976e-08
, O 0 4.981875675880154e-11
some O 0 3.141574500542532e-11
of O 0 1.414517461495457e-11
which O 0 4.16733730856933e-10
alter O 0 4.7846381079352795e-08
splice O 0 7.533969892392633e-07
sites O 0 5.930175461799081e-08
, O 0 3.3004050603580026e-09
and O 0 2.0546024881440417e-09
others O 0 1.0528311555901837e-08
codons O 0 1.9880054935583757e-07
. O 0 3.256000979945384e-08

They O 0 4.452896362749925e-08
are O 0 2.1010757023098847e-10
distributed O 0 4.652626200973842e-11
along O 0 2.3888543920769223e-10
the O 0 1.2974364915763203e-09
C7 O 0 4.4220925587978854e-07
gene O 0 1.1823195755766847e-08
, O 0 4.177810319916375e-10
but O 0 2.8326177514692574e-10
predominantly O 0 1.4072229492789745e-10
towards O 0 1.949123917821538e-10
the O 0 9.916306664692343e-10
3 O 0 7.2570180975617404e-09
end O 0 2.2698972657053673e-07
. O 0 6.491851678447347e-08

All O 0 2.4539550835811497e-08
were O 0 1.2250383818468435e-08
found O 0 2.9020448266692256e-09
in O 0 6.065440372182707e-10
compound O 0 1.8195454032365888e-08
heterozygous O 0 2.2935789445455157e-07
individuals O 0 3.00288149901462e-09
. O 0 2.6119773011146208e-08

The O 0 1.5729834558442235e-05
C6 O 1 0.9884234070777893
/ O 0 0.046023037284612656
C7 O 0 0.000822442292701453
marker O 0 8.870178135111928e-06
haplotypes O 0 2.0054601918673143e-05
associated O 0 3.104671009168669e-07
with O 0 2.693261613728737e-08
most O 0 8.468039595754817e-06
C7 B-Disease 1 0.9999711513519287
defects I-Disease 1 0.6915950775146484
are O 0 6.1739000578597825e-09
tabulated O 0 2.661113001067861e-07
. O 0 2.5332562714197593e-09
. O 0 1.1228940444141244e-08

A O 0 2.14797182707116e-06
genome O 0 2.9100954179739347e-07
- O 0 2.0230952486599563e-06
wide O 0 7.412457136979356e-08
search O 0 3.382529456530392e-08
for O 0 1.870683608018453e-09
chromosomal O 0 3.8357352423190605e-06
loci O 0 2.9802259859934566e-07
linked O 0 1.677384602771781e-06
to O 0 7.370501009518193e-08
mental O 0 1.6705802408978343e-05
health O 0 8.434525256006964e-08
wellness O 0 2.4827210154398927e-07
in O 0 4.8272323915909965e-09
relatives O 0 1.7284905950987195e-08
at O 0 6.370029126401278e-08
high O 0 5.869242158951238e-07
risk O 0 4.937140261063178e-07
for O 0 7.420860015372455e-08
bipolar B-Disease 1 0.9999563694000244
affective I-Disease 0 0.1285719871520996
disorder I-Disease 0 0.020801536738872528
among O 0 8.159144471164836e-09
the O 0 3.4462632747533917e-09
Old O 0 5.077292826172197e-06
Order O 0 2.33340795574577e-08
Amish O 0 2.5429759261896834e-05
. O 0 1.3766916140411922e-07

Bipolar B-Disease 1 0.9999994039535522
affective I-Disease 1 0.9999496936798096
disorder I-Disease 1 0.9999943971633911
( O 0 7.496208127122372e-05
BPAD B-Disease 1 1.0
; O 0 0.0002813503087963909
manic B-Disease 1 1.0
- I-Disease 1 1.0
depressive I-Disease 1 1.0
illness I-Disease 1 0.9999552965164185
) O 0 1.3385355046580116e-08
is O 0 9.978348147754446e-10
characterized O 0 6.500919802476801e-09
by O 0 7.19157733364284e-10
episodes O 0 1.4814563087384158e-07
of O 0 8.603814549701383e-09
mania B-Disease 0 0.0010488532716408372
and O 0 2.1268894556669693e-07
/ O 0 2.0412608137121424e-05
or O 0 2.9713714866375085e-07
hypomania B-Disease 0 6.731288885930553e-05
interspersed O 0 1.5217891302654607e-07
with O 0 1.1258572962802305e-09
periods O 0 6.718858713838927e-08
of O 0 2.5628290600820947e-09
depression B-Disease 0 2.530390020183404e-06
. O 0 3.921191904510124e-08

Compelling O 0 3.294770067441277e-06
evidence O 0 7.139307456327515e-08
supports O 0 9.63383062213552e-09
a O 0 1.745242506068223e-09
significant O 0 1.5530711161559907e-09
genetic O 0 1.4480889376500272e-08
component O 0 1.3513154151212348e-08
in O 0 3.366058320963816e-09
the O 0 9.585510163390154e-10
susceptibility O 0 2.2507592234433105e-08
to O 0 1.7075745262218334e-08
develop O 0 1.5018425756352372e-06
BPAD B-Disease 1 1.0
. O 0 5.237595814833185e-07

To O 0 6.22765696789429e-08
date O 0 1.9919130522794148e-07
, O 0 5.249862211620382e-10
however O 0 5.270439640270297e-10
, O 0 1.6352272314001937e-10
linkage O 0 2.8515390937400298e-08
studies O 0 2.9330848860809056e-09
have O 0 7.173630578449774e-10
attempted O 0 4.221540006454916e-09
only O 0 1.6973150662735748e-10
to O 0 4.1851080934129925e-10
identify O 0 1.330786503217496e-08
chromosomal O 0 4.5067437781654007e-07
loci O 0 1.699821083889219e-08
that O 0 1.2338359223207362e-09
cause O 0 5.388711254994405e-09
or O 0 5.837843541911525e-09
increase O 0 8.053328670598603e-09
the O 0 7.214469910366006e-09
risk O 0 3.7332654301280854e-08
of O 0 8.100835557911523e-10
developing O 0 3.4797304238054494e-07
BPAD B-Disease 1 0.9999998807907104
. O 0 5.231206046119041e-07

To O 0 3.897443079381446e-08
determine O 0 1.0677151607296764e-08
whether O 0 1.644235525510851e-09
there O 0 7.379835076370966e-10
could O 0 9.268156908603942e-09
be O 0 6.149405429312083e-10
protective O 0 6.691282639081919e-09
alleles O 0 2.437793744647365e-09
that O 0 1.5875792347408435e-10
prevent O 0 7.595702955498496e-10
or O 0 3.0367433012656875e-09
reduce O 0 4.094764083362179e-09
the O 0 1.0690962559678496e-09
risk O 0 4.494328909032674e-09
of O 0 6.2369318043487e-11
developing O 0 7.285188274863685e-08
BPAD B-Disease 1 1.0
, O 0 5.499279920329059e-10
similar O 0 1.761390477916791e-10
to O 0 2.9516764032955223e-10
what O 0 7.371366295139126e-10
is O 0 6.030415750091223e-11
observed O 0 9.543438261871984e-11
in O 0 2.4416466626320243e-09
other O 0 3.3472824156888237e-07
genetic B-Disease 1 1.0
disorders I-Disease 1 1.0
, O 0 2.137683807745816e-09
we O 0 5.9593925350043264e-09
used O 0 8.766621562017463e-08
mental O 0 3.924852717318572e-05
health O 0 2.2794834819706011e-07
wellness O 0 6.628660003116238e-07
( O 0 3.84638187966857e-09
absence O 0 1.5364660654881845e-08
of O 0 5.564729788076761e-10
any O 0 2.767394562397385e-07
psychiatric B-Disease 1 0.7136120796203613
disorder I-Disease 0 3.8271129596978426e-05
) O 0 7.200072760227272e-10
as O 0 1.519167458496895e-09
the O 0 4.6857246971399036e-09
phenotype O 0 3.866711608679907e-07
in O 0 3.863161524009229e-08
our O 0 7.633279786034564e-09
genome O 0 2.1720815368553303e-08
- O 0 1.2786480283466517e-06
wide O 0 2.4097943196466076e-07
linkage O 0 2.565424256317783e-05
scan O 0 0.00016406372014898807
of O 0 7.218471931302872e-10
several O 0 1.6097249921909196e-10
large O 0 1.6240168099201924e-09
multigeneration O 0 3.713480737133068e-06
Old O 0 9.776493925528484e-07
Order O 0 3.180319341211657e-09
Amish O 0 1.994330204979633e-06
pedigrees O 0 9.519904438093363e-07
exhibiting O 0 1.6652568035624427e-07
an O 0 1.5525202234911717e-09
extremely O 0 4.1967672359533026e-07
high O 0 3.655012733361218e-06
incidence O 0 1.0828737686097156e-05
of O 0 9.680417178969947e-08
BPAD B-Disease 1 1.0
. O 0 1.22731603369175e-06

We O 0 1.8128378087567398e-07
have O 0 1.9215509183823087e-09
found O 0 4.894399330268584e-10
strong O 0 4.905801320731484e-10
evidence O 0 2.51251047744816e-10
for O 0 3.3517362496571224e-11
a O 0 5.450315754274015e-10
locus O 0 1.839024754701768e-08
on O 0 1.9270559903361573e-07
chromosome O 0 2.8071970518794842e-05
4p O 0 1.912319021357689e-05
at O 0 1.1642407571343938e-07
D4S2949 O 0 3.53052257651143e-07
( O 0 3.249590374565514e-09
maximum O 0 7.281420799643001e-09
GENEHUNTER O 0 3.625836370702018e-06
- O 0 3.04104901260871e-07
PLUS O 0 1.1150318357522337e-07
nonparametric O 0 1.289492843170592e-06
linkage O 0 1.233405782841146e-06
score O 0 6.658095941247666e-08
= O 0 1.491305923195796e-08
4 O 0 1.4685178628681683e-09
. O 0 2.798730414088624e-10
05 O 0 3.2879537315011476e-08
, O 0 4.875986836516688e-10
P O 0 5.206207447372435e-07
= O 0 6.362182780605963e-09
5 O 0 1.9004722240367755e-09
. O 0 2.5838053918647574e-10
22 O 0 4.691680377533203e-09
x O 0 1.0848957998632613e-07
10 O 0 2.6459593627237155e-08
( O 0 3.3434137680643516e-09
- O 0 2.461789279095683e-07
4 O 0 8.101180171138367e-09
) O 0 2.4404395171373494e-10
; O 0 2.6544486053659e-10
SIBPAL O 0 4.865253231400857e-07
Pempirical O 0 6.912188155183685e-08
value O 0 3.829764061435981e-09
< O 0 7.564939785709157e-09
3 O 0 4.822766075385232e-10
x O 0 2.4295509604144172e-08
10 O 0 9.191736261016104e-09
( O 0 1.7516589290167417e-09
- O 0 2.8421192155292374e-07
5 O 0 3.807302473290974e-09
) O 0 1.0719665433089887e-10
) O 0 7.285178016402938e-11
and O 0 3.8522826595333015e-10
suggestive O 0 5.166366889852725e-08
evidence O 0 8.294396836028284e-10
for O 0 9.195286199137342e-11
a O 0 9.13850162209684e-10
locus O 0 2.815770905328918e-08
on O 0 2.17847997419085e-07
chromosome O 0 6.36738768662326e-05
4q O 0 0.001701930770650506
at O 0 9.264255140806199e-08
D4S397 O 0 2.591795009720954e-07
( O 0 1.986313558077768e-09
maximum O 0 1.1858066528702693e-08
GENEHUNTER O 0 1.4053264749236405e-05
- O 0 6.116260919952765e-07
PLUS O 0 1.5327670155329542e-07
nonparametric O 0 9.321378797721991e-07
linkage O 0 8.758672151998326e-07
score O 0 7.36167820036826e-08
= O 0 2.172707347369851e-08
3 O 0 1.5439888256807421e-09
. O 0 5.396052493722436e-10
29 O 0 2.026020240464277e-08
, O 0 6.344656466872323e-10
P O 0 2.2776175683247857e-06
= O 0 6.380411310402678e-09
2 O 0 1.0952718731971345e-09
. O 0 2.9901517373254194e-10
57 O 0 8.298911780002527e-09
x O 0 1.654475170198566e-07
10 O 0 3.058274700151742e-08
( O 0 3.838254158949894e-09
- O 0 3.956351406486647e-07
3 O 0 3.2614255740526232e-09
) O 0 5.32363320093765e-10
; O 0 5.228317778716018e-10
SIBPAL O 0 9.64029254646448e-07
Pempirical O 0 1.0618178691856883e-07
value O 0 3.5047831303813837e-09
< O 0 1.0824088292338274e-08
1 O 0 5.595584551265631e-10
x O 0 3.1310865011846545e-08
10 O 0 1.287419149065272e-08
( O 0 3.1428599722715944e-09
- O 0 3.0420264351960213e-07
3 O 0 5.853610041128832e-09
) O 0 1.3289208622424553e-10
) O 0 3.3641037872067514e-11
that O 0 5.22004453551439e-11
are O 0 5.164190949868974e-11
linked O 0 6.79857663499206e-08
to O 0 2.342272509281429e-08
mental O 0 9.468554708291776e-06
health O 0 2.876296036902204e-07
wellness O 0 2.6655325200408697e-06
. O 0 1.2193461884635326e-07

These O 0 3.320055341760053e-08
findings O 0 2.5785499957464708e-08
are O 0 2.907123430873071e-10
consistent O 0 2.0776482756446057e-09
with O 0 4.612810480808527e-11
the O 0 1.5346077186784157e-10
hypothesis O 0 1.193650733810614e-09
that O 0 1.113111547379475e-10
certain O 0 4.726933289234125e-10
alleles O 0 6.033344490674608e-09
could O 0 1.498917256981258e-08
prevent O 0 5.821298998398561e-09
or O 0 3.373552770469246e-09
modify O 0 1.922130898890373e-08
the O 0 1.697387119747873e-09
clinical O 0 4.350907190087128e-08
manifestations O 0 6.431879029378251e-08
of O 0 1.5742619652314715e-08
BPAD B-Disease 1 1.0
and O 0 9.802805323033681e-08
perhaps O 0 1.633878987661319e-08
other O 0 3.0015472329836257e-09
related O 0 1.1103888937213924e-06
affective B-Disease 0 0.00044120303937233984
disorders I-Disease 0 0.18749432265758514
. O 0 2.3141902261158975e-07

Segregation O 0 0.001439122250303626
distortion O 0 0.003228062530979514
in O 0 0.00013994133041705936
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 0 9.740294444782194e-06

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.997564435005188
DM B-Disease 1 1.0
) O 0 1.7077788072583644e-07
is O 0 5.542657444124188e-09
an O 0 6.6067205040099e-09
autosomal B-Disease 0 0.347922146320343
dominant I-Disease 1 0.9303944110870361
disease I-Disease 0 0.08739053457975388
which O 0 1.79231687269521e-08
, O 0 5.102102074161508e-10
in O 0 1.7696416554358052e-09
the O 0 1.7296836185565212e-09
typical O 0 3.548433085143188e-07
pedigree O 0 1.4901279428158887e-06
, O 0 3.092421874129059e-10
shows O 0 2.5810680259752417e-09
a O 0 2.062160220361875e-09
three O 0 3.99986355148485e-09
generation O 0 6.996121726388083e-08
anticipation O 0 2.5759675281733507e-07
cascade O 0 2.370003585383529e-06
. O 0 2.03767825723844e-07

This O 0 2.386487381045299e-07
results O 0 2.7309752681503596e-07
in O 0 3.1435365599463694e-07
infertility B-Disease 1 0.9962693452835083
and O 0 0.10758331418037415
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 1.5345733572758036e-06
CDM B-Disease 0 1.799137498892378e-05
) O 0 2.9591751271595967e-09
with O 0 2.9711180737912457e-10
the O 0 1.9404857720672908e-09
disappearance O 0 6.885108660981132e-08
of O 0 5.81200199079035e-09
DM B-Disease 1 1.0
in O 0 2.494739987923822e-07
that O 0 2.1986791054473542e-08
pedigree O 0 1.1082571518272744e-06
. O 0 4.5460861741730696e-08

The O 0 1.0542478001696054e-08
concept O 0 1.2515801728341103e-08
of O 0 9.54140433329087e-10
segregation O 0 9.387611044076039e-08
distortion O 0 2.1144131778783049e-07
, O 0 2.3639884494386365e-10
where O 0 9.293834452028804e-11
there O 0 1.0758624546802764e-10
is O 0 5.0851368255111495e-11
preferential O 0 4.819274757039693e-09
transmission O 0 7.324045725454198e-08
of O 0 1.52671625341938e-10
the O 0 1.999407167607714e-10
larger O 0 1.1908195540755173e-09
allele O 0 8.94061855660766e-08
at O 0 3.396992909188157e-08
the O 0 2.8959139086737196e-08
DM B-Disease 1 1.0
locus O 0 3.3090422846271395e-08
, O 0 2.697372769588924e-09
has O 0 1.0628158353398476e-09
been O 0 3.3453015912954243e-09
put O 0 4.0707330839495626e-09
forward O 0 4.820708721098299e-09
to O 0 4.088877292307558e-10
explain O 0 3.1848783610399778e-09
partially O 0 7.818411695836858e-09
the O 0 2.4134079179560786e-09
maintenance O 0 1.601972030584875e-07
of O 0 7.554587178049132e-09
DM B-Disease 1 1.0
in O 0 3.302207574051863e-08
the O 0 2.3109729685444336e-09
population O 0 1.0328885524657494e-09
. O 0 1.576272090630937e-08

In O 0 2.3266400717147917e-07
a O 0 2.9247123833897604e-08
survey O 0 4.053983104768122e-08
of O 0 2.664839238164518e-09
DM B-Disease 1 1.0
in O 0 4.563878874819238e-08
Northern O 0 3.81009392924625e-08
Ireland O 0 4.910309598926688e-07
, O 0 1.955596795610859e-09
59 O 0 3.0755547442140596e-08
pedigrees O 0 3.7209605352472863e-07
were O 0 1.2497343959694263e-07
ascertained O 0 6.129159260126471e-07
. O 0 2.5157161687161533e-08

Sibships O 0 9.455388862988912e-06
where O 0 5.403573588580457e-09
the O 0 1.9436739717715312e-10
status O 0 2.702325307968323e-10
of O 0 6.407695121030121e-12
all O 0 1.927436682480632e-11
the O 0 1.2662252323047962e-11
members O 0 5.375627373793712e-11
had O 0 9.043554349830174e-09
been O 0 5.047569029414944e-10
identified O 0 5.584815387926767e-10
were O 0 2.0963610847246628e-09
examined O 0 1.0416489892861591e-09
to O 0 5.0040270538342924e-11
determine O 0 1.6330330143699e-10
the O 0 2.582652425253684e-10
transmission O 0 5.5549158162193635e-08
of O 0 4.3176284769685935e-10
the O 0 5.248426049320187e-08
DM B-Disease 1 1.0
expansion O 0 8.126421313647825e-09
from O 0 1.3204547455458737e-09
affected O 0 2.6551589815682064e-09
parents O 0 9.274659928948381e-10
to O 0 1.6591610030314285e-10
their O 0 7.352256026216253e-10
offspring O 0 1.6809888592206335e-08
. O 0 2.7801755564382802e-08

Where O 0 1.220295331449961e-07
the O 0 1.1140302014212011e-08
transmitting O 0 2.040977960859891e-06
parent O 0 1.6360734207410133e-06
was O 0 1.354832647848525e-06
male O 0 2.3205632970757506e-08
, O 0 2.7320123940910435e-09
58 O 0 6.140842856439122e-08
. O 0 2.363224638202155e-08

3 O 0 1.6412462855441845e-07
% O 0 3.400679959852937e-09
of O 0 6.786621958854155e-11
the O 0 3.5336913950523297e-10
offspring O 0 1.9727852684781055e-09
were O 0 5.887425214012865e-09
affected O 0 5.14216780267418e-10
, O 0 7.448786032426824e-11
and O 0 2.753564321000823e-10
in O 0 5.52884349414029e-10
the O 0 2.963709277992166e-10
case O 0 1.5323592394977936e-09
of O 0 3.053082786586003e-11
a O 0 1.2679085559241798e-09
female O 0 5.102717803850965e-09
transmitting O 0 3.904474965565896e-07
parent O 0 1.7483660030848114e-07
, O 0 4.889885385495063e-09
68 O 0 3.7837838817722513e-07
. O 0 3.8214331254948775e-08

7 O 0 6.918915005371673e-06
% O 0 1.1424510404367538e-07
were O 0 1.0536009398265378e-07
affected O 0 1.3673205501163466e-07
. O 0 5.2968186281532326e-08

Studies O 0 3.270851721026702e-06
on O 0 3.3788870723583386e-07
meiotic O 0 4.128478849452222e-06
drive O 0 6.42970803710341e-07
in O 0 5.348540980776306e-06
DM B-Disease 1 1.0
have O 0 9.721953908581327e-09
shown O 0 7.408068602998696e-10
increased O 0 8.529058570516668e-10
transmission O 0 2.2817774336658658e-08
of O 0 5.743626754761699e-11
the O 0 2.281496658262938e-10
larger O 0 1.1710032943312854e-09
allele O 0 1.936176516892374e-07
at O 0 9.052566696254871e-08
the O 0 4.461082880879985e-08
DM B-Disease 1 1.0
locus O 0 1.4920236424131872e-07
in O 0 7.727328465989558e-08
non O 0 0.00038471841253340244
- O 1 0.9995352029800415
DM O 1 1.0
heterozygotes O 0 2.3077946025296114e-05
for O 0 3.092442568686238e-08
CTGn O 0 7.254319370986195e-06
. O 0 1.0620427559615564e-07

This O 0 2.164005508120681e-08
study O 0 1.2167360452508547e-09
provides O 0 4.75178341119431e-10
further O 0 1.8390194922446312e-10
evidence O 0 9.555755076107175e-10
that O 0 6.2742327999743e-10
the O 0 1.4560459504764367e-08
DM B-Disease 1 1.0
expansion O 0 6.80162486332847e-08
tends O 0 4.231893768746886e-08
to O 0 6.56243448471372e-10
be O 0 2.1438044672805745e-09
transmitted O 0 1.4687027771742578e-07
preferentially O 0 3.097992475886713e-07
. O 0 6.100531635411244e-08

Diagnosis O 1 0.9970505237579346
of O 0 6.372329153236933e-06
hemochromatosis B-Disease 1 1.0
. O 0 4.295792678021826e-06

If O 0 5.1610950322356075e-05
untreated O 0 0.4864194989204407
, O 0 2.930581331384019e-06
hemochromatosis B-Disease 1 1.0
can O 0 1.1214203368581366e-05
cause O 0 1.2987518857698888e-05
serious O 0 0.10397937148809433
illness O 0 0.0007649754988960922
and O 0 9.167140291310716e-08
early B-Disease 0 3.062026371480897e-05
death I-Disease 0 9.142240031678739e-08
, O 0 6.301805188790865e-10
but O 0 2.9159767933606418e-09
the O 0 2.776485708011478e-09
disease O 0 1.4419542537780217e-07
is O 0 1.829766116401288e-09
still O 0 3.884944632659426e-08
substantially O 0 5.647937655339774e-07
under O 0 3.029657591469004e-06
- O 1 0.9991095662117004
diagnosed O 0 0.024503247812390327
. O 0 1.9896063463420433e-07

The O 0 7.788974443201369e-08
cornerstone O 0 3.7139767528060474e-07
of O 0 7.306458771338953e-10
screening O 0 2.0456839777693858e-08
and O 0 8.650954952393874e-10
case O 0 1.8878634211461076e-09
detection O 0 2.3734594289948063e-09
is O 0 8.989441829809763e-11
the O 0 1.1439309915983742e-10
measurement O 0 7.83599851672534e-09
of O 0 1.6220749743389717e-10
serum O 0 1.247937841952762e-08
transferrin O 0 1.0120521665157867e-07
saturation O 0 5.384070789204998e-08
and O 0 2.1495651925107495e-09
the O 0 1.4900854994337465e-09
serum O 0 1.0568776076524955e-07
ferritin O 0 4.231452294334304e-06
level O 0 3.729020932041749e-07
. O 0 4.182215462833483e-08

Once O 0 3.693592589115724e-06
the O 0 9.522976540665695e-08
diagnosis O 0 1.8277116396347992e-05
is O 0 1.3985834712570977e-09
suspected O 0 2.8894652359667816e-07
, O 0 1.6535951496976509e-09
physicians O 0 9.752969098997255e-09
must O 0 6.219234571780419e-10
use O 0 6.527421714253023e-09
serum O 0 3.709537850227207e-07
ferritin O 0 1.4560380805050954e-05
levels O 0 7.009070941421669e-07
and O 0 3.3388140252554876e-08
hepatic O 0 1.20485483421362e-05
iron O 0 0.0012272396124899387
stores O 0 0.00013858273450750858
on O 0 2.488854261173401e-05
liver O 0 3.822685175691731e-05
biopsy O 0 2.670546200533863e-05
specimens O 0 3.785434632419538e-09
to O 0 1.1716490000424074e-09
assess O 0 2.6633163230371792e-08
patients O 0 2.5657355351427213e-08
for O 0 1.2967876772407294e-10
the O 0 2.649749308858418e-10
presence O 0 4.63268889916435e-09
of O 0 4.0557908143057375e-09
iron B-Disease 0 0.017926594242453575
overload I-Disease 0 1.849356158345472e-05
. O 0 1.3340043381049327e-07

Liver O 1 0.9996974468231201
biopsy O 1 0.6806504130363464
is O 0 3.6613141407570993e-09
also O 0 4.3130107818534213e-10
used O 0 2.4416363375578953e-10
to O 0 1.3946961641142508e-10
establish O 0 4.240785500542188e-10
the O 0 2.327631282161846e-10
presence O 0 2.2965165324961845e-09
or O 0 5.714282380608893e-09
absence O 0 1.0287680041187741e-08
of O 0 5.082521070676194e-10
cirrhosis B-Disease 0 1.6678602321462677e-07
, O 0 5.019869520062059e-10
which O 0 6.404378694035984e-10
can O 0 1.699691409839943e-08
affect O 0 1.0938881587208016e-06
prognosis O 0 0.000106760737253353
and O 0 2.6644137562925607e-08
management O 0 1.0083239487812534e-07
. O 0 4.266004438591153e-08

A O 0 8.298176794596657e-07
DNA O 0 9.889707826005179e-07
- O 0 2.9495475928342785e-07
based O 0 6.743235747563858e-09
test O 0 1.0079543422136794e-08
for O 0 7.958190356704975e-11
the O 0 1.6039294892244982e-10
HFE O 0 2.594520083221141e-07
gene O 0 3.995814346069437e-09
is O 0 5.130408944897802e-11
commercially O 0 1.751675582362111e-09
available O 0 6.071783631433902e-10
, O 0 8.032963183524089e-11
but O 0 8.975650084286357e-11
its O 0 2.7674949137912463e-11
place O 0 1.3245260443994766e-09
in O 0 6.979654632033316e-10
the O 0 2.2983919212293813e-09
diagnosis O 0 1.1543007531145122e-05
of O 0 2.6217501059022652e-08
hemochromatosis B-Disease 1 1.0
is O 0 1.7470050295287365e-08
still O 0 3.137722259793918e-08
being O 0 8.261339168313953e-09
evaluated O 0 9.366078046468829e-08
. O 0 3.773369172677121e-08

Currently O 0 2.3331348586452805e-07
, O 0 1.4449236251934394e-09
the O 0 8.381111776811778e-11
most O 0 6.963721266295408e-11
useful O 0 1.4407701420804386e-10
role O 0 1.125077461749946e-10
for O 0 1.482967394716983e-11
this O 0 3.399372797141531e-11
test O 0 9.338742001929745e-10
is O 0 8.182821607805035e-12
in O 0 2.3439626975485517e-11
the O 0 6.663752882829499e-11
detection O 0 8.370655280032224e-09
of O 0 4.78024775318886e-09
hemochromatosis B-Disease 1 1.0
in O 0 1.9574189380477947e-08
the O 0 2.395608600380683e-09
family O 0 1.1158585166981538e-09
members O 0 5.450157339326189e-11
of O 0 4.246530210805233e-11
patients O 0 2.618430583467557e-09
with O 0 7.322862455305668e-11
a O 0 3.183293184605418e-09
proven O 0 8.675895060150651e-07
case O 0 2.909844809551032e-08
of O 0 1.970482804702911e-10
the O 0 2.828711487268265e-08
disease O 0 2.839821036104695e-06
. O 0 6.456880186078706e-08

It O 0 3.345323307257786e-07
is O 0 1.855744358181255e-08
crucial O 0 1.5626031313331623e-07
to O 0 3.6113385704084067e-07
diagnose O 1 0.9999862909317017
hemochromatosis B-Disease 1 1.0
before O 0 0.4178558588027954
hepatic B-Disease 1 0.9999192953109741
cirrhosis I-Disease 1 0.9506725072860718
develops O 0 1.3094161658955272e-05
because O 0 3.4467524301362573e-07
phlebotomy O 0 0.0011107642203569412
therapy O 0 0.00045549863716587424
can O 0 3.1276149456971325e-06
avert O 0 0.23065444827079773
serious O 1 0.9999843835830688
chronic O 1 0.9999998807907104
disease O 0 0.19664207100868225
and O 0 3.659731007132905e-08
can O 0 2.6356070659261377e-09
even O 0 4.867914515926941e-09
lead O 0 4.365551475871143e-09
to O 0 1.6544533520956861e-09
normal O 0 8.446099997172496e-08
life O 0 2.0536790046321585e-08
expectancy O 0 1.7911309768692263e-08
. O 0 7.543453639513586e-10
. O 0 6.3035039410408444e-09

Prevalence O 0 8.455263741780072e-05
of O 0 9.63504298567841e-09
the O 0 9.887697771659987e-09
I1307K O 0 5.1023215519308e-07
APC B-Disease 0 1.5536696196249977e-07
gene O 0 4.711726120376625e-08
variant O 0 5.432500529423123e-07
in O 0 1.4459002883882022e-08
Israeli O 0 1.6814240666462865e-07
Jews O 0 4.8467447832933885e-09
of O 0 6.818279968401342e-11
differing O 0 4.165326694671734e-10
ethnic O 0 4.99919272645144e-10
origin O 0 6.2612293127983776e-09
and O 0 1.2956671469055436e-07
risk O 0 4.4812441046815366e-06
for O 0 9.275999764213338e-05
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 1.11534188818041e-06

BACKGROUND O 0 0.00030733461608178914
& O 0 8.350130883627571e-06
AIMS O 0 1.7453740497330728e-07
Israeli O 0 7.81945956873642e-08
Jews O 0 2.4742947690725714e-09
of O 0 5.861603563639406e-11
European O 0 5.440921668764531e-08
birth O 0 2.4446443092074333e-08
, O 0 4.797718888838176e-10
i O 0 6.991732703909292e-08
. O 0 1.8245262939364792e-11
e O 0 8.439682841476781e-10
. O 0 8.63991864163971e-11
, O 0 2.589681524778342e-10
Ashkenazim O 0 1.3449262326048483e-07
, O 0 6.481796349655511e-11
have O 0 9.228568464969555e-10
the O 0 5.0115801286665373e-08
highest O 1 0.9999936819076538
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
incidence O 0 1.2057962521794252e-05
of O 0 5.674862801896552e-10
any O 0 2.9327380524080127e-09
Israeli O 0 2.3913057134450355e-07
ethnic O 0 9.677994405876689e-09
group O 0 1.0370388991987056e-07
. O 0 6.079019954086107e-08

The O 0 5.973973316031334e-07
I1307K O 0 5.9189815146964975e-06
APC B-Disease 0 1.2158711797383148e-06
gene O 0 3.8139006619530846e-07
variant O 0 7.292107966350159e-06
was O 0 5.126424184709322e-06
found O 0 3.300211659507113e-08
in O 0 9.607039608283685e-09
6 O 0 8.003473084272628e-08
. O 0 3.641245172048002e-08

1 O 0 1.1778409714224836e-07
% O 0 1.234325530674596e-09
of O 0 2.2827576634520952e-11
American O 0 3.5137370790749856e-10
Jews O 0 5.488622889515682e-10
, O 0 8.979605253811584e-11
28 O 0 5.058439778160562e-10
% O 0 3.303884943406388e-11
of O 0 1.7211787550763802e-10
their O 0 2.664877001734567e-06
familial O 1 1.0
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
cases O 0 1.0501817087060772e-06
, O 0 1.4536726267166955e-09
but O 0 3.525970848627935e-09
not O 0 1.2038711139084057e-09
in O 0 5.786461532153453e-09
non O 0 4.130914703637245e-07
- O 0 1.1277576277279877e-06
Jews O 0 5.960782090141947e-08
. O 0 1.7477750802186165e-08

We O 0 7.3091410968118e-07
assessed O 0 5.5151826927613e-07
the O 0 6.60621690684593e-09
I1307K O 0 4.227460692618479e-07
prevalence O 0 2.8475179192355426e-07
in O 0 3.6984220130875656e-09
Israeli O 0 3.6168938066794e-08
Jews O 0 8.588004196674603e-10
of O 0 2.8281193359402934e-11
differing O 0 3.606495380115149e-10
ethnic O 0 2.8857494172029874e-10
origin O 0 5.41970646139589e-09
and O 0 9.705319570230131e-08
risk O 0 7.3425958362349775e-06
for O 0 0.0001320120063610375
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 1.099302266993618e-06

METHODS O 0 3.994878170487937e-06
DNA O 0 4.1706181264089537e-07
samples O 0 3.4566333795282844e-08
from O 0 1.321581066804356e-09
500 O 0 1.0108571757427853e-09
unrelated O 0 1.2212396649502466e-09
Jews O 0 6.069421631949012e-10
of O 0 3.68664300476329e-11
European O 0 7.441636196148238e-09
or O 0 2.2952553191402103e-09
non O 0 5.35007416146982e-08
- O 0 1.4830945360699843e-07
European O 0 2.4658911357278157e-08
origin O 0 9.886995666619214e-10
, O 0 1.0613344925136659e-10
with O 0 2.0297536221236534e-11
or O 0 4.4150971767464853e-10
without O 0 5.526356039453617e-10
a O 0 7.688464864763489e-10
personal O 0 1.3577019508659305e-08
and O 0 1.7234184213066328e-07
/ O 0 4.3081622607132886e-06
or O 0 2.6222103599593538e-08
family O 0 2.5986683915846243e-09
history O 0 2.330608817047164e-09
of O 0 3.4492536604702195e-10
neoplasia B-Disease 0 2.8871065751445713e-06
, O 0 1.5674029851808768e-09
were O 0 3.767831557865975e-08
examined O 0 1.6906641420177948e-08
for O 0 1.1573932090502836e-10
the O 0 4.768825334622306e-10
I1307K O 0 3.16504156216979e-08
variant O 0 6.220236770104748e-08
by O 0 7.963372183894535e-10
the O 0 2.2929362852863733e-09
allele O 0 2.550396231981722e-07
- O 0 2.1536770589136722e-07
specific O 0 2.0311430759534232e-08
oligonucleotide O 0 2.1153879060875624e-05
( O 0 1.85956778864238e-07
ASO O 0 9.158469765679911e-05
) O 0 3.279333915529037e-09
method O 0 5.8194814300804865e-08
. O 0 3.8997853835098795e-08

RESULTS O 0 8.594700375397224e-06
In O 0 1.7718244649245207e-08
persons O 0 1.9526300576444555e-09
at O 0 5.813642456331536e-09
average O 0 6.62211476765151e-08
risk O 0 1.8566649941931246e-06
for O 0 0.00725937495008111
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, O 0 3.063412634674023e-08
I1307K O 0 4.271923899068497e-07
was O 0 9.330096872872673e-08
found O 0 5.064678898492048e-09
in O 0 4.179781409874295e-09
5 O 0 2.237806029370404e-08
. O 0 3.168019091503993e-08

0 O 0 6.176117608447385e-07
% O 0 7.164527637826268e-09
of O 0 2.4343821403149946e-10
120 O 0 3.3578440028492196e-09
European O 0 1.4133053127807216e-07
and O 0 1.1294432056274673e-08
1 O 0 3.129360948150861e-08
. O 0 4.618566151748382e-08

6 O 0 1.6189552525247564e-06
% O 0 7.938672830221094e-09
of O 0 4.5020656647132284e-10
188 O 0 5.397262015094384e-08
non O 0 3.5678496601576626e-07
- O 0 5.502062322193524e-06
European O 0 1.90897679885893e-07
Jews O 0 1.750267131228611e-08
( O 0 2.625026418456855e-09
P O 0 3.7519831153076666e-07
= O 0 1.6743074482405973e-08
0 O 0 3.4146017124925265e-09
. O 0 1.6170806915738467e-09
08 O 0 1.0750147794169607e-07
) O 0 3.013548077746009e-09
. O 0 1.6097175148388487e-08

It O 0 3.663950280952122e-07
occurred O 0 2.943382355624635e-07
in O 0 1.3572669210759614e-08
15 O 0 3.506918133666659e-08
. O 0 1.4006770854280148e-08

4 O 0 2.9215243557700887e-07
% O 0 1.0034542086145848e-08
of O 0 8.046138755268828e-10
52 O 0 4.3374012648200733e-07
Ashkenazi O 0 1.562963552714791e-05
Israelis O 0 9.973968190024607e-06
with O 0 7.042552851999062e-08
familial O 0 0.00424599414691329
cancer B-Disease 0 0.0005011424655094743
( O 0 9.516766397155152e-08
P O 0 2.9400616767816246e-05
= O 0 5.914857581501565e-08
0 O 0 5.8811853165252614e-09
. O 0 1.467649779485214e-09
02 O 0 4.5385576186163235e-08
) O 0 1.764161039474743e-10
and O 0 2.6081761750340604e-10
was O 0 1.8710339944050247e-08
not O 0 1.2027121520929995e-09
detected O 0 9.42345135257483e-09
in O 0 2.065762227942969e-09
51 O 0 1.215277745103549e-08
non O 0 4.516114415764605e-08
- O 0 3.1157020430327975e-07
European O 0 2.3036246687979656e-08
Jews O 0 2.0258725808020017e-09
at O 0 9.220410213117702e-09
increased O 0 4.0478713714264813e-08
cancer B-Disease 0 9.787034969122033e-07
risk O 0 2.55705970175768e-07
. O 0 5.118843660056882e-08

Colorectal B-Disease 1 0.9996167421340942
neoplasia I-Disease 0 0.10152682662010193
occurred O 0 1.9849638192681596e-05
personally O 0 2.5007784643094055e-07
or O 0 1.084429879227855e-08
in O 0 1.2036116547875508e-09
the O 0 2.207560106937123e-10
families O 0 1.2263509652221671e-10
of O 0 1.902628402050688e-11
13 O 0 7.341255936488267e-10
of O 0 3.5322949426541683e-11
20 O 0 7.498928589200204e-09
Ashkenazi O 0 7.86187186463394e-08
I1307K O 0 1.63613371739757e-08
carriers O 0 1.4388409574905836e-08
, O 0 1.418806461206401e-10
8 O 0 2.4131993625609027e-10
of O 0 2.1924694698638447e-11
whom O 0 9.332389083738235e-09
also O 0 1.9333194600790193e-08
had O 0 2.8078343916604354e-07
a O 0 1.1812191225146762e-09
personal O 0 2.2782808528631904e-08
or O 0 3.197692777234806e-08
family O 0 7.043423178032526e-09
history O 0 6.501539751013752e-09
of O 0 4.1172252274179755e-09
noncolonic O 0 3.979137181886472e-05
neoplasia B-Disease 0 0.00016837027214933187
. O 0 8.44685473566642e-07

CONCLUSIONS O 0 3.3223634090973064e-05
The O 0 1.2051816611347022e-07
I1307K O 0 3.509994485284551e-06
APC O 0 1.418477268089191e-06
variant O 0 7.64669766795123e-06
may O 0 1.2443517505289492e-07
represent O 0 7.701145277039245e-10
a O 0 5.786858991996269e-09
susceptibility O 0 1.5666348929244123e-07
gene O 0 3.833449682133505e-07
for O 0 1.2332864685049572e-07
colorectal B-Disease 1 1.0
, I-Disease 0 4.5706194384820265e-09
or I-Disease 0 3.1807803058114814e-09
other I-Disease 0 4.828622834907037e-09
, I-Disease 0 5.7290947097499156e-08
cancers I-Disease 0 1.948656063177623e-05
in O 0 9.117982813222625e-08
Ashkenazi O 0 5.200515147407714e-07
Jews O 0 3.173048490623387e-09
, O 0 3.1564592606336817e-10
and O 0 3.215695765224069e-10
partially O 0 7.757642528360975e-09
explains O 0 6.110194572528371e-09
the O 0 9.352361107772822e-10
higher O 0 2.669712557690218e-06
incidence O 0 0.0020742902997881174
of O 0 0.04398138076066971
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
in O 0 5.430376859294483e-07
European O 0 1.0863168427022174e-06
Israelis O 0 7.4955951276933774e-06
. O 0 5.457822283005953e-08

Systematic O 0 1.6596711702732136e-06
analysis O 0 2.530824190216663e-07
of O 0 1.2546706784632988e-08
coproporphyrinogen O 0 1.56807236635359e-05
oxidase O 0 7.917004404589534e-05
gene O 0 0.0008449676097370684
defects O 1 0.8820879459381104
in O 0 6.061918611521833e-07
hereditary B-Disease 1 0.5271304249763489
coproporphyria I-Disease 0 0.0015820423141121864
and O 0 9.769820508154226e-07
mutation O 0 4.622890173777705e-06
update O 0 1.5218794032989535e-05
. O 0 2.851811871096288e-07

Hereditary B-Disease 1 0.9995081424713135
coproporphyria I-Disease 0 0.05513077974319458
( O 0 3.5461159768601647e-06
HC B-Disease 0 0.004769804421812296
) O 0 2.3431885765035076e-08
is O 0 7.626076659050796e-09
an O 0 3.009327897984804e-08
acute O 1 0.9988781809806824
hepatic B-Disease 1 0.9999998807907104
porphyria I-Disease 1 0.9999996423721313
with O 0 4.756574708153494e-05
autosomal O 1 0.9999464750289917
dominant O 1 0.7812568545341492
inheritance O 0 0.004246657248586416
caused O 0 9.154608051176183e-06
by O 0 3.187693664585822e-08
deficient B-Disease 0 3.3154072298202664e-05
activity I-Disease 0 1.0449252840771805e-07
of I-Disease 0 1.70860636750092e-09
coproporphyrinogen I-Disease 0 2.683631919353502e-06
III I-Disease 0 1.5711714240751462e-06
oxidase I-Disease 0 7.36364370368392e-07
( O 0 2.6169091782435316e-08
CPO O 0 2.2349026949086692e-06
) O 0 1.857266873628305e-08
. O 0 3.287332717150093e-08

Clinical O 0 2.854694685083814e-05
manifestations O 0 2.1521566395676928e-06
of O 0 2.9918307831167112e-09
the O 0 4.517509921697638e-08
disease O 0 6.476432645285968e-06
are O 0 2.5968200922932283e-09
characterized O 0 1.1619553319519582e-08
by O 0 6.224625703765696e-09
acute O 0 2.273225436510984e-05
attacks O 0 1.681835601630155e-05
of O 0 9.828792002508635e-08
neurological B-Disease 1 0.5594794154167175
dysfunction I-Disease 0 4.0796225221129134e-05
often O 0 1.2471479848841227e-08
precipitated O 0 1.8376749011395077e-08
by O 0 5.29994603759576e-10
drugs O 0 9.022847535788969e-08
, O 0 4.412169740675154e-09
fasting O 0 5.209688538343471e-07
, O 0 1.8230392750950841e-09
cyclical O 0 7.248883775901049e-06
hormonal O 0 2.542157517382293e-06
changes O 0 7.791886957875249e-08
, O 0 9.388539723431677e-09
or O 0 7.533056987085729e-07
infectious B-Disease 0 0.00030739090288989246
diseases I-Disease 0 0.0003263514372520149
. O 0 1.7490130232999945e-07

Skin O 1 0.9999997615814209
photosensitivity O 1 0.9991726279258728
may O 0 0.0012902980670332909
also O 0 1.8841053162077515e-08
be O 0 1.2514124181350894e-09
present O 0 3.0125364425259704e-09
. O 0 3.07619991701813e-08

The O 0 1.0722052934397652e-07
seven O 0 6.925886708586404e-08
exons O 0 1.0412983186824931e-07
, O 0 1.161797436033396e-09
the O 0 6.561921561676343e-10
exon O 0 2.574771258423425e-07
/ O 0 3.866870486035623e-07
intron O 0 9.675476349002565e-07
boundaries O 0 5.820191617544879e-08
and O 0 2.2391368759144825e-09
part O 0 1.040717623190801e-09
of O 0 1.4946160975526368e-10
3 O 0 1.1611439587611017e-09
noncoding O 0 1.2535823046277983e-08
sequence O 0 1.5288413868219664e-09
of O 0 9.51697123885431e-11
the O 0 7.376711463891183e-10
CPO O 0 1.6527752677575336e-07
gene O 0 9.479154350344743e-09
were O 0 6.4854637216171795e-09
systematically O 0 5.413869352821621e-09
analyzed O 0 1.6551191528435538e-09
by O 0 8.338283535858082e-11
an O 0 1.4026940720057723e-10
exon O 0 1.8917969413223545e-08
- O 0 3.2915174585923523e-08
by O 0 5.398526070621301e-09
- O 0 1.1234369594603777e-06
exon O 0 2.363514340686379e-06
denaturing O 0 6.45545223960653e-05
gradient O 0 3.460480684225331e-06
gel O 0 1.3005118489672896e-05
electrophoresis O 0 1.0225684263787116e-06
( O 0 2.5708596140816553e-08
DGGE O 0 7.641278898518067e-07
) O 0 1.140119665343775e-09
strategy O 0 5.022889215666737e-09
followed O 0 4.593742330971651e-10
by O 0 5.3907003860764746e-11
direct O 0 5.168884764650272e-10
sequencing O 0 1.1075301564744677e-08
in O 0 4.306362821893117e-09
seven O 0 7.540220892110483e-09
unrelated O 0 8.91293367999424e-08
heterozygous O 0 3.2161087801796384e-06
HC B-Disease 0 0.00034048224915750325
patients O 0 5.858264557900839e-07
from O 0 3.993719133177365e-09
France O 0 8.279092980956193e-06
, O 0 4.656341534570174e-09
Holland O 0 6.1388095673464704e-06
, O 0 3.4624449973819083e-09
and O 0 3.250985258773653e-09
Czech O 0 1.0633825553441056e-07
Republic O 0 1.3802589293732126e-08
. O 0 7.846770699870831e-08

Seven O 0 7.458846766894567e-07
novel O 0 1.1986058723323367e-07
mutations O 0 2.6063941049869754e-07
and O 0 5.1045576654473734e-09
two O 0 1.3957478506299026e-09
new O 0 1.5908240058593037e-08
polymorphisms O 0 8.785944487499364e-07
were O 0 5.670561904480564e-07
detected O 0 4.886009264737368e-06
. O 0 7.93714605151763e-08

Among O 0 2.466625801389455e-07
these O 0 5.184912943434483e-09
mutations O 0 6.048705358807638e-08
two O 0 3.2646556569204677e-09
are O 0 1.272608796121233e-09
missense O 0 3.076927214351599e-06
( O 0 1.5823660604041834e-08
G197W O 0 3.8422999182330386e-07
, O 0 2.6095410277093833e-09
W427R O 0 6.73456241884196e-08
) O 0 2.12115630615628e-10
, O 0 7.013493952268135e-11
two O 0 1.653805703494271e-10
are O 0 1.0200064126664188e-09
nonsense O 0 4.0126219573721755e-06
( O 0 7.160617099266631e-10
Q306X O 0 3.2821638740188064e-08
, O 0 2.822979350280974e-10
Q385X O 0 1.1688795709119404e-08
) O 0 9.897009600745577e-11
, O 0 5.621394322252726e-11
two O 0 1.2909216751122443e-10
are O 0 1.0141745082625775e-10
small O 0 9.300311076820833e-10
deletions O 0 1.3316922320427693e-07
( O 0 4.126911257174015e-09
662de14bp O 0 5.080820031366784e-08
; O 0 5.896975130426085e-10
1168del3bp O 0 7.303344773390563e-08
removing O 0 1.4462478326038308e-08
a O 0 2.6419133547506135e-09
glycine O 0 5.712759687526159e-08
at O 0 8.360252934380696e-09
position O 0 4.625184679696304e-09
390 O 0 4.461982783254825e-09
) O 0 9.27230375813437e-11
, O 0 3.097071904489823e-11
and O 0 1.5379893192335459e-10
one O 0 7.48863415722667e-10
is O 0 1.933424670363948e-10
a O 0 1.922379366803284e-09
splicing O 0 1.4584579730581027e-06
mutation O 0 3.335167662044114e-07
( O 0 1.2865820409047046e-08
IVS1 O 0 2.1705676772398874e-05
- O 0 6.1615432969119865e-06
15c O 0 4.158967567491345e-05
- O 0 1.4615471627621446e-05
- O 0 1.0088708222610876e-05
> O 0 6.463188384486784e-08
g O 0 5.878798958747211e-08
) O 0 1.9251891747451566e-10
which O 0 3.358598121838696e-10
creates O 0 1.8621467701152028e-09
a O 0 2.438895752021608e-09
new O 0 3.7873071789817914e-08
acceptor O 0 1.4957191751818755e-07
splice O 0 1.3009398571739439e-05
site O 0 1.407286845278577e-06
. O 0 1.6988786910587805e-07

The O 0 5.745410902591175e-08
pathological O 0 2.9476294116648205e-07
significance O 0 5.2477027168151835e-09
of O 0 2.052400333019122e-10
the O 0 9.854237426054624e-10
point O 0 3.835028650200911e-08
mutations O 0 4.666782160711591e-08
G197W O 0 8.932777717518547e-08
, O 0 6.895629622860611e-10
W427R O 0 2.250965280836681e-08
, O 0 1.2769896251541013e-10
and O 0 1.7932896834160772e-10
the O 0 4.053020419281239e-10
in O 0 1.6266099578388094e-07
- O 0 0.00010139237565454096
frame O 0 4.2153602407779545e-05
deletion O 0 9.335843742519501e-07
390delGly O 0 4.044461263674748e-07
were O 0 1.9340831158842775e-08
assessed O 0 5.244220613320749e-09
by O 0 6.71454489231671e-11
their O 0 1.5215968762749554e-10
respective O 0 3.4870645260198785e-10
expression O 0 9.155721181208776e-10
in O 0 1.1177927472516558e-09
a O 0 1.7276987618330963e-09
prokaryotic O 0 2.846375579679261e-09
system O 0 2.2870003668629124e-09
using O 0 9.549966151212175e-09
site O 0 2.4789827079985116e-07
- O 0 2.563256202847697e-07
directed O 0 5.874539610317697e-08
mutagenesis O 0 5.2763120947929565e-06
. O 0 5.123102937432122e-07

These O 0 1.3681579957847134e-07
mutations O 0 4.398895896429167e-07
resulted O 0 1.7712771693823015e-08
in O 0 8.492555103600807e-09
the O 0 1.8295881476504405e-09
absence O 0 2.2000088861773293e-08
or O 0 4.1530956451651946e-09
a O 0 6.395787899293737e-09
dramatic O 0 1.0694031260527481e-07
decrease O 0 5.034420524907546e-08
of O 0 7.889895958790305e-10
CPO O 0 2.63434276348562e-06
activity O 0 3.252054341373878e-07
. O 0 3.725725150616199e-08

The O 0 8.600044765216808e-08
two O 0 1.6441736860883793e-08
polymorphisms O 0 5.730886414312408e-07
were O 0 2.3050397146562318e-08
localized O 0 3.0881398771498425e-08
in O 0 7.162805903959679e-09
noncoding O 0 4.2461479665689694e-08
part O 0 1.0021339313937005e-09
of O 0 4.183996898943221e-11
the O 0 2.110945168665168e-10
gene O 0 1.9502777170998797e-09
1 O 0 4.201375913837069e-10
) O 0 7.889740943900492e-11
a O 0 1.693280515802087e-09
C O 0 0.0001348732184851542
/ O 0 1.1001005987054668e-05
G O 0 4.2846231735893525e-06
polymorphism O 0 7.171215656853747e-07
in O 0 1.6577329731148893e-08
the O 0 2.5508808398910787e-09
promotor O 0 2.304497712657394e-07
region O 0 1.131629723261085e-08
, O 0 1.3294589873424911e-09
142 O 0 6.132998109364962e-09
bp O 0 1.3766062068043539e-07
upstream O 0 7.001071722356755e-09
from O 0 2.5612051368639754e-10
the O 0 7.607951768573429e-11
transcriptional O 0 8.276211715951831e-09
initiation O 0 1.151172046576221e-09
site O 0 3.735984854813523e-09
( O 0 1.261578730371582e-09
- O 0 3.2281838002745644e-07
142C O 0 7.771446917104186e-07
/ O 0 2.2336018901114585e-07
G O 0 7.182125472127154e-08
) O 0 1.4868084541319604e-10
, O 0 6.322667389646597e-11
and O 0 1.5867315794615422e-10
2 O 0 2.0292824365331086e-10
) O 0 9.046201981943724e-11
a O 0 1.9007151408345635e-09
6 O 0 2.0667368261229058e-08
bp O 0 1.0817360589499003e-06
deletion O 0 4.412601128933602e-08
polymorphism O 0 4.743891324210381e-08
in O 0 1.2540408711458895e-09
the O 0 6.025636101192333e-10
3 O 0 2.8012900887830483e-09
noncoding O 0 1.706933083767126e-08
part O 0 1.0322582788546697e-09
of O 0 1.216102080148218e-10
the O 0 8.45092607004716e-10
CPO O 0 3.951343785502104e-07
gene O 0 4.1929503424853465e-08
, O 0 2.0117716381662376e-09
574 O 0 3.981612550774116e-08
bp O 0 1.646727412207838e-07
downstream O 0 7.288687431383778e-09
of O 0 8.191242129029774e-11
the O 0 2.2153465173424536e-10
last O 0 8.584324362459483e-09
base O 0 2.381539132567667e-10
of O 0 2.5736225650607736e-11
the O 0 5.538596248300109e-10
normal O 0 5.7638612105392895e-08
termination O 0 2.91396673901545e-07
codon O 0 8.581002362006984e-07
( O 0 8.201803680663033e-09
+ O 0 1.2392759174417733e-07
574 O 0 3.014854996763461e-07
delATTCTT O 0 7.549886618107848e-07
) O 0 1.4248201729571974e-08
. O 0 2.3658584424879336e-08

Five O 0 9.516128898212628e-07
intragenic O 0 1.663535658735782e-05
dimorphisms O 0 8.301419256895315e-06
are O 0 4.589129520837787e-09
now O 0 2.7903848121013652e-09
well O 0 6.6200250836701e-10
characterized O 0 1.8949632973885855e-09
and O 0 1.0936269667638499e-09
the O 0 2.589617131842914e-10
high O 0 1.1555767898130398e-08
degree O 0 1.4130419501157121e-08
of O 0 5.715227735514361e-10
allelic O 0 6.590236267811633e-08
heterogeneity O 0 8.863465694730621e-08
in O 0 1.0400557926004694e-07
HC B-Disease 0 0.0033425730653107166
is O 0 2.9916877863911395e-09
demonstrated O 0 5.952168091738486e-09
with O 0 2.2546754741004094e-10
seven O 0 1.5307670686581787e-09
new O 0 1.0189330490462112e-09
different O 0 1.7271113705863428e-10
mutations O 0 3.6370300104948683e-09
making O 0 1.7930478213301626e-09
a O 0 2.905355123150599e-10
total O 0 1.9456138089513075e-10
of O 0 2.962596001854223e-10
nineteen O 0 2.9666031764463696e-07
CPO O 0 9.687611054687295e-06
gene B-Disease 0 5.452668119687587e-06
defects I-Disease 0 0.003957267850637436
reported O 0 5.51505195289792e-07
so O 0 1.8660802680869892e-08
far O 0 2.0562817226732477e-08
. O 0 4.52339676826341e-09
. O 0 2.4989017077814424e-08

Coincidence O 0 9.071387466974556e-06
of O 0 6.832920451671498e-09
two O 0 6.7111969315192255e-09
novel O 0 3.393372693949459e-08
arylsulfatase O 0 3.976948846684536e-06
A O 0 9.58716412924332e-08
alleles O 0 4.51317816896335e-07
and O 0 8.297395481804415e-08
mutation O 0 6.339545848277339e-07
459 O 0 9.805654599404079e-07
+ O 0 4.0296228576153226e-07
1G O 0 6.069235496397596e-06
> O 0 1.9692943453719636e-07
A O 0 1.063276666712909e-08
within O 0 1.5409732379012553e-09
a O 0 3.8464786911163173e-08
family O 0 1.4259748581935128e-07
with O 0 1.2181385500298347e-07
metachromatic B-Disease 1 1.0
leukodystrophy I-Disease 1 0.9999985694885254
: O 0 3.733534370553571e-09
molecular O 0 8.124545480825418e-09
basis O 0 3.3017149014824554e-09
of O 0 1.3360810235951703e-09
phenotypic O 0 5.492973969012382e-07
heterogeneity O 0 2.283577032358153e-06
. O 0 6.399195058293117e-07

In O 0 2.0226349306540214e-07
a O 0 2.9956236602401987e-08
family O 0 8.135152107513477e-09
with O 0 5.002292469136194e-10
three O 0 7.37516714366393e-09
siblings O 0 5.6411550986013026e-08
, O 0 4.186273550033093e-10
one O 0 1.2111397440506266e-09
developed O 0 4.421278632094072e-08
classical O 0 1.0628999916661996e-05
late O 1 0.9885929822921753
infantile O 1 0.9999532699584961
metachromatic B-Disease 1 1.0
leukodystrophy I-Disease 1 0.9999998807907104
( O 0 2.1170222680666484e-05
MLD B-Disease 1 0.9999959468841553
) O 0 3.306594109631078e-08
, O 0 3.4349822986001755e-09
fatal O 0 3.0402738957491238e-06
at O 0 1.6993629969874746e-06
age O 0 7.9278265729954e-08
5 O 0 2.150902345121608e-09
years O 0 3.5175675705545473e-09
, O 0 3.1552674362167465e-10
with O 0 1.2684020500586257e-09
deficient O 0 0.002757750451564789
arylsulfatase O 0 5.475951638800325e-06
A O 0 1.83200612013934e-07
( O 0 1.035690377904075e-08
ARSA O 0 4.855037332163192e-06
) O 0 3.652892988093015e-10
activity O 0 5.577696970959778e-09
and O 0 6.068692215421834e-10
increased O 0 1.1386837250881854e-08
galactosylsulfatide O 0 1.0990991540893447e-05
( O 0 1.640049305251523e-07
GS O 1 0.9999982118606567
) O 0 2.20170051079549e-08
excretion O 0 2.2199070315309655e-07
. O 0 6.8277898890301e-08

The O 0 4.071270964800533e-08
two O 0 2.375859953218651e-09
other O 0 1.0553860008144511e-09
siblings O 0 5.1972627090890455e-08
, O 0 6.314594958034547e-10
apparently O 0 2.3011880045942235e-07
healthy O 0 1.0382679960230234e-07
at O 0 2.1993502130612796e-08
12 O 0 2.7674500469032637e-09
( O 0 2.8673582952443155e-10
1 O 0 3.699297090875575e-09
/ O 0 7.939069490703332e-08
2 O 0 1.3486524119699084e-09
) O 0 7.752132963334546e-11
and O 0 5.896513832759354e-10
15 O 0 3.648981339310353e-09
years O 0 4.5115383651150864e-10
, O 0 1.6096566787804356e-11
respectively O 0 1.4341187959399093e-10
, O 0 3.1885036277934375e-11
and O 0 1.3818379773766765e-10
their O 0 1.4434520245742988e-10
father O 0 2.4297966305653063e-08
, O 0 5.861047203126191e-10
apparently O 0 1.595629299799839e-07
healthy O 0 1.2940069460398718e-08
as O 0 5.242417611128758e-10
well O 0 9.330693995224237e-10
, O 0 2.398982124063309e-10
presented O 0 6.726369683462963e-09
ARSA O 0 6.704581755911931e-05
and O 0 6.617183885282429e-07
GS O 1 0.9999988079071045
values O 0 2.2925688014652224e-09
within O 0 4.534269626432774e-10
the O 0 1.3021096423315726e-09
range O 0 3.337254383950494e-08
of O 0 3.02159577358907e-08
MLD B-Disease 1 0.9999997615814209
patients O 0 1.3315452633833047e-05
. O 0 5.979935480127097e-08

Mutation O 0 1.7194524843944237e-05
screening O 0 1.8181771110903355e-06
and O 0 1.1170920188874334e-08
sequence O 0 3.6206884157508057e-09
analysis O 0 4.345422688345479e-09
disclosed O 0 3.3580249692022335e-08
the O 0 4.246621665426886e-10
involvement O 0 4.704943101785375e-09
of O 0 1.2051477871199978e-10
three O 0 5.866058194747836e-10
different O 0 1.0324138211004197e-09
ARSA O 0 2.9215705581009388e-05
mutations O 0 9.817419055480059e-08
being O 0 5.064196173520941e-09
the O 0 1.840205487990687e-10
molecular O 0 1.915692049436757e-09
basis O 0 6.810813690805162e-09
of O 0 2.069694415851586e-09
intrafamilial O 0 6.469530944741564e-06
phenotypic O 0 2.3839786535972962e-06
heterogeneity O 0 6.950176157261012e-06
. O 0 5.249387413641671e-07

The O 0 1.1015944210157613e-06
late O 0 0.0002057123783743009
infantile O 1 0.7424526810646057
patient O 0 0.0015337032964453101
inherited O 0 6.084988126531243e-05
from O 0 1.687134272287949e-07
his O 0 6.511631767125436e-08
mother O 0 6.026353815968832e-08
the O 0 3.6150901716602846e-10
frequent O 0 8.418930441678185e-09
0 O 0 5.408103120885244e-08
- O 0 4.4210441956238355e-06
type O 0 2.0714051061077043e-05
mutation O 0 9.518706747257966e-07
459 O 0 2.0307815873366053e-07
+ O 0 1.0061031474606352e-07
1G O 0 1.1355667766110855e-06
> O 0 2.1513219650159954e-08
A O 0 1.3287447586662893e-08
, O 0 8.752061297911951e-10
and O 0 7.645019617363857e-10
from O 0 3.5078795423970632e-09
his O 0 7.0879360158926374e-09
father O 0 5.402944758259309e-09
a O 0 3.968007589172373e-10
novel O 0 1.2960983397647396e-09
, O 0 1.924124470864541e-10
single O 0 2.4222113204075413e-09
basepair O 0 2.0809477518923813e-07
microdeletion O 0 1.6552622383869675e-08
of O 0 4.876580042556533e-11
guanine O 0 1.1099722252438937e-09
at O 0 9.58103263393184e-10
nucleotide O 0 2.1232582358976515e-09
7 O 0 2.004700849767005e-09
in O 0 1.7655622519541225e-09
exon O 0 1.0121815563479686e-07
1 O 0 5.08624040662653e-08
( O 0 1.2205533472808838e-08
7delG O 0 8.914223599276738e-07
) O 0 1.0215353007936301e-08
. O 0 2.7064338325999415e-08

The O 0 2.0058440952652745e-07
two O 0 7.973547866413355e-08
clinically O 0 0.000348608911735937
unaffected O 0 1.9059192709391937e-05
siblings O 0 2.185221603667742e-07
carried O 0 1.9682685703514835e-08
the O 0 6.1232849901671216e-09
maternal O 0 4.3936296378888073e-07
mutation O 0 3.0739425938008935e-07
459 O 0 7.14607836016512e-07
+ O 0 3.326261150959908e-07
1G O 0 2.3858531221776502e-06
> O 0 7.114676492392391e-08
A O 0 1.731998722220851e-08
and O 0 3.240423929184999e-09
, O 0 1.788609815811526e-10
on O 0 2.6046924617162404e-09
their O 0 6.406369879030649e-10
paternal O 0 8.037066123733894e-08
allele O 0 7.115449562888898e-08
, O 0 2.9409821800108205e-10
a O 0 2.7321098161614543e-10
novel O 0 2.0548809320786177e-09
cytosine O 0 1.602918864307412e-08
to O 0 1.516773040499686e-09
thymidine O 0 1.7941387397968356e-07
transition O 0 1.4735578091062962e-08
at O 0 9.400329403774776e-09
nucleotide O 0 2.911471241873187e-08
2435 O 0 6.368255753841368e-07
in O 0 6.789011131047573e-09
exon O 0 1.2889834977158898e-07
8 O 0 2.052738956592748e-08
, O 0 4.6029341449482786e-10
resulting O 0 4.092607086558786e-10
in O 0 7.875266549994819e-10
substitution O 0 9.113962029516642e-09
of O 0 7.547842906241442e-10
alanine O 0 3.3144212352453906e-07
464 O 0 1.0689523577411819e-07
by O 0 1.763113210984102e-08
valine O 0 3.912990359822288e-05
( O 0 3.6557544547122234e-08
A464V O 0 7.061436235744623e-07
) O 0 1.3776209506488613e-08
. O 0 3.723175012737556e-08

The O 0 2.826323282079102e-07
fathers O 0 9.559151976645808e-07
genotype O 0 3.1519259664491983e-06
thus O 0 5.485572529551064e-08
was O 0 1.1842221283586696e-06
7delG O 0 1.1578994417504873e-05
/ O 0 1.3103705896355677e-05
A464V O 0 4.827465090784244e-06
. O 0 1.6437290639714774e-07

Mutation O 0 6.562871567439288e-05
A464V O 0 2.8589471185114235e-05
was O 0 7.366973022726597e-07
not O 0 4.372009421160783e-09
found O 0 4.1220027391375424e-09
in O 0 4.118740903891194e-09
18 O 0 4.7819192161568935e-08
unrelated O 0 4.751172127726022e-06
MLD B-Disease 1 1.0
patients O 0 4.107565473532304e-05
and O 0 2.69467967939363e-08
50 O 0 1.9693050745672736e-08
controls O 0 7.120986992958933e-06
. O 0 2.2475167327229428e-07

A464V O 0 5.175387559575029e-05
, O 0 4.7023441140936484e-08
although O 0 1.1608388916783952e-08
clearly O 0 4.2571119962531156e-08
modifying O 0 2.0092174679575692e-07
ARSA O 0 0.00019944901578128338
and O 0 1.4208221728040371e-06
GS O 1 1.0
levels O 0 2.7540696123651287e-07
, O 0 1.2299449236863325e-09
apparently O 0 3.217822097667522e-08
bears O 0 1.4768724021507751e-08
little O 0 2.1852253340171046e-08
significance O 0 3.932567160802591e-09
for O 0 5.586583973204995e-10
clinical O 0 2.034334123379722e-08
manifestation O 0 1.7014664877024188e-07
of O 0 6.04657159897215e-08
MLD B-Disease 1 0.9999996423721313
, O 0 2.5935298353374492e-08
mimicking O 0 4.907215043203905e-07
the O 0 2.749861671702547e-08
frequent O 0 2.4092319108603988e-06
ARSA O 0 0.020536379888653755
pseudodeficiency O 0 0.00017968312022276223
allele O 0 8.678709127707407e-05
. O 0 8.419012260674208e-07

Our O 0 2.590243184386054e-07
results O 0 3.072453225172467e-08
demonstrate O 0 7.2454695576595896e-09
that O 0 1.7801590757038355e-10
in O 0 2.389301256844334e-10
certain O 0 3.3985789738011363e-09
genetic O 0 3.044023060283507e-07
conditions O 0 0.00012063514441251755
MLD B-Disease 1 1.0
- O 0 0.00020196106925141066
like O 0 4.903813533019274e-07
ARSA O 0 0.0009643150842748582
and O 0 3.9205755797411257e-07
GS O 1 0.9999978542327881
values O 0 2.2736956761804095e-09
need O 0 1.0101479652746548e-09
not O 0 2.210408245328921e-10
be O 0 8.41924377437131e-11
paralleled O 0 1.7800207974261184e-09
by O 0 5.838865502205692e-10
clinical O 0 7.033497126940347e-07
disease O 0 8.094447139228578e-07
, O 0 9.327277838977466e-10
a O 0 2.6374877837298527e-09
finding O 0 8.427718967141118e-09
with O 0 2.3518469394190333e-09
serious O 0 6.870848665130325e-06
diagnostic O 0 1.7360973288305104e-05
and O 0 3.919054165635316e-07
prognostic O 0 1.9643737687147222e-05
implications O 0 4.809557594853686e-06
. O 0 2.7201437546864327e-07

Moreover O 0 4.892368906439515e-06
, O 0 2.0656647947703277e-08
further O 0 1.4121501301644912e-08
ARSA O 0 0.00011921986879315227
alleles O 0 2.3127671511247172e-07
functionally O 0 1.4613634391480446e-07
similar O 0 4.827416244523874e-09
to O 0 4.3197228016822464e-09
A464V O 0 1.4926753522104264e-07
might O 0 1.4578466434045367e-08
exist O 0 7.337224716685853e-10
which O 0 2.2132051746837078e-10
, O 0 5.967701333098319e-11
together O 0 3.2875535627141517e-11
with O 0 3.5640820156279673e-11
0 O 0 3.377533275283895e-08
- O 0 6.877783016534522e-05
type O 0 0.0003689047589432448
mutations O 0 2.236211685158196e-06
, O 0 4.995258429119076e-09
may O 0 1.7351655401398602e-07
cause O 0 5.556462667755113e-08
pathological O 0 1.2591205631906632e-05
ARSA O 0 0.004574339836835861
and O 0 4.050662937515881e-06
GS O 1 1.0
levels O 0 5.701939187474636e-08
, O 0 1.7514108219263136e-10
but O 0 6.283909503856933e-10
not O 0 5.51277523630489e-10
clinical O 0 8.680529184346142e-09
outbreak O 0 2.2429551549407734e-08
of O 0 4.048369417475328e-10
the O 0 2.6169091782435316e-08
disease O 0 1.5063292266859207e-06
. O 0 6.86126000459808e-09
. O 0 3.4200397180939035e-08

Human O 0 0.0001430672564310953
MLH1 O 1 0.9997168183326721
deficiency O 1 0.99981290102005
predisposes O 0 0.0009390058694407344
to O 0 2.907658881667885e-06
hematological B-Disease 1 0.9882912039756775
malignancy I-Disease 1 0.9633370637893677
and O 0 1.1384337312847492e-06
neurofibromatosis B-Disease 0 0.031887784600257874
type I-Disease 0 0.00026033681933768094
1 I-Disease 0 7.816520337655675e-07
. O 0 2.727994683482393e-07

Heterozygous O 0 0.00030014265212230384
germ O 0 0.21309511363506317
- O 0 0.27952834963798523
line O 0 2.428695324852015e-06
mutations O 0 1.3083895566978754e-07
in O 0 2.0380459542224116e-09
the O 0 1.2252900916109866e-09
DNA O 0 6.526272500195773e-07
mismatch O 0 5.5814514780649915e-05
repair O 0 0.0002370767469983548
genes O 0 3.198059346232185e-07
lead O 0 2.518621613489813e-07
to O 0 6.256253186620597e-07
hereditary B-Disease 1 0.9999997615814209
nonpolyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 4.742480541608529e-06

The O 0 1.7392490008205641e-06
disease O 0 2.2061154595576227e-05
susceptibility O 0 5.221586434345227e-07
of O 0 1.4279154525453919e-09
individuals O 0 4.254682384186026e-09
who O 0 2.212803025258836e-07
constitutionally O 0 1.5525498042734398e-07
lack O 0 3.8587138817547384e-08
both O 0 8.789521999119643e-09
wild O 0 5.587133244944198e-08
- O 0 1.1511655429785606e-05
type O 0 5.915979272685945e-06
alleles O 0 1.7273576702336868e-07
is O 0 1.561376450354146e-08
unknown O 0 3.408403017601813e-07
. O 0 1.41768992989455e-07

We O 0 2.2544655564615823e-07
have O 0 5.001188352338204e-09
identified O 0 3.118366453946919e-09
three O 0 5.13265263624163e-10
offspring O 0 1.2526018000613703e-09
in O 0 2.751780581178309e-09
a O 0 1.8131763681594748e-06
hereditary B-Disease 1 1.0
nonpolyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
family O 0 1.9729495761566795e-06
who O 0 7.705031634941406e-08
developed O 0 6.989292273829051e-07
hematological B-Disease 0 0.28444552421569824
malignancy I-Disease 0 0.02017972245812416
at O 0 1.619945351194474e-07
a O 0 6.72554900660316e-09
very O 0 6.136241381682339e-08
early O 0 4.3456843741296325e-06
age O 0 1.916390957035219e-08
, O 0 1.0124234089969875e-10
and O 0 4.3940107108397797e-10
at O 0 3.027859518667242e-09
least O 0 2.473142524106464e-10
two O 0 6.458546197851689e-11
of O 0 1.9346704793754554e-11
them O 0 2.7764368581983945e-10
displayed O 0 3.344907995028734e-08
signs O 0 4.921495246890117e-07
of O 0 1.3021146383351834e-09
neurofibromatosis B-Disease 0 6.296073115663603e-05
type I-Disease 0 2.9141077902750112e-05
1 I-Disease 0 1.7302231469784601e-07
( O 0 3.000450021772849e-08
NF1 B-Disease 0 1.6819174561533146e-05
) O 0 1.690654372055178e-08
. O 0 4.208863302324062e-08

DNA O 0 1.5631785572622903e-06
sequence O 0 6.734279622833128e-08
analysis O 0 1.4005515858173112e-08
and O 0 3.356249722585858e-09
allele O 0 2.518052326649922e-07
- O 0 2.195316710640327e-07
specific O 0 7.239433053030098e-09
amplification O 0 1.6909905298234662e-07
in O 0 2.2763696705396796e-08
two O 0 3.4183308628144005e-08
siblings O 0 1.9204256318516855e-07
revealed O 0 2.2853234327158134e-07
a O 0 4.6790287200337843e-08
homozygous O 0 1.8562328477855772e-05
MLH1 O 0 0.0003462315071374178
mutation O 0 2.163262479371042e-06
( O 0 3.1835316605111075e-08
C676T O 0 3.666900738608092e-06
- O 0 0.00026569372857920825
- O 0 0.00030463625444099307
> O 0 8.80000698089134e-07
Arg226Stop O 0 3.1209526696329704e-06
) O 0 3.526477243553927e-08
. O 0 1.0310078124575739e-07

Thus O 0 4.835348477172374e-07
, O 0 1.8566364445860017e-08
a O 0 2.5826254912431068e-08
homozygous O 0 3.184666411470971e-06
germ O 0 0.019017022103071213
- O 0 0.00942712090909481
line O 0 0.00037626983248628676
MLH1 O 0 0.005287963896989822
mutation O 0 6.41235601506196e-06
and O 0 6.080087189275218e-08
consequent O 0 1.2716950550384354e-05
mismatch O 1 0.9988495111465454
repair O 1 0.9999986886978149
deficiency O 1 0.9993308782577515
results O 0 3.3432309010095196e-07
in O 0 2.3407450200352287e-08
a O 0 1.8088485376210883e-07
mutator O 0 0.032941631972789764
phenotype O 0 0.00011891636677319184
characterized O 0 5.30571185208828e-07
by O 0 1.0495553937062141e-07
leukemia B-Disease 1 0.9992616772651672
and O 0 2.389475775999017e-05
/ O 1 0.99998939037323
or O 1 0.9998316764831543
lymphoma B-Disease 1 1.0
associated O 0 1.2643720310734352e-06
with O 0 1.6791879886568495e-08
neurofibromatosis B-Disease 0 0.007927321828901768
type I-Disease 0 6.527257937705144e-05
1 I-Disease 0 1.11021037696446e-07
. O 0 1.0982220466360104e-08
. O 0 3.2184541254309806e-08

Missense O 0 0.0005633801920339465
mutations O 0 1.6322850569849834e-05
in O 0 4.463891656314445e-08
the O 0 8.212568958221311e-10
most O 0 3.2219701906477383e-10
ancient O 0 1.0320535537289288e-09
residues O 0 1.1063816529599535e-08
of O 0 1.497626744839664e-10
the O 0 1.092238632871556e-09
PAX6 O 0 1.4233135061658686e-06
paired O 0 1.381497298780232e-07
domain O 0 6.511706374112691e-08
underlie O 0 1.2045313724229345e-07
a O 0 5.355360155334665e-09
spectrum O 0 1.5312518542032194e-07
of O 0 6.452175238536029e-09
human O 0 1.3899559235142078e-05
congenital B-Disease 1 1.0
eye I-Disease 1 0.9999973773956299
malformations I-Disease 1 0.9997981190681458
. O 0 1.3551440360970446e-06

Mutations O 0 2.6820031052920967e-05
of O 0 1.3511144203448566e-08
the O 0 8.90687967824988e-09
human O 0 2.3119174130670217e-08
PAX6 O 0 0.00032764085335657
gene O 0 0.00019943607912864536
underlie O 0 0.07130062580108643
aniridia B-Disease 1 1.0
( O 0 0.06605356931686401
congenital B-Disease 1 0.9999994039535522
absence I-Disease 0 4.5868830511608394e-07
of I-Disease 0 3.9752875991005965e-10
the I-Disease 0 2.4150195176986244e-09
iris I-Disease 0 4.985390205547446e-06
) O 0 5.386920909344894e-10
, O 0 2.6867938429653293e-10
a O 0 5.499051880519801e-09
rare O 0 4.552804057311732e-06
dominant O 1 0.6520139575004578
malformation B-Disease 1 0.5332630276679993
of I-Disease 0 4.13838785462417e-09
the I-Disease 0 1.0691032770182574e-07
eye I-Disease 0 0.02516206167638302
. O 0 7.338447858273867e-07

The O 0 1.1966379531713756e-07
spectrum O 0 4.187619708773127e-07
of O 0 1.0566957975299829e-08
PAX6 O 0 0.00013034141738899052
mutations O 0 9.910045264405198e-06
in O 0 8.39875553992897e-07
aniridia B-Disease 1 1.0
patients O 0 6.996454885666026e-06
is O 0 6.828930199098693e-10
highly O 0 1.6526429114094299e-09
biased O 0 1.4172059081829502e-07
, O 0 1.399351190478626e-10
with O 0 5.243214890038317e-11
92 O 0 8.49038528372148e-09
% O 0 5.5118153097222233e-11
of O 0 1.0891834309467718e-11
all O 0 4.3979264674476326e-10
reported O 0 4.203844810035662e-07
mutations O 0 1.877798361249461e-08
leading O 0 2.3777742441666305e-08
to O 0 5.911279465919961e-09
premature O 0 1.1247851006146448e-07
truncation O 0 2.5640282785843738e-08
of O 0 1.3014883615269923e-10
the O 0 6.167870658657648e-10
protein O 0 6.5950369609879544e-09
( O 0 3.4049636443711506e-09
nonsense O 0 7.226116167657892e-07
, O 0 4.0235356713047565e-10
splicing O 0 2.5088256805361198e-08
, O 0 4.1630868197195525e-10
insertions O 0 1.9744350154837775e-08
and O 0 1.4427975481012822e-09
deletions O 0 1.0615238466016308e-08
) O 0 1.5104267836463237e-10
and O 0 3.4420769012832864e-10
just O 0 1.7556761600090454e-09
2 O 0 1.3609802174130436e-10
% O 0 2.453146193126532e-11
leading O 0 2.8776583893552754e-10
to O 0 4.016203689061193e-11
substitution O 0 6.912933558922418e-10
of O 0 4.877277401393876e-11
one O 0 5.925918089566551e-10
amino O 0 7.215195663157203e-10
acid O 0 2.481700123180275e-10
by O 0 1.0960927304681789e-10
another O 0 7.724982431511762e-09
( O 0 4.111010198926124e-09
missense O 0 1.8734679088083794e-06
) O 0 1.9247394789090322e-08
. O 0 6.225376836255236e-08

The O 0 7.440901583777304e-08
extraordinary O 0 2.725154324423329e-08
conservation O 0 1.6446118911161989e-09
of O 0 9.517189120122893e-11
the O 0 4.981887680166608e-10
PAX6 O 0 4.13841064528242e-07
protein O 0 2.0815880574787116e-08
at O 0 7.4107013858792925e-09
the O 0 4.20535245515552e-10
amino O 0 4.069164560860372e-09
acid O 0 1.1774181629675695e-08
level O 0 7.879236818553181e-09
amongst O 0 2.152987566006459e-09
vertebrates O 0 2.3965148088223032e-08
predicts O 0 1.0269608452517787e-07
that O 0 2.549703781440371e-09
pathological O 0 1.0541331221247674e-06
missense O 0 1.6309017155435868e-05
mutations O 0 1.083301071957976e-06
should O 0 1.3620802263858423e-08
in O 0 1.2722448650137608e-09
fact O 0 9.31252353009171e-10
be O 0 2.1378632197865954e-09
common O 0 2.5229516253943984e-09
even O 0 1.535549110087686e-08
though O 0 3.795657566030286e-09
they O 0 8.759576397565638e-10
are O 0 1.704484747788726e-10
hardly O 0 8.322387223813621e-09
ever O 0 1.1846332803600035e-08
seen O 0 6.370272132016908e-08
in O 0 1.2350426459306618e-07
aniridia B-Disease 1 0.9999996423721313
patients O 0 3.355507487867726e-06
. O 0 5.467460084673803e-08

This O 0 4.578893353368585e-08
indicates O 0 3.86095919679974e-08
that O 0 4.696620314881272e-10
there O 0 2.870170767721447e-10
is O 0 3.6220176163892503e-11
a O 0 9.143976131831266e-10
heavy O 0 7.6135597737447824e-06
ascertainment O 0 4.760224783240119e-06
bias O 0 1.396212724102952e-06
in O 0 7.022510128962267e-09
the O 0 3.142150983848069e-10
selection O 0 7.684624048209798e-10
of O 0 2.368185647583232e-10
patients O 0 6.823646980791409e-09
for O 0 3.219998157000248e-10
PAX6 O 0 1.690153453637322e-06
mutation O 0 6.065121738174639e-08
analysis O 0 1.0586021836900272e-08
and O 0 2.3136543791935082e-09
that O 0 8.330641176890197e-10
the O 0 7.200997131917575e-09
missing O 0 7.270068635989446e-06
PAX6 O 0 0.00019321389845572412
missense O 0 0.00024231921997852623
mutations O 0 1.534877810627222e-05
frequently O 0 1.4066388303035637e-06
may O 0 5.57670045964187e-06
underlie O 0 3.112834974672296e-06
phenotypes O 0 1.0522509228394483e-06
distinct O 0 1.46660894984052e-07
from O 0 5.527636517399515e-07
textbook O 0 0.029848212376236916
aniridia B-Disease 1 0.9999997615814209
. O 0 1.5759947018523235e-06

Here O 0 1.9770068320212886e-06
we O 0 1.8377168231609176e-08
present O 0 5.68783409260476e-10
four O 0 1.2086797118726622e-09
novel O 0 2.20378026938306e-08
PAX6 O 0 2.0468631191761233e-05
missense O 0 1.4811901564826258e-05
mutations O 0 7.902642096269119e-07
, O 0 2.111981256547324e-09
two O 0 6.241396843797986e-10
in O 0 7.615538422101054e-09
association O 0 2.9697615033796865e-08
with O 0 4.5023167416502474e-09
atypical O 0 0.00018527626525610685
phenotypes O 0 6.43169623799622e-05
ectopia B-Disease 0 0.00042712767026387155
pupillae I-Disease 0 7.311840454349294e-05
( O 0 3.451323493663949e-08
displaced B-Disease 0 2.0939125988661544e-08
pupils I-Disease 0 5.863669230166124e-07
) O 0 1.1091685792052886e-08
and O 0 5.492353466252098e-06
congenital B-Disease 1 0.9999992847442627
nystagmus I-Disease 0 0.00010976053454214707
( O 0 1.148908879144983e-08
searching B-Disease 0 1.219071776858982e-07
gaze I-Disease 0 6.781118599974434e-07
) O 0 3.2755942402928895e-10
, O 0 7.956824782384686e-11
and O 0 2.646531882533054e-10
two O 0 5.485190079923541e-10
in O 0 3.0692728358872046e-08
association O 0 6.045739464610733e-09
with O 0 2.816718802645113e-10
more O 0 7.167507476424362e-09
recognizable O 0 1.3222016605141107e-05
aniridia B-Disease 1 0.9999997615814209
phenotypes O 0 7.272828952409327e-06
. O 0 1.5036968648018956e-07

Strikingly O 0 0.00029393250588327646
, O 0 1.9401200646029793e-08
all O 0 1.1138405753285952e-09
four O 0 8.909628590458851e-10
mutations O 0 3.0366273939819166e-09
are O 0 4.321465407741698e-11
located O 0 2.766572804180356e-10
within O 0 2.337780247163579e-10
the O 0 1.7558334786116347e-09
PAX6 O 0 9.676185754869948e-07
paired O 0 6.066174762509036e-08
domain O 0 1.4518168889310346e-08
and O 0 1.2336712762461843e-09
affect O 0 3.2217690737468274e-09
amino O 0 3.87813697821926e-10
acids O 0 2.3000178150933692e-10
which O 0 7.739869856138171e-11
are O 0 1.9780808935276895e-11
highly O 0 6.787372747174558e-11
conserved O 0 2.1099508251687382e-10
in O 0 1.6220045306880593e-09
all O 0 7.79465519906708e-11
known O 0 3.820365135354109e-10
paired O 0 6.7840666417851025e-09
domain O 0 1.1852888448515841e-08
proteins O 0 1.8704989557249974e-08
. O 0 3.400772285999665e-08

Our O 0 1.5111278628410219e-07
results O 0 2.6552919862865565e-08
support O 0 2.2334074867291775e-10
the O 0 1.1367599223044422e-10
hypothesis O 0 6.39727271156687e-10
that O 0 6.211241937448264e-11
the O 0 4.679093223991515e-11
under O 0 7.821331915458529e-10
- O 0 8.645499427473169e-09
representation O 0 1.2976096863681619e-09
of O 0 6.718596234911445e-10
missense O 0 3.952326551370788e-06
mutations O 0 5.519345336324477e-07
is O 0 2.430875500891716e-09
caused O 0 1.2619980616079829e-08
by O 0 2.3361810264077576e-09
ascertainment O 0 2.400846597083728e-06
bias O 0 6.344375378830591e-06
and O 0 5.609896547298376e-09
suggest O 0 2.4106980855975735e-09
that O 0 9.312003945716185e-11
a O 0 4.5921830227335647e-10
substantial O 0 5.905690159124788e-09
burden O 0 1.0950451923008586e-07
of O 0 1.0592197119407842e-09
PAX6 B-Disease 0 0.001429038937203586
- I-Disease 0 0.032482217997312546
related I-Disease 0 5.2544433856382966e-05
disease I-Disease 0 0.0007795012788847089
remains O 0 4.2804757072190114e-07
to O 0 7.936821200260624e-10
be O 0 3.65011598724152e-09
uncovered O 0 2.658977109604166e-07
. O 0 4.390896535255706e-09
. O 0 1.003530769594363e-08

The O 0 1.0908154735034259e-07
chromosomal O 0 3.0301719107228564e-06
order O 0 5.126295832269534e-09
of O 0 2.700387968790352e-10
genes O 0 1.652725778455988e-08
controlling O 0 1.1462564941666642e-07
the O 0 7.053788220190427e-09
major O 0 5.80819232709473e-08
histocompatibility O 0 1.3528751878766343e-06
complex O 0 5.0356685932229084e-08
, O 0 2.690841771624264e-09
properdin O 0 2.6539561304161907e-07
factor O 0 1.614686695461387e-08
B O 0 2.275641691085184e-06
, O 0 3.871192255644473e-09
and O 0 1.3840504209383653e-07
deficiency B-Disease 0 1.6051178590714699e-06
of I-Disease 0 5.002719419278101e-11
the I-Disease 0 7.26550486440658e-10
second I-Disease 0 9.472088002837609e-09
component I-Disease 0 3.73457398339383e-09
of I-Disease 0 3.023005179514371e-10
complement I-Disease 0 3.6584609119927336e-08
. O 0 4.936170583391686e-08

The O 0 4.780022422323782e-08
relationship O 0 4.098055583767746e-08
of O 0 1.8713748606291603e-10
the O 0 3.3495398121807796e-10
genes O 0 1.19230882944521e-08
coding O 0 6.119795870063172e-08
for O 0 1.5326251379121913e-09
HLA O 0 1.902590156532824e-07
to O 0 4.768488937045845e-10
those O 0 6.529597418314381e-10
coding O 0 1.570875518552839e-08
for O 0 3.408600346421764e-10
properdin O 0 6.862139656504951e-08
Factor O 0 1.2924431302963058e-08
B O 0 4.5879770027568156e-07
allotypes O 0 4.624313305612304e-07
and O 0 5.4703468421735124e-09
for O 0 3.5822416144526414e-09
deficiency B-Disease 0 1.7212043701420043e-07
of I-Disease 0 4.332821948449528e-11
the I-Disease 0 3.458107133980093e-10
second I-Disease 0 2.5861337515920013e-09
component I-Disease 0 1.3366902029687822e-09
of I-Disease 0 4.530878797148752e-11
complement I-Disease 0 3.6787164425788887e-09
( O 0 1.7767813886848671e-09
C2 O 0 1.2988762421173305e-07
) O 0 2.5853827412269936e-10
was O 0 9.188527272385727e-09
studied O 0 6.8332330904752325e-09
in O 0 1.0552834162069757e-09
families O 0 2.4521604191640733e-10
of O 0 2.2599538906931116e-10
patients O 0 9.213539442498586e-08
with O 0 1.4302903750262885e-08
connective O 0 0.3645179271697998
tissue O 1 0.9995539784431458
disorders O 1 0.955246090888977
. O 0 2.761394171102438e-07

Patients O 0 0.000363388768164441
were O 0 7.376380040113872e-08
selected O 0 1.362557622286431e-09
because O 0 6.77790656933297e-10
they O 0 2.976852930824947e-10
were O 0 2.848596913906931e-09
heterozygous O 0 5.35907176413275e-08
or O 0 1.1388857856786672e-08
homozygous O 0 3.7591423733829288e-06
for O 0 2.0068720914423466e-05
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
. O 0 8.000052389434131e-07

12 O 0 1.7047813116732868e-06
families O 0 3.02331351065277e-08
with O 0 1.4260156389056533e-09
15 O 0 2.355093720041168e-08
matings O 0 1.7412388615412056e-06
informative O 0 2.926949855464045e-05
for O 0 0.0011320431949570775
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
were O 0 7.669591468584258e-07
found O 0 1.003027847445992e-07
. O 0 3.261539305299266e-08

Of O 0 4.7963702343167824e-08
57 O 0 6.038585524947848e-07
informative O 0 3.079347266066179e-07
meioses O 0 6.534607564390171e-06
, O 0 1.0927762028600796e-09
two O 0 2.813856647687629e-10
crossovers O 0 1.373842284380089e-08
were O 0 7.308092797586596e-09
noted O 0 2.7556146253715497e-09
between O 0 8.024426456643141e-09
the O 0 0.0002943590225186199
C2 B-Disease 1 1.0
deficiency I-Disease 1 0.9999881982803345
gene O 0 3.270927351195496e-08
and O 0 1.7201229329799617e-09
the O 0 1.9449803989601833e-09
HLA O 0 7.136094382076408e-07
- O 0 8.25283876793037e-08
B O 0 1.5127197627862188e-07
gene O 0 1.019145479119743e-08
, O 0 2.7384380874018177e-10
with O 0 2.092695808308953e-11
a O 0 2.2233893892664724e-10
recombinant O 0 2.299360923885274e-09
fraction O 0 5.942344394327392e-09
of O 0 1.5374708173254703e-09
0 O 0 6.294903442949362e-08
. O 0 7.900082010792175e-08

035 O 0 0.014864396303892136
. O 0 1.8071455997414887e-05

A O 0 4.09298945669434e-06
lod O 0 0.00011534729856066406
score O 0 2.70492250820098e-07
of O 0 5.021382198933111e-10
13 O 0 1.219685241693469e-08
was O 0 6.617377312778672e-09
calculated O 0 2.303131241276901e-09
for O 0 6.800451313182521e-10
linkage O 0 1.4160269529384095e-05
between O 1 0.5031864047050476
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
and O 0 1.7819102637872675e-08
HLA O 0 1.3677017705049366e-06
- O 0 2.340250233601182e-07
B O 0 1.7378432914938458e-07
at O 0 1.228510071449307e-09
a O 0 1.2338070842776716e-10
maximum O 0 3.226484079910108e-10
likelihood O 0 4.065082437332279e-10
value O 0 8.498184794758501e-11
of O 0 7.03054064618569e-12
the O 0 4.0415466112664333e-11
recombinant O 0 6.113292649878588e-10
fraction O 0 3.411594118318817e-09
of O 0 8.811439355937978e-10
0 O 0 2.8828859299778742e-08
. O 0 2.153666223136952e-08

04 O 0 0.0021939831785857677
. O 0 7.405973974528024e-06

18 O 0 4.187031208857661e-06
families O 0 2.576357438499599e-08
with O 0 1.7153363174315928e-09
21 O 0 2.778203622710862e-08
informative O 0 6.90642920631035e-08
matings O 0 3.2740706501499517e-07
for O 0 9.590704896922375e-10
both O 0 1.2561690576617934e-09
properdin O 0 2.940094248060632e-07
Factor O 0 1.2711564245648788e-08
B O 0 3.426739851875027e-07
allotype O 0 2.979623445753532e-07
and O 0 1.1020367729486225e-08
HLA O 0 1.3472565569827566e-06
- O 0 4.642917303954164e-07
B O 0 7.050601880109753e-07
were O 0 3.637760315200467e-08
found O 0 2.4594372760589067e-08
. O 0 2.6203153424830816e-08

Of O 0 1.1467124494402015e-07
72 O 0 1.6087635685835266e-06
informative O 0 5.250318508842611e-07
meioses O 0 5.373090971261263e-06
, O 0 2.0956896218393695e-09
three O 0 7.276140800982489e-10
recombinants O 0 7.390703160581324e-08
were O 0 2.0389800070574893e-08
found O 0 7.239498445166248e-10
, O 0 1.5388981755570796e-11
giving O 0 3.6531212083135145e-11
a O 0 8.906667070540664e-11
recombinant O 0 1.3437557733197991e-09
fraction O 0 3.3065044036106883e-09
of O 0 7.026083048700116e-10
0 O 0 5.134361558134515e-08
. O 0 4.1638529069132346e-08

042 O 0 0.0027302110102027655
. O 0 1.5693229215685278e-05

A O 0 3.489022446956369e-06
lod O 0 2.29393808695022e-05
score O 0 4.387323926380304e-08
of O 0 1.9371305948201467e-10
16 O 0 3.453323627056193e-09
between O 0 1.972845664610645e-09
HLA O 0 1.3173633988117217e-06
- O 0 2.33399163107606e-07
B O 0 1.1674517708115673e-07
and O 0 5.335404340556238e-10
Factor O 0 1.9430932418629254e-09
B O 0 9.72295808310264e-08
allotypes O 0 1.2113071079511428e-07
was O 0 1.7452865819223007e-08
calculated O 0 2.032266133156213e-09
at O 0 7.012120328830918e-10
a O 0 1.411270961204636e-10
maximum O 0 1.386852160889518e-10
likelihood O 0 3.0570876385915824e-10
value O 0 7.606849178332098e-11
of O 0 5.957485373075944e-12
the O 0 7.617084740729752e-11
recombinant O 0 6.093862636724623e-10
fraction O 0 2.663888887255439e-09
of O 0 5.612623144024553e-10
0 O 0 2.498372708714669e-08
. O 0 2.4800794307111573e-08

04 O 0 0.003948630765080452
. O 0 1.2849328413722105e-05

A O 0 3.2572560826338304e-07
crossover O 0 2.0676365863891988e-07
was O 0 1.393748618738755e-07
shown O 0 2.3506854240906705e-09
to O 0 2.0364362973701589e-10
have O 0 1.2236015534128342e-09
occurred O 0 3.1570148717463553e-09
between O 0 1.251822534520386e-10
genes O 0 7.810360136417671e-10
for O 0 6.6042442348202e-11
Factor O 0 6.516135964140801e-10
B O 0 3.694475836368838e-08
and O 0 3.477210297475608e-09
HLA O 0 5.303723469296528e-07
- O 0 2.407359716016799e-07
D O 0 6.725185812683776e-07
, O 0 2.3768831347581454e-10
in O 0 4.5088974220952593e-10
which O 0 8.027288167511415e-09
HLA O 0 3.4905533539131284e-06
- O 0 7.890322422099416e-07
D O 0 1.3710435950997635e-06
segregared O 0 3.171743685470574e-07
with O 0 2.565440748725223e-09
HLA O 0 1.2415050605341094e-06
- O 0 9.383995802636491e-08
A O 0 4.425826460874305e-08
and O 0 1.998833454308624e-08
B O 0 1.6812634839880047e-06
. O 0 3.159691175369517e-08

These O 0 2.6869708236176848e-08
studies O 0 1.092509993583235e-08
suggest O 0 4.185078061880176e-09
that O 0 6.746162656279253e-11
the O 0 2.7521138146191504e-11
genes O 0 2.6720295420723517e-10
for O 0 6.016307591005798e-11
Factor O 0 5.134378699978015e-09
B O 0 0.0078044189140200615
and O 0 0.1759050488471985
C2 B-Disease 1 1.0
deficiency I-Disease 1 0.9999994039535522
are O 0 3.142534565903077e-10
located O 0 4.3430509188979727e-10
outside O 0 9.3833785186348e-10
those O 0 1.9188579891693536e-10
for O 0 1.8172406635041938e-10
HLA O 0 3.4458377484725133e-08
, O 0 8.473421270194237e-11
that O 0 6.473814539997846e-11
the O 0 5.947078246526516e-11
order O 0 2.7210741992966803e-10
of O 0 6.943720598506786e-11
genese O 0 1.1454249460030042e-07
is O 0 8.029565901068736e-10
HLA O 0 1.4847587692656816e-07
- O 0 1.1625539642068361e-08
A O 0 1.1088577167583935e-08
, O 0 7.593183304344109e-10
- O 0 1.6877416797456135e-08
B O 0 2.872937443498813e-07
, O 0 9.663675415438888e-10
- O 0 6.69662298946605e-08
D O 0 1.466008967554444e-07
, O 0 2.76911216179343e-10
Factor O 0 2.3667914295089076e-09
B O 0 1.1909448858204996e-06
allotype O 0 4.38675306213554e-05
, O 0 2.3579270418849774e-05
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
, O 0 4.713177070847507e-10
that O 0 6.175437244904103e-11
the O 0 2.678576527248566e-10
genes O 0 5.8294570948191904e-08
coding O 0 4.104797881154809e-06
for O 0 8.789324056124315e-06
C2 B-Disease 1 1.0
deficiency I-Disease 1 0.9999998807907104
and O 0 5.815683490340007e-09
Factor O 0 6.576195143992436e-09
B O 0 5.553442861128133e-07
allotypes O 0 1.1881299144533841e-07
are O 0 1.8658434519647216e-10
approximately O 0 2.046158104063167e-10
3 O 0 1.8258928813352782e-09
- O 0 3.1149858159551513e-07
- O 0 3.942780040233629e-07
5 O 0 5.252869694771789e-09
centimorgans O 0 5.814688108785049e-08
from O 0 5.727002205802023e-10
the O 0 7.211357067049562e-10
HLA O 0 1.1916510800347169e-07
- O 0 1.2044597319516015e-08
A O 0 5.650035994619884e-09
and O 0 7.484711517236065e-09
HLA O 0 5.116955321682326e-07
- O 0 5.518714019103754e-08
B O 0 5.0954259478430686e-08
loci O 0 6.1786478156022895e-09
, O 0 3.526930969499631e-10
and O 0 1.2176942787434086e-10
that O 0 6.930607476807182e-11
the O 0 1.0643651932040754e-10
apparent O 0 7.934040091583938e-09
lack O 0 5.024729077263146e-09
of O 0 8.634482018265999e-11
recombinants O 0 5.035918704265896e-08
between O 0 2.1055689136684208e-10
the O 0 2.1594885601938785e-10
Factor O 0 3.0802498329762784e-09
B O 0 3.685010767640051e-07
gene O 0 1.1354142088748631e-06
and O 0 0.23512157797813416
C2 B-Disease 1 1.0
deficiency I-Disease 1 0.9999997615814209
gene O 0 1.1262083177143722e-07
suggests O 0 1.506058566747015e-08
that O 0 2.7444044259361533e-10
these O 0 9.769082764954362e-11
two O 0 4.367106676284038e-10
genes O 0 4.31968150138573e-09
lie O 0 1.0978764564129051e-08
in O 0 1.3165241119494908e-09
close O 0 1.1482910622362397e-08
proximity O 0 3.961611927394415e-09
to O 0 4.6173749268518804e-09
one O 0 1.1981059699905927e-08
another O 0 2.9013101254804496e-08
. O 0 3.619896205009354e-08

Distribution O 0 1.367850046563035e-07
of O 0 4.4529366860501796e-09
emerin O 0 2.7593300728767645e-06
and O 0 2.0661060418092347e-08
lamins O 0 3.6591841308108997e-06
in O 0 4.5902002199227354e-08
the O 0 8.29949708958111e-09
heart O 0 7.510138857469428e-07
and O 0 4.427529898265448e-09
implications O 0 2.2106508623664922e-08
for O 0 5.492552634933645e-09
Emery B-Disease 1 0.9991350769996643
- I-Disease 1 0.9999644756317139
Dreifuss I-Disease 1 0.997053861618042
muscular I-Disease 1 0.9992745518684387
dystrophy I-Disease 1 0.995238184928894
. O 0 1.1729116522474214e-06

Emerin O 0 0.00018143972556572407
is O 0 3.040465657022651e-08
a O 0 3.1362190622274966e-09
nuclear O 0 7.212461294869854e-09
membrane O 0 7.281268032954813e-09
protein O 0 5.861531260364927e-09
which O 0 7.952868918970069e-10
is O 0 1.8752337183070011e-10
missing O 0 2.09048458543748e-08
or O 0 3.5809302190159542e-09
defective O 0 3.9348387872450985e-06
in O 0 2.073799123536446e-06
Emery B-Disease 1 0.9999955892562866
- I-Disease 1 0.9999889135360718
Dreifuss I-Disease 1 0.9998704195022583
muscular I-Disease 1 0.9999914169311523
dystrophy I-Disease 1 0.9999822378158569
( O 0 2.800036554617691e-06
EDMD B-Disease 1 0.9999992847442627
) O 0 1.2335263477325498e-07
. O 0 9.316546112358992e-08

It O 0 4.546155807361174e-08
is O 0 8.717025434812342e-10
one O 0 2.253845582389502e-10
member O 0 6.801575969106466e-11
of O 0 1.6236031616378988e-11
a O 0 1.0896624713652159e-09
family O 0 2.011088851006093e-09
of O 0 2.3905136203872246e-10
lamina O 0 2.447089570978278e-07
- O 0 2.3249630487498507e-07
associated O 0 3.737125275904418e-09
proteins O 0 1.2041971864107381e-09
which O 0 3.2366789803894847e-10
includes O 0 6.08588290873513e-10
LAP1 O 0 2.3234481432155007e-06
, O 0 4.7233310596084266e-09
LAP2 O 0 1.7469704971517785e-06
and O 0 1.4505824097454934e-08
lamin O 0 1.568216475789086e-06
B O 0 4.1589450461287925e-07
receptor O 0 9.327889927135402e-08
( O 0 1.9413491259001603e-08
LBR O 0 1.0804681551235262e-05
) O 0 2.5312530738119676e-08
. O 0 6.695077559015772e-08

A O 0 3.1083495741768274e-06
panel O 0 8.587077218180639e-07
of O 0 1.936998561546943e-09
16 O 0 8.850014943106999e-09
monoclonal O 0 1.1589975201786729e-07
antibodies O 0 1.8995207540228876e-07
( O 0 2.8553490238891754e-08
mAbs O 0 3.24142746421785e-07
) O 0 2.279496813528681e-09
has O 0 1.5752553705894456e-09
been O 0 3.1756459684118e-09
mapped O 0 1.9388726180125104e-09
to O 0 1.9211468527124964e-10
six O 0 1.323351150883667e-10
specific O 0 3.6349041832028917e-11
sites O 0 2.9558452907529897e-10
throughout O 0 5.67183300326235e-10
the O 0 2.1252627435686122e-10
emerin O 0 1.8435553528206583e-08
molecule O 0 1.1241384489935058e-09
using O 0 1.7001348107115177e-09
phage O 0 4.562051714174231e-08
- O 0 2.259770859325272e-08
displayed O 0 1.979962860332307e-09
peptide O 0 6.912300731798382e-10
libraries O 0 1.114125236512109e-09
and O 0 6.022510823378013e-10
has O 0 1.8865631279396666e-10
been O 0 1.8198768880761662e-10
used O 0 4.021893929007092e-10
to O 0 1.22219967479964e-09
localize O 0 2.683785851331777e-07
emerin O 0 8.205810786421353e-07
in O 0 7.188591943929623e-09
human O 0 3.2692417661905893e-09
and O 0 3.653231317457539e-08
rabbit O 0 1.8893229935201816e-05
heart O 0 9.924562618834898e-05
. O 0 1.966085534377271e-07

Several O 0 2.565555234923522e-07
mAbs O 0 4.0568406802776735e-06
against O 0 2.0066414307962077e-08
different O 0 4.5403996118409395e-09
emerin O 0 5.000084684070316e-07
epitopes O 0 9.378126009096377e-08
did O 0 7.277382962911361e-08
not O 0 2.493167061690116e-10
recognize O 0 6.434695554169423e-10
intercalated O 0 1.690070838833435e-08
discs O 0 5.33709965111484e-07
in O 0 5.5785687180787136e-09
the O 0 2.4082393856872386e-09
heart O 0 4.966996698385628e-07
, O 0 4.6514131435415607e-10
though O 0 2.34910202401295e-10
they O 0 1.369636487558168e-10
recognized O 0 1.1347388306770512e-10
cardiomyocyte O 0 2.7520076884002265e-08
nuclei O 0 1.4019593264080754e-09
strongly O 0 1.834592144867031e-09
, O 0 1.214004730076823e-10
both O 0 1.647266906212863e-10
at O 0 3.8761793774710895e-09
the O 0 6.797766793908977e-10
rim O 0 1.5524581442605268e-07
and O 0 4.749909798817953e-09
in O 0 7.787767764000364e-09
intranuclear O 0 7.696100396969996e-07
spots O 0 8.084943914354881e-08
or O 0 1.4519803137602594e-08
channels O 0 3.827437069503503e-07
. O 0 1.0035081032810922e-07

A O 0 1.1129926861030981e-05
polyclonal O 0 0.00017243075126316398
rabbit O 0 0.00017630380170885473
antiserum O 0 5.1613114919746295e-05
against O 0 1.7565129155627801e-06
emerin O 0 4.313674435252324e-05
did O 0 3.164815325362724e-07
recognize O 0 4.699293398857662e-09
both O 0 5.075875275650787e-10
nuclear O 0 8.130095707770124e-09
membrane O 0 8.280838237340049e-09
and O 0 3.6215241916437435e-09
intercalated O 0 2.2465087567979936e-08
discs O 0 6.552884315169649e-07
but O 0 1.8891852526792263e-09
, O 0 3.50561524253834e-11
after O 0 1.2345886812870077e-10
affinity O 0 5.808696301734528e-10
purification O 0 8.38210667541972e-10
against O 0 7.144478342269167e-10
a O 0 1.1653016329660204e-09
pure O 0 7.378139343927614e-08
- O 0 2.557226616772823e-05
emerin O 0 1.4456294366027578e-06
band O 0 2.1267450023287893e-08
on O 0 4.051492030754389e-09
a O 0 7.117587630389721e-10
western O 0 1.732431442746929e-08
blot O 0 4.130859815631993e-05
, O 0 8.063657297441296e-09
it O 0 1.8566143067388907e-09
stained O 0 4.713623184215976e-06
only O 0 1.7719519185277477e-09
the O 0 9.45095002258256e-10
nuclear O 0 5.648552203751933e-08
membrane O 0 1.5422949672938557e-07
. O 0 6.425183585179184e-08

These O 0 3.457873276602186e-08
results O 0 4.346063064986083e-08
would O 0 1.3975647306097017e-09
not O 0 2.4742655146958725e-10
be O 0 2.390477260583168e-10
expected O 0 2.0166739389537724e-09
if O 0 5.582568296524926e-10
immunostaining O 0 3.09128083131327e-08
at O 0 3.1501636854613935e-09
intercalated O 0 7.07679204126066e-09
discs O 0 2.7489028298077756e-07
were O 0 1.7302619781389694e-08
due O 0 4.470883108176338e-10
to O 0 4.857289917503671e-11
a O 0 1.215911954455251e-10
product O 0 3.3920105613205465e-10
of O 0 1.2454082903845531e-11
the O 0 2.7164642757426805e-10
emerin O 0 2.862607040299281e-08
gene O 0 6.833441812403862e-09
and O 0 1.255074599804118e-09
, O 0 8.350156677217058e-11
therefore O 0 2.401312204636241e-10
, O 0 3.584903554565422e-11
cast O 0 1.036080998773059e-09
some O 0 3.3216226991150677e-10
doubt O 0 1.6733744390151628e-09
upon O 0 5.5652368130543195e-11
the O 0 1.137707913989594e-10
hypothesis O 0 5.143906189886138e-09
that O 0 2.303756474475449e-08
cardiac B-Disease 1 0.7032099962234497
defects I-Disease 1 0.7511076331138611
in O 0 3.869847205351107e-06
EDMD B-Disease 1 1.0
are O 0 3.815009463892238e-08
caused O 0 3.2447918130174e-08
by O 0 7.136537472085536e-10
absence O 0 3.1677895862003425e-08
of O 0 8.834477038810462e-10
emerin O 0 1.7792972357710823e-06
from O 0 3.594768926973302e-08
intercalated O 0 1.6051882312240195e-06
discs O 0 2.19470002775779e-05
. O 0 1.2793928760856943e-07

Although O 0 8.900411785361939e-07
emerin O 0 4.352768428361742e-06
was O 0 3.6034595751743836e-08
abundant O 0 9.887259899699075e-10
in O 0 3.8826150627890854e-10
the O 0 2.9132959933342306e-10
membranes O 0 5.662885715906896e-09
of O 0 2.5717986074091925e-10
cardiomyocyte O 0 1.8986440863955067e-07
nuclei O 0 1.1466277705096672e-08
, O 0 2.2942179267460006e-09
it O 0 2.302138923937491e-09
was O 0 3.5649517826641386e-07
absent O 0 6.560585408266206e-09
from O 0 2.2432995738785877e-10
many O 0 7.794997286536542e-11
non O 0 2.5657405089418717e-08
- O 0 1.208572939503938e-06
myocyte O 0 1.0903096381298383e-06
cells O 0 1.913618774551651e-08
in O 0 7.92073429067841e-09
the O 0 9.695066083281745e-09
heart O 0 2.613288643260603e-06
. O 0 1.292616218506737e-07

This O 0 9.33714439099731e-09
distribution O 0 1.4363614742052278e-09
of O 0 1.7644773142588832e-10
emerin O 0 8.273530625046988e-07
was O 0 1.9971338360846858e-08
similar O 0 1.450913000855536e-10
to O 0 1.396713994461507e-10
that O 0 1.5965311017662742e-10
of O 0 1.307696589902818e-10
lamin O 0 2.3278030880646838e-07
A O 0 9.8843981888308e-09
, O 0 2.4201782244936965e-10
a O 0 3.462529152287175e-10
candidate O 0 2.3155259931684213e-09
gene O 0 2.424792100441664e-08
for O 0 2.2218813455765485e-09
an O 0 2.8142124186558704e-09
autosomal O 0 3.220580765628256e-06
form O 0 3.7280858578014886e-07
of O 0 6.755236086064542e-07
EDMD B-Disease 1 1.0
. O 0 1.762143710948294e-06

In O 0 4.193390168438782e-07
contrast O 0 4.1795124161581043e-07
, O 0 3.7029415977940516e-08
lamin O 0 4.327262649894692e-05
B1 O 0 0.0006783097051084042
was O 0 1.7889020398342836e-07
absent O 0 4.1647506776598675e-08
from O 0 2.425313283538344e-09
cardiomyocyte O 0 7.314609007380568e-08
nuclei O 0 4.857554358750349e-09
, O 0 3.875482712523137e-10
showing O 0 3.035297169162732e-08
that O 0 3.902484557727348e-09
lamin O 0 3.5949824450653978e-06
B1 O 0 8.755726412346121e-06
is O 0 1.8061623030529717e-10
not O 0 1.2860702780503885e-10
essential O 0 2.15590392760312e-10
for O 0 6.647313949281752e-11
localization O 0 9.92183579739958e-09
of O 0 1.1021848711489923e-10
emerin O 0 1.1067113092622094e-07
to O 0 1.3941569010356147e-09
the O 0 8.100052184545348e-09
nuclear O 0 2.0756942831212655e-06
lamina O 0 6.8426720645220485e-06
. O 0 2.4282499566652405e-07

Lamin O 0 0.2799071967601776
B1 O 1 0.9704171419143677
is O 0 8.095808112784653e-08
also O 0 1.0398509608933182e-08
almost O 0 3.787731461812882e-09
completely O 0 2.442077118303132e-07
absent O 0 4.6488631255670043e-07
from O 0 3.286141847524959e-08
skeletal O 0 6.897868297528476e-05
muscle O 0 6.514497272291919e-06
nuclei O 0 8.27542464776343e-07
. O 0 2.0881439866116125e-07

In O 0 5.086375040264102e-06
EDMD B-Disease 1 0.9999998807907104
, O 0 4.0343115514929195e-09
the O 0 3.869588260929646e-10
additional O 0 7.186449213492097e-10
absence O 0 8.885873370445552e-09
of O 0 9.01511643114361e-10
lamin O 0 2.9533535780501552e-05
B1 O 0 0.00024592693080194294
from O 0 3.025320793881292e-08
heart O 0 1.1058984455303289e-05
and O 0 2.8016020792165364e-07
skeletal O 0 9.327800216851756e-05
muscle O 0 1.8593423192214686e-06
nuclei O 0 1.0134503902747838e-08
which O 0 2.350331262945815e-09
already O 0 2.6063240454732295e-08
lack O 0 8.480625979245815e-09
emerin O 0 4.744416401081253e-06
may O 0 1.2572726859616523e-07
offer O 0 2.230717832674145e-09
an O 0 1.0084513779595738e-10
alternative O 0 1.7379045980092656e-09
explanation O 0 2.9725368833055654e-09
of O 0 1.77312761695525e-10
why O 0 6.3373546410616655e-09
these O 0 1.6341486497317703e-10
tissues O 0 2.7006057390366323e-09
are O 0 3.0339281087421455e-10
particularly O 0 6.553332099201725e-09
affected O 0 7.7592261504833e-09
. O 0 1.9512524929155006e-09
. O 0 1.0209217471413012e-08

Genetic O 0 8.095488738035783e-06
mapping O 0 6.531122949127166e-07
of O 0 4.254114394086628e-09
the O 0 1.5917224871486724e-08
copper B-Disease 0 1.549023909319658e-05
toxicosis I-Disease 0 5.282170604914427e-05
locus O 0 4.3299701246724e-07
in O 0 1.3996026382301352e-07
Bedlington O 0 0.0005467702867463231
terriers O 0 0.0001802036858862266
to O 0 3.577954998945643e-08
dog O 0 1.2268338878129725e-06
chromosome O 0 1.800125232875871e-06
10 O 0 1.974250452008164e-08
, O 0 7.033659210620158e-10
in O 0 1.8000895218861501e-09
a O 0 7.237209942445588e-09
region O 0 3.7885712345087086e-08
syntenic O 0 3.0206215342332143e-06
to O 0 1.1474847738668359e-09
human O 0 5.281159065617658e-09
chromosome O 0 1.9768369838857325e-06
region O 0 4.556946748834889e-07
2p13 O 0 2.4589538952568546e-05
- O 0 1.273002999369055e-05
p16 O 0 1.9088098270003684e-05
. O 0 2.8488815928540134e-07

Abnormal O 1 0.998089611530304
hepatic B-Disease 1 0.983680248260498
copper I-Disease 0 0.0005041331751272082
accumulation I-Disease 0 4.305490790557087e-07
is O 0 1.2859066034209832e-09
recognized O 0 6.78439970869249e-10
as O 0 3.5865352909780768e-09
an O 0 1.0944584261096679e-07
inherited B-Disease 1 1.0
disorder I-Disease 1 1.0
in O 0 2.737292788879131e-06
man O 0 8.380961662624031e-05
, O 0 6.110159489480793e-09
mouse O 0 3.140739636364742e-06
, O 0 3.916938595693864e-08
rat O 0 2.2780284780310467e-05
and O 0 1.0604254185864193e-07
dog O 0 9.028301974467468e-06
. O 0 1.9192503941667383e-07

The O 0 8.755642966207233e-08
major O 0 9.683648016789448e-08
cause O 0 1.2430861318080133e-07
of O 0 6.4651222153599974e-09
hepatic B-Disease 0 0.0019065102096647024
copper I-Disease 0 0.005870250519365072
accumulation I-Disease 0 1.9943327345117723e-07
in O 0 3.251879832077975e-08
man O 0 2.405664190519019e-06
is O 0 9.143539814182589e-10
a O 0 7.258859735514989e-09
dysfunctional O 0 1.3147001709512551e-06
ATP7B O 0 7.956796252983622e-06
gene O 0 9.434638741367962e-07
, O 0 1.7817029629441095e-08
causing O 0 7.270937771863828e-07
Wilson B-Disease 0 5.459261228679679e-05
disease I-Disease 0 0.000288983661448583
( O 0 1.445193618110352e-07
WD B-Disease 0 0.0035240929573774338
) O 0 7.179577465876719e-08
. O 0 1.0272390227328287e-07

Mutations O 0 1.4844793440715875e-05
in O 0 7.241217758746643e-08
the O 0 1.0651136861383748e-08
ATP7B O 0 2.1746573111158796e-06
genes O 0 2.8605384727597993e-08
have O 0 1.0041127929127924e-08
also O 0 1.844926322824847e-09
been O 0 2.7638999977597223e-09
demonstrated O 0 6.962692200573883e-09
in O 0 2.1340875733244502e-08
mouse O 0 5.0681878747127485e-06
and O 0 3.3868653304125473e-07
rat O 0 2.2538588382303715e-05
. O 0 1.3977313528812374e-07

The O 0 2.1111712555921258e-07
ATP7B O 0 8.594388418714516e-06
gene O 0 3.35207431589879e-07
has O 0 3.930092695725307e-09
been O 0 1.2603712518099996e-09
excluded O 0 2.6215989379352322e-09
in O 0 5.151287174598451e-10
the O 0 2.0605707418130947e-10
much O 0 4.511695461673071e-09
rarer O 0 6.854022558400175e-07
human O 0 1.0308894182742279e-08
copper B-Disease 0 0.0002723833022173494
overload I-Disease 0 4.912801523460075e-05
disease O 0 2.4231080715253484e-06
non B-Disease 0 5.510898404281761e-07
- I-Disease 0 1.7529553588246927e-05
Indian I-Disease 0 1.0299837782667964e-07
childhood I-Disease 0 3.9333526729024015e-06
cirrhosis I-Disease 0 1.574747329868842e-05
, O 0 5.319555906879714e-09
indicating O 0 3.9554987552037346e-07
genetic O 0 5.109226322019822e-07
heterogeneity O 0 1.628517225071846e-06
. O 0 4.3193711007916136e-07

By O 0 3.8528162349393824e-07
investigating O 0 8.370577120331291e-07
the O 0 9.62292503459139e-08
common O 0 7.034596819721628e-06
autosomal O 1 0.9978954792022705
recessive O 1 0.9999136924743652
copper B-Disease 0 0.07148126512765884
toxicosis I-Disease 0 0.005585256032645702
( O 0 3.4398070170027495e-07
CT B-Disease 1 0.9154635071754456
) O 0 1.444582675702577e-08
in O 0 3.087933464485104e-08
Bedlington O 0 0.007033056113868952
terriers O 0 0.01900959573686123
, O 0 3.902030698554881e-09
we O 0 1.461350929155003e-09
have O 0 2.51839271658838e-10
identified O 0 1.0246414827719263e-09
a O 0 3.1670668865224627e-10
new O 0 1.6501703337112872e-09
locus O 0 1.2758662570888646e-08
involved O 0 7.055607653683182e-08
in O 0 8.297311069327407e-06
progressive O 1 0.9957265853881836
liver B-Disease 1 1.0
disease I-Disease 1 1.0
. O 0 1.8248130118081463e-06

We O 0 2.5965348982026626e-07
examined O 0 1.5369738548542955e-07
whether O 0 6.152833798012125e-09
the O 0 2.5381845514260704e-09
WD B-Disease 0 1.7686708815745078e-05
gene O 0 6.306356681307079e-07
ATP7B O 0 2.941318234661594e-05
was O 0 1.0975271891311422e-07
also O 0 1.0470332378886837e-09
causative O 0 8.06651900830957e-09
for O 0 2.9673632995219634e-10
CT B-Disease 0 0.0002610237861517817
by O 0 6.863822288316612e-10
investigating O 0 6.935402030450177e-09
the O 0 1.8189685313529935e-09
chromosomal O 0 4.580082531902008e-06
co O 0 1.4431293493544217e-06
- O 0 2.4860905796231236e-06
localization O 0 6.597517767659156e-07
of O 0 1.0671221684077636e-09
ATP7B O 0 2.743596496657119e-06
and O 0 3.2443199238230136e-09
C04107 O 0 3.824283822950747e-08
, O 0 8.615333446648776e-11
using O 0 3.947783489000045e-10
fluorescence O 0 6.852000744572706e-09
in O 0 5.4147264449966315e-09
situ O 0 3.1819350709838545e-08
hybridization O 0 1.2216876399406829e-08
( O 0 2.387849029616973e-09
FISH O 0 4.337177728075403e-08
) O 0 4.586862889510712e-09
. O 0 2.021970679777496e-08

C04107 O 0 0.00012177680036984384
is O 0 5.237275857439272e-08
an O 0 2.1740740319131646e-09
anonymous O 0 8.641497117878316e-08
microsatellite O 0 2.8842005121987313e-06
marker O 0 7.298567652469501e-07
closely O 0 1.0386284543528745e-07
linked O 0 8.331235221703537e-07
to O 0 1.2357070033885975e-07
CT B-Disease 1 0.9999117851257324
. O 0 8.502573223267973e-07

However O 0 2.77140861726366e-06
, O 0 5.4971778240542335e-08
BAC O 0 1.0950658179353923e-05
clones O 0 3.0778997484048887e-07
containing O 0 1.5364193473033083e-08
ATP7B O 0 1.0681676940293983e-05
and O 0 1.0492507307446886e-08
C04107 O 0 2.2969913970882772e-07
mapped O 0 4.1323009014604395e-08
to O 0 1.6391940027560281e-09
the O 0 2.011610655827667e-09
canine O 0 7.921702831481525e-07
chromosome O 0 6.527474170070491e-07
regions O 0 3.111167501401724e-08
CFA22q11 O 0 4.296145107218763e-06
and O 0 2.3106919044835195e-08
CFA10q26 O 0 5.850320121680852e-07
, O 0 3.884325916470033e-10
respectively O 0 9.638235765052627e-10
, O 0 9.26136251022669e-11
demonstrating O 0 5.765009580827041e-10
that O 0 4.3570230756628803e-10
WD B-Disease 0 1.085583562598913e-06
cannot O 0 7.312847216667251e-09
be O 0 7.299925663950546e-10
homologous O 0 1.133697224986463e-08
to O 0 1.5019221422107876e-08
CT B-Disease 1 0.9333993196487427
. O 0 2.742796141319559e-07

The O 0 1.385949701671052e-07
copper O 0 9.167714551949757e-07
transport O 0 8.457271150064116e-08
genes O 0 2.0674529821462784e-07
CTR1 O 0 1.4202667443896644e-05
and O 0 1.2266048621256687e-08
CTR2 O 0 3.448673169259564e-06
were O 0 2.5911566226000105e-08
also O 0 7.091840448225639e-10
excluded O 0 1.303173124966861e-09
as O 0 4.2938774758027876e-10
candidate O 0 7.401318447008975e-10
genes O 0 1.4107414125774653e-09
for O 0 5.110166179100872e-10
CT B-Disease 1 0.9972919821739197
since O 0 1.3522235065011046e-07
they O 0 4.344245851939377e-09
both O 0 8.103401283321432e-10
mapped O 0 1.9443804788465968e-08
to O 0 5.574856576373577e-09
canine O 0 2.2747935872757807e-06
chromosome O 0 5.362954652810004e-06
region O 0 7.605255518683407e-07
CFA11q22 O 0 4.306658956920728e-05
. O 0 4.3849229314218974e-07

2 O 0 8.251252438640222e-06
- O 0 0.000244279857724905
22 O 0 8.366586712327262e-07
. O 0 6.389839768417005e-08

5 O 0 3.0070930733927526e-05
. O 0 4.563441052596318e-06

A O 0 8.14502811863349e-07
transcribed O 0 9.056760745806969e-07
sequence O 0 1.7036997590480496e-08
identified O 0 1.288499973384205e-08
from O 0 5.514331213873902e-10
the O 0 6.92809976055031e-10
C04107 O 0 7.956168701639399e-08
- O 0 2.6181174561656917e-08
containing O 0 4.6853845248051584e-09
BAC O 0 3.949169240513584e-06
was O 0 4.7291660365544885e-08
found O 0 5.528612012639655e-10
to O 0 3.501258311056077e-11
be O 0 6.028713639416594e-11
homologous O 0 2.2631374552162242e-10
to O 0 1.0900070429586961e-10
a O 0 4.984814783171032e-10
gene O 0 4.201369918632736e-09
expressed O 0 2.8777738525498364e-10
from O 0 4.4326223247459495e-10
human O 0 1.2672218829834492e-09
chromosome O 0 1.0071511269416078e-06
2p13 O 0 9.477256526224664e-07
- O 0 2.1900859792367555e-06
p16 O 0 1.1803186907854979e-06
, O 0 1.2302523444418512e-09
a O 0 9.608355222567866e-10
region O 0 3.622864452879071e-09
devoid O 0 1.634075275092073e-08
of O 0 1.5052530055736923e-10
any O 0 3.040405927023926e-09
positional O 0 6.81698850257817e-07
candidate O 0 2.6891763127423474e-07
genes O 0 6.827815468568588e-07
. O 0 2.525225966110156e-07

Molecular O 0 5.563291551879956e-07
analysis O 0 3.78306914683435e-08
of O 0 7.948440794436351e-10
the O 0 1.6229794175259826e-09
APC B-Disease 0 5.390585045006446e-08
gene O 0 1.5747454895631563e-08
in O 0 3.053167718647387e-09
205 O 0 3.182614705110609e-08
families O 0 1.1180741887883983e-09
: O 0 3.9210459878979975e-10
extended O 0 2.8028360077314574e-08
genotype O 0 0.0013005981454625726
- O 0 0.01995752565562725
phenotype O 0 8.837551831675228e-06
correlations O 0 1.0532759233683464e-06
in O 0 2.088221151552716e-08
FAP B-Disease 0 3.649157065410691e-08
and O 0 4.3976494668029886e-10
evidence O 0 4.1360345703900236e-10
for O 0 1.629814685988329e-11
the O 0 2.989899300365195e-11
role O 0 4.946353326928943e-10
of O 0 1.9118291672004517e-10
APC B-Disease 0 3.6542349590718004e-08
amino O 0 4.108752449383246e-09
acid O 0 2.3685222672042983e-08
changes O 0 1.4851029561668838e-07
in O 1 0.9533312916755676
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
predisposition O 0 0.00028798854327760637
. O 0 3.7998830748620094e-07

BACKGROUND O 0 0.00023256728309206665
/ O 0 5.629419320030138e-06
AIMS O 0 1.5709316869561007e-07
The O 0 2.8218394287904403e-09
development O 0 5.545705761278441e-08
of O 0 0.0013803441543132067
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 5.5184614211611915e-08
a O 0 5.8579434636385486e-09
variable O 0 1.5492435778696745e-08
range O 0 6.962641663221802e-08
of O 0 3.232127676611185e-09
extracolonic O 0 1.6004776625777595e-05
manifestations O 0 9.690346814750228e-06
in O 0 0.0008245131466537714
familial B-Disease 1 1.0
adenomatous I-Disease 1 0.999997615814209
polyposis I-Disease 1 1.0
( O 0 6.569975084858015e-06
FAP B-Disease 0 4.9512841542309616e-06
) O 0 1.0036973030480567e-08
is O 0 7.456778527981101e-10
the O 0 4.421383814623425e-10
result O 0 4.6383474838762595e-09
of O 0 2.709127089328689e-10
the O 0 7.469836305062927e-09
dominant O 0 1.7545911759953015e-05
inheritance O 0 0.00012599705951288342
of O 0 1.5245536815200467e-05
adenomatous B-Disease 1 1.0
polyposis I-Disease 1 0.9999916553497314
coli I-Disease 1 0.9999998807907104
( O 0 4.5980432332726195e-06
APC B-Disease 0 4.562052708934061e-06
) O 0 3.46842874421327e-08
gene O 0 1.5774892290210119e-06
mutations O 0 6.0095094340795185e-06
. O 0 3.499231695514027e-07

In O 0 6.788806672375358e-08
this O 0 1.3967226264455235e-09
study O 0 5.051999374394711e-10
, O 0 3.7386399531769143e-11
direct O 0 2.551477917833722e-10
mutation O 0 3.1619080687050882e-09
analysis O 0 3.5852953939041754e-10
of O 0 4.818460908051492e-11
the O 0 5.57200507955713e-10
APC B-Disease 0 1.1970895386070879e-08
gene O 0 1.0434451525043187e-08
was O 0 2.2512658404139074e-08
performed O 0 2.898377315929679e-09
to O 0 6.504909944027304e-10
determine O 0 5.2834995045714095e-08
genotype O 0 0.000543931673746556
- O 0 0.036171164363622665
phenotype O 0 2.1680416466551833e-06
correlations O 0 7.869438150009955e-07
for O 0 2.378489849519383e-09
nine O 0 4.755460025762659e-08
extracolonic O 0 8.459931564175349e-07
manifestations O 0 4.074728110481374e-08
and O 0 7.879353280948465e-10
to O 0 2.8911592564462296e-10
investigate O 0 2.568917079059929e-09
the O 0 1.463668963808118e-09
incidence O 0 3.002602966262202e-07
of O 0 2.3009096850046262e-09
APC B-Disease 0 4.226686769470689e-07
mutations O 0 3.0640964610029187e-07
in O 0 7.328126372385668e-08
non O 1 0.6317082643508911
- O 1 1.0
FAP O 1 0.9999957084655762
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 2.1475887024280382e-06

METHODS O 0 4.810048267245293e-06
The O 0 7.479519581465865e-08
APC B-Disease 0 5.992141609567625e-07
gene O 0 1.4583075369500875e-07
was O 0 6.771296767738022e-08
analysed O 0 3.246104185450349e-08
in O 0 2.5632200806313676e-09
190 O 0 2.3485668521061598e-08
unrelated O 0 7.521306599755917e-08
FAP B-Disease 0 3.4438576790307707e-07
and O 0 9.821405022591989e-09
15 O 0 1.9449873889243463e-07
non O 0 0.28643107414245605
- O 1 1.0
FAP O 1 0.9999991655349731
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 0 7.838700184947811e-06
using O 0 2.1504915537207125e-07
denaturing O 0 8.159351273206994e-05
gradient O 0 3.5161122013960266e-06
gel O 0 9.672453415987547e-06
electrophoresis O 0 5.039704547016299e-07
, O 0 7.236102828045432e-10
the O 0 4.2844364167571314e-10
protein O 0 3.974622408975392e-09
truncation O 0 1.9376061288767232e-07
test O 0 2.3444050611942657e-07
, O 0 2.8714300381871283e-10
and O 0 3.9704603493895263e-10
direct O 0 5.241930445265552e-09
sequencing O 0 4.436069502844475e-07
. O 0 1.3043008095792175e-07

RESULTS O 0 4.126782187086064e-06
Chain O 0 8.399068747166893e-07
terminating O 0 8.73471492468525e-07
signals O 0 3.4870754461735487e-07
were O 0 1.4698890105080409e-08
only O 0 2.5273816373072577e-10
identified O 0 1.0528146132671168e-09
in O 0 7.289198133975106e-10
patients O 0 1.2340924948617271e-09
belonging O 0 3.920232582999006e-09
to O 0 8.379229532451404e-10
the O 0 4.017387311705534e-09
FAP B-Disease 0 7.443356508929355e-08
group O 0 1.106003910678055e-08
( O 0 3.447782059851079e-09
105 O 0 1.9641139203940838e-07
patients O 0 6.737350304319989e-07
) O 0 1.0416058238149617e-08
. O 0 7.759289388786783e-08

Amino O 0 3.0726048407814233e-06
acid O 0 3.238313013298466e-07
changes O 0 1.0277873663255832e-08
were O 0 1.8468133688998023e-09
identified O 0 1.5608516701348663e-09
in O 0 4.020083710365441e-10
four O 0 7.246516720016416e-10
patients O 0 2.3427539908027484e-09
, O 0 2.7602885255273435e-11
three O 0 2.8452924044630734e-11
of O 0 2.350705394227326e-11
whom O 0 2.4323874026066505e-09
belonged O 0 1.8855649486226866e-08
to O 0 3.6151523441496636e-10
the O 0 4.0843411985846956e-10
non O 0 6.169571520331374e-07
- O 0 1.0707093679229729e-05
FAP O 0 3.536746646659594e-07
group O 0 2.483801040398248e-07
of O 0 7.411562364723068e-06
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 0 0.00010915994789684191
. O 0 4.0862551031750627e-07

Genotype O 1 0.9995090961456299
- O 1 0.9994938373565674
phenotype O 0 0.00017920642858371139
correlations O 0 9.279476216761395e-06
identified O 0 2.349649435018364e-07
significant O 0 1.7904104865351655e-08
differences O 0 1.4244253065953671e-07
in O 0 2.9465043738241548e-08
the O 0 6.932343032950428e-10
nature O 0 6.141435138218299e-10
of O 0 4.966884889490153e-11
certain O 0 2.663518072765214e-09
extracolonic O 0 4.925387884213706e-07
manifestations O 0 7.180290140240686e-08
in O 0 3.931009473490121e-08
FAP B-Disease 0 3.530175831656379e-07
patients O 0 8.340601453937779e-08
belonging O 0 1.7900724458286277e-08
to O 0 2.592188241834492e-09
three O 0 7.112542999010429e-09
mutation O 0 1.332791157437896e-07
subgroups O 0 5.142879331287986e-07
. O 0 1.280305923501146e-07

CONCLUSIONS O 0 4.9904196202987805e-05
Extended O 0 4.920500032312702e-06
genotype O 0 0.005933335050940514
- O 0 0.19817282259464264
phenotype O 0 1.35047730509541e-05
correlations O 0 3.5223608847445576e-06
made O 0 6.165476662545188e-08
in O 0 2.757002626196936e-09
this O 0 1.8657721201353894e-10
study O 0 5.670091618448225e-10
may O 0 9.928727173758034e-09
have O 0 2.3849211494564315e-10
the O 0 2.261367308686868e-11
potential O 0 9.468573841653338e-11
to O 0 6.402433444518962e-11
determine O 0 2.1512869263773382e-10
the O 0 4.9246991901119586e-11
most O 0 2.2321001991176814e-10
appropriate O 0 9.945969603464277e-10
surveillance O 0 3.4327701570191493e-08
and O 0 1.2435747986927481e-09
prophylactic O 0 5.313697215569846e-07
treatment O 0 9.731473937790724e-08
regimens O 0 6.144322384216139e-08
for O 0 1.9342065449290402e-10
those O 0 8.757922720370459e-10
patients O 0 5.828186822043335e-09
with O 0 1.9164768383372888e-10
mutations O 0 2.27943726116564e-08
associated O 0 3.755288524587286e-09
with O 0 2.060504877832159e-09
life O 0 8.316042965361703e-08
threatening O 0 1.6977892300928943e-05
conditions O 0 5.286158739181701e-06
. O 0 1.1261761301284423e-07

This O 0 2.9326669093165947e-08
study O 0 3.2573721497897168e-09
also O 0 3.076760513032184e-10
provided O 0 1.0363987446027068e-10
evidence O 0 2.5675542247860506e-10
for O 0 5.6715923624217623e-11
the O 0 2.5406970971530995e-10
pathological O 0 1.2845885244416877e-08
nature O 0 5.26333754358177e-10
of O 0 6.582664274779049e-11
amino O 0 1.4837695516689564e-09
acid O 0 1.3817939015225988e-09
changes O 0 4.737538694676857e-10
in O 0 1.4583826368763653e-09
APC O 0 2.0591544469539258e-08
associated O 0 1.3219012551246578e-09
with O 0 2.6633489857985637e-10
both O 0 4.979809453686812e-09
FAP B-Disease 0 1.5897040839263354e-07
and O 0 2.03951699973004e-08
non O 0 0.10842680931091309
- O 1 1.0
FAP O 1 0.9999985694885254
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 0 0.00013227360614109784
. O 0 1.1380975273311833e-08
. O 0 1.7915274597157804e-08

Inherited B-Disease 1 0.9999998807907104
colorectal I-Disease 1 1.0
polyposis I-Disease 1 0.999974250793457
and O 0 5.8513258409220725e-05
cancer B-Disease 0 0.00026265016640536487
risk O 0 2.8376015848152747e-07
of O 0 1.0288537799496567e-09
the O 0 1.23054624268093e-08
APC O 0 3.19405876325618e-06
I1307K O 0 3.7603329019475495e-06
polymorphism O 0 1.0051715435110964e-05
. O 0 3.5046787161263637e-07

Germ O 0 0.09214264899492264
- O 0 0.04163491725921631
line O 0 5.7334350458404515e-06
and O 0 3.457596520206607e-08
somatic O 0 9.210918960889103e-07
truncating O 0 1.7918764569913037e-06
mutations O 0 3.3441844493609096e-07
of O 0 1.2070302535249766e-09
the O 0 2.4648554308726034e-09
APC B-Disease 0 3.923975100406096e-08
gene O 0 1.7493960058345692e-08
are O 0 1.2221648137966667e-09
thought O 0 3.9535894558184737e-08
to O 0 2.5445842766202986e-08
initiate O 0 0.00016677947132848203
colorectal B-Disease 1 1.0
tumor I-Disease 0 0.00034318678081035614
formation O 0 1.6728157561374246e-06
in O 0 3.722573455888778e-05
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
syndrome I-Disease 1 1.0
and O 0 0.00012034503743052483
sporadic O 1 0.9999790191650391
colorectal O 1 1.0
carcinogenesis O 0 0.32330241799354553
, O 0 2.9078012175887125e-07
respectively O 0 5.388004069573071e-07
. O 0 1.552068624732783e-07

Recently O 0 7.419298981403699e-06
, O 0 3.525743963450623e-08
an O 0 6.755040526940093e-09
isoleucine O 0 9.879766730591655e-05
- O 0 3.873155219480395e-05
- O 0 4.056826219311915e-05
> O 0 5.197074415264069e-07
lysine O 0 3.3769840683817165e-06
polymorphism O 0 2.4946739358711056e-06
at O 0 1.6005030545329646e-07
codon O 0 1.2606816426341538e-06
1307 O 0 2.9776026622130303e-06
( O 0 5.3882596162679874e-09
I1307K O 0 2.898937090378695e-08
) O 0 6.390147438972704e-11
of O 0 1.3804779368242759e-11
the O 0 9.850248394727146e-11
APC B-Disease 0 5.7253664031975404e-09
gene O 0 5.774124733903818e-09
has O 0 3.7201758340543734e-10
been O 0 2.4486643268595287e-10
identified O 0 7.57589602162767e-10
in O 0 1.990245190874873e-10
6 O 0 8.376001559007307e-10
% O 0 2.702531531895147e-10
- O 0 1.8234889154200573e-08
7 O 0 4.4721386593948864e-09
% O 0 1.0004451433953676e-10
of O 0 2.6425356694503854e-11
the O 0 1.0940984784824082e-09
Ashkenazi O 0 7.328154083552363e-08
Jewish O 0 3.2866351862281817e-09
population O 0 9.118131250041017e-10
. O 0 9.752858076694793e-09

To O 0 7.748965913378925e-08
assess O 0 1.6379298983792978e-07
the O 0 4.096842420864277e-09
risk O 0 2.3534365567456916e-08
of O 0 9.086043029071789e-11
this O 0 5.020865390115148e-10
common O 0 1.6704987615412392e-08
APC B-Disease 0 2.965446412872552e-07
allelic O 0 9.733912520459853e-07
variant O 0 0.0002533766091801226
in O 0 0.05267772078514099
colorectal O 1 1.0
carcinogenesis O 0 0.0004124055558349937
, O 0 2.045668523464883e-08
we O 0 4.472522796561407e-09
have O 0 2.841410995380045e-10
analyzed O 0 3.898926181911122e-10
a O 0 3.315824559368963e-10
large O 0 1.5468687442066198e-09
cohort O 0 9.196701711289279e-08
of O 0 9.965528402489099e-10
unselected O 0 1.767452158674132e-05
Ashkenazi O 0 7.462578196282266e-06
Jewish O 0 1.8610724339396256e-07
subjects O 0 5.039339612267213e-07
with O 0 5.325131624545065e-08
adenomatous B-Disease 0 0.00012898830755148083
polyps I-Disease 0 1.9272913050372154e-05
and O 0 2.3674202154211343e-08
. O 0 4.940399378483562e-08
or O 1 0.999900221824646
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, I-Disease 0 2.9052789063399587e-09
for O 0 4.898246808160422e-10
the O 0 7.46707229382082e-09
APC O 0 1.2127813988627167e-06
I1307K O 0 2.5924919100361876e-06
polymorphism O 0 1.2973555385542568e-05
. O 0 2.784281036838365e-07

The O 0 4.1818609020083386e-07
APC O 0 3.352871772221988e-06
I1307K O 0 1.8481940742276493e-06
allele O 0 2.6638247163646156e-06
was O 0 1.5715416168404772e-07
identified O 0 9.582426407916955e-09
in O 0 1.533677851384141e-09
48 O 0 6.245461481313441e-09
( O 0 3.109295598768824e-10
10 O 0 2.7284019488149625e-10
. O 0 3.9047143990389444e-11
1 O 0 2.456068959322266e-10
% O 0 1.3264948861557713e-10
) O 0 9.854082133609054e-11
of O 0 2.2704528535033575e-10
476 O 0 4.772251713802689e-07
patients O 0 1.2774132756021572e-06
. O 0 6.038641942041068e-08

Compared O 0 6.952370199542202e-07
with O 0 1.4473289233762898e-09
the O 0 4.626929117623746e-10
frequency O 0 3.824028382837241e-08
in O 0 1.6648457057399924e-09
two O 0 6.844300126651603e-11
separate O 0 6.139429242768557e-11
population O 0 1.4308884806191191e-11
control O 0 6.424553666839472e-10
groups O 0 1.2394420212391566e-10
, O 0 1.0659640531374137e-10
the O 0 4.723310076393261e-10
APC O 0 7.883991059998152e-08
I1307K O 0 4.907959194611067e-08
allele O 0 3.8022967885353864e-08
is O 0 1.8156330605645365e-10
associated O 0 2.916843433453664e-10
with O 0 5.831395089028746e-11
an O 0 1.0928798838127918e-10
estimated O 0 3.1553154533625616e-10
relative O 0 3.7349803250208424e-09
risk O 0 1.596657561719894e-08
of O 0 3.858018071678515e-10
1 O 0 4.998120317623034e-08
. O 0 4.9481890584957e-08

5 O 0 1.4720229955855757e-05
- O 0 3.349688267917372e-05
1 O 0 3.3317121506115654e-07
. O 0 1.1485905559993626e-07

7 O 0 2.7239850169280544e-05
for O 0 2.6604025151755195e-06
colorectal B-Disease 1 1.0
neoplasia I-Disease 0 0.05925239622592926
( O 0 7.317804318063281e-08
both O 0 8.083294034122446e-08
P O 0 0.005661712493747473
= O 0 3.2175830710912123e-07
. O 0 8.261544337528903e-09
01 O 0 1.6076055544544943e-06
) O 0 1.341827804424156e-08
. O 0 3.247410873541412e-08

Furthermore O 0 5.153538609192765e-07
, O 0 1.0608741440876202e-08
compared O 0 1.0333659261618777e-08
with O 0 7.242233479587412e-10
noncarriers O 0 2.2263593564275652e-06
, O 0 1.6136330049931757e-09
APC O 0 6.031471144751777e-08
I1307K O 0 3.9670428719773554e-08
carriers O 0 3.651301838658583e-08
had O 0 8.895775671646788e-09
increased O 0 1.4546517324021124e-09
numbers O 0 1.5446309786781853e-09
of O 0 1.3944707610846763e-09
adenomas B-Disease 0 0.0010596420615911484
and O 0 0.4992239475250244
colorectal B-Disease 1 1.0
cancers I-Disease 0 0.030398134142160416
per O 0 3.6929651514583384e-07
patient O 0 4.818201887246687e-06
( O 0 2.5603972275689557e-08
P O 0 5.607624916592613e-05
= O 0 1.1861271786983707e-07
. O 0 2.5478077425589163e-09
03 O 0 5.7378322537715576e-08
) O 0 1.5198391156712177e-10
, O 0 6.350513864772367e-11
as O 0 2.1048621179353688e-10
well O 0 5.600283015105845e-10
as O 0 1.585407249926618e-09
a O 0 5.068022446153009e-09
younger O 0 2.389459154983342e-07
age O 0 1.7870021906674083e-08
at O 0 6.98530797649255e-08
diagnosis O 0 2.149801730411127e-06
. O 0 4.390823349353923e-08

We O 0 5.094551625006716e-07
conclude O 0 3.496399472169287e-07
that O 0 6.396028706667778e-10
the O 0 9.582109550265727e-10
APC O 0 7.123190215452269e-08
I1307K O 0 9.537173184526182e-08
variant O 0 4.2589883264554373e-07
leads O 0 6.850484624010278e-09
to O 0 3.732893549823757e-09
increased O 0 7.955628461786546e-06
adenoma B-Disease 1 0.9999997615814209
formation O 0 5.740105724072464e-09
and O 0 3.2587377241100057e-10
directly O 0 2.1208690359486582e-10
contributes O 0 3.3915187325206375e-10
to O 0 1.4670305248376536e-10
3 O 0 9.104662024306265e-10
% O 0 5.574800621133136e-10
- O 0 2.52349181550926e-08
4 O 0 2.503929064090471e-09
% O 0 2.2779744757173148e-10
of O 0 1.5914750073342532e-10
all O 0 2.115247710321455e-08
Ashkenazi O 0 0.007153401616960764
Jewish O 1 0.9799174666404724
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
. O 0 4.771537192027608e-07

The O 0 3.278666582673395e-08
estimated O 0 6.492543391800609e-09
relative O 0 6.8253913632077e-09
risk O 0 5.2875899214654964e-09
for O 0 2.58219418070027e-10
carriers O 0 5.5753169192485075e-08
may O 0 5.916547252127202e-09
justify O 0 1.5809744624561972e-09
specific O 0 6.320210466093101e-10
clinical O 0 5.0027533227137155e-09
screening O 0 5.436665784230854e-09
for O 0 1.1469328958790825e-10
the O 0 2.0679886969521277e-10
360 O 0 4.019549137979084e-09
, O 0 7.304657573259377e-11
000 O 0 5.282889126156931e-10
Americans O 0 2.9599470097174674e-10
expected O 0 1.1446605885367944e-09
to O 0 2.1095282465299903e-10
harbor O 0 6.395958429550319e-09
this O 0 1.9796066175192806e-10
allele O 0 2.490071082661416e-08
, O 0 1.697768314823378e-10
and O 0 3.5578825996473995e-10
genetic O 0 2.901181517245277e-09
testing O 0 5.872217823110759e-09
in O 0 4.95524843380224e-10
the O 0 9.788853755354765e-11
setting O 0 1.644759328733869e-09
of O 0 1.2117400138844658e-10
long O 0 4.37614176007628e-08
- O 0 2.560205530244275e-06
term O 0 1.4807218349233153e-06
- O 0 1.4995955552876694e-06
outcome O 0 3.063821196747085e-08
studies O 0 6.939146590667633e-09
may O 0 1.1168150848561709e-08
impact O 0 8.743639590136354e-09
significantly O 0 9.10114249563776e-06
on O 1 0.9999910593032837
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
prevention O 0 5.736036996495386e-07
in O 0 5.1888600083316305e-09
this O 0 1.08755493499757e-09
population O 0 1.152619999444937e-09
. O 0 1.2831192996998197e-08

Localization O 0 1.2572728337545414e-05
of O 0 6.4100764696206625e-09
human O 0 5.496839428076328e-09
BRCA1 O 0 2.136105194949778e-06
and O 0 5.792325286080313e-09
its O 0 1.4748955390331275e-09
loss O 0 2.418095057521441e-08
in O 0 1.9297202058510265e-08
high O 0 4.843614078708924e-06
- O 0 2.4079934519249946e-05
grade O 0 4.6731834117963444e-06
, O 0 2.5257778091258842e-09
non B-Disease 0 0.0014608997153118253
- I-Disease 1 0.9999698400497437
inherited I-Disease 1 0.9999665021896362
breast I-Disease 1 0.9999978542327881
carcinomas I-Disease 1 0.9999998807907104
. O 0 2.099398898280924e-06

Although O 0 1.3196149950545077e-07
the O 0 2.0981774095929495e-09
link O 0 3.709840967758282e-08
between O 0 1.9598660472297524e-08
the O 0 2.913255343628407e-07
BRCA1 O 1 0.9996954202651978
tumour B-Disease 1 1.0
- O 0 5.709000106435269e-05
suppressor O 0 6.217061581992311e-06
gene O 0 2.580245563876815e-06
and O 0 5.327201051841257e-06
hereditary B-Disease 1 0.9999994039535522
breast I-Disease 1 1.0
and I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
is O 0 1.1567317104166364e-09
established O 0 4.5337855691940376e-10
, O 0 1.1345570316567688e-10
the O 0 6.633862209559638e-11
role O 0 1.4538168446875943e-09
, O 0 1.2558737383372431e-10
if O 0 1.2746560751342173e-10
any O 0 2.0053346483361878e-10
, O 0 5.773799147124059e-11
of O 0 2.612984828509468e-11
BRCA1 O 0 1.3654583597144665e-07
in O 0 4.5962099903817943e-08
non B-Disease 0 0.017009060829877853
- I-Disease 1 0.9982031583786011
familial I-Disease 0 0.03571763634681702
cancers I-Disease 1 0.6024869680404663
is O 0 4.289330490792054e-08
unclear O 0 7.225633567031764e-07
. O 0 5.248165635407531e-08

BRCA1 O 0 0.06367188692092896
mutations O 0 2.298847903148271e-05
are O 0 2.9162563919271633e-08
rare O 0 3.188052133396013e-08
in O 0 4.3096108015561185e-08
sporadic B-Disease 0 0.22380945086479187
cancers I-Disease 1 0.9834308624267578
, O 0 8.351231706171802e-09
but O 0 1.846592390108981e-08
loss O 0 1.1723000348240475e-08
of O 0 1.3842199608760097e-10
BRCA1 O 0 3.465592328666389e-07
resulting O 0 1.8149485248031283e-09
from O 0 1.3380345720293008e-09
reduced O 0 6.717574496661882e-09
expression O 0 5.853855622461879e-09
or O 0 4.127509889428893e-09
incorrect O 0 8.912508775438255e-08
subcellular O 0 5.766708568444301e-07
localization O 0 2.969858599044528e-07
is O 0 2.4141846854952576e-10
postulated O 0 1.683140737895883e-09
to O 0 2.0394722022309963e-10
be O 0 1.5208309611658422e-10
important O 0 2.270487547972877e-10
in O 0 3.964484296403725e-09
non B-Disease 0 1.084202631318476e-05
- I-Disease 1 0.9698157906532288
familial I-Disease 1 0.9859333634376526
breast I-Disease 1 0.9999985694885254
and I-Disease 1 0.9999861717224121
ovarian I-Disease 1 1.0
cancers I-Disease 1 1.0
. O 0 7.707727718297974e-07

Epigenetic O 0 0.0008661584579385817
loss O 0 1.3269108421809506e-05
, O 0 8.844192933565864e-09
however O 0 4.725286384399396e-09
, O 0 2.856751502022803e-10
has O 0 6.812443664738765e-11
not O 0 6.750976860869784e-11
received O 0 7.803476614887117e-11
general O 0 1.8794661660326284e-10
acceptance O 0 1.57527946242908e-09
due O 0 1.5241711226465782e-09
to O 0 1.6359075205585327e-10
controversy O 0 7.324542083964047e-10
regarding O 0 2.7892338438917363e-10
the O 0 1.9285592567364063e-10
subcellular O 0 4.398626884949408e-08
localization O 0 2.614085659047305e-08
of O 0 5.931320018470743e-11
BRCA1 O 0 3.394628933506283e-08
proteins O 0 1.2145449090894544e-09
, O 0 1.9707646625732878e-10
reports O 0 5.350885290411611e-10
of O 0 1.0083258013271479e-11
which O 0 2.2049258252554438e-10
have O 0 2.0150128232643283e-09
ranged O 0 3.470782772296843e-09
from O 0 8.089513781062152e-11
exclusively O 0 3.1975125325267584e-10
nuclear O 0 1.7453698930580686e-08
, O 0 1.3664763764964505e-10
to O 0 1.455194853505759e-10
conditionally O 0 6.110800754299817e-09
nuclear O 0 4.155615407341884e-09
, O 0 7.215949365813046e-11
to O 0 7.320893197215739e-11
the O 0 2.012270572393504e-09
ER O 0 1.0390211173216812e-05
/ O 0 2.9632892051267845e-07
golgi O 0 9.79131982603576e-07
, O 0 1.4918883906034353e-09
to O 0 4.946296705554687e-10
cytoplasmic O 0 5.7803973163572664e-08
invaginations O 0 3.045649350497115e-07
into O 0 3.580561180882569e-09
the O 0 2.431097989585851e-09
nucleus O 0 4.080093773950466e-08
. O 0 2.7317478057398148e-08

In O 0 1.4636675871315674e-07
an O 0 1.3319285674384673e-09
attempt O 0 1.414724781767518e-08
to O 0 2.514016994581425e-09
resolve O 0 7.144661395841467e-08
this O 0 8.744669433013996e-10
issue O 0 7.526699263848968e-09
, O 0 3.6683656112757035e-10
we O 0 1.1057081916732159e-09
have O 0 5.732783137091246e-10
comprehensively O 0 2.9036295146056545e-08
characterized O 0 1.0597537070111684e-08
19 O 0 2.971030532705754e-08
anti O 0 4.375649496068945e-07
- O 0 6.766159003745997e-06
BRCA1 O 0 5.598895768343937e-06
antibodies O 0 3.154452770104399e-07
. O 0 1.7159433696178894e-07

These O 0 2.581419664693385e-07
reagents O 0 8.183366162484162e-07
detect O 0 6.07525350915239e-07
a O 0 2.301639412394252e-08
220 O 0 3.1461007665711804e-07
- O 0 1.4660148508482962e-06
kD O 0 1.956232381417067e-06
protein O 0 1.0119673277131369e-07
localized O 0 1.81374744556706e-07
in O 0 7.505496668613887e-09
discrete O 0 4.872756775853304e-08
nuclear O 0 6.45795182663278e-07
foci O 0 6.812101673858706e-07
in O 0 5.457205354275629e-09
all O 0 5.917729084536916e-10
epithelial O 0 6.340329150589241e-09
cell O 0 1.1463291684776777e-06
lines O 0 3.0119755933810666e-07
, O 0 1.6843119954312868e-10
including O 0 4.980298465295796e-11
those O 0 9.540689072107256e-11
derived O 0 3.973409601343292e-09
from O 0 1.330180481318166e-07
breast B-Disease 0 3.7622161471517757e-05
malignancies I-Disease 0 5.075581793789752e-05
. O 0 3.3516971598146483e-07

Immunohistochemical O 0 0.0007603006670251489
staining O 0 9.076465357793495e-05
of O 0 2.2002353716743528e-08
human O 0 6.122282769638332e-08
breast O 0 3.089251185883768e-05
specimens O 0 3.629685707551289e-08
also O 0 2.9069267881709493e-08
revealed O 0 8.948744607550907e-07
BRCA1 O 0 1.5641147911082953e-05
nuclear O 0 3.201567324140342e-06
foci O 0 3.454686884651892e-05
in O 0 4.701505986304255e-06
benign O 1 0.9988414645195007
breast O 1 0.9667951464653015
, O 0 7.28420104678662e-07
invasive B-Disease 0 0.3675295412540436
lobular I-Disease 1 0.999990701675415
cancers I-Disease 1 0.9998565912246704
and O 0 2.5490010102657834e-06
low B-Disease 1 0.995049774646759
- I-Disease 1 0.9999843835830688
grade I-Disease 1 0.9510524868965149
ductal I-Disease 1 0.9987228512763977
carcinomas I-Disease 1 1.0
. O 0 9.531619070912711e-06

Conversely O 0 1.2765322935592849e-05
, O 0 7.228756260246882e-08
BRCA1 O 0 1.102787450690812e-06
expression O 0 3.8399182500370443e-08
was O 0 5.921935297692471e-08
reduced O 0 2.089770134716673e-09
or O 0 1.4487263610973855e-09
undetectable O 0 2.620625316751557e-08
in O 0 1.2413826633306257e-09
the O 0 1.1921530429503946e-10
majority O 0 1.0307035086531968e-10
of O 0 2.7012639347567813e-10
high O 0 1.4977522369008511e-05
- O 0 0.013285934925079346
grade O 0 0.0017795076128095388
, O 0 6.487148596079351e-08
ductal B-Disease 0 0.10127227008342743
carcinomas I-Disease 1 1.0
, O 0 6.898158932955312e-09
suggesting O 0 3.515704705137068e-08
that O 0 1.0484501045127104e-09
absence O 0 2.277124266925057e-09
of O 0 1.8310393479215037e-10
BRCA1 O 0 5.386308998822642e-07
may O 0 7.3751951212841504e-09
contribute O 0 1.5309999101820182e-10
to O 0 9.417871343897488e-11
the O 0 6.050015488590077e-10
pathogenesis O 0 1.814485628415241e-08
of O 0 3.067547257873393e-11
a O 0 8.323747802130299e-10
significant O 0 4.834243672036109e-09
percentage O 0 1.4226482392132311e-07
of O 0 3.500594258909473e-09
sporadic B-Disease 1 0.879483163356781
breast I-Disease 1 0.9996190071105957
cancers I-Disease 0 0.022479023784399033
. O 0 1.7822502584863287e-08
. O 0 4.340554227155735e-08

